id,llm_model_name,edge,context_input_data,schema_dep_validity,verb,num_options,correct,prompt,reasoning,evidences,answer,answer_choice_probablities,critique_consistent,critique_answer,critique_reasoning
0,gpt-4o,"Presence_of_Metastasis_in_Lymph_Nodes_5,Computed_Tomography_CT_Scans_8","""{'NODE1': {'id': 'Presence_of_Metastasis_in_Lymph_Nodes_5', 'label': 'Metastasis in Nearby Lymph Nodes', 'description': 'This node represents the clinical situation regarding whether metastasis is present in the nearby lymph nodes of a patient. It is a critical factor in determining the stage and prognosis of cancer, as the spread of cancer to lymph nodes often indicates a more advanced disease and may influence treatment decisions.', 'type': 'Patient Situation', 'observability': 'Unobserved', 'states': [{'state_name': 'unknown', 'state_description': 'The status of metastasis in the lymph nodes is not determined. It is unclear whether cancer has spread to these nodes.'}, {'state_name': 'present', 'state_description': 'Metastasis is confirmed in the lymph nodes, indicating that cancer has spread to these nodes.'}, {'state_name': 'absent', 'state_description': 'There is no metastasis in the lymph nodes, indicating that cancer has not spread to these nodes.'}]}, 'NODE2': {'id': 'Computed_Tomography_CT_Scans_8', 'label': 'Computed Tomography (CT) Scans Examination Result', 'description': 'This node represents the result of a Computed Tomography (CT) scan, which is a diagnostic imaging procedure used to detect abnormalities or confirm the absence of disease in the body. The node indicates whether significant findings are present or absent based on the CT scan results.', 'type': 'Examination Result', 'observability': 'Observed', 'states': [{'state_name': 'present', 'state_description': 'The CT scan has detected significant findings, such as lesions, tumors, or other abnormalities.'}, {'state_name': 'absent', 'state_description': 'The CT scan did not detect any abnormalities or significant findings.'}]}, 'EDGE1': {'edges_ids': ['Presence_of_Metastasis_in_Lymph_Nodes_5', 'Computed_Tomography_CT_Scans_8'], 'edge': '(Presence_of_Metastasis_in_Lymph_Nodes_5) causes (Computed_Tomography_CT_Scans_8)', 'explanation': ['The edge represents the causal relationship where the presence of metastasis in lymph nodes leads to significant findings on a CT scan.', 'Metastasis in lymph nodes can cause changes detectable by CT scans, such as enlarged nodes or other abnormalities.', 'The causal direction is positive because the presence of metastasis leads to positive findings on the CT scan.', 'The presence of metastasis is a sufficient condition for the CT scan to show abnormalities related to metastasis, but not necessary as other conditions can also cause abnormalities.', 'The causal distance is proximal because the presence of metastasis directly affects the CT scan results.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': True}, 'causal_distance': 'Proximal'}, 'EDGE2': {'edges_ids': ['Computed_Tomography_CT_Scans_8', 'Presence_of_Metastasis_in_Lymph_Nodes_5'], 'edge': '(Computed_Tomography_CT_Scans_8) causes (Presence_of_Metastasis_in_Lymph_Nodes_5)', 'explanation': ['The edge represents the idea that the result of a CT scan could cause the presence of metastasis in lymph nodes.', 'CT scans are diagnostic tools that detect existing conditions, such as metastasis, but do not cause them.', 'The presence of metastasis in lymph nodes is due to the spread of cancer, not the result of a CT scan.', 'Therefore, the edge is not valid as the CT scan does not cause metastasis.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}, 'ENTITIES_MATCHING_PAGES_INFO': {'94': {'matching_entities': [{'TOMOGRAPHY, X-RAY COMPUTED': 0.9942913}, {'NEOPLASM METASTASIS': 0.96748203}, {'COMPUTED TOMOGRAPHY': 0.9552146}, {'LYMPHATIC METASTASIS': 0.94962627}, {'POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY': 0.9421292}, {'LYMPH NODE METASTASIS': 0.9418514}, {'MAGNETIC RESONANCE IMAGING': 0.92989886}], 'count': 7}, '93': {'matching_entities': [{'TOMOGRAPHY, X-RAY COMPUTED': 0.9942913}, {'COMPUTED TOMOGRAPHY': 0.9552146}, {'MALIGNANT NEOPLASTIC DISEASE': 0.9424237}, {'POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY': 0.9421292}, {'MAGNETIC RESONANCE IMAGING': 0.92989886}, {'CANCER': 0.92851335}], 'count': 6}, '41': {'matching_entities': [{'METASTASIS': 0.9630129}, {'COMPUTED TOMOGRAPHY (CT)': 0.9533483}, {'LYMPHATIC METASTASIS': 0.94962627}, {'MAGNETIC RESONANCE IMAGING (MRI)': 0.9313307}, {'CANCER': 0.92851335}, {'IMAGING': 0.922603}], 'count': 6}, '44': {'matching_entities': [{'TOMOGRAPHY, X-RAY COMPUTED': 0.9942913}, {'COMPUTED TOMOGRAPHY': 0.9552146}, {'LYMPHATIC METASTASIS': 0.94962627}, {'MALIGNANT NEOPLASTIC DISEASE': 0.9424237}, {'MAGNETIC RESONANCE IMAGING': 0.92989886}, {'CANCER': 0.92851335}], 'count': 6}, '92': {'matching_entities': [{'METASTASIS': 0.9630129}, {'COMPUTED TOMOGRAPHY': 0.9552146}, {'MALIGNANT NEOPLASM': 0.9448747}, {'MAGNETIC RESONANCE IMAGING': 0.92989886}, {'CANCER': 0.92851335}], 'count': 5}}, 'GUIDELINE_PAGES_INFO': '--------------------------------------------------\\nPage Number: 94\\n\\nSection Name: Head and Neck Cancers - Principles of Imaging\\n====================\\nEntities:-\\nPositron Emission Tomography Computed Tomography : A medical imaging technique combining PET and CT capabilities to provide detailed information about the body\\'s function and structure.\\nPositron Emission Tomography : A nuclear medicine functional imaging technique that is used to observe metabolic processes in the body.\\nComputed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.\\nHead And Neck Neoplasms : Cancers that arise in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\n\\nRelationships:-\\n1. Entity1: \""PET/CT\"", Entity2: \""PET scan\"", Relationship: \""preferred over\""\\n2. Entity1: \""PET-CT\"", Entity2: \""head neck cancers\"", Relationship: \""used in study of\""\\n\\nCausalities:-\\n<A> PET/CT is preferred over PET scan alone (i.e., without superimposed CT scan) </A>. <C> PET/CT provides more accurate anatomical localization of abnormalities </C> <E> more accurate anatomical localization of abnormalities </E>.\\n\\nSection Name: Initial Workup - Nodal Metastases\\n====================\\nEntities:-\\nLymphatic Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site via the lymphatic system.\\nTomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient, producing signals that are processed by the machine\\'s computer to generate cross-sectional images.\\nMagnetic Resonance Imaging : A non-invasive imaging technique that uses magnetic fields and radio waves to create detailed images of the organs and tissues within the body.\\nPositron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption.\\nLymph Node Metastasis : The spread of cancer cells to lymph nodes, which are part of the lymphatic system.\\nCt Of Neck : A computed tomography scan of the neck region.\\nMri Of Neck : A magnetic resonance imaging scan of the neck region.\\nFdg-Pet Scan : A type of positron emission tomography using fluorodeoxyglucose to assess metabolic activity.\\nComputed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.\\nPositron Emission Tomography : A nuclear medicine functional imaging technique that is used to observe metabolic processes in the body.\\n\\nRelationships:-\\n1. Entity1: \""CT\"", Entity2: \""lymph node metastases\"", Relationship: \""used to evaluate\""\\n2. Entity1: \""MRI\"", Entity2: \""lymph node metastases\"", Relationship: \""used to evaluate\""\\n3. Entity1: \""FDG-PET/CT\"", Entity2: \""lymph node metastases\"", Relationship: \""used for detection\""\\n4. Entity1: \""FDG-PET/CT\"", Entity2: \""surgical primary approach\"", Relationship: \""used to determine\""\\n5. Entity1: \""FDG-PET/CT\"", Entity2: \""definitive RT approach\"", Relationship: \""used to identify\""\\n\\nCausalities:-\\n<A> Evaluation of lymph node metastases should be conducted with CT or MRI of the neck </A>, using whichever imaging study is suitable for primary site evaluation (IMG-A, 1 of 4).\\n<CO> For patients with multistation or lower neck nodal involvement or high-grade tumor histology </CO>, <A> consider CT of the chest to assess for mediastinal lymph node metastases or FDG-PET/CT </A>, <C> which is associated with higher sensitivity for both nodal and distant metastases </C>.\\n<CO> For patients who are under consideration for a surgical primary approach </CO>, <A> the higher sensitivity of FDG-PET/CT is warranted for tumors approaching the midline, to determine the surgical approach to the contralateral neck </A>. <CO> Similarly, patients who are scheduled for a definitive RT approach </CO> <A> may benefit from the higher sensitivity of FDG-PET/CT for identifying involved lymph nodes </A>.\\n\\nSection Name: Initial Workup - Distant Metastases\\n====================\\nEntities:-\\nPositron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption.\\nMagnetic Resonance Imaging : A non-invasive imaging technique that uses magnetic fields and radio waves to create detailed images of the organs and tissues within the body.\\nTomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient, producing signals that are processed by the machine\\'s computer to generate cross-sectional images.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nLung Neoplasms : Tumors or cancer of the lung.\\nSmoking : The inhalation of the smoke of burning tobacco encased in cigarettes, pipes, and cigars.\\n\\nRelationships:-\\n1. Entity1: \""FDG-PET/CT\"", Entity2: \""Distant Metastases\"", Relationship: \""used to evaluate\""\\n2. Entity1: \""Contrast-enhanced brain MRI\"", Entity2: \""Brain Metastasis\"", Relationship: \""recommended for evaluation\""\\n3. Entity1: \""CT of the chest\"", Entity2: \""Pulmonary Metastases\"", Relationship: \""performed to assess\""\\n4. Entity1: \""Non-contrast CT of the chest\"", Entity2: \""Lung Parenchymal Metastases\"", Relationship: \""used to screen\""\\n5. Entity1: \""Annual CT screening\"", Entity2: \""Lung Metastasis\"", Relationship: \""considered for high risk\""\\n6. Entity1: \""Directed CT or MRI\"", Entity2: \""Distant Disease\"", Relationship: \""used for assessment\""\\n7. Entity1: \""FDG-PET/CT\"", Entity2: \""Recurrent Disease\"", Relationship: \""used for staging\""\\n\\nCausalities:-\\n<C> Patients with locoregionally advanced cancer (e.g., T3\u2013T4 primary or \u2265N1 nodal staging) </C>, <A> FDG-PET/CT is preferred to evaluate for distant disease and thoracic metastases </A>. <CO> For cancers where brain metastasis is a concern, such as mucosal melanoma or high-grade neuroendocrine carcinomas or adenocarcinomas </CO>, <A> contrast-enhanced brain MRI should be additionally obtained </A>.\\n<CO> If FDG-PET/CT is not performed </CO>, <A> CT of the chest should be performed to assess for presence of pulmonary metastases as well as mediastinal lymph node involvement </A>.\\n<CO> Non-contrast CT of the chest can be sufficient to screen for lung parenchymal metastases </CO> but <CO> is not adequate for assessment of mediastinal adenopathy </CO>. <CO> This is an appropriate lung cancer screening intervention for patients with a history of smoking </CO>.\\n<CO> Following primary definitive treatment (surgery, RT, or systemic therapy/RT) </CO> the role of annual CT screening for lung metastasis is controversial. <E> While this approach does detect early metastasis </E>, <CO> further study is needed to determine the extent of the positive effect and/or cost-effectiveness of this approach in specific subpopulations and timepoints post-treatment </CO>. <CO> For patients with a substantial smoking history or who are at high risk for lung metastases </CO>, <A> annual chest CT can be considered </A>.\\n<CO> If clinical concern for metastatic disease is confined to a specific anatomical area </CO>, <A> the assessment of distant disease can be performed with directed CT or MRI examination </A>.\\n<CO> FDG-PET/CT may complement or replace other imaging modalities when staging recurrent disease before any therapy for relapsed/refractory disease </CO> <A> in order to explore distant disease or second primaries that may significantly impact choice of therapy </A>.\\n--------------------------------------------------\\nPage Number: 93\\n\\nSection Name: PRINCIPLES OF IMAGING\\n====================\\nEntities:-\\nImaging, Diagnostic : The production of a visual representation of parts of the body, for the purpose of clinical analysis and medical intervention.\\nHead And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\nTomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.\\nMagnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body\\'s soft tissue and bones.\\nContrast Media : Substances used to enhance the contrast of structures or fluids within the body in medical imaging.\\n\\nRelationships:-\\n1. Entity1: \""Imaging, Diagnostic\"", Entity2: \""Head and Neck Neoplasms\"", Relationship: \""used for\""\\n2. Entity1: \""Tomography, X-Ray Computed\"", Entity2: \""Contrast Media\"", Relationship: \""uses\""\\n3. Entity1: \""Magnetic Resonance Imaging\"", Entity2: \""Contrast Media\"", Relationship: \""uses\""\\n\\nCausalities:-\\n<C> Imaging </C> plays an essential role in the clinical care of patients with head and neck cancer. <A> The proper selection and utilization of imaging studies </A> is critical in caring for patients with head and neck cancer. <A> CT is performed with contrast </A>, while <A> CT imaging of the chest can be performed with or without contrast </A>, <CO> as clinically indicated </CO>. <A> MRI is performed with and without contrast </A>, <CO> unless contraindicated </CO>.\\n\\nSection Name: Initial Workup - Primary Site\\n====================\\nEntities:-\\nTomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.\\nMagnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body\\'s soft tissue and bones.\\nHead And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\nNeck Structure : The anatomical structure of the neck, which is the part of the body that connects the head to the torso.\\nSkull Base : The bottom part of the skull, which separates the brain from other facial structures.\\nThoracic Inlet : The opening at the top of the thoracic cavity, through which pass the trachea, esophagus, and major blood vessels.\\n\\nRelationships:-\\n1. Entity1: \""CT\"", Entity2: \""MRI\"", Relationship: \""complementary in imaging head and neck cancers\""\\n2. Entity1: \""CT\"", Entity2: \""Head and Neck Neoplasms\"", Relationship: \""used to evaluate\""\\n3. Entity1: \""MRI\"", Entity2: \""Head and Neck Neoplasms\"", Relationship: \""preferred for evaluating\""\\n4. Entity1: \""Skull base\"", Entity2: \""Thoracic inlet\"", Relationship: \""imaging range for evaluation\""\\n\\nCausalities:-\\n<A>Imaging assessment of the primary site</A> can be performed with <A>CT of the soft tissues of the neck</A> or <A>MRI of the neck</A>. <C>CT is complementary to MRI for head and neck cancers</C>. <A>It is utilized to evaluate cortical bone erosion or periosteal invasion, cartilage invasion, and bony erosion or destruction</A>. <CO>in certain conditions, such as evaluating the extent of bone marrow invasion or in patients with extensive dental amalgam obscuring anatomy on CT, assessing skull base invasion and cranial nerve involvement, and differentiating tumor from obstructed sinuses</CO>, <A>MRI is preferred over CT</A>. <CO>when involved lymph nodes or upper mediastinal cancers are present</CO>, <A>Complete evaluation of primary and nodal disease requires imaging from the skull base to the thoracic inlet, extending to the carina</A>.\\n\\nSection Name: PET/CT and Biopsy\\n====================\\nEntities:-\\nPositron Emission Tomography Computed Tomography : A medical imaging technique that combines PET and CT capabilities to provide detailed images of the body.\\nExamination Under Anesthesia : A procedure where a patient is examined while under anesthesia to allow for a more thorough examination.\\nBiopsy : A medical test involving the extraction of sample cells or tissues for examination to determine the presence or extent of a disease.\\nTonsillectomy : A surgical procedure to remove the tonsils, often performed to treat recurrent tonsillitis or sleep apnea.\\nFine Needle Aspiration : A type of biopsy procedure that uses a thin, hollow needle to extract cells from a lump or mass for examination.\\nUltrasound : A medical imaging technique that uses high-frequency sound waves to visualize internal organs and structures.\\nComputed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.\\n\\nRelationships:-\\n1. Entity1: \""PET/CT\"", Entity2: \""EUA\"", Relationship: \""recommended before\""\\n2. Entity1: \""Fine Needle Aspiration (FNA)\"", Entity2: \""metastatic nodes\"", Relationship: \""used for biopsy of\""\\n3. Entity1: \""Image-guided needle biopsy\"", Entity2: \""cystic neck nodes\"", Relationship: \""recommended for initial diagnosis of\""\\n\\nCausalities:-\\n<CO> If imaging does not reveal an obvious primary cancer </CO>, <A> a PET/CT should be ordered before EUA, biopsies, and tonsillectomy </A>. <E> This helps identify potential primary sites </E> before any interventions take place. Additionally, <A> Fine Needle Aspiration (FNA) biopsy of metastatic nodes </A> <E> may provide pathologically informative results </E>. <CO> For initial diagnosis in cystic neck nodes </CO>, <A> image-guided needle biopsy (ultrasound or CT) </A> <E> may yield better results than FNA by palpation alone </E>.\\n\\nSection Name: Postoperative Imaging Advice\\n====================\\nEntities:-\\nPanoramic Radiography : A type of dental x-ray that provides a wide view of the upper and lower jaws, teeth, temporomandibular joints, and sinuses.\\nOral Cavity : The cavity of the mouth, including the lips, the lining inside the cheeks and lips, the front two-thirds of the tongue, the gums, the floor of the mouth under the tongue, the hard palate, and the small area of the gum behind the wisdom teeth.\\nRadiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.\\nMandibulotomy : A surgical procedure involving the cutting of the mandible.\\nMandibulectomy : A surgical procedure involving the removal of part or all of the mandible.\\nOropharynx : The part of the throat at the back of the mouth behind the oral cavity.\\n\\nRelationships:-\\n1. Entity1: \""panoramic dental x-ray\"", Entity2: \""oral cavity cancers\"", Relationship: \""recommended for\""\\n2. Entity1: \""panoramic dental x-ray\"", Entity2: \""postoperative radiotherapy\"", Relationship: \""essential for pre-radiation evaluation\""\\n3. Entity1: \""pre-radiation dental evaluation\"", Entity2: \""dental procedures or extractions\"", Relationship: \""determine necessity of\""\\n\\nCausalities:-\\n<A> A panoramic dental x-ray is recommended </A> <C> for oral cavity cancers requiring mandibulotomy and/or mandibulectomy </C>. <CO> When postoperative radiotherapy (RT) is anticipated for areas like the lip, oral cavity subsites, or oropharynx </CO>, <A> panoramic x-ray is essential for a comprehensive pre-radiation dental evaluation </A> <E> to assess the health of affected teeth and determine if pre-radiation dental procedures or extractions are necessary </E>.\\n\\nSection Name: NCCN Guidelines Note\\n====================\\nEntities:-\\nNeoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.\\nMalignant Neoplastic Disease : A disease characterized by uncontrolled, abnormal growth of cells that can invade or spread to other parts of the body.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\nClinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.\\nClinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\n\\nRelationships:-\\n1. Entity1: \""NCCN\"", Entity2: \""Clinical Trials\"", Relationship: \""encourages participation in\""\\n2. Entity1: \""NCCN\"", Entity2: \""Cancer\"", Relationship: \""recommends clinical trials for\""\\n\\nCausalities:-\\n<A> NCCN believes that the best management of any patient with cancer is through participation in clinical trials </A>, <A> which is especially encouraged </A>.\\n--------------------------------------------------\\nPage Number: 41\\n\\nSection Name: Workup\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.\\nHistory And Physical Examination : A comprehensive assessment of a patient\\'s medical history and physical condition.\\nTobacco Smoking : The act of smoking tobacco products, which is a risk factor for many diseases.\\nAlcohol Drinking : The consumption of beverages containing ethyl alcohol.\\nSmoking Cessation : The process of discontinuing tobacco smoking.\\nBiopsy : A medical test involving the extraction of sample cells or tissues for examination.\\nLaryngoscopy : A procedure to examine the larynx, often using a scope.\\nComputed Tomography (Ct) : A diagnostic imaging procedure that uses computer-processed combinations of many X-ray measurements taken from different angles to produce cross-sectional images of specific areas of a scanned object.\\nMagnetic Resonance Imaging (Mri) : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.\\nPositron-Emission Tomography : A type of nuclear medicine imaging that measures metabolic activity of the cells of body tissues.\\nPulmonary Function Test : Tests that measure how well the lungs are working.\\nDental Examination : An evaluation of the teeth and gums to assess oral health.\\nNutritional Support : Therapies to provide nutrition to patients who cannot obtain nutrition by mouth.\\nSpeech Therapy : Therapy to improve speech and communication skills.\\nSwallowing Therapy : Therapy to help individuals with swallowing difficulties.\\nMultidisciplinary Care Team : A group of healthcare professionals from different specialties working together to manage patient care.\\n\\nRelationships:-\\n1. Entity1: \""glottic larynx cancer\"", Entity2: \""history and physical examination\"", Relationship: \""initial diagnostic step\""\\n2. Entity1: \""glottic larynx cancer\"", Entity2: \""biopsy\"", Relationship: \""required diagnostic procedure\""\\n3. Entity1: \""glottic larynx cancer\"", Entity2: \""direct laryngoscopy\"", Relationship: \""recommended procedure\""\\n4. Entity1: \""glottic larynx cancer\"", Entity2: \""CT scans\"", Relationship: \""imaging study\""\\n5. Entity1: \""glottic larynx cancer\"", Entity2: \""MRI\"", Relationship: \""imaging study\""\\n6. Entity1: \""glottic larynx cancer\"", Entity2: \""multidisciplinary consultation\"", Relationship: \""advised as clinically indicated\""\\n\\nCausalities:-\\nThe workup section outlines the initial steps for diagnosing <C>glottic larynx cancer</C>. It includes <A>a comprehensive history and physical examination (H&P)</A>, which should document tobacco and alcohol use, and provide counseling for smoking cessation. <A>A biopsy of the primary site is required</A>, and <A>direct laryngoscopy under anesthesia is generally recommended</A>. <A>Imaging studies such as CT scans with contrast and possibly MRI are used to evaluate the larynx and neck</A>. Additional evaluations may include <A>chest CT, FDG-PET/CT, pulmonary function tests, dental evaluation, and nutrition, speech, and swallowing therapy</A>. <A>Multidisciplinary consultation is advised</A> <CO>as clinically indicated</CO>.\\n\\nSection Name: Clinical Staging\\n====================\\nEntities:-\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\nCarcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.\\nBiopsy : A medical test involving the extraction of sample cells or tissues for examination.\\nLaryngectomy : A surgical procedure to remove the larynx.\\n\\nRelationships:-\\n1. Entity1: \""Clinical staging\"", Entity2: \""Cancer\"", Relationship: \""involves\""\\n2. Entity1: \""Carcinoma in situ\"", Entity2: \""Stages T1-T4\"", Relationship: \""is a stage of\""\\n3. Entity1: \""Biopsy\"", Entity2: \""Cancer\"", Relationship: \""used in staging\""\\n4. Entity1: \""Larynx-preserving surgeries\"", Entity2: \""Stages T1-T2\"", Relationship: \""considered for\""\\n5. Entity1: \""Total laryngectomy\"", Entity2: \""Stages T3-T4\"", Relationship: \""required for\""\\n\\nCausalities:-\\n<C> Clinical staging involves categorizing the cancer based on its aggressiveness </C>. It starts with carcinoma in situ, which is non-invasive, and progresses through stages T1-T4. <CO> Staging is based on H&P, biopsy, and imaging studies </CO>. <CO> For T1-T2 </CO>, <A> larynx-preserving surgeries are considered </A>, while <CO> more advanced stages like T3 or T4 </CO> <A> may require total laryngectomy </A>. <A> Additional evaluations such as videostrobe, audiogram, and fertility counseling may be considered </A>.\\n\\nSection Name: Treatment\\n====================\\nEntities:-\\nCarcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.\\nLaryngectomy : A surgical procedure to remove the larynx.\\nMetastasis : The transfer of a disease from one organ or part to another not directly connected with it.\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\n\\nRelationships:-\\n1. Entity1: \""Carcinoma in situ\"", Entity2: \""Larynx-preserving surgery\"", Relationship: \""treated with\""\\n2. Entity1: \""T1-T2 stages\"", Entity2: \""Conservation surgery\"", Relationship: \""treated with\""\\n3. Entity1: \""T3 stages\"", Entity2: \""Total laryngectomy\"", Relationship: \""may require\""\\n4. Entity1: \""T4a disease\"", Entity2: \""Complex interventions\"", Relationship: \""require\""\\n5. Entity1: \""Guidelines\"", Entity2: \""Multidisciplinary consultations\"", Relationship: \""emphasize importance of\""\\n6. Entity1: \""Guidelines\"", Entity2: \""Clinical trials\"", Relationship: \""consider as best option\""\\n\\nCausalities:-\\n<CO>Treatment recommendations vary by stage</CO>. <CO>Carcinoma in situ</CO> <A>may be treated with larynx-preserving surgery</A>. <CO>T1-T2 stages</CO> <A>may also be amenable to conservation surgery</A>. <CO>T3 stages</CO> <A>may require total laryngectomy</A>, <CO>especially if nodal involvement is present</CO>. <CO>T4a disease and unresectable or metastatic cases</CO> <A>require more complex interventions</A>. <A>The guidelines emphasize the importance of multidisciplinary consultations</A> and <A>consider clinical trials as the best management option</A>.\\n\\nSection Name: Additional Notes\\n====================\\nEntities:-\\nBiopsy, Needle : A procedure to remove a small sample of tissue for examination under a microscope.\\nImage-Guided Biopsy : A biopsy procedure that uses imaging techniques to guide the needle to the precise location of the tissue to be sampled.\\nBiopsy : A medical test involving the extraction of sample cells or tissues for examination.\\nDiagnostic Techniques And Procedures : Methods and procedures for the diagnosis of disease or dysfunction.\\nImaging : The process of producing images of the body for clinical purposes.\\nDental Care : The total of dental diagnostic, preventive, and corrective procedures.\\nNutritional Physiological Phenomena : The functions and properties of nutrients in living organisms.\\nFertility : The capacity to conceive or induce conception.\\nReproductive Health : A state of physical, mental, and social well-being in all matters relating to the reproductive system.\\nLymphatic Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nGlottis : The part of the larynx consisting of the vocal cords and the opening between them.\\n\\nRelationships:-\\n1. Entity1: \""image-guided needle biopsy\"", Entity2: \""diagnostic yield\"", Relationship: \""used for\""\\n2. Entity1: \""nodal disease\"", Entity2: \""glottic tumors\"", Relationship: \""is rare in\""\\n\\nCausalities:-\\n<A> use of image-guided needle biopsy </A> for <E> better diagnostic yield </E>, principles of imaging, dental evaluation, and nutrition management. The guidelines also address fertility and reproductive considerations, and note that <CO> nodal disease in glottic tumors is rare </CO>.\\n--------------------------------------------------\\nPage Number: 44\\n\\nSection Name: Flowchart Structure\\n====================\\nEntities:-\\nNeoplasm Staging : Methods used for staging neoplasms based on extent of tumor spread according to standardized criteria.\\nLaryngectomy : Surgical procedure to remove the larynx, often used to treat laryngeal cancer.\\nChemotherapy, Adjuvant : Drug therapy given in addition to the primary treatment to enhance its effectiveness.\\nRadiotherapy : The use of radiation, usually high-energy X-rays, to damage cancer cells and treat cancer.\\nTomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.\\nMagnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body\\'s soft tissue and bones.\\nNeoplasm Recurrence, Local : The return of a tumor at the original site after treatment.\\n\\nRelationships:-\\n1. Entity1: \""Clinical Staging\"", Entity2: \""T3 tumors\"", Relationship: \""determines treatment approach\""\\n2. Entity1: \""Adverse Pathologic Features\"", Entity2: \""Systemic Therapy\"", Relationship: \""directs to\""\\n3. Entity1: \""Adverse Pathologic Features\"", Entity2: \""Radiation Treatment\"", Relationship: \""directs to\""\\n4. Entity1: \""Induction Chemotherapy\"", Entity2: \""Imaging (CT or MRI)\"", Relationship: \""leads to\""\\n\\nCausalities:-\\n1. <A> The flow begins with the clinical staging of T3 tumors </A> <C> that require total laryngectomy (N2\u20133) </C>. <CO> This staging </CO> <E> is crucial for determining the appropriate therapeutic approach </E>.\\n\\n2. The flowchart provides multiple pathways for treatment, indicating that <CO> patients </CO> <A> may undergo either \""Concurrent systemic therapy/RT\"" or \""Surgery\"" </A>. There is also an <A> option for \""Induction chemotherapy,\"" leading to further imaging (CT or MRI) to assess the primary site and neck status </A>.\\n\\n3. For <CO> patients who have surgery </CO>, the flowchart distinguishes between those with adverse pathologic features and those without. <CO> Patients with adverse features\u2014such as extranodal extension or positive margins </CO>\u2014are <A> directed toward systemic therapy or radiation treatment </A>, while those without may follow a different management path.\\n\\n4. The flowchart concludes by <A> outlining follow-up procedures for recurrent or persistent disease </A>, suggesting additional assessments and treatments based on the risk features identified during earlier stages.\\n\\nSection Name: Detailed Explanation\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.\\nAdverse Pathological Feature : A pathological feature that indicates a worse prognosis or outcome.\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\n\\nRelationships:-\\n1. Entity1: \""Systemic therapy\"", Entity2: \""Radiation\"", Relationship: \""Concurrent treatment\""\\n2. Entity1: \""Clinical trials\"", Entity2: \""Personalized treatment plans\"", Relationship: \""Development of\""\\n\\nCausalities:-\\n<A> The flowchart is designed to provide healthcare professionals with a systematic pathway for managing glottic larynx cancer </A>. Each step is meticulously organized to ensure that important factors are considered, such as <C> the presence of adverse pathological features </C>, which <E> strongly influence treatment decisions </E>.\\n\\n<A> The emphasis on concurrent treatments, such as systemic therapy combined with radiation </A>, reflects current best practices in oncology, where multimodal approaches are often necessary to achieve better outcomes. <A> The inclusion of clinical trials </A> indicates an emphasis on maintaining up-to-date practices and personalized treatment plans as part of patient management strategies.\\n\\nFurthermore, <A> the chart\\'s organization into treatment and follow-up segments </A> allows for a straightforward interpretation, guiding oncologists through complex decisions in a logical manner. This can <E> improve consistency in care and enhance patient safety through meticulous monitoring and responses to treatment efficacy or disease progression </E>.\\n\\nIn summary, <E> this flowchart serves as an essential resource for oncologists, facilitating a better understanding of treatment protocols for glottic larynx cancer while promoting a patient-centered approach to oncological care </E>.\\n\\nSection Name: NCCN Guidelines Version 4.2024\\n====================\\nEntities:-\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\nClinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nNeoplasms : New abnormal growth of tissue that may be benign or malignant.\\nMalignant Neoplastic Disease : A disease in which abnormal cells divide uncontrollably and destroy body tissue.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\nNational Comprehensive Cancer Network : An alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network\"", Entity2: \""NCCN Guidelines\"", Relationship: \""publishes\""\\n2. Entity1: \""Clinical trial\"", Entity2: \""Cancer\"", Relationship: \""manages\""\\n\\nCausalities:-\\n<C> any patient with cancer </C> <E> the best management is in a clinical trial </E>. <A> Participation in clinical trials is especially encouraged </A>.\\n\\nSection Name: Principles of Treatment\\n====================\\nEntities:-\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nExtranodal Extension : The spread of cancer beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margins : Cancer cells are found at the edge of the material removed during surgery, indicating that some cancer may have been left behind.\\nPerineural Invasion : Cancer cells are found surrounding or tracking along a nerve within the perineural space.\\nVascular Invasion : The presence of cancer cells within blood vessels.\\nLymphatic Metastasis : The spread of cancer cells through the lymphatic system to distant sites.\\n\\nRelationships:-\\n1. Entity1: \""Principles of Radiation Therapy\"", Entity2: \""Extranodal Extension\"", Relationship: \""management of\""\\n2. Entity1: \""Principles of Surgery\"", Entity2: \""Positive Surgical Margins\"", Relationship: \""concerned with avoiding\""\\n3. Entity1: \""Principles of Radiation Therapy\"", Entity2: \""Perineural Invasion\"", Relationship: \""consideration in treatment planning\""\\n\\nCausalities:-\\n<C> Extranodal extension </C> <C> Positive margins </C> <C> Close margins </C> <C> pT4 primary </C> <C> pN2 or pN3 nodal disease </C> <C> Perineural invasion </C> <C> Vascular invasion </C> <C> Lymphatic invasion </C> <C> Subglottic extension </C>\\n\\nSection Name: Clinical Staging\\n====================\\nEntities:-\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to enhance its effectiveness.\\nAdjuvant Therapy : A therapy given in addition to the primary or initial therapy to maximize its effectiveness.\\nFollow-Up Studies : Studies that continue to monitor patients after treatment to assess long-term outcomes.\\nFollow-Up Procedure : A procedure performed to monitor the progress of a patient after initial treatment.\\nFollow-Up : The act of monitoring a patient\\'s health over time after treatment.\\nNeoplasm Recurrence, Local : The return of a tumor at the original site after treatment.\\nRecurrent Disease : A disease that has returned after a period of remission.\\n\\nRelationships:-\\n1. Entity1: \""Adjuvant Treatment\"", Entity2: \""Recurrent or Persistent Disease\"", Relationship: \""prevention\""\\n2. Entity1: \""Follow-up\"", Entity2: \""Recurrent or Persistent Disease\"", Relationship: \""monitoring\""\\n\\nSection Name: Treatment Options\\n====================\\nEntities:-\\nLaryngectomy : Surgical procedure to remove the larynx, often used to treat laryngeal cancer.\\nTotal Laryngectomy : A surgical procedure to remove the entire larynx.\\nChemotherapy, Adjuvant : Drug therapy given in addition to the primary treatment to enhance its effectiveness.\\nInduction Chemotherapy : Chemotherapy given as a first step to shrink a tumor before the main treatment.\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\nClinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\n\\nRelationships:-\\n1. Entity1: \""T3 requiring total laryngectomy\"", Entity2: \""Concurrent systemic therapy/RT\"", Relationship: \""treatment option\""\\n2. Entity1: \""T3 requiring total laryngectomy\"", Entity2: \""Induction chemotherapy\"", Relationship: \""treatment option\""\\n3. Entity1: \""T3 requiring total laryngectomy\"", Entity2: \""Clinical trials\"", Relationship: \""research option\""\\n\\nCausalities:-\\n<CO> T3 requiring (amenable to) total laryngectomy (N2\u20133) </CO> <A> Concurrent systemic therapy/RT </A> <A> Surgery </A> <A> Induction chemotherapy </A> <A> Clinical trials </A>\\n\\nSection Name: Surgical Considerations\\n====================\\nEntities:-\\nLaryngectomy : Surgical procedure to remove the larynx, often used to treat laryngeal cancer.\\nThyroidectomy : Surgical removal of all or part of the thyroid gland.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue in the neck.\\nLymph Node Excision : Surgical removal of one or more lymph nodes.\\nLymph Node Dissection : A surgical procedure to remove lymph nodes.\\nLymphadenectomy : Surgical removal of one or more groups of lymph nodes.\\n\\nRelationships:-\\n1. Entity1: \""Laryngectomy\"", Entity2: \""Thyroidectomy\"", Relationship: \""performed with\""\\n2. Entity1: \""Neck Dissection\"", Entity2: \""Lymph Node Excision\"", Relationship: \""includes\""\\n3. Entity1: \""Neck Dissection\"", Entity2: \""Lymph Node Excision\"", Relationship: \""includes specific types\""\\n\\nCausalities:-\\n<A> Laryngectomy with thyroidectomy as indicated, ipsilateral or bilateral neck dissection, and pretracheal and ipsilateral paratracheal lymph node dissection </A>\\n\\nSection Name: Pathologic Features\\n====================\\nEntities:-\\nExtranodal Extension : The spread of cancer beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margins : Cancer cells are found at the edge of the material removed during surgery, indicating that some cancer may have been left behind.\\nPositive Margin : A surgical margin that contains residual tumor cells.\\n\\nRelationships:-\\n1. Entity1: \""Adverse pathologic features\"", Entity2: \""Extranodal extension\"", Relationship: \""includes\""\\n2. Entity1: \""Adverse pathologic features\"", Entity2: \""Positive margin\"", Relationship: \""includes\""\\n\\nCausalities:-\\n- **No adverse pathologic features**\\n- **Adverse pathologic features**\\n  - <C> Extranodal extension and/or positive margin </C>\\n  - Other risk features\\n\\nSection Name: Systemic Therapy\\n====================\\nEntities:-\\nAntineoplastic Agents : Drugs used to treat cancer by inhibiting the growth of cancerous cells.\\nSystemic Therapy : A treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiotherapy : The use of radiation, usually high-energy X-rays, to damage cancer cells and treat cancer.\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\n\\nRelationships:-\\n1. Entity1: \""Systemic therapy\"", Entity2: \""RT\"", Relationship: \""Consideration\""\\n\\nCausalities:-\\n<A> Systemic therapy/RT (category 1) </A>\\n<A> RT </A>\\n<A> Consider systemic therapy/RT </A>\\n\\nSection Name: Imaging\\n====================\\nEntities:-\\nTomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.\\nMagnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body\\'s soft tissue and bones.\\nNeck : Part of the body, on many terrestrial or secondarily aquatic vertebrates, that distinguishes the head from the torso or trunk.\\nComputed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images (often called slices), both horizontally and vertically, of the body.\\nNeck Structure : The anatomical structure that connects the head to the torso.\\n\\nRelationships:-\\n1. Entity1: \""CT\"", Entity2: \""Neck\"", Relationship: \""imaging of\""\\n2. Entity1: \""MRI\"", Entity2: \""Neck\"", Relationship: \""imaging of\""\\n\\nCausalities:-\\n<A> CT (with contrast) or MRI (with and without contrast) of primary and neck </A>\\n\\nSection Name: Post-Treatment Evaluation\\n====================\\nEntities:-\\nRadiotherapy : The use of radiation, usually high-energy X-rays, to damage cancer cells and treat cancer.\\nPn1 Category : A pathological classification indicating regional lymph node metastasis in cancer staging.\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\n\\nRelationships:-\\n1. Entity1: \""Post Systemic Therapy/RT or RT Neck Evaluation\"", Entity2: \""pN1\"", Relationship: \""evaluation of cancer staging\""\\n2. Entity1: \""pN1\"", Entity2: \""Consider RT\"", Relationship: \""treatment recommendation\""\\n\\nCausalities:-\\n<CO> pN1 without other risk features </CO> <A> Consider RT </A>\\n\\nSection Name: Additional Notes\\n====================\\nEntities:-\\nAntineoplastic Combined Chemotherapy Protocols : Protocols for the administration of more than one antineoplastic agent in combination to treat malignant neoplasms.\\nCisplatin : A platinum-containing antineoplastic agent used in the treatment of various cancers.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Non-Nasopharyngeal Cancers\"", Relationship: \""used for\""\\n2. Entity1: \""Cisplatin\"", Entity2: \""Systemic Therapy\"", Relationship: \""preferred agent in\""\\n3. Entity1: \""Induction Chemotherapy\"", Entity2: \""Systemic Therapy\"", Relationship: \""discussed in context of\""\\n\\nCausalities:-\\n- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**\\n- **<CO> When using concurrent systemic therapy/RT </CO>, <A> the preferred agent is cisplatin (category 1) </A>. See Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A).**\\n- **<A> See Discussion on induction chemotherapy. </A>**\\n--------------------------------------------------\\nPage Number: 92\\n\\nSection Name: NCCN Guidelines Overview\\n====================\\nEntities:-\\nHead And Neck Neoplasms : Cancers that arise in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\nMalignant Neoplasm Of Head And Neck : A malignant tumor located in the head and neck region.\\nHead And Neck Cancer : A group of cancers that originate in the head and neck region.\\nAntineoplastic Agents : Drugs used to treat cancer by inhibiting the growth of cancerous cells.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.\\nRadiation Therapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.\\n\\nRelationships:-\\n1. Entity1: \""Head and neck cancers\"", Entity2: \""Systemic therapy\"", Relationship: \""follow-up recommendations after\""\\n2. Entity1: \""Head and neck cancers\"", Entity2: \""Radiation therapy\"", Relationship: \""follow-up recommendations after\""\\n\\nCausalities:-\\nThe image presents a flowchart from the National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2024, especially focusing on <A> follow-up recommendations </A> for <CO> patients with head and neck cancers after systemic therapy or radiation therapy (RT) </CO>. All recommendations are categorized as level A unless stated otherwise, highlighting the importance of clinical trials in cancer management.\\n\\nSection Name: Imaging and Assessment Protocols\\n====================\\nEntities:-\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.\\nClinical Assessment : A systematic evaluation of a patient\\'s health status, often involving a physical examination and medical history.\\nPositron-Emission Tomography : An imaging technique using a radioactive substance called a tracer to look for disease in the body.\\nComputed Tomography : A medical imaging technique used in radiology to obtain detailed internal images of the body.\\nMagnetic Resonance Imaging : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis.\\nDisease : A disorder of structure or function in a human, animal, or plant, especially one that produces specific symptoms.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\nResidual Neoplasm : Remaining cancer cells after treatment.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Clinical Assessment\"", Relationship: \""occurs before\""\\n2. Entity1: \""FDG-PET/CT Scan\"", Entity2: \""Distant Metastases\"", Relationship: \""assesses\""\\n3. Entity1: \""FDG-PET/CT Scan\"", Entity2: \""Observation\"", Relationship: \""leads to if negative\""\\n4. Entity1: \""FDG-PET/CT Scan\"", Entity2: \""CT Scan\"", Relationship: \""leads to if strongly positive\""\\n5. Entity1: \""CT Scan\"", Entity2: \""Neck Dissection\"", Relationship: \""leads to if positive\""\\n\\nCausalities:-\\n<CO> After systemic therapy or RT </CO>, <A> a clinical assessment should occur 4 to 8 weeks later </A>. <CO> If there is a response </CO>, <A> it is necessary to assess the extent of disease or distant metastases, preferably through a FDG-PET/CT scan at a minimum of 12 weeks post-treatment </A>. <CO> If the FDG-PET/CT results are negative </CO>, <A> the patient may continue with monitoring through observation </A>. <CO> In cases where the results are equivocal </CO>, <A> observation or repeat FDG-PET/CT within 3 to 6 months is prescribed </A>.\\n\\n<CO> In cases where the FDG-PET/CT results are strongly positive </CO>, <A> further imaging via CT scan with contrast of the primary site and neck, or MRI with and without contrast, becomes necessary </A>. <CO> If these imaging results confirm positive findings </CO>, <A> neck dissection may be considered, depending on the evidence of residual or persistent disease </A>. <CO> If the imaging findings are negative </CO>, <A> the patient might continue in observation </A>.\\n\\nSection Name: Outcomes Based on Disease Resectability\\n====================\\nEntities:-\\nDisease : A disorder of structure or function in a human, animal, or plant, especially one that produces specific symptoms.\\nResectable : Capable of being surgically removed.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis.\\n\\nRelationships:-\\n1. Entity1: \""Disease\"", Entity2: \""Resectable\"", Relationship: \""Classification\""\\n2. Entity1: \""Unresectable\"", Entity2: \""Treatment plans (ADV-3)\"", Relationship: \""Treatment recommendation\""\\n3. Entity1: \""Resectable\"", Entity2: \""Resection and/or Neck dissection\"", Relationship: \""Surgical procedure\""\\n\\nCausalities:-\\n<CO> If there is confirmed residual or persistent disease </CO>, the options split into two pathways: \\'Unresectable\\' or \\'Resectable.\\' <CO> If the disease is classified as unresectable </CO>, <A> advances in treatment plans (labeled ADV-3) are called for </A>. Conversely, <CO> if it is deemed resectable </CO>, <A> a resection of the primary and/or neck dissection may occur </A>, <CO> contingent upon the disease status </CO>.\\n\\nSection Name: Important Notes\\n====================\\nEntities:-\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\nClinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.\\nPositron-Emission Tomography : An imaging technique using a radioactive substance called a tracer to look for disease in the body.\\nPositron Emission Tomography (Procedure) : A diagnostic imaging procedure that uses a radioactive tracer to visualize and measure changes in metabolic processes.\\nPositron Emission Tomography : A nuclear medicine functional imaging technique used to observe metabolic processes in the body.\\nNeoplasms : New abnormal growth of tissue in animals or plants; a tumor.\\nMalignant Neoplasm : A cancerous growth that has the potential to spread to other parts of the body.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""NCCN\"", Entity2: \""Clinical trials\"", Relationship: \""emphasizes participation in\""\\n2. Entity1: \""FDG-PET/CT\"", Entity2: \""Persistent cancer\"", Relationship: \""used to detect\""\\n3. Entity1: \""FDG-PET/CT\"", Entity2: \""PET negative\"", Relationship: \""interpretation of results\""\\n4. Entity1: \""FDG-PET/CT\"", Entity2: \""PET positive\"", Relationship: \""interpretation of results\""\\n\\nCausalities:-\\n<A> NCCN emphasizes that the best management for any cancer patient is participation in clinical trials </A>, especially encouraged for all patients. Additional notes clarify that <CO> if the FDG-PET/CT is negative for persistent cancer </CO>, <A> further cross-sectional imaging is optional </A>. The interpretations define <CO> PET negative as no or low-grade uptake not suspicious for disease </CO>, while <CO> PET positive implies suspicion for disease </CO>.\\n'}""",valid,increases risk,2,B,"edge - The edge which needs to be verified.
explanation - Explanation of what the edge represents and its validity.
causal_direction - Either Positive or Negative or Unknown. A positive influence direction indicates that both factors change in the same direction (e.g. an increase causes an increase effect). A negative influence direction indicates the opposite changes (e.g. an increase causes a decrease effect).
causal_factor - Is necessary or sufficient condition for an effect to occur. Exposure is a term commonly used in epidemiology to denote any condition that is considered as a possible cause of disease. Exposure is considered necessary when it always precedes the effects (e.g. symptoms) and always presents when the effects occur. A sufficient cause is a causal factor whose presence or occurrence guarantees the occurrence of symptom.
causal_distance - Either Distal or Proximal or Unknown. The distal factors lie towards the beginning of causal chain (i.e. indirect causal factors). The the proximal factors lie towards the end of the chain (i.e. cause directly or almost directly the effect).

Causality Tags:
<A> for action, <C> for cause, <CO> for condition and <E> for effect.
Cause (C): The reason or origin that leads to an effect. Causes often involve disease conditions, risk factors, or underlying mechanisms.
Effect (E): The outcome or result of a cause. Effects usually represent clinical outcomes, complications, or results of a specific cause.
Condition (CO): The circumstance or prerequisite required for an action or effect to occur. Conditions may include patient characteristics, clinical scenarios, or specific diagnostic criteria.
Action (A): The recommended or described response or activity to address a cause or condition. Actions typically involve clinical interventions, diagnostic procedures, or treatment recommendations.


`NODE1`:
id: Presence_of_Metastasis_in_Lymph_Nodes_5
label: Metastasis in Nearby Lymph Nodes
description: This node represents the clinical situation regarding whether metastasis is present in the nearby lymph nodes of a patient. It is a critical factor in determining the stage and prognosis of cancer, as the spread of cancer to lymph nodes often indicates a more advanced disease and may influence treatment decisions.
type: Patient Situation
observability: Unobserved
states: [{'state_name': 'unknown', 'state_description': 'The status of metastasis in the lymph nodes is not determined. It is unclear whether cancer has spread to these nodes.'}, {'state_name': 'present', 'state_description': 'Metastasis is confirmed in the lymph nodes, indicating that cancer has spread to these nodes.'}, {'state_name': 'absent', 'state_description': 'There is no metastasis in the lymph nodes, indicating that cancer has not spread to these nodes.'}]

`NODE2`:
id: Computed_Tomography_CT_Scans_8
label: Computed Tomography (CT) Scans Examination Result
description: This node represents the result of a Computed Tomography (CT) scan, which is a diagnostic imaging procedure used to detect abnormalities or confirm the absence of disease in the body. The node indicates whether significant findings are present or absent based on the CT scan results.
type: Examination Result
observability: Observed
states: [{'state_name': 'present', 'state_description': 'The CT scan has detected significant findings, such as lesions, tumors, or other abnormalities.'}, {'state_name': 'absent', 'state_description': 'The CT scan did not detect any abnormalities or significant findings.'}]

`EDGE1`:
{'edges_ids': ['Presence_of_Metastasis_in_Lymph_Nodes_5', 'Computed_Tomography_CT_Scans_8'], 'edge': '(Presence_of_Metastasis_in_Lymph_Nodes_5) causes (Computed_Tomography_CT_Scans_8)', 'explanation': ['The edge represents the causal relationship where the presence of metastasis in lymph nodes leads to significant findings on a CT scan.', 'Metastasis in lymph nodes can cause changes detectable by CT scans, such as enlarged nodes or other abnormalities.', 'The causal direction is positive because the presence of metastasis leads to positive findings on the CT scan.', 'The presence of metastasis is a sufficient condition for the CT scan to show abnormalities related to metastasis, but not necessary as other conditions can also cause abnormalities.', 'The causal distance is proximal because the presence of metastasis directly affects the CT scan results.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': True}, 'causal_distance': 'Proximal'}

`EDGE2`:
{'edges_ids': ['Computed_Tomography_CT_Scans_8', 'Presence_of_Metastasis_in_Lymph_Nodes_5'], 'edge': '(Computed_Tomography_CT_Scans_8) causes (Presence_of_Metastasis_in_Lymph_Nodes_5)', 'explanation': ['The edge represents the idea that the result of a CT scan could cause the presence of metastasis in lymph nodes.', 'CT scans are diagnostic tools that detect existing conditions, such as metastasis, but do not cause them.', 'The presence of metastasis in lymph nodes is due to the spread of cancer, not the result of a CT scan.', 'Therefore, the edge is not valid as the CT scan does not cause metastasis.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}

`INFORMATION FROM KNOWLEDGE BASE`:
--------------------------------------------------
Page Number: 94

Section Name: Head and Neck Cancers - Principles of Imaging
====================
Entities:-
Positron Emission Tomography Computed Tomography : A medical imaging technique combining PET and CT capabilities to provide detailed information about the body's function and structure.
Positron Emission Tomography : A nuclear medicine functional imaging technique that is used to observe metabolic processes in the body.
Computed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.
Head And Neck Neoplasms : Cancers that arise in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.

Relationships:-
1. Entity1: ""PET/CT"", Entity2: ""PET scan"", Relationship: ""preferred over""
2. Entity1: ""PET-CT"", Entity2: ""head neck cancers"", Relationship: ""used in study of""

Causalities:-
<A> PET/CT is preferred over PET scan alone (i.e., without superimposed CT scan) </A>. <C> PET/CT provides more accurate anatomical localization of abnormalities </C> <E> more accurate anatomical localization of abnormalities </E>.

Section Name: Initial Workup - Nodal Metastases
====================
Entities:-
Lymphatic Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site via the lymphatic system.
Tomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient, producing signals that are processed by the machine's computer to generate cross-sectional images.
Magnetic Resonance Imaging : A non-invasive imaging technique that uses magnetic fields and radio waves to create detailed images of the organs and tissues within the body.
Positron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption.
Lymph Node Metastasis : The spread of cancer cells to lymph nodes, which are part of the lymphatic system.
Ct Of Neck : A computed tomography scan of the neck region.
Mri Of Neck : A magnetic resonance imaging scan of the neck region.
Fdg-Pet Scan : A type of positron emission tomography using fluorodeoxyglucose to assess metabolic activity.
Computed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.
Positron Emission Tomography : A nuclear medicine functional imaging technique that is used to observe metabolic processes in the body.

Relationships:-
1. Entity1: ""CT"", Entity2: ""lymph node metastases"", Relationship: ""used to evaluate""
2. Entity1: ""MRI"", Entity2: ""lymph node metastases"", Relationship: ""used to evaluate""
3. Entity1: ""FDG-PET/CT"", Entity2: ""lymph node metastases"", Relationship: ""used for detection""
4. Entity1: ""FDG-PET/CT"", Entity2: ""surgical primary approach"", Relationship: ""used to determine""
5. Entity1: ""FDG-PET/CT"", Entity2: ""definitive RT approach"", Relationship: ""used to identify""

Causalities:-
<A> Evaluation of lymph node metastases should be conducted with CT or MRI of the neck </A>, using whichever imaging study is suitable for primary site evaluation (IMG-A, 1 of 4).
<CO> For patients with multistation or lower neck nodal involvement or high-grade tumor histology </CO>, <A> consider CT of the chest to assess for mediastinal lymph node metastases or FDG-PET/CT </A>, <C> which is associated with higher sensitivity for both nodal and distant metastases </C>.
<CO> For patients who are under consideration for a surgical primary approach </CO>, <A> the higher sensitivity of FDG-PET/CT is warranted for tumors approaching the midline, to determine the surgical approach to the contralateral neck </A>. <CO> Similarly, patients who are scheduled for a definitive RT approach </CO> <A> may benefit from the higher sensitivity of FDG-PET/CT for identifying involved lymph nodes </A>.

Section Name: Initial Workup - Distant Metastases
====================
Entities:-
Positron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption.
Magnetic Resonance Imaging : A non-invasive imaging technique that uses magnetic fields and radio waves to create detailed images of the organs and tissues within the body.
Tomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient, producing signals that are processed by the machine's computer to generate cross-sectional images.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Lung Neoplasms : Tumors or cancer of the lung.
Smoking : The inhalation of the smoke of burning tobacco encased in cigarettes, pipes, and cigars.

Relationships:-
1. Entity1: ""FDG-PET/CT"", Entity2: ""Distant Metastases"", Relationship: ""used to evaluate""
2. Entity1: ""Contrast-enhanced brain MRI"", Entity2: ""Brain Metastasis"", Relationship: ""recommended for evaluation""
3. Entity1: ""CT of the chest"", Entity2: ""Pulmonary Metastases"", Relationship: ""performed to assess""
4. Entity1: ""Non-contrast CT of the chest"", Entity2: ""Lung Parenchymal Metastases"", Relationship: ""used to screen""
5. Entity1: ""Annual CT screening"", Entity2: ""Lung Metastasis"", Relationship: ""considered for high risk""
6. Entity1: ""Directed CT or MRI"", Entity2: ""Distant Disease"", Relationship: ""used for assessment""
7. Entity1: ""FDG-PET/CT"", Entity2: ""Recurrent Disease"", Relationship: ""used for staging""

Causalities:-
<C> Patients with locoregionally advanced cancer (e.g., T3–T4 primary or ≥N1 nodal staging) </C>, <A> FDG-PET/CT is preferred to evaluate for distant disease and thoracic metastases </A>. <CO> For cancers where brain metastasis is a concern, such as mucosal melanoma or high-grade neuroendocrine carcinomas or adenocarcinomas </CO>, <A> contrast-enhanced brain MRI should be additionally obtained </A>.
<CO> If FDG-PET/CT is not performed </CO>, <A> CT of the chest should be performed to assess for presence of pulmonary metastases as well as mediastinal lymph node involvement </A>.
<CO> Non-contrast CT of the chest can be sufficient to screen for lung parenchymal metastases </CO> but <CO> is not adequate for assessment of mediastinal adenopathy </CO>. <CO> This is an appropriate lung cancer screening intervention for patients with a history of smoking </CO>.
<CO> Following primary definitive treatment (surgery, RT, or systemic therapy/RT) </CO> the role of annual CT screening for lung metastasis is controversial. <E> While this approach does detect early metastasis </E>, <CO> further study is needed to determine the extent of the positive effect and/or cost-effectiveness of this approach in specific subpopulations and timepoints post-treatment </CO>. <CO> For patients with a substantial smoking history or who are at high risk for lung metastases </CO>, <A> annual chest CT can be considered </A>.
<CO> If clinical concern for metastatic disease is confined to a specific anatomical area </CO>, <A> the assessment of distant disease can be performed with directed CT or MRI examination </A>.
<CO> FDG-PET/CT may complement or replace other imaging modalities when staging recurrent disease before any therapy for relapsed/refractory disease </CO> <A> in order to explore distant disease or second primaries that may significantly impact choice of therapy </A>.
--------------------------------------------------
Page Number: 93

Section Name: PRINCIPLES OF IMAGING
====================
Entities:-
Imaging, Diagnostic : The production of a visual representation of parts of the body, for the purpose of clinical analysis and medical intervention.
Head And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Tomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.
Magnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body's soft tissue and bones.
Contrast Media : Substances used to enhance the contrast of structures or fluids within the body in medical imaging.

Relationships:-
1. Entity1: ""Imaging, Diagnostic"", Entity2: ""Head and Neck Neoplasms"", Relationship: ""used for""
2. Entity1: ""Tomography, X-Ray Computed"", Entity2: ""Contrast Media"", Relationship: ""uses""
3. Entity1: ""Magnetic Resonance Imaging"", Entity2: ""Contrast Media"", Relationship: ""uses""

Causalities:-
<C> Imaging </C> plays an essential role in the clinical care of patients with head and neck cancer. <A> The proper selection and utilization of imaging studies </A> is critical in caring for patients with head and neck cancer. <A> CT is performed with contrast </A>, while <A> CT imaging of the chest can be performed with or without contrast </A>, <CO> as clinically indicated </CO>. <A> MRI is performed with and without contrast </A>, <CO> unless contraindicated </CO>.

Section Name: Initial Workup - Primary Site
====================
Entities:-
Tomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.
Magnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body's soft tissue and bones.
Head And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Neck Structure : The anatomical structure of the neck, which is the part of the body that connects the head to the torso.
Skull Base : The bottom part of the skull, which separates the brain from other facial structures.
Thoracic Inlet : The opening at the top of the thoracic cavity, through which pass the trachea, esophagus, and major blood vessels.

Relationships:-
1. Entity1: ""CT"", Entity2: ""MRI"", Relationship: ""complementary in imaging head and neck cancers""
2. Entity1: ""CT"", Entity2: ""Head and Neck Neoplasms"", Relationship: ""used to evaluate""
3. Entity1: ""MRI"", Entity2: ""Head and Neck Neoplasms"", Relationship: ""preferred for evaluating""
4. Entity1: ""Skull base"", Entity2: ""Thoracic inlet"", Relationship: ""imaging range for evaluation""

Causalities:-
<A>Imaging assessment of the primary site</A> can be performed with <A>CT of the soft tissues of the neck</A> or <A>MRI of the neck</A>. <C>CT is complementary to MRI for head and neck cancers</C>. <A>It is utilized to evaluate cortical bone erosion or periosteal invasion, cartilage invasion, and bony erosion or destruction</A>. <CO>in certain conditions, such as evaluating the extent of bone marrow invasion or in patients with extensive dental amalgam obscuring anatomy on CT, assessing skull base invasion and cranial nerve involvement, and differentiating tumor from obstructed sinuses</CO>, <A>MRI is preferred over CT</A>. <CO>when involved lymph nodes or upper mediastinal cancers are present</CO>, <A>Complete evaluation of primary and nodal disease requires imaging from the skull base to the thoracic inlet, extending to the carina</A>.

Section Name: PET/CT and Biopsy
====================
Entities:-
Positron Emission Tomography Computed Tomography : A medical imaging technique that combines PET and CT capabilities to provide detailed images of the body.
Examination Under Anesthesia : A procedure where a patient is examined while under anesthesia to allow for a more thorough examination.
Biopsy : A medical test involving the extraction of sample cells or tissues for examination to determine the presence or extent of a disease.
Tonsillectomy : A surgical procedure to remove the tonsils, often performed to treat recurrent tonsillitis or sleep apnea.
Fine Needle Aspiration : A type of biopsy procedure that uses a thin, hollow needle to extract cells from a lump or mass for examination.
Ultrasound : A medical imaging technique that uses high-frequency sound waves to visualize internal organs and structures.
Computed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.

Relationships:-
1. Entity1: ""PET/CT"", Entity2: ""EUA"", Relationship: ""recommended before""
2. Entity1: ""Fine Needle Aspiration (FNA)"", Entity2: ""metastatic nodes"", Relationship: ""used for biopsy of""
3. Entity1: ""Image-guided needle biopsy"", Entity2: ""cystic neck nodes"", Relationship: ""recommended for initial diagnosis of""

Causalities:-
<CO> If imaging does not reveal an obvious primary cancer </CO>, <A> a PET/CT should be ordered before EUA, biopsies, and tonsillectomy </A>. <E> This helps identify potential primary sites </E> before any interventions take place. Additionally, <A> Fine Needle Aspiration (FNA) biopsy of metastatic nodes </A> <E> may provide pathologically informative results </E>. <CO> For initial diagnosis in cystic neck nodes </CO>, <A> image-guided needle biopsy (ultrasound or CT) </A> <E> may yield better results than FNA by palpation alone </E>.

Section Name: Postoperative Imaging Advice
====================
Entities:-
Panoramic Radiography : A type of dental x-ray that provides a wide view of the upper and lower jaws, teeth, temporomandibular joints, and sinuses.
Oral Cavity : The cavity of the mouth, including the lips, the lining inside the cheeks and lips, the front two-thirds of the tongue, the gums, the floor of the mouth under the tongue, the hard palate, and the small area of the gum behind the wisdom teeth.
Radiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.
Mandibulotomy : A surgical procedure involving the cutting of the mandible.
Mandibulectomy : A surgical procedure involving the removal of part or all of the mandible.
Oropharynx : The part of the throat at the back of the mouth behind the oral cavity.

Relationships:-
1. Entity1: ""panoramic dental x-ray"", Entity2: ""oral cavity cancers"", Relationship: ""recommended for""
2. Entity1: ""panoramic dental x-ray"", Entity2: ""postoperative radiotherapy"", Relationship: ""essential for pre-radiation evaluation""
3. Entity1: ""pre-radiation dental evaluation"", Entity2: ""dental procedures or extractions"", Relationship: ""determine necessity of""

Causalities:-
<A> A panoramic dental x-ray is recommended </A> <C> for oral cavity cancers requiring mandibulotomy and/or mandibulectomy </C>. <CO> When postoperative radiotherapy (RT) is anticipated for areas like the lip, oral cavity subsites, or oropharynx </CO>, <A> panoramic x-ray is essential for a comprehensive pre-radiation dental evaluation </A> <E> to assess the health of affected teeth and determine if pre-radiation dental procedures or extractions are necessary </E>.

Section Name: NCCN Guidelines Note
====================
Entities:-
Neoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.
Malignant Neoplastic Disease : A disease characterized by uncontrolled, abnormal growth of cells that can invade or spread to other parts of the body.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.
Clinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.
Clinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.

Relationships:-
1. Entity1: ""NCCN"", Entity2: ""Clinical Trials"", Relationship: ""encourages participation in""
2. Entity1: ""NCCN"", Entity2: ""Cancer"", Relationship: ""recommends clinical trials for""

Causalities:-
<A> NCCN believes that the best management of any patient with cancer is through participation in clinical trials </A>, <A> which is especially encouraged </A>.
--------------------------------------------------
Page Number: 41

Section Name: Workup
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.
History And Physical Examination : A comprehensive assessment of a patient's medical history and physical condition.
Tobacco Smoking : The act of smoking tobacco products, which is a risk factor for many diseases.
Alcohol Drinking : The consumption of beverages containing ethyl alcohol.
Smoking Cessation : The process of discontinuing tobacco smoking.
Biopsy : A medical test involving the extraction of sample cells or tissues for examination.
Laryngoscopy : A procedure to examine the larynx, often using a scope.
Computed Tomography (Ct) : A diagnostic imaging procedure that uses computer-processed combinations of many X-ray measurements taken from different angles to produce cross-sectional images of specific areas of a scanned object.
Magnetic Resonance Imaging (Mri) : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.
Positron-Emission Tomography : A type of nuclear medicine imaging that measures metabolic activity of the cells of body tissues.
Pulmonary Function Test : Tests that measure how well the lungs are working.
Dental Examination : An evaluation of the teeth and gums to assess oral health.
Nutritional Support : Therapies to provide nutrition to patients who cannot obtain nutrition by mouth.
Speech Therapy : Therapy to improve speech and communication skills.
Swallowing Therapy : Therapy to help individuals with swallowing difficulties.
Multidisciplinary Care Team : A group of healthcare professionals from different specialties working together to manage patient care.

Relationships:-
1. Entity1: ""glottic larynx cancer"", Entity2: ""history and physical examination"", Relationship: ""initial diagnostic step""
2. Entity1: ""glottic larynx cancer"", Entity2: ""biopsy"", Relationship: ""required diagnostic procedure""
3. Entity1: ""glottic larynx cancer"", Entity2: ""direct laryngoscopy"", Relationship: ""recommended procedure""
4. Entity1: ""glottic larynx cancer"", Entity2: ""CT scans"", Relationship: ""imaging study""
5. Entity1: ""glottic larynx cancer"", Entity2: ""MRI"", Relationship: ""imaging study""
6. Entity1: ""glottic larynx cancer"", Entity2: ""multidisciplinary consultation"", Relationship: ""advised as clinically indicated""

Causalities:-
The workup section outlines the initial steps for diagnosing <C>glottic larynx cancer</C>. It includes <A>a comprehensive history and physical examination (H&P)</A>, which should document tobacco and alcohol use, and provide counseling for smoking cessation. <A>A biopsy of the primary site is required</A>, and <A>direct laryngoscopy under anesthesia is generally recommended</A>. <A>Imaging studies such as CT scans with contrast and possibly MRI are used to evaluate the larynx and neck</A>. Additional evaluations may include <A>chest CT, FDG-PET/CT, pulmonary function tests, dental evaluation, and nutrition, speech, and swallowing therapy</A>. <A>Multidisciplinary consultation is advised</A> <CO>as clinically indicated</CO>.

Section Name: Clinical Staging
====================
Entities:-
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.
Carcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.
Biopsy : A medical test involving the extraction of sample cells or tissues for examination.
Laryngectomy : A surgical procedure to remove the larynx.

Relationships:-
1. Entity1: ""Clinical staging"", Entity2: ""Cancer"", Relationship: ""involves""
2. Entity1: ""Carcinoma in situ"", Entity2: ""Stages T1-T4"", Relationship: ""is a stage of""
3. Entity1: ""Biopsy"", Entity2: ""Cancer"", Relationship: ""used in staging""
4. Entity1: ""Larynx-preserving surgeries"", Entity2: ""Stages T1-T2"", Relationship: ""considered for""
5. Entity1: ""Total laryngectomy"", Entity2: ""Stages T3-T4"", Relationship: ""required for""

Causalities:-
<C> Clinical staging involves categorizing the cancer based on its aggressiveness </C>. It starts with carcinoma in situ, which is non-invasive, and progresses through stages T1-T4. <CO> Staging is based on H&P, biopsy, and imaging studies </CO>. <CO> For T1-T2 </CO>, <A> larynx-preserving surgeries are considered </A>, while <CO> more advanced stages like T3 or T4 </CO> <A> may require total laryngectomy </A>. <A> Additional evaluations such as videostrobe, audiogram, and fertility counseling may be considered </A>.

Section Name: Treatment
====================
Entities:-
Carcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.
Laryngectomy : A surgical procedure to remove the larynx.
Metastasis : The transfer of a disease from one organ or part to another not directly connected with it.
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.

Relationships:-
1. Entity1: ""Carcinoma in situ"", Entity2: ""Larynx-preserving surgery"", Relationship: ""treated with""
2. Entity1: ""T1-T2 stages"", Entity2: ""Conservation surgery"", Relationship: ""treated with""
3. Entity1: ""T3 stages"", Entity2: ""Total laryngectomy"", Relationship: ""may require""
4. Entity1: ""T4a disease"", Entity2: ""Complex interventions"", Relationship: ""require""
5. Entity1: ""Guidelines"", Entity2: ""Multidisciplinary consultations"", Relationship: ""emphasize importance of""
6. Entity1: ""Guidelines"", Entity2: ""Clinical trials"", Relationship: ""consider as best option""

Causalities:-
<CO>Treatment recommendations vary by stage</CO>. <CO>Carcinoma in situ</CO> <A>may be treated with larynx-preserving surgery</A>. <CO>T1-T2 stages</CO> <A>may also be amenable to conservation surgery</A>. <CO>T3 stages</CO> <A>may require total laryngectomy</A>, <CO>especially if nodal involvement is present</CO>. <CO>T4a disease and unresectable or metastatic cases</CO> <A>require more complex interventions</A>. <A>The guidelines emphasize the importance of multidisciplinary consultations</A> and <A>consider clinical trials as the best management option</A>.

Section Name: Additional Notes
====================
Entities:-
Biopsy, Needle : A procedure to remove a small sample of tissue for examination under a microscope.
Image-Guided Biopsy : A biopsy procedure that uses imaging techniques to guide the needle to the precise location of the tissue to be sampled.
Biopsy : A medical test involving the extraction of sample cells or tissues for examination.
Diagnostic Techniques And Procedures : Methods and procedures for the diagnosis of disease or dysfunction.
Imaging : The process of producing images of the body for clinical purposes.
Dental Care : The total of dental diagnostic, preventive, and corrective procedures.
Nutritional Physiological Phenomena : The functions and properties of nutrients in living organisms.
Fertility : The capacity to conceive or induce conception.
Reproductive Health : A state of physical, mental, and social well-being in all matters relating to the reproductive system.
Lymphatic Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Glottis : The part of the larynx consisting of the vocal cords and the opening between them.

Relationships:-
1. Entity1: ""image-guided needle biopsy"", Entity2: ""diagnostic yield"", Relationship: ""used for""
2. Entity1: ""nodal disease"", Entity2: ""glottic tumors"", Relationship: ""is rare in""

Causalities:-
<A> use of image-guided needle biopsy </A> for <E> better diagnostic yield </E>, principles of imaging, dental evaluation, and nutrition management. The guidelines also address fertility and reproductive considerations, and note that <CO> nodal disease in glottic tumors is rare </CO>.
--------------------------------------------------
Page Number: 44

Section Name: Flowchart Structure
====================
Entities:-
Neoplasm Staging : Methods used for staging neoplasms based on extent of tumor spread according to standardized criteria.
Laryngectomy : Surgical procedure to remove the larynx, often used to treat laryngeal cancer.
Chemotherapy, Adjuvant : Drug therapy given in addition to the primary treatment to enhance its effectiveness.
Radiotherapy : The use of radiation, usually high-energy X-rays, to damage cancer cells and treat cancer.
Tomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.
Magnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body's soft tissue and bones.
Neoplasm Recurrence, Local : The return of a tumor at the original site after treatment.

Relationships:-
1. Entity1: ""Clinical Staging"", Entity2: ""T3 tumors"", Relationship: ""determines treatment approach""
2. Entity1: ""Adverse Pathologic Features"", Entity2: ""Systemic Therapy"", Relationship: ""directs to""
3. Entity1: ""Adverse Pathologic Features"", Entity2: ""Radiation Treatment"", Relationship: ""directs to""
4. Entity1: ""Induction Chemotherapy"", Entity2: ""Imaging (CT or MRI)"", Relationship: ""leads to""

Causalities:-
1. <A> The flow begins with the clinical staging of T3 tumors </A> <C> that require total laryngectomy (N2–3) </C>. <CO> This staging </CO> <E> is crucial for determining the appropriate therapeutic approach </E>.

2. The flowchart provides multiple pathways for treatment, indicating that <CO> patients </CO> <A> may undergo either ""Concurrent systemic therapy/RT"" or ""Surgery"" </A>. There is also an <A> option for ""Induction chemotherapy,"" leading to further imaging (CT or MRI) to assess the primary site and neck status </A>.

3. For <CO> patients who have surgery </CO>, the flowchart distinguishes between those with adverse pathologic features and those without. <CO> Patients with adverse features—such as extranodal extension or positive margins </CO>—are <A> directed toward systemic therapy or radiation treatment </A>, while those without may follow a different management path.

4. The flowchart concludes by <A> outlining follow-up procedures for recurrent or persistent disease </A>, suggesting additional assessments and treatments based on the risk features identified during earlier stages.

Section Name: Detailed Explanation
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.
Adverse Pathological Feature : A pathological feature that indicates a worse prognosis or outcome.
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.

Relationships:-
1. Entity1: ""Systemic therapy"", Entity2: ""Radiation"", Relationship: ""Concurrent treatment""
2. Entity1: ""Clinical trials"", Entity2: ""Personalized treatment plans"", Relationship: ""Development of""

Causalities:-
<A> The flowchart is designed to provide healthcare professionals with a systematic pathway for managing glottic larynx cancer </A>. Each step is meticulously organized to ensure that important factors are considered, such as <C> the presence of adverse pathological features </C>, which <E> strongly influence treatment decisions </E>.

<A> The emphasis on concurrent treatments, such as systemic therapy combined with radiation </A>, reflects current best practices in oncology, where multimodal approaches are often necessary to achieve better outcomes. <A> The inclusion of clinical trials </A> indicates an emphasis on maintaining up-to-date practices and personalized treatment plans as part of patient management strategies.

Furthermore, <A> the chart's organization into treatment and follow-up segments </A> allows for a straightforward interpretation, guiding oncologists through complex decisions in a logical manner. This can <E> improve consistency in care and enhance patient safety through meticulous monitoring and responses to treatment efficacy or disease progression </E>.

In summary, <E> this flowchart serves as an essential resource for oncologists, facilitating a better understanding of treatment protocols for glottic larynx cancer while promoting a patient-centered approach to oncological care </E>.

Section Name: NCCN Guidelines Version 4.2024
====================
Entities:-
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.
Clinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Neoplasms : New abnormal growth of tissue that may be benign or malignant.
Malignant Neoplastic Disease : A disease in which abnormal cells divide uncontrollably and destroy body tissue.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.
National Comprehensive Cancer Network : An alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network"", Entity2: ""NCCN Guidelines"", Relationship: ""publishes""
2. Entity1: ""Clinical trial"", Entity2: ""Cancer"", Relationship: ""manages""

Causalities:-
<C> any patient with cancer </C> <E> the best management is in a clinical trial </E>. <A> Participation in clinical trials is especially encouraged </A>.

Section Name: Principles of Treatment
====================
Entities:-
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Extranodal Extension : The spread of cancer beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margins : Cancer cells are found at the edge of the material removed during surgery, indicating that some cancer may have been left behind.
Perineural Invasion : Cancer cells are found surrounding or tracking along a nerve within the perineural space.
Vascular Invasion : The presence of cancer cells within blood vessels.
Lymphatic Metastasis : The spread of cancer cells through the lymphatic system to distant sites.

Relationships:-
1. Entity1: ""Principles of Radiation Therapy"", Entity2: ""Extranodal Extension"", Relationship: ""management of""
2. Entity1: ""Principles of Surgery"", Entity2: ""Positive Surgical Margins"", Relationship: ""concerned with avoiding""
3. Entity1: ""Principles of Radiation Therapy"", Entity2: ""Perineural Invasion"", Relationship: ""consideration in treatment planning""

Causalities:-
<C> Extranodal extension </C> <C> Positive margins </C> <C> Close margins </C> <C> pT4 primary </C> <C> pN2 or pN3 nodal disease </C> <C> Perineural invasion </C> <C> Vascular invasion </C> <C> Lymphatic invasion </C> <C> Subglottic extension </C>

Section Name: Clinical Staging
====================
Entities:-
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to enhance its effectiveness.
Adjuvant Therapy : A therapy given in addition to the primary or initial therapy to maximize its effectiveness.
Follow-Up Studies : Studies that continue to monitor patients after treatment to assess long-term outcomes.
Follow-Up Procedure : A procedure performed to monitor the progress of a patient after initial treatment.
Follow-Up : The act of monitoring a patient's health over time after treatment.
Neoplasm Recurrence, Local : The return of a tumor at the original site after treatment.
Recurrent Disease : A disease that has returned after a period of remission.

Relationships:-
1. Entity1: ""Adjuvant Treatment"", Entity2: ""Recurrent or Persistent Disease"", Relationship: ""prevention""
2. Entity1: ""Follow-up"", Entity2: ""Recurrent or Persistent Disease"", Relationship: ""monitoring""

Section Name: Treatment Options
====================
Entities:-
Laryngectomy : Surgical procedure to remove the larynx, often used to treat laryngeal cancer.
Total Laryngectomy : A surgical procedure to remove the entire larynx.
Chemotherapy, Adjuvant : Drug therapy given in addition to the primary treatment to enhance its effectiveness.
Induction Chemotherapy : Chemotherapy given as a first step to shrink a tumor before the main treatment.
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.
Clinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.

Relationships:-
1. Entity1: ""T3 requiring total laryngectomy"", Entity2: ""Concurrent systemic therapy/RT"", Relationship: ""treatment option""
2. Entity1: ""T3 requiring total laryngectomy"", Entity2: ""Induction chemotherapy"", Relationship: ""treatment option""
3. Entity1: ""T3 requiring total laryngectomy"", Entity2: ""Clinical trials"", Relationship: ""research option""

Causalities:-
<CO> T3 requiring (amenable to) total laryngectomy (N2–3) </CO> <A> Concurrent systemic therapy/RT </A> <A> Surgery </A> <A> Induction chemotherapy </A> <A> Clinical trials </A>

Section Name: Surgical Considerations
====================
Entities:-
Laryngectomy : Surgical procedure to remove the larynx, often used to treat laryngeal cancer.
Thyroidectomy : Surgical removal of all or part of the thyroid gland.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue in the neck.
Lymph Node Excision : Surgical removal of one or more lymph nodes.
Lymph Node Dissection : A surgical procedure to remove lymph nodes.
Lymphadenectomy : Surgical removal of one or more groups of lymph nodes.

Relationships:-
1. Entity1: ""Laryngectomy"", Entity2: ""Thyroidectomy"", Relationship: ""performed with""
2. Entity1: ""Neck Dissection"", Entity2: ""Lymph Node Excision"", Relationship: ""includes""
3. Entity1: ""Neck Dissection"", Entity2: ""Lymph Node Excision"", Relationship: ""includes specific types""

Causalities:-
<A> Laryngectomy with thyroidectomy as indicated, ipsilateral or bilateral neck dissection, and pretracheal and ipsilateral paratracheal lymph node dissection </A>

Section Name: Pathologic Features
====================
Entities:-
Extranodal Extension : The spread of cancer beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margins : Cancer cells are found at the edge of the material removed during surgery, indicating that some cancer may have been left behind.
Positive Margin : A surgical margin that contains residual tumor cells.

Relationships:-
1. Entity1: ""Adverse pathologic features"", Entity2: ""Extranodal extension"", Relationship: ""includes""
2. Entity1: ""Adverse pathologic features"", Entity2: ""Positive margin"", Relationship: ""includes""

Causalities:-
- **No adverse pathologic features**
- **Adverse pathologic features**
  - <C> Extranodal extension and/or positive margin </C>
  - Other risk features

Section Name: Systemic Therapy
====================
Entities:-
Antineoplastic Agents : Drugs used to treat cancer by inhibiting the growth of cancerous cells.
Systemic Therapy : A treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiotherapy : The use of radiation, usually high-energy X-rays, to damage cancer cells and treat cancer.
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.

Relationships:-
1. Entity1: ""Systemic therapy"", Entity2: ""RT"", Relationship: ""Consideration""

Causalities:-
<A> Systemic therapy/RT (category 1) </A>
<A> RT </A>
<A> Consider systemic therapy/RT </A>

Section Name: Imaging
====================
Entities:-
Tomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.
Magnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body's soft tissue and bones.
Neck : Part of the body, on many terrestrial or secondarily aquatic vertebrates, that distinguishes the head from the torso or trunk.
Computed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images (often called slices), both horizontally and vertically, of the body.
Neck Structure : The anatomical structure that connects the head to the torso.

Relationships:-
1. Entity1: ""CT"", Entity2: ""Neck"", Relationship: ""imaging of""
2. Entity1: ""MRI"", Entity2: ""Neck"", Relationship: ""imaging of""

Causalities:-
<A> CT (with contrast) or MRI (with and without contrast) of primary and neck </A>

Section Name: Post-Treatment Evaluation
====================
Entities:-
Radiotherapy : The use of radiation, usually high-energy X-rays, to damage cancer cells and treat cancer.
Pn1 Category : A pathological classification indicating regional lymph node metastasis in cancer staging.
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.

Relationships:-
1. Entity1: ""Post Systemic Therapy/RT or RT Neck Evaluation"", Entity2: ""pN1"", Relationship: ""evaluation of cancer staging""
2. Entity1: ""pN1"", Entity2: ""Consider RT"", Relationship: ""treatment recommendation""

Causalities:-
<CO> pN1 without other risk features </CO> <A> Consider RT </A>

Section Name: Additional Notes
====================
Entities:-
Antineoplastic Combined Chemotherapy Protocols : Protocols for the administration of more than one antineoplastic agent in combination to treat malignant neoplasms.
Cisplatin : A platinum-containing antineoplastic agent used in the treatment of various cancers.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Non-Nasopharyngeal Cancers"", Relationship: ""used for""
2. Entity1: ""Cisplatin"", Entity2: ""Systemic Therapy"", Relationship: ""preferred agent in""
3. Entity1: ""Induction Chemotherapy"", Entity2: ""Systemic Therapy"", Relationship: ""discussed in context of""

Causalities:-
- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**
- **<CO> When using concurrent systemic therapy/RT </CO>, <A> the preferred agent is cisplatin (category 1) </A>. See Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A).**
- **<A> See Discussion on induction chemotherapy. </A>**
--------------------------------------------------
Page Number: 92

Section Name: NCCN Guidelines Overview
====================
Entities:-
Head And Neck Neoplasms : Cancers that arise in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Malignant Neoplasm Of Head And Neck : A malignant tumor located in the head and neck region.
Head And Neck Cancer : A group of cancers that originate in the head and neck region.
Antineoplastic Agents : Drugs used to treat cancer by inhibiting the growth of cancerous cells.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.
Radiation Therapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.

Relationships:-
1. Entity1: ""Head and neck cancers"", Entity2: ""Systemic therapy"", Relationship: ""follow-up recommendations after""
2. Entity1: ""Head and neck cancers"", Entity2: ""Radiation therapy"", Relationship: ""follow-up recommendations after""

Causalities:-
The image presents a flowchart from the National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2024, especially focusing on <A> follow-up recommendations </A> for <CO> patients with head and neck cancers after systemic therapy or radiation therapy (RT) </CO>. All recommendations are categorized as level A unless stated otherwise, highlighting the importance of clinical trials in cancer management.

Section Name: Imaging and Assessment Protocols
====================
Entities:-
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.
Clinical Assessment : A systematic evaluation of a patient's health status, often involving a physical examination and medical history.
Positron-Emission Tomography : An imaging technique using a radioactive substance called a tracer to look for disease in the body.
Computed Tomography : A medical imaging technique used in radiology to obtain detailed internal images of the body.
Magnetic Resonance Imaging : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis.
Disease : A disorder of structure or function in a human, animal, or plant, especially one that produces specific symptoms.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.
Residual Neoplasm : Remaining cancer cells after treatment.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Clinical Assessment"", Relationship: ""occurs before""
2. Entity1: ""FDG-PET/CT Scan"", Entity2: ""Distant Metastases"", Relationship: ""assesses""
3. Entity1: ""FDG-PET/CT Scan"", Entity2: ""Observation"", Relationship: ""leads to if negative""
4. Entity1: ""FDG-PET/CT Scan"", Entity2: ""CT Scan"", Relationship: ""leads to if strongly positive""
5. Entity1: ""CT Scan"", Entity2: ""Neck Dissection"", Relationship: ""leads to if positive""

Causalities:-
<CO> After systemic therapy or RT </CO>, <A> a clinical assessment should occur 4 to 8 weeks later </A>. <CO> If there is a response </CO>, <A> it is necessary to assess the extent of disease or distant metastases, preferably through a FDG-PET/CT scan at a minimum of 12 weeks post-treatment </A>. <CO> If the FDG-PET/CT results are negative </CO>, <A> the patient may continue with monitoring through observation </A>. <CO> In cases where the results are equivocal </CO>, <A> observation or repeat FDG-PET/CT within 3 to 6 months is prescribed </A>.

<CO> In cases where the FDG-PET/CT results are strongly positive </CO>, <A> further imaging via CT scan with contrast of the primary site and neck, or MRI with and without contrast, becomes necessary </A>. <CO> If these imaging results confirm positive findings </CO>, <A> neck dissection may be considered, depending on the evidence of residual or persistent disease </A>. <CO> If the imaging findings are negative </CO>, <A> the patient might continue in observation </A>.

Section Name: Outcomes Based on Disease Resectability
====================
Entities:-
Disease : A disorder of structure or function in a human, animal, or plant, especially one that produces specific symptoms.
Resectable : Capable of being surgically removed.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis.

Relationships:-
1. Entity1: ""Disease"", Entity2: ""Resectable"", Relationship: ""Classification""
2. Entity1: ""Unresectable"", Entity2: ""Treatment plans (ADV-3)"", Relationship: ""Treatment recommendation""
3. Entity1: ""Resectable"", Entity2: ""Resection and/or Neck dissection"", Relationship: ""Surgical procedure""

Causalities:-
<CO> If there is confirmed residual or persistent disease </CO>, the options split into two pathways: 'Unresectable' or 'Resectable.' <CO> If the disease is classified as unresectable </CO>, <A> advances in treatment plans (labeled ADV-3) are called for </A>. Conversely, <CO> if it is deemed resectable </CO>, <A> a resection of the primary and/or neck dissection may occur </A>, <CO> contingent upon the disease status </CO>.

Section Name: Important Notes
====================
Entities:-
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.
Clinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.
Positron-Emission Tomography : An imaging technique using a radioactive substance called a tracer to look for disease in the body.
Positron Emission Tomography (Procedure) : A diagnostic imaging procedure that uses a radioactive tracer to visualize and measure changes in metabolic processes.
Positron Emission Tomography : A nuclear medicine functional imaging technique used to observe metabolic processes in the body.
Neoplasms : New abnormal growth of tissue in animals or plants; a tumor.
Malignant Neoplasm : A cancerous growth that has the potential to spread to other parts of the body.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""NCCN"", Entity2: ""Clinical trials"", Relationship: ""emphasizes participation in""
2. Entity1: ""FDG-PET/CT"", Entity2: ""Persistent cancer"", Relationship: ""used to detect""
3. Entity1: ""FDG-PET/CT"", Entity2: ""PET negative"", Relationship: ""interpretation of results""
4. Entity1: ""FDG-PET/CT"", Entity2: ""PET positive"", Relationship: ""interpretation of results""

Causalities:-
<A> NCCN emphasizes that the best management for any cancer patient is participation in clinical trials </A>, especially encouraged for all patients. Additional notes clarify that <CO> if the FDG-PET/CT is negative for persistent cancer </CO>, <A> further cross-sectional imaging is optional </A>. The interpretations define <CO> PET negative as no or low-grade uptake not suspicious for disease </CO>, while <CO> PET positive implies suspicion for disease </CO>.


Among these two options which one is the most likely true:

(A) `Presence_of_Metastasis_in_Lymph_Nodes_5` increases risk `Computed_Tomography_CT_Scans_8`
(B) `Computed_Tomography_CT_Scans_8` `increases risk `Presence_of_Metastasis_in_Lymph_Nodes_5`

The answer is: ...

1. State the evidences in detail of the validity of option (A) or (B) by cross referencing
NCCN Clinical Practitioner’s Guidelines for Head and Neck Cancer.
2. If the evidences are obtained from `INFORMATION FROM KNOWLEDGE BASE`,
mention their corresponding Page Numbers, Section Name, entities, relationships and causalities.

DESIRED OUTPUT FORMAT:
<thinking>
...
</thinking>
<answer>
{
   ""thinking"": [""..."", ...],
   ""evidences"": [""..."", ...],
   ""answer"": ...
}
</answer>

Before providing the answer in <answer> tags, think step by step in detail in <thinking> tags and analyze every part.
Output inside <answer> tag in JSON format. Only output valid JSON.
DO NOT HALLUCINATE. DO NOT MAKE UP FACTUAL INFORMATION.
","1. The edge (A) suggests that the presence of metastasis in lymph nodes leads to significant findings on a CT scan. This is a logical causal relationship because metastasis in lymph nodes can cause changes detectable by CT scans, such as enlarged nodes or other abnormalities.
2. The edge (B) suggests that the result of a CT scan could cause the presence of metastasis in lymph nodes. This is not a valid causal relationship because CT scans are diagnostic tools that detect existing conditions, such as metastasis, but do not cause them.
3. The causal direction for edge (A) is positive because the presence of metastasis leads to positive findings on the CT scan. The presence of metastasis is a sufficient condition for the CT scan to show abnormalities related to metastasis, but not necessary as other conditions can also cause abnormalities.
4. The causal distance for edge (A) is proximal because the presence of metastasis directly affects the CT scan results.
5. The causal direction for edge (B) is unknown, and the causal factor is neither necessary nor sufficient, indicating that the edge is not valid.
6. From the INFORMATION FROM KNOWLEDGE BASE, it is clear that CT scans are used to evaluate lymph node metastases, but they do not cause metastasis. This supports the validity of edge (A) and invalidates edge (B).
7. Page 94, Section Name: Initial Workup - Nodal Metastases, states that CT is used to evaluate lymph node metastases, supporting the causal relationship in edge (A).
8. Page 93, Section Name: Principles of Imaging, mentions that CT is used for imaging head and neck neoplasms, further supporting the diagnostic role of CT scans.
","1. Page 94, Section Name: Initial Workup - Nodal Metastases, Entity1: 'CT', Entity2: 'lymph node metastases', Relationship: 'used to evaluate'.
2. Page 93, Section Name: Principles of Imaging, Entity1: 'CT', Entity2: 'Head and Neck Neoplasms', Relationship: 'used to evaluate'.
",A,"{'A': 100.0, 'B': 0.0}",yes,A,"1. The AI assistant's reasoning for option (A) is consistent with the information provided. It correctly identifies that the presence of metastasis in lymph nodes can lead to significant findings on a CT scan, which is a logical causal relationship. This is supported by the explanation that metastasis can cause changes detectable by CT scans, such as enlarged nodes or other abnormalities.
2. The assistant also correctly identifies that the causal direction for edge (A) is positive, as the presence of metastasis leads to positive findings on the CT scan. The causal factor is sufficient but not necessary, which aligns with the explanation provided.
3. The causal distance for edge (A) is proximal, indicating a direct effect on the CT scan results, which is consistent with the explanation.
4. The assistant's reasoning for option (B) is also consistent with the information provided. It correctly identifies that a CT scan cannot cause metastasis, as CT scans are diagnostic tools that detect existing conditions. This invalidates edge (B).
5. The assistant correctly references the INFORMATION FROM KNOWLEDGE BASE, which supports the validity of edge (A) and invalidates edge (B). The references to Page 94 and Page 93 provide evidence that CT scans are used to evaluate lymph node metastases, supporting the causal relationship in edge (A).
6. Overall, the assistant's reasoning is consistent with the information provided, and the final answer (A) is supported by the reasoning.
"
1,gpt-4o,"Presence_of_Metastasis_in_Lymph_Nodes_5,Magnetic_Resonance_Imaging_MRI_9","""{'NODE1': {'id': 'Presence_of_Metastasis_in_Lymph_Nodes_5', 'label': 'Metastasis in Nearby Lymph Nodes', 'description': 'This node represents the clinical situation regarding whether metastasis is present in the nearby lymph nodes of a patient. It is a critical factor in determining the stage and prognosis of cancer, as the spread of cancer to lymph nodes often indicates a more advanced disease and may influence treatment decisions.', 'type': 'Patient Situation', 'observability': 'Unobserved', 'states': [{'state_name': 'unknown', 'state_description': 'The status of metastasis in the lymph nodes is not determined. It is unclear whether cancer has spread to these nodes.'}, {'state_name': 'present', 'state_description': 'Metastasis is confirmed in the lymph nodes, indicating that cancer has spread to these nodes.'}, {'state_name': 'absent', 'state_description': 'There is no metastasis in the lymph nodes, indicating that cancer has not spread to these nodes.'}]}, 'NODE2': {'id': 'Magnetic_Resonance_Imaging_MRI_9', 'label': 'Magnetic Resonance Imaging (MRI) Examination Result', 'description': 'This node represents the result of a Magnetic Resonance Imaging (MRI) examination, which is a diagnostic tool used to create detailed images of organs and tissues in the body. The MRI can help in diagnosing various conditions, including the presence of tumors, metastasis, or other abnormalities.', 'type': 'Examination Result', 'observability': 'Observed', 'states': [{'state_name': 'present', 'state_description': \""The 'present' state indicates that the MRI examination has detected an abnormality or finding of interest, such as a tumor or lesion.\""}, {'state_name': 'absent', 'state_description': \""The 'absent' state indicates that the MRI examination did not detect any abnormalities or findings of interest.\""}]}, 'EDGE1': {'edges_ids': ['Presence_of_Metastasis_in_Lymph_Nodes_5', 'Magnetic_Resonance_Imaging_MRI_9'], 'edge': '(Presence_of_Metastasis_in_Lymph_Nodes_5) causes (Magnetic_Resonance_Imaging_MRI_9)', 'explanation': ['The edge suggests that the presence of metastasis in lymph nodes causes a specific result in an MRI examination.', 'In reality, the MRI examination is a diagnostic tool that detects the presence of metastasis, rather than being caused by it.', 'The presence of metastasis is a condition that can be observed by MRI, but it does not cause the MRI result.', 'Therefore, the edge is not valid as a causal relationship because the MRI result is an observation, not an effect.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Proximal'}, 'EDGE2': {'edges_ids': ['Magnetic_Resonance_Imaging_MRI_9', 'Presence_of_Metastasis_in_Lymph_Nodes_5'], 'edge': '(Magnetic_Resonance_Imaging_MRI_9) causes (Presence_of_Metastasis_in_Lymph_Nodes_5)', 'explanation': ['The edge represents the idea that the result of an MRI examination causes the presence of metastasis in lymph nodes.', 'This is not a valid causal relationship because an MRI is a diagnostic tool that detects existing conditions, such as metastasis, rather than causing them.', 'The MRI examination can reveal the presence of metastasis, but it does not influence whether metastasis occurs in the lymph nodes.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Proximal'}, 'ENTITIES_MATCHING_PAGES_INFO': {'41': {'matching_entities': [{'METASTASIS': 0.9630129}, {'LYMPHATIC METASTASIS': 0.94962627}, {'MAGNETIC RESONANCE IMAGING (MRI)': 0.94132537}, {'COMPUTED TOMOGRAPHY (CT)': 0.9349672}, {'CANCER': 0.92851335}, {'IMAGING': 0.9221975}], 'count': 6}, '44': {'matching_entities': [{'MAGNETIC RESONANCE IMAGING': 0.9692417}, {'LYMPHATIC METASTASIS': 0.94962627}, {'MALIGNANT NEOPLASTIC DISEASE': 0.9424237}, {'CANCER': 0.92851335}, {'COMPUTED TOMOGRAPHY': 0.9228411}, {'TOMOGRAPHY, X-RAY COMPUTED': 0.9212845}], 'count': 6}, '94': {'matching_entities': [{'MAGNETIC RESONANCE IMAGING': 0.9692417}, {'NEOPLASM METASTASIS': 0.96748203}, {'LYMPHATIC METASTASIS': 0.94962627}, {'LYMPH NODE METASTASIS': 0.9418514}, {'COMPUTED TOMOGRAPHY': 0.9228411}, {'TOMOGRAPHY, X-RAY COMPUTED': 0.9212845}], 'count': 6}, '93': {'matching_entities': [{'MAGNETIC RESONANCE IMAGING': 0.9692417}, {'MALIGNANT NEOPLASTIC DISEASE': 0.9424237}, {'CANCER': 0.92851335}, {'COMPUTED TOMOGRAPHY': 0.9228411}, {'TOMOGRAPHY, X-RAY COMPUTED': 0.9212845}], 'count': 5}, '92': {'matching_entities': [{'MAGNETIC RESONANCE IMAGING': 0.9692417}, {'METASTASIS': 0.9630129}, {'MALIGNANT NEOPLASM': 0.9448747}, {'CANCER': 0.92851335}, {'COMPUTED TOMOGRAPHY': 0.9228411}], 'count': 5}}, 'GUIDELINE_PAGES_INFO': '--------------------------------------------------\\nPage Number: 41\\n\\nSection Name: Workup\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.\\nHistory And Physical Examination : A comprehensive assessment of a patient\\'s medical history and physical condition.\\nTobacco Smoking : The act of smoking tobacco products, which is a risk factor for many diseases.\\nAlcohol Drinking : The consumption of beverages containing ethyl alcohol.\\nSmoking Cessation : The process of discontinuing tobacco smoking.\\nBiopsy : A medical test involving the extraction of sample cells or tissues for examination.\\nLaryngoscopy : A procedure to examine the larynx, often using a scope.\\nComputed Tomography (Ct) : A diagnostic imaging procedure that uses computer-processed combinations of many X-ray measurements taken from different angles to produce cross-sectional images of specific areas of a scanned object.\\nMagnetic Resonance Imaging (Mri) : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.\\nPositron-Emission Tomography : A type of nuclear medicine imaging that measures metabolic activity of the cells of body tissues.\\nPulmonary Function Test : Tests that measure how well the lungs are working.\\nDental Examination : An evaluation of the teeth and gums to assess oral health.\\nNutritional Support : Therapies to provide nutrition to patients who cannot obtain nutrition by mouth.\\nSpeech Therapy : Therapy to improve speech and communication skills.\\nSwallowing Therapy : Therapy to help individuals with swallowing difficulties.\\nMultidisciplinary Care Team : A group of healthcare professionals from different specialties working together to manage patient care.\\n\\nRelationships:-\\n1. Entity1: \""glottic larynx cancer\"", Entity2: \""history and physical examination\"", Relationship: \""initial diagnostic step\""\\n2. Entity1: \""glottic larynx cancer\"", Entity2: \""biopsy\"", Relationship: \""required diagnostic procedure\""\\n3. Entity1: \""glottic larynx cancer\"", Entity2: \""direct laryngoscopy\"", Relationship: \""recommended procedure\""\\n4. Entity1: \""glottic larynx cancer\"", Entity2: \""CT scans\"", Relationship: \""imaging study\""\\n5. Entity1: \""glottic larynx cancer\"", Entity2: \""MRI\"", Relationship: \""imaging study\""\\n6. Entity1: \""glottic larynx cancer\"", Entity2: \""multidisciplinary consultation\"", Relationship: \""advised as clinically indicated\""\\n\\nCausalities:-\\nThe workup section outlines the initial steps for diagnosing <C>glottic larynx cancer</C>. It includes <A>a comprehensive history and physical examination (H&P)</A>, which should document tobacco and alcohol use, and provide counseling for smoking cessation. <A>A biopsy of the primary site is required</A>, and <A>direct laryngoscopy under anesthesia is generally recommended</A>. <A>Imaging studies such as CT scans with contrast and possibly MRI are used to evaluate the larynx and neck</A>. Additional evaluations may include <A>chest CT, FDG-PET/CT, pulmonary function tests, dental evaluation, and nutrition, speech, and swallowing therapy</A>. <A>Multidisciplinary consultation is advised</A> <CO>as clinically indicated</CO>.\\n\\nSection Name: Clinical Staging\\n====================\\nEntities:-\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\nCarcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.\\nBiopsy : A medical test involving the extraction of sample cells or tissues for examination.\\nLaryngectomy : A surgical procedure to remove the larynx.\\n\\nRelationships:-\\n1. Entity1: \""Clinical staging\"", Entity2: \""Cancer\"", Relationship: \""involves\""\\n2. Entity1: \""Carcinoma in situ\"", Entity2: \""Stages T1-T4\"", Relationship: \""is a stage of\""\\n3. Entity1: \""Biopsy\"", Entity2: \""Cancer\"", Relationship: \""used in staging\""\\n4. Entity1: \""Larynx-preserving surgeries\"", Entity2: \""Stages T1-T2\"", Relationship: \""considered for\""\\n5. Entity1: \""Total laryngectomy\"", Entity2: \""Stages T3-T4\"", Relationship: \""required for\""\\n\\nCausalities:-\\n<C> Clinical staging involves categorizing the cancer based on its aggressiveness </C>. It starts with carcinoma in situ, which is non-invasive, and progresses through stages T1-T4. <CO> Staging is based on H&P, biopsy, and imaging studies </CO>. <CO> For T1-T2 </CO>, <A> larynx-preserving surgeries are considered </A>, while <CO> more advanced stages like T3 or T4 </CO> <A> may require total laryngectomy </A>. <A> Additional evaluations such as videostrobe, audiogram, and fertility counseling may be considered </A>.\\n\\nSection Name: Treatment\\n====================\\nEntities:-\\nCarcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.\\nLaryngectomy : A surgical procedure to remove the larynx.\\nMetastasis : The transfer of a disease from one organ or part to another not directly connected with it.\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\n\\nRelationships:-\\n1. Entity1: \""Carcinoma in situ\"", Entity2: \""Larynx-preserving surgery\"", Relationship: \""treated with\""\\n2. Entity1: \""T1-T2 stages\"", Entity2: \""Conservation surgery\"", Relationship: \""treated with\""\\n3. Entity1: \""T3 stages\"", Entity2: \""Total laryngectomy\"", Relationship: \""may require\""\\n4. Entity1: \""T4a disease\"", Entity2: \""Complex interventions\"", Relationship: \""require\""\\n5. Entity1: \""Guidelines\"", Entity2: \""Multidisciplinary consultations\"", Relationship: \""emphasize importance of\""\\n6. Entity1: \""Guidelines\"", Entity2: \""Clinical trials\"", Relationship: \""consider as best option\""\\n\\nCausalities:-\\n<CO>Treatment recommendations vary by stage</CO>. <CO>Carcinoma in situ</CO> <A>may be treated with larynx-preserving surgery</A>. <CO>T1-T2 stages</CO> <A>may also be amenable to conservation surgery</A>. <CO>T3 stages</CO> <A>may require total laryngectomy</A>, <CO>especially if nodal involvement is present</CO>. <CO>T4a disease and unresectable or metastatic cases</CO> <A>require more complex interventions</A>. <A>The guidelines emphasize the importance of multidisciplinary consultations</A> and <A>consider clinical trials as the best management option</A>.\\n\\nSection Name: Additional Notes\\n====================\\nEntities:-\\nBiopsy, Needle : A procedure to remove a small sample of tissue for examination under a microscope.\\nImage-Guided Biopsy : A biopsy procedure that uses imaging techniques to guide the needle to the precise location of the tissue to be sampled.\\nBiopsy : A medical test involving the extraction of sample cells or tissues for examination.\\nDiagnostic Techniques And Procedures : Methods and procedures for the diagnosis of disease or dysfunction.\\nImaging : The process of producing images of the body for clinical purposes.\\nDental Care : The total of dental diagnostic, preventive, and corrective procedures.\\nNutritional Physiological Phenomena : The functions and properties of nutrients in living organisms.\\nFertility : The capacity to conceive or induce conception.\\nReproductive Health : A state of physical, mental, and social well-being in all matters relating to the reproductive system.\\nLymphatic Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nGlottis : The part of the larynx consisting of the vocal cords and the opening between them.\\n\\nRelationships:-\\n1. Entity1: \""image-guided needle biopsy\"", Entity2: \""diagnostic yield\"", Relationship: \""used for\""\\n2. Entity1: \""nodal disease\"", Entity2: \""glottic tumors\"", Relationship: \""is rare in\""\\n\\nCausalities:-\\n<A> use of image-guided needle biopsy </A> for <E> better diagnostic yield </E>, principles of imaging, dental evaluation, and nutrition management. The guidelines also address fertility and reproductive considerations, and note that <CO> nodal disease in glottic tumors is rare </CO>.\\n--------------------------------------------------\\nPage Number: 44\\n\\nSection Name: Flowchart Structure\\n====================\\nEntities:-\\nNeoplasm Staging : Methods used for staging neoplasms based on extent of tumor spread according to standardized criteria.\\nLaryngectomy : Surgical procedure to remove the larynx, often used to treat laryngeal cancer.\\nChemotherapy, Adjuvant : Drug therapy given in addition to the primary treatment to enhance its effectiveness.\\nRadiotherapy : The use of radiation, usually high-energy X-rays, to damage cancer cells and treat cancer.\\nTomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.\\nMagnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body\\'s soft tissue and bones.\\nNeoplasm Recurrence, Local : The return of a tumor at the original site after treatment.\\n\\nRelationships:-\\n1. Entity1: \""Clinical Staging\"", Entity2: \""T3 tumors\"", Relationship: \""determines treatment approach\""\\n2. Entity1: \""Adverse Pathologic Features\"", Entity2: \""Systemic Therapy\"", Relationship: \""directs to\""\\n3. Entity1: \""Adverse Pathologic Features\"", Entity2: \""Radiation Treatment\"", Relationship: \""directs to\""\\n4. Entity1: \""Induction Chemotherapy\"", Entity2: \""Imaging (CT or MRI)\"", Relationship: \""leads to\""\\n\\nCausalities:-\\n1. <A> The flow begins with the clinical staging of T3 tumors </A> <C> that require total laryngectomy (N2\u20133) </C>. <CO> This staging </CO> <E> is crucial for determining the appropriate therapeutic approach </E>.\\n\\n2. The flowchart provides multiple pathways for treatment, indicating that <CO> patients </CO> <A> may undergo either \""Concurrent systemic therapy/RT\"" or \""Surgery\"" </A>. There is also an <A> option for \""Induction chemotherapy,\"" leading to further imaging (CT or MRI) to assess the primary site and neck status </A>.\\n\\n3. For <CO> patients who have surgery </CO>, the flowchart distinguishes between those with adverse pathologic features and those without. <CO> Patients with adverse features\u2014such as extranodal extension or positive margins </CO>\u2014are <A> directed toward systemic therapy or radiation treatment </A>, while those without may follow a different management path.\\n\\n4. The flowchart concludes by <A> outlining follow-up procedures for recurrent or persistent disease </A>, suggesting additional assessments and treatments based on the risk features identified during earlier stages.\\n\\nSection Name: Detailed Explanation\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.\\nAdverse Pathological Feature : A pathological feature that indicates a worse prognosis or outcome.\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\n\\nRelationships:-\\n1. Entity1: \""Systemic therapy\"", Entity2: \""Radiation\"", Relationship: \""Concurrent treatment\""\\n2. Entity1: \""Clinical trials\"", Entity2: \""Personalized treatment plans\"", Relationship: \""Development of\""\\n\\nCausalities:-\\n<A> The flowchart is designed to provide healthcare professionals with a systematic pathway for managing glottic larynx cancer </A>. Each step is meticulously organized to ensure that important factors are considered, such as <C> the presence of adverse pathological features </C>, which <E> strongly influence treatment decisions </E>.\\n\\n<A> The emphasis on concurrent treatments, such as systemic therapy combined with radiation </A>, reflects current best practices in oncology, where multimodal approaches are often necessary to achieve better outcomes. <A> The inclusion of clinical trials </A> indicates an emphasis on maintaining up-to-date practices and personalized treatment plans as part of patient management strategies.\\n\\nFurthermore, <A> the chart\\'s organization into treatment and follow-up segments </A> allows for a straightforward interpretation, guiding oncologists through complex decisions in a logical manner. This can <E> improve consistency in care and enhance patient safety through meticulous monitoring and responses to treatment efficacy or disease progression </E>.\\n\\nIn summary, <E> this flowchart serves as an essential resource for oncologists, facilitating a better understanding of treatment protocols for glottic larynx cancer while promoting a patient-centered approach to oncological care </E>.\\n\\nSection Name: NCCN Guidelines Version 4.2024\\n====================\\nEntities:-\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\nClinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nNeoplasms : New abnormal growth of tissue that may be benign or malignant.\\nMalignant Neoplastic Disease : A disease in which abnormal cells divide uncontrollably and destroy body tissue.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\nNational Comprehensive Cancer Network : An alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network\"", Entity2: \""NCCN Guidelines\"", Relationship: \""publishes\""\\n2. Entity1: \""Clinical trial\"", Entity2: \""Cancer\"", Relationship: \""manages\""\\n\\nCausalities:-\\n<C> any patient with cancer </C> <E> the best management is in a clinical trial </E>. <A> Participation in clinical trials is especially encouraged </A>.\\n\\nSection Name: Principles of Treatment\\n====================\\nEntities:-\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nExtranodal Extension : The spread of cancer beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margins : Cancer cells are found at the edge of the material removed during surgery, indicating that some cancer may have been left behind.\\nPerineural Invasion : Cancer cells are found surrounding or tracking along a nerve within the perineural space.\\nVascular Invasion : The presence of cancer cells within blood vessels.\\nLymphatic Metastasis : The spread of cancer cells through the lymphatic system to distant sites.\\n\\nRelationships:-\\n1. Entity1: \""Principles of Radiation Therapy\"", Entity2: \""Extranodal Extension\"", Relationship: \""management of\""\\n2. Entity1: \""Principles of Surgery\"", Entity2: \""Positive Surgical Margins\"", Relationship: \""concerned with avoiding\""\\n3. Entity1: \""Principles of Radiation Therapy\"", Entity2: \""Perineural Invasion\"", Relationship: \""consideration in treatment planning\""\\n\\nCausalities:-\\n<C> Extranodal extension </C> <C> Positive margins </C> <C> Close margins </C> <C> pT4 primary </C> <C> pN2 or pN3 nodal disease </C> <C> Perineural invasion </C> <C> Vascular invasion </C> <C> Lymphatic invasion </C> <C> Subglottic extension </C>\\n\\nSection Name: Clinical Staging\\n====================\\nEntities:-\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to enhance its effectiveness.\\nAdjuvant Therapy : A therapy given in addition to the primary or initial therapy to maximize its effectiveness.\\nFollow-Up Studies : Studies that continue to monitor patients after treatment to assess long-term outcomes.\\nFollow-Up Procedure : A procedure performed to monitor the progress of a patient after initial treatment.\\nFollow-Up : The act of monitoring a patient\\'s health over time after treatment.\\nNeoplasm Recurrence, Local : The return of a tumor at the original site after treatment.\\nRecurrent Disease : A disease that has returned after a period of remission.\\n\\nRelationships:-\\n1. Entity1: \""Adjuvant Treatment\"", Entity2: \""Recurrent or Persistent Disease\"", Relationship: \""prevention\""\\n2. Entity1: \""Follow-up\"", Entity2: \""Recurrent or Persistent Disease\"", Relationship: \""monitoring\""\\n\\nSection Name: Treatment Options\\n====================\\nEntities:-\\nLaryngectomy : Surgical procedure to remove the larynx, often used to treat laryngeal cancer.\\nTotal Laryngectomy : A surgical procedure to remove the entire larynx.\\nChemotherapy, Adjuvant : Drug therapy given in addition to the primary treatment to enhance its effectiveness.\\nInduction Chemotherapy : Chemotherapy given as a first step to shrink a tumor before the main treatment.\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\nClinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\n\\nRelationships:-\\n1. Entity1: \""T3 requiring total laryngectomy\"", Entity2: \""Concurrent systemic therapy/RT\"", Relationship: \""treatment option\""\\n2. Entity1: \""T3 requiring total laryngectomy\"", Entity2: \""Induction chemotherapy\"", Relationship: \""treatment option\""\\n3. Entity1: \""T3 requiring total laryngectomy\"", Entity2: \""Clinical trials\"", Relationship: \""research option\""\\n\\nCausalities:-\\n<CO> T3 requiring (amenable to) total laryngectomy (N2\u20133) </CO> <A> Concurrent systemic therapy/RT </A> <A> Surgery </A> <A> Induction chemotherapy </A> <A> Clinical trials </A>\\n\\nSection Name: Surgical Considerations\\n====================\\nEntities:-\\nLaryngectomy : Surgical procedure to remove the larynx, often used to treat laryngeal cancer.\\nThyroidectomy : Surgical removal of all or part of the thyroid gland.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue in the neck.\\nLymph Node Excision : Surgical removal of one or more lymph nodes.\\nLymph Node Dissection : A surgical procedure to remove lymph nodes.\\nLymphadenectomy : Surgical removal of one or more groups of lymph nodes.\\n\\nRelationships:-\\n1. Entity1: \""Laryngectomy\"", Entity2: \""Thyroidectomy\"", Relationship: \""performed with\""\\n2. Entity1: \""Neck Dissection\"", Entity2: \""Lymph Node Excision\"", Relationship: \""includes\""\\n3. Entity1: \""Neck Dissection\"", Entity2: \""Lymph Node Excision\"", Relationship: \""includes specific types\""\\n\\nCausalities:-\\n<A> Laryngectomy with thyroidectomy as indicated, ipsilateral or bilateral neck dissection, and pretracheal and ipsilateral paratracheal lymph node dissection </A>\\n\\nSection Name: Pathologic Features\\n====================\\nEntities:-\\nExtranodal Extension : The spread of cancer beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margins : Cancer cells are found at the edge of the material removed during surgery, indicating that some cancer may have been left behind.\\nPositive Margin : A surgical margin that contains residual tumor cells.\\n\\nRelationships:-\\n1. Entity1: \""Adverse pathologic features\"", Entity2: \""Extranodal extension\"", Relationship: \""includes\""\\n2. Entity1: \""Adverse pathologic features\"", Entity2: \""Positive margin\"", Relationship: \""includes\""\\n\\nCausalities:-\\n- **No adverse pathologic features**\\n- **Adverse pathologic features**\\n  - <C> Extranodal extension and/or positive margin </C>\\n  - Other risk features\\n\\nSection Name: Systemic Therapy\\n====================\\nEntities:-\\nAntineoplastic Agents : Drugs used to treat cancer by inhibiting the growth of cancerous cells.\\nSystemic Therapy : A treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiotherapy : The use of radiation, usually high-energy X-rays, to damage cancer cells and treat cancer.\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\n\\nRelationships:-\\n1. Entity1: \""Systemic therapy\"", Entity2: \""RT\"", Relationship: \""Consideration\""\\n\\nCausalities:-\\n<A> Systemic therapy/RT (category 1) </A>\\n<A> RT </A>\\n<A> Consider systemic therapy/RT </A>\\n\\nSection Name: Imaging\\n====================\\nEntities:-\\nTomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.\\nMagnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body\\'s soft tissue and bones.\\nNeck : Part of the body, on many terrestrial or secondarily aquatic vertebrates, that distinguishes the head from the torso or trunk.\\nComputed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images (often called slices), both horizontally and vertically, of the body.\\nNeck Structure : The anatomical structure that connects the head to the torso.\\n\\nRelationships:-\\n1. Entity1: \""CT\"", Entity2: \""Neck\"", Relationship: \""imaging of\""\\n2. Entity1: \""MRI\"", Entity2: \""Neck\"", Relationship: \""imaging of\""\\n\\nCausalities:-\\n<A> CT (with contrast) or MRI (with and without contrast) of primary and neck </A>\\n\\nSection Name: Post-Treatment Evaluation\\n====================\\nEntities:-\\nRadiotherapy : The use of radiation, usually high-energy X-rays, to damage cancer cells and treat cancer.\\nPn1 Category : A pathological classification indicating regional lymph node metastasis in cancer staging.\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\n\\nRelationships:-\\n1. Entity1: \""Post Systemic Therapy/RT or RT Neck Evaluation\"", Entity2: \""pN1\"", Relationship: \""evaluation of cancer staging\""\\n2. Entity1: \""pN1\"", Entity2: \""Consider RT\"", Relationship: \""treatment recommendation\""\\n\\nCausalities:-\\n<CO> pN1 without other risk features </CO> <A> Consider RT </A>\\n\\nSection Name: Additional Notes\\n====================\\nEntities:-\\nAntineoplastic Combined Chemotherapy Protocols : Protocols for the administration of more than one antineoplastic agent in combination to treat malignant neoplasms.\\nCisplatin : A platinum-containing antineoplastic agent used in the treatment of various cancers.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Non-Nasopharyngeal Cancers\"", Relationship: \""used for\""\\n2. Entity1: \""Cisplatin\"", Entity2: \""Systemic Therapy\"", Relationship: \""preferred agent in\""\\n3. Entity1: \""Induction Chemotherapy\"", Entity2: \""Systemic Therapy\"", Relationship: \""discussed in context of\""\\n\\nCausalities:-\\n- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**\\n- **<CO> When using concurrent systemic therapy/RT </CO>, <A> the preferred agent is cisplatin (category 1) </A>. See Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A).**\\n- **<A> See Discussion on induction chemotherapy. </A>**\\n--------------------------------------------------\\nPage Number: 94\\n\\nSection Name: Head and Neck Cancers - Principles of Imaging\\n====================\\nEntities:-\\nPositron Emission Tomography Computed Tomography : A medical imaging technique combining PET and CT capabilities to provide detailed information about the body\\'s function and structure.\\nPositron Emission Tomography : A nuclear medicine functional imaging technique that is used to observe metabolic processes in the body.\\nComputed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.\\nHead And Neck Neoplasms : Cancers that arise in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\n\\nRelationships:-\\n1. Entity1: \""PET/CT\"", Entity2: \""PET scan\"", Relationship: \""preferred over\""\\n2. Entity1: \""PET-CT\"", Entity2: \""head neck cancers\"", Relationship: \""used in study of\""\\n\\nCausalities:-\\n<A> PET/CT is preferred over PET scan alone (i.e., without superimposed CT scan) </A>. <C> PET/CT provides more accurate anatomical localization of abnormalities </C> <E> more accurate anatomical localization of abnormalities </E>.\\n\\nSection Name: Initial Workup - Nodal Metastases\\n====================\\nEntities:-\\nLymphatic Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site via the lymphatic system.\\nTomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient, producing signals that are processed by the machine\\'s computer to generate cross-sectional images.\\nMagnetic Resonance Imaging : A non-invasive imaging technique that uses magnetic fields and radio waves to create detailed images of the organs and tissues within the body.\\nPositron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption.\\nLymph Node Metastasis : The spread of cancer cells to lymph nodes, which are part of the lymphatic system.\\nCt Of Neck : A computed tomography scan of the neck region.\\nMri Of Neck : A magnetic resonance imaging scan of the neck region.\\nFdg-Pet Scan : A type of positron emission tomography using fluorodeoxyglucose to assess metabolic activity.\\nComputed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.\\nPositron Emission Tomography : A nuclear medicine functional imaging technique that is used to observe metabolic processes in the body.\\n\\nRelationships:-\\n1. Entity1: \""CT\"", Entity2: \""lymph node metastases\"", Relationship: \""used to evaluate\""\\n2. Entity1: \""MRI\"", Entity2: \""lymph node metastases\"", Relationship: \""used to evaluate\""\\n3. Entity1: \""FDG-PET/CT\"", Entity2: \""lymph node metastases\"", Relationship: \""used for detection\""\\n4. Entity1: \""FDG-PET/CT\"", Entity2: \""surgical primary approach\"", Relationship: \""used to determine\""\\n5. Entity1: \""FDG-PET/CT\"", Entity2: \""definitive RT approach\"", Relationship: \""used to identify\""\\n\\nCausalities:-\\n<A> Evaluation of lymph node metastases should be conducted with CT or MRI of the neck </A>, using whichever imaging study is suitable for primary site evaluation (IMG-A, 1 of 4).\\n<CO> For patients with multistation or lower neck nodal involvement or high-grade tumor histology </CO>, <A> consider CT of the chest to assess for mediastinal lymph node metastases or FDG-PET/CT </A>, <C> which is associated with higher sensitivity for both nodal and distant metastases </C>.\\n<CO> For patients who are under consideration for a surgical primary approach </CO>, <A> the higher sensitivity of FDG-PET/CT is warranted for tumors approaching the midline, to determine the surgical approach to the contralateral neck </A>. <CO> Similarly, patients who are scheduled for a definitive RT approach </CO> <A> may benefit from the higher sensitivity of FDG-PET/CT for identifying involved lymph nodes </A>.\\n\\nSection Name: Initial Workup - Distant Metastases\\n====================\\nEntities:-\\nPositron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption.\\nMagnetic Resonance Imaging : A non-invasive imaging technique that uses magnetic fields and radio waves to create detailed images of the organs and tissues within the body.\\nTomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient, producing signals that are processed by the machine\\'s computer to generate cross-sectional images.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nLung Neoplasms : Tumors or cancer of the lung.\\nSmoking : The inhalation of the smoke of burning tobacco encased in cigarettes, pipes, and cigars.\\n\\nRelationships:-\\n1. Entity1: \""FDG-PET/CT\"", Entity2: \""Distant Metastases\"", Relationship: \""used to evaluate\""\\n2. Entity1: \""Contrast-enhanced brain MRI\"", Entity2: \""Brain Metastasis\"", Relationship: \""recommended for evaluation\""\\n3. Entity1: \""CT of the chest\"", Entity2: \""Pulmonary Metastases\"", Relationship: \""performed to assess\""\\n4. Entity1: \""Non-contrast CT of the chest\"", Entity2: \""Lung Parenchymal Metastases\"", Relationship: \""used to screen\""\\n5. Entity1: \""Annual CT screening\"", Entity2: \""Lung Metastasis\"", Relationship: \""considered for high risk\""\\n6. Entity1: \""Directed CT or MRI\"", Entity2: \""Distant Disease\"", Relationship: \""used for assessment\""\\n7. Entity1: \""FDG-PET/CT\"", Entity2: \""Recurrent Disease\"", Relationship: \""used for staging\""\\n\\nCausalities:-\\n<C> Patients with locoregionally advanced cancer (e.g., T3\u2013T4 primary or \u2265N1 nodal staging) </C>, <A> FDG-PET/CT is preferred to evaluate for distant disease and thoracic metastases </A>. <CO> For cancers where brain metastasis is a concern, such as mucosal melanoma or high-grade neuroendocrine carcinomas or adenocarcinomas </CO>, <A> contrast-enhanced brain MRI should be additionally obtained </A>.\\n<CO> If FDG-PET/CT is not performed </CO>, <A> CT of the chest should be performed to assess for presence of pulmonary metastases as well as mediastinal lymph node involvement </A>.\\n<CO> Non-contrast CT of the chest can be sufficient to screen for lung parenchymal metastases </CO> but <CO> is not adequate for assessment of mediastinal adenopathy </CO>. <CO> This is an appropriate lung cancer screening intervention for patients with a history of smoking </CO>.\\n<CO> Following primary definitive treatment (surgery, RT, or systemic therapy/RT) </CO> the role of annual CT screening for lung metastasis is controversial. <E> While this approach does detect early metastasis </E>, <CO> further study is needed to determine the extent of the positive effect and/or cost-effectiveness of this approach in specific subpopulations and timepoints post-treatment </CO>. <CO> For patients with a substantial smoking history or who are at high risk for lung metastases </CO>, <A> annual chest CT can be considered </A>.\\n<CO> If clinical concern for metastatic disease is confined to a specific anatomical area </CO>, <A> the assessment of distant disease can be performed with directed CT or MRI examination </A>.\\n<CO> FDG-PET/CT may complement or replace other imaging modalities when staging recurrent disease before any therapy for relapsed/refractory disease </CO> <A> in order to explore distant disease or second primaries that may significantly impact choice of therapy </A>.\\n--------------------------------------------------\\nPage Number: 93\\n\\nSection Name: PRINCIPLES OF IMAGING\\n====================\\nEntities:-\\nImaging, Diagnostic : The production of a visual representation of parts of the body, for the purpose of clinical analysis and medical intervention.\\nHead And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\nTomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.\\nMagnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body\\'s soft tissue and bones.\\nContrast Media : Substances used to enhance the contrast of structures or fluids within the body in medical imaging.\\n\\nRelationships:-\\n1. Entity1: \""Imaging, Diagnostic\"", Entity2: \""Head and Neck Neoplasms\"", Relationship: \""used for\""\\n2. Entity1: \""Tomography, X-Ray Computed\"", Entity2: \""Contrast Media\"", Relationship: \""uses\""\\n3. Entity1: \""Magnetic Resonance Imaging\"", Entity2: \""Contrast Media\"", Relationship: \""uses\""\\n\\nCausalities:-\\n<C> Imaging </C> plays an essential role in the clinical care of patients with head and neck cancer. <A> The proper selection and utilization of imaging studies </A> is critical in caring for patients with head and neck cancer. <A> CT is performed with contrast </A>, while <A> CT imaging of the chest can be performed with or without contrast </A>, <CO> as clinically indicated </CO>. <A> MRI is performed with and without contrast </A>, <CO> unless contraindicated </CO>.\\n\\nSection Name: Initial Workup - Primary Site\\n====================\\nEntities:-\\nTomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.\\nMagnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body\\'s soft tissue and bones.\\nHead And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\nNeck Structure : The anatomical structure of the neck, which is the part of the body that connects the head to the torso.\\nSkull Base : The bottom part of the skull, which separates the brain from other facial structures.\\nThoracic Inlet : The opening at the top of the thoracic cavity, through which pass the trachea, esophagus, and major blood vessels.\\n\\nRelationships:-\\n1. Entity1: \""CT\"", Entity2: \""MRI\"", Relationship: \""complementary in imaging head and neck cancers\""\\n2. Entity1: \""CT\"", Entity2: \""Head and Neck Neoplasms\"", Relationship: \""used to evaluate\""\\n3. Entity1: \""MRI\"", Entity2: \""Head and Neck Neoplasms\"", Relationship: \""preferred for evaluating\""\\n4. Entity1: \""Skull base\"", Entity2: \""Thoracic inlet\"", Relationship: \""imaging range for evaluation\""\\n\\nCausalities:-\\n<A>Imaging assessment of the primary site</A> can be performed with <A>CT of the soft tissues of the neck</A> or <A>MRI of the neck</A>. <C>CT is complementary to MRI for head and neck cancers</C>. <A>It is utilized to evaluate cortical bone erosion or periosteal invasion, cartilage invasion, and bony erosion or destruction</A>. <CO>in certain conditions, such as evaluating the extent of bone marrow invasion or in patients with extensive dental amalgam obscuring anatomy on CT, assessing skull base invasion and cranial nerve involvement, and differentiating tumor from obstructed sinuses</CO>, <A>MRI is preferred over CT</A>. <CO>when involved lymph nodes or upper mediastinal cancers are present</CO>, <A>Complete evaluation of primary and nodal disease requires imaging from the skull base to the thoracic inlet, extending to the carina</A>.\\n\\nSection Name: PET/CT and Biopsy\\n====================\\nEntities:-\\nPositron Emission Tomography Computed Tomography : A medical imaging technique that combines PET and CT capabilities to provide detailed images of the body.\\nExamination Under Anesthesia : A procedure where a patient is examined while under anesthesia to allow for a more thorough examination.\\nBiopsy : A medical test involving the extraction of sample cells or tissues for examination to determine the presence or extent of a disease.\\nTonsillectomy : A surgical procedure to remove the tonsils, often performed to treat recurrent tonsillitis or sleep apnea.\\nFine Needle Aspiration : A type of biopsy procedure that uses a thin, hollow needle to extract cells from a lump or mass for examination.\\nUltrasound : A medical imaging technique that uses high-frequency sound waves to visualize internal organs and structures.\\nComputed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.\\n\\nRelationships:-\\n1. Entity1: \""PET/CT\"", Entity2: \""EUA\"", Relationship: \""recommended before\""\\n2. Entity1: \""Fine Needle Aspiration (FNA)\"", Entity2: \""metastatic nodes\"", Relationship: \""used for biopsy of\""\\n3. Entity1: \""Image-guided needle biopsy\"", Entity2: \""cystic neck nodes\"", Relationship: \""recommended for initial diagnosis of\""\\n\\nCausalities:-\\n<CO> If imaging does not reveal an obvious primary cancer </CO>, <A> a PET/CT should be ordered before EUA, biopsies, and tonsillectomy </A>. <E> This helps identify potential primary sites </E> before any interventions take place. Additionally, <A> Fine Needle Aspiration (FNA) biopsy of metastatic nodes </A> <E> may provide pathologically informative results </E>. <CO> For initial diagnosis in cystic neck nodes </CO>, <A> image-guided needle biopsy (ultrasound or CT) </A> <E> may yield better results than FNA by palpation alone </E>.\\n\\nSection Name: Postoperative Imaging Advice\\n====================\\nEntities:-\\nPanoramic Radiography : A type of dental x-ray that provides a wide view of the upper and lower jaws, teeth, temporomandibular joints, and sinuses.\\nOral Cavity : The cavity of the mouth, including the lips, the lining inside the cheeks and lips, the front two-thirds of the tongue, the gums, the floor of the mouth under the tongue, the hard palate, and the small area of the gum behind the wisdom teeth.\\nRadiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.\\nMandibulotomy : A surgical procedure involving the cutting of the mandible.\\nMandibulectomy : A surgical procedure involving the removal of part or all of the mandible.\\nOropharynx : The part of the throat at the back of the mouth behind the oral cavity.\\n\\nRelationships:-\\n1. Entity1: \""panoramic dental x-ray\"", Entity2: \""oral cavity cancers\"", Relationship: \""recommended for\""\\n2. Entity1: \""panoramic dental x-ray\"", Entity2: \""postoperative radiotherapy\"", Relationship: \""essential for pre-radiation evaluation\""\\n3. Entity1: \""pre-radiation dental evaluation\"", Entity2: \""dental procedures or extractions\"", Relationship: \""determine necessity of\""\\n\\nCausalities:-\\n<A> A panoramic dental x-ray is recommended </A> <C> for oral cavity cancers requiring mandibulotomy and/or mandibulectomy </C>. <CO> When postoperative radiotherapy (RT) is anticipated for areas like the lip, oral cavity subsites, or oropharynx </CO>, <A> panoramic x-ray is essential for a comprehensive pre-radiation dental evaluation </A> <E> to assess the health of affected teeth and determine if pre-radiation dental procedures or extractions are necessary </E>.\\n\\nSection Name: NCCN Guidelines Note\\n====================\\nEntities:-\\nNeoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.\\nMalignant Neoplastic Disease : A disease characterized by uncontrolled, abnormal growth of cells that can invade or spread to other parts of the body.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\nClinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.\\nClinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\n\\nRelationships:-\\n1. Entity1: \""NCCN\"", Entity2: \""Clinical Trials\"", Relationship: \""encourages participation in\""\\n2. Entity1: \""NCCN\"", Entity2: \""Cancer\"", Relationship: \""recommends clinical trials for\""\\n\\nCausalities:-\\n<A> NCCN believes that the best management of any patient with cancer is through participation in clinical trials </A>, <A> which is especially encouraged </A>.\\n--------------------------------------------------\\nPage Number: 92\\n\\nSection Name: NCCN Guidelines Overview\\n====================\\nEntities:-\\nHead And Neck Neoplasms : Cancers that arise in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\nMalignant Neoplasm Of Head And Neck : A malignant tumor located in the head and neck region.\\nHead And Neck Cancer : A group of cancers that originate in the head and neck region.\\nAntineoplastic Agents : Drugs used to treat cancer by inhibiting the growth of cancerous cells.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.\\nRadiation Therapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.\\n\\nRelationships:-\\n1. Entity1: \""Head and neck cancers\"", Entity2: \""Systemic therapy\"", Relationship: \""follow-up recommendations after\""\\n2. Entity1: \""Head and neck cancers\"", Entity2: \""Radiation therapy\"", Relationship: \""follow-up recommendations after\""\\n\\nCausalities:-\\nThe image presents a flowchart from the National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2024, especially focusing on <A> follow-up recommendations </A> for <CO> patients with head and neck cancers after systemic therapy or radiation therapy (RT) </CO>. All recommendations are categorized as level A unless stated otherwise, highlighting the importance of clinical trials in cancer management.\\n\\nSection Name: Imaging and Assessment Protocols\\n====================\\nEntities:-\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.\\nClinical Assessment : A systematic evaluation of a patient\\'s health status, often involving a physical examination and medical history.\\nPositron-Emission Tomography : An imaging technique using a radioactive substance called a tracer to look for disease in the body.\\nComputed Tomography : A medical imaging technique used in radiology to obtain detailed internal images of the body.\\nMagnetic Resonance Imaging : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis.\\nDisease : A disorder of structure or function in a human, animal, or plant, especially one that produces specific symptoms.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\nResidual Neoplasm : Remaining cancer cells after treatment.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Clinical Assessment\"", Relationship: \""occurs before\""\\n2. Entity1: \""FDG-PET/CT Scan\"", Entity2: \""Distant Metastases\"", Relationship: \""assesses\""\\n3. Entity1: \""FDG-PET/CT Scan\"", Entity2: \""Observation\"", Relationship: \""leads to if negative\""\\n4. Entity1: \""FDG-PET/CT Scan\"", Entity2: \""CT Scan\"", Relationship: \""leads to if strongly positive\""\\n5. Entity1: \""CT Scan\"", Entity2: \""Neck Dissection\"", Relationship: \""leads to if positive\""\\n\\nCausalities:-\\n<CO> After systemic therapy or RT </CO>, <A> a clinical assessment should occur 4 to 8 weeks later </A>. <CO> If there is a response </CO>, <A> it is necessary to assess the extent of disease or distant metastases, preferably through a FDG-PET/CT scan at a minimum of 12 weeks post-treatment </A>. <CO> If the FDG-PET/CT results are negative </CO>, <A> the patient may continue with monitoring through observation </A>. <CO> In cases where the results are equivocal </CO>, <A> observation or repeat FDG-PET/CT within 3 to 6 months is prescribed </A>.\\n\\n<CO> In cases where the FDG-PET/CT results are strongly positive </CO>, <A> further imaging via CT scan with contrast of the primary site and neck, or MRI with and without contrast, becomes necessary </A>. <CO> If these imaging results confirm positive findings </CO>, <A> neck dissection may be considered, depending on the evidence of residual or persistent disease </A>. <CO> If the imaging findings are negative </CO>, <A> the patient might continue in observation </A>.\\n\\nSection Name: Outcomes Based on Disease Resectability\\n====================\\nEntities:-\\nDisease : A disorder of structure or function in a human, animal, or plant, especially one that produces specific symptoms.\\nResectable : Capable of being surgically removed.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis.\\n\\nRelationships:-\\n1. Entity1: \""Disease\"", Entity2: \""Resectable\"", Relationship: \""Classification\""\\n2. Entity1: \""Unresectable\"", Entity2: \""Treatment plans (ADV-3)\"", Relationship: \""Treatment recommendation\""\\n3. Entity1: \""Resectable\"", Entity2: \""Resection and/or Neck dissection\"", Relationship: \""Surgical procedure\""\\n\\nCausalities:-\\n<CO> If there is confirmed residual or persistent disease </CO>, the options split into two pathways: \\'Unresectable\\' or \\'Resectable.\\' <CO> If the disease is classified as unresectable </CO>, <A> advances in treatment plans (labeled ADV-3) are called for </A>. Conversely, <CO> if it is deemed resectable </CO>, <A> a resection of the primary and/or neck dissection may occur </A>, <CO> contingent upon the disease status </CO>.\\n\\nSection Name: Important Notes\\n====================\\nEntities:-\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\nClinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.\\nPositron-Emission Tomography : An imaging technique using a radioactive substance called a tracer to look for disease in the body.\\nPositron Emission Tomography (Procedure) : A diagnostic imaging procedure that uses a radioactive tracer to visualize and measure changes in metabolic processes.\\nPositron Emission Tomography : A nuclear medicine functional imaging technique used to observe metabolic processes in the body.\\nNeoplasms : New abnormal growth of tissue in animals or plants; a tumor.\\nMalignant Neoplasm : A cancerous growth that has the potential to spread to other parts of the body.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""NCCN\"", Entity2: \""Clinical trials\"", Relationship: \""emphasizes participation in\""\\n2. Entity1: \""FDG-PET/CT\"", Entity2: \""Persistent cancer\"", Relationship: \""used to detect\""\\n3. Entity1: \""FDG-PET/CT\"", Entity2: \""PET negative\"", Relationship: \""interpretation of results\""\\n4. Entity1: \""FDG-PET/CT\"", Entity2: \""PET positive\"", Relationship: \""interpretation of results\""\\n\\nCausalities:-\\n<A> NCCN emphasizes that the best management for any cancer patient is participation in clinical trials </A>, especially encouraged for all patients. Additional notes clarify that <CO> if the FDG-PET/CT is negative for persistent cancer </CO>, <A> further cross-sectional imaging is optional </A>. The interpretations define <CO> PET negative as no or low-grade uptake not suspicious for disease </CO>, while <CO> PET positive implies suspicion for disease </CO>.\\n'}""",valid,increases risk,2,B,"edge - The edge which needs to be verified.
explanation - Explanation of what the edge represents and its validity.
causal_direction - Either Positive or Negative or Unknown. A positive influence direction indicates that both factors change in the same direction (e.g. an increase causes an increase effect). A negative influence direction indicates the opposite changes (e.g. an increase causes a decrease effect).
causal_factor - Is necessary or sufficient condition for an effect to occur. Exposure is a term commonly used in epidemiology to denote any condition that is considered as a possible cause of disease. Exposure is considered necessary when it always precedes the effects (e.g. symptoms) and always presents when the effects occur. A sufficient cause is a causal factor whose presence or occurrence guarantees the occurrence of symptom.
causal_distance - Either Distal or Proximal or Unknown. The distal factors lie towards the beginning of causal chain (i.e. indirect causal factors). The the proximal factors lie towards the end of the chain (i.e. cause directly or almost directly the effect).

Causality Tags:
<A> for action, <C> for cause, <CO> for condition and <E> for effect.
Cause (C): The reason or origin that leads to an effect. Causes often involve disease conditions, risk factors, or underlying mechanisms.
Effect (E): The outcome or result of a cause. Effects usually represent clinical outcomes, complications, or results of a specific cause.
Condition (CO): The circumstance or prerequisite required for an action or effect to occur. Conditions may include patient characteristics, clinical scenarios, or specific diagnostic criteria.
Action (A): The recommended or described response or activity to address a cause or condition. Actions typically involve clinical interventions, diagnostic procedures, or treatment recommendations.


`NODE1`:
id: Presence_of_Metastasis_in_Lymph_Nodes_5
label: Metastasis in Nearby Lymph Nodes
description: This node represents the clinical situation regarding whether metastasis is present in the nearby lymph nodes of a patient. It is a critical factor in determining the stage and prognosis of cancer, as the spread of cancer to lymph nodes often indicates a more advanced disease and may influence treatment decisions.
type: Patient Situation
observability: Unobserved
states: [{'state_name': 'unknown', 'state_description': 'The status of metastasis in the lymph nodes is not determined. It is unclear whether cancer has spread to these nodes.'}, {'state_name': 'present', 'state_description': 'Metastasis is confirmed in the lymph nodes, indicating that cancer has spread to these nodes.'}, {'state_name': 'absent', 'state_description': 'There is no metastasis in the lymph nodes, indicating that cancer has not spread to these nodes.'}]

`NODE2`:
id: Magnetic_Resonance_Imaging_MRI_9
label: Magnetic Resonance Imaging (MRI) Examination Result
description: This node represents the result of a Magnetic Resonance Imaging (MRI) examination, which is a diagnostic tool used to create detailed images of organs and tissues in the body. The MRI can help in diagnosing various conditions, including the presence of tumors, metastasis, or other abnormalities.
type: Examination Result
observability: Observed
states: [{'state_name': 'present', 'state_description': ""The 'present' state indicates that the MRI examination has detected an abnormality or finding of interest, such as a tumor or lesion.""}, {'state_name': 'absent', 'state_description': ""The 'absent' state indicates that the MRI examination did not detect any abnormalities or findings of interest.""}]

`EDGE1`:
{'edges_ids': ['Presence_of_Metastasis_in_Lymph_Nodes_5', 'Magnetic_Resonance_Imaging_MRI_9'], 'edge': '(Presence_of_Metastasis_in_Lymph_Nodes_5) causes (Magnetic_Resonance_Imaging_MRI_9)', 'explanation': ['The edge suggests that the presence of metastasis in lymph nodes causes a specific result in an MRI examination.', 'In reality, the MRI examination is a diagnostic tool that detects the presence of metastasis, rather than being caused by it.', 'The presence of metastasis is a condition that can be observed by MRI, but it does not cause the MRI result.', 'Therefore, the edge is not valid as a causal relationship because the MRI result is an observation, not an effect.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Proximal'}

`EDGE2`:
{'edges_ids': ['Magnetic_Resonance_Imaging_MRI_9', 'Presence_of_Metastasis_in_Lymph_Nodes_5'], 'edge': '(Magnetic_Resonance_Imaging_MRI_9) causes (Presence_of_Metastasis_in_Lymph_Nodes_5)', 'explanation': ['The edge represents the idea that the result of an MRI examination causes the presence of metastasis in lymph nodes.', 'This is not a valid causal relationship because an MRI is a diagnostic tool that detects existing conditions, such as metastasis, rather than causing them.', 'The MRI examination can reveal the presence of metastasis, but it does not influence whether metastasis occurs in the lymph nodes.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Proximal'}

`INFORMATION FROM KNOWLEDGE BASE`:
--------------------------------------------------
Page Number: 41

Section Name: Workup
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.
History And Physical Examination : A comprehensive assessment of a patient's medical history and physical condition.
Tobacco Smoking : The act of smoking tobacco products, which is a risk factor for many diseases.
Alcohol Drinking : The consumption of beverages containing ethyl alcohol.
Smoking Cessation : The process of discontinuing tobacco smoking.
Biopsy : A medical test involving the extraction of sample cells or tissues for examination.
Laryngoscopy : A procedure to examine the larynx, often using a scope.
Computed Tomography (Ct) : A diagnostic imaging procedure that uses computer-processed combinations of many X-ray measurements taken from different angles to produce cross-sectional images of specific areas of a scanned object.
Magnetic Resonance Imaging (Mri) : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.
Positron-Emission Tomography : A type of nuclear medicine imaging that measures metabolic activity of the cells of body tissues.
Pulmonary Function Test : Tests that measure how well the lungs are working.
Dental Examination : An evaluation of the teeth and gums to assess oral health.
Nutritional Support : Therapies to provide nutrition to patients who cannot obtain nutrition by mouth.
Speech Therapy : Therapy to improve speech and communication skills.
Swallowing Therapy : Therapy to help individuals with swallowing difficulties.
Multidisciplinary Care Team : A group of healthcare professionals from different specialties working together to manage patient care.

Relationships:-
1. Entity1: ""glottic larynx cancer"", Entity2: ""history and physical examination"", Relationship: ""initial diagnostic step""
2. Entity1: ""glottic larynx cancer"", Entity2: ""biopsy"", Relationship: ""required diagnostic procedure""
3. Entity1: ""glottic larynx cancer"", Entity2: ""direct laryngoscopy"", Relationship: ""recommended procedure""
4. Entity1: ""glottic larynx cancer"", Entity2: ""CT scans"", Relationship: ""imaging study""
5. Entity1: ""glottic larynx cancer"", Entity2: ""MRI"", Relationship: ""imaging study""
6. Entity1: ""glottic larynx cancer"", Entity2: ""multidisciplinary consultation"", Relationship: ""advised as clinically indicated""

Causalities:-
The workup section outlines the initial steps for diagnosing <C>glottic larynx cancer</C>. It includes <A>a comprehensive history and physical examination (H&P)</A>, which should document tobacco and alcohol use, and provide counseling for smoking cessation. <A>A biopsy of the primary site is required</A>, and <A>direct laryngoscopy under anesthesia is generally recommended</A>. <A>Imaging studies such as CT scans with contrast and possibly MRI are used to evaluate the larynx and neck</A>. Additional evaluations may include <A>chest CT, FDG-PET/CT, pulmonary function tests, dental evaluation, and nutrition, speech, and swallowing therapy</A>. <A>Multidisciplinary consultation is advised</A> <CO>as clinically indicated</CO>.

Section Name: Clinical Staging
====================
Entities:-
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.
Carcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.
Biopsy : A medical test involving the extraction of sample cells or tissues for examination.
Laryngectomy : A surgical procedure to remove the larynx.

Relationships:-
1. Entity1: ""Clinical staging"", Entity2: ""Cancer"", Relationship: ""involves""
2. Entity1: ""Carcinoma in situ"", Entity2: ""Stages T1-T4"", Relationship: ""is a stage of""
3. Entity1: ""Biopsy"", Entity2: ""Cancer"", Relationship: ""used in staging""
4. Entity1: ""Larynx-preserving surgeries"", Entity2: ""Stages T1-T2"", Relationship: ""considered for""
5. Entity1: ""Total laryngectomy"", Entity2: ""Stages T3-T4"", Relationship: ""required for""

Causalities:-
<C> Clinical staging involves categorizing the cancer based on its aggressiveness </C>. It starts with carcinoma in situ, which is non-invasive, and progresses through stages T1-T4. <CO> Staging is based on H&P, biopsy, and imaging studies </CO>. <CO> For T1-T2 </CO>, <A> larynx-preserving surgeries are considered </A>, while <CO> more advanced stages like T3 or T4 </CO> <A> may require total laryngectomy </A>. <A> Additional evaluations such as videostrobe, audiogram, and fertility counseling may be considered </A>.

Section Name: Treatment
====================
Entities:-
Carcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.
Laryngectomy : A surgical procedure to remove the larynx.
Metastasis : The transfer of a disease from one organ or part to another not directly connected with it.
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.

Relationships:-
1. Entity1: ""Carcinoma in situ"", Entity2: ""Larynx-preserving surgery"", Relationship: ""treated with""
2. Entity1: ""T1-T2 stages"", Entity2: ""Conservation surgery"", Relationship: ""treated with""
3. Entity1: ""T3 stages"", Entity2: ""Total laryngectomy"", Relationship: ""may require""
4. Entity1: ""T4a disease"", Entity2: ""Complex interventions"", Relationship: ""require""
5. Entity1: ""Guidelines"", Entity2: ""Multidisciplinary consultations"", Relationship: ""emphasize importance of""
6. Entity1: ""Guidelines"", Entity2: ""Clinical trials"", Relationship: ""consider as best option""

Causalities:-
<CO>Treatment recommendations vary by stage</CO>. <CO>Carcinoma in situ</CO> <A>may be treated with larynx-preserving surgery</A>. <CO>T1-T2 stages</CO> <A>may also be amenable to conservation surgery</A>. <CO>T3 stages</CO> <A>may require total laryngectomy</A>, <CO>especially if nodal involvement is present</CO>. <CO>T4a disease and unresectable or metastatic cases</CO> <A>require more complex interventions</A>. <A>The guidelines emphasize the importance of multidisciplinary consultations</A> and <A>consider clinical trials as the best management option</A>.

Section Name: Additional Notes
====================
Entities:-
Biopsy, Needle : A procedure to remove a small sample of tissue for examination under a microscope.
Image-Guided Biopsy : A biopsy procedure that uses imaging techniques to guide the needle to the precise location of the tissue to be sampled.
Biopsy : A medical test involving the extraction of sample cells or tissues for examination.
Diagnostic Techniques And Procedures : Methods and procedures for the diagnosis of disease or dysfunction.
Imaging : The process of producing images of the body for clinical purposes.
Dental Care : The total of dental diagnostic, preventive, and corrective procedures.
Nutritional Physiological Phenomena : The functions and properties of nutrients in living organisms.
Fertility : The capacity to conceive or induce conception.
Reproductive Health : A state of physical, mental, and social well-being in all matters relating to the reproductive system.
Lymphatic Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Glottis : The part of the larynx consisting of the vocal cords and the opening between them.

Relationships:-
1. Entity1: ""image-guided needle biopsy"", Entity2: ""diagnostic yield"", Relationship: ""used for""
2. Entity1: ""nodal disease"", Entity2: ""glottic tumors"", Relationship: ""is rare in""

Causalities:-
<A> use of image-guided needle biopsy </A> for <E> better diagnostic yield </E>, principles of imaging, dental evaluation, and nutrition management. The guidelines also address fertility and reproductive considerations, and note that <CO> nodal disease in glottic tumors is rare </CO>.
--------------------------------------------------
Page Number: 44

Section Name: Flowchart Structure
====================
Entities:-
Neoplasm Staging : Methods used for staging neoplasms based on extent of tumor spread according to standardized criteria.
Laryngectomy : Surgical procedure to remove the larynx, often used to treat laryngeal cancer.
Chemotherapy, Adjuvant : Drug therapy given in addition to the primary treatment to enhance its effectiveness.
Radiotherapy : The use of radiation, usually high-energy X-rays, to damage cancer cells and treat cancer.
Tomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.
Magnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body's soft tissue and bones.
Neoplasm Recurrence, Local : The return of a tumor at the original site after treatment.

Relationships:-
1. Entity1: ""Clinical Staging"", Entity2: ""T3 tumors"", Relationship: ""determines treatment approach""
2. Entity1: ""Adverse Pathologic Features"", Entity2: ""Systemic Therapy"", Relationship: ""directs to""
3. Entity1: ""Adverse Pathologic Features"", Entity2: ""Radiation Treatment"", Relationship: ""directs to""
4. Entity1: ""Induction Chemotherapy"", Entity2: ""Imaging (CT or MRI)"", Relationship: ""leads to""

Causalities:-
1. <A> The flow begins with the clinical staging of T3 tumors </A> <C> that require total laryngectomy (N2–3) </C>. <CO> This staging </CO> <E> is crucial for determining the appropriate therapeutic approach </E>.

2. The flowchart provides multiple pathways for treatment, indicating that <CO> patients </CO> <A> may undergo either ""Concurrent systemic therapy/RT"" or ""Surgery"" </A>. There is also an <A> option for ""Induction chemotherapy,"" leading to further imaging (CT or MRI) to assess the primary site and neck status </A>.

3. For <CO> patients who have surgery </CO>, the flowchart distinguishes between those with adverse pathologic features and those without. <CO> Patients with adverse features—such as extranodal extension or positive margins </CO>—are <A> directed toward systemic therapy or radiation treatment </A>, while those without may follow a different management path.

4. The flowchart concludes by <A> outlining follow-up procedures for recurrent or persistent disease </A>, suggesting additional assessments and treatments based on the risk features identified during earlier stages.

Section Name: Detailed Explanation
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.
Adverse Pathological Feature : A pathological feature that indicates a worse prognosis or outcome.
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.

Relationships:-
1. Entity1: ""Systemic therapy"", Entity2: ""Radiation"", Relationship: ""Concurrent treatment""
2. Entity1: ""Clinical trials"", Entity2: ""Personalized treatment plans"", Relationship: ""Development of""

Causalities:-
<A> The flowchart is designed to provide healthcare professionals with a systematic pathway for managing glottic larynx cancer </A>. Each step is meticulously organized to ensure that important factors are considered, such as <C> the presence of adverse pathological features </C>, which <E> strongly influence treatment decisions </E>.

<A> The emphasis on concurrent treatments, such as systemic therapy combined with radiation </A>, reflects current best practices in oncology, where multimodal approaches are often necessary to achieve better outcomes. <A> The inclusion of clinical trials </A> indicates an emphasis on maintaining up-to-date practices and personalized treatment plans as part of patient management strategies.

Furthermore, <A> the chart's organization into treatment and follow-up segments </A> allows for a straightforward interpretation, guiding oncologists through complex decisions in a logical manner. This can <E> improve consistency in care and enhance patient safety through meticulous monitoring and responses to treatment efficacy or disease progression </E>.

In summary, <E> this flowchart serves as an essential resource for oncologists, facilitating a better understanding of treatment protocols for glottic larynx cancer while promoting a patient-centered approach to oncological care </E>.

Section Name: NCCN Guidelines Version 4.2024
====================
Entities:-
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.
Clinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Neoplasms : New abnormal growth of tissue that may be benign or malignant.
Malignant Neoplastic Disease : A disease in which abnormal cells divide uncontrollably and destroy body tissue.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.
National Comprehensive Cancer Network : An alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network"", Entity2: ""NCCN Guidelines"", Relationship: ""publishes""
2. Entity1: ""Clinical trial"", Entity2: ""Cancer"", Relationship: ""manages""

Causalities:-
<C> any patient with cancer </C> <E> the best management is in a clinical trial </E>. <A> Participation in clinical trials is especially encouraged </A>.

Section Name: Principles of Treatment
====================
Entities:-
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Extranodal Extension : The spread of cancer beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margins : Cancer cells are found at the edge of the material removed during surgery, indicating that some cancer may have been left behind.
Perineural Invasion : Cancer cells are found surrounding or tracking along a nerve within the perineural space.
Vascular Invasion : The presence of cancer cells within blood vessels.
Lymphatic Metastasis : The spread of cancer cells through the lymphatic system to distant sites.

Relationships:-
1. Entity1: ""Principles of Radiation Therapy"", Entity2: ""Extranodal Extension"", Relationship: ""management of""
2. Entity1: ""Principles of Surgery"", Entity2: ""Positive Surgical Margins"", Relationship: ""concerned with avoiding""
3. Entity1: ""Principles of Radiation Therapy"", Entity2: ""Perineural Invasion"", Relationship: ""consideration in treatment planning""

Causalities:-
<C> Extranodal extension </C> <C> Positive margins </C> <C> Close margins </C> <C> pT4 primary </C> <C> pN2 or pN3 nodal disease </C> <C> Perineural invasion </C> <C> Vascular invasion </C> <C> Lymphatic invasion </C> <C> Subglottic extension </C>

Section Name: Clinical Staging
====================
Entities:-
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to enhance its effectiveness.
Adjuvant Therapy : A therapy given in addition to the primary or initial therapy to maximize its effectiveness.
Follow-Up Studies : Studies that continue to monitor patients after treatment to assess long-term outcomes.
Follow-Up Procedure : A procedure performed to monitor the progress of a patient after initial treatment.
Follow-Up : The act of monitoring a patient's health over time after treatment.
Neoplasm Recurrence, Local : The return of a tumor at the original site after treatment.
Recurrent Disease : A disease that has returned after a period of remission.

Relationships:-
1. Entity1: ""Adjuvant Treatment"", Entity2: ""Recurrent or Persistent Disease"", Relationship: ""prevention""
2. Entity1: ""Follow-up"", Entity2: ""Recurrent or Persistent Disease"", Relationship: ""monitoring""

Section Name: Treatment Options
====================
Entities:-
Laryngectomy : Surgical procedure to remove the larynx, often used to treat laryngeal cancer.
Total Laryngectomy : A surgical procedure to remove the entire larynx.
Chemotherapy, Adjuvant : Drug therapy given in addition to the primary treatment to enhance its effectiveness.
Induction Chemotherapy : Chemotherapy given as a first step to shrink a tumor before the main treatment.
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.
Clinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.

Relationships:-
1. Entity1: ""T3 requiring total laryngectomy"", Entity2: ""Concurrent systemic therapy/RT"", Relationship: ""treatment option""
2. Entity1: ""T3 requiring total laryngectomy"", Entity2: ""Induction chemotherapy"", Relationship: ""treatment option""
3. Entity1: ""T3 requiring total laryngectomy"", Entity2: ""Clinical trials"", Relationship: ""research option""

Causalities:-
<CO> T3 requiring (amenable to) total laryngectomy (N2–3) </CO> <A> Concurrent systemic therapy/RT </A> <A> Surgery </A> <A> Induction chemotherapy </A> <A> Clinical trials </A>

Section Name: Surgical Considerations
====================
Entities:-
Laryngectomy : Surgical procedure to remove the larynx, often used to treat laryngeal cancer.
Thyroidectomy : Surgical removal of all or part of the thyroid gland.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue in the neck.
Lymph Node Excision : Surgical removal of one or more lymph nodes.
Lymph Node Dissection : A surgical procedure to remove lymph nodes.
Lymphadenectomy : Surgical removal of one or more groups of lymph nodes.

Relationships:-
1. Entity1: ""Laryngectomy"", Entity2: ""Thyroidectomy"", Relationship: ""performed with""
2. Entity1: ""Neck Dissection"", Entity2: ""Lymph Node Excision"", Relationship: ""includes""
3. Entity1: ""Neck Dissection"", Entity2: ""Lymph Node Excision"", Relationship: ""includes specific types""

Causalities:-
<A> Laryngectomy with thyroidectomy as indicated, ipsilateral or bilateral neck dissection, and pretracheal and ipsilateral paratracheal lymph node dissection </A>

Section Name: Pathologic Features
====================
Entities:-
Extranodal Extension : The spread of cancer beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margins : Cancer cells are found at the edge of the material removed during surgery, indicating that some cancer may have been left behind.
Positive Margin : A surgical margin that contains residual tumor cells.

Relationships:-
1. Entity1: ""Adverse pathologic features"", Entity2: ""Extranodal extension"", Relationship: ""includes""
2. Entity1: ""Adverse pathologic features"", Entity2: ""Positive margin"", Relationship: ""includes""

Causalities:-
- **No adverse pathologic features**
- **Adverse pathologic features**
  - <C> Extranodal extension and/or positive margin </C>
  - Other risk features

Section Name: Systemic Therapy
====================
Entities:-
Antineoplastic Agents : Drugs used to treat cancer by inhibiting the growth of cancerous cells.
Systemic Therapy : A treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiotherapy : The use of radiation, usually high-energy X-rays, to damage cancer cells and treat cancer.
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.

Relationships:-
1. Entity1: ""Systemic therapy"", Entity2: ""RT"", Relationship: ""Consideration""

Causalities:-
<A> Systemic therapy/RT (category 1) </A>
<A> RT </A>
<A> Consider systemic therapy/RT </A>

Section Name: Imaging
====================
Entities:-
Tomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.
Magnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body's soft tissue and bones.
Neck : Part of the body, on many terrestrial or secondarily aquatic vertebrates, that distinguishes the head from the torso or trunk.
Computed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images (often called slices), both horizontally and vertically, of the body.
Neck Structure : The anatomical structure that connects the head to the torso.

Relationships:-
1. Entity1: ""CT"", Entity2: ""Neck"", Relationship: ""imaging of""
2. Entity1: ""MRI"", Entity2: ""Neck"", Relationship: ""imaging of""

Causalities:-
<A> CT (with contrast) or MRI (with and without contrast) of primary and neck </A>

Section Name: Post-Treatment Evaluation
====================
Entities:-
Radiotherapy : The use of radiation, usually high-energy X-rays, to damage cancer cells and treat cancer.
Pn1 Category : A pathological classification indicating regional lymph node metastasis in cancer staging.
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.

Relationships:-
1. Entity1: ""Post Systemic Therapy/RT or RT Neck Evaluation"", Entity2: ""pN1"", Relationship: ""evaluation of cancer staging""
2. Entity1: ""pN1"", Entity2: ""Consider RT"", Relationship: ""treatment recommendation""

Causalities:-
<CO> pN1 without other risk features </CO> <A> Consider RT </A>

Section Name: Additional Notes
====================
Entities:-
Antineoplastic Combined Chemotherapy Protocols : Protocols for the administration of more than one antineoplastic agent in combination to treat malignant neoplasms.
Cisplatin : A platinum-containing antineoplastic agent used in the treatment of various cancers.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Non-Nasopharyngeal Cancers"", Relationship: ""used for""
2. Entity1: ""Cisplatin"", Entity2: ""Systemic Therapy"", Relationship: ""preferred agent in""
3. Entity1: ""Induction Chemotherapy"", Entity2: ""Systemic Therapy"", Relationship: ""discussed in context of""

Causalities:-
- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**
- **<CO> When using concurrent systemic therapy/RT </CO>, <A> the preferred agent is cisplatin (category 1) </A>. See Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A).**
- **<A> See Discussion on induction chemotherapy. </A>**
--------------------------------------------------
Page Number: 94

Section Name: Head and Neck Cancers - Principles of Imaging
====================
Entities:-
Positron Emission Tomography Computed Tomography : A medical imaging technique combining PET and CT capabilities to provide detailed information about the body's function and structure.
Positron Emission Tomography : A nuclear medicine functional imaging technique that is used to observe metabolic processes in the body.
Computed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.
Head And Neck Neoplasms : Cancers that arise in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.

Relationships:-
1. Entity1: ""PET/CT"", Entity2: ""PET scan"", Relationship: ""preferred over""
2. Entity1: ""PET-CT"", Entity2: ""head neck cancers"", Relationship: ""used in study of""

Causalities:-
<A> PET/CT is preferred over PET scan alone (i.e., without superimposed CT scan) </A>. <C> PET/CT provides more accurate anatomical localization of abnormalities </C> <E> more accurate anatomical localization of abnormalities </E>.

Section Name: Initial Workup - Nodal Metastases
====================
Entities:-
Lymphatic Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site via the lymphatic system.
Tomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient, producing signals that are processed by the machine's computer to generate cross-sectional images.
Magnetic Resonance Imaging : A non-invasive imaging technique that uses magnetic fields and radio waves to create detailed images of the organs and tissues within the body.
Positron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption.
Lymph Node Metastasis : The spread of cancer cells to lymph nodes, which are part of the lymphatic system.
Ct Of Neck : A computed tomography scan of the neck region.
Mri Of Neck : A magnetic resonance imaging scan of the neck region.
Fdg-Pet Scan : A type of positron emission tomography using fluorodeoxyglucose to assess metabolic activity.
Computed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.
Positron Emission Tomography : A nuclear medicine functional imaging technique that is used to observe metabolic processes in the body.

Relationships:-
1. Entity1: ""CT"", Entity2: ""lymph node metastases"", Relationship: ""used to evaluate""
2. Entity1: ""MRI"", Entity2: ""lymph node metastases"", Relationship: ""used to evaluate""
3. Entity1: ""FDG-PET/CT"", Entity2: ""lymph node metastases"", Relationship: ""used for detection""
4. Entity1: ""FDG-PET/CT"", Entity2: ""surgical primary approach"", Relationship: ""used to determine""
5. Entity1: ""FDG-PET/CT"", Entity2: ""definitive RT approach"", Relationship: ""used to identify""

Causalities:-
<A> Evaluation of lymph node metastases should be conducted with CT or MRI of the neck </A>, using whichever imaging study is suitable for primary site evaluation (IMG-A, 1 of 4).
<CO> For patients with multistation or lower neck nodal involvement or high-grade tumor histology </CO>, <A> consider CT of the chest to assess for mediastinal lymph node metastases or FDG-PET/CT </A>, <C> which is associated with higher sensitivity for both nodal and distant metastases </C>.
<CO> For patients who are under consideration for a surgical primary approach </CO>, <A> the higher sensitivity of FDG-PET/CT is warranted for tumors approaching the midline, to determine the surgical approach to the contralateral neck </A>. <CO> Similarly, patients who are scheduled for a definitive RT approach </CO> <A> may benefit from the higher sensitivity of FDG-PET/CT for identifying involved lymph nodes </A>.

Section Name: Initial Workup - Distant Metastases
====================
Entities:-
Positron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption.
Magnetic Resonance Imaging : A non-invasive imaging technique that uses magnetic fields and radio waves to create detailed images of the organs and tissues within the body.
Tomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient, producing signals that are processed by the machine's computer to generate cross-sectional images.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Lung Neoplasms : Tumors or cancer of the lung.
Smoking : The inhalation of the smoke of burning tobacco encased in cigarettes, pipes, and cigars.

Relationships:-
1. Entity1: ""FDG-PET/CT"", Entity2: ""Distant Metastases"", Relationship: ""used to evaluate""
2. Entity1: ""Contrast-enhanced brain MRI"", Entity2: ""Brain Metastasis"", Relationship: ""recommended for evaluation""
3. Entity1: ""CT of the chest"", Entity2: ""Pulmonary Metastases"", Relationship: ""performed to assess""
4. Entity1: ""Non-contrast CT of the chest"", Entity2: ""Lung Parenchymal Metastases"", Relationship: ""used to screen""
5. Entity1: ""Annual CT screening"", Entity2: ""Lung Metastasis"", Relationship: ""considered for high risk""
6. Entity1: ""Directed CT or MRI"", Entity2: ""Distant Disease"", Relationship: ""used for assessment""
7. Entity1: ""FDG-PET/CT"", Entity2: ""Recurrent Disease"", Relationship: ""used for staging""

Causalities:-
<C> Patients with locoregionally advanced cancer (e.g., T3–T4 primary or ≥N1 nodal staging) </C>, <A> FDG-PET/CT is preferred to evaluate for distant disease and thoracic metastases </A>. <CO> For cancers where brain metastasis is a concern, such as mucosal melanoma or high-grade neuroendocrine carcinomas or adenocarcinomas </CO>, <A> contrast-enhanced brain MRI should be additionally obtained </A>.
<CO> If FDG-PET/CT is not performed </CO>, <A> CT of the chest should be performed to assess for presence of pulmonary metastases as well as mediastinal lymph node involvement </A>.
<CO> Non-contrast CT of the chest can be sufficient to screen for lung parenchymal metastases </CO> but <CO> is not adequate for assessment of mediastinal adenopathy </CO>. <CO> This is an appropriate lung cancer screening intervention for patients with a history of smoking </CO>.
<CO> Following primary definitive treatment (surgery, RT, or systemic therapy/RT) </CO> the role of annual CT screening for lung metastasis is controversial. <E> While this approach does detect early metastasis </E>, <CO> further study is needed to determine the extent of the positive effect and/or cost-effectiveness of this approach in specific subpopulations and timepoints post-treatment </CO>. <CO> For patients with a substantial smoking history or who are at high risk for lung metastases </CO>, <A> annual chest CT can be considered </A>.
<CO> If clinical concern for metastatic disease is confined to a specific anatomical area </CO>, <A> the assessment of distant disease can be performed with directed CT or MRI examination </A>.
<CO> FDG-PET/CT may complement or replace other imaging modalities when staging recurrent disease before any therapy for relapsed/refractory disease </CO> <A> in order to explore distant disease or second primaries that may significantly impact choice of therapy </A>.
--------------------------------------------------
Page Number: 93

Section Name: PRINCIPLES OF IMAGING
====================
Entities:-
Imaging, Diagnostic : The production of a visual representation of parts of the body, for the purpose of clinical analysis and medical intervention.
Head And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Tomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.
Magnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body's soft tissue and bones.
Contrast Media : Substances used to enhance the contrast of structures or fluids within the body in medical imaging.

Relationships:-
1. Entity1: ""Imaging, Diagnostic"", Entity2: ""Head and Neck Neoplasms"", Relationship: ""used for""
2. Entity1: ""Tomography, X-Ray Computed"", Entity2: ""Contrast Media"", Relationship: ""uses""
3. Entity1: ""Magnetic Resonance Imaging"", Entity2: ""Contrast Media"", Relationship: ""uses""

Causalities:-
<C> Imaging </C> plays an essential role in the clinical care of patients with head and neck cancer. <A> The proper selection and utilization of imaging studies </A> is critical in caring for patients with head and neck cancer. <A> CT is performed with contrast </A>, while <A> CT imaging of the chest can be performed with or without contrast </A>, <CO> as clinically indicated </CO>. <A> MRI is performed with and without contrast </A>, <CO> unless contraindicated </CO>.

Section Name: Initial Workup - Primary Site
====================
Entities:-
Tomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.
Magnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body's soft tissue and bones.
Head And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Neck Structure : The anatomical structure of the neck, which is the part of the body that connects the head to the torso.
Skull Base : The bottom part of the skull, which separates the brain from other facial structures.
Thoracic Inlet : The opening at the top of the thoracic cavity, through which pass the trachea, esophagus, and major blood vessels.

Relationships:-
1. Entity1: ""CT"", Entity2: ""MRI"", Relationship: ""complementary in imaging head and neck cancers""
2. Entity1: ""CT"", Entity2: ""Head and Neck Neoplasms"", Relationship: ""used to evaluate""
3. Entity1: ""MRI"", Entity2: ""Head and Neck Neoplasms"", Relationship: ""preferred for evaluating""
4. Entity1: ""Skull base"", Entity2: ""Thoracic inlet"", Relationship: ""imaging range for evaluation""

Causalities:-
<A>Imaging assessment of the primary site</A> can be performed with <A>CT of the soft tissues of the neck</A> or <A>MRI of the neck</A>. <C>CT is complementary to MRI for head and neck cancers</C>. <A>It is utilized to evaluate cortical bone erosion or periosteal invasion, cartilage invasion, and bony erosion or destruction</A>. <CO>in certain conditions, such as evaluating the extent of bone marrow invasion or in patients with extensive dental amalgam obscuring anatomy on CT, assessing skull base invasion and cranial nerve involvement, and differentiating tumor from obstructed sinuses</CO>, <A>MRI is preferred over CT</A>. <CO>when involved lymph nodes or upper mediastinal cancers are present</CO>, <A>Complete evaluation of primary and nodal disease requires imaging from the skull base to the thoracic inlet, extending to the carina</A>.

Section Name: PET/CT and Biopsy
====================
Entities:-
Positron Emission Tomography Computed Tomography : A medical imaging technique that combines PET and CT capabilities to provide detailed images of the body.
Examination Under Anesthesia : A procedure where a patient is examined while under anesthesia to allow for a more thorough examination.
Biopsy : A medical test involving the extraction of sample cells or tissues for examination to determine the presence or extent of a disease.
Tonsillectomy : A surgical procedure to remove the tonsils, often performed to treat recurrent tonsillitis or sleep apnea.
Fine Needle Aspiration : A type of biopsy procedure that uses a thin, hollow needle to extract cells from a lump or mass for examination.
Ultrasound : A medical imaging technique that uses high-frequency sound waves to visualize internal organs and structures.
Computed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.

Relationships:-
1. Entity1: ""PET/CT"", Entity2: ""EUA"", Relationship: ""recommended before""
2. Entity1: ""Fine Needle Aspiration (FNA)"", Entity2: ""metastatic nodes"", Relationship: ""used for biopsy of""
3. Entity1: ""Image-guided needle biopsy"", Entity2: ""cystic neck nodes"", Relationship: ""recommended for initial diagnosis of""

Causalities:-
<CO> If imaging does not reveal an obvious primary cancer </CO>, <A> a PET/CT should be ordered before EUA, biopsies, and tonsillectomy </A>. <E> This helps identify potential primary sites </E> before any interventions take place. Additionally, <A> Fine Needle Aspiration (FNA) biopsy of metastatic nodes </A> <E> may provide pathologically informative results </E>. <CO> For initial diagnosis in cystic neck nodes </CO>, <A> image-guided needle biopsy (ultrasound or CT) </A> <E> may yield better results than FNA by palpation alone </E>.

Section Name: Postoperative Imaging Advice
====================
Entities:-
Panoramic Radiography : A type of dental x-ray that provides a wide view of the upper and lower jaws, teeth, temporomandibular joints, and sinuses.
Oral Cavity : The cavity of the mouth, including the lips, the lining inside the cheeks and lips, the front two-thirds of the tongue, the gums, the floor of the mouth under the tongue, the hard palate, and the small area of the gum behind the wisdom teeth.
Radiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.
Mandibulotomy : A surgical procedure involving the cutting of the mandible.
Mandibulectomy : A surgical procedure involving the removal of part or all of the mandible.
Oropharynx : The part of the throat at the back of the mouth behind the oral cavity.

Relationships:-
1. Entity1: ""panoramic dental x-ray"", Entity2: ""oral cavity cancers"", Relationship: ""recommended for""
2. Entity1: ""panoramic dental x-ray"", Entity2: ""postoperative radiotherapy"", Relationship: ""essential for pre-radiation evaluation""
3. Entity1: ""pre-radiation dental evaluation"", Entity2: ""dental procedures or extractions"", Relationship: ""determine necessity of""

Causalities:-
<A> A panoramic dental x-ray is recommended </A> <C> for oral cavity cancers requiring mandibulotomy and/or mandibulectomy </C>. <CO> When postoperative radiotherapy (RT) is anticipated for areas like the lip, oral cavity subsites, or oropharynx </CO>, <A> panoramic x-ray is essential for a comprehensive pre-radiation dental evaluation </A> <E> to assess the health of affected teeth and determine if pre-radiation dental procedures or extractions are necessary </E>.

Section Name: NCCN Guidelines Note
====================
Entities:-
Neoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.
Malignant Neoplastic Disease : A disease characterized by uncontrolled, abnormal growth of cells that can invade or spread to other parts of the body.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.
Clinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.
Clinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.

Relationships:-
1. Entity1: ""NCCN"", Entity2: ""Clinical Trials"", Relationship: ""encourages participation in""
2. Entity1: ""NCCN"", Entity2: ""Cancer"", Relationship: ""recommends clinical trials for""

Causalities:-
<A> NCCN believes that the best management of any patient with cancer is through participation in clinical trials </A>, <A> which is especially encouraged </A>.
--------------------------------------------------
Page Number: 92

Section Name: NCCN Guidelines Overview
====================
Entities:-
Head And Neck Neoplasms : Cancers that arise in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Malignant Neoplasm Of Head And Neck : A malignant tumor located in the head and neck region.
Head And Neck Cancer : A group of cancers that originate in the head and neck region.
Antineoplastic Agents : Drugs used to treat cancer by inhibiting the growth of cancerous cells.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.
Radiation Therapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.

Relationships:-
1. Entity1: ""Head and neck cancers"", Entity2: ""Systemic therapy"", Relationship: ""follow-up recommendations after""
2. Entity1: ""Head and neck cancers"", Entity2: ""Radiation therapy"", Relationship: ""follow-up recommendations after""

Causalities:-
The image presents a flowchart from the National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2024, especially focusing on <A> follow-up recommendations </A> for <CO> patients with head and neck cancers after systemic therapy or radiation therapy (RT) </CO>. All recommendations are categorized as level A unless stated otherwise, highlighting the importance of clinical trials in cancer management.

Section Name: Imaging and Assessment Protocols
====================
Entities:-
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.
Clinical Assessment : A systematic evaluation of a patient's health status, often involving a physical examination and medical history.
Positron-Emission Tomography : An imaging technique using a radioactive substance called a tracer to look for disease in the body.
Computed Tomography : A medical imaging technique used in radiology to obtain detailed internal images of the body.
Magnetic Resonance Imaging : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis.
Disease : A disorder of structure or function in a human, animal, or plant, especially one that produces specific symptoms.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.
Residual Neoplasm : Remaining cancer cells after treatment.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Clinical Assessment"", Relationship: ""occurs before""
2. Entity1: ""FDG-PET/CT Scan"", Entity2: ""Distant Metastases"", Relationship: ""assesses""
3. Entity1: ""FDG-PET/CT Scan"", Entity2: ""Observation"", Relationship: ""leads to if negative""
4. Entity1: ""FDG-PET/CT Scan"", Entity2: ""CT Scan"", Relationship: ""leads to if strongly positive""
5. Entity1: ""CT Scan"", Entity2: ""Neck Dissection"", Relationship: ""leads to if positive""

Causalities:-
<CO> After systemic therapy or RT </CO>, <A> a clinical assessment should occur 4 to 8 weeks later </A>. <CO> If there is a response </CO>, <A> it is necessary to assess the extent of disease or distant metastases, preferably through a FDG-PET/CT scan at a minimum of 12 weeks post-treatment </A>. <CO> If the FDG-PET/CT results are negative </CO>, <A> the patient may continue with monitoring through observation </A>. <CO> In cases where the results are equivocal </CO>, <A> observation or repeat FDG-PET/CT within 3 to 6 months is prescribed </A>.

<CO> In cases where the FDG-PET/CT results are strongly positive </CO>, <A> further imaging via CT scan with contrast of the primary site and neck, or MRI with and without contrast, becomes necessary </A>. <CO> If these imaging results confirm positive findings </CO>, <A> neck dissection may be considered, depending on the evidence of residual or persistent disease </A>. <CO> If the imaging findings are negative </CO>, <A> the patient might continue in observation </A>.

Section Name: Outcomes Based on Disease Resectability
====================
Entities:-
Disease : A disorder of structure or function in a human, animal, or plant, especially one that produces specific symptoms.
Resectable : Capable of being surgically removed.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis.

Relationships:-
1. Entity1: ""Disease"", Entity2: ""Resectable"", Relationship: ""Classification""
2. Entity1: ""Unresectable"", Entity2: ""Treatment plans (ADV-3)"", Relationship: ""Treatment recommendation""
3. Entity1: ""Resectable"", Entity2: ""Resection and/or Neck dissection"", Relationship: ""Surgical procedure""

Causalities:-
<CO> If there is confirmed residual or persistent disease </CO>, the options split into two pathways: 'Unresectable' or 'Resectable.' <CO> If the disease is classified as unresectable </CO>, <A> advances in treatment plans (labeled ADV-3) are called for </A>. Conversely, <CO> if it is deemed resectable </CO>, <A> a resection of the primary and/or neck dissection may occur </A>, <CO> contingent upon the disease status </CO>.

Section Name: Important Notes
====================
Entities:-
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.
Clinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.
Positron-Emission Tomography : An imaging technique using a radioactive substance called a tracer to look for disease in the body.
Positron Emission Tomography (Procedure) : A diagnostic imaging procedure that uses a radioactive tracer to visualize and measure changes in metabolic processes.
Positron Emission Tomography : A nuclear medicine functional imaging technique used to observe metabolic processes in the body.
Neoplasms : New abnormal growth of tissue in animals or plants; a tumor.
Malignant Neoplasm : A cancerous growth that has the potential to spread to other parts of the body.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""NCCN"", Entity2: ""Clinical trials"", Relationship: ""emphasizes participation in""
2. Entity1: ""FDG-PET/CT"", Entity2: ""Persistent cancer"", Relationship: ""used to detect""
3. Entity1: ""FDG-PET/CT"", Entity2: ""PET negative"", Relationship: ""interpretation of results""
4. Entity1: ""FDG-PET/CT"", Entity2: ""PET positive"", Relationship: ""interpretation of results""

Causalities:-
<A> NCCN emphasizes that the best management for any cancer patient is participation in clinical trials </A>, especially encouraged for all patients. Additional notes clarify that <CO> if the FDG-PET/CT is negative for persistent cancer </CO>, <A> further cross-sectional imaging is optional </A>. The interpretations define <CO> PET negative as no or low-grade uptake not suspicious for disease </CO>, while <CO> PET positive implies suspicion for disease </CO>.


Among these two options which one is the most likely true:

(A) `Presence_of_Metastasis_in_Lymph_Nodes_5` increases risk `Magnetic_Resonance_Imaging_MRI_9`
(B) `Magnetic_Resonance_Imaging_MRI_9` `increases risk `Presence_of_Metastasis_in_Lymph_Nodes_5`

The answer is: ...

1. State the evidences in detail of the validity of option (A) or (B) by cross referencing
NCCN Clinical Practitioner’s Guidelines for Head and Neck Cancer.
2. If the evidences are obtained from `INFORMATION FROM KNOWLEDGE BASE`,
mention their corresponding Page Numbers, Section Name, entities, relationships and causalities.

DESIRED OUTPUT FORMAT:
<thinking>
...
</thinking>
<answer>
{
   ""thinking"": [""..."", ...],
   ""evidences"": [""..."", ...],
   ""answer"": ...
}
</answer>

Before providing the answer in <answer> tags, think step by step in detail in <thinking> tags and analyze every part.
Output inside <answer> tag in JSON format. Only output valid JSON.
DO NOT HALLUCINATE. DO NOT MAKE UP FACTUAL INFORMATION.
","1. The edge (Presence_of_Metastasis_in_Lymph_Nodes_5) causes (Magnetic_Resonance_Imaging_MRI_9) is not valid because MRI is a diagnostic tool that detects metastasis, not caused by it.
2. The edge (Magnetic_Resonance_Imaging_MRI_9) causes (Presence_of_Metastasis_in_Lymph_Nodes_5) is also not valid because MRI does not cause metastasis; it only detects it.
3. The causal direction for both edges is marked as 'Unknown', indicating no clear causal relationship.
4. The causal factor for both edges is neither necessary nor sufficient, further indicating the lack of a causal relationship.
5. The causal distance is marked as 'Proximal', suggesting a direct observation rather than a causal effect.
6. From the knowledge base, MRI is used as an imaging study to evaluate the presence of metastasis, not to cause it (Page 41, Section Name: Workup).
7. MRI is a diagnostic tool used to detect abnormalities, including metastasis, as per the NCCN guidelines (Page 92, Section Name: Imaging and Assessment Protocols).
","1. Page 41, Section Name: Workup, MRI is used to evaluate the presence of metastasis.
2. Page 92, Section Name: Imaging and Assessment Protocols, MRI is a diagnostic tool for detecting abnormalities.
",A,"{'A': 86.7, 'B': 13.3}",yes,A,"1. The AI assistant's reasoning is based on the understanding that MRI is a diagnostic tool, not a causal factor in the presence of metastasis.
2. The assistant correctly identifies that the causal direction for both edges is marked as 'Unknown', indicating no clear causal relationship.
3. The assistant notes that the causal factor for both edges is neither necessary nor sufficient, which aligns with the understanding that MRI is used for detection, not causation.
4. The assistant references the knowledge base, specifically Page 41, Section Name: Workup, to support the claim that MRI is used to evaluate the presence of metastasis.
5. The assistant also references Page 92, Section Name: Imaging and Assessment Protocols, to further support the role of MRI as a diagnostic tool.
6. The final answer provided by the assistant is consistent with the reasoning, as it concludes that option (A) is more likely true, given that the presence of metastasis is detected by MRI, not caused by it.
"
2,gpt-4o,"Presence_of_Metastasis_in_Lymph_Nodes_5,Positron_Emission_Tomography_PET_Scans_10","""{'NODE1': {'id': 'Presence_of_Metastasis_in_Lymph_Nodes_5', 'label': 'Metastasis in Nearby Lymph Nodes', 'description': 'This node represents the clinical situation regarding whether metastasis is present in the nearby lymph nodes of a patient. It is a critical factor in determining the stage and prognosis of cancer, as the spread of cancer to lymph nodes often indicates a more advanced disease and may influence treatment decisions.', 'type': 'Patient Situation', 'observability': 'Unobserved', 'states': [{'state_name': 'unknown', 'state_description': 'The status of metastasis in the lymph nodes is not determined. It is unclear whether cancer has spread to these nodes.'}, {'state_name': 'present', 'state_description': 'Metastasis is confirmed in the lymph nodes, indicating that cancer has spread to these nodes.'}, {'state_name': 'absent', 'state_description': 'There is no metastasis in the lymph nodes, indicating that cancer has not spread to these nodes.'}]}, 'NODE2': {'id': 'Positron_Emission_Tomography_PET_Scans_10', 'label': 'Positron Emission Tomography (PET) Scan Result', 'description': 'This node represents the result of a Positron Emission Tomography (PET) scan, which is an imaging test used to observe metabolic processes in the body. It is often used in oncology to detect cancerous tissues, assess the spread of cancer, and evaluate the effectiveness of treatment.', 'type': 'Examination Result', 'observability': 'Observed', 'states': [{'state_name': 'present', 'state_description': \""The 'present' state indicates that the PET scan has detected abnormal metabolic activity, which may suggest the presence of cancerous tissues or other pathological conditions.\""}, {'state_name': 'absent', 'state_description': \""The 'absent' state indicates that the PET scan did not detect any abnormal metabolic activity, suggesting the absence of cancerous tissues or other significant pathological conditions.\""}]}, 'EDGE1': {'edges_ids': ['Presence_of_Metastasis_in_Lymph_Nodes_5', 'Positron_Emission_Tomography_PET_Scans_10'], 'edge': '(Presence_of_Metastasis_in_Lymph_Nodes_5) causes (Positron_Emission_Tomography_PET_Scans_10)', 'explanation': ['The presence of metastasis in lymph nodes is a critical factor in cancer staging and prognosis.', 'A PET scan is an imaging test used to detect abnormal metabolic activity, often associated with cancer.', 'If metastasis is present in the lymph nodes, it is likely to be detected as abnormal metabolic activity on a PET scan.', 'Therefore, there is a valid causal relationship where the presence of metastasis in lymph nodes can cause a positive PET scan result.', 'The causal direction is positive because the presence of metastasis leads to a positive PET scan result.', 'The presence of metastasis is a sufficient condition for a positive PET scan result, as it would typically show up as abnormal activity.', 'The causal distance is proximal because the presence of metastasis directly affects the PET scan result.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': True}, 'causal_distance': 'Proximal'}, 'EDGE2': {'edges_ids': ['Positron_Emission_Tomography_PET_Scans_10', 'Presence_of_Metastasis_in_Lymph_Nodes_5'], 'edge': '(Positron_Emission_Tomography_PET_Scans_10) causes (Presence_of_Metastasis_in_Lymph_Nodes_5)', 'explanation': ['The edge suggests that the result of a PET scan causes the presence of metastasis in lymph nodes.', 'However, a PET scan is a diagnostic tool that detects existing conditions, such as metastasis, rather than causing them.', 'The presence of metastasis in lymph nodes is a pathological condition that occurs independently of the PET scan.', 'The PET scan can reveal the presence of metastasis by showing abnormal metabolic activity, but it does not cause the metastasis to occur.', 'Therefore, the edge is not valid as a causal relationship.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}, 'ENTITIES_MATCHING_PAGES_INFO': {'92': {'matching_entities': [{'POSITRON EMISSION TOMOGRAPHY (PROCEDURE)': 0.9864658}, {'POSITRON-EMISSION TOMOGRAPHY': 0.9655257}, {'METASTASIS': 0.9630129}, {'POSITRON EMISSION TOMOGRAPHY': 0.9552841}, {'MALIGNANT NEOPLASM': 0.9448747}, {'CANCER': 0.92851335}, {'MAGNETIC RESONANCE IMAGING': 0.9216922}], 'count': 7}, '94': {'matching_entities': [{'NEOPLASM METASTASIS': 0.96748203}, {'POSITRON-EMISSION TOMOGRAPHY': 0.9655257}, {'POSITRON EMISSION TOMOGRAPHY': 0.9552841}, {'LYMPHATIC METASTASIS': 0.94962627}, {'LYMPH NODE METASTASIS': 0.9418514}, {'POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY': 0.94104874}, {'MAGNETIC RESONANCE IMAGING': 0.9216922}], 'count': 7}, '55': {'matching_entities': [{'NEOPLASM METASTASIS': 0.96748203}, {'METASTASIS': 0.9630129}, {'METASTATIC NEOPLASM': 0.96172774}, {'MALIGNANT NEOPLASTIC DISEASE': 0.9424237}, {'CANCER': 0.92851335}], 'count': 5}, '130': {'matching_entities': [{'LYMPH NODE STRUCTURE': 0.99134904}, {'LYMPH NODE': 0.98570025}, {'LYMPH NODES': 0.97445965}, {'NEOPLASM METASTASIS': 0.96748203}, {'METASTASIS': 0.9630129}], 'count': 5}, '93': {'matching_entities': [{'MALIGNANT NEOPLASTIC DISEASE': 0.9424237}, {'POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY': 0.94104874}, {'CANCER': 0.92851335}, {'MAGNETIC RESONANCE IMAGING': 0.9216922}], 'count': 4}}, 'GUIDELINE_PAGES_INFO': '--------------------------------------------------\\nPage Number: 92\\n\\nSection Name: NCCN Guidelines Overview\\n====================\\nEntities:-\\nHead And Neck Neoplasms : Cancers that arise in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\nMalignant Neoplasm Of Head And Neck : A malignant tumor located in the head and neck region.\\nHead And Neck Cancer : A group of cancers that originate in the head and neck region.\\nAntineoplastic Agents : Drugs used to treat cancer by inhibiting the growth of cancerous cells.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.\\nRadiation Therapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.\\n\\nRelationships:-\\n1. Entity1: \""Head and neck cancers\"", Entity2: \""Systemic therapy\"", Relationship: \""follow-up recommendations after\""\\n2. Entity1: \""Head and neck cancers\"", Entity2: \""Radiation therapy\"", Relationship: \""follow-up recommendations after\""\\n\\nCausalities:-\\nThe image presents a flowchart from the National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2024, especially focusing on <A> follow-up recommendations </A> for <CO> patients with head and neck cancers after systemic therapy or radiation therapy (RT) </CO>. All recommendations are categorized as level A unless stated otherwise, highlighting the importance of clinical trials in cancer management.\\n\\nSection Name: Imaging and Assessment Protocols\\n====================\\nEntities:-\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.\\nClinical Assessment : A systematic evaluation of a patient\\'s health status, often involving a physical examination and medical history.\\nPositron-Emission Tomography : An imaging technique using a radioactive substance called a tracer to look for disease in the body.\\nComputed Tomography : A medical imaging technique used in radiology to obtain detailed internal images of the body.\\nMagnetic Resonance Imaging : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis.\\nDisease : A disorder of structure or function in a human, animal, or plant, especially one that produces specific symptoms.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\nResidual Neoplasm : Remaining cancer cells after treatment.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Clinical Assessment\"", Relationship: \""occurs before\""\\n2. Entity1: \""FDG-PET/CT Scan\"", Entity2: \""Distant Metastases\"", Relationship: \""assesses\""\\n3. Entity1: \""FDG-PET/CT Scan\"", Entity2: \""Observation\"", Relationship: \""leads to if negative\""\\n4. Entity1: \""FDG-PET/CT Scan\"", Entity2: \""CT Scan\"", Relationship: \""leads to if strongly positive\""\\n5. Entity1: \""CT Scan\"", Entity2: \""Neck Dissection\"", Relationship: \""leads to if positive\""\\n\\nCausalities:-\\n<CO> After systemic therapy or RT </CO>, <A> a clinical assessment should occur 4 to 8 weeks later </A>. <CO> If there is a response </CO>, <A> it is necessary to assess the extent of disease or distant metastases, preferably through a FDG-PET/CT scan at a minimum of 12 weeks post-treatment </A>. <CO> If the FDG-PET/CT results are negative </CO>, <A> the patient may continue with monitoring through observation </A>. <CO> In cases where the results are equivocal </CO>, <A> observation or repeat FDG-PET/CT within 3 to 6 months is prescribed </A>.\\n\\n<CO> In cases where the FDG-PET/CT results are strongly positive </CO>, <A> further imaging via CT scan with contrast of the primary site and neck, or MRI with and without contrast, becomes necessary </A>. <CO> If these imaging results confirm positive findings </CO>, <A> neck dissection may be considered, depending on the evidence of residual or persistent disease </A>. <CO> If the imaging findings are negative </CO>, <A> the patient might continue in observation </A>.\\n\\nSection Name: Outcomes Based on Disease Resectability\\n====================\\nEntities:-\\nDisease : A disorder of structure or function in a human, animal, or plant, especially one that produces specific symptoms.\\nResectable : Capable of being surgically removed.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis.\\n\\nRelationships:-\\n1. Entity1: \""Disease\"", Entity2: \""Resectable\"", Relationship: \""Classification\""\\n2. Entity1: \""Unresectable\"", Entity2: \""Treatment plans (ADV-3)\"", Relationship: \""Treatment recommendation\""\\n3. Entity1: \""Resectable\"", Entity2: \""Resection and/or Neck dissection\"", Relationship: \""Surgical procedure\""\\n\\nCausalities:-\\n<CO> If there is confirmed residual or persistent disease </CO>, the options split into two pathways: \\'Unresectable\\' or \\'Resectable.\\' <CO> If the disease is classified as unresectable </CO>, <A> advances in treatment plans (labeled ADV-3) are called for </A>. Conversely, <CO> if it is deemed resectable </CO>, <A> a resection of the primary and/or neck dissection may occur </A>, <CO> contingent upon the disease status </CO>.\\n\\nSection Name: Important Notes\\n====================\\nEntities:-\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\nClinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.\\nPositron-Emission Tomography : An imaging technique using a radioactive substance called a tracer to look for disease in the body.\\nPositron Emission Tomography (Procedure) : A diagnostic imaging procedure that uses a radioactive tracer to visualize and measure changes in metabolic processes.\\nPositron Emission Tomography : A nuclear medicine functional imaging technique used to observe metabolic processes in the body.\\nNeoplasms : New abnormal growth of tissue in animals or plants; a tumor.\\nMalignant Neoplasm : A cancerous growth that has the potential to spread to other parts of the body.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""NCCN\"", Entity2: \""Clinical trials\"", Relationship: \""emphasizes participation in\""\\n2. Entity1: \""FDG-PET/CT\"", Entity2: \""Persistent cancer\"", Relationship: \""used to detect\""\\n3. Entity1: \""FDG-PET/CT\"", Entity2: \""PET negative\"", Relationship: \""interpretation of results\""\\n4. Entity1: \""FDG-PET/CT\"", Entity2: \""PET positive\"", Relationship: \""interpretation of results\""\\n\\nCausalities:-\\n<A> NCCN emphasizes that the best management for any cancer patient is participation in clinical trials </A>, especially encouraged for all patients. Additional notes clarify that <CO> if the FDG-PET/CT is negative for persistent cancer </CO>, <A> further cross-sectional imaging is optional </A>. The interpretations define <CO> PET negative as no or low-grade uptake not suspicious for disease </CO>, while <CO> PET positive implies suspicion for disease </CO>.\\n--------------------------------------------------\\nPage Number: 94\\n\\nSection Name: Head and Neck Cancers - Principles of Imaging\\n====================\\nEntities:-\\nPositron Emission Tomography Computed Tomography : A medical imaging technique combining PET and CT capabilities to provide detailed information about the body\\'s function and structure.\\nPositron Emission Tomography : A nuclear medicine functional imaging technique that is used to observe metabolic processes in the body.\\nComputed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.\\nHead And Neck Neoplasms : Cancers that arise in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\n\\nRelationships:-\\n1. Entity1: \""PET/CT\"", Entity2: \""PET scan\"", Relationship: \""preferred over\""\\n2. Entity1: \""PET-CT\"", Entity2: \""head neck cancers\"", Relationship: \""used in study of\""\\n\\nCausalities:-\\n<A> PET/CT is preferred over PET scan alone (i.e., without superimposed CT scan) </A>. <C> PET/CT provides more accurate anatomical localization of abnormalities </C> <E> more accurate anatomical localization of abnormalities </E>.\\n\\nSection Name: Initial Workup - Nodal Metastases\\n====================\\nEntities:-\\nLymphatic Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site via the lymphatic system.\\nTomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient, producing signals that are processed by the machine\\'s computer to generate cross-sectional images.\\nMagnetic Resonance Imaging : A non-invasive imaging technique that uses magnetic fields and radio waves to create detailed images of the organs and tissues within the body.\\nPositron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption.\\nLymph Node Metastasis : The spread of cancer cells to lymph nodes, which are part of the lymphatic system.\\nCt Of Neck : A computed tomography scan of the neck region.\\nMri Of Neck : A magnetic resonance imaging scan of the neck region.\\nFdg-Pet Scan : A type of positron emission tomography using fluorodeoxyglucose to assess metabolic activity.\\nComputed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.\\nPositron Emission Tomography : A nuclear medicine functional imaging technique that is used to observe metabolic processes in the body.\\n\\nRelationships:-\\n1. Entity1: \""CT\"", Entity2: \""lymph node metastases\"", Relationship: \""used to evaluate\""\\n2. Entity1: \""MRI\"", Entity2: \""lymph node metastases\"", Relationship: \""used to evaluate\""\\n3. Entity1: \""FDG-PET/CT\"", Entity2: \""lymph node metastases\"", Relationship: \""used for detection\""\\n4. Entity1: \""FDG-PET/CT\"", Entity2: \""surgical primary approach\"", Relationship: \""used to determine\""\\n5. Entity1: \""FDG-PET/CT\"", Entity2: \""definitive RT approach\"", Relationship: \""used to identify\""\\n\\nCausalities:-\\n<A> Evaluation of lymph node metastases should be conducted with CT or MRI of the neck </A>, using whichever imaging study is suitable for primary site evaluation (IMG-A, 1 of 4).\\n<CO> For patients with multistation or lower neck nodal involvement or high-grade tumor histology </CO>, <A> consider CT of the chest to assess for mediastinal lymph node metastases or FDG-PET/CT </A>, <C> which is associated with higher sensitivity for both nodal and distant metastases </C>.\\n<CO> For patients who are under consideration for a surgical primary approach </CO>, <A> the higher sensitivity of FDG-PET/CT is warranted for tumors approaching the midline, to determine the surgical approach to the contralateral neck </A>. <CO> Similarly, patients who are scheduled for a definitive RT approach </CO> <A> may benefit from the higher sensitivity of FDG-PET/CT for identifying involved lymph nodes </A>.\\n\\nSection Name: Initial Workup - Distant Metastases\\n====================\\nEntities:-\\nPositron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption.\\nMagnetic Resonance Imaging : A non-invasive imaging technique that uses magnetic fields and radio waves to create detailed images of the organs and tissues within the body.\\nTomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient, producing signals that are processed by the machine\\'s computer to generate cross-sectional images.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nLung Neoplasms : Tumors or cancer of the lung.\\nSmoking : The inhalation of the smoke of burning tobacco encased in cigarettes, pipes, and cigars.\\n\\nRelationships:-\\n1. Entity1: \""FDG-PET/CT\"", Entity2: \""Distant Metastases\"", Relationship: \""used to evaluate\""\\n2. Entity1: \""Contrast-enhanced brain MRI\"", Entity2: \""Brain Metastasis\"", Relationship: \""recommended for evaluation\""\\n3. Entity1: \""CT of the chest\"", Entity2: \""Pulmonary Metastases\"", Relationship: \""performed to assess\""\\n4. Entity1: \""Non-contrast CT of the chest\"", Entity2: \""Lung Parenchymal Metastases\"", Relationship: \""used to screen\""\\n5. Entity1: \""Annual CT screening\"", Entity2: \""Lung Metastasis\"", Relationship: \""considered for high risk\""\\n6. Entity1: \""Directed CT or MRI\"", Entity2: \""Distant Disease\"", Relationship: \""used for assessment\""\\n7. Entity1: \""FDG-PET/CT\"", Entity2: \""Recurrent Disease\"", Relationship: \""used for staging\""\\n\\nCausalities:-\\n<C> Patients with locoregionally advanced cancer (e.g., T3\u2013T4 primary or \u2265N1 nodal staging) </C>, <A> FDG-PET/CT is preferred to evaluate for distant disease and thoracic metastases </A>. <CO> For cancers where brain metastasis is a concern, such as mucosal melanoma or high-grade neuroendocrine carcinomas or adenocarcinomas </CO>, <A> contrast-enhanced brain MRI should be additionally obtained </A>.\\n<CO> If FDG-PET/CT is not performed </CO>, <A> CT of the chest should be performed to assess for presence of pulmonary metastases as well as mediastinal lymph node involvement </A>.\\n<CO> Non-contrast CT of the chest can be sufficient to screen for lung parenchymal metastases </CO> but <CO> is not adequate for assessment of mediastinal adenopathy </CO>. <CO> This is an appropriate lung cancer screening intervention for patients with a history of smoking </CO>.\\n<CO> Following primary definitive treatment (surgery, RT, or systemic therapy/RT) </CO> the role of annual CT screening for lung metastasis is controversial. <E> While this approach does detect early metastasis </E>, <CO> further study is needed to determine the extent of the positive effect and/or cost-effectiveness of this approach in specific subpopulations and timepoints post-treatment </CO>. <CO> For patients with a substantial smoking history or who are at high risk for lung metastases </CO>, <A> annual chest CT can be considered </A>.\\n<CO> If clinical concern for metastatic disease is confined to a specific anatomical area </CO>, <A> the assessment of distant disease can be performed with directed CT or MRI examination </A>.\\n<CO> FDG-PET/CT may complement or replace other imaging modalities when staging recurrent disease before any therapy for relapsed/refractory disease </CO> <A> in order to explore distant disease or second primaries that may significantly impact choice of therapy </A>.\\n--------------------------------------------------\\nPage Number: 55\\n\\nSection Name: General Information\\n====================\\nEntities:-\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nNccn Guidelines : Clinical practice guidelines in oncology developed by the National Comprehensive Cancer Network.\\n\\nRelationships:-\\n1. Entity1: \""NCCN Guidelines\"", Entity2: \""National Comprehensive Cancer Network\"", Relationship: \""produced by\""\\n\\nSection Name: Important Notes\\n====================\\nEntities:-\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medical, surgical, or behavioral interventions.\\nClinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nNeoplasms : New abnormal growth of tissue that can be benign or malignant.\\nMalignant Neoplastic Disease : A disease resulting from the growth of malignant neoplasms.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""Clinical Trials\"", Entity2: \""Cancer\"", Relationship: \""recommended for\""\\n2. Entity1: \""NCCN\"", Entity2: \""Clinical Trials\"", Relationship: \""encourages participation in\""\\n\\nCausalities:-\\n<C> NCCN believes that the best management of any patient with cancer is in a clinical trial </C>. <A> Participation in clinical trials is especially encouraged </A>.\\n\\nSection Name: Principles\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nChemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.\\n\\nRelationships:-\\n1. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Radiation Therapy\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n2. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n3. Entity1: \""Principles of Radiation Therapy\"", Entity2: \""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n\\nCausalities:-\\n### Principles\\n\\n- **Principles of Surgery (SURG-A)**\\n- **Principles of Radiation Therapy (SUPRA-A)**\\n- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**\\n\\nSection Name: Adverse Pathologic Features\\n====================\\nEntities:-\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.\\nPerineural Invasion : The presence of cancer cells surrounding or tracking along a nerve within the perineural space.\\nVascular Invasion : The invasion of cancer cells into blood vessels.\\nLymphatic Invasion : The invasion of cancer cells into lymphatic vessels.\\n\\nRelationships:-\\n1. Entity1: \""Extranodal extension\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n2. Entity1: \""Positive margins\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n3. Entity1: \""Close margins\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n4. Entity1: \""pT3 or pT4 primary\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n5. Entity1: \""pN2 or pN3 nodal disease\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n6. Entity1: \""Perineural invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n7. Entity1: \""Vascular invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n8. Entity1: \""Lymphatic invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n\\nCausalities:-\\n<C> Extranodal extension </C>\\n<C> Positive margins </C>\\n<C> Close margins </C>\\n<C> pT3 or pT4 primary </C>\\n<C> pN2 or pN3 nodal disease </C>\\n<C> Perineural invasion </C>\\n<C> Vascular invasion </C>\\n<C> Lymphatic invasion </C>\\n\\nSection Name: Response Assessment\\n====================\\nEntities:-\\nChemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nPrimary Site : The original location where a tumor or cancer begins.\\nComplete Remission : The disappearance of all signs of cancer in response to treatment.\\nPartial Remission : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.\\nRadiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""induction chemotherapy\"", Entity2: \""Primary site\"", Relationship: \""treatment outcome\""\\n2. Entity1: \""Definitive RT\"", Entity2: \""Primary site\"", Relationship: \""treatment option\""\\n3. Entity1: \""RT\"", Entity2: \""Primary site\"", Relationship: \""treatment option\""\\n4. Entity1: \""Surgery\"", Entity2: \""unresectable nodal disease\"", Relationship: \""treatment option\""\\n\\nCausalities:-\\n<C> Response after induction chemotherapy </C>: <E> Primary site: CR </E> <E> Primary site: PR </E> <E> Primary site: < PR </E> <A> Definitive RT </A> (category 1) <A> RT </A> (category 1) or <A> systemic therapy/RT </A> (category 2B) <A> Surgery </A> or <A> unresectable nodal disease </A>\\n\\nSection Name: Follow-up\\n====================\\nEntities:-\\nFollow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.\\nFollow-Up Procedure : A procedure where a patient is monitored over time to assess the progress of a condition or the effects of treatment.\\nFollow-Up (Medicine) : The process of monitoring a patient\\'s health over time after treatment or diagnosis.\\nDisease Recurrence : The return of a sign, symptom, or disease after a remission.\\nRecurrent Disease : A disease that returns after a period of remission.\\nRecurrence (Medicine) : The return of a disease or condition after a period of improvement.\\n\\nRelationships:-\\n1. Entity1: \""Follow-up\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""monitoring\""\\n\\nCausalities:-\\n### Follow-up\\n\\n- **Follow-up** (FOLL-A, 1 of 2)\\n- **Recurrent or persistent disease** (ADV-3)\\n\\nSection Name: Risk Features\\n====================\\nEntities:-\\nRadiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Adverse pathologic features\"", Entity2: \""RT\"", Relationship: \""Consideration for treatment\""\\n2. Entity1: \""Adverse pathologic features\"", Entity2: \""Systemic therapy\"", Relationship: \""Consideration for treatment\""\\n\\nCausalities:-\\n- **No adverse pathologic features**\\n- **Other risk features**\\n- **Adverse pathologic features**:\\n  - <C> Extranodal extension and/or positive margin </C>\\n  - <A> RT or consider systemic therapy/RT </A>\\n\\nSection Name: Post-Therapy Evaluation\\n====================\\nEntities:-\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nNeck : The neck is the part of the body that separates the head from the torso and provides the mobility and movements of the head.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Neck Evaluation\"", Relationship: \""evaluated in\""\\n2. Entity1: \""RT\"", Entity2: \""Neck Evaluation\"", Relationship: \""evaluated in\""\\n\\nCausalities:-\\n<CO> Post Systemic Therapy/RT or RT Neck </CO> <A> Evaluation </A>\\n\\nSection Name: Flowchart Overview\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nSupraglottic Larynx : The part of the larynx located above the vocal cords, including the epiglottis and aryepiglottic folds.\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\n\\nRelationships:-\\n1. Entity1: \""NCCN Guidelines\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""guides management of\""\\n2. Entity1: \""NCCN Guidelines\"", Entity2: \""healthcare professionals\"", Relationship: \""used by\""\\n\\nCausalities:-\\n<C> cancer of the supraglottic larynx </C> <E> evaluate patient responses following treatment </E> <CO> based on observed outcomes </CO> <A> evaluation of the primary site and determining subsequent steps </A>.\\n\\nSection Name: Assessment and Treatment Decisions\\n====================\\nEntities:-\\nInduction Chemotherapy : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nComplete Response : The disappearance of all signs of cancer in response to treatment.\\nPartial Response : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Complete Response\"", Entity2: \""Radiation Therapy\"", Relationship: \""leads to\""\\n2. Entity1: \""Complete Response\"", Entity2: \""Surgery\"", Relationship: \""leads to\""\\n3. Entity1: \""Partial Response\"", Entity2: \""Systemic Therapy\"", Relationship: \""leads to\""\\n4. Entity1: \""Partial Response\"", Entity2: \""Radiation Therapy\"", Relationship: \""leads to\""\\n\\nCausalities:-\\n<C> responses to initial treatments such as induction chemotherapy </C> <E> Three main response categories are recognized: Complete Response (CR), Partial Response (PR), and less than Partial Response (< PR) </E>. These categories are pivotal in determining the next steps. <C> CR </C> <E> indicates full resolution of the disease at the primary site </E>, <A> leading to the consideration of definitive radiation therapy or the likelihood of surgery </A>. Conversely, <C> PR </C> <E> suggests that the disease has improved but not completely resolved </E>, <A> which directs the pathway towards either systemic therapy or continued radiation therapy </A>, <A> with further evaluation necessary </A>.\\n\\nSection Name: Adverse Pathologic Features and Follow-up\\n====================\\nEntities:-\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nNeoplasm Recurrence, Local : The return of a tumor or cancer, at the original site, after it has been treated.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nRecurrent Neoplasm : A neoplasm that has returned after treatment.\\nMetastatic Neoplasm : A neoplasm that has spread from its original site to one or more other places in the body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nCancer Recurrence : The return of cancer after treatment and after a period of time during which the cancer was undetectable.\\nMetastasis : Spread of a cancer or other disease from one organ or part to another not directly connected with it.\\n\\nRelationships:-\\n1. Entity1: \""Adverse pathologic features\"", Entity2: \""Treatment decisions\"", Relationship: \""Influence\""\\n2. Entity1: \""Adverse features\"", Entity2: \""Surgical intervention\"", Relationship: \""Recommendation\""\\n3. Entity1: \""Absence of adverse features\"", Entity2: \""Radiation therapy\"", Relationship: \""Pathway\""\\n4. Entity1: \""Follow-up process\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""Detection\""\\n5. Entity1: \""Recurrent or persistent disease\"", Entity2: \""Advanced disease management\"", Relationship: \""Necessity\""\\n\\nCausalities:-\\n<C> The presence of adverse pathologic features \u2014 such as extranodal extension or positive margins </C> <E> can directly influence treatment decisions </E>. <CO> If adverse features are found </CO>, <A> surgical intervention is recommended </A>. <CO> In cases where there are no adverse features </CO>, the patient may proceed directly to radiation therapy or continued systemic treatment, emphasizing the tailored approach based on the individual patient\\'s disease characteristics.\\n\\nFurthermore, the chart includes a section addressing the follow-up process after initial treatment. <CO> If there are signs of recurrent or persistent disease </CO>, <A> additional evaluations and treatment modalities may be necessary </A>. These evaluations <E> lead to specific recommendations for advanced disease management, denoted as ADV-3 on the chart </E>, emphasizing the importance of continuous monitoring and assessment in cancer care.\\n--------------------------------------------------\\nPage Number: 130\\n\\nSection Name: Pathological N (pN)\\n====================\\nEntities:-\\nLymph Nodes : Small, bean-shaped structures that are part of the body\\'s lymphatic system. They filter lymph fluid and store white blood cells that help fight infection.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nTnm Staging : A system used to describe the size and spread of cancer in a standardized way. T refers to the size of the tumor, N to the involvement of lymph nodes, and M to metastasis.\\nLymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\nTnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient\\'s body.\\nLymph Node : An organ of the lymphatic system and the adaptive immune system.\\n\\nRelationships:-\\n1. Entity1: \""Lymph Nodes\"", Entity2: \""Neoplasm Metastasis\"", Relationship: \""involved in\""\\n2. Entity1: \""TNM Staging\"", Entity2: \""Lymph Nodes\"", Relationship: \""includes\""\\n3. Entity1: \""TNM Staging\"", Entity2: \""Neoplasm Metastasis\"", Relationship: \""describes\""\\n\\nCausalities:-\\n<CO> NX: Regional lymph nodes cannot be assessed </CO>\\n<CO> N0: No regional lymph node metastasis </CO>\\n<CO> N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(\u2013) </CO>\\n<CO> N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2212); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(\u2212); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2a: Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N3: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(\u2212); or metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>\\n<CO> N3a: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N3b: Metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>\\n<CO> Note: A designation of \u201cU\u201d or \u201cL\u201d may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L). Similarly, clinical and pathological ENE should be recorded as ENE(\u2212) or ENE(+). </CO>\\n\\nSection Name: Distant Metastasis (M)\\n====================\\nEntities:-\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\n\\nRelationships:-\\n1. Entity1: \""M0\"", Entity2: \""Distant Metastasis\"", Relationship: \""is a category of\""\\n2. Entity1: \""M1\"", Entity2: \""Distant Metastasis\"", Relationship: \""is a category of\""\\n\\nCausalities:-\\n### Distant Metastasis (M)\\n\\n- **M0**: No distant metastasis\\n- **M1**: Distant metastasis\\n\\nSection Name: Histologic Grade (G)\\n====================\\nEntities:-\\nNeoplasm Grading : A system of classifying cancer cells in terms of how abnormal they look under a microscope and how quickly the tumor is likely to grow and spread.\\nHistologic Grade : A measure of how much tumor cells differ from healthy cells, used to assess the aggressiveness of cancer.\\n\\nRelationships:-\\n1. Entity1: \""GX\"", Entity2: \""Grade cannot be assessed\"", Relationship: \""is described as\""\\n2. Entity1: \""G1\"", Entity2: \""Well differentiated\"", Relationship: \""is described as\""\\n3. Entity1: \""G2\"", Entity2: \""Moderately differentiated\"", Relationship: \""is described as\""\\n4. Entity1: \""G3\"", Entity2: \""Poorly differentiated\"", Relationship: \""is described as\""\\n\\nCausalities:-\\n<CO>GX</CO>: <E>Grade cannot be assessed</E>\\n<CO>G1</CO>: <E>Well differentiated</E>\\n<CO>G2</CO>: <E>Moderately differentiated</E>\\n<CO>G3</CO>: <E>Poorly differentiated</E>\\n\\nSection Name: Prognostic Stage Groups\\n====================\\nEntities:-\\nNeoplasm Staging : Methods and systems of classifying neoplasms according to extent of disease.\\nTumor Staging : A system for describing the size and spread of cancer within the body.\\nTnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient\\'s body.\\n\\nRelationships:-\\n1. Entity1: \""Stage 0\"", Entity2: \""Tis N0 M0\"", Relationship: \""defined by\""\\n2. Entity1: \""Stage I\"", Entity2: \""T1 N0 M0\"", Relationship: \""defined by\""\\n3. Entity1: \""Stage II\"", Entity2: \""T2 N0 M0\"", Relationship: \""defined by\""\\n4. Entity1: \""Stage III\"", Entity2: \""T3 N0 M0, T1 N1 M0, T2 N1 M0, T3 N1 M0\"", Relationship: \""defined by\""\\n5. Entity1: \""Stage IVA\"", Entity2: \""T1 N2 M0, T2 N2 M0, T3 N2 M0, T4a N0,N1,N2 M0\"", Relationship: \""defined by\""\\n6. Entity1: \""Stage IVB\"", Entity2: \""Any T N3 M0, T4b Any N M0\"", Relationship: \""defined by\""\\n7. Entity1: \""Stage IVC\"", Entity2: \""Any T Any N M1\"", Relationship: \""defined by\""\\n--------------------------------------------------\\nPage Number: 93\\n\\nSection Name: PRINCIPLES OF IMAGING\\n====================\\nEntities:-\\nImaging, Diagnostic : The production of a visual representation of parts of the body, for the purpose of clinical analysis and medical intervention.\\nHead And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\nTomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.\\nMagnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body\\'s soft tissue and bones.\\nContrast Media : Substances used to enhance the contrast of structures or fluids within the body in medical imaging.\\n\\nRelationships:-\\n1. Entity1: \""Imaging, Diagnostic\"", Entity2: \""Head and Neck Neoplasms\"", Relationship: \""used for\""\\n2. Entity1: \""Tomography, X-Ray Computed\"", Entity2: \""Contrast Media\"", Relationship: \""uses\""\\n3. Entity1: \""Magnetic Resonance Imaging\"", Entity2: \""Contrast Media\"", Relationship: \""uses\""\\n\\nCausalities:-\\n<C> Imaging </C> plays an essential role in the clinical care of patients with head and neck cancer. <A> The proper selection and utilization of imaging studies </A> is critical in caring for patients with head and neck cancer. <A> CT is performed with contrast </A>, while <A> CT imaging of the chest can be performed with or without contrast </A>, <CO> as clinically indicated </CO>. <A> MRI is performed with and without contrast </A>, <CO> unless contraindicated </CO>.\\n\\nSection Name: Initial Workup - Primary Site\\n====================\\nEntities:-\\nTomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.\\nMagnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body\\'s soft tissue and bones.\\nHead And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\nNeck Structure : The anatomical structure of the neck, which is the part of the body that connects the head to the torso.\\nSkull Base : The bottom part of the skull, which separates the brain from other facial structures.\\nThoracic Inlet : The opening at the top of the thoracic cavity, through which pass the trachea, esophagus, and major blood vessels.\\n\\nRelationships:-\\n1. Entity1: \""CT\"", Entity2: \""MRI\"", Relationship: \""complementary in imaging head and neck cancers\""\\n2. Entity1: \""CT\"", Entity2: \""Head and Neck Neoplasms\"", Relationship: \""used to evaluate\""\\n3. Entity1: \""MRI\"", Entity2: \""Head and Neck Neoplasms\"", Relationship: \""preferred for evaluating\""\\n4. Entity1: \""Skull base\"", Entity2: \""Thoracic inlet\"", Relationship: \""imaging range for evaluation\""\\n\\nCausalities:-\\n<A>Imaging assessment of the primary site</A> can be performed with <A>CT of the soft tissues of the neck</A> or <A>MRI of the neck</A>. <C>CT is complementary to MRI for head and neck cancers</C>. <A>It is utilized to evaluate cortical bone erosion or periosteal invasion, cartilage invasion, and bony erosion or destruction</A>. <CO>in certain conditions, such as evaluating the extent of bone marrow invasion or in patients with extensive dental amalgam obscuring anatomy on CT, assessing skull base invasion and cranial nerve involvement, and differentiating tumor from obstructed sinuses</CO>, <A>MRI is preferred over CT</A>. <CO>when involved lymph nodes or upper mediastinal cancers are present</CO>, <A>Complete evaluation of primary and nodal disease requires imaging from the skull base to the thoracic inlet, extending to the carina</A>.\\n\\nSection Name: PET/CT and Biopsy\\n====================\\nEntities:-\\nPositron Emission Tomography Computed Tomography : A medical imaging technique that combines PET and CT capabilities to provide detailed images of the body.\\nExamination Under Anesthesia : A procedure where a patient is examined while under anesthesia to allow for a more thorough examination.\\nBiopsy : A medical test involving the extraction of sample cells or tissues for examination to determine the presence or extent of a disease.\\nTonsillectomy : A surgical procedure to remove the tonsils, often performed to treat recurrent tonsillitis or sleep apnea.\\nFine Needle Aspiration : A type of biopsy procedure that uses a thin, hollow needle to extract cells from a lump or mass for examination.\\nUltrasound : A medical imaging technique that uses high-frequency sound waves to visualize internal organs and structures.\\nComputed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.\\n\\nRelationships:-\\n1. Entity1: \""PET/CT\"", Entity2: \""EUA\"", Relationship: \""recommended before\""\\n2. Entity1: \""Fine Needle Aspiration (FNA)\"", Entity2: \""metastatic nodes\"", Relationship: \""used for biopsy of\""\\n3. Entity1: \""Image-guided needle biopsy\"", Entity2: \""cystic neck nodes\"", Relationship: \""recommended for initial diagnosis of\""\\n\\nCausalities:-\\n<CO> If imaging does not reveal an obvious primary cancer </CO>, <A> a PET/CT should be ordered before EUA, biopsies, and tonsillectomy </A>. <E> This helps identify potential primary sites </E> before any interventions take place. Additionally, <A> Fine Needle Aspiration (FNA) biopsy of metastatic nodes </A> <E> may provide pathologically informative results </E>. <CO> For initial diagnosis in cystic neck nodes </CO>, <A> image-guided needle biopsy (ultrasound or CT) </A> <E> may yield better results than FNA by palpation alone </E>.\\n\\nSection Name: Postoperative Imaging Advice\\n====================\\nEntities:-\\nPanoramic Radiography : A type of dental x-ray that provides a wide view of the upper and lower jaws, teeth, temporomandibular joints, and sinuses.\\nOral Cavity : The cavity of the mouth, including the lips, the lining inside the cheeks and lips, the front two-thirds of the tongue, the gums, the floor of the mouth under the tongue, the hard palate, and the small area of the gum behind the wisdom teeth.\\nRadiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.\\nMandibulotomy : A surgical procedure involving the cutting of the mandible.\\nMandibulectomy : A surgical procedure involving the removal of part or all of the mandible.\\nOropharynx : The part of the throat at the back of the mouth behind the oral cavity.\\n\\nRelationships:-\\n1. Entity1: \""panoramic dental x-ray\"", Entity2: \""oral cavity cancers\"", Relationship: \""recommended for\""\\n2. Entity1: \""panoramic dental x-ray\"", Entity2: \""postoperative radiotherapy\"", Relationship: \""essential for pre-radiation evaluation\""\\n3. Entity1: \""pre-radiation dental evaluation\"", Entity2: \""dental procedures or extractions\"", Relationship: \""determine necessity of\""\\n\\nCausalities:-\\n<A> A panoramic dental x-ray is recommended </A> <C> for oral cavity cancers requiring mandibulotomy and/or mandibulectomy </C>. <CO> When postoperative radiotherapy (RT) is anticipated for areas like the lip, oral cavity subsites, or oropharynx </CO>, <A> panoramic x-ray is essential for a comprehensive pre-radiation dental evaluation </A> <E> to assess the health of affected teeth and determine if pre-radiation dental procedures or extractions are necessary </E>.\\n\\nSection Name: NCCN Guidelines Note\\n====================\\nEntities:-\\nNeoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.\\nMalignant Neoplastic Disease : A disease characterized by uncontrolled, abnormal growth of cells that can invade or spread to other parts of the body.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\nClinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.\\nClinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\n\\nRelationships:-\\n1. Entity1: \""NCCN\"", Entity2: \""Clinical Trials\"", Relationship: \""encourages participation in\""\\n2. Entity1: \""NCCN\"", Entity2: \""Cancer\"", Relationship: \""recommends clinical trials for\""\\n\\nCausalities:-\\n<A> NCCN believes that the best management of any patient with cancer is through participation in clinical trials </A>, <A> which is especially encouraged </A>.\\n'}""",valid,increases risk,2,B,"edge - The edge which needs to be verified.
explanation - Explanation of what the edge represents and its validity.
causal_direction - Either Positive or Negative or Unknown. A positive influence direction indicates that both factors change in the same direction (e.g. an increase causes an increase effect). A negative influence direction indicates the opposite changes (e.g. an increase causes a decrease effect).
causal_factor - Is necessary or sufficient condition for an effect to occur. Exposure is a term commonly used in epidemiology to denote any condition that is considered as a possible cause of disease. Exposure is considered necessary when it always precedes the effects (e.g. symptoms) and always presents when the effects occur. A sufficient cause is a causal factor whose presence or occurrence guarantees the occurrence of symptom.
causal_distance - Either Distal or Proximal or Unknown. The distal factors lie towards the beginning of causal chain (i.e. indirect causal factors). The the proximal factors lie towards the end of the chain (i.e. cause directly or almost directly the effect).

Causality Tags:
<A> for action, <C> for cause, <CO> for condition and <E> for effect.
Cause (C): The reason or origin that leads to an effect. Causes often involve disease conditions, risk factors, or underlying mechanisms.
Effect (E): The outcome or result of a cause. Effects usually represent clinical outcomes, complications, or results of a specific cause.
Condition (CO): The circumstance or prerequisite required for an action or effect to occur. Conditions may include patient characteristics, clinical scenarios, or specific diagnostic criteria.
Action (A): The recommended or described response or activity to address a cause or condition. Actions typically involve clinical interventions, diagnostic procedures, or treatment recommendations.


`NODE1`:
id: Presence_of_Metastasis_in_Lymph_Nodes_5
label: Metastasis in Nearby Lymph Nodes
description: This node represents the clinical situation regarding whether metastasis is present in the nearby lymph nodes of a patient. It is a critical factor in determining the stage and prognosis of cancer, as the spread of cancer to lymph nodes often indicates a more advanced disease and may influence treatment decisions.
type: Patient Situation
observability: Unobserved
states: [{'state_name': 'unknown', 'state_description': 'The status of metastasis in the lymph nodes is not determined. It is unclear whether cancer has spread to these nodes.'}, {'state_name': 'present', 'state_description': 'Metastasis is confirmed in the lymph nodes, indicating that cancer has spread to these nodes.'}, {'state_name': 'absent', 'state_description': 'There is no metastasis in the lymph nodes, indicating that cancer has not spread to these nodes.'}]

`NODE2`:
id: Positron_Emission_Tomography_PET_Scans_10
label: Positron Emission Tomography (PET) Scan Result
description: This node represents the result of a Positron Emission Tomography (PET) scan, which is an imaging test used to observe metabolic processes in the body. It is often used in oncology to detect cancerous tissues, assess the spread of cancer, and evaluate the effectiveness of treatment.
type: Examination Result
observability: Observed
states: [{'state_name': 'present', 'state_description': ""The 'present' state indicates that the PET scan has detected abnormal metabolic activity, which may suggest the presence of cancerous tissues or other pathological conditions.""}, {'state_name': 'absent', 'state_description': ""The 'absent' state indicates that the PET scan did not detect any abnormal metabolic activity, suggesting the absence of cancerous tissues or other significant pathological conditions.""}]

`EDGE1`:
{'edges_ids': ['Presence_of_Metastasis_in_Lymph_Nodes_5', 'Positron_Emission_Tomography_PET_Scans_10'], 'edge': '(Presence_of_Metastasis_in_Lymph_Nodes_5) causes (Positron_Emission_Tomography_PET_Scans_10)', 'explanation': ['The presence of metastasis in lymph nodes is a critical factor in cancer staging and prognosis.', 'A PET scan is an imaging test used to detect abnormal metabolic activity, often associated with cancer.', 'If metastasis is present in the lymph nodes, it is likely to be detected as abnormal metabolic activity on a PET scan.', 'Therefore, there is a valid causal relationship where the presence of metastasis in lymph nodes can cause a positive PET scan result.', 'The causal direction is positive because the presence of metastasis leads to a positive PET scan result.', 'The presence of metastasis is a sufficient condition for a positive PET scan result, as it would typically show up as abnormal activity.', 'The causal distance is proximal because the presence of metastasis directly affects the PET scan result.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': True}, 'causal_distance': 'Proximal'}

`EDGE2`:
{'edges_ids': ['Positron_Emission_Tomography_PET_Scans_10', 'Presence_of_Metastasis_in_Lymph_Nodes_5'], 'edge': '(Positron_Emission_Tomography_PET_Scans_10) causes (Presence_of_Metastasis_in_Lymph_Nodes_5)', 'explanation': ['The edge suggests that the result of a PET scan causes the presence of metastasis in lymph nodes.', 'However, a PET scan is a diagnostic tool that detects existing conditions, such as metastasis, rather than causing them.', 'The presence of metastasis in lymph nodes is a pathological condition that occurs independently of the PET scan.', 'The PET scan can reveal the presence of metastasis by showing abnormal metabolic activity, but it does not cause the metastasis to occur.', 'Therefore, the edge is not valid as a causal relationship.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}

`INFORMATION FROM KNOWLEDGE BASE`:
--------------------------------------------------
Page Number: 92

Section Name: NCCN Guidelines Overview
====================
Entities:-
Head And Neck Neoplasms : Cancers that arise in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Malignant Neoplasm Of Head And Neck : A malignant tumor located in the head and neck region.
Head And Neck Cancer : A group of cancers that originate in the head and neck region.
Antineoplastic Agents : Drugs used to treat cancer by inhibiting the growth of cancerous cells.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.
Radiation Therapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.

Relationships:-
1. Entity1: ""Head and neck cancers"", Entity2: ""Systemic therapy"", Relationship: ""follow-up recommendations after""
2. Entity1: ""Head and neck cancers"", Entity2: ""Radiation therapy"", Relationship: ""follow-up recommendations after""

Causalities:-
The image presents a flowchart from the National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2024, especially focusing on <A> follow-up recommendations </A> for <CO> patients with head and neck cancers after systemic therapy or radiation therapy (RT) </CO>. All recommendations are categorized as level A unless stated otherwise, highlighting the importance of clinical trials in cancer management.

Section Name: Imaging and Assessment Protocols
====================
Entities:-
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.
Clinical Assessment : A systematic evaluation of a patient's health status, often involving a physical examination and medical history.
Positron-Emission Tomography : An imaging technique using a radioactive substance called a tracer to look for disease in the body.
Computed Tomography : A medical imaging technique used in radiology to obtain detailed internal images of the body.
Magnetic Resonance Imaging : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis.
Disease : A disorder of structure or function in a human, animal, or plant, especially one that produces specific symptoms.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.
Residual Neoplasm : Remaining cancer cells after treatment.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Clinical Assessment"", Relationship: ""occurs before""
2. Entity1: ""FDG-PET/CT Scan"", Entity2: ""Distant Metastases"", Relationship: ""assesses""
3. Entity1: ""FDG-PET/CT Scan"", Entity2: ""Observation"", Relationship: ""leads to if negative""
4. Entity1: ""FDG-PET/CT Scan"", Entity2: ""CT Scan"", Relationship: ""leads to if strongly positive""
5. Entity1: ""CT Scan"", Entity2: ""Neck Dissection"", Relationship: ""leads to if positive""

Causalities:-
<CO> After systemic therapy or RT </CO>, <A> a clinical assessment should occur 4 to 8 weeks later </A>. <CO> If there is a response </CO>, <A> it is necessary to assess the extent of disease or distant metastases, preferably through a FDG-PET/CT scan at a minimum of 12 weeks post-treatment </A>. <CO> If the FDG-PET/CT results are negative </CO>, <A> the patient may continue with monitoring through observation </A>. <CO> In cases where the results are equivocal </CO>, <A> observation or repeat FDG-PET/CT within 3 to 6 months is prescribed </A>.

<CO> In cases where the FDG-PET/CT results are strongly positive </CO>, <A> further imaging via CT scan with contrast of the primary site and neck, or MRI with and without contrast, becomes necessary </A>. <CO> If these imaging results confirm positive findings </CO>, <A> neck dissection may be considered, depending on the evidence of residual or persistent disease </A>. <CO> If the imaging findings are negative </CO>, <A> the patient might continue in observation </A>.

Section Name: Outcomes Based on Disease Resectability
====================
Entities:-
Disease : A disorder of structure or function in a human, animal, or plant, especially one that produces specific symptoms.
Resectable : Capable of being surgically removed.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis.

Relationships:-
1. Entity1: ""Disease"", Entity2: ""Resectable"", Relationship: ""Classification""
2. Entity1: ""Unresectable"", Entity2: ""Treatment plans (ADV-3)"", Relationship: ""Treatment recommendation""
3. Entity1: ""Resectable"", Entity2: ""Resection and/or Neck dissection"", Relationship: ""Surgical procedure""

Causalities:-
<CO> If there is confirmed residual or persistent disease </CO>, the options split into two pathways: 'Unresectable' or 'Resectable.' <CO> If the disease is classified as unresectable </CO>, <A> advances in treatment plans (labeled ADV-3) are called for </A>. Conversely, <CO> if it is deemed resectable </CO>, <A> a resection of the primary and/or neck dissection may occur </A>, <CO> contingent upon the disease status </CO>.

Section Name: Important Notes
====================
Entities:-
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.
Clinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.
Positron-Emission Tomography : An imaging technique using a radioactive substance called a tracer to look for disease in the body.
Positron Emission Tomography (Procedure) : A diagnostic imaging procedure that uses a radioactive tracer to visualize and measure changes in metabolic processes.
Positron Emission Tomography : A nuclear medicine functional imaging technique used to observe metabolic processes in the body.
Neoplasms : New abnormal growth of tissue in animals or plants; a tumor.
Malignant Neoplasm : A cancerous growth that has the potential to spread to other parts of the body.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""NCCN"", Entity2: ""Clinical trials"", Relationship: ""emphasizes participation in""
2. Entity1: ""FDG-PET/CT"", Entity2: ""Persistent cancer"", Relationship: ""used to detect""
3. Entity1: ""FDG-PET/CT"", Entity2: ""PET negative"", Relationship: ""interpretation of results""
4. Entity1: ""FDG-PET/CT"", Entity2: ""PET positive"", Relationship: ""interpretation of results""

Causalities:-
<A> NCCN emphasizes that the best management for any cancer patient is participation in clinical trials </A>, especially encouraged for all patients. Additional notes clarify that <CO> if the FDG-PET/CT is negative for persistent cancer </CO>, <A> further cross-sectional imaging is optional </A>. The interpretations define <CO> PET negative as no or low-grade uptake not suspicious for disease </CO>, while <CO> PET positive implies suspicion for disease </CO>.
--------------------------------------------------
Page Number: 94

Section Name: Head and Neck Cancers - Principles of Imaging
====================
Entities:-
Positron Emission Tomography Computed Tomography : A medical imaging technique combining PET and CT capabilities to provide detailed information about the body's function and structure.
Positron Emission Tomography : A nuclear medicine functional imaging technique that is used to observe metabolic processes in the body.
Computed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.
Head And Neck Neoplasms : Cancers that arise in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.

Relationships:-
1. Entity1: ""PET/CT"", Entity2: ""PET scan"", Relationship: ""preferred over""
2. Entity1: ""PET-CT"", Entity2: ""head neck cancers"", Relationship: ""used in study of""

Causalities:-
<A> PET/CT is preferred over PET scan alone (i.e., without superimposed CT scan) </A>. <C> PET/CT provides more accurate anatomical localization of abnormalities </C> <E> more accurate anatomical localization of abnormalities </E>.

Section Name: Initial Workup - Nodal Metastases
====================
Entities:-
Lymphatic Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site via the lymphatic system.
Tomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient, producing signals that are processed by the machine's computer to generate cross-sectional images.
Magnetic Resonance Imaging : A non-invasive imaging technique that uses magnetic fields and radio waves to create detailed images of the organs and tissues within the body.
Positron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption.
Lymph Node Metastasis : The spread of cancer cells to lymph nodes, which are part of the lymphatic system.
Ct Of Neck : A computed tomography scan of the neck region.
Mri Of Neck : A magnetic resonance imaging scan of the neck region.
Fdg-Pet Scan : A type of positron emission tomography using fluorodeoxyglucose to assess metabolic activity.
Computed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.
Positron Emission Tomography : A nuclear medicine functional imaging technique that is used to observe metabolic processes in the body.

Relationships:-
1. Entity1: ""CT"", Entity2: ""lymph node metastases"", Relationship: ""used to evaluate""
2. Entity1: ""MRI"", Entity2: ""lymph node metastases"", Relationship: ""used to evaluate""
3. Entity1: ""FDG-PET/CT"", Entity2: ""lymph node metastases"", Relationship: ""used for detection""
4. Entity1: ""FDG-PET/CT"", Entity2: ""surgical primary approach"", Relationship: ""used to determine""
5. Entity1: ""FDG-PET/CT"", Entity2: ""definitive RT approach"", Relationship: ""used to identify""

Causalities:-
<A> Evaluation of lymph node metastases should be conducted with CT or MRI of the neck </A>, using whichever imaging study is suitable for primary site evaluation (IMG-A, 1 of 4).
<CO> For patients with multistation or lower neck nodal involvement or high-grade tumor histology </CO>, <A> consider CT of the chest to assess for mediastinal lymph node metastases or FDG-PET/CT </A>, <C> which is associated with higher sensitivity for both nodal and distant metastases </C>.
<CO> For patients who are under consideration for a surgical primary approach </CO>, <A> the higher sensitivity of FDG-PET/CT is warranted for tumors approaching the midline, to determine the surgical approach to the contralateral neck </A>. <CO> Similarly, patients who are scheduled for a definitive RT approach </CO> <A> may benefit from the higher sensitivity of FDG-PET/CT for identifying involved lymph nodes </A>.

Section Name: Initial Workup - Distant Metastases
====================
Entities:-
Positron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption.
Magnetic Resonance Imaging : A non-invasive imaging technique that uses magnetic fields and radio waves to create detailed images of the organs and tissues within the body.
Tomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient, producing signals that are processed by the machine's computer to generate cross-sectional images.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Lung Neoplasms : Tumors or cancer of the lung.
Smoking : The inhalation of the smoke of burning tobacco encased in cigarettes, pipes, and cigars.

Relationships:-
1. Entity1: ""FDG-PET/CT"", Entity2: ""Distant Metastases"", Relationship: ""used to evaluate""
2. Entity1: ""Contrast-enhanced brain MRI"", Entity2: ""Brain Metastasis"", Relationship: ""recommended for evaluation""
3. Entity1: ""CT of the chest"", Entity2: ""Pulmonary Metastases"", Relationship: ""performed to assess""
4. Entity1: ""Non-contrast CT of the chest"", Entity2: ""Lung Parenchymal Metastases"", Relationship: ""used to screen""
5. Entity1: ""Annual CT screening"", Entity2: ""Lung Metastasis"", Relationship: ""considered for high risk""
6. Entity1: ""Directed CT or MRI"", Entity2: ""Distant Disease"", Relationship: ""used for assessment""
7. Entity1: ""FDG-PET/CT"", Entity2: ""Recurrent Disease"", Relationship: ""used for staging""

Causalities:-
<C> Patients with locoregionally advanced cancer (e.g., T3–T4 primary or ≥N1 nodal staging) </C>, <A> FDG-PET/CT is preferred to evaluate for distant disease and thoracic metastases </A>. <CO> For cancers where brain metastasis is a concern, such as mucosal melanoma or high-grade neuroendocrine carcinomas or adenocarcinomas </CO>, <A> contrast-enhanced brain MRI should be additionally obtained </A>.
<CO> If FDG-PET/CT is not performed </CO>, <A> CT of the chest should be performed to assess for presence of pulmonary metastases as well as mediastinal lymph node involvement </A>.
<CO> Non-contrast CT of the chest can be sufficient to screen for lung parenchymal metastases </CO> but <CO> is not adequate for assessment of mediastinal adenopathy </CO>. <CO> This is an appropriate lung cancer screening intervention for patients with a history of smoking </CO>.
<CO> Following primary definitive treatment (surgery, RT, or systemic therapy/RT) </CO> the role of annual CT screening for lung metastasis is controversial. <E> While this approach does detect early metastasis </E>, <CO> further study is needed to determine the extent of the positive effect and/or cost-effectiveness of this approach in specific subpopulations and timepoints post-treatment </CO>. <CO> For patients with a substantial smoking history or who are at high risk for lung metastases </CO>, <A> annual chest CT can be considered </A>.
<CO> If clinical concern for metastatic disease is confined to a specific anatomical area </CO>, <A> the assessment of distant disease can be performed with directed CT or MRI examination </A>.
<CO> FDG-PET/CT may complement or replace other imaging modalities when staging recurrent disease before any therapy for relapsed/refractory disease </CO> <A> in order to explore distant disease or second primaries that may significantly impact choice of therapy </A>.
--------------------------------------------------
Page Number: 55

Section Name: General Information
====================
Entities:-
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Nccn Guidelines : Clinical practice guidelines in oncology developed by the National Comprehensive Cancer Network.

Relationships:-
1. Entity1: ""NCCN Guidelines"", Entity2: ""National Comprehensive Cancer Network"", Relationship: ""produced by""

Section Name: Important Notes
====================
Entities:-
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medical, surgical, or behavioral interventions.
Clinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Neoplasms : New abnormal growth of tissue that can be benign or malignant.
Malignant Neoplastic Disease : A disease resulting from the growth of malignant neoplasms.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""Clinical Trials"", Entity2: ""Cancer"", Relationship: ""recommended for""
2. Entity1: ""NCCN"", Entity2: ""Clinical Trials"", Relationship: ""encourages participation in""

Causalities:-
<C> NCCN believes that the best management of any patient with cancer is in a clinical trial </C>. <A> Participation in clinical trials is especially encouraged </A>.

Section Name: Principles
====================
Entities:-
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Chemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.

Relationships:-
1. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Radiation Therapy"", Relationship: ""Both are principles of cancer treatment methods.""
2. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""Both are principles of cancer treatment methods.""
3. Entity1: ""Principles of Radiation Therapy"", Entity2: ""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""Both are principles of cancer treatment methods.""

Causalities:-
### Principles

- **Principles of Surgery (SURG-A)**
- **Principles of Radiation Therapy (SUPRA-A)**
- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**

Section Name: Adverse Pathologic Features
====================
Entities:-
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.
Perineural Invasion : The presence of cancer cells surrounding or tracking along a nerve within the perineural space.
Vascular Invasion : The invasion of cancer cells into blood vessels.
Lymphatic Invasion : The invasion of cancer cells into lymphatic vessels.

Relationships:-
1. Entity1: ""Extranodal extension"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
2. Entity1: ""Positive margins"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
3. Entity1: ""Close margins"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
4. Entity1: ""pT3 or pT4 primary"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
5. Entity1: ""pN2 or pN3 nodal disease"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
6. Entity1: ""Perineural invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
7. Entity1: ""Vascular invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
8. Entity1: ""Lymphatic invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""

Causalities:-
<C> Extranodal extension </C>
<C> Positive margins </C>
<C> Close margins </C>
<C> pT3 or pT4 primary </C>
<C> pN2 or pN3 nodal disease </C>
<C> Perineural invasion </C>
<C> Vascular invasion </C>
<C> Lymphatic invasion </C>

Section Name: Response Assessment
====================
Entities:-
Chemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Primary Site : The original location where a tumor or cancer begins.
Complete Remission : The disappearance of all signs of cancer in response to treatment.
Partial Remission : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
Radiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.

Relationships:-
1. Entity1: ""induction chemotherapy"", Entity2: ""Primary site"", Relationship: ""treatment outcome""
2. Entity1: ""Definitive RT"", Entity2: ""Primary site"", Relationship: ""treatment option""
3. Entity1: ""RT"", Entity2: ""Primary site"", Relationship: ""treatment option""
4. Entity1: ""Surgery"", Entity2: ""unresectable nodal disease"", Relationship: ""treatment option""

Causalities:-
<C> Response after induction chemotherapy </C>: <E> Primary site: CR </E> <E> Primary site: PR </E> <E> Primary site: < PR </E> <A> Definitive RT </A> (category 1) <A> RT </A> (category 1) or <A> systemic therapy/RT </A> (category 2B) <A> Surgery </A> or <A> unresectable nodal disease </A>

Section Name: Follow-up
====================
Entities:-
Follow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.
Follow-Up Procedure : A procedure where a patient is monitored over time to assess the progress of a condition or the effects of treatment.
Follow-Up (Medicine) : The process of monitoring a patient's health over time after treatment or diagnosis.
Disease Recurrence : The return of a sign, symptom, or disease after a remission.
Recurrent Disease : A disease that returns after a period of remission.
Recurrence (Medicine) : The return of a disease or condition after a period of improvement.

Relationships:-
1. Entity1: ""Follow-up"", Entity2: ""Recurrent or persistent disease"", Relationship: ""monitoring""

Causalities:-
### Follow-up

- **Follow-up** (FOLL-A, 1 of 2)
- **Recurrent or persistent disease** (ADV-3)

Section Name: Risk Features
====================
Entities:-
Radiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Adverse pathologic features"", Entity2: ""RT"", Relationship: ""Consideration for treatment""
2. Entity1: ""Adverse pathologic features"", Entity2: ""Systemic therapy"", Relationship: ""Consideration for treatment""

Causalities:-
- **No adverse pathologic features**
- **Other risk features**
- **Adverse pathologic features**:
  - <C> Extranodal extension and/or positive margin </C>
  - <A> RT or consider systemic therapy/RT </A>

Section Name: Post-Therapy Evaluation
====================
Entities:-
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Neck : The neck is the part of the body that separates the head from the torso and provides the mobility and movements of the head.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Neck Evaluation"", Relationship: ""evaluated in""
2. Entity1: ""RT"", Entity2: ""Neck Evaluation"", Relationship: ""evaluated in""

Causalities:-
<CO> Post Systemic Therapy/RT or RT Neck </CO> <A> Evaluation </A>

Section Name: Flowchart Overview
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Supraglottic Larynx : The part of the larynx located above the vocal cords, including the epiglottis and aryepiglottic folds.
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.

Relationships:-
1. Entity1: ""NCCN Guidelines"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""guides management of""
2. Entity1: ""NCCN Guidelines"", Entity2: ""healthcare professionals"", Relationship: ""used by""

Causalities:-
<C> cancer of the supraglottic larynx </C> <E> evaluate patient responses following treatment </E> <CO> based on observed outcomes </CO> <A> evaluation of the primary site and determining subsequent steps </A>.

Section Name: Assessment and Treatment Decisions
====================
Entities:-
Induction Chemotherapy : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Complete Response : The disappearance of all signs of cancer in response to treatment.
Partial Response : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Complete Response"", Entity2: ""Radiation Therapy"", Relationship: ""leads to""
2. Entity1: ""Complete Response"", Entity2: ""Surgery"", Relationship: ""leads to""
3. Entity1: ""Partial Response"", Entity2: ""Systemic Therapy"", Relationship: ""leads to""
4. Entity1: ""Partial Response"", Entity2: ""Radiation Therapy"", Relationship: ""leads to""

Causalities:-
<C> responses to initial treatments such as induction chemotherapy </C> <E> Three main response categories are recognized: Complete Response (CR), Partial Response (PR), and less than Partial Response (< PR) </E>. These categories are pivotal in determining the next steps. <C> CR </C> <E> indicates full resolution of the disease at the primary site </E>, <A> leading to the consideration of definitive radiation therapy or the likelihood of surgery </A>. Conversely, <C> PR </C> <E> suggests that the disease has improved but not completely resolved </E>, <A> which directs the pathway towards either systemic therapy or continued radiation therapy </A>, <A> with further evaluation necessary </A>.

Section Name: Adverse Pathologic Features and Follow-up
====================
Entities:-
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Neoplasm Recurrence, Local : The return of a tumor or cancer, at the original site, after it has been treated.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Recurrent Neoplasm : A neoplasm that has returned after treatment.
Metastatic Neoplasm : A neoplasm that has spread from its original site to one or more other places in the body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Cancer Recurrence : The return of cancer after treatment and after a period of time during which the cancer was undetectable.
Metastasis : Spread of a cancer or other disease from one organ or part to another not directly connected with it.

Relationships:-
1. Entity1: ""Adverse pathologic features"", Entity2: ""Treatment decisions"", Relationship: ""Influence""
2. Entity1: ""Adverse features"", Entity2: ""Surgical intervention"", Relationship: ""Recommendation""
3. Entity1: ""Absence of adverse features"", Entity2: ""Radiation therapy"", Relationship: ""Pathway""
4. Entity1: ""Follow-up process"", Entity2: ""Recurrent or persistent disease"", Relationship: ""Detection""
5. Entity1: ""Recurrent or persistent disease"", Entity2: ""Advanced disease management"", Relationship: ""Necessity""

Causalities:-
<C> The presence of adverse pathologic features — such as extranodal extension or positive margins </C> <E> can directly influence treatment decisions </E>. <CO> If adverse features are found </CO>, <A> surgical intervention is recommended </A>. <CO> In cases where there are no adverse features </CO>, the patient may proceed directly to radiation therapy or continued systemic treatment, emphasizing the tailored approach based on the individual patient's disease characteristics.

Furthermore, the chart includes a section addressing the follow-up process after initial treatment. <CO> If there are signs of recurrent or persistent disease </CO>, <A> additional evaluations and treatment modalities may be necessary </A>. These evaluations <E> lead to specific recommendations for advanced disease management, denoted as ADV-3 on the chart </E>, emphasizing the importance of continuous monitoring and assessment in cancer care.
--------------------------------------------------
Page Number: 130

Section Name: Pathological N (pN)
====================
Entities:-
Lymph Nodes : Small, bean-shaped structures that are part of the body's lymphatic system. They filter lymph fluid and store white blood cells that help fight infection.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Tnm Staging : A system used to describe the size and spread of cancer in a standardized way. T refers to the size of the tumor, N to the involvement of lymph nodes, and M to metastasis.
Lymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.
Tnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient's body.
Lymph Node : An organ of the lymphatic system and the adaptive immune system.

Relationships:-
1. Entity1: ""Lymph Nodes"", Entity2: ""Neoplasm Metastasis"", Relationship: ""involved in""
2. Entity1: ""TNM Staging"", Entity2: ""Lymph Nodes"", Relationship: ""includes""
3. Entity1: ""TNM Staging"", Entity2: ""Neoplasm Metastasis"", Relationship: ""describes""

Causalities:-
<CO> NX: Regional lymph nodes cannot be assessed </CO>
<CO> N0: No regional lymph node metastasis </CO>
<CO> N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(–) </CO>
<CO> N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2a: Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N3: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(−); or metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>
<CO> N3a: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N3b: Metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>
<CO> Note: A designation of “U” or “L” may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L). Similarly, clinical and pathological ENE should be recorded as ENE(−) or ENE(+). </CO>

Section Name: Distant Metastasis (M)
====================
Entities:-
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.

Relationships:-
1. Entity1: ""M0"", Entity2: ""Distant Metastasis"", Relationship: ""is a category of""
2. Entity1: ""M1"", Entity2: ""Distant Metastasis"", Relationship: ""is a category of""

Causalities:-
### Distant Metastasis (M)

- **M0**: No distant metastasis
- **M1**: Distant metastasis

Section Name: Histologic Grade (G)
====================
Entities:-
Neoplasm Grading : A system of classifying cancer cells in terms of how abnormal they look under a microscope and how quickly the tumor is likely to grow and spread.
Histologic Grade : A measure of how much tumor cells differ from healthy cells, used to assess the aggressiveness of cancer.

Relationships:-
1. Entity1: ""GX"", Entity2: ""Grade cannot be assessed"", Relationship: ""is described as""
2. Entity1: ""G1"", Entity2: ""Well differentiated"", Relationship: ""is described as""
3. Entity1: ""G2"", Entity2: ""Moderately differentiated"", Relationship: ""is described as""
4. Entity1: ""G3"", Entity2: ""Poorly differentiated"", Relationship: ""is described as""

Causalities:-
<CO>GX</CO>: <E>Grade cannot be assessed</E>
<CO>G1</CO>: <E>Well differentiated</E>
<CO>G2</CO>: <E>Moderately differentiated</E>
<CO>G3</CO>: <E>Poorly differentiated</E>

Section Name: Prognostic Stage Groups
====================
Entities:-
Neoplasm Staging : Methods and systems of classifying neoplasms according to extent of disease.
Tumor Staging : A system for describing the size and spread of cancer within the body.
Tnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient's body.

Relationships:-
1. Entity1: ""Stage 0"", Entity2: ""Tis N0 M0"", Relationship: ""defined by""
2. Entity1: ""Stage I"", Entity2: ""T1 N0 M0"", Relationship: ""defined by""
3. Entity1: ""Stage II"", Entity2: ""T2 N0 M0"", Relationship: ""defined by""
4. Entity1: ""Stage III"", Entity2: ""T3 N0 M0, T1 N1 M0, T2 N1 M0, T3 N1 M0"", Relationship: ""defined by""
5. Entity1: ""Stage IVA"", Entity2: ""T1 N2 M0, T2 N2 M0, T3 N2 M0, T4a N0,N1,N2 M0"", Relationship: ""defined by""
6. Entity1: ""Stage IVB"", Entity2: ""Any T N3 M0, T4b Any N M0"", Relationship: ""defined by""
7. Entity1: ""Stage IVC"", Entity2: ""Any T Any N M1"", Relationship: ""defined by""
--------------------------------------------------
Page Number: 93

Section Name: PRINCIPLES OF IMAGING
====================
Entities:-
Imaging, Diagnostic : The production of a visual representation of parts of the body, for the purpose of clinical analysis and medical intervention.
Head And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Tomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.
Magnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body's soft tissue and bones.
Contrast Media : Substances used to enhance the contrast of structures or fluids within the body in medical imaging.

Relationships:-
1. Entity1: ""Imaging, Diagnostic"", Entity2: ""Head and Neck Neoplasms"", Relationship: ""used for""
2. Entity1: ""Tomography, X-Ray Computed"", Entity2: ""Contrast Media"", Relationship: ""uses""
3. Entity1: ""Magnetic Resonance Imaging"", Entity2: ""Contrast Media"", Relationship: ""uses""

Causalities:-
<C> Imaging </C> plays an essential role in the clinical care of patients with head and neck cancer. <A> The proper selection and utilization of imaging studies </A> is critical in caring for patients with head and neck cancer. <A> CT is performed with contrast </A>, while <A> CT imaging of the chest can be performed with or without contrast </A>, <CO> as clinically indicated </CO>. <A> MRI is performed with and without contrast </A>, <CO> unless contraindicated </CO>.

Section Name: Initial Workup - Primary Site
====================
Entities:-
Tomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.
Magnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body's soft tissue and bones.
Head And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Neck Structure : The anatomical structure of the neck, which is the part of the body that connects the head to the torso.
Skull Base : The bottom part of the skull, which separates the brain from other facial structures.
Thoracic Inlet : The opening at the top of the thoracic cavity, through which pass the trachea, esophagus, and major blood vessels.

Relationships:-
1. Entity1: ""CT"", Entity2: ""MRI"", Relationship: ""complementary in imaging head and neck cancers""
2. Entity1: ""CT"", Entity2: ""Head and Neck Neoplasms"", Relationship: ""used to evaluate""
3. Entity1: ""MRI"", Entity2: ""Head and Neck Neoplasms"", Relationship: ""preferred for evaluating""
4. Entity1: ""Skull base"", Entity2: ""Thoracic inlet"", Relationship: ""imaging range for evaluation""

Causalities:-
<A>Imaging assessment of the primary site</A> can be performed with <A>CT of the soft tissues of the neck</A> or <A>MRI of the neck</A>. <C>CT is complementary to MRI for head and neck cancers</C>. <A>It is utilized to evaluate cortical bone erosion or periosteal invasion, cartilage invasion, and bony erosion or destruction</A>. <CO>in certain conditions, such as evaluating the extent of bone marrow invasion or in patients with extensive dental amalgam obscuring anatomy on CT, assessing skull base invasion and cranial nerve involvement, and differentiating tumor from obstructed sinuses</CO>, <A>MRI is preferred over CT</A>. <CO>when involved lymph nodes or upper mediastinal cancers are present</CO>, <A>Complete evaluation of primary and nodal disease requires imaging from the skull base to the thoracic inlet, extending to the carina</A>.

Section Name: PET/CT and Biopsy
====================
Entities:-
Positron Emission Tomography Computed Tomography : A medical imaging technique that combines PET and CT capabilities to provide detailed images of the body.
Examination Under Anesthesia : A procedure where a patient is examined while under anesthesia to allow for a more thorough examination.
Biopsy : A medical test involving the extraction of sample cells or tissues for examination to determine the presence or extent of a disease.
Tonsillectomy : A surgical procedure to remove the tonsils, often performed to treat recurrent tonsillitis or sleep apnea.
Fine Needle Aspiration : A type of biopsy procedure that uses a thin, hollow needle to extract cells from a lump or mass for examination.
Ultrasound : A medical imaging technique that uses high-frequency sound waves to visualize internal organs and structures.
Computed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.

Relationships:-
1. Entity1: ""PET/CT"", Entity2: ""EUA"", Relationship: ""recommended before""
2. Entity1: ""Fine Needle Aspiration (FNA)"", Entity2: ""metastatic nodes"", Relationship: ""used for biopsy of""
3. Entity1: ""Image-guided needle biopsy"", Entity2: ""cystic neck nodes"", Relationship: ""recommended for initial diagnosis of""

Causalities:-
<CO> If imaging does not reveal an obvious primary cancer </CO>, <A> a PET/CT should be ordered before EUA, biopsies, and tonsillectomy </A>. <E> This helps identify potential primary sites </E> before any interventions take place. Additionally, <A> Fine Needle Aspiration (FNA) biopsy of metastatic nodes </A> <E> may provide pathologically informative results </E>. <CO> For initial diagnosis in cystic neck nodes </CO>, <A> image-guided needle biopsy (ultrasound or CT) </A> <E> may yield better results than FNA by palpation alone </E>.

Section Name: Postoperative Imaging Advice
====================
Entities:-
Panoramic Radiography : A type of dental x-ray that provides a wide view of the upper and lower jaws, teeth, temporomandibular joints, and sinuses.
Oral Cavity : The cavity of the mouth, including the lips, the lining inside the cheeks and lips, the front two-thirds of the tongue, the gums, the floor of the mouth under the tongue, the hard palate, and the small area of the gum behind the wisdom teeth.
Radiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.
Mandibulotomy : A surgical procedure involving the cutting of the mandible.
Mandibulectomy : A surgical procedure involving the removal of part or all of the mandible.
Oropharynx : The part of the throat at the back of the mouth behind the oral cavity.

Relationships:-
1. Entity1: ""panoramic dental x-ray"", Entity2: ""oral cavity cancers"", Relationship: ""recommended for""
2. Entity1: ""panoramic dental x-ray"", Entity2: ""postoperative radiotherapy"", Relationship: ""essential for pre-radiation evaluation""
3. Entity1: ""pre-radiation dental evaluation"", Entity2: ""dental procedures or extractions"", Relationship: ""determine necessity of""

Causalities:-
<A> A panoramic dental x-ray is recommended </A> <C> for oral cavity cancers requiring mandibulotomy and/or mandibulectomy </C>. <CO> When postoperative radiotherapy (RT) is anticipated for areas like the lip, oral cavity subsites, or oropharynx </CO>, <A> panoramic x-ray is essential for a comprehensive pre-radiation dental evaluation </A> <E> to assess the health of affected teeth and determine if pre-radiation dental procedures or extractions are necessary </E>.

Section Name: NCCN Guidelines Note
====================
Entities:-
Neoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.
Malignant Neoplastic Disease : A disease characterized by uncontrolled, abnormal growth of cells that can invade or spread to other parts of the body.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.
Clinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.
Clinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.

Relationships:-
1. Entity1: ""NCCN"", Entity2: ""Clinical Trials"", Relationship: ""encourages participation in""
2. Entity1: ""NCCN"", Entity2: ""Cancer"", Relationship: ""recommends clinical trials for""

Causalities:-
<A> NCCN believes that the best management of any patient with cancer is through participation in clinical trials </A>, <A> which is especially encouraged </A>.


Among these two options which one is the most likely true:

(A) `Presence_of_Metastasis_in_Lymph_Nodes_5` increases risk `Positron_Emission_Tomography_PET_Scans_10`
(B) `Positron_Emission_Tomography_PET_Scans_10` `increases risk `Presence_of_Metastasis_in_Lymph_Nodes_5`

The answer is: ...

1. State the evidences in detail of the validity of option (A) or (B) by cross referencing
NCCN Clinical Practitioner’s Guidelines for Head and Neck Cancer.
2. If the evidences are obtained from `INFORMATION FROM KNOWLEDGE BASE`,
mention their corresponding Page Numbers, Section Name, entities, relationships and causalities.

DESIRED OUTPUT FORMAT:
<thinking>
...
</thinking>
<answer>
{
   ""thinking"": [""..."", ...],
   ""evidences"": [""..."", ...],
   ""answer"": ...
}
</answer>

Before providing the answer in <answer> tags, think step by step in detail in <thinking> tags and analyze every part.
Output inside <answer> tag in JSON format. Only output valid JSON.
DO NOT HALLUCINATE. DO NOT MAKE UP FACTUAL INFORMATION.
","1. The edge (A) suggests that the presence of metastasis in lymph nodes increases the likelihood of a positive PET scan result. This is a logical causal relationship because metastasis in lymph nodes is a pathological condition that can be detected by PET scans, which are designed to identify abnormal metabolic activity associated with cancer.
2. The edge (B) suggests that a PET scan result increases the risk of metastasis in lymph nodes. This is not a valid causal relationship because a PET scan is a diagnostic tool that detects existing conditions rather than causing them.
3. The NCCN Guidelines emphasize the use of PET scans to detect existing metastasis rather than causing it. PET scans are used to assess the extent of disease, including lymph node involvement, as part of the diagnostic process.
4. The causal direction for edge (A) is positive, as the presence of metastasis leads to a positive PET scan result. The causal factor is sufficient because the presence of metastasis is enough to cause a positive PET scan result.
5. The causal distance for edge (A) is proximal because the presence of metastasis directly affects the PET scan result.
6. The NCCN Guidelines (Page 92, Section: Imaging and Assessment Protocols) mention that FDG-PET/CT scans are used to assess distant metastases and nodal involvement, supporting the validity of edge (A).
7. The NCCN Guidelines (Page 94, Section: Initial Workup - Nodal Metastases) state that FDG-PET/CT is used for the detection of lymph node metastases, further supporting edge (A).
","1. Page 92, Section: Imaging and Assessment Protocols - FDG-PET/CT scans are used to assess distant metastases and nodal involvement.
2. Page 94, Section: Initial Workup - Nodal Metastases - FDG-PET/CT is used for the detection of lymph node metastases.
",A,"{'A': 100.0, 'B': 0.0}",yes,A,"1. The AI assistant's reasoning for option (A) is based on the logical relationship between the presence of metastasis in lymph nodes and the detection capabilities of PET scans. The assistant correctly identifies that PET scans are diagnostic tools used to detect existing conditions, such as metastasis, rather than causing them.
2. The assistant's reasoning for option (B) is also accurate, as it points out the invalidity of a PET scan causing metastasis. PET scans are used to detect and assess the extent of existing disease, not to influence or cause it.
3. The assistant references the NCCN Guidelines to support the validity of option (A). The guidelines emphasize the use of PET scans for detecting metastasis, which aligns with the causal relationship described in option (A).
4. The assistant correctly identifies the causal direction as positive for option (A), as the presence of metastasis leads to a positive PET scan result. This is consistent with the explanation provided in the edge description.
5. The assistant also correctly identifies the causal factor as sufficient for option (A), as the presence of metastasis is enough to cause a positive PET scan result. This aligns with the explanation that metastasis is a critical factor in cancer staging and prognosis.
6. The causal distance is identified as proximal for option (A), which is consistent with the explanation that the presence of metastasis directly affects the PET scan result.
7. The references to the NCCN Guidelines on Page 92 and Page 94 support the assistant's reasoning for option (A). These sections discuss the use of PET scans for assessing metastasis, which aligns with the causal relationship described in option (A).
"
3,gpt-4o,"Presence_of_Metastasis_in_Lymph_Nodes_5,Ultrasound_11","""{'NODE1': {'id': 'Presence_of_Metastasis_in_Lymph_Nodes_5', 'label': 'Metastasis in Nearby Lymph Nodes', 'description': 'This node represents the clinical situation regarding whether metastasis is present in the nearby lymph nodes of a patient. It is a critical factor in determining the stage and prognosis of cancer, as the spread of cancer to lymph nodes often indicates a more advanced disease and may influence treatment decisions.', 'type': 'Patient Situation', 'observability': 'Unobserved', 'states': [{'state_name': 'unknown', 'state_description': 'The status of metastasis in the lymph nodes is not determined. It is unclear whether cancer has spread to these nodes.'}, {'state_name': 'present', 'state_description': 'Metastasis is confirmed in the lymph nodes, indicating that cancer has spread to these nodes.'}, {'state_name': 'absent', 'state_description': 'There is no metastasis in the lymph nodes, indicating that cancer has not spread to these nodes.'}]}, 'NODE2': {'id': 'Ultrasound_11', 'label': 'Ultrasound Examination Result', 'description': 'This node represents the result of an ultrasound examination, which is a diagnostic imaging technique used to visualize internal organs and structures. The result can indicate whether certain features or abnormalities are present or absent.', 'type': 'Examination Result', 'observability': 'Observed', 'states': [{'state_name': 'present', 'state_description': 'The ultrasound examination detected the presence of a feature or abnormality of interest.'}, {'state_name': 'absent', 'state_description': 'The ultrasound examination did not detect any features or abnormalities of interest.'}]}, 'EDGE1': {'edges_ids': ['Presence_of_Metastasis_in_Lymph_Nodes_5', 'Ultrasound_11'], 'edge': '(Presence_of_Metastasis_in_Lymph_Nodes_5) causes (Ultrasound_11)', 'explanation': ['The edge `(Presence_of_Metastasis_in_Lymph_Nodes_5) causes (Ultrasound_11)` is not valid because the presence of metastasis in lymph nodes does not cause an ultrasound result.', 'Instead, an ultrasound is a diagnostic tool used to detect the presence of metastasis in lymph nodes.', 'The causal direction is not from the presence of metastasis to the ultrasound result, but rather the ultrasound result is used to infer the presence of metastasis.', 'Therefore, the causal direction is unknown, and the causal factor is neither necessary nor sufficient.', 'The causal distance is unknown because the relationship is not a direct causal one.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}, 'EDGE2': {'edges_ids': ['Ultrasound_11', 'Presence_of_Metastasis_in_Lymph_Nodes_5'], 'edge': '(Ultrasound_11) causes (Presence_of_Metastasis_in_Lymph_Nodes_5)', 'explanation': ['The edge represents a supposed causal relationship where the result of an ultrasound examination (Ultrasound_11) causes the presence of metastasis in lymph nodes (Presence_of_Metastasis_in_Lymph_Nodes_5).', 'This is not a valid causal relationship because an ultrasound is a diagnostic tool used to detect existing conditions, not to cause them.', 'The presence of metastasis in lymph nodes is a pathological condition that occurs due to the spread of cancer, not due to the result of an ultrasound examination.', 'Therefore, the edge is invalid as the ultrasound result does not cause metastasis; it merely detects it if present.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}, 'ENTITIES_MATCHING_PAGES_INFO': {'55': {'matching_entities': [{'NEOPLASM METASTASIS': 0.96748203}, {'METASTASIS': 0.9630129}, {'METASTATIC NEOPLASM': 0.96172774}, {'MALIGNANT NEOPLASTIC DISEASE': 0.9424237}, {'CANCER': 0.92851335}], 'count': 5}, '130': {'matching_entities': [{'LYMPH NODE STRUCTURE': 0.99134904}, {'LYMPH NODE': 0.98570025}, {'LYMPH NODES': 0.97445965}, {'NEOPLASM METASTASIS': 0.96748203}, {'METASTASIS': 0.9630129}], 'count': 5}, '92': {'matching_entities': [{'METASTASIS': 0.9630129}, {'MALIGNANT NEOPLASM': 0.9448747}, {'CANCER': 0.92851335}, {'CLINICAL ASSESSMENT': 0.9249019}], 'count': 4}, '41': {'matching_entities': [{'METASTASIS': 0.9630129}, {'LYMPHATIC METASTASIS': 0.94962627}, {'CANCER': 0.92851335}, {'IMAGING': 0.9209789}], 'count': 4}, '68': {'matching_entities': [{'NEOPLASM METASTASIS': 0.96748203}, {'METASTASIS': 0.9630129}, {'METASTATIC DISEASE': 0.95668894}, {'METASTATIC MALIGNANT NEOPLASM': 0.93472815}], 'count': 4}}, 'GUIDELINE_PAGES_INFO': '--------------------------------------------------\\nPage Number: 55\\n\\nSection Name: General Information\\n====================\\nEntities:-\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nNccn Guidelines : Clinical practice guidelines in oncology developed by the National Comprehensive Cancer Network.\\n\\nRelationships:-\\n1. Entity1: \""NCCN Guidelines\"", Entity2: \""National Comprehensive Cancer Network\"", Relationship: \""produced by\""\\n\\nSection Name: Important Notes\\n====================\\nEntities:-\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medical, surgical, or behavioral interventions.\\nClinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nNeoplasms : New abnormal growth of tissue that can be benign or malignant.\\nMalignant Neoplastic Disease : A disease resulting from the growth of malignant neoplasms.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""Clinical Trials\"", Entity2: \""Cancer\"", Relationship: \""recommended for\""\\n2. Entity1: \""NCCN\"", Entity2: \""Clinical Trials\"", Relationship: \""encourages participation in\""\\n\\nCausalities:-\\n<C> NCCN believes that the best management of any patient with cancer is in a clinical trial </C>. <A> Participation in clinical trials is especially encouraged </A>.\\n\\nSection Name: Principles\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nChemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.\\n\\nRelationships:-\\n1. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Radiation Therapy\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n2. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n3. Entity1: \""Principles of Radiation Therapy\"", Entity2: \""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n\\nCausalities:-\\n### Principles\\n\\n- **Principles of Surgery (SURG-A)**\\n- **Principles of Radiation Therapy (SUPRA-A)**\\n- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**\\n\\nSection Name: Adverse Pathologic Features\\n====================\\nEntities:-\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.\\nPerineural Invasion : The presence of cancer cells surrounding or tracking along a nerve within the perineural space.\\nVascular Invasion : The invasion of cancer cells into blood vessels.\\nLymphatic Invasion : The invasion of cancer cells into lymphatic vessels.\\n\\nRelationships:-\\n1. Entity1: \""Extranodal extension\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n2. Entity1: \""Positive margins\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n3. Entity1: \""Close margins\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n4. Entity1: \""pT3 or pT4 primary\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n5. Entity1: \""pN2 or pN3 nodal disease\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n6. Entity1: \""Perineural invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n7. Entity1: \""Vascular invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n8. Entity1: \""Lymphatic invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n\\nCausalities:-\\n<C> Extranodal extension </C>\\n<C> Positive margins </C>\\n<C> Close margins </C>\\n<C> pT3 or pT4 primary </C>\\n<C> pN2 or pN3 nodal disease </C>\\n<C> Perineural invasion </C>\\n<C> Vascular invasion </C>\\n<C> Lymphatic invasion </C>\\n\\nSection Name: Response Assessment\\n====================\\nEntities:-\\nChemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nPrimary Site : The original location where a tumor or cancer begins.\\nComplete Remission : The disappearance of all signs of cancer in response to treatment.\\nPartial Remission : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.\\nRadiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""induction chemotherapy\"", Entity2: \""Primary site\"", Relationship: \""treatment outcome\""\\n2. Entity1: \""Definitive RT\"", Entity2: \""Primary site\"", Relationship: \""treatment option\""\\n3. Entity1: \""RT\"", Entity2: \""Primary site\"", Relationship: \""treatment option\""\\n4. Entity1: \""Surgery\"", Entity2: \""unresectable nodal disease\"", Relationship: \""treatment option\""\\n\\nCausalities:-\\n<C> Response after induction chemotherapy </C>: <E> Primary site: CR </E> <E> Primary site: PR </E> <E> Primary site: < PR </E> <A> Definitive RT </A> (category 1) <A> RT </A> (category 1) or <A> systemic therapy/RT </A> (category 2B) <A> Surgery </A> or <A> unresectable nodal disease </A>\\n\\nSection Name: Follow-up\\n====================\\nEntities:-\\nFollow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.\\nFollow-Up Procedure : A procedure where a patient is monitored over time to assess the progress of a condition or the effects of treatment.\\nFollow-Up (Medicine) : The process of monitoring a patient\\'s health over time after treatment or diagnosis.\\nDisease Recurrence : The return of a sign, symptom, or disease after a remission.\\nRecurrent Disease : A disease that returns after a period of remission.\\nRecurrence (Medicine) : The return of a disease or condition after a period of improvement.\\n\\nRelationships:-\\n1. Entity1: \""Follow-up\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""monitoring\""\\n\\nCausalities:-\\n### Follow-up\\n\\n- **Follow-up** (FOLL-A, 1 of 2)\\n- **Recurrent or persistent disease** (ADV-3)\\n\\nSection Name: Risk Features\\n====================\\nEntities:-\\nRadiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Adverse pathologic features\"", Entity2: \""RT\"", Relationship: \""Consideration for treatment\""\\n2. Entity1: \""Adverse pathologic features\"", Entity2: \""Systemic therapy\"", Relationship: \""Consideration for treatment\""\\n\\nCausalities:-\\n- **No adverse pathologic features**\\n- **Other risk features**\\n- **Adverse pathologic features**:\\n  - <C> Extranodal extension and/or positive margin </C>\\n  - <A> RT or consider systemic therapy/RT </A>\\n\\nSection Name: Post-Therapy Evaluation\\n====================\\nEntities:-\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nNeck : The neck is the part of the body that separates the head from the torso and provides the mobility and movements of the head.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Neck Evaluation\"", Relationship: \""evaluated in\""\\n2. Entity1: \""RT\"", Entity2: \""Neck Evaluation\"", Relationship: \""evaluated in\""\\n\\nCausalities:-\\n<CO> Post Systemic Therapy/RT or RT Neck </CO> <A> Evaluation </A>\\n\\nSection Name: Flowchart Overview\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nSupraglottic Larynx : The part of the larynx located above the vocal cords, including the epiglottis and aryepiglottic folds.\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\n\\nRelationships:-\\n1. Entity1: \""NCCN Guidelines\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""guides management of\""\\n2. Entity1: \""NCCN Guidelines\"", Entity2: \""healthcare professionals\"", Relationship: \""used by\""\\n\\nCausalities:-\\n<C> cancer of the supraglottic larynx </C> <E> evaluate patient responses following treatment </E> <CO> based on observed outcomes </CO> <A> evaluation of the primary site and determining subsequent steps </A>.\\n\\nSection Name: Assessment and Treatment Decisions\\n====================\\nEntities:-\\nInduction Chemotherapy : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nComplete Response : The disappearance of all signs of cancer in response to treatment.\\nPartial Response : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Complete Response\"", Entity2: \""Radiation Therapy\"", Relationship: \""leads to\""\\n2. Entity1: \""Complete Response\"", Entity2: \""Surgery\"", Relationship: \""leads to\""\\n3. Entity1: \""Partial Response\"", Entity2: \""Systemic Therapy\"", Relationship: \""leads to\""\\n4. Entity1: \""Partial Response\"", Entity2: \""Radiation Therapy\"", Relationship: \""leads to\""\\n\\nCausalities:-\\n<C> responses to initial treatments such as induction chemotherapy </C> <E> Three main response categories are recognized: Complete Response (CR), Partial Response (PR), and less than Partial Response (< PR) </E>. These categories are pivotal in determining the next steps. <C> CR </C> <E> indicates full resolution of the disease at the primary site </E>, <A> leading to the consideration of definitive radiation therapy or the likelihood of surgery </A>. Conversely, <C> PR </C> <E> suggests that the disease has improved but not completely resolved </E>, <A> which directs the pathway towards either systemic therapy or continued radiation therapy </A>, <A> with further evaluation necessary </A>.\\n\\nSection Name: Adverse Pathologic Features and Follow-up\\n====================\\nEntities:-\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nNeoplasm Recurrence, Local : The return of a tumor or cancer, at the original site, after it has been treated.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nRecurrent Neoplasm : A neoplasm that has returned after treatment.\\nMetastatic Neoplasm : A neoplasm that has spread from its original site to one or more other places in the body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nCancer Recurrence : The return of cancer after treatment and after a period of time during which the cancer was undetectable.\\nMetastasis : Spread of a cancer or other disease from one organ or part to another not directly connected with it.\\n\\nRelationships:-\\n1. Entity1: \""Adverse pathologic features\"", Entity2: \""Treatment decisions\"", Relationship: \""Influence\""\\n2. Entity1: \""Adverse features\"", Entity2: \""Surgical intervention\"", Relationship: \""Recommendation\""\\n3. Entity1: \""Absence of adverse features\"", Entity2: \""Radiation therapy\"", Relationship: \""Pathway\""\\n4. Entity1: \""Follow-up process\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""Detection\""\\n5. Entity1: \""Recurrent or persistent disease\"", Entity2: \""Advanced disease management\"", Relationship: \""Necessity\""\\n\\nCausalities:-\\n<C> The presence of adverse pathologic features \u2014 such as extranodal extension or positive margins </C> <E> can directly influence treatment decisions </E>. <CO> If adverse features are found </CO>, <A> surgical intervention is recommended </A>. <CO> In cases where there are no adverse features </CO>, the patient may proceed directly to radiation therapy or continued systemic treatment, emphasizing the tailored approach based on the individual patient\\'s disease characteristics.\\n\\nFurthermore, the chart includes a section addressing the follow-up process after initial treatment. <CO> If there are signs of recurrent or persistent disease </CO>, <A> additional evaluations and treatment modalities may be necessary </A>. These evaluations <E> lead to specific recommendations for advanced disease management, denoted as ADV-3 on the chart </E>, emphasizing the importance of continuous monitoring and assessment in cancer care.\\n--------------------------------------------------\\nPage Number: 130\\n\\nSection Name: Pathological N (pN)\\n====================\\nEntities:-\\nLymph Nodes : Small, bean-shaped structures that are part of the body\\'s lymphatic system. They filter lymph fluid and store white blood cells that help fight infection.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nTnm Staging : A system used to describe the size and spread of cancer in a standardized way. T refers to the size of the tumor, N to the involvement of lymph nodes, and M to metastasis.\\nLymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\nTnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient\\'s body.\\nLymph Node : An organ of the lymphatic system and the adaptive immune system.\\n\\nRelationships:-\\n1. Entity1: \""Lymph Nodes\"", Entity2: \""Neoplasm Metastasis\"", Relationship: \""involved in\""\\n2. Entity1: \""TNM Staging\"", Entity2: \""Lymph Nodes\"", Relationship: \""includes\""\\n3. Entity1: \""TNM Staging\"", Entity2: \""Neoplasm Metastasis\"", Relationship: \""describes\""\\n\\nCausalities:-\\n<CO> NX: Regional lymph nodes cannot be assessed </CO>\\n<CO> N0: No regional lymph node metastasis </CO>\\n<CO> N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(\u2013) </CO>\\n<CO> N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2212); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(\u2212); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2a: Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N3: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(\u2212); or metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>\\n<CO> N3a: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N3b: Metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>\\n<CO> Note: A designation of \u201cU\u201d or \u201cL\u201d may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L). Similarly, clinical and pathological ENE should be recorded as ENE(\u2212) or ENE(+). </CO>\\n\\nSection Name: Distant Metastasis (M)\\n====================\\nEntities:-\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\n\\nRelationships:-\\n1. Entity1: \""M0\"", Entity2: \""Distant Metastasis\"", Relationship: \""is a category of\""\\n2. Entity1: \""M1\"", Entity2: \""Distant Metastasis\"", Relationship: \""is a category of\""\\n\\nCausalities:-\\n### Distant Metastasis (M)\\n\\n- **M0**: No distant metastasis\\n- **M1**: Distant metastasis\\n\\nSection Name: Histologic Grade (G)\\n====================\\nEntities:-\\nNeoplasm Grading : A system of classifying cancer cells in terms of how abnormal they look under a microscope and how quickly the tumor is likely to grow and spread.\\nHistologic Grade : A measure of how much tumor cells differ from healthy cells, used to assess the aggressiveness of cancer.\\n\\nRelationships:-\\n1. Entity1: \""GX\"", Entity2: \""Grade cannot be assessed\"", Relationship: \""is described as\""\\n2. Entity1: \""G1\"", Entity2: \""Well differentiated\"", Relationship: \""is described as\""\\n3. Entity1: \""G2\"", Entity2: \""Moderately differentiated\"", Relationship: \""is described as\""\\n4. Entity1: \""G3\"", Entity2: \""Poorly differentiated\"", Relationship: \""is described as\""\\n\\nCausalities:-\\n<CO>GX</CO>: <E>Grade cannot be assessed</E>\\n<CO>G1</CO>: <E>Well differentiated</E>\\n<CO>G2</CO>: <E>Moderately differentiated</E>\\n<CO>G3</CO>: <E>Poorly differentiated</E>\\n\\nSection Name: Prognostic Stage Groups\\n====================\\nEntities:-\\nNeoplasm Staging : Methods and systems of classifying neoplasms according to extent of disease.\\nTumor Staging : A system for describing the size and spread of cancer within the body.\\nTnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient\\'s body.\\n\\nRelationships:-\\n1. Entity1: \""Stage 0\"", Entity2: \""Tis N0 M0\"", Relationship: \""defined by\""\\n2. Entity1: \""Stage I\"", Entity2: \""T1 N0 M0\"", Relationship: \""defined by\""\\n3. Entity1: \""Stage II\"", Entity2: \""T2 N0 M0\"", Relationship: \""defined by\""\\n4. Entity1: \""Stage III\"", Entity2: \""T3 N0 M0, T1 N1 M0, T2 N1 M0, T3 N1 M0\"", Relationship: \""defined by\""\\n5. Entity1: \""Stage IVA\"", Entity2: \""T1 N2 M0, T2 N2 M0, T3 N2 M0, T4a N0,N1,N2 M0\"", Relationship: \""defined by\""\\n6. Entity1: \""Stage IVB\"", Entity2: \""Any T N3 M0, T4b Any N M0\"", Relationship: \""defined by\""\\n7. Entity1: \""Stage IVC\"", Entity2: \""Any T Any N M1\"", Relationship: \""defined by\""\\n--------------------------------------------------\\nPage Number: 92\\n\\nSection Name: NCCN Guidelines Overview\\n====================\\nEntities:-\\nHead And Neck Neoplasms : Cancers that arise in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\nMalignant Neoplasm Of Head And Neck : A malignant tumor located in the head and neck region.\\nHead And Neck Cancer : A group of cancers that originate in the head and neck region.\\nAntineoplastic Agents : Drugs used to treat cancer by inhibiting the growth of cancerous cells.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.\\nRadiation Therapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.\\n\\nRelationships:-\\n1. Entity1: \""Head and neck cancers\"", Entity2: \""Systemic therapy\"", Relationship: \""follow-up recommendations after\""\\n2. Entity1: \""Head and neck cancers\"", Entity2: \""Radiation therapy\"", Relationship: \""follow-up recommendations after\""\\n\\nCausalities:-\\nThe image presents a flowchart from the National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2024, especially focusing on <A> follow-up recommendations </A> for <CO> patients with head and neck cancers after systemic therapy or radiation therapy (RT) </CO>. All recommendations are categorized as level A unless stated otherwise, highlighting the importance of clinical trials in cancer management.\\n\\nSection Name: Imaging and Assessment Protocols\\n====================\\nEntities:-\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.\\nClinical Assessment : A systematic evaluation of a patient\\'s health status, often involving a physical examination and medical history.\\nPositron-Emission Tomography : An imaging technique using a radioactive substance called a tracer to look for disease in the body.\\nComputed Tomography : A medical imaging technique used in radiology to obtain detailed internal images of the body.\\nMagnetic Resonance Imaging : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis.\\nDisease : A disorder of structure or function in a human, animal, or plant, especially one that produces specific symptoms.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\nResidual Neoplasm : Remaining cancer cells after treatment.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Clinical Assessment\"", Relationship: \""occurs before\""\\n2. Entity1: \""FDG-PET/CT Scan\"", Entity2: \""Distant Metastases\"", Relationship: \""assesses\""\\n3. Entity1: \""FDG-PET/CT Scan\"", Entity2: \""Observation\"", Relationship: \""leads to if negative\""\\n4. Entity1: \""FDG-PET/CT Scan\"", Entity2: \""CT Scan\"", Relationship: \""leads to if strongly positive\""\\n5. Entity1: \""CT Scan\"", Entity2: \""Neck Dissection\"", Relationship: \""leads to if positive\""\\n\\nCausalities:-\\n<CO> After systemic therapy or RT </CO>, <A> a clinical assessment should occur 4 to 8 weeks later </A>. <CO> If there is a response </CO>, <A> it is necessary to assess the extent of disease or distant metastases, preferably through a FDG-PET/CT scan at a minimum of 12 weeks post-treatment </A>. <CO> If the FDG-PET/CT results are negative </CO>, <A> the patient may continue with monitoring through observation </A>. <CO> In cases where the results are equivocal </CO>, <A> observation or repeat FDG-PET/CT within 3 to 6 months is prescribed </A>.\\n\\n<CO> In cases where the FDG-PET/CT results are strongly positive </CO>, <A> further imaging via CT scan with contrast of the primary site and neck, or MRI with and without contrast, becomes necessary </A>. <CO> If these imaging results confirm positive findings </CO>, <A> neck dissection may be considered, depending on the evidence of residual or persistent disease </A>. <CO> If the imaging findings are negative </CO>, <A> the patient might continue in observation </A>.\\n\\nSection Name: Outcomes Based on Disease Resectability\\n====================\\nEntities:-\\nDisease : A disorder of structure or function in a human, animal, or plant, especially one that produces specific symptoms.\\nResectable : Capable of being surgically removed.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis.\\n\\nRelationships:-\\n1. Entity1: \""Disease\"", Entity2: \""Resectable\"", Relationship: \""Classification\""\\n2. Entity1: \""Unresectable\"", Entity2: \""Treatment plans (ADV-3)\"", Relationship: \""Treatment recommendation\""\\n3. Entity1: \""Resectable\"", Entity2: \""Resection and/or Neck dissection\"", Relationship: \""Surgical procedure\""\\n\\nCausalities:-\\n<CO> If there is confirmed residual or persistent disease </CO>, the options split into two pathways: \\'Unresectable\\' or \\'Resectable.\\' <CO> If the disease is classified as unresectable </CO>, <A> advances in treatment plans (labeled ADV-3) are called for </A>. Conversely, <CO> if it is deemed resectable </CO>, <A> a resection of the primary and/or neck dissection may occur </A>, <CO> contingent upon the disease status </CO>.\\n\\nSection Name: Important Notes\\n====================\\nEntities:-\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\nClinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.\\nPositron-Emission Tomography : An imaging technique using a radioactive substance called a tracer to look for disease in the body.\\nPositron Emission Tomography (Procedure) : A diagnostic imaging procedure that uses a radioactive tracer to visualize and measure changes in metabolic processes.\\nPositron Emission Tomography : A nuclear medicine functional imaging technique used to observe metabolic processes in the body.\\nNeoplasms : New abnormal growth of tissue in animals or plants; a tumor.\\nMalignant Neoplasm : A cancerous growth that has the potential to spread to other parts of the body.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""NCCN\"", Entity2: \""Clinical trials\"", Relationship: \""emphasizes participation in\""\\n2. Entity1: \""FDG-PET/CT\"", Entity2: \""Persistent cancer\"", Relationship: \""used to detect\""\\n3. Entity1: \""FDG-PET/CT\"", Entity2: \""PET negative\"", Relationship: \""interpretation of results\""\\n4. Entity1: \""FDG-PET/CT\"", Entity2: \""PET positive\"", Relationship: \""interpretation of results\""\\n\\nCausalities:-\\n<A> NCCN emphasizes that the best management for any cancer patient is participation in clinical trials </A>, especially encouraged for all patients. Additional notes clarify that <CO> if the FDG-PET/CT is negative for persistent cancer </CO>, <A> further cross-sectional imaging is optional </A>. The interpretations define <CO> PET negative as no or low-grade uptake not suspicious for disease </CO>, while <CO> PET positive implies suspicion for disease </CO>.\\n--------------------------------------------------\\nPage Number: 41\\n\\nSection Name: Workup\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.\\nHistory And Physical Examination : A comprehensive assessment of a patient\\'s medical history and physical condition.\\nTobacco Smoking : The act of smoking tobacco products, which is a risk factor for many diseases.\\nAlcohol Drinking : The consumption of beverages containing ethyl alcohol.\\nSmoking Cessation : The process of discontinuing tobacco smoking.\\nBiopsy : A medical test involving the extraction of sample cells or tissues for examination.\\nLaryngoscopy : A procedure to examine the larynx, often using a scope.\\nComputed Tomography (Ct) : A diagnostic imaging procedure that uses computer-processed combinations of many X-ray measurements taken from different angles to produce cross-sectional images of specific areas of a scanned object.\\nMagnetic Resonance Imaging (Mri) : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.\\nPositron-Emission Tomography : A type of nuclear medicine imaging that measures metabolic activity of the cells of body tissues.\\nPulmonary Function Test : Tests that measure how well the lungs are working.\\nDental Examination : An evaluation of the teeth and gums to assess oral health.\\nNutritional Support : Therapies to provide nutrition to patients who cannot obtain nutrition by mouth.\\nSpeech Therapy : Therapy to improve speech and communication skills.\\nSwallowing Therapy : Therapy to help individuals with swallowing difficulties.\\nMultidisciplinary Care Team : A group of healthcare professionals from different specialties working together to manage patient care.\\n\\nRelationships:-\\n1. Entity1: \""glottic larynx cancer\"", Entity2: \""history and physical examination\"", Relationship: \""initial diagnostic step\""\\n2. Entity1: \""glottic larynx cancer\"", Entity2: \""biopsy\"", Relationship: \""required diagnostic procedure\""\\n3. Entity1: \""glottic larynx cancer\"", Entity2: \""direct laryngoscopy\"", Relationship: \""recommended procedure\""\\n4. Entity1: \""glottic larynx cancer\"", Entity2: \""CT scans\"", Relationship: \""imaging study\""\\n5. Entity1: \""glottic larynx cancer\"", Entity2: \""MRI\"", Relationship: \""imaging study\""\\n6. Entity1: \""glottic larynx cancer\"", Entity2: \""multidisciplinary consultation\"", Relationship: \""advised as clinically indicated\""\\n\\nCausalities:-\\nThe workup section outlines the initial steps for diagnosing <C>glottic larynx cancer</C>. It includes <A>a comprehensive history and physical examination (H&P)</A>, which should document tobacco and alcohol use, and provide counseling for smoking cessation. <A>A biopsy of the primary site is required</A>, and <A>direct laryngoscopy under anesthesia is generally recommended</A>. <A>Imaging studies such as CT scans with contrast and possibly MRI are used to evaluate the larynx and neck</A>. Additional evaluations may include <A>chest CT, FDG-PET/CT, pulmonary function tests, dental evaluation, and nutrition, speech, and swallowing therapy</A>. <A>Multidisciplinary consultation is advised</A> <CO>as clinically indicated</CO>.\\n\\nSection Name: Clinical Staging\\n====================\\nEntities:-\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\nCarcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.\\nBiopsy : A medical test involving the extraction of sample cells or tissues for examination.\\nLaryngectomy : A surgical procedure to remove the larynx.\\n\\nRelationships:-\\n1. Entity1: \""Clinical staging\"", Entity2: \""Cancer\"", Relationship: \""involves\""\\n2. Entity1: \""Carcinoma in situ\"", Entity2: \""Stages T1-T4\"", Relationship: \""is a stage of\""\\n3. Entity1: \""Biopsy\"", Entity2: \""Cancer\"", Relationship: \""used in staging\""\\n4. Entity1: \""Larynx-preserving surgeries\"", Entity2: \""Stages T1-T2\"", Relationship: \""considered for\""\\n5. Entity1: \""Total laryngectomy\"", Entity2: \""Stages T3-T4\"", Relationship: \""required for\""\\n\\nCausalities:-\\n<C> Clinical staging involves categorizing the cancer based on its aggressiveness </C>. It starts with carcinoma in situ, which is non-invasive, and progresses through stages T1-T4. <CO> Staging is based on H&P, biopsy, and imaging studies </CO>. <CO> For T1-T2 </CO>, <A> larynx-preserving surgeries are considered </A>, while <CO> more advanced stages like T3 or T4 </CO> <A> may require total laryngectomy </A>. <A> Additional evaluations such as videostrobe, audiogram, and fertility counseling may be considered </A>.\\n\\nSection Name: Treatment\\n====================\\nEntities:-\\nCarcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.\\nLaryngectomy : A surgical procedure to remove the larynx.\\nMetastasis : The transfer of a disease from one organ or part to another not directly connected with it.\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\n\\nRelationships:-\\n1. Entity1: \""Carcinoma in situ\"", Entity2: \""Larynx-preserving surgery\"", Relationship: \""treated with\""\\n2. Entity1: \""T1-T2 stages\"", Entity2: \""Conservation surgery\"", Relationship: \""treated with\""\\n3. Entity1: \""T3 stages\"", Entity2: \""Total laryngectomy\"", Relationship: \""may require\""\\n4. Entity1: \""T4a disease\"", Entity2: \""Complex interventions\"", Relationship: \""require\""\\n5. Entity1: \""Guidelines\"", Entity2: \""Multidisciplinary consultations\"", Relationship: \""emphasize importance of\""\\n6. Entity1: \""Guidelines\"", Entity2: \""Clinical trials\"", Relationship: \""consider as best option\""\\n\\nCausalities:-\\n<CO>Treatment recommendations vary by stage</CO>. <CO>Carcinoma in situ</CO> <A>may be treated with larynx-preserving surgery</A>. <CO>T1-T2 stages</CO> <A>may also be amenable to conservation surgery</A>. <CO>T3 stages</CO> <A>may require total laryngectomy</A>, <CO>especially if nodal involvement is present</CO>. <CO>T4a disease and unresectable or metastatic cases</CO> <A>require more complex interventions</A>. <A>The guidelines emphasize the importance of multidisciplinary consultations</A> and <A>consider clinical trials as the best management option</A>.\\n\\nSection Name: Additional Notes\\n====================\\nEntities:-\\nBiopsy, Needle : A procedure to remove a small sample of tissue for examination under a microscope.\\nImage-Guided Biopsy : A biopsy procedure that uses imaging techniques to guide the needle to the precise location of the tissue to be sampled.\\nBiopsy : A medical test involving the extraction of sample cells or tissues for examination.\\nDiagnostic Techniques And Procedures : Methods and procedures for the diagnosis of disease or dysfunction.\\nImaging : The process of producing images of the body for clinical purposes.\\nDental Care : The total of dental diagnostic, preventive, and corrective procedures.\\nNutritional Physiological Phenomena : The functions and properties of nutrients in living organisms.\\nFertility : The capacity to conceive or induce conception.\\nReproductive Health : A state of physical, mental, and social well-being in all matters relating to the reproductive system.\\nLymphatic Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nGlottis : The part of the larynx consisting of the vocal cords and the opening between them.\\n\\nRelationships:-\\n1. Entity1: \""image-guided needle biopsy\"", Entity2: \""diagnostic yield\"", Relationship: \""used for\""\\n2. Entity1: \""nodal disease\"", Entity2: \""glottic tumors\"", Relationship: \""is rare in\""\\n\\nCausalities:-\\n<A> use of image-guided needle biopsy </A> for <E> better diagnostic yield </E>, principles of imaging, dental evaluation, and nutrition management. The guidelines also address fertility and reproductive considerations, and note that <CO> nodal disease in glottic tumors is rare </CO>.\\n--------------------------------------------------\\nPage Number: 68\\n\\nSection Name: Diagnosis Section\\n====================\\nEntities:-\\nDiagnosis : The process of determining which disease or condition explains a person\\'s symptoms and signs.\\nMetastatic Disease : A disease in which cancer cells spread from the place where they first formed to another part of the body.\\nClinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nLocoregional Therapy : Treatment that is directed to a specific area of the body, often used in cancer treatment.\\n\\nRelationships:-\\n1. Entity1: \""Diagnosis\"", Entity2: \""Decision-making process\"", Relationship: \""initiates\""\\n2. Entity1: \""Metastatic disease\"", Entity2: \""Clinical trial\"", Relationship: \""preferred pathway\""\\n3. Entity1: \""Locoregional treatment\"", Entity2: \""Primary site algorithms\"", Relationship: \""based on\""\\n\\nCausalities:-\\n<CO> for patients presenting with metastatic disease </CO>, <A> a clinical trial is the preferred pathway </A>, emphasizing the critical nature of innovative therapies in advanced cancer care. The option to <A> \""Consider locoregional treatment based on primary site algorithms\"" </A> suggests that specific treatment strategies may be tailored <CO> depending on the exact location and characteristics of the cancer </CO>.\\n\\nSection Name: Treatment Pathways\\n====================\\nEntities:-\\nPerformance Status : A measure of a patient\\'s general well-being and ability to perform ordinary tasks, often used in oncology to determine the appropriate treatment.\\nSystemic Therapy : A treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nSurgery : A medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nPalliative Care : Specialized medical care for people living with a serious illness, focused on providing relief from the symptoms and stress of the illness.\\nSupportive Care : Care given to improve the quality of life of patients who have a serious or life-threatening disease.\\n\\nRelationships:-\\n1. Entity1: \""Performance Status\"", Entity2: \""Systemic Therapy\"", Relationship: \""affects choice of\""\\n2. Entity1: \""Performance Status\"", Entity2: \""Surgery\"", Relationship: \""affects choice of\""\\n3. Entity1: \""Performance Status\"", Entity2: \""Radiation Therapy\"", Relationship: \""affects choice of\""\\n4. Entity1: \""Performance Status\"", Entity2: \""Palliative Care\"", Relationship: \""affects choice of\""\\n5. Entity1: \""Performance Status\"", Entity2: \""Supportive Care\"", Relationship: \""affects choice of\""\\n6. Entity1: \""PS 0-1 Patients\"", Entity2: \""Combination Systemic Therapy\"", Relationship: \""suitable for\""\\n7. Entity1: \""PS 2 Patients\"", Entity2: \""Palliative Radiation Therapy\"", Relationship: \""may receive\""\\n8. Entity1: \""PS 3 Patients\"", Entity2: \""Supportive Care\"", Relationship: \""recommended\""\\n\\nCausalities:-\\nThe treatment section branches into various pathways depending on <CO> the patient\u2019s performance status (PS) </CO>, which is a measure of their general well-being and ability to function. - **For PS 0-1 Patients:** The flowchart indicates several treatment options, including <A> combination systemic therapy, single-agent systemic therapy, surgery, and radiation therapy (RT) </A>. This group is highlighted as those who are most capable of handling intensive treatments and <E> may benefit significantly from combination therapies </E>. - **For PS 2 Patients:** The recommended approach varies slightly, with a continued emphasis on <A> systemic therapies, palliative radiation therapy, or best supportive care </A>. This indicates a level of compromise in treatment options, suggesting that while aggressive treatment is still possible, <E> the focus might shift more towards quality of life </E>. - **For PS 3 Patients:** The treatment options further narrow, still recommending <A> systemic therapy or supportive care </A> but highlighting palliative approaches, reflecting a recognition of <E> the more advanced disease and potentially limited treatment efficacy </E>.\\n\\nSection Name: Principles of Treatment\\n====================\\nEntities:-\\nAntineoplastic Combined Chemotherapy Protocols : Protocols for the administration of more than one antineoplastic agent in combination to treat malignant neoplasms.\\nRadiotherapy : The use of radiation, usually X-rays or gamma rays, to treat disease, especially cancer.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nSystemic Therapy : A treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nSurgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nChemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.\\nSurgery : A medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Radiation Therapy\"", Relationship: \""Different modalities of cancer treatment\""\\n2. Entity1: \""Systemic Therapy\"", Entity2: \""Surgery\"", Relationship: \""Different modalities of cancer treatment\""\\n3. Entity1: \""Radiation Therapy\"", Entity2: \""Surgery\"", Relationship: \""Different modalities of cancer treatment\""\\n\\nCausalities:-\\n- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)** - **Principles of Radiation Therapy (ADV-A)** - **Principles of Surgery (SURG-A)**\\n\\nSection Name: Diagnosis and Treatment of Head and Neck Cancer\\n====================\\nEntities:-\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nMetastatic Malignant Neoplasm : A malignant neoplasm that has spread from its original site to a different site.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\nClinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nPerformance Status : A measure of a patient\\'s general well-being and ability to perform ordinary tasks, often used in oncology to determine the appropriate treatment.\\n\\nRelationships:-\\n1. Entity1: \""Metastatic disease\"", Entity2: \""Clinical trial\"", Relationship: \""preferred treatment option\""\\n2. Entity1: \""Performance Status 0-1\"", Entity2: \""Combination systemic therapy\"", Relationship: \""treatment option\""\\n3. Entity1: \""Performance Status 2\"", Entity2: \""Single-agent systemic therapy\"", Relationship: \""treatment option\""\\n4. Entity1: \""Performance Status 3\"", Entity2: \""Systemic therapy\"", Relationship: \""treatment option\""\\n\\nCausalities:-\\n- <CO>Metastatic (M1) disease at initial presentation</CO>\\n  <A>Clinical trial preferred</A>\\n  <E>Distant metastases</E>\\n  <A>Consider locoregional treatment based on primary site algorithms (Table of Contents)</A>\\n\\n#### Performance Status (PS)\\n- <CO>PS 0\u20131</CO>\\n  <A>Combination systemic therapy</A> or <A>Single-agent systemic therapy</A> or <A>Surgery</A> or <A>RT</A> or <A>systemic therapy/RT for selected patients with limited metastases</A> or <A>Best supportive care</A>\\n- <CO>PS 2</CO>\\n  <A>Single-agent systemic therapy</A> or <A>Best supportive care \u00b1 Palliative RT</A> or <A>Palliative surgery</A>\\n- <CO>PS 3</CO>\\n  <A>Systemic therapy, clinical trial preferred</A> or <A>Palliative RT</A> or <A>Best supportive care</A>\\n\\nSection Name: Persistent Disease or Progression\\n====================\\nEntities:-\\nPalliative Care : Specialized medical care for people living with a serious illness, focused on providing relief from the symptoms and stress of the illness.\\nSupportive Care : Care given to improve the quality of life of patients who have a serious or life-threatening disease.\\nAntineoplastic Agents : Substances that inhibit or prevent the proliferation of neoplasms.\\nSystemic Therapy : A treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nChemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.\\nRadiotherapy : The use of radiation, usually X-rays or gamma rays, to treat disease, especially cancer.\\nPalliative Radiotherapy : Radiotherapy given to relieve symptoms and reduce suffering caused by cancer.\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\n\\nRelationships:-\\n1. Entity1: \""Best supportive care\"", Entity2: \""Alternate single-agent systemic therapy\"", Relationship: \""alternative treatment options\""\\n2. Entity1: \""Best supportive care\"", Entity2: \""Palliative RT\"", Relationship: \""alternative treatment options\""\\n3. Entity1: \""Alternate single-agent systemic therapy\"", Entity2: \""Palliative RT\"", Relationship: \""alternative treatment options\""\\n\\nCausalities:-\\n<A> Best supportive care </A> or <A> Alternate single-agent systemic therapy </A> or <A> Palliative RT </A>\\n'}""",valid,increases risk,2,B,"edge - The edge which needs to be verified.
explanation - Explanation of what the edge represents and its validity.
causal_direction - Either Positive or Negative or Unknown. A positive influence direction indicates that both factors change in the same direction (e.g. an increase causes an increase effect). A negative influence direction indicates the opposite changes (e.g. an increase causes a decrease effect).
causal_factor - Is necessary or sufficient condition for an effect to occur. Exposure is a term commonly used in epidemiology to denote any condition that is considered as a possible cause of disease. Exposure is considered necessary when it always precedes the effects (e.g. symptoms) and always presents when the effects occur. A sufficient cause is a causal factor whose presence or occurrence guarantees the occurrence of symptom.
causal_distance - Either Distal or Proximal or Unknown. The distal factors lie towards the beginning of causal chain (i.e. indirect causal factors). The the proximal factors lie towards the end of the chain (i.e. cause directly or almost directly the effect).

Causality Tags:
<A> for action, <C> for cause, <CO> for condition and <E> for effect.
Cause (C): The reason or origin that leads to an effect. Causes often involve disease conditions, risk factors, or underlying mechanisms.
Effect (E): The outcome or result of a cause. Effects usually represent clinical outcomes, complications, or results of a specific cause.
Condition (CO): The circumstance or prerequisite required for an action or effect to occur. Conditions may include patient characteristics, clinical scenarios, or specific diagnostic criteria.
Action (A): The recommended or described response or activity to address a cause or condition. Actions typically involve clinical interventions, diagnostic procedures, or treatment recommendations.


`NODE1`:
id: Presence_of_Metastasis_in_Lymph_Nodes_5
label: Metastasis in Nearby Lymph Nodes
description: This node represents the clinical situation regarding whether metastasis is present in the nearby lymph nodes of a patient. It is a critical factor in determining the stage and prognosis of cancer, as the spread of cancer to lymph nodes often indicates a more advanced disease and may influence treatment decisions.
type: Patient Situation
observability: Unobserved
states: [{'state_name': 'unknown', 'state_description': 'The status of metastasis in the lymph nodes is not determined. It is unclear whether cancer has spread to these nodes.'}, {'state_name': 'present', 'state_description': 'Metastasis is confirmed in the lymph nodes, indicating that cancer has spread to these nodes.'}, {'state_name': 'absent', 'state_description': 'There is no metastasis in the lymph nodes, indicating that cancer has not spread to these nodes.'}]

`NODE2`:
id: Ultrasound_11
label: Ultrasound Examination Result
description: This node represents the result of an ultrasound examination, which is a diagnostic imaging technique used to visualize internal organs and structures. The result can indicate whether certain features or abnormalities are present or absent.
type: Examination Result
observability: Observed
states: [{'state_name': 'present', 'state_description': 'The ultrasound examination detected the presence of a feature or abnormality of interest.'}, {'state_name': 'absent', 'state_description': 'The ultrasound examination did not detect any features or abnormalities of interest.'}]

`EDGE1`:
{'edges_ids': ['Presence_of_Metastasis_in_Lymph_Nodes_5', 'Ultrasound_11'], 'edge': '(Presence_of_Metastasis_in_Lymph_Nodes_5) causes (Ultrasound_11)', 'explanation': ['The edge `(Presence_of_Metastasis_in_Lymph_Nodes_5) causes (Ultrasound_11)` is not valid because the presence of metastasis in lymph nodes does not cause an ultrasound result.', 'Instead, an ultrasound is a diagnostic tool used to detect the presence of metastasis in lymph nodes.', 'The causal direction is not from the presence of metastasis to the ultrasound result, but rather the ultrasound result is used to infer the presence of metastasis.', 'Therefore, the causal direction is unknown, and the causal factor is neither necessary nor sufficient.', 'The causal distance is unknown because the relationship is not a direct causal one.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}

`EDGE2`:
{'edges_ids': ['Ultrasound_11', 'Presence_of_Metastasis_in_Lymph_Nodes_5'], 'edge': '(Ultrasound_11) causes (Presence_of_Metastasis_in_Lymph_Nodes_5)', 'explanation': ['The edge represents a supposed causal relationship where the result of an ultrasound examination (Ultrasound_11) causes the presence of metastasis in lymph nodes (Presence_of_Metastasis_in_Lymph_Nodes_5).', 'This is not a valid causal relationship because an ultrasound is a diagnostic tool used to detect existing conditions, not to cause them.', 'The presence of metastasis in lymph nodes is a pathological condition that occurs due to the spread of cancer, not due to the result of an ultrasound examination.', 'Therefore, the edge is invalid as the ultrasound result does not cause metastasis; it merely detects it if present.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}

`INFORMATION FROM KNOWLEDGE BASE`:
--------------------------------------------------
Page Number: 55

Section Name: General Information
====================
Entities:-
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Nccn Guidelines : Clinical practice guidelines in oncology developed by the National Comprehensive Cancer Network.

Relationships:-
1. Entity1: ""NCCN Guidelines"", Entity2: ""National Comprehensive Cancer Network"", Relationship: ""produced by""

Section Name: Important Notes
====================
Entities:-
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medical, surgical, or behavioral interventions.
Clinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Neoplasms : New abnormal growth of tissue that can be benign or malignant.
Malignant Neoplastic Disease : A disease resulting from the growth of malignant neoplasms.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""Clinical Trials"", Entity2: ""Cancer"", Relationship: ""recommended for""
2. Entity1: ""NCCN"", Entity2: ""Clinical Trials"", Relationship: ""encourages participation in""

Causalities:-
<C> NCCN believes that the best management of any patient with cancer is in a clinical trial </C>. <A> Participation in clinical trials is especially encouraged </A>.

Section Name: Principles
====================
Entities:-
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Chemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.

Relationships:-
1. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Radiation Therapy"", Relationship: ""Both are principles of cancer treatment methods.""
2. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""Both are principles of cancer treatment methods.""
3. Entity1: ""Principles of Radiation Therapy"", Entity2: ""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""Both are principles of cancer treatment methods.""

Causalities:-
### Principles

- **Principles of Surgery (SURG-A)**
- **Principles of Radiation Therapy (SUPRA-A)**
- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**

Section Name: Adverse Pathologic Features
====================
Entities:-
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.
Perineural Invasion : The presence of cancer cells surrounding or tracking along a nerve within the perineural space.
Vascular Invasion : The invasion of cancer cells into blood vessels.
Lymphatic Invasion : The invasion of cancer cells into lymphatic vessels.

Relationships:-
1. Entity1: ""Extranodal extension"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
2. Entity1: ""Positive margins"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
3. Entity1: ""Close margins"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
4. Entity1: ""pT3 or pT4 primary"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
5. Entity1: ""pN2 or pN3 nodal disease"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
6. Entity1: ""Perineural invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
7. Entity1: ""Vascular invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
8. Entity1: ""Lymphatic invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""

Causalities:-
<C> Extranodal extension </C>
<C> Positive margins </C>
<C> Close margins </C>
<C> pT3 or pT4 primary </C>
<C> pN2 or pN3 nodal disease </C>
<C> Perineural invasion </C>
<C> Vascular invasion </C>
<C> Lymphatic invasion </C>

Section Name: Response Assessment
====================
Entities:-
Chemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Primary Site : The original location where a tumor or cancer begins.
Complete Remission : The disappearance of all signs of cancer in response to treatment.
Partial Remission : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
Radiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.

Relationships:-
1. Entity1: ""induction chemotherapy"", Entity2: ""Primary site"", Relationship: ""treatment outcome""
2. Entity1: ""Definitive RT"", Entity2: ""Primary site"", Relationship: ""treatment option""
3. Entity1: ""RT"", Entity2: ""Primary site"", Relationship: ""treatment option""
4. Entity1: ""Surgery"", Entity2: ""unresectable nodal disease"", Relationship: ""treatment option""

Causalities:-
<C> Response after induction chemotherapy </C>: <E> Primary site: CR </E> <E> Primary site: PR </E> <E> Primary site: < PR </E> <A> Definitive RT </A> (category 1) <A> RT </A> (category 1) or <A> systemic therapy/RT </A> (category 2B) <A> Surgery </A> or <A> unresectable nodal disease </A>

Section Name: Follow-up
====================
Entities:-
Follow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.
Follow-Up Procedure : A procedure where a patient is monitored over time to assess the progress of a condition or the effects of treatment.
Follow-Up (Medicine) : The process of monitoring a patient's health over time after treatment or diagnosis.
Disease Recurrence : The return of a sign, symptom, or disease after a remission.
Recurrent Disease : A disease that returns after a period of remission.
Recurrence (Medicine) : The return of a disease or condition after a period of improvement.

Relationships:-
1. Entity1: ""Follow-up"", Entity2: ""Recurrent or persistent disease"", Relationship: ""monitoring""

Causalities:-
### Follow-up

- **Follow-up** (FOLL-A, 1 of 2)
- **Recurrent or persistent disease** (ADV-3)

Section Name: Risk Features
====================
Entities:-
Radiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Adverse pathologic features"", Entity2: ""RT"", Relationship: ""Consideration for treatment""
2. Entity1: ""Adverse pathologic features"", Entity2: ""Systemic therapy"", Relationship: ""Consideration for treatment""

Causalities:-
- **No adverse pathologic features**
- **Other risk features**
- **Adverse pathologic features**:
  - <C> Extranodal extension and/or positive margin </C>
  - <A> RT or consider systemic therapy/RT </A>

Section Name: Post-Therapy Evaluation
====================
Entities:-
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Neck : The neck is the part of the body that separates the head from the torso and provides the mobility and movements of the head.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Neck Evaluation"", Relationship: ""evaluated in""
2. Entity1: ""RT"", Entity2: ""Neck Evaluation"", Relationship: ""evaluated in""

Causalities:-
<CO> Post Systemic Therapy/RT or RT Neck </CO> <A> Evaluation </A>

Section Name: Flowchart Overview
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Supraglottic Larynx : The part of the larynx located above the vocal cords, including the epiglottis and aryepiglottic folds.
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.

Relationships:-
1. Entity1: ""NCCN Guidelines"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""guides management of""
2. Entity1: ""NCCN Guidelines"", Entity2: ""healthcare professionals"", Relationship: ""used by""

Causalities:-
<C> cancer of the supraglottic larynx </C> <E> evaluate patient responses following treatment </E> <CO> based on observed outcomes </CO> <A> evaluation of the primary site and determining subsequent steps </A>.

Section Name: Assessment and Treatment Decisions
====================
Entities:-
Induction Chemotherapy : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Complete Response : The disappearance of all signs of cancer in response to treatment.
Partial Response : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Complete Response"", Entity2: ""Radiation Therapy"", Relationship: ""leads to""
2. Entity1: ""Complete Response"", Entity2: ""Surgery"", Relationship: ""leads to""
3. Entity1: ""Partial Response"", Entity2: ""Systemic Therapy"", Relationship: ""leads to""
4. Entity1: ""Partial Response"", Entity2: ""Radiation Therapy"", Relationship: ""leads to""

Causalities:-
<C> responses to initial treatments such as induction chemotherapy </C> <E> Three main response categories are recognized: Complete Response (CR), Partial Response (PR), and less than Partial Response (< PR) </E>. These categories are pivotal in determining the next steps. <C> CR </C> <E> indicates full resolution of the disease at the primary site </E>, <A> leading to the consideration of definitive radiation therapy or the likelihood of surgery </A>. Conversely, <C> PR </C> <E> suggests that the disease has improved but not completely resolved </E>, <A> which directs the pathway towards either systemic therapy or continued radiation therapy </A>, <A> with further evaluation necessary </A>.

Section Name: Adverse Pathologic Features and Follow-up
====================
Entities:-
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Neoplasm Recurrence, Local : The return of a tumor or cancer, at the original site, after it has been treated.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Recurrent Neoplasm : A neoplasm that has returned after treatment.
Metastatic Neoplasm : A neoplasm that has spread from its original site to one or more other places in the body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Cancer Recurrence : The return of cancer after treatment and after a period of time during which the cancer was undetectable.
Metastasis : Spread of a cancer or other disease from one organ or part to another not directly connected with it.

Relationships:-
1. Entity1: ""Adverse pathologic features"", Entity2: ""Treatment decisions"", Relationship: ""Influence""
2. Entity1: ""Adverse features"", Entity2: ""Surgical intervention"", Relationship: ""Recommendation""
3. Entity1: ""Absence of adverse features"", Entity2: ""Radiation therapy"", Relationship: ""Pathway""
4. Entity1: ""Follow-up process"", Entity2: ""Recurrent or persistent disease"", Relationship: ""Detection""
5. Entity1: ""Recurrent or persistent disease"", Entity2: ""Advanced disease management"", Relationship: ""Necessity""

Causalities:-
<C> The presence of adverse pathologic features — such as extranodal extension or positive margins </C> <E> can directly influence treatment decisions </E>. <CO> If adverse features are found </CO>, <A> surgical intervention is recommended </A>. <CO> In cases where there are no adverse features </CO>, the patient may proceed directly to radiation therapy or continued systemic treatment, emphasizing the tailored approach based on the individual patient's disease characteristics.

Furthermore, the chart includes a section addressing the follow-up process after initial treatment. <CO> If there are signs of recurrent or persistent disease </CO>, <A> additional evaluations and treatment modalities may be necessary </A>. These evaluations <E> lead to specific recommendations for advanced disease management, denoted as ADV-3 on the chart </E>, emphasizing the importance of continuous monitoring and assessment in cancer care.
--------------------------------------------------
Page Number: 130

Section Name: Pathological N (pN)
====================
Entities:-
Lymph Nodes : Small, bean-shaped structures that are part of the body's lymphatic system. They filter lymph fluid and store white blood cells that help fight infection.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Tnm Staging : A system used to describe the size and spread of cancer in a standardized way. T refers to the size of the tumor, N to the involvement of lymph nodes, and M to metastasis.
Lymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.
Tnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient's body.
Lymph Node : An organ of the lymphatic system and the adaptive immune system.

Relationships:-
1. Entity1: ""Lymph Nodes"", Entity2: ""Neoplasm Metastasis"", Relationship: ""involved in""
2. Entity1: ""TNM Staging"", Entity2: ""Lymph Nodes"", Relationship: ""includes""
3. Entity1: ""TNM Staging"", Entity2: ""Neoplasm Metastasis"", Relationship: ""describes""

Causalities:-
<CO> NX: Regional lymph nodes cannot be assessed </CO>
<CO> N0: No regional lymph node metastasis </CO>
<CO> N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(–) </CO>
<CO> N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2a: Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N3: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(−); or metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>
<CO> N3a: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N3b: Metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>
<CO> Note: A designation of “U” or “L” may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L). Similarly, clinical and pathological ENE should be recorded as ENE(−) or ENE(+). </CO>

Section Name: Distant Metastasis (M)
====================
Entities:-
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.

Relationships:-
1. Entity1: ""M0"", Entity2: ""Distant Metastasis"", Relationship: ""is a category of""
2. Entity1: ""M1"", Entity2: ""Distant Metastasis"", Relationship: ""is a category of""

Causalities:-
### Distant Metastasis (M)

- **M0**: No distant metastasis
- **M1**: Distant metastasis

Section Name: Histologic Grade (G)
====================
Entities:-
Neoplasm Grading : A system of classifying cancer cells in terms of how abnormal they look under a microscope and how quickly the tumor is likely to grow and spread.
Histologic Grade : A measure of how much tumor cells differ from healthy cells, used to assess the aggressiveness of cancer.

Relationships:-
1. Entity1: ""GX"", Entity2: ""Grade cannot be assessed"", Relationship: ""is described as""
2. Entity1: ""G1"", Entity2: ""Well differentiated"", Relationship: ""is described as""
3. Entity1: ""G2"", Entity2: ""Moderately differentiated"", Relationship: ""is described as""
4. Entity1: ""G3"", Entity2: ""Poorly differentiated"", Relationship: ""is described as""

Causalities:-
<CO>GX</CO>: <E>Grade cannot be assessed</E>
<CO>G1</CO>: <E>Well differentiated</E>
<CO>G2</CO>: <E>Moderately differentiated</E>
<CO>G3</CO>: <E>Poorly differentiated</E>

Section Name: Prognostic Stage Groups
====================
Entities:-
Neoplasm Staging : Methods and systems of classifying neoplasms according to extent of disease.
Tumor Staging : A system for describing the size and spread of cancer within the body.
Tnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient's body.

Relationships:-
1. Entity1: ""Stage 0"", Entity2: ""Tis N0 M0"", Relationship: ""defined by""
2. Entity1: ""Stage I"", Entity2: ""T1 N0 M0"", Relationship: ""defined by""
3. Entity1: ""Stage II"", Entity2: ""T2 N0 M0"", Relationship: ""defined by""
4. Entity1: ""Stage III"", Entity2: ""T3 N0 M0, T1 N1 M0, T2 N1 M0, T3 N1 M0"", Relationship: ""defined by""
5. Entity1: ""Stage IVA"", Entity2: ""T1 N2 M0, T2 N2 M0, T3 N2 M0, T4a N0,N1,N2 M0"", Relationship: ""defined by""
6. Entity1: ""Stage IVB"", Entity2: ""Any T N3 M0, T4b Any N M0"", Relationship: ""defined by""
7. Entity1: ""Stage IVC"", Entity2: ""Any T Any N M1"", Relationship: ""defined by""
--------------------------------------------------
Page Number: 92

Section Name: NCCN Guidelines Overview
====================
Entities:-
Head And Neck Neoplasms : Cancers that arise in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Malignant Neoplasm Of Head And Neck : A malignant tumor located in the head and neck region.
Head And Neck Cancer : A group of cancers that originate in the head and neck region.
Antineoplastic Agents : Drugs used to treat cancer by inhibiting the growth of cancerous cells.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.
Radiation Therapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.

Relationships:-
1. Entity1: ""Head and neck cancers"", Entity2: ""Systemic therapy"", Relationship: ""follow-up recommendations after""
2. Entity1: ""Head and neck cancers"", Entity2: ""Radiation therapy"", Relationship: ""follow-up recommendations after""

Causalities:-
The image presents a flowchart from the National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2024, especially focusing on <A> follow-up recommendations </A> for <CO> patients with head and neck cancers after systemic therapy or radiation therapy (RT) </CO>. All recommendations are categorized as level A unless stated otherwise, highlighting the importance of clinical trials in cancer management.

Section Name: Imaging and Assessment Protocols
====================
Entities:-
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.
Clinical Assessment : A systematic evaluation of a patient's health status, often involving a physical examination and medical history.
Positron-Emission Tomography : An imaging technique using a radioactive substance called a tracer to look for disease in the body.
Computed Tomography : A medical imaging technique used in radiology to obtain detailed internal images of the body.
Magnetic Resonance Imaging : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis.
Disease : A disorder of structure or function in a human, animal, or plant, especially one that produces specific symptoms.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.
Residual Neoplasm : Remaining cancer cells after treatment.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Clinical Assessment"", Relationship: ""occurs before""
2. Entity1: ""FDG-PET/CT Scan"", Entity2: ""Distant Metastases"", Relationship: ""assesses""
3. Entity1: ""FDG-PET/CT Scan"", Entity2: ""Observation"", Relationship: ""leads to if negative""
4. Entity1: ""FDG-PET/CT Scan"", Entity2: ""CT Scan"", Relationship: ""leads to if strongly positive""
5. Entity1: ""CT Scan"", Entity2: ""Neck Dissection"", Relationship: ""leads to if positive""

Causalities:-
<CO> After systemic therapy or RT </CO>, <A> a clinical assessment should occur 4 to 8 weeks later </A>. <CO> If there is a response </CO>, <A> it is necessary to assess the extent of disease or distant metastases, preferably through a FDG-PET/CT scan at a minimum of 12 weeks post-treatment </A>. <CO> If the FDG-PET/CT results are negative </CO>, <A> the patient may continue with monitoring through observation </A>. <CO> In cases where the results are equivocal </CO>, <A> observation or repeat FDG-PET/CT within 3 to 6 months is prescribed </A>.

<CO> In cases where the FDG-PET/CT results are strongly positive </CO>, <A> further imaging via CT scan with contrast of the primary site and neck, or MRI with and without contrast, becomes necessary </A>. <CO> If these imaging results confirm positive findings </CO>, <A> neck dissection may be considered, depending on the evidence of residual or persistent disease </A>. <CO> If the imaging findings are negative </CO>, <A> the patient might continue in observation </A>.

Section Name: Outcomes Based on Disease Resectability
====================
Entities:-
Disease : A disorder of structure or function in a human, animal, or plant, especially one that produces specific symptoms.
Resectable : Capable of being surgically removed.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis.

Relationships:-
1. Entity1: ""Disease"", Entity2: ""Resectable"", Relationship: ""Classification""
2. Entity1: ""Unresectable"", Entity2: ""Treatment plans (ADV-3)"", Relationship: ""Treatment recommendation""
3. Entity1: ""Resectable"", Entity2: ""Resection and/or Neck dissection"", Relationship: ""Surgical procedure""

Causalities:-
<CO> If there is confirmed residual or persistent disease </CO>, the options split into two pathways: 'Unresectable' or 'Resectable.' <CO> If the disease is classified as unresectable </CO>, <A> advances in treatment plans (labeled ADV-3) are called for </A>. Conversely, <CO> if it is deemed resectable </CO>, <A> a resection of the primary and/or neck dissection may occur </A>, <CO> contingent upon the disease status </CO>.

Section Name: Important Notes
====================
Entities:-
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.
Clinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.
Positron-Emission Tomography : An imaging technique using a radioactive substance called a tracer to look for disease in the body.
Positron Emission Tomography (Procedure) : A diagnostic imaging procedure that uses a radioactive tracer to visualize and measure changes in metabolic processes.
Positron Emission Tomography : A nuclear medicine functional imaging technique used to observe metabolic processes in the body.
Neoplasms : New abnormal growth of tissue in animals or plants; a tumor.
Malignant Neoplasm : A cancerous growth that has the potential to spread to other parts of the body.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""NCCN"", Entity2: ""Clinical trials"", Relationship: ""emphasizes participation in""
2. Entity1: ""FDG-PET/CT"", Entity2: ""Persistent cancer"", Relationship: ""used to detect""
3. Entity1: ""FDG-PET/CT"", Entity2: ""PET negative"", Relationship: ""interpretation of results""
4. Entity1: ""FDG-PET/CT"", Entity2: ""PET positive"", Relationship: ""interpretation of results""

Causalities:-
<A> NCCN emphasizes that the best management for any cancer patient is participation in clinical trials </A>, especially encouraged for all patients. Additional notes clarify that <CO> if the FDG-PET/CT is negative for persistent cancer </CO>, <A> further cross-sectional imaging is optional </A>. The interpretations define <CO> PET negative as no or low-grade uptake not suspicious for disease </CO>, while <CO> PET positive implies suspicion for disease </CO>.
--------------------------------------------------
Page Number: 41

Section Name: Workup
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.
History And Physical Examination : A comprehensive assessment of a patient's medical history and physical condition.
Tobacco Smoking : The act of smoking tobacco products, which is a risk factor for many diseases.
Alcohol Drinking : The consumption of beverages containing ethyl alcohol.
Smoking Cessation : The process of discontinuing tobacco smoking.
Biopsy : A medical test involving the extraction of sample cells or tissues for examination.
Laryngoscopy : A procedure to examine the larynx, often using a scope.
Computed Tomography (Ct) : A diagnostic imaging procedure that uses computer-processed combinations of many X-ray measurements taken from different angles to produce cross-sectional images of specific areas of a scanned object.
Magnetic Resonance Imaging (Mri) : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.
Positron-Emission Tomography : A type of nuclear medicine imaging that measures metabolic activity of the cells of body tissues.
Pulmonary Function Test : Tests that measure how well the lungs are working.
Dental Examination : An evaluation of the teeth and gums to assess oral health.
Nutritional Support : Therapies to provide nutrition to patients who cannot obtain nutrition by mouth.
Speech Therapy : Therapy to improve speech and communication skills.
Swallowing Therapy : Therapy to help individuals with swallowing difficulties.
Multidisciplinary Care Team : A group of healthcare professionals from different specialties working together to manage patient care.

Relationships:-
1. Entity1: ""glottic larynx cancer"", Entity2: ""history and physical examination"", Relationship: ""initial diagnostic step""
2. Entity1: ""glottic larynx cancer"", Entity2: ""biopsy"", Relationship: ""required diagnostic procedure""
3. Entity1: ""glottic larynx cancer"", Entity2: ""direct laryngoscopy"", Relationship: ""recommended procedure""
4. Entity1: ""glottic larynx cancer"", Entity2: ""CT scans"", Relationship: ""imaging study""
5. Entity1: ""glottic larynx cancer"", Entity2: ""MRI"", Relationship: ""imaging study""
6. Entity1: ""glottic larynx cancer"", Entity2: ""multidisciplinary consultation"", Relationship: ""advised as clinically indicated""

Causalities:-
The workup section outlines the initial steps for diagnosing <C>glottic larynx cancer</C>. It includes <A>a comprehensive history and physical examination (H&P)</A>, which should document tobacco and alcohol use, and provide counseling for smoking cessation. <A>A biopsy of the primary site is required</A>, and <A>direct laryngoscopy under anesthesia is generally recommended</A>. <A>Imaging studies such as CT scans with contrast and possibly MRI are used to evaluate the larynx and neck</A>. Additional evaluations may include <A>chest CT, FDG-PET/CT, pulmonary function tests, dental evaluation, and nutrition, speech, and swallowing therapy</A>. <A>Multidisciplinary consultation is advised</A> <CO>as clinically indicated</CO>.

Section Name: Clinical Staging
====================
Entities:-
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.
Carcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.
Biopsy : A medical test involving the extraction of sample cells or tissues for examination.
Laryngectomy : A surgical procedure to remove the larynx.

Relationships:-
1. Entity1: ""Clinical staging"", Entity2: ""Cancer"", Relationship: ""involves""
2. Entity1: ""Carcinoma in situ"", Entity2: ""Stages T1-T4"", Relationship: ""is a stage of""
3. Entity1: ""Biopsy"", Entity2: ""Cancer"", Relationship: ""used in staging""
4. Entity1: ""Larynx-preserving surgeries"", Entity2: ""Stages T1-T2"", Relationship: ""considered for""
5. Entity1: ""Total laryngectomy"", Entity2: ""Stages T3-T4"", Relationship: ""required for""

Causalities:-
<C> Clinical staging involves categorizing the cancer based on its aggressiveness </C>. It starts with carcinoma in situ, which is non-invasive, and progresses through stages T1-T4. <CO> Staging is based on H&P, biopsy, and imaging studies </CO>. <CO> For T1-T2 </CO>, <A> larynx-preserving surgeries are considered </A>, while <CO> more advanced stages like T3 or T4 </CO> <A> may require total laryngectomy </A>. <A> Additional evaluations such as videostrobe, audiogram, and fertility counseling may be considered </A>.

Section Name: Treatment
====================
Entities:-
Carcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.
Laryngectomy : A surgical procedure to remove the larynx.
Metastasis : The transfer of a disease from one organ or part to another not directly connected with it.
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.

Relationships:-
1. Entity1: ""Carcinoma in situ"", Entity2: ""Larynx-preserving surgery"", Relationship: ""treated with""
2. Entity1: ""T1-T2 stages"", Entity2: ""Conservation surgery"", Relationship: ""treated with""
3. Entity1: ""T3 stages"", Entity2: ""Total laryngectomy"", Relationship: ""may require""
4. Entity1: ""T4a disease"", Entity2: ""Complex interventions"", Relationship: ""require""
5. Entity1: ""Guidelines"", Entity2: ""Multidisciplinary consultations"", Relationship: ""emphasize importance of""
6. Entity1: ""Guidelines"", Entity2: ""Clinical trials"", Relationship: ""consider as best option""

Causalities:-
<CO>Treatment recommendations vary by stage</CO>. <CO>Carcinoma in situ</CO> <A>may be treated with larynx-preserving surgery</A>. <CO>T1-T2 stages</CO> <A>may also be amenable to conservation surgery</A>. <CO>T3 stages</CO> <A>may require total laryngectomy</A>, <CO>especially if nodal involvement is present</CO>. <CO>T4a disease and unresectable or metastatic cases</CO> <A>require more complex interventions</A>. <A>The guidelines emphasize the importance of multidisciplinary consultations</A> and <A>consider clinical trials as the best management option</A>.

Section Name: Additional Notes
====================
Entities:-
Biopsy, Needle : A procedure to remove a small sample of tissue for examination under a microscope.
Image-Guided Biopsy : A biopsy procedure that uses imaging techniques to guide the needle to the precise location of the tissue to be sampled.
Biopsy : A medical test involving the extraction of sample cells or tissues for examination.
Diagnostic Techniques And Procedures : Methods and procedures for the diagnosis of disease or dysfunction.
Imaging : The process of producing images of the body for clinical purposes.
Dental Care : The total of dental diagnostic, preventive, and corrective procedures.
Nutritional Physiological Phenomena : The functions and properties of nutrients in living organisms.
Fertility : The capacity to conceive or induce conception.
Reproductive Health : A state of physical, mental, and social well-being in all matters relating to the reproductive system.
Lymphatic Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Glottis : The part of the larynx consisting of the vocal cords and the opening between them.

Relationships:-
1. Entity1: ""image-guided needle biopsy"", Entity2: ""diagnostic yield"", Relationship: ""used for""
2. Entity1: ""nodal disease"", Entity2: ""glottic tumors"", Relationship: ""is rare in""

Causalities:-
<A> use of image-guided needle biopsy </A> for <E> better diagnostic yield </E>, principles of imaging, dental evaluation, and nutrition management. The guidelines also address fertility and reproductive considerations, and note that <CO> nodal disease in glottic tumors is rare </CO>.
--------------------------------------------------
Page Number: 68

Section Name: Diagnosis Section
====================
Entities:-
Diagnosis : The process of determining which disease or condition explains a person's symptoms and signs.
Metastatic Disease : A disease in which cancer cells spread from the place where they first formed to another part of the body.
Clinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Locoregional Therapy : Treatment that is directed to a specific area of the body, often used in cancer treatment.

Relationships:-
1. Entity1: ""Diagnosis"", Entity2: ""Decision-making process"", Relationship: ""initiates""
2. Entity1: ""Metastatic disease"", Entity2: ""Clinical trial"", Relationship: ""preferred pathway""
3. Entity1: ""Locoregional treatment"", Entity2: ""Primary site algorithms"", Relationship: ""based on""

Causalities:-
<CO> for patients presenting with metastatic disease </CO>, <A> a clinical trial is the preferred pathway </A>, emphasizing the critical nature of innovative therapies in advanced cancer care. The option to <A> ""Consider locoregional treatment based on primary site algorithms"" </A> suggests that specific treatment strategies may be tailored <CO> depending on the exact location and characteristics of the cancer </CO>.

Section Name: Treatment Pathways
====================
Entities:-
Performance Status : A measure of a patient's general well-being and ability to perform ordinary tasks, often used in oncology to determine the appropriate treatment.
Systemic Therapy : A treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Surgery : A medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Palliative Care : Specialized medical care for people living with a serious illness, focused on providing relief from the symptoms and stress of the illness.
Supportive Care : Care given to improve the quality of life of patients who have a serious or life-threatening disease.

Relationships:-
1. Entity1: ""Performance Status"", Entity2: ""Systemic Therapy"", Relationship: ""affects choice of""
2. Entity1: ""Performance Status"", Entity2: ""Surgery"", Relationship: ""affects choice of""
3. Entity1: ""Performance Status"", Entity2: ""Radiation Therapy"", Relationship: ""affects choice of""
4. Entity1: ""Performance Status"", Entity2: ""Palliative Care"", Relationship: ""affects choice of""
5. Entity1: ""Performance Status"", Entity2: ""Supportive Care"", Relationship: ""affects choice of""
6. Entity1: ""PS 0-1 Patients"", Entity2: ""Combination Systemic Therapy"", Relationship: ""suitable for""
7. Entity1: ""PS 2 Patients"", Entity2: ""Palliative Radiation Therapy"", Relationship: ""may receive""
8. Entity1: ""PS 3 Patients"", Entity2: ""Supportive Care"", Relationship: ""recommended""

Causalities:-
The treatment section branches into various pathways depending on <CO> the patient’s performance status (PS) </CO>, which is a measure of their general well-being and ability to function. - **For PS 0-1 Patients:** The flowchart indicates several treatment options, including <A> combination systemic therapy, single-agent systemic therapy, surgery, and radiation therapy (RT) </A>. This group is highlighted as those who are most capable of handling intensive treatments and <E> may benefit significantly from combination therapies </E>. - **For PS 2 Patients:** The recommended approach varies slightly, with a continued emphasis on <A> systemic therapies, palliative radiation therapy, or best supportive care </A>. This indicates a level of compromise in treatment options, suggesting that while aggressive treatment is still possible, <E> the focus might shift more towards quality of life </E>. - **For PS 3 Patients:** The treatment options further narrow, still recommending <A> systemic therapy or supportive care </A> but highlighting palliative approaches, reflecting a recognition of <E> the more advanced disease and potentially limited treatment efficacy </E>.

Section Name: Principles of Treatment
====================
Entities:-
Antineoplastic Combined Chemotherapy Protocols : Protocols for the administration of more than one antineoplastic agent in combination to treat malignant neoplasms.
Radiotherapy : The use of radiation, usually X-rays or gamma rays, to treat disease, especially cancer.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Systemic Therapy : A treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Surgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Chemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.
Surgery : A medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Radiation Therapy"", Relationship: ""Different modalities of cancer treatment""
2. Entity1: ""Systemic Therapy"", Entity2: ""Surgery"", Relationship: ""Different modalities of cancer treatment""
3. Entity1: ""Radiation Therapy"", Entity2: ""Surgery"", Relationship: ""Different modalities of cancer treatment""

Causalities:-
- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)** - **Principles of Radiation Therapy (ADV-A)** - **Principles of Surgery (SURG-A)**

Section Name: Diagnosis and Treatment of Head and Neck Cancer
====================
Entities:-
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Metastatic Malignant Neoplasm : A malignant neoplasm that has spread from its original site to a different site.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.
Clinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Performance Status : A measure of a patient's general well-being and ability to perform ordinary tasks, often used in oncology to determine the appropriate treatment.

Relationships:-
1. Entity1: ""Metastatic disease"", Entity2: ""Clinical trial"", Relationship: ""preferred treatment option""
2. Entity1: ""Performance Status 0-1"", Entity2: ""Combination systemic therapy"", Relationship: ""treatment option""
3. Entity1: ""Performance Status 2"", Entity2: ""Single-agent systemic therapy"", Relationship: ""treatment option""
4. Entity1: ""Performance Status 3"", Entity2: ""Systemic therapy"", Relationship: ""treatment option""

Causalities:-
- <CO>Metastatic (M1) disease at initial presentation</CO>
  <A>Clinical trial preferred</A>
  <E>Distant metastases</E>
  <A>Consider locoregional treatment based on primary site algorithms (Table of Contents)</A>

#### Performance Status (PS)
- <CO>PS 0–1</CO>
  <A>Combination systemic therapy</A> or <A>Single-agent systemic therapy</A> or <A>Surgery</A> or <A>RT</A> or <A>systemic therapy/RT for selected patients with limited metastases</A> or <A>Best supportive care</A>
- <CO>PS 2</CO>
  <A>Single-agent systemic therapy</A> or <A>Best supportive care ± Palliative RT</A> or <A>Palliative surgery</A>
- <CO>PS 3</CO>
  <A>Systemic therapy, clinical trial preferred</A> or <A>Palliative RT</A> or <A>Best supportive care</A>

Section Name: Persistent Disease or Progression
====================
Entities:-
Palliative Care : Specialized medical care for people living with a serious illness, focused on providing relief from the symptoms and stress of the illness.
Supportive Care : Care given to improve the quality of life of patients who have a serious or life-threatening disease.
Antineoplastic Agents : Substances that inhibit or prevent the proliferation of neoplasms.
Systemic Therapy : A treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Chemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.
Radiotherapy : The use of radiation, usually X-rays or gamma rays, to treat disease, especially cancer.
Palliative Radiotherapy : Radiotherapy given to relieve symptoms and reduce suffering caused by cancer.
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.

Relationships:-
1. Entity1: ""Best supportive care"", Entity2: ""Alternate single-agent systemic therapy"", Relationship: ""alternative treatment options""
2. Entity1: ""Best supportive care"", Entity2: ""Palliative RT"", Relationship: ""alternative treatment options""
3. Entity1: ""Alternate single-agent systemic therapy"", Entity2: ""Palliative RT"", Relationship: ""alternative treatment options""

Causalities:-
<A> Best supportive care </A> or <A> Alternate single-agent systemic therapy </A> or <A> Palliative RT </A>


Among these two options which one is the most likely true:

(A) `Presence_of_Metastasis_in_Lymph_Nodes_5` increases risk `Ultrasound_11`
(B) `Ultrasound_11` `increases risk `Presence_of_Metastasis_in_Lymph_Nodes_5`

The answer is: ...

1. State the evidences in detail of the validity of option (A) or (B) by cross referencing
NCCN Clinical Practitioner’s Guidelines for Head and Neck Cancer.
2. If the evidences are obtained from `INFORMATION FROM KNOWLEDGE BASE`,
mention their corresponding Page Numbers, Section Name, entities, relationships and causalities.

DESIRED OUTPUT FORMAT:
<thinking>
...
</thinking>
<answer>
{
   ""thinking"": [""..."", ...],
   ""evidences"": [""..."", ...],
   ""answer"": ...
}
</answer>

Before providing the answer in <answer> tags, think step by step in detail in <thinking> tags and analyze every part.
Output inside <answer> tag in JSON format. Only output valid JSON.
DO NOT HALLUCINATE. DO NOT MAKE UP FACTUAL INFORMATION.
","1. The edge (Presence_of_Metastasis_in_Lymph_Nodes_5) causes (Ultrasound_11) is not valid because the presence of metastasis in lymph nodes does not cause an ultrasound result. Instead, an ultrasound is a diagnostic tool used to detect the presence of metastasis in lymph nodes.
2. The edge (Ultrasound_11) causes (Presence_of_Metastasis_in_Lymph_Nodes_5) is also not valid because an ultrasound is a diagnostic tool used to detect existing conditions, not to cause them. The presence of metastasis in lymph nodes is a pathological condition that occurs due to the spread of cancer, not due to the result of an ultrasound examination.
3. The causal direction for both edges is unknown, and the causal factor is neither necessary nor sufficient. The causal distance is unknown because the relationship is not a direct causal one.
4. According to the NCCN Guidelines, the presence of metastasis in lymph nodes is a critical factor in determining the stage and prognosis of cancer, as the spread of cancer to lymph nodes often indicates a more advanced disease and may influence treatment decisions. However, the guidelines do not suggest that the presence of metastasis causes an ultrasound result or vice versa.
5. The NCCN Guidelines emphasize the use of diagnostic tools like ultrasound to detect metastasis, but they do not imply a causal relationship between the ultrasound result and the presence of metastasis.
","1. Page Number: 55, Section Name: General Information, Entities: National Comprehensive Cancer Network, NCCN Guidelines, Relationships: NCCN Guidelines produced by National Comprehensive Cancer Network.
2. Page Number: 130, Section Name: Pathological N (pN), Entities: Lymph Nodes, Neoplasm Metastasis, TNM Staging, Relationships: Lymph Nodes involved in Neoplasm Metastasis, TNM Staging includes Lymph Nodes.
3. Page Number: 92, Section Name: NCCN Guidelines Overview, Entities: Head And Neck Neoplasms, Malignant Neoplasm Of Head And Neck, Head And Neck Cancer, Relationships: Head and neck cancers follow-up recommendations after Systemic therapy, Radiation therapy.
",A,"{'A': 85.2, 'B': 14.8}",yes,A,"1. The AI assistant's reasoning is based on the understanding that the presence of metastasis in lymph nodes and the result of an ultrasound are not causally related in the way described by the options.
2. The assistant correctly identifies that the presence of metastasis in lymph nodes does not cause an ultrasound result. Instead, an ultrasound is a diagnostic tool used to detect the presence of metastasis, which aligns with the explanation provided in the EDGE1 and EDGE2 analyses.
3. The assistant also correctly identifies that an ultrasound result does not cause metastasis in lymph nodes, as metastasis is a pathological condition resulting from the spread of cancer, not from the diagnostic process itself.
4. The assistant's reasoning is consistent with the information from the NCCN Guidelines, which emphasize the use of diagnostic tools like ultrasound to detect metastasis but do not imply a causal relationship between the ultrasound result and the presence of metastasis.
5. The assistant's conclusion that option (A) is more likely true is consistent with the reasoning provided, as the presence of metastasis is a condition that can be detected by ultrasound, but not caused by it.
"
4,gpt-4o,"Location_of_Involved_Lymph_Nodes_4,Computerized_Tomography_CT_12","""{'NODE1': {'id': 'Location_of_Involved_Lymph_Nodes_4', 'label': 'Position of Affected Lymph Nodes in Patient', 'description': \""This node represents the location of lymph nodes that are involved or affected in a patient's condition. Understanding whether the lymph nodes are ipsilateral, bilateral, or contralateral is crucial for determining the extent of disease spread and planning appropriate treatment strategies.\"", 'type': 'Patient Situation', 'observability': 'Unobserved', 'states': [{'state_name': 'ipsilateral', 'state_description': 'The involved lymph nodes are on the same side of the body as the primary tumor or reference point. This can indicate localized spread of disease.'}, {'state_name': 'bilateral', 'state_description': 'The involved lymph nodes are on both sides of the body. This may suggest a more extensive spread of disease and can impact treatment decisions.'}, {'state_name': 'contralateral', 'state_description': 'The involved lymph nodes are on the opposite side of the body from the primary tumor or reference point. This can indicate metastatic spread and may affect staging and treatment planning.'}]}, 'NODE2': {'id': 'Computerized_Tomography_CT_12', 'label': 'CT Scan Examination Result for Lymph Node Metastasis', 'description': 'This node represents the results of a CT scan examination, specifically focusing on the detection of lymph node metastasis. It provides information on whether the metastasis is bilateral, ipsilateral, or contralateral, which is crucial for staging cancer and planning treatment.', 'type': 'Examination Result', 'observability': 'Observed', 'states': [{'state_name': 'bilateral_lymph_node_metastasis', 'state_description': 'The CT scan shows metastasis in lymph nodes on both sides of the body, indicating a more advanced spread of cancer.'}, {'state_name': 'ipsilateral_lymph_node_metastasis', 'state_description': 'The CT scan shows metastasis in lymph nodes on the same side of the body as the primary tumor, suggesting localized spread.'}, {'state_name': 'contralateral_lymph_node_metastasis', 'state_description': 'The CT scan shows metastasis in lymph nodes on the opposite side of the body from the primary tumor, indicating cross-body spread.'}]}, 'EDGE1': {'edges_ids': ['Location_of_Involved_Lymph_Nodes_4', 'Computerized_Tomography_CT_12'], 'edge': '(Location_of_Involved_Lymph_Nodes_4) causes (Computerized_Tomography_CT_12)', 'explanation': ['The edge suggests that the location of involved lymph nodes causes the CT scan results, which is not valid.', 'The location of involved lymph nodes is a patient situation that exists independently of the CT scan results.', 'The CT scan results are an observation of the lymph node involvement, not a cause of it.', 'Therefore, the causal relationship is not valid in the direction given.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}, 'EDGE2': {'edges_ids': ['Computerized_Tomography_CT_12', 'Location_of_Involved_Lymph_Nodes_4'], 'edge': '(Computerized_Tomography_CT_12) causes (Location_of_Involved_Lymph_Nodes_4)', 'explanation': ['The edge suggests that the results of a CT scan examination (Computerized_Tomography_CT_12) cause the location of involved lymph nodes (Location_of_Involved_Lymph_Nodes_4).', 'However, the CT scan is a diagnostic tool that observes and reports on the state of lymph node involvement, such as whether metastasis is bilateral, ipsilateral, or contralateral.', 'The location of involved lymph nodes is a description of the patient`s condition and is not caused by the CT scan results.', \""The CT scan results provide information about the lymph nodes' state but do not influence or change their location.\"", 'Therefore, the edge is not valid as a causal relationship because the CT scan results do not cause the lymph nodes to be in a particular location; they only detect and report on their state.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}, 'ENTITIES_MATCHING_PAGES_INFO': {'93': {'matching_entities': [{'TOMOGRAPHY, X-RAY COMPUTED': 0.9942913}, {'COMPUTED TOMOGRAPHY': 0.9634981}, {'MALIGNANT NEOPLASTIC DISEASE': 0.9424237}, {'MAGNETIC RESONANCE IMAGING': 0.93858624}, {'POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY': 0.93146056}, {'CANCER': 0.92851335}], 'count': 6}, '41': {'matching_entities': [{'COMPUTED TOMOGRAPHY (CT)': 0.98698086}, {'LYMPHATIC METASTASIS': 0.97019297}, {'METASTASIS': 0.9630129}, {'MAGNETIC RESONANCE IMAGING (MRI)': 0.93140477}, {'CANCER': 0.92851335}, {'IMAGING': 0.9228251}], 'count': 6}, '44': {'matching_entities': [{'TOMOGRAPHY, X-RAY COMPUTED': 0.9942913}, {'LYMPHATIC METASTASIS': 0.97019297}, {'COMPUTED TOMOGRAPHY': 0.9634981}, {'MALIGNANT NEOPLASTIC DISEASE': 0.9424237}, {'MAGNETIC RESONANCE IMAGING': 0.93858624}, {'CANCER': 0.92851335}], 'count': 6}, '94': {'matching_entities': [{'NEOPLASM METASTASIS': 1.0}, {'TOMOGRAPHY, X-RAY COMPUTED': 0.9942913}, {'LYMPHATIC METASTASIS': 0.97019297}, {'COMPUTED TOMOGRAPHY': 0.9634981}, {'MAGNETIC RESONANCE IMAGING': 0.93858624}, {'POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY': 0.93146056}], 'count': 6}, '92': {'matching_entities': [{'COMPUTED TOMOGRAPHY': 0.9634981}, {'METASTASIS': 0.9630129}, {'MALIGNANT NEOPLASM': 0.9448747}, {'MAGNETIC RESONANCE IMAGING': 0.93858624}, {'CANCER': 0.92851335}], 'count': 5}}, 'GUIDELINE_PAGES_INFO': '--------------------------------------------------\\nPage Number: 93\\n\\nSection Name: PRINCIPLES OF IMAGING\\n====================\\nEntities:-\\nImaging, Diagnostic : The production of a visual representation of parts of the body, for the purpose of clinical analysis and medical intervention.\\nHead And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\nTomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.\\nMagnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body\\'s soft tissue and bones.\\nContrast Media : Substances used to enhance the contrast of structures or fluids within the body in medical imaging.\\n\\nRelationships:-\\n1. Entity1: \""Imaging, Diagnostic\"", Entity2: \""Head and Neck Neoplasms\"", Relationship: \""used for\""\\n2. Entity1: \""Tomography, X-Ray Computed\"", Entity2: \""Contrast Media\"", Relationship: \""uses\""\\n3. Entity1: \""Magnetic Resonance Imaging\"", Entity2: \""Contrast Media\"", Relationship: \""uses\""\\n\\nCausalities:-\\n<C> Imaging </C> plays an essential role in the clinical care of patients with head and neck cancer. <A> The proper selection and utilization of imaging studies </A> is critical in caring for patients with head and neck cancer. <A> CT is performed with contrast </A>, while <A> CT imaging of the chest can be performed with or without contrast </A>, <CO> as clinically indicated </CO>. <A> MRI is performed with and without contrast </A>, <CO> unless contraindicated </CO>.\\n\\nSection Name: Initial Workup - Primary Site\\n====================\\nEntities:-\\nTomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.\\nMagnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body\\'s soft tissue and bones.\\nHead And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\nNeck Structure : The anatomical structure of the neck, which is the part of the body that connects the head to the torso.\\nSkull Base : The bottom part of the skull, which separates the brain from other facial structures.\\nThoracic Inlet : The opening at the top of the thoracic cavity, through which pass the trachea, esophagus, and major blood vessels.\\n\\nRelationships:-\\n1. Entity1: \""CT\"", Entity2: \""MRI\"", Relationship: \""complementary in imaging head and neck cancers\""\\n2. Entity1: \""CT\"", Entity2: \""Head and Neck Neoplasms\"", Relationship: \""used to evaluate\""\\n3. Entity1: \""MRI\"", Entity2: \""Head and Neck Neoplasms\"", Relationship: \""preferred for evaluating\""\\n4. Entity1: \""Skull base\"", Entity2: \""Thoracic inlet\"", Relationship: \""imaging range for evaluation\""\\n\\nCausalities:-\\n<A>Imaging assessment of the primary site</A> can be performed with <A>CT of the soft tissues of the neck</A> or <A>MRI of the neck</A>. <C>CT is complementary to MRI for head and neck cancers</C>. <A>It is utilized to evaluate cortical bone erosion or periosteal invasion, cartilage invasion, and bony erosion or destruction</A>. <CO>in certain conditions, such as evaluating the extent of bone marrow invasion or in patients with extensive dental amalgam obscuring anatomy on CT, assessing skull base invasion and cranial nerve involvement, and differentiating tumor from obstructed sinuses</CO>, <A>MRI is preferred over CT</A>. <CO>when involved lymph nodes or upper mediastinal cancers are present</CO>, <A>Complete evaluation of primary and nodal disease requires imaging from the skull base to the thoracic inlet, extending to the carina</A>.\\n\\nSection Name: PET/CT and Biopsy\\n====================\\nEntities:-\\nPositron Emission Tomography Computed Tomography : A medical imaging technique that combines PET and CT capabilities to provide detailed images of the body.\\nExamination Under Anesthesia : A procedure where a patient is examined while under anesthesia to allow for a more thorough examination.\\nBiopsy : A medical test involving the extraction of sample cells or tissues for examination to determine the presence or extent of a disease.\\nTonsillectomy : A surgical procedure to remove the tonsils, often performed to treat recurrent tonsillitis or sleep apnea.\\nFine Needle Aspiration : A type of biopsy procedure that uses a thin, hollow needle to extract cells from a lump or mass for examination.\\nUltrasound : A medical imaging technique that uses high-frequency sound waves to visualize internal organs and structures.\\nComputed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.\\n\\nRelationships:-\\n1. Entity1: \""PET/CT\"", Entity2: \""EUA\"", Relationship: \""recommended before\""\\n2. Entity1: \""Fine Needle Aspiration (FNA)\"", Entity2: \""metastatic nodes\"", Relationship: \""used for biopsy of\""\\n3. Entity1: \""Image-guided needle biopsy\"", Entity2: \""cystic neck nodes\"", Relationship: \""recommended for initial diagnosis of\""\\n\\nCausalities:-\\n<CO> If imaging does not reveal an obvious primary cancer </CO>, <A> a PET/CT should be ordered before EUA, biopsies, and tonsillectomy </A>. <E> This helps identify potential primary sites </E> before any interventions take place. Additionally, <A> Fine Needle Aspiration (FNA) biopsy of metastatic nodes </A> <E> may provide pathologically informative results </E>. <CO> For initial diagnosis in cystic neck nodes </CO>, <A> image-guided needle biopsy (ultrasound or CT) </A> <E> may yield better results than FNA by palpation alone </E>.\\n\\nSection Name: Postoperative Imaging Advice\\n====================\\nEntities:-\\nPanoramic Radiography : A type of dental x-ray that provides a wide view of the upper and lower jaws, teeth, temporomandibular joints, and sinuses.\\nOral Cavity : The cavity of the mouth, including the lips, the lining inside the cheeks and lips, the front two-thirds of the tongue, the gums, the floor of the mouth under the tongue, the hard palate, and the small area of the gum behind the wisdom teeth.\\nRadiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.\\nMandibulotomy : A surgical procedure involving the cutting of the mandible.\\nMandibulectomy : A surgical procedure involving the removal of part or all of the mandible.\\nOropharynx : The part of the throat at the back of the mouth behind the oral cavity.\\n\\nRelationships:-\\n1. Entity1: \""panoramic dental x-ray\"", Entity2: \""oral cavity cancers\"", Relationship: \""recommended for\""\\n2. Entity1: \""panoramic dental x-ray\"", Entity2: \""postoperative radiotherapy\"", Relationship: \""essential for pre-radiation evaluation\""\\n3. Entity1: \""pre-radiation dental evaluation\"", Entity2: \""dental procedures or extractions\"", Relationship: \""determine necessity of\""\\n\\nCausalities:-\\n<A> A panoramic dental x-ray is recommended </A> <C> for oral cavity cancers requiring mandibulotomy and/or mandibulectomy </C>. <CO> When postoperative radiotherapy (RT) is anticipated for areas like the lip, oral cavity subsites, or oropharynx </CO>, <A> panoramic x-ray is essential for a comprehensive pre-radiation dental evaluation </A> <E> to assess the health of affected teeth and determine if pre-radiation dental procedures or extractions are necessary </E>.\\n\\nSection Name: NCCN Guidelines Note\\n====================\\nEntities:-\\nNeoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.\\nMalignant Neoplastic Disease : A disease characterized by uncontrolled, abnormal growth of cells that can invade or spread to other parts of the body.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\nClinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.\\nClinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\n\\nRelationships:-\\n1. Entity1: \""NCCN\"", Entity2: \""Clinical Trials\"", Relationship: \""encourages participation in\""\\n2. Entity1: \""NCCN\"", Entity2: \""Cancer\"", Relationship: \""recommends clinical trials for\""\\n\\nCausalities:-\\n<A> NCCN believes that the best management of any patient with cancer is through participation in clinical trials </A>, <A> which is especially encouraged </A>.\\n--------------------------------------------------\\nPage Number: 41\\n\\nSection Name: Workup\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.\\nHistory And Physical Examination : A comprehensive assessment of a patient\\'s medical history and physical condition.\\nTobacco Smoking : The act of smoking tobacco products, which is a risk factor for many diseases.\\nAlcohol Drinking : The consumption of beverages containing ethyl alcohol.\\nSmoking Cessation : The process of discontinuing tobacco smoking.\\nBiopsy : A medical test involving the extraction of sample cells or tissues for examination.\\nLaryngoscopy : A procedure to examine the larynx, often using a scope.\\nComputed Tomography (Ct) : A diagnostic imaging procedure that uses computer-processed combinations of many X-ray measurements taken from different angles to produce cross-sectional images of specific areas of a scanned object.\\nMagnetic Resonance Imaging (Mri) : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.\\nPositron-Emission Tomography : A type of nuclear medicine imaging that measures metabolic activity of the cells of body tissues.\\nPulmonary Function Test : Tests that measure how well the lungs are working.\\nDental Examination : An evaluation of the teeth and gums to assess oral health.\\nNutritional Support : Therapies to provide nutrition to patients who cannot obtain nutrition by mouth.\\nSpeech Therapy : Therapy to improve speech and communication skills.\\nSwallowing Therapy : Therapy to help individuals with swallowing difficulties.\\nMultidisciplinary Care Team : A group of healthcare professionals from different specialties working together to manage patient care.\\n\\nRelationships:-\\n1. Entity1: \""glottic larynx cancer\"", Entity2: \""history and physical examination\"", Relationship: \""initial diagnostic step\""\\n2. Entity1: \""glottic larynx cancer\"", Entity2: \""biopsy\"", Relationship: \""required diagnostic procedure\""\\n3. Entity1: \""glottic larynx cancer\"", Entity2: \""direct laryngoscopy\"", Relationship: \""recommended procedure\""\\n4. Entity1: \""glottic larynx cancer\"", Entity2: \""CT scans\"", Relationship: \""imaging study\""\\n5. Entity1: \""glottic larynx cancer\"", Entity2: \""MRI\"", Relationship: \""imaging study\""\\n6. Entity1: \""glottic larynx cancer\"", Entity2: \""multidisciplinary consultation\"", Relationship: \""advised as clinically indicated\""\\n\\nCausalities:-\\nThe workup section outlines the initial steps for diagnosing <C>glottic larynx cancer</C>. It includes <A>a comprehensive history and physical examination (H&P)</A>, which should document tobacco and alcohol use, and provide counseling for smoking cessation. <A>A biopsy of the primary site is required</A>, and <A>direct laryngoscopy under anesthesia is generally recommended</A>. <A>Imaging studies such as CT scans with contrast and possibly MRI are used to evaluate the larynx and neck</A>. Additional evaluations may include <A>chest CT, FDG-PET/CT, pulmonary function tests, dental evaluation, and nutrition, speech, and swallowing therapy</A>. <A>Multidisciplinary consultation is advised</A> <CO>as clinically indicated</CO>.\\n\\nSection Name: Clinical Staging\\n====================\\nEntities:-\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\nCarcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.\\nBiopsy : A medical test involving the extraction of sample cells or tissues for examination.\\nLaryngectomy : A surgical procedure to remove the larynx.\\n\\nRelationships:-\\n1. Entity1: \""Clinical staging\"", Entity2: \""Cancer\"", Relationship: \""involves\""\\n2. Entity1: \""Carcinoma in situ\"", Entity2: \""Stages T1-T4\"", Relationship: \""is a stage of\""\\n3. Entity1: \""Biopsy\"", Entity2: \""Cancer\"", Relationship: \""used in staging\""\\n4. Entity1: \""Larynx-preserving surgeries\"", Entity2: \""Stages T1-T2\"", Relationship: \""considered for\""\\n5. Entity1: \""Total laryngectomy\"", Entity2: \""Stages T3-T4\"", Relationship: \""required for\""\\n\\nCausalities:-\\n<C> Clinical staging involves categorizing the cancer based on its aggressiveness </C>. It starts with carcinoma in situ, which is non-invasive, and progresses through stages T1-T4. <CO> Staging is based on H&P, biopsy, and imaging studies </CO>. <CO> For T1-T2 </CO>, <A> larynx-preserving surgeries are considered </A>, while <CO> more advanced stages like T3 or T4 </CO> <A> may require total laryngectomy </A>. <A> Additional evaluations such as videostrobe, audiogram, and fertility counseling may be considered </A>.\\n\\nSection Name: Treatment\\n====================\\nEntities:-\\nCarcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.\\nLaryngectomy : A surgical procedure to remove the larynx.\\nMetastasis : The transfer of a disease from one organ or part to another not directly connected with it.\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\n\\nRelationships:-\\n1. Entity1: \""Carcinoma in situ\"", Entity2: \""Larynx-preserving surgery\"", Relationship: \""treated with\""\\n2. Entity1: \""T1-T2 stages\"", Entity2: \""Conservation surgery\"", Relationship: \""treated with\""\\n3. Entity1: \""T3 stages\"", Entity2: \""Total laryngectomy\"", Relationship: \""may require\""\\n4. Entity1: \""T4a disease\"", Entity2: \""Complex interventions\"", Relationship: \""require\""\\n5. Entity1: \""Guidelines\"", Entity2: \""Multidisciplinary consultations\"", Relationship: \""emphasize importance of\""\\n6. Entity1: \""Guidelines\"", Entity2: \""Clinical trials\"", Relationship: \""consider as best option\""\\n\\nCausalities:-\\n<CO>Treatment recommendations vary by stage</CO>. <CO>Carcinoma in situ</CO> <A>may be treated with larynx-preserving surgery</A>. <CO>T1-T2 stages</CO> <A>may also be amenable to conservation surgery</A>. <CO>T3 stages</CO> <A>may require total laryngectomy</A>, <CO>especially if nodal involvement is present</CO>. <CO>T4a disease and unresectable or metastatic cases</CO> <A>require more complex interventions</A>. <A>The guidelines emphasize the importance of multidisciplinary consultations</A> and <A>consider clinical trials as the best management option</A>.\\n\\nSection Name: Additional Notes\\n====================\\nEntities:-\\nBiopsy, Needle : A procedure to remove a small sample of tissue for examination under a microscope.\\nImage-Guided Biopsy : A biopsy procedure that uses imaging techniques to guide the needle to the precise location of the tissue to be sampled.\\nBiopsy : A medical test involving the extraction of sample cells or tissues for examination.\\nDiagnostic Techniques And Procedures : Methods and procedures for the diagnosis of disease or dysfunction.\\nImaging : The process of producing images of the body for clinical purposes.\\nDental Care : The total of dental diagnostic, preventive, and corrective procedures.\\nNutritional Physiological Phenomena : The functions and properties of nutrients in living organisms.\\nFertility : The capacity to conceive or induce conception.\\nReproductive Health : A state of physical, mental, and social well-being in all matters relating to the reproductive system.\\nLymphatic Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nGlottis : The part of the larynx consisting of the vocal cords and the opening between them.\\n\\nRelationships:-\\n1. Entity1: \""image-guided needle biopsy\"", Entity2: \""diagnostic yield\"", Relationship: \""used for\""\\n2. Entity1: \""nodal disease\"", Entity2: \""glottic tumors\"", Relationship: \""is rare in\""\\n\\nCausalities:-\\n<A> use of image-guided needle biopsy </A> for <E> better diagnostic yield </E>, principles of imaging, dental evaluation, and nutrition management. The guidelines also address fertility and reproductive considerations, and note that <CO> nodal disease in glottic tumors is rare </CO>.\\n--------------------------------------------------\\nPage Number: 44\\n\\nSection Name: Flowchart Structure\\n====================\\nEntities:-\\nNeoplasm Staging : Methods used for staging neoplasms based on extent of tumor spread according to standardized criteria.\\nLaryngectomy : Surgical procedure to remove the larynx, often used to treat laryngeal cancer.\\nChemotherapy, Adjuvant : Drug therapy given in addition to the primary treatment to enhance its effectiveness.\\nRadiotherapy : The use of radiation, usually high-energy X-rays, to damage cancer cells and treat cancer.\\nTomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.\\nMagnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body\\'s soft tissue and bones.\\nNeoplasm Recurrence, Local : The return of a tumor at the original site after treatment.\\n\\nRelationships:-\\n1. Entity1: \""Clinical Staging\"", Entity2: \""T3 tumors\"", Relationship: \""determines treatment approach\""\\n2. Entity1: \""Adverse Pathologic Features\"", Entity2: \""Systemic Therapy\"", Relationship: \""directs to\""\\n3. Entity1: \""Adverse Pathologic Features\"", Entity2: \""Radiation Treatment\"", Relationship: \""directs to\""\\n4. Entity1: \""Induction Chemotherapy\"", Entity2: \""Imaging (CT or MRI)\"", Relationship: \""leads to\""\\n\\nCausalities:-\\n1. <A> The flow begins with the clinical staging of T3 tumors </A> <C> that require total laryngectomy (N2\u20133) </C>. <CO> This staging </CO> <E> is crucial for determining the appropriate therapeutic approach </E>.\\n\\n2. The flowchart provides multiple pathways for treatment, indicating that <CO> patients </CO> <A> may undergo either \""Concurrent systemic therapy/RT\"" or \""Surgery\"" </A>. There is also an <A> option for \""Induction chemotherapy,\"" leading to further imaging (CT or MRI) to assess the primary site and neck status </A>.\\n\\n3. For <CO> patients who have surgery </CO>, the flowchart distinguishes between those with adverse pathologic features and those without. <CO> Patients with adverse features\u2014such as extranodal extension or positive margins </CO>\u2014are <A> directed toward systemic therapy or radiation treatment </A>, while those without may follow a different management path.\\n\\n4. The flowchart concludes by <A> outlining follow-up procedures for recurrent or persistent disease </A>, suggesting additional assessments and treatments based on the risk features identified during earlier stages.\\n\\nSection Name: Detailed Explanation\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.\\nAdverse Pathological Feature : A pathological feature that indicates a worse prognosis or outcome.\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\n\\nRelationships:-\\n1. Entity1: \""Systemic therapy\"", Entity2: \""Radiation\"", Relationship: \""Concurrent treatment\""\\n2. Entity1: \""Clinical trials\"", Entity2: \""Personalized treatment plans\"", Relationship: \""Development of\""\\n\\nCausalities:-\\n<A> The flowchart is designed to provide healthcare professionals with a systematic pathway for managing glottic larynx cancer </A>. Each step is meticulously organized to ensure that important factors are considered, such as <C> the presence of adverse pathological features </C>, which <E> strongly influence treatment decisions </E>.\\n\\n<A> The emphasis on concurrent treatments, such as systemic therapy combined with radiation </A>, reflects current best practices in oncology, where multimodal approaches are often necessary to achieve better outcomes. <A> The inclusion of clinical trials </A> indicates an emphasis on maintaining up-to-date practices and personalized treatment plans as part of patient management strategies.\\n\\nFurthermore, <A> the chart\\'s organization into treatment and follow-up segments </A> allows for a straightforward interpretation, guiding oncologists through complex decisions in a logical manner. This can <E> improve consistency in care and enhance patient safety through meticulous monitoring and responses to treatment efficacy or disease progression </E>.\\n\\nIn summary, <E> this flowchart serves as an essential resource for oncologists, facilitating a better understanding of treatment protocols for glottic larynx cancer while promoting a patient-centered approach to oncological care </E>.\\n\\nSection Name: NCCN Guidelines Version 4.2024\\n====================\\nEntities:-\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\nClinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nNeoplasms : New abnormal growth of tissue that may be benign or malignant.\\nMalignant Neoplastic Disease : A disease in which abnormal cells divide uncontrollably and destroy body tissue.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\nNational Comprehensive Cancer Network : An alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network\"", Entity2: \""NCCN Guidelines\"", Relationship: \""publishes\""\\n2. Entity1: \""Clinical trial\"", Entity2: \""Cancer\"", Relationship: \""manages\""\\n\\nCausalities:-\\n<C> any patient with cancer </C> <E> the best management is in a clinical trial </E>. <A> Participation in clinical trials is especially encouraged </A>.\\n\\nSection Name: Principles of Treatment\\n====================\\nEntities:-\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nExtranodal Extension : The spread of cancer beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margins : Cancer cells are found at the edge of the material removed during surgery, indicating that some cancer may have been left behind.\\nPerineural Invasion : Cancer cells are found surrounding or tracking along a nerve within the perineural space.\\nVascular Invasion : The presence of cancer cells within blood vessels.\\nLymphatic Metastasis : The spread of cancer cells through the lymphatic system to distant sites.\\n\\nRelationships:-\\n1. Entity1: \""Principles of Radiation Therapy\"", Entity2: \""Extranodal Extension\"", Relationship: \""management of\""\\n2. Entity1: \""Principles of Surgery\"", Entity2: \""Positive Surgical Margins\"", Relationship: \""concerned with avoiding\""\\n3. Entity1: \""Principles of Radiation Therapy\"", Entity2: \""Perineural Invasion\"", Relationship: \""consideration in treatment planning\""\\n\\nCausalities:-\\n<C> Extranodal extension </C> <C> Positive margins </C> <C> Close margins </C> <C> pT4 primary </C> <C> pN2 or pN3 nodal disease </C> <C> Perineural invasion </C> <C> Vascular invasion </C> <C> Lymphatic invasion </C> <C> Subglottic extension </C>\\n\\nSection Name: Clinical Staging\\n====================\\nEntities:-\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to enhance its effectiveness.\\nAdjuvant Therapy : A therapy given in addition to the primary or initial therapy to maximize its effectiveness.\\nFollow-Up Studies : Studies that continue to monitor patients after treatment to assess long-term outcomes.\\nFollow-Up Procedure : A procedure performed to monitor the progress of a patient after initial treatment.\\nFollow-Up : The act of monitoring a patient\\'s health over time after treatment.\\nNeoplasm Recurrence, Local : The return of a tumor at the original site after treatment.\\nRecurrent Disease : A disease that has returned after a period of remission.\\n\\nRelationships:-\\n1. Entity1: \""Adjuvant Treatment\"", Entity2: \""Recurrent or Persistent Disease\"", Relationship: \""prevention\""\\n2. Entity1: \""Follow-up\"", Entity2: \""Recurrent or Persistent Disease\"", Relationship: \""monitoring\""\\n\\nSection Name: Treatment Options\\n====================\\nEntities:-\\nLaryngectomy : Surgical procedure to remove the larynx, often used to treat laryngeal cancer.\\nTotal Laryngectomy : A surgical procedure to remove the entire larynx.\\nChemotherapy, Adjuvant : Drug therapy given in addition to the primary treatment to enhance its effectiveness.\\nInduction Chemotherapy : Chemotherapy given as a first step to shrink a tumor before the main treatment.\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\nClinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\n\\nRelationships:-\\n1. Entity1: \""T3 requiring total laryngectomy\"", Entity2: \""Concurrent systemic therapy/RT\"", Relationship: \""treatment option\""\\n2. Entity1: \""T3 requiring total laryngectomy\"", Entity2: \""Induction chemotherapy\"", Relationship: \""treatment option\""\\n3. Entity1: \""T3 requiring total laryngectomy\"", Entity2: \""Clinical trials\"", Relationship: \""research option\""\\n\\nCausalities:-\\n<CO> T3 requiring (amenable to) total laryngectomy (N2\u20133) </CO> <A> Concurrent systemic therapy/RT </A> <A> Surgery </A> <A> Induction chemotherapy </A> <A> Clinical trials </A>\\n\\nSection Name: Surgical Considerations\\n====================\\nEntities:-\\nLaryngectomy : Surgical procedure to remove the larynx, often used to treat laryngeal cancer.\\nThyroidectomy : Surgical removal of all or part of the thyroid gland.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue in the neck.\\nLymph Node Excision : Surgical removal of one or more lymph nodes.\\nLymph Node Dissection : A surgical procedure to remove lymph nodes.\\nLymphadenectomy : Surgical removal of one or more groups of lymph nodes.\\n\\nRelationships:-\\n1. Entity1: \""Laryngectomy\"", Entity2: \""Thyroidectomy\"", Relationship: \""performed with\""\\n2. Entity1: \""Neck Dissection\"", Entity2: \""Lymph Node Excision\"", Relationship: \""includes\""\\n3. Entity1: \""Neck Dissection\"", Entity2: \""Lymph Node Excision\"", Relationship: \""includes specific types\""\\n\\nCausalities:-\\n<A> Laryngectomy with thyroidectomy as indicated, ipsilateral or bilateral neck dissection, and pretracheal and ipsilateral paratracheal lymph node dissection </A>\\n\\nSection Name: Pathologic Features\\n====================\\nEntities:-\\nExtranodal Extension : The spread of cancer beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margins : Cancer cells are found at the edge of the material removed during surgery, indicating that some cancer may have been left behind.\\nPositive Margin : A surgical margin that contains residual tumor cells.\\n\\nRelationships:-\\n1. Entity1: \""Adverse pathologic features\"", Entity2: \""Extranodal extension\"", Relationship: \""includes\""\\n2. Entity1: \""Adverse pathologic features\"", Entity2: \""Positive margin\"", Relationship: \""includes\""\\n\\nCausalities:-\\n- **No adverse pathologic features**\\n- **Adverse pathologic features**\\n  - <C> Extranodal extension and/or positive margin </C>\\n  - Other risk features\\n\\nSection Name: Systemic Therapy\\n====================\\nEntities:-\\nAntineoplastic Agents : Drugs used to treat cancer by inhibiting the growth of cancerous cells.\\nSystemic Therapy : A treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiotherapy : The use of radiation, usually high-energy X-rays, to damage cancer cells and treat cancer.\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\n\\nRelationships:-\\n1. Entity1: \""Systemic therapy\"", Entity2: \""RT\"", Relationship: \""Consideration\""\\n\\nCausalities:-\\n<A> Systemic therapy/RT (category 1) </A>\\n<A> RT </A>\\n<A> Consider systemic therapy/RT </A>\\n\\nSection Name: Imaging\\n====================\\nEntities:-\\nTomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.\\nMagnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body\\'s soft tissue and bones.\\nNeck : Part of the body, on many terrestrial or secondarily aquatic vertebrates, that distinguishes the head from the torso or trunk.\\nComputed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images (often called slices), both horizontally and vertically, of the body.\\nNeck Structure : The anatomical structure that connects the head to the torso.\\n\\nRelationships:-\\n1. Entity1: \""CT\"", Entity2: \""Neck\"", Relationship: \""imaging of\""\\n2. Entity1: \""MRI\"", Entity2: \""Neck\"", Relationship: \""imaging of\""\\n\\nCausalities:-\\n<A> CT (with contrast) or MRI (with and without contrast) of primary and neck </A>\\n\\nSection Name: Post-Treatment Evaluation\\n====================\\nEntities:-\\nRadiotherapy : The use of radiation, usually high-energy X-rays, to damage cancer cells and treat cancer.\\nPn1 Category : A pathological classification indicating regional lymph node metastasis in cancer staging.\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\n\\nRelationships:-\\n1. Entity1: \""Post Systemic Therapy/RT or RT Neck Evaluation\"", Entity2: \""pN1\"", Relationship: \""evaluation of cancer staging\""\\n2. Entity1: \""pN1\"", Entity2: \""Consider RT\"", Relationship: \""treatment recommendation\""\\n\\nCausalities:-\\n<CO> pN1 without other risk features </CO> <A> Consider RT </A>\\n\\nSection Name: Additional Notes\\n====================\\nEntities:-\\nAntineoplastic Combined Chemotherapy Protocols : Protocols for the administration of more than one antineoplastic agent in combination to treat malignant neoplasms.\\nCisplatin : A platinum-containing antineoplastic agent used in the treatment of various cancers.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Non-Nasopharyngeal Cancers\"", Relationship: \""used for\""\\n2. Entity1: \""Cisplatin\"", Entity2: \""Systemic Therapy\"", Relationship: \""preferred agent in\""\\n3. Entity1: \""Induction Chemotherapy\"", Entity2: \""Systemic Therapy\"", Relationship: \""discussed in context of\""\\n\\nCausalities:-\\n- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**\\n- **<CO> When using concurrent systemic therapy/RT </CO>, <A> the preferred agent is cisplatin (category 1) </A>. See Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A).**\\n- **<A> See Discussion on induction chemotherapy. </A>**\\n--------------------------------------------------\\nPage Number: 94\\n\\nSection Name: Head and Neck Cancers - Principles of Imaging\\n====================\\nEntities:-\\nPositron Emission Tomography Computed Tomography : A medical imaging technique combining PET and CT capabilities to provide detailed information about the body\\'s function and structure.\\nPositron Emission Tomography : A nuclear medicine functional imaging technique that is used to observe metabolic processes in the body.\\nComputed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.\\nHead And Neck Neoplasms : Cancers that arise in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\n\\nRelationships:-\\n1. Entity1: \""PET/CT\"", Entity2: \""PET scan\"", Relationship: \""preferred over\""\\n2. Entity1: \""PET-CT\"", Entity2: \""head neck cancers\"", Relationship: \""used in study of\""\\n\\nCausalities:-\\n<A> PET/CT is preferred over PET scan alone (i.e., without superimposed CT scan) </A>. <C> PET/CT provides more accurate anatomical localization of abnormalities </C> <E> more accurate anatomical localization of abnormalities </E>.\\n\\nSection Name: Initial Workup - Nodal Metastases\\n====================\\nEntities:-\\nLymphatic Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site via the lymphatic system.\\nTomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient, producing signals that are processed by the machine\\'s computer to generate cross-sectional images.\\nMagnetic Resonance Imaging : A non-invasive imaging technique that uses magnetic fields and radio waves to create detailed images of the organs and tissues within the body.\\nPositron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption.\\nLymph Node Metastasis : The spread of cancer cells to lymph nodes, which are part of the lymphatic system.\\nCt Of Neck : A computed tomography scan of the neck region.\\nMri Of Neck : A magnetic resonance imaging scan of the neck region.\\nFdg-Pet Scan : A type of positron emission tomography using fluorodeoxyglucose to assess metabolic activity.\\nComputed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.\\nPositron Emission Tomography : A nuclear medicine functional imaging technique that is used to observe metabolic processes in the body.\\n\\nRelationships:-\\n1. Entity1: \""CT\"", Entity2: \""lymph node metastases\"", Relationship: \""used to evaluate\""\\n2. Entity1: \""MRI\"", Entity2: \""lymph node metastases\"", Relationship: \""used to evaluate\""\\n3. Entity1: \""FDG-PET/CT\"", Entity2: \""lymph node metastases\"", Relationship: \""used for detection\""\\n4. Entity1: \""FDG-PET/CT\"", Entity2: \""surgical primary approach\"", Relationship: \""used to determine\""\\n5. Entity1: \""FDG-PET/CT\"", Entity2: \""definitive RT approach\"", Relationship: \""used to identify\""\\n\\nCausalities:-\\n<A> Evaluation of lymph node metastases should be conducted with CT or MRI of the neck </A>, using whichever imaging study is suitable for primary site evaluation (IMG-A, 1 of 4).\\n<CO> For patients with multistation or lower neck nodal involvement or high-grade tumor histology </CO>, <A> consider CT of the chest to assess for mediastinal lymph node metastases or FDG-PET/CT </A>, <C> which is associated with higher sensitivity for both nodal and distant metastases </C>.\\n<CO> For patients who are under consideration for a surgical primary approach </CO>, <A> the higher sensitivity of FDG-PET/CT is warranted for tumors approaching the midline, to determine the surgical approach to the contralateral neck </A>. <CO> Similarly, patients who are scheduled for a definitive RT approach </CO> <A> may benefit from the higher sensitivity of FDG-PET/CT for identifying involved lymph nodes </A>.\\n\\nSection Name: Initial Workup - Distant Metastases\\n====================\\nEntities:-\\nPositron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption.\\nMagnetic Resonance Imaging : A non-invasive imaging technique that uses magnetic fields and radio waves to create detailed images of the organs and tissues within the body.\\nTomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient, producing signals that are processed by the machine\\'s computer to generate cross-sectional images.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nLung Neoplasms : Tumors or cancer of the lung.\\nSmoking : The inhalation of the smoke of burning tobacco encased in cigarettes, pipes, and cigars.\\n\\nRelationships:-\\n1. Entity1: \""FDG-PET/CT\"", Entity2: \""Distant Metastases\"", Relationship: \""used to evaluate\""\\n2. Entity1: \""Contrast-enhanced brain MRI\"", Entity2: \""Brain Metastasis\"", Relationship: \""recommended for evaluation\""\\n3. Entity1: \""CT of the chest\"", Entity2: \""Pulmonary Metastases\"", Relationship: \""performed to assess\""\\n4. Entity1: \""Non-contrast CT of the chest\"", Entity2: \""Lung Parenchymal Metastases\"", Relationship: \""used to screen\""\\n5. Entity1: \""Annual CT screening\"", Entity2: \""Lung Metastasis\"", Relationship: \""considered for high risk\""\\n6. Entity1: \""Directed CT or MRI\"", Entity2: \""Distant Disease\"", Relationship: \""used for assessment\""\\n7. Entity1: \""FDG-PET/CT\"", Entity2: \""Recurrent Disease\"", Relationship: \""used for staging\""\\n\\nCausalities:-\\n<C> Patients with locoregionally advanced cancer (e.g., T3\u2013T4 primary or \u2265N1 nodal staging) </C>, <A> FDG-PET/CT is preferred to evaluate for distant disease and thoracic metastases </A>. <CO> For cancers where brain metastasis is a concern, such as mucosal melanoma or high-grade neuroendocrine carcinomas or adenocarcinomas </CO>, <A> contrast-enhanced brain MRI should be additionally obtained </A>.\\n<CO> If FDG-PET/CT is not performed </CO>, <A> CT of the chest should be performed to assess for presence of pulmonary metastases as well as mediastinal lymph node involvement </A>.\\n<CO> Non-contrast CT of the chest can be sufficient to screen for lung parenchymal metastases </CO> but <CO> is not adequate for assessment of mediastinal adenopathy </CO>. <CO> This is an appropriate lung cancer screening intervention for patients with a history of smoking </CO>.\\n<CO> Following primary definitive treatment (surgery, RT, or systemic therapy/RT) </CO> the role of annual CT screening for lung metastasis is controversial. <E> While this approach does detect early metastasis </E>, <CO> further study is needed to determine the extent of the positive effect and/or cost-effectiveness of this approach in specific subpopulations and timepoints post-treatment </CO>. <CO> For patients with a substantial smoking history or who are at high risk for lung metastases </CO>, <A> annual chest CT can be considered </A>.\\n<CO> If clinical concern for metastatic disease is confined to a specific anatomical area </CO>, <A> the assessment of distant disease can be performed with directed CT or MRI examination </A>.\\n<CO> FDG-PET/CT may complement or replace other imaging modalities when staging recurrent disease before any therapy for relapsed/refractory disease </CO> <A> in order to explore distant disease or second primaries that may significantly impact choice of therapy </A>.\\n--------------------------------------------------\\nPage Number: 92\\n\\nSection Name: NCCN Guidelines Overview\\n====================\\nEntities:-\\nHead And Neck Neoplasms : Cancers that arise in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\nMalignant Neoplasm Of Head And Neck : A malignant tumor located in the head and neck region.\\nHead And Neck Cancer : A group of cancers that originate in the head and neck region.\\nAntineoplastic Agents : Drugs used to treat cancer by inhibiting the growth of cancerous cells.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.\\nRadiation Therapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.\\n\\nRelationships:-\\n1. Entity1: \""Head and neck cancers\"", Entity2: \""Systemic therapy\"", Relationship: \""follow-up recommendations after\""\\n2. Entity1: \""Head and neck cancers\"", Entity2: \""Radiation therapy\"", Relationship: \""follow-up recommendations after\""\\n\\nCausalities:-\\nThe image presents a flowchart from the National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2024, especially focusing on <A> follow-up recommendations </A> for <CO> patients with head and neck cancers after systemic therapy or radiation therapy (RT) </CO>. All recommendations are categorized as level A unless stated otherwise, highlighting the importance of clinical trials in cancer management.\\n\\nSection Name: Imaging and Assessment Protocols\\n====================\\nEntities:-\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.\\nClinical Assessment : A systematic evaluation of a patient\\'s health status, often involving a physical examination and medical history.\\nPositron-Emission Tomography : An imaging technique using a radioactive substance called a tracer to look for disease in the body.\\nComputed Tomography : A medical imaging technique used in radiology to obtain detailed internal images of the body.\\nMagnetic Resonance Imaging : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis.\\nDisease : A disorder of structure or function in a human, animal, or plant, especially one that produces specific symptoms.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\nResidual Neoplasm : Remaining cancer cells after treatment.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Clinical Assessment\"", Relationship: \""occurs before\""\\n2. Entity1: \""FDG-PET/CT Scan\"", Entity2: \""Distant Metastases\"", Relationship: \""assesses\""\\n3. Entity1: \""FDG-PET/CT Scan\"", Entity2: \""Observation\"", Relationship: \""leads to if negative\""\\n4. Entity1: \""FDG-PET/CT Scan\"", Entity2: \""CT Scan\"", Relationship: \""leads to if strongly positive\""\\n5. Entity1: \""CT Scan\"", Entity2: \""Neck Dissection\"", Relationship: \""leads to if positive\""\\n\\nCausalities:-\\n<CO> After systemic therapy or RT </CO>, <A> a clinical assessment should occur 4 to 8 weeks later </A>. <CO> If there is a response </CO>, <A> it is necessary to assess the extent of disease or distant metastases, preferably through a FDG-PET/CT scan at a minimum of 12 weeks post-treatment </A>. <CO> If the FDG-PET/CT results are negative </CO>, <A> the patient may continue with monitoring through observation </A>. <CO> In cases where the results are equivocal </CO>, <A> observation or repeat FDG-PET/CT within 3 to 6 months is prescribed </A>.\\n\\n<CO> In cases where the FDG-PET/CT results are strongly positive </CO>, <A> further imaging via CT scan with contrast of the primary site and neck, or MRI with and without contrast, becomes necessary </A>. <CO> If these imaging results confirm positive findings </CO>, <A> neck dissection may be considered, depending on the evidence of residual or persistent disease </A>. <CO> If the imaging findings are negative </CO>, <A> the patient might continue in observation </A>.\\n\\nSection Name: Outcomes Based on Disease Resectability\\n====================\\nEntities:-\\nDisease : A disorder of structure or function in a human, animal, or plant, especially one that produces specific symptoms.\\nResectable : Capable of being surgically removed.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis.\\n\\nRelationships:-\\n1. Entity1: \""Disease\"", Entity2: \""Resectable\"", Relationship: \""Classification\""\\n2. Entity1: \""Unresectable\"", Entity2: \""Treatment plans (ADV-3)\"", Relationship: \""Treatment recommendation\""\\n3. Entity1: \""Resectable\"", Entity2: \""Resection and/or Neck dissection\"", Relationship: \""Surgical procedure\""\\n\\nCausalities:-\\n<CO> If there is confirmed residual or persistent disease </CO>, the options split into two pathways: \\'Unresectable\\' or \\'Resectable.\\' <CO> If the disease is classified as unresectable </CO>, <A> advances in treatment plans (labeled ADV-3) are called for </A>. Conversely, <CO> if it is deemed resectable </CO>, <A> a resection of the primary and/or neck dissection may occur </A>, <CO> contingent upon the disease status </CO>.\\n\\nSection Name: Important Notes\\n====================\\nEntities:-\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\nClinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.\\nPositron-Emission Tomography : An imaging technique using a radioactive substance called a tracer to look for disease in the body.\\nPositron Emission Tomography (Procedure) : A diagnostic imaging procedure that uses a radioactive tracer to visualize and measure changes in metabolic processes.\\nPositron Emission Tomography : A nuclear medicine functional imaging technique used to observe metabolic processes in the body.\\nNeoplasms : New abnormal growth of tissue in animals or plants; a tumor.\\nMalignant Neoplasm : A cancerous growth that has the potential to spread to other parts of the body.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""NCCN\"", Entity2: \""Clinical trials\"", Relationship: \""emphasizes participation in\""\\n2. Entity1: \""FDG-PET/CT\"", Entity2: \""Persistent cancer\"", Relationship: \""used to detect\""\\n3. Entity1: \""FDG-PET/CT\"", Entity2: \""PET negative\"", Relationship: \""interpretation of results\""\\n4. Entity1: \""FDG-PET/CT\"", Entity2: \""PET positive\"", Relationship: \""interpretation of results\""\\n\\nCausalities:-\\n<A> NCCN emphasizes that the best management for any cancer patient is participation in clinical trials </A>, especially encouraged for all patients. Additional notes clarify that <CO> if the FDG-PET/CT is negative for persistent cancer </CO>, <A> further cross-sectional imaging is optional </A>. The interpretations define <CO> PET negative as no or low-grade uptake not suspicious for disease </CO>, while <CO> PET positive implies suspicion for disease </CO>.\\n'}""",valid,increases risk,2,B,"edge - The edge which needs to be verified.
explanation - Explanation of what the edge represents and its validity.
causal_direction - Either Positive or Negative or Unknown. A positive influence direction indicates that both factors change in the same direction (e.g. an increase causes an increase effect). A negative influence direction indicates the opposite changes (e.g. an increase causes a decrease effect).
causal_factor - Is necessary or sufficient condition for an effect to occur. Exposure is a term commonly used in epidemiology to denote any condition that is considered as a possible cause of disease. Exposure is considered necessary when it always precedes the effects (e.g. symptoms) and always presents when the effects occur. A sufficient cause is a causal factor whose presence or occurrence guarantees the occurrence of symptom.
causal_distance - Either Distal or Proximal or Unknown. The distal factors lie towards the beginning of causal chain (i.e. indirect causal factors). The the proximal factors lie towards the end of the chain (i.e. cause directly or almost directly the effect).

Causality Tags:
<A> for action, <C> for cause, <CO> for condition and <E> for effect.
Cause (C): The reason or origin that leads to an effect. Causes often involve disease conditions, risk factors, or underlying mechanisms.
Effect (E): The outcome or result of a cause. Effects usually represent clinical outcomes, complications, or results of a specific cause.
Condition (CO): The circumstance or prerequisite required for an action or effect to occur. Conditions may include patient characteristics, clinical scenarios, or specific diagnostic criteria.
Action (A): The recommended or described response or activity to address a cause or condition. Actions typically involve clinical interventions, diagnostic procedures, or treatment recommendations.


`NODE1`:
id: Location_of_Involved_Lymph_Nodes_4
label: Position of Affected Lymph Nodes in Patient
description: This node represents the location of lymph nodes that are involved or affected in a patient's condition. Understanding whether the lymph nodes are ipsilateral, bilateral, or contralateral is crucial for determining the extent of disease spread and planning appropriate treatment strategies.
type: Patient Situation
observability: Unobserved
states: [{'state_name': 'ipsilateral', 'state_description': 'The involved lymph nodes are on the same side of the body as the primary tumor or reference point. This can indicate localized spread of disease.'}, {'state_name': 'bilateral', 'state_description': 'The involved lymph nodes are on both sides of the body. This may suggest a more extensive spread of disease and can impact treatment decisions.'}, {'state_name': 'contralateral', 'state_description': 'The involved lymph nodes are on the opposite side of the body from the primary tumor or reference point. This can indicate metastatic spread and may affect staging and treatment planning.'}]

`NODE2`:
id: Computerized_Tomography_CT_12
label: CT Scan Examination Result for Lymph Node Metastasis
description: This node represents the results of a CT scan examination, specifically focusing on the detection of lymph node metastasis. It provides information on whether the metastasis is bilateral, ipsilateral, or contralateral, which is crucial for staging cancer and planning treatment.
type: Examination Result
observability: Observed
states: [{'state_name': 'bilateral_lymph_node_metastasis', 'state_description': 'The CT scan shows metastasis in lymph nodes on both sides of the body, indicating a more advanced spread of cancer.'}, {'state_name': 'ipsilateral_lymph_node_metastasis', 'state_description': 'The CT scan shows metastasis in lymph nodes on the same side of the body as the primary tumor, suggesting localized spread.'}, {'state_name': 'contralateral_lymph_node_metastasis', 'state_description': 'The CT scan shows metastasis in lymph nodes on the opposite side of the body from the primary tumor, indicating cross-body spread.'}]

`EDGE1`:
{'edges_ids': ['Location_of_Involved_Lymph_Nodes_4', 'Computerized_Tomography_CT_12'], 'edge': '(Location_of_Involved_Lymph_Nodes_4) causes (Computerized_Tomography_CT_12)', 'explanation': ['The edge suggests that the location of involved lymph nodes causes the CT scan results, which is not valid.', 'The location of involved lymph nodes is a patient situation that exists independently of the CT scan results.', 'The CT scan results are an observation of the lymph node involvement, not a cause of it.', 'Therefore, the causal relationship is not valid in the direction given.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}

`EDGE2`:
{'edges_ids': ['Computerized_Tomography_CT_12', 'Location_of_Involved_Lymph_Nodes_4'], 'edge': '(Computerized_Tomography_CT_12) causes (Location_of_Involved_Lymph_Nodes_4)', 'explanation': ['The edge suggests that the results of a CT scan examination (Computerized_Tomography_CT_12) cause the location of involved lymph nodes (Location_of_Involved_Lymph_Nodes_4).', 'However, the CT scan is a diagnostic tool that observes and reports on the state of lymph node involvement, such as whether metastasis is bilateral, ipsilateral, or contralateral.', 'The location of involved lymph nodes is a description of the patient`s condition and is not caused by the CT scan results.', 'The CT scan results provide information about the lymph nodes` state but do not influence or change their location.', 'Therefore, the edge is not valid as a causal relationship because the CT scan results do not cause the lymph nodes to be in a particular location; they only detect and report on their state.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}

`INFORMATION FROM KNOWLEDGE BASE`:
--------------------------------------------------
Page Number: 93

Section Name: PRINCIPLES OF IMAGING
====================
Entities:-
Imaging, Diagnostic : The production of a visual representation of parts of the body, for the purpose of clinical analysis and medical intervention.
Head And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Tomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.
Magnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body's soft tissue and bones.
Contrast Media : Substances used to enhance the contrast of structures or fluids within the body in medical imaging.

Relationships:-
1. Entity1: ""Imaging, Diagnostic"", Entity2: ""Head and Neck Neoplasms"", Relationship: ""used for""
2. Entity1: ""Tomography, X-Ray Computed"", Entity2: ""Contrast Media"", Relationship: ""uses""
3. Entity1: ""Magnetic Resonance Imaging"", Entity2: ""Contrast Media"", Relationship: ""uses""

Causalities:-
<C> Imaging </C> plays an essential role in the clinical care of patients with head and neck cancer. <A> The proper selection and utilization of imaging studies </A> is critical in caring for patients with head and neck cancer. <A> CT is performed with contrast </A>, while <A> CT imaging of the chest can be performed with or without contrast </A>, <CO> as clinically indicated </CO>. <A> MRI is performed with and without contrast </A>, <CO> unless contraindicated </CO>.

Section Name: Initial Workup - Primary Site
====================
Entities:-
Tomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.
Magnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body's soft tissue and bones.
Head And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Neck Structure : The anatomical structure of the neck, which is the part of the body that connects the head to the torso.
Skull Base : The bottom part of the skull, which separates the brain from other facial structures.
Thoracic Inlet : The opening at the top of the thoracic cavity, through which pass the trachea, esophagus, and major blood vessels.

Relationships:-
1. Entity1: ""CT"", Entity2: ""MRI"", Relationship: ""complementary in imaging head and neck cancers""
2. Entity1: ""CT"", Entity2: ""Head and Neck Neoplasms"", Relationship: ""used to evaluate""
3. Entity1: ""MRI"", Entity2: ""Head and Neck Neoplasms"", Relationship: ""preferred for evaluating""
4. Entity1: ""Skull base"", Entity2: ""Thoracic inlet"", Relationship: ""imaging range for evaluation""

Causalities:-
<A>Imaging assessment of the primary site</A> can be performed with <A>CT of the soft tissues of the neck</A> or <A>MRI of the neck</A>. <C>CT is complementary to MRI for head and neck cancers</C>. <A>It is utilized to evaluate cortical bone erosion or periosteal invasion, cartilage invasion, and bony erosion or destruction</A>. <CO>in certain conditions, such as evaluating the extent of bone marrow invasion or in patients with extensive dental amalgam obscuring anatomy on CT, assessing skull base invasion and cranial nerve involvement, and differentiating tumor from obstructed sinuses</CO>, <A>MRI is preferred over CT</A>. <CO>when involved lymph nodes or upper mediastinal cancers are present</CO>, <A>Complete evaluation of primary and nodal disease requires imaging from the skull base to the thoracic inlet, extending to the carina</A>.

Section Name: PET/CT and Biopsy
====================
Entities:-
Positron Emission Tomography Computed Tomography : A medical imaging technique that combines PET and CT capabilities to provide detailed images of the body.
Examination Under Anesthesia : A procedure where a patient is examined while under anesthesia to allow for a more thorough examination.
Biopsy : A medical test involving the extraction of sample cells or tissues for examination to determine the presence or extent of a disease.
Tonsillectomy : A surgical procedure to remove the tonsils, often performed to treat recurrent tonsillitis or sleep apnea.
Fine Needle Aspiration : A type of biopsy procedure that uses a thin, hollow needle to extract cells from a lump or mass for examination.
Ultrasound : A medical imaging technique that uses high-frequency sound waves to visualize internal organs and structures.
Computed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.

Relationships:-
1. Entity1: ""PET/CT"", Entity2: ""EUA"", Relationship: ""recommended before""
2. Entity1: ""Fine Needle Aspiration (FNA)"", Entity2: ""metastatic nodes"", Relationship: ""used for biopsy of""
3. Entity1: ""Image-guided needle biopsy"", Entity2: ""cystic neck nodes"", Relationship: ""recommended for initial diagnosis of""

Causalities:-
<CO> If imaging does not reveal an obvious primary cancer </CO>, <A> a PET/CT should be ordered before EUA, biopsies, and tonsillectomy </A>. <E> This helps identify potential primary sites </E> before any interventions take place. Additionally, <A> Fine Needle Aspiration (FNA) biopsy of metastatic nodes </A> <E> may provide pathologically informative results </E>. <CO> For initial diagnosis in cystic neck nodes </CO>, <A> image-guided needle biopsy (ultrasound or CT) </A> <E> may yield better results than FNA by palpation alone </E>.

Section Name: Postoperative Imaging Advice
====================
Entities:-
Panoramic Radiography : A type of dental x-ray that provides a wide view of the upper and lower jaws, teeth, temporomandibular joints, and sinuses.
Oral Cavity : The cavity of the mouth, including the lips, the lining inside the cheeks and lips, the front two-thirds of the tongue, the gums, the floor of the mouth under the tongue, the hard palate, and the small area of the gum behind the wisdom teeth.
Radiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.
Mandibulotomy : A surgical procedure involving the cutting of the mandible.
Mandibulectomy : A surgical procedure involving the removal of part or all of the mandible.
Oropharynx : The part of the throat at the back of the mouth behind the oral cavity.

Relationships:-
1. Entity1: ""panoramic dental x-ray"", Entity2: ""oral cavity cancers"", Relationship: ""recommended for""
2. Entity1: ""panoramic dental x-ray"", Entity2: ""postoperative radiotherapy"", Relationship: ""essential for pre-radiation evaluation""
3. Entity1: ""pre-radiation dental evaluation"", Entity2: ""dental procedures or extractions"", Relationship: ""determine necessity of""

Causalities:-
<A> A panoramic dental x-ray is recommended </A> <C> for oral cavity cancers requiring mandibulotomy and/or mandibulectomy </C>. <CO> When postoperative radiotherapy (RT) is anticipated for areas like the lip, oral cavity subsites, or oropharynx </CO>, <A> panoramic x-ray is essential for a comprehensive pre-radiation dental evaluation </A> <E> to assess the health of affected teeth and determine if pre-radiation dental procedures or extractions are necessary </E>.

Section Name: NCCN Guidelines Note
====================
Entities:-
Neoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.
Malignant Neoplastic Disease : A disease characterized by uncontrolled, abnormal growth of cells that can invade or spread to other parts of the body.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.
Clinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.
Clinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.

Relationships:-
1. Entity1: ""NCCN"", Entity2: ""Clinical Trials"", Relationship: ""encourages participation in""
2. Entity1: ""NCCN"", Entity2: ""Cancer"", Relationship: ""recommends clinical trials for""

Causalities:-
<A> NCCN believes that the best management of any patient with cancer is through participation in clinical trials </A>, <A> which is especially encouraged </A>.
--------------------------------------------------
Page Number: 41

Section Name: Workup
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.
History And Physical Examination : A comprehensive assessment of a patient's medical history and physical condition.
Tobacco Smoking : The act of smoking tobacco products, which is a risk factor for many diseases.
Alcohol Drinking : The consumption of beverages containing ethyl alcohol.
Smoking Cessation : The process of discontinuing tobacco smoking.
Biopsy : A medical test involving the extraction of sample cells or tissues for examination.
Laryngoscopy : A procedure to examine the larynx, often using a scope.
Computed Tomography (Ct) : A diagnostic imaging procedure that uses computer-processed combinations of many X-ray measurements taken from different angles to produce cross-sectional images of specific areas of a scanned object.
Magnetic Resonance Imaging (Mri) : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.
Positron-Emission Tomography : A type of nuclear medicine imaging that measures metabolic activity of the cells of body tissues.
Pulmonary Function Test : Tests that measure how well the lungs are working.
Dental Examination : An evaluation of the teeth and gums to assess oral health.
Nutritional Support : Therapies to provide nutrition to patients who cannot obtain nutrition by mouth.
Speech Therapy : Therapy to improve speech and communication skills.
Swallowing Therapy : Therapy to help individuals with swallowing difficulties.
Multidisciplinary Care Team : A group of healthcare professionals from different specialties working together to manage patient care.

Relationships:-
1. Entity1: ""glottic larynx cancer"", Entity2: ""history and physical examination"", Relationship: ""initial diagnostic step""
2. Entity1: ""glottic larynx cancer"", Entity2: ""biopsy"", Relationship: ""required diagnostic procedure""
3. Entity1: ""glottic larynx cancer"", Entity2: ""direct laryngoscopy"", Relationship: ""recommended procedure""
4. Entity1: ""glottic larynx cancer"", Entity2: ""CT scans"", Relationship: ""imaging study""
5. Entity1: ""glottic larynx cancer"", Entity2: ""MRI"", Relationship: ""imaging study""
6. Entity1: ""glottic larynx cancer"", Entity2: ""multidisciplinary consultation"", Relationship: ""advised as clinically indicated""

Causalities:-
The workup section outlines the initial steps for diagnosing <C>glottic larynx cancer</C>. It includes <A>a comprehensive history and physical examination (H&P)</A>, which should document tobacco and alcohol use, and provide counseling for smoking cessation. <A>A biopsy of the primary site is required</A>, and <A>direct laryngoscopy under anesthesia is generally recommended</A>. <A>Imaging studies such as CT scans with contrast and possibly MRI are used to evaluate the larynx and neck</A>. Additional evaluations may include <A>chest CT, FDG-PET/CT, pulmonary function tests, dental evaluation, and nutrition, speech, and swallowing therapy</A>. <A>Multidisciplinary consultation is advised</A> <CO>as clinically indicated</CO>.

Section Name: Clinical Staging
====================
Entities:-
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.
Carcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.
Biopsy : A medical test involving the extraction of sample cells or tissues for examination.
Laryngectomy : A surgical procedure to remove the larynx.

Relationships:-
1. Entity1: ""Clinical staging"", Entity2: ""Cancer"", Relationship: ""involves""
2. Entity1: ""Carcinoma in situ"", Entity2: ""Stages T1-T4"", Relationship: ""is a stage of""
3. Entity1: ""Biopsy"", Entity2: ""Cancer"", Relationship: ""used in staging""
4. Entity1: ""Larynx-preserving surgeries"", Entity2: ""Stages T1-T2"", Relationship: ""considered for""
5. Entity1: ""Total laryngectomy"", Entity2: ""Stages T3-T4"", Relationship: ""required for""

Causalities:-
<C> Clinical staging involves categorizing the cancer based on its aggressiveness </C>. It starts with carcinoma in situ, which is non-invasive, and progresses through stages T1-T4. <CO> Staging is based on H&P, biopsy, and imaging studies </CO>. <CO> For T1-T2 </CO>, <A> larynx-preserving surgeries are considered </A>, while <CO> more advanced stages like T3 or T4 </CO> <A> may require total laryngectomy </A>. <A> Additional evaluations such as videostrobe, audiogram, and fertility counseling may be considered </A>.

Section Name: Treatment
====================
Entities:-
Carcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.
Laryngectomy : A surgical procedure to remove the larynx.
Metastasis : The transfer of a disease from one organ or part to another not directly connected with it.
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.

Relationships:-
1. Entity1: ""Carcinoma in situ"", Entity2: ""Larynx-preserving surgery"", Relationship: ""treated with""
2. Entity1: ""T1-T2 stages"", Entity2: ""Conservation surgery"", Relationship: ""treated with""
3. Entity1: ""T3 stages"", Entity2: ""Total laryngectomy"", Relationship: ""may require""
4. Entity1: ""T4a disease"", Entity2: ""Complex interventions"", Relationship: ""require""
5. Entity1: ""Guidelines"", Entity2: ""Multidisciplinary consultations"", Relationship: ""emphasize importance of""
6. Entity1: ""Guidelines"", Entity2: ""Clinical trials"", Relationship: ""consider as best option""

Causalities:-
<CO>Treatment recommendations vary by stage</CO>. <CO>Carcinoma in situ</CO> <A>may be treated with larynx-preserving surgery</A>. <CO>T1-T2 stages</CO> <A>may also be amenable to conservation surgery</A>. <CO>T3 stages</CO> <A>may require total laryngectomy</A>, <CO>especially if nodal involvement is present</CO>. <CO>T4a disease and unresectable or metastatic cases</CO> <A>require more complex interventions</A>. <A>The guidelines emphasize the importance of multidisciplinary consultations</A> and <A>consider clinical trials as the best management option</A>.

Section Name: Additional Notes
====================
Entities:-
Biopsy, Needle : A procedure to remove a small sample of tissue for examination under a microscope.
Image-Guided Biopsy : A biopsy procedure that uses imaging techniques to guide the needle to the precise location of the tissue to be sampled.
Biopsy : A medical test involving the extraction of sample cells or tissues for examination.
Diagnostic Techniques And Procedures : Methods and procedures for the diagnosis of disease or dysfunction.
Imaging : The process of producing images of the body for clinical purposes.
Dental Care : The total of dental diagnostic, preventive, and corrective procedures.
Nutritional Physiological Phenomena : The functions and properties of nutrients in living organisms.
Fertility : The capacity to conceive or induce conception.
Reproductive Health : A state of physical, mental, and social well-being in all matters relating to the reproductive system.
Lymphatic Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Glottis : The part of the larynx consisting of the vocal cords and the opening between them.

Relationships:-
1. Entity1: ""image-guided needle biopsy"", Entity2: ""diagnostic yield"", Relationship: ""used for""
2. Entity1: ""nodal disease"", Entity2: ""glottic tumors"", Relationship: ""is rare in""

Causalities:-
<A> use of image-guided needle biopsy </A> for <E> better diagnostic yield </E>, principles of imaging, dental evaluation, and nutrition management. The guidelines also address fertility and reproductive considerations, and note that <CO> nodal disease in glottic tumors is rare </CO>.
--------------------------------------------------
Page Number: 44

Section Name: Flowchart Structure
====================
Entities:-
Neoplasm Staging : Methods used for staging neoplasms based on extent of tumor spread according to standardized criteria.
Laryngectomy : Surgical procedure to remove the larynx, often used to treat laryngeal cancer.
Chemotherapy, Adjuvant : Drug therapy given in addition to the primary treatment to enhance its effectiveness.
Radiotherapy : The use of radiation, usually high-energy X-rays, to damage cancer cells and treat cancer.
Tomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.
Magnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body's soft tissue and bones.
Neoplasm Recurrence, Local : The return of a tumor at the original site after treatment.

Relationships:-
1. Entity1: ""Clinical Staging"", Entity2: ""T3 tumors"", Relationship: ""determines treatment approach""
2. Entity1: ""Adverse Pathologic Features"", Entity2: ""Systemic Therapy"", Relationship: ""directs to""
3. Entity1: ""Adverse Pathologic Features"", Entity2: ""Radiation Treatment"", Relationship: ""directs to""
4. Entity1: ""Induction Chemotherapy"", Entity2: ""Imaging (CT or MRI)"", Relationship: ""leads to""

Causalities:-
1. <A> The flow begins with the clinical staging of T3 tumors </A> <C> that require total laryngectomy (N2–3) </C>. <CO> This staging </CO> <E> is crucial for determining the appropriate therapeutic approach </E>.

2. The flowchart provides multiple pathways for treatment, indicating that <CO> patients </CO> <A> may undergo either ""Concurrent systemic therapy/RT"" or ""Surgery"" </A>. There is also an <A> option for ""Induction chemotherapy,"" leading to further imaging (CT or MRI) to assess the primary site and neck status </A>.

3. For <CO> patients who have surgery </CO>, the flowchart distinguishes between those with adverse pathologic features and those without. <CO> Patients with adverse features—such as extranodal extension or positive margins </CO>—are <A> directed toward systemic therapy or radiation treatment </A>, while those without may follow a different management path.

4. The flowchart concludes by <A> outlining follow-up procedures for recurrent or persistent disease </A>, suggesting additional assessments and treatments based on the risk features identified during earlier stages.

Section Name: Detailed Explanation
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.
Adverse Pathological Feature : A pathological feature that indicates a worse prognosis or outcome.
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.

Relationships:-
1. Entity1: ""Systemic therapy"", Entity2: ""Radiation"", Relationship: ""Concurrent treatment""
2. Entity1: ""Clinical trials"", Entity2: ""Personalized treatment plans"", Relationship: ""Development of""

Causalities:-
<A> The flowchart is designed to provide healthcare professionals with a systematic pathway for managing glottic larynx cancer </A>. Each step is meticulously organized to ensure that important factors are considered, such as <C> the presence of adverse pathological features </C>, which <E> strongly influence treatment decisions </E>.

<A> The emphasis on concurrent treatments, such as systemic therapy combined with radiation </A>, reflects current best practices in oncology, where multimodal approaches are often necessary to achieve better outcomes. <A> The inclusion of clinical trials </A> indicates an emphasis on maintaining up-to-date practices and personalized treatment plans as part of patient management strategies.

Furthermore, <A> the chart's organization into treatment and follow-up segments </A> allows for a straightforward interpretation, guiding oncologists through complex decisions in a logical manner. This can <E> improve consistency in care and enhance patient safety through meticulous monitoring and responses to treatment efficacy or disease progression </E>.

In summary, <E> this flowchart serves as an essential resource for oncologists, facilitating a better understanding of treatment protocols for glottic larynx cancer while promoting a patient-centered approach to oncological care </E>.

Section Name: NCCN Guidelines Version 4.2024
====================
Entities:-
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.
Clinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Neoplasms : New abnormal growth of tissue that may be benign or malignant.
Malignant Neoplastic Disease : A disease in which abnormal cells divide uncontrollably and destroy body tissue.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.
National Comprehensive Cancer Network : An alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network"", Entity2: ""NCCN Guidelines"", Relationship: ""publishes""
2. Entity1: ""Clinical trial"", Entity2: ""Cancer"", Relationship: ""manages""

Causalities:-
<C> any patient with cancer </C> <E> the best management is in a clinical trial </E>. <A> Participation in clinical trials is especially encouraged </A>.

Section Name: Principles of Treatment
====================
Entities:-
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Extranodal Extension : The spread of cancer beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margins : Cancer cells are found at the edge of the material removed during surgery, indicating that some cancer may have been left behind.
Perineural Invasion : Cancer cells are found surrounding or tracking along a nerve within the perineural space.
Vascular Invasion : The presence of cancer cells within blood vessels.
Lymphatic Metastasis : The spread of cancer cells through the lymphatic system to distant sites.

Relationships:-
1. Entity1: ""Principles of Radiation Therapy"", Entity2: ""Extranodal Extension"", Relationship: ""management of""
2. Entity1: ""Principles of Surgery"", Entity2: ""Positive Surgical Margins"", Relationship: ""concerned with avoiding""
3. Entity1: ""Principles of Radiation Therapy"", Entity2: ""Perineural Invasion"", Relationship: ""consideration in treatment planning""

Causalities:-
<C> Extranodal extension </C> <C> Positive margins </C> <C> Close margins </C> <C> pT4 primary </C> <C> pN2 or pN3 nodal disease </C> <C> Perineural invasion </C> <C> Vascular invasion </C> <C> Lymphatic invasion </C> <C> Subglottic extension </C>

Section Name: Clinical Staging
====================
Entities:-
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to enhance its effectiveness.
Adjuvant Therapy : A therapy given in addition to the primary or initial therapy to maximize its effectiveness.
Follow-Up Studies : Studies that continue to monitor patients after treatment to assess long-term outcomes.
Follow-Up Procedure : A procedure performed to monitor the progress of a patient after initial treatment.
Follow-Up : The act of monitoring a patient's health over time after treatment.
Neoplasm Recurrence, Local : The return of a tumor at the original site after treatment.
Recurrent Disease : A disease that has returned after a period of remission.

Relationships:-
1. Entity1: ""Adjuvant Treatment"", Entity2: ""Recurrent or Persistent Disease"", Relationship: ""prevention""
2. Entity1: ""Follow-up"", Entity2: ""Recurrent or Persistent Disease"", Relationship: ""monitoring""

Section Name: Treatment Options
====================
Entities:-
Laryngectomy : Surgical procedure to remove the larynx, often used to treat laryngeal cancer.
Total Laryngectomy : A surgical procedure to remove the entire larynx.
Chemotherapy, Adjuvant : Drug therapy given in addition to the primary treatment to enhance its effectiveness.
Induction Chemotherapy : Chemotherapy given as a first step to shrink a tumor before the main treatment.
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.
Clinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.

Relationships:-
1. Entity1: ""T3 requiring total laryngectomy"", Entity2: ""Concurrent systemic therapy/RT"", Relationship: ""treatment option""
2. Entity1: ""T3 requiring total laryngectomy"", Entity2: ""Induction chemotherapy"", Relationship: ""treatment option""
3. Entity1: ""T3 requiring total laryngectomy"", Entity2: ""Clinical trials"", Relationship: ""research option""

Causalities:-
<CO> T3 requiring (amenable to) total laryngectomy (N2–3) </CO> <A> Concurrent systemic therapy/RT </A> <A> Surgery </A> <A> Induction chemotherapy </A> <A> Clinical trials </A>

Section Name: Surgical Considerations
====================
Entities:-
Laryngectomy : Surgical procedure to remove the larynx, often used to treat laryngeal cancer.
Thyroidectomy : Surgical removal of all or part of the thyroid gland.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue in the neck.
Lymph Node Excision : Surgical removal of one or more lymph nodes.
Lymph Node Dissection : A surgical procedure to remove lymph nodes.
Lymphadenectomy : Surgical removal of one or more groups of lymph nodes.

Relationships:-
1. Entity1: ""Laryngectomy"", Entity2: ""Thyroidectomy"", Relationship: ""performed with""
2. Entity1: ""Neck Dissection"", Entity2: ""Lymph Node Excision"", Relationship: ""includes""
3. Entity1: ""Neck Dissection"", Entity2: ""Lymph Node Excision"", Relationship: ""includes specific types""

Causalities:-
<A> Laryngectomy with thyroidectomy as indicated, ipsilateral or bilateral neck dissection, and pretracheal and ipsilateral paratracheal lymph node dissection </A>

Section Name: Pathologic Features
====================
Entities:-
Extranodal Extension : The spread of cancer beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margins : Cancer cells are found at the edge of the material removed during surgery, indicating that some cancer may have been left behind.
Positive Margin : A surgical margin that contains residual tumor cells.

Relationships:-
1. Entity1: ""Adverse pathologic features"", Entity2: ""Extranodal extension"", Relationship: ""includes""
2. Entity1: ""Adverse pathologic features"", Entity2: ""Positive margin"", Relationship: ""includes""

Causalities:-
- **No adverse pathologic features**
- **Adverse pathologic features**
  - <C> Extranodal extension and/or positive margin </C>
  - Other risk features

Section Name: Systemic Therapy
====================
Entities:-
Antineoplastic Agents : Drugs used to treat cancer by inhibiting the growth of cancerous cells.
Systemic Therapy : A treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiotherapy : The use of radiation, usually high-energy X-rays, to damage cancer cells and treat cancer.
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.

Relationships:-
1. Entity1: ""Systemic therapy"", Entity2: ""RT"", Relationship: ""Consideration""

Causalities:-
<A> Systemic therapy/RT (category 1) </A>
<A> RT </A>
<A> Consider systemic therapy/RT </A>

Section Name: Imaging
====================
Entities:-
Tomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.
Magnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body's soft tissue and bones.
Neck : Part of the body, on many terrestrial or secondarily aquatic vertebrates, that distinguishes the head from the torso or trunk.
Computed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images (often called slices), both horizontally and vertically, of the body.
Neck Structure : The anatomical structure that connects the head to the torso.

Relationships:-
1. Entity1: ""CT"", Entity2: ""Neck"", Relationship: ""imaging of""
2. Entity1: ""MRI"", Entity2: ""Neck"", Relationship: ""imaging of""

Causalities:-
<A> CT (with contrast) or MRI (with and without contrast) of primary and neck </A>

Section Name: Post-Treatment Evaluation
====================
Entities:-
Radiotherapy : The use of radiation, usually high-energy X-rays, to damage cancer cells and treat cancer.
Pn1 Category : A pathological classification indicating regional lymph node metastasis in cancer staging.
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.

Relationships:-
1. Entity1: ""Post Systemic Therapy/RT or RT Neck Evaluation"", Entity2: ""pN1"", Relationship: ""evaluation of cancer staging""
2. Entity1: ""pN1"", Entity2: ""Consider RT"", Relationship: ""treatment recommendation""

Causalities:-
<CO> pN1 without other risk features </CO> <A> Consider RT </A>

Section Name: Additional Notes
====================
Entities:-
Antineoplastic Combined Chemotherapy Protocols : Protocols for the administration of more than one antineoplastic agent in combination to treat malignant neoplasms.
Cisplatin : A platinum-containing antineoplastic agent used in the treatment of various cancers.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Non-Nasopharyngeal Cancers"", Relationship: ""used for""
2. Entity1: ""Cisplatin"", Entity2: ""Systemic Therapy"", Relationship: ""preferred agent in""
3. Entity1: ""Induction Chemotherapy"", Entity2: ""Systemic Therapy"", Relationship: ""discussed in context of""

Causalities:-
- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**
- **<CO> When using concurrent systemic therapy/RT </CO>, <A> the preferred agent is cisplatin (category 1) </A>. See Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A).**
- **<A> See Discussion on induction chemotherapy. </A>**
--------------------------------------------------
Page Number: 94

Section Name: Head and Neck Cancers - Principles of Imaging
====================
Entities:-
Positron Emission Tomography Computed Tomography : A medical imaging technique combining PET and CT capabilities to provide detailed information about the body's function and structure.
Positron Emission Tomography : A nuclear medicine functional imaging technique that is used to observe metabolic processes in the body.
Computed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.
Head And Neck Neoplasms : Cancers that arise in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.

Relationships:-
1. Entity1: ""PET/CT"", Entity2: ""PET scan"", Relationship: ""preferred over""
2. Entity1: ""PET-CT"", Entity2: ""head neck cancers"", Relationship: ""used in study of""

Causalities:-
<A> PET/CT is preferred over PET scan alone (i.e., without superimposed CT scan) </A>. <C> PET/CT provides more accurate anatomical localization of abnormalities </C> <E> more accurate anatomical localization of abnormalities </E>.

Section Name: Initial Workup - Nodal Metastases
====================
Entities:-
Lymphatic Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site via the lymphatic system.
Tomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient, producing signals that are processed by the machine's computer to generate cross-sectional images.
Magnetic Resonance Imaging : A non-invasive imaging technique that uses magnetic fields and radio waves to create detailed images of the organs and tissues within the body.
Positron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption.
Lymph Node Metastasis : The spread of cancer cells to lymph nodes, which are part of the lymphatic system.
Ct Of Neck : A computed tomography scan of the neck region.
Mri Of Neck : A magnetic resonance imaging scan of the neck region.
Fdg-Pet Scan : A type of positron emission tomography using fluorodeoxyglucose to assess metabolic activity.
Computed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.
Positron Emission Tomography : A nuclear medicine functional imaging technique that is used to observe metabolic processes in the body.

Relationships:-
1. Entity1: ""CT"", Entity2: ""lymph node metastases"", Relationship: ""used to evaluate""
2. Entity1: ""MRI"", Entity2: ""lymph node metastases"", Relationship: ""used to evaluate""
3. Entity1: ""FDG-PET/CT"", Entity2: ""lymph node metastases"", Relationship: ""used for detection""
4. Entity1: ""FDG-PET/CT"", Entity2: ""surgical primary approach"", Relationship: ""used to determine""
5. Entity1: ""FDG-PET/CT"", Entity2: ""definitive RT approach"", Relationship: ""used to identify""

Causalities:-
<A> Evaluation of lymph node metastases should be conducted with CT or MRI of the neck </A>, using whichever imaging study is suitable for primary site evaluation (IMG-A, 1 of 4).
<CO> For patients with multistation or lower neck nodal involvement or high-grade tumor histology </CO>, <A> consider CT of the chest to assess for mediastinal lymph node metastases or FDG-PET/CT </A>, <C> which is associated with higher sensitivity for both nodal and distant metastases </C>.
<CO> For patients who are under consideration for a surgical primary approach </CO>, <A> the higher sensitivity of FDG-PET/CT is warranted for tumors approaching the midline, to determine the surgical approach to the contralateral neck </A>. <CO> Similarly, patients who are scheduled for a definitive RT approach </CO> <A> may benefit from the higher sensitivity of FDG-PET/CT for identifying involved lymph nodes </A>.

Section Name: Initial Workup - Distant Metastases
====================
Entities:-
Positron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption.
Magnetic Resonance Imaging : A non-invasive imaging technique that uses magnetic fields and radio waves to create detailed images of the organs and tissues within the body.
Tomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient, producing signals that are processed by the machine's computer to generate cross-sectional images.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Lung Neoplasms : Tumors or cancer of the lung.
Smoking : The inhalation of the smoke of burning tobacco encased in cigarettes, pipes, and cigars.

Relationships:-
1. Entity1: ""FDG-PET/CT"", Entity2: ""Distant Metastases"", Relationship: ""used to evaluate""
2. Entity1: ""Contrast-enhanced brain MRI"", Entity2: ""Brain Metastasis"", Relationship: ""recommended for evaluation""
3. Entity1: ""CT of the chest"", Entity2: ""Pulmonary Metastases"", Relationship: ""performed to assess""
4. Entity1: ""Non-contrast CT of the chest"", Entity2: ""Lung Parenchymal Metastases"", Relationship: ""used to screen""
5. Entity1: ""Annual CT screening"", Entity2: ""Lung Metastasis"", Relationship: ""considered for high risk""
6. Entity1: ""Directed CT or MRI"", Entity2: ""Distant Disease"", Relationship: ""used for assessment""
7. Entity1: ""FDG-PET/CT"", Entity2: ""Recurrent Disease"", Relationship: ""used for staging""

Causalities:-
<C> Patients with locoregionally advanced cancer (e.g., T3–T4 primary or ≥N1 nodal staging) </C>, <A> FDG-PET/CT is preferred to evaluate for distant disease and thoracic metastases </A>. <CO> For cancers where brain metastasis is a concern, such as mucosal melanoma or high-grade neuroendocrine carcinomas or adenocarcinomas </CO>, <A> contrast-enhanced brain MRI should be additionally obtained </A>.
<CO> If FDG-PET/CT is not performed </CO>, <A> CT of the chest should be performed to assess for presence of pulmonary metastases as well as mediastinal lymph node involvement </A>.
<CO> Non-contrast CT of the chest can be sufficient to screen for lung parenchymal metastases </CO> but <CO> is not adequate for assessment of mediastinal adenopathy </CO>. <CO> This is an appropriate lung cancer screening intervention for patients with a history of smoking </CO>.
<CO> Following primary definitive treatment (surgery, RT, or systemic therapy/RT) </CO> the role of annual CT screening for lung metastasis is controversial. <E> While this approach does detect early metastasis </E>, <CO> further study is needed to determine the extent of the positive effect and/or cost-effectiveness of this approach in specific subpopulations and timepoints post-treatment </CO>. <CO> For patients with a substantial smoking history or who are at high risk for lung metastases </CO>, <A> annual chest CT can be considered </A>.
<CO> If clinical concern for metastatic disease is confined to a specific anatomical area </CO>, <A> the assessment of distant disease can be performed with directed CT or MRI examination </A>.
<CO> FDG-PET/CT may complement or replace other imaging modalities when staging recurrent disease before any therapy for relapsed/refractory disease </CO> <A> in order to explore distant disease or second primaries that may significantly impact choice of therapy </A>.
--------------------------------------------------
Page Number: 92

Section Name: NCCN Guidelines Overview
====================
Entities:-
Head And Neck Neoplasms : Cancers that arise in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Malignant Neoplasm Of Head And Neck : A malignant tumor located in the head and neck region.
Head And Neck Cancer : A group of cancers that originate in the head and neck region.
Antineoplastic Agents : Drugs used to treat cancer by inhibiting the growth of cancerous cells.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.
Radiation Therapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.

Relationships:-
1. Entity1: ""Head and neck cancers"", Entity2: ""Systemic therapy"", Relationship: ""follow-up recommendations after""
2. Entity1: ""Head and neck cancers"", Entity2: ""Radiation therapy"", Relationship: ""follow-up recommendations after""

Causalities:-
The image presents a flowchart from the National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2024, especially focusing on <A> follow-up recommendations </A> for <CO> patients with head and neck cancers after systemic therapy or radiation therapy (RT) </CO>. All recommendations are categorized as level A unless stated otherwise, highlighting the importance of clinical trials in cancer management.

Section Name: Imaging and Assessment Protocols
====================
Entities:-
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.
Clinical Assessment : A systematic evaluation of a patient's health status, often involving a physical examination and medical history.
Positron-Emission Tomography : An imaging technique using a radioactive substance called a tracer to look for disease in the body.
Computed Tomography : A medical imaging technique used in radiology to obtain detailed internal images of the body.
Magnetic Resonance Imaging : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis.
Disease : A disorder of structure or function in a human, animal, or plant, especially one that produces specific symptoms.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.
Residual Neoplasm : Remaining cancer cells after treatment.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Clinical Assessment"", Relationship: ""occurs before""
2. Entity1: ""FDG-PET/CT Scan"", Entity2: ""Distant Metastases"", Relationship: ""assesses""
3. Entity1: ""FDG-PET/CT Scan"", Entity2: ""Observation"", Relationship: ""leads to if negative""
4. Entity1: ""FDG-PET/CT Scan"", Entity2: ""CT Scan"", Relationship: ""leads to if strongly positive""
5. Entity1: ""CT Scan"", Entity2: ""Neck Dissection"", Relationship: ""leads to if positive""

Causalities:-
<CO> After systemic therapy or RT </CO>, <A> a clinical assessment should occur 4 to 8 weeks later </A>. <CO> If there is a response </CO>, <A> it is necessary to assess the extent of disease or distant metastases, preferably through a FDG-PET/CT scan at a minimum of 12 weeks post-treatment </A>. <CO> If the FDG-PET/CT results are negative </CO>, <A> the patient may continue with monitoring through observation </A>. <CO> In cases where the results are equivocal </CO>, <A> observation or repeat FDG-PET/CT within 3 to 6 months is prescribed </A>.

<CO> In cases where the FDG-PET/CT results are strongly positive </CO>, <A> further imaging via CT scan with contrast of the primary site and neck, or MRI with and without contrast, becomes necessary </A>. <CO> If these imaging results confirm positive findings </CO>, <A> neck dissection may be considered, depending on the evidence of residual or persistent disease </A>. <CO> If the imaging findings are negative </CO>, <A> the patient might continue in observation </A>.

Section Name: Outcomes Based on Disease Resectability
====================
Entities:-
Disease : A disorder of structure or function in a human, animal, or plant, especially one that produces specific symptoms.
Resectable : Capable of being surgically removed.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis.

Relationships:-
1. Entity1: ""Disease"", Entity2: ""Resectable"", Relationship: ""Classification""
2. Entity1: ""Unresectable"", Entity2: ""Treatment plans (ADV-3)"", Relationship: ""Treatment recommendation""
3. Entity1: ""Resectable"", Entity2: ""Resection and/or Neck dissection"", Relationship: ""Surgical procedure""

Causalities:-
<CO> If there is confirmed residual or persistent disease </CO>, the options split into two pathways: 'Unresectable' or 'Resectable.' <CO> If the disease is classified as unresectable </CO>, <A> advances in treatment plans (labeled ADV-3) are called for </A>. Conversely, <CO> if it is deemed resectable </CO>, <A> a resection of the primary and/or neck dissection may occur </A>, <CO> contingent upon the disease status </CO>.

Section Name: Important Notes
====================
Entities:-
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.
Clinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.
Positron-Emission Tomography : An imaging technique using a radioactive substance called a tracer to look for disease in the body.
Positron Emission Tomography (Procedure) : A diagnostic imaging procedure that uses a radioactive tracer to visualize and measure changes in metabolic processes.
Positron Emission Tomography : A nuclear medicine functional imaging technique used to observe metabolic processes in the body.
Neoplasms : New abnormal growth of tissue in animals or plants; a tumor.
Malignant Neoplasm : A cancerous growth that has the potential to spread to other parts of the body.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""NCCN"", Entity2: ""Clinical trials"", Relationship: ""emphasizes participation in""
2. Entity1: ""FDG-PET/CT"", Entity2: ""Persistent cancer"", Relationship: ""used to detect""
3. Entity1: ""FDG-PET/CT"", Entity2: ""PET negative"", Relationship: ""interpretation of results""
4. Entity1: ""FDG-PET/CT"", Entity2: ""PET positive"", Relationship: ""interpretation of results""

Causalities:-
<A> NCCN emphasizes that the best management for any cancer patient is participation in clinical trials </A>, especially encouraged for all patients. Additional notes clarify that <CO> if the FDG-PET/CT is negative for persistent cancer </CO>, <A> further cross-sectional imaging is optional </A>. The interpretations define <CO> PET negative as no or low-grade uptake not suspicious for disease </CO>, while <CO> PET positive implies suspicion for disease </CO>.


Among these two options which one is the most likely true:

(A) `Location_of_Involved_Lymph_Nodes_4` increases risk `Computerized_Tomography_CT_12`
(B) `Computerized_Tomography_CT_12` `increases risk `Location_of_Involved_Lymph_Nodes_4`

The answer is: ...

1. State the evidences in detail of the validity of option (A) or (B) by cross referencing
NCCN Clinical Practitioner’s Guidelines for Head and Neck Cancer.
2. If the evidences are obtained from `INFORMATION FROM KNOWLEDGE BASE`,
mention their corresponding Page Numbers, Section Name, entities, relationships and causalities.

DESIRED OUTPUT FORMAT:
<thinking>
...
</thinking>
<answer>
{
   ""thinking"": [""..."", ...],
   ""evidences"": [""..."", ...],
   ""answer"": ...
}
</answer>

Before providing the answer in <answer> tags, think step by step in detail in <thinking> tags and analyze every part.
Output inside <answer> tag in JSON format. Only output valid JSON.
DO NOT HALLUCINATE. DO NOT MAKE UP FACTUAL INFORMATION.
","1. The edge in question is between 'Location_of_Involved_Lymph_Nodes_4' and 'Computerized_Tomography_CT_12'.
2. Option (A) suggests that the location of involved lymph nodes increases the risk of certain CT scan results. This implies a causal relationship where the lymph node location affects the CT scan findings.
3. Option (B) suggests that the CT scan results increase the risk of lymph node involvement, implying that the diagnostic results influence the physical state of the lymph nodes.
4. From the knowledge base, CT scans are diagnostic tools used to observe and report on the state of lymph node involvement, not to influence or change their state.
5. The NCCN guidelines emphasize the role of imaging, such as CT scans, in evaluating the extent of disease spread, not in causing or influencing the physical state of lymph nodes.
6. The causal relationship in option (A) is more aligned with the role of CT scans as diagnostic tools that report on existing conditions rather than influencing them.
","1. Page Number: 93, Section Name: PRINCIPLES OF IMAGING - CT scans are used for clinical analysis and medical intervention, not as causal factors for lymph node involvement.
2. Page Number: 94, Section Name: Head and Neck Cancers - Principles of Imaging - CT scans are used to provide detailed information about the body's function and structure, not to influence it.
3. Page Number: 92, Section Name: NCCN Guidelines Overview - Imaging is used for follow-up recommendations after systemic therapy or radiation therapy, indicating its role in observation rather than causation.
",A,"{'A': 99.87, 'B': 0.13}",yes,A,"1. The AI assistant's reasoning revolves around the causal relationship between the location of lymph nodes and CT scan results.
2. Option (A) suggests that the location of involved lymph nodes increases the risk of certain CT scan results, implying a causal relationship where the lymph node location affects the CT scan findings.
3. Option (B) suggests that the CT scan results increase the risk of lymph node involvement, implying that the diagnostic results influence the physical state of the lymph nodes.
4. The AI assistant correctly identifies that CT scans are diagnostic tools used to observe and report on the state of lymph node involvement, not to influence or change their state.
5. The NCCN guidelines emphasize the role of imaging, such as CT scans, in evaluating the extent of disease spread, not in causing or influencing the physical state of lymph nodes.
6. The AI assistant's conclusion that option (A) is more aligned with the role of CT scans as diagnostic tools that report on existing conditions rather than influencing them is consistent with the provided evidence.
"
5,gpt-4o,"Location_of_Involved_Lymph_Nodes_4,Examination_13","""{'NODE1': {'id': 'Location_of_Involved_Lymph_Nodes_4', 'label': 'Position of Affected Lymph Nodes in Patient', 'description': \""This node represents the location of lymph nodes that are involved or affected in a patient's condition. Understanding whether the lymph nodes are ipsilateral, bilateral, or contralateral is crucial for determining the extent of disease spread and planning appropriate treatment strategies.\"", 'type': 'Patient Situation', 'observability': 'Unobserved', 'states': [{'state_name': 'ipsilateral', 'state_description': 'The involved lymph nodes are on the same side of the body as the primary tumor or reference point. This can indicate localized spread of disease.'}, {'state_name': 'bilateral', 'state_description': 'The involved lymph nodes are on both sides of the body. This may suggest a more extensive spread of disease and can impact treatment decisions.'}, {'state_name': 'contralateral', 'state_description': 'The involved lymph nodes are on the opposite side of the body from the primary tumor or reference point. This can indicate metastatic spread and may affect staging and treatment planning.'}]}, 'NODE2': {'id': 'Examination_13', 'label': 'Diagnostic Examination Result', 'description': 'This node represents the result of a diagnostic examination focused on identifying patterns of lymph node metastasis, which is crucial for cancer staging and determining the appropriate treatment strategy.', 'type': 'Examination Result', 'observability': 'Observed', 'states': [{'state_name': 'bilateral_lymph_node_metastasis', 'state_description': 'Metastasis is present in lymph nodes on both sides of the body, indicating a more advanced spread of cancer.'}, {'state_name': 'ipsilateral_lymph_node_metastasis', 'state_description': 'Metastasis is present in lymph nodes on the same side of the body as the primary tumor, suggesting a localized spread.'}, {'state_name': 'contralateral_lymph_node_metastasis', 'state_description': 'Metastasis is present in lymph nodes on the opposite side of the body from the primary tumor, indicating a more extensive spread of cancer.'}]}, 'EDGE1': {'edges_ids': ['Location_of_Involved_Lymph_Nodes_4', 'Examination_13'], 'edge': '(Location_of_Involved_Lymph_Nodes_4) causes (Examination_13)', 'explanation': ['The edge represents the causal relationship between the position of involved lymph nodes and the results of a diagnostic examination.', 'The `Location_of_Involved_Lymph_Nodes_4` node describes the position of lymph nodes (ipsilateral, bilateral, contralateral) in a patient.', \""The 'Examination_13' node describes the result of a diagnostic examination that identifies patterns of lymph node metastasis.\"", 'The position of involved lymph nodes directly influences the examination results, as the examination is designed to detect these patterns.', 'Therefore, the edge is valid as the location of lymph nodes can cause the examination to show corresponding metastasis patterns.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': True}, 'causal_distance': 'Proximal'}, 'EDGE2': {'edges_ids': ['Examination_13', 'Location_of_Involved_Lymph_Nodes_4'], 'edge': '(Examination_13) causes (Location_of_Involved_Lymph_Nodes_4)', 'explanation': ['The edge represents the causal relationship where the result of a diagnostic examination (Examination_13) determines the location of involved lymph nodes (Location_of_Involved_Lymph_Nodes_4).', 'Examination_13 provides information about the presence and pattern of lymph node metastasis, which directly informs the location of involved lymph nodes.', 'The causal direction is positive because the examination result directly influences the determination of lymph node location.', 'The examination result is necessary for determining the lymph node location, but not sufficient by itself, as other clinical factors may also play a role.', 'The causal distance is proximal because the examination result directly informs the location of involved lymph nodes.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': True, 'sufficient': False}, 'causal_distance': 'Proximal'}, 'ENTITIES_MATCHING_PAGES_INFO': {'51': {'matching_entities': [{'LYMPHATIC METASTASIS': 0.9638432}, {'CLINICAL TRIALS': 0.9367982}, {'CLINICAL TRIALS AS TOPIC': 0.9333815}, {'RESPONSE EVALUATION': 0.9307092}, {'FOLLOW-UP PROCEDURE': 0.9293796}, {'SURGICAL PROCEDURE': 0.9255254}, {'SURGERY': 0.9254029}, {'RESPONSE TO TREATMENT': 0.9204324}], 'count': 8}, '70': {'matching_entities': [{'NEOPLASM METASTASIS': 0.95823944}, {'CLINICAL TRIALS': 0.9367982}, {'CLINICAL TRIALS AS TOPIC': 0.9333815}, {'BIOMARKERS': 0.9266646}, {'BIOMARKER': 0.9259977}, {'SUPPORTIVE CARE': 0.92568463}, {'SURGICAL PROCEDURE': 0.9255254}, {'SURGERY': 0.9254029}], 'count': 8}, '55': {'matching_entities': [{'NEOPLASM METASTASIS': 0.95823944}, {'METASTATIC NEOPLASM': 0.9350836}, {'CLINICAL TRIALS AS TOPIC': 0.9333815}, {'FOLLOW-UP PROCEDURE': 0.9293796}, {'METASTASIS': 0.9265935}, {'SURGICAL PROCEDURE': 0.9255254}, {'SURGERY': 0.9254029}], 'count': 7}, '68': {'matching_entities': [{'NEOPLASM METASTASIS': 0.95823944}, {'DIAGNOSIS': 0.9335496}, {'CLINICAL TRIALS AS TOPIC': 0.9333815}, {'METASTASIS': 0.9265935}, {'SUPPORTIVE CARE': 0.92568463}, {'SURGICAL PROCEDURE': 0.9255254}, {'SURGERY': 0.9254029}], 'count': 7}, '53': {'matching_entities': [{'CLINICAL TRIALS AS TOPIC': 0.9333815}, {'FOLLOW-UP PROCEDURE': 0.9293796}, {'TREATMENT STRATEGIES': 0.92767245}, {'IMAGING': 0.9261862}, {'SURGICAL PROCEDURE': 0.9255254}, {'FOLLOW-UP EVALUATIONS': 0.9244507}], 'count': 6}}, 'GUIDELINE_PAGES_INFO': '--------------------------------------------------\\nPage Number: 51\\n\\nSection Name: Introduction\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nMalignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.\\nSupraglottic Laryngeal Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is above the vocal cords.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network (NCCN)\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""provides guidelines for\""\\n2. Entity1: \""healthcare professionals\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""manage\""\\n\\nCausalities:-\\nThe provided image is a detailed flowchart from the National Comprehensive Cancer Network (NCCN) guidelines regarding the <C> clinical staging and treatment protocols for cancer of the supraglottic larynx </C>. This flowchart is structured to <A> guide healthcare professionals through the stages of treatment </A> based on <CO> clinical findings </CO>, emphasizing the <E> complexity and systematic approach required in managing this type of cancer </E>.\\n\\nSection Name: Clinical Staging\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nTotal Laryngectomy : A surgical procedure to remove the entire larynx, often used in the treatment of advanced laryngeal cancer.\\nNeoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.\\nCancer Staging : The process of determining the extent of cancer in the body, often using the TNM system.\\nTnm Staging System : A cancer staging system that describes the extent of cancer using Tumor size (T), Node involvement (N), and Metastasis (M).\\n\\nRelationships:-\\n1. Entity1: \""Clinical staging criteria\"", Entity2: \""Total laryngectomy\"", Relationship: \""determines necessity of\""\\n2. Entity1: \""T3, N0\"", Entity2: \""Clinical staging criteria\"", Relationship: \""is a categorization of\""\\n\\nCausalities:-\\nThe flowchart begins with the <C> clinical staging criteria </C>, specifically focusing on <CO> cases that require total laryngectomy, denoted as requiring (amenable to) total laryngectomy (T3, N0) </CO>. This <A> categorization </A> is crucial as it <E> forms the basis for determining the appropriate treatment strategy </E>.\\n\\nSection Name: Treatment of Primary and Neck\\n====================\\nEntities:-\\nNeoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.\\nLymphatic Metastasis : Transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Radiation Therapy\"", Relationship: \""combined with\""\\n2. Entity1: \""Laryngectomy\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n3. Entity1: \""Thyroidectomy\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n4. Entity1: \""Neck Dissection\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n\\nCausalities:-\\n<CO> Once clinical staging is established </CO>, the chart outlines various treatment options. <A> The initial step may involve either concurrent systemic therapy combined with radiation therapy (RT) or opting for RT alone </A>, <CO> especially if the patient is not a medical candidate for both therapies </CO>. <A> Laryngectomy, thyroidectomy, and neck dissection are considered </A> <CO> based on the extent of lymph node involvement </CO>.\\n\\nSection Name: Surgical Options\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nLymph Node Excision : Surgical removal of one or more lymph nodes.\\nLymphadenectomy : Surgical removal of one or more groups of lymph nodes.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""Laryngectomy\"", Entity2: \""Thyroidectomy\"", Relationship: \""combined with\""\\n2. Entity1: \""Lymph Node Dissection\"", Entity2: \""Surgical Intervention\"", Relationship: \""extent of\""\\n3. Entity1: \""Surgical Intervention\"", Entity2: \""Advanced Cases\"", Relationship: \""management option for\""\\n\\nCausalities:-\\n<CO> If concurrent therapies are not suitable </CO>, <A> the chart presents laryngectomy combined with thyroidectomy </A>, <CO> depending on the extent of lymph node dissection required </CO>. <E> This highlights surgical intervention as a viable option in the management of advanced cases </E>.\\n\\nSection Name: Induction Chemotherapy\\n====================\\nEntities:-\\nInduction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nTherapeutic Approach : A method or strategy used in the treatment of disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""Induction Chemotherapy\"", Entity2: \""Surgical Intervention\"", Relationship: \""alternative or sequential treatment option\""\\n\\nCausalities:-\\n<C> immediate surgical intervention is either not feasible or considered insufficient </C> <E> The flowchart also considers the option of induction chemotherapy </E> <CO> in cases where immediate surgical intervention is either not feasible or considered insufficient </CO>. <A> tailoring therapeutic approaches tailored to individual patient needs </A>.\\n\\nSection Name: Adjuvant Treatment\\n====================\\nEntities:-\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nNeoplasm Recurrence, Local : The return of a cancer, at the same site, after it has been treated.\\nDisease Progression : The worsening of a disease over time.\\n\\nRelationships:-\\n1. Entity1: \""Primary Treatment\"", Entity2: \""Adjuvant Treatment\"", Relationship: \""followed by\""\\n2. Entity1: \""Adjuvant Treatment\"", Entity2: \""Systemic Therapy\"", Relationship: \""includes\""\\n3. Entity1: \""Adjuvant Treatment\"", Entity2: \""Radiotherapy\"", Relationship: \""includes\""\\n4. Entity1: \""Follow-up Assessments\"", Entity2: \""Treatment Efficacy\"", Relationship: \""used to evaluate\""\\n\\nCausalities:-\\n<C> Following primary treatment </C>, <E> the flowchart addresses the potential for adjuvant treatment pathways </E>. This may include systemic therapy, RT, or further evaluations based on <CO> the patient\\'s response and any recurrence or persistent disease </CO>. It emphasizes <A> the need for follow-up assessments to evaluate treatment efficacy </A>.\\n\\nSection Name: Risk Features and Response Assessment\\n====================\\nEntities:-\\nNeoplasm Invasiveness : The property of a neoplasm to infiltrate and destroy surrounding tissue.\\nSurgical Margins : The edge or border of the tissue removed in cancer surgery.\\nNeoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.\\nExtramural Extension : Extension of a tumor beyond the wall of an organ.\\nPositive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.\\nCancer Management : The process of planning and coordinating the treatment of cancer.\\nCancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""Extramural extension\"", Entity2: \""Treatment decisions\"", Relationship: \""influences\""\\n2. Entity1: \""Positive surgical margin\"", Entity2: \""Treatment decisions\"", Relationship: \""influences\""\\n3. Entity1: \""Ongoing assessment\"", Entity2: \""Response evaluation\"", Relationship: \""leads to\""\\n4. Entity1: \""Response evaluation\"", Entity2: \""Adjustments to treatment\"", Relationship: \""leads to\""\\n5. Entity1: \""Management of cancer\"", Entity2: \""Treatment decisions\"", Relationship: \""involves\""\\n6. Entity1: \""Management of cancer\"", Entity2: \""Ongoing assessment\"", Relationship: \""involves\""\\n7. Entity1: \""Management of cancer\"", Entity2: \""Adjustments to treatment\"", Relationship: \""involves\""\\n\\nCausalities:-\\nThe chart incorporates a segment that takes into account <CO> adverse pathologic features, such as extramural extension or positive margins </CO>, <E> which could influence subsequent treatment decisions </E>. This highlights the importance of <A> ongoing assessment in the management of cancer, leading to response evaluation and adjustments to treatment as necessary </A>.\\n\\nSection Name: NCCN Guidelines Version 4.2024\\n====================\\nEntities:-\\nClinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.\\nNeoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.\\nClinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nMalignant Neoplasm : A malignant neoplasm is a cancerous growth that has the potential to invade and destroy nearby tissue and spread to other parts of the body.\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nCancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network\"", Entity2: \""NCCN Guidelines\"", Relationship: \""provides\""\\n2. Entity1: \""NCCN Guidelines\"", Entity2: \""Clinical Trials\"", Relationship: \""recommend\""\\n3. Entity1: \""NCCN Guidelines\"", Entity2: \""Cancer\"", Relationship: \""related to management of\""\\n\\nCausalities:-\\n<CO> any patient with cancer </CO> <A> the best management is in a clinical trial </A>. <A> Participation in clinical trials is especially encouraged </A>.\\n\\nSection Name: SUPRA-3\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.\\nChemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nClinical Trials As Topic : Research studies that prospectively assign human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nInduction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.\\nClinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\n\\nRelationships:-\\n1. Entity1: \""Total laryngectomy\"", Entity2: \""Laryngectomy\"", Relationship: \""is a type of\""\\n2. Entity1: \""Systemic therapy\"", Entity2: \""RT\"", Relationship: \""concurrent treatment option\""\\n3. Entity1: \""Induction chemotherapy\"", Entity2: \""Other treatments\"", Relationship: \""initial treatment option before\""\\n\\nCausalities:-\\n<CO> Requiring (amenable to) total laryngectomy (T3,N0) </CO>\\n  - <A> Concurrent systemic therapy/RT </A> or <A> RT if patient not medical candidate for concurrent systemic therapy/RT </A>\\n  - <A> Laryngectomy, thyroidectomy and with ipsilateral, central, or bilateral neck dissection </A>\\n  - or\\n  - <A> Induction chemotherapy </A>\\n  - or\\n  - <A> Clinical trials </A>\\n\\nSection Name: Follow-up\\n====================\\nEntities:-\\nFollow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.\\nFollow-Up Procedure : A procedure performed to monitor the progress of a patient\\'s condition after initial treatment.\\nFollow-Up : Medical care given to a patient over time after initial treatment.\\nDisease Recurrence : The return of a sign, symptom, or disease after a remission.\\nRecurrent Disease : The reappearance of a disease after a period of improvement.\\n\\nRelationships:-\\n1. Entity1: \""Follow-up\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""monitoring\""\\n\\nCausalities:-\\n- **Follow-up (FOLL-A, 1 of 2)**\\n  - <CO> Recurrent or persistent disease </CO> (ADV-3)\\n\\nSection Name: Adverse Pathologic Features\\n====================\\nEntities:-\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nExtranodal Extension : The spread of cancer beyond the lymph node capsule.\\nPositive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""pN1\"", Entity2: \""Radiotherapy\"", Relationship: \""Consideration for treatment\""\\n2. Entity1: \""Extranodal extension\"", Entity2: \""Systemic Therapy\"", Relationship: \""Treatment option\""\\n3. Entity1: \""Extranodal extension\"", Entity2: \""Radiotherapy\"", Relationship: \""Treatment option\""\\n4. Entity1: \""Positive surgical margin\"", Entity2: \""Systemic Therapy\"", Relationship: \""Treatment option\""\\n5. Entity1: \""Positive surgical margin\"", Entity2: \""Radiotherapy\"", Relationship: \""Treatment option\""\\n\\nCausalities:-\\n- <CO>pN1 without other risk features</CO>\\n  - <C>Adverse pathologic features</C>\\n  - <A>Consider RT</A>\\n  - <CO>Extranodal extension and/or positive margin</CO>\\n  - <CO>Other risk features</CO>\\n  - <A>Systemic therapy/RT (category 1)</A>\\n  - <A>RT or Consider systemic therapy/RT</A>\\n\\nSection Name: Response Assessment\\n====================\\nEntities:-\\nResponse Evaluation : The process of assessing the response of a disease to treatment, often used in clinical trials to determine the effectiveness of a therapy.\\nResponse To Treatment : A clinical finding indicating the response of a condition to a therapeutic intervention.\\n\\nRelationships:-\\n\\nSection Name: Principles of Surgery and Radiation Therapy\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nRadiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\n\\nRelationships:-\\n1. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Radiation Therapy\"", Relationship: \""complementary treatments\""\\n\\nCausalities:-\\n**Principles of Surgery (SURG-A).**\\n\\n**Principles of Radiation Therapy (SUPRA-A).**\\n\\nSection Name: Principles of Systemic Therapy\\n====================\\nEntities:-\\nCisplatin : An inorganic and water-soluble platinum complex, cisplatin is an antineoplastic agent that is used in the treatment of various cancers.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nRadiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\n\\nRelationships:-\\n1. Entity1: \""Cisplatin\"", Entity2: \""Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""preferred agent\""\\n2. Entity1: \""Cisplatin\"", Entity2: \""Concurrent Systemic Therapy/RT\"", Relationship: \""used in\""\\n\\nCausalities:-\\n<CO> When using concurrent systemic therapy/RT </CO>, <A> the preferred agent is cisplatin (category 1) </A>.\\n--------------------------------------------------\\nPage Number: 70\\n\\nSection Name: Diagnosis\\n====================\\nEntities:-\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nClinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nPersonalized Medicine : A medical model that proposes the customization of healthcare, with medical decisions, practices, and/or products being tailored to the individual patient.\\n\\nRelationships:-\\n1. Entity1: \""recurrent or persistent disease\"", Entity2: \""distant metastases\"", Relationship: \""has condition\""\\n2. Entity1: \""Clinical trials\"", Entity2: \""recurrent or persistent disease with distant metastases\"", Relationship: \""recommended for\""\\n3. Entity1: \""locoregional failure\"", Entity2: \""locoregional treatment\"", Relationship: \""treatment response to\""\\n\\nCausalities:-\\nIn the **Diagnosis** section, the focus is on <C> recurrent or persistent disease with distant metastases </C>. <A> Clinical trials are preferred </A> for <CO> patients diagnosed at this stage </CO>. <CO> If there is locoregional failure </CO>, <A> locoregional treatment should be considered based on the extent of the disease and symptoms presented </A>. This highlights the importance of personalized treatment approaches, taking into account the unique circumstances of each patient.\\n\\nSection Name: Treatment\\n====================\\nEntities:-\\nTherapeutics : The branch of medicine concerned with the treatment of disease and the action of remedial agents.\\nPerformance Status : A measure of how well a patient is able to perform ordinary tasks and carry out daily activities.\\nSystemic Therapy : A type of treatment that uses substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nPalliative Care : An interdisciplinary medical caregiving approach aimed at optimizing quality of life and mitigating suffering among people with serious, complex illness.\\nRadiation Therapy : The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\n\\nRelationships:-\\n1. Entity1: \""Performance Status\"", Entity2: \""Systemic Therapy\"", Relationship: \""Treatment option for PS 0-1, PS 2, and PS 3 patients\""\\n2. Entity1: \""Performance Status\"", Entity2: \""Surgery\"", Relationship: \""Treatment option for PS 0-1 patients\""\\n3. Entity1: \""Performance Status\"", Entity2: \""Best Supportive Care\"", Relationship: \""Treatment option for PS 0-1 and PS 3 patients\""\\n4. Entity1: \""Performance Status\"", Entity2: \""Palliative Treatments\"", Relationship: \""Treatment option for PS 2 and PS 3 patients\""\\n5. Entity1: \""Performance Status\"", Entity2: \""Radiation Therapy\"", Relationship: \""Consideration for PS 3 patients\""\\n\\nCausalities:-\\nThe <C> Treatment section </C> outlines pathways based on <C> performance status (PS) </C>. For <CO> PS 0-1 patients </CO>, <A> options include combination systemic therapy, single-agent systemic therapy, surgery, or best supportive care for those with limited metastases </A>. For <CO> PS 2 patients </CO>, <A> recommendations include single-agent systemic therapy, supportive care, or palliative treatments </A>. For <CO> PS 3 patients </CO>, <A> the focus is on single-agent therapy and best supportive care, with consideration of palliative radiation therapy (RT) and palliative surgery </A>. This section addresses the evolving needs of patients as their <C> performance status declines </C>.\\n\\nSection Name: Persistent Disease or Progression\\n====================\\nEntities:-\\nDisease Progression : The worsening of a disease over time.\\nSystemic Therapy : A type of treatment that uses substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nClinical Trials : Research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.\\nPalliative Care : An interdisciplinary medical caregiving approach aimed at optimizing quality of life and mitigating suffering among people with serious, complex illness.\\nQuality Of Life : An individual\\'s overall appraisal of their situation and well-being.\\nSupportive Care : Care given to improve the quality of life of patients who have a serious or life-threatening disease.\\n\\nRelationships:-\\n1. Entity1: \""Persistent Disease or Progression\"", Entity2: \""Systemic Therapy\"", Relationship: \""option for management\""\\n2. Entity1: \""Persistent Disease or Progression\"", Entity2: \""Clinical Trials\"", Relationship: \""option for management\""\\n3. Entity1: \""Persistent Disease or Progression\"", Entity2: \""Palliative Care\"", Relationship: \""option for management\""\\n4. Entity1: \""Best Supportive Care\"", Entity2: \""Quality of Life\"", Relationship: \""improves\""\\n5. Entity1: \""Best Supportive Care\"", Entity2: \""Advanced Illness\"", Relationship: \""applied in context of\""\\n\\nCausalities:-\\n<A> continued evaluation of treatment efficacy </A> is reiterated. <A> Options include systemic therapy, clinical trials, or palliative care </A> <CO> based on the specific patient condition </CO>. <A> Best supportive care is emphasized </A>, <E> prioritizing the patient\\'s quality of life </E>, <CO> particularly in the context of advanced illness </CO>.\\n\\nSection Name: NCCN Guidelines Overview\\n====================\\nEntities:-\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\nClinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nNeoplasms : New abnormal growth of tissue that may be benign or malignant.\\nMalignant Neoplastic Disease : A disease in which abnormal cells divide uncontrollably and destroy body tissue.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""cancer\"", Entity2: \""clinical trial\"", Relationship: \""best management through\""\\n\\nCausalities:-\\n<CO> any patient with cancer </CO> <A> Participation in clinical trials is especially encouraged </A>.\\n\\nSection Name: Principles and Considerations\\n====================\\nEntities:-\\nRadiation Therapy : The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nSurgery : A medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nSurgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nGenomic Profiling : The measurement of the activity (the expression) of thousands of genes at once, to create a global picture of cellular function.\\nBiomarkers : Biological molecules found in blood, other body fluids, or tissues that are a sign of a normal or abnormal process, or of a condition or disease.\\nBiomarker : A biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease.\\nPalliative Care : An interdisciplinary medical caregiving approach aimed at optimizing quality of life and mitigating suffering among people with serious, complex illness.\\nBone Neoplasms : Tumors or cancer of the bone.\\nBone Metastasis : The spread of cancer cells from their original site to a bone.\\n\\nRelationships:-\\n1. Entity1: \""Palliative RT\"", Entity2: \""Bone Metastases\"", Relationship: \""treatment for\""\\n\\nCausalities:-\\n- **Principles of Radiation Therapy (ADV-A).**\\n- **Principles of Surgery (SURG-A).**\\n<A> Consider NGS genomic profiling for biomarker identification. </A>\\n<A> Consider palliative RT </A> <CO> as clinically indicated (e.g., bone metastases) </CO> (RAD-A).\\n- See Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A) or Systemic Therapy for Nasopharyngeal Cancers (NASO-B).\\n--------------------------------------------------\\nPage Number: 55\\n\\nSection Name: General Information\\n====================\\nEntities:-\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nNccn Guidelines : Clinical practice guidelines in oncology developed by the National Comprehensive Cancer Network.\\n\\nRelationships:-\\n1. Entity1: \""NCCN Guidelines\"", Entity2: \""National Comprehensive Cancer Network\"", Relationship: \""produced by\""\\n\\nSection Name: Important Notes\\n====================\\nEntities:-\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medical, surgical, or behavioral interventions.\\nClinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nNeoplasms : New abnormal growth of tissue that can be benign or malignant.\\nMalignant Neoplastic Disease : A disease resulting from the growth of malignant neoplasms.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""Clinical Trials\"", Entity2: \""Cancer\"", Relationship: \""recommended for\""\\n2. Entity1: \""NCCN\"", Entity2: \""Clinical Trials\"", Relationship: \""encourages participation in\""\\n\\nCausalities:-\\n<C> NCCN believes that the best management of any patient with cancer is in a clinical trial </C>. <A> Participation in clinical trials is especially encouraged </A>.\\n\\nSection Name: Principles\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nChemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.\\n\\nRelationships:-\\n1. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Radiation Therapy\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n2. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n3. Entity1: \""Principles of Radiation Therapy\"", Entity2: \""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n\\nCausalities:-\\n### Principles\\n\\n- **Principles of Surgery (SURG-A)**\\n- **Principles of Radiation Therapy (SUPRA-A)**\\n- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**\\n\\nSection Name: Adverse Pathologic Features\\n====================\\nEntities:-\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.\\nPerineural Invasion : The presence of cancer cells surrounding or tracking along a nerve within the perineural space.\\nVascular Invasion : The invasion of cancer cells into blood vessels.\\nLymphatic Invasion : The invasion of cancer cells into lymphatic vessels.\\n\\nRelationships:-\\n1. Entity1: \""Extranodal extension\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n2. Entity1: \""Positive margins\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n3. Entity1: \""Close margins\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n4. Entity1: \""pT3 or pT4 primary\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n5. Entity1: \""pN2 or pN3 nodal disease\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n6. Entity1: \""Perineural invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n7. Entity1: \""Vascular invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n8. Entity1: \""Lymphatic invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n\\nCausalities:-\\n<C> Extranodal extension </C>\\n<C> Positive margins </C>\\n<C> Close margins </C>\\n<C> pT3 or pT4 primary </C>\\n<C> pN2 or pN3 nodal disease </C>\\n<C> Perineural invasion </C>\\n<C> Vascular invasion </C>\\n<C> Lymphatic invasion </C>\\n\\nSection Name: Response Assessment\\n====================\\nEntities:-\\nChemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nPrimary Site : The original location where a tumor or cancer begins.\\nComplete Remission : The disappearance of all signs of cancer in response to treatment.\\nPartial Remission : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.\\nRadiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""induction chemotherapy\"", Entity2: \""Primary site\"", Relationship: \""treatment outcome\""\\n2. Entity1: \""Definitive RT\"", Entity2: \""Primary site\"", Relationship: \""treatment option\""\\n3. Entity1: \""RT\"", Entity2: \""Primary site\"", Relationship: \""treatment option\""\\n4. Entity1: \""Surgery\"", Entity2: \""unresectable nodal disease\"", Relationship: \""treatment option\""\\n\\nCausalities:-\\n<C> Response after induction chemotherapy </C>: <E> Primary site: CR </E> <E> Primary site: PR </E> <E> Primary site: < PR </E> <A> Definitive RT </A> (category 1) <A> RT </A> (category 1) or <A> systemic therapy/RT </A> (category 2B) <A> Surgery </A> or <A> unresectable nodal disease </A>\\n\\nSection Name: Follow-up\\n====================\\nEntities:-\\nFollow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.\\nFollow-Up Procedure : A procedure where a patient is monitored over time to assess the progress of a condition or the effects of treatment.\\nFollow-Up (Medicine) : The process of monitoring a patient\\'s health over time after treatment or diagnosis.\\nDisease Recurrence : The return of a sign, symptom, or disease after a remission.\\nRecurrent Disease : A disease that returns after a period of remission.\\nRecurrence (Medicine) : The return of a disease or condition after a period of improvement.\\n\\nRelationships:-\\n1. Entity1: \""Follow-up\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""monitoring\""\\n\\nCausalities:-\\n### Follow-up\\n\\n- **Follow-up** (FOLL-A, 1 of 2)\\n- **Recurrent or persistent disease** (ADV-3)\\n\\nSection Name: Risk Features\\n====================\\nEntities:-\\nRadiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Adverse pathologic features\"", Entity2: \""RT\"", Relationship: \""Consideration for treatment\""\\n2. Entity1: \""Adverse pathologic features\"", Entity2: \""Systemic therapy\"", Relationship: \""Consideration for treatment\""\\n\\nCausalities:-\\n- **No adverse pathologic features**\\n- **Other risk features**\\n- **Adverse pathologic features**:\\n  - <C> Extranodal extension and/or positive margin </C>\\n  - <A> RT or consider systemic therapy/RT </A>\\n\\nSection Name: Post-Therapy Evaluation\\n====================\\nEntities:-\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nNeck : The neck is the part of the body that separates the head from the torso and provides the mobility and movements of the head.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Neck Evaluation\"", Relationship: \""evaluated in\""\\n2. Entity1: \""RT\"", Entity2: \""Neck Evaluation\"", Relationship: \""evaluated in\""\\n\\nCausalities:-\\n<CO> Post Systemic Therapy/RT or RT Neck </CO> <A> Evaluation </A>\\n\\nSection Name: Flowchart Overview\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nSupraglottic Larynx : The part of the larynx located above the vocal cords, including the epiglottis and aryepiglottic folds.\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\n\\nRelationships:-\\n1. Entity1: \""NCCN Guidelines\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""guides management of\""\\n2. Entity1: \""NCCN Guidelines\"", Entity2: \""healthcare professionals\"", Relationship: \""used by\""\\n\\nCausalities:-\\n<C> cancer of the supraglottic larynx </C> <E> evaluate patient responses following treatment </E> <CO> based on observed outcomes </CO> <A> evaluation of the primary site and determining subsequent steps </A>.\\n\\nSection Name: Assessment and Treatment Decisions\\n====================\\nEntities:-\\nInduction Chemotherapy : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nComplete Response : The disappearance of all signs of cancer in response to treatment.\\nPartial Response : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Complete Response\"", Entity2: \""Radiation Therapy\"", Relationship: \""leads to\""\\n2. Entity1: \""Complete Response\"", Entity2: \""Surgery\"", Relationship: \""leads to\""\\n3. Entity1: \""Partial Response\"", Entity2: \""Systemic Therapy\"", Relationship: \""leads to\""\\n4. Entity1: \""Partial Response\"", Entity2: \""Radiation Therapy\"", Relationship: \""leads to\""\\n\\nCausalities:-\\n<C> responses to initial treatments such as induction chemotherapy </C> <E> Three main response categories are recognized: Complete Response (CR), Partial Response (PR), and less than Partial Response (< PR) </E>. These categories are pivotal in determining the next steps. <C> CR </C> <E> indicates full resolution of the disease at the primary site </E>, <A> leading to the consideration of definitive radiation therapy or the likelihood of surgery </A>. Conversely, <C> PR </C> <E> suggests that the disease has improved but not completely resolved </E>, <A> which directs the pathway towards either systemic therapy or continued radiation therapy </A>, <A> with further evaluation necessary </A>.\\n\\nSection Name: Adverse Pathologic Features and Follow-up\\n====================\\nEntities:-\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nNeoplasm Recurrence, Local : The return of a tumor or cancer, at the original site, after it has been treated.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nRecurrent Neoplasm : A neoplasm that has returned after treatment.\\nMetastatic Neoplasm : A neoplasm that has spread from its original site to one or more other places in the body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nCancer Recurrence : The return of cancer after treatment and after a period of time during which the cancer was undetectable.\\nMetastasis : Spread of a cancer or other disease from one organ or part to another not directly connected with it.\\n\\nRelationships:-\\n1. Entity1: \""Adverse pathologic features\"", Entity2: \""Treatment decisions\"", Relationship: \""Influence\""\\n2. Entity1: \""Adverse features\"", Entity2: \""Surgical intervention\"", Relationship: \""Recommendation\""\\n3. Entity1: \""Absence of adverse features\"", Entity2: \""Radiation therapy\"", Relationship: \""Pathway\""\\n4. Entity1: \""Follow-up process\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""Detection\""\\n5. Entity1: \""Recurrent or persistent disease\"", Entity2: \""Advanced disease management\"", Relationship: \""Necessity\""\\n\\nCausalities:-\\n<C> The presence of adverse pathologic features \u2014 such as extranodal extension or positive margins </C> <E> can directly influence treatment decisions </E>. <CO> If adverse features are found </CO>, <A> surgical intervention is recommended </A>. <CO> In cases where there are no adverse features </CO>, the patient may proceed directly to radiation therapy or continued systemic treatment, emphasizing the tailored approach based on the individual patient\\'s disease characteristics.\\n\\nFurthermore, the chart includes a section addressing the follow-up process after initial treatment. <CO> If there are signs of recurrent or persistent disease </CO>, <A> additional evaluations and treatment modalities may be necessary </A>. These evaluations <E> lead to specific recommendations for advanced disease management, denoted as ADV-3 on the chart </E>, emphasizing the importance of continuous monitoring and assessment in cancer care.\\n--------------------------------------------------\\nPage Number: 68\\n\\nSection Name: Diagnosis Section\\n====================\\nEntities:-\\nDiagnosis : The process of determining which disease or condition explains a person\\'s symptoms and signs.\\nMetastatic Disease : A disease in which cancer cells spread from the place where they first formed to another part of the body.\\nClinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nLocoregional Therapy : Treatment that is directed to a specific area of the body, often used in cancer treatment.\\n\\nRelationships:-\\n1. Entity1: \""Diagnosis\"", Entity2: \""Decision-making process\"", Relationship: \""initiates\""\\n2. Entity1: \""Metastatic disease\"", Entity2: \""Clinical trial\"", Relationship: \""preferred pathway\""\\n3. Entity1: \""Locoregional treatment\"", Entity2: \""Primary site algorithms\"", Relationship: \""based on\""\\n\\nCausalities:-\\n<CO> for patients presenting with metastatic disease </CO>, <A> a clinical trial is the preferred pathway </A>, emphasizing the critical nature of innovative therapies in advanced cancer care. The option to <A> \""Consider locoregional treatment based on primary site algorithms\"" </A> suggests that specific treatment strategies may be tailored <CO> depending on the exact location and characteristics of the cancer </CO>.\\n\\nSection Name: Treatment Pathways\\n====================\\nEntities:-\\nPerformance Status : A measure of a patient\\'s general well-being and ability to perform ordinary tasks, often used in oncology to determine the appropriate treatment.\\nSystemic Therapy : A treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nSurgery : A medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nPalliative Care : Specialized medical care for people living with a serious illness, focused on providing relief from the symptoms and stress of the illness.\\nSupportive Care : Care given to improve the quality of life of patients who have a serious or life-threatening disease.\\n\\nRelationships:-\\n1. Entity1: \""Performance Status\"", Entity2: \""Systemic Therapy\"", Relationship: \""affects choice of\""\\n2. Entity1: \""Performance Status\"", Entity2: \""Surgery\"", Relationship: \""affects choice of\""\\n3. Entity1: \""Performance Status\"", Entity2: \""Radiation Therapy\"", Relationship: \""affects choice of\""\\n4. Entity1: \""Performance Status\"", Entity2: \""Palliative Care\"", Relationship: \""affects choice of\""\\n5. Entity1: \""Performance Status\"", Entity2: \""Supportive Care\"", Relationship: \""affects choice of\""\\n6. Entity1: \""PS 0-1 Patients\"", Entity2: \""Combination Systemic Therapy\"", Relationship: \""suitable for\""\\n7. Entity1: \""PS 2 Patients\"", Entity2: \""Palliative Radiation Therapy\"", Relationship: \""may receive\""\\n8. Entity1: \""PS 3 Patients\"", Entity2: \""Supportive Care\"", Relationship: \""recommended\""\\n\\nCausalities:-\\nThe treatment section branches into various pathways depending on <CO> the patient\u2019s performance status (PS) </CO>, which is a measure of their general well-being and ability to function. - **For PS 0-1 Patients:** The flowchart indicates several treatment options, including <A> combination systemic therapy, single-agent systemic therapy, surgery, and radiation therapy (RT) </A>. This group is highlighted as those who are most capable of handling intensive treatments and <E> may benefit significantly from combination therapies </E>. - **For PS 2 Patients:** The recommended approach varies slightly, with a continued emphasis on <A> systemic therapies, palliative radiation therapy, or best supportive care </A>. This indicates a level of compromise in treatment options, suggesting that while aggressive treatment is still possible, <E> the focus might shift more towards quality of life </E>. - **For PS 3 Patients:** The treatment options further narrow, still recommending <A> systemic therapy or supportive care </A> but highlighting palliative approaches, reflecting a recognition of <E> the more advanced disease and potentially limited treatment efficacy </E>.\\n\\nSection Name: Principles of Treatment\\n====================\\nEntities:-\\nAntineoplastic Combined Chemotherapy Protocols : Protocols for the administration of more than one antineoplastic agent in combination to treat malignant neoplasms.\\nRadiotherapy : The use of radiation, usually X-rays or gamma rays, to treat disease, especially cancer.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nSystemic Therapy : A treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nSurgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nChemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.\\nSurgery : A medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Radiation Therapy\"", Relationship: \""Different modalities of cancer treatment\""\\n2. Entity1: \""Systemic Therapy\"", Entity2: \""Surgery\"", Relationship: \""Different modalities of cancer treatment\""\\n3. Entity1: \""Radiation Therapy\"", Entity2: \""Surgery\"", Relationship: \""Different modalities of cancer treatment\""\\n\\nCausalities:-\\n- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)** - **Principles of Radiation Therapy (ADV-A)** - **Principles of Surgery (SURG-A)**\\n\\nSection Name: Diagnosis and Treatment of Head and Neck Cancer\\n====================\\nEntities:-\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nMetastatic Malignant Neoplasm : A malignant neoplasm that has spread from its original site to a different site.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\nClinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nPerformance Status : A measure of a patient\\'s general well-being and ability to perform ordinary tasks, often used in oncology to determine the appropriate treatment.\\n\\nRelationships:-\\n1. Entity1: \""Metastatic disease\"", Entity2: \""Clinical trial\"", Relationship: \""preferred treatment option\""\\n2. Entity1: \""Performance Status 0-1\"", Entity2: \""Combination systemic therapy\"", Relationship: \""treatment option\""\\n3. Entity1: \""Performance Status 2\"", Entity2: \""Single-agent systemic therapy\"", Relationship: \""treatment option\""\\n4. Entity1: \""Performance Status 3\"", Entity2: \""Systemic therapy\"", Relationship: \""treatment option\""\\n\\nCausalities:-\\n- <CO>Metastatic (M1) disease at initial presentation</CO>\\n  <A>Clinical trial preferred</A>\\n  <E>Distant metastases</E>\\n  <A>Consider locoregional treatment based on primary site algorithms (Table of Contents)</A>\\n\\n#### Performance Status (PS)\\n- <CO>PS 0\u20131</CO>\\n  <A>Combination systemic therapy</A> or <A>Single-agent systemic therapy</A> or <A>Surgery</A> or <A>RT</A> or <A>systemic therapy/RT for selected patients with limited metastases</A> or <A>Best supportive care</A>\\n- <CO>PS 2</CO>\\n  <A>Single-agent systemic therapy</A> or <A>Best supportive care \u00b1 Palliative RT</A> or <A>Palliative surgery</A>\\n- <CO>PS 3</CO>\\n  <A>Systemic therapy, clinical trial preferred</A> or <A>Palliative RT</A> or <A>Best supportive care</A>\\n\\nSection Name: Persistent Disease or Progression\\n====================\\nEntities:-\\nPalliative Care : Specialized medical care for people living with a serious illness, focused on providing relief from the symptoms and stress of the illness.\\nSupportive Care : Care given to improve the quality of life of patients who have a serious or life-threatening disease.\\nAntineoplastic Agents : Substances that inhibit or prevent the proliferation of neoplasms.\\nSystemic Therapy : A treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nChemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.\\nRadiotherapy : The use of radiation, usually X-rays or gamma rays, to treat disease, especially cancer.\\nPalliative Radiotherapy : Radiotherapy given to relieve symptoms and reduce suffering caused by cancer.\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\n\\nRelationships:-\\n1. Entity1: \""Best supportive care\"", Entity2: \""Alternate single-agent systemic therapy\"", Relationship: \""alternative treatment options\""\\n2. Entity1: \""Best supportive care\"", Entity2: \""Palliative RT\"", Relationship: \""alternative treatment options\""\\n3. Entity1: \""Alternate single-agent systemic therapy\"", Entity2: \""Palliative RT\"", Relationship: \""alternative treatment options\""\\n\\nCausalities:-\\n<A> Best supportive care </A> or <A> Alternate single-agent systemic therapy </A> or <A> Palliative RT </A>\\n--------------------------------------------------\\nPage Number: 53\\n\\nSection Name: Introduction\\n====================\\nEntities:-\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives.\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nMalignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network\"", Entity2: \""Malignant neoplasm of supraglottis\"", Relationship: \""provides guidelines for\""\\n2. Entity1: \""clinical staging\"", Entity2: \""treatment strategies\"", Relationship: \""part of flowchart for\""\\n\\nCausalities:-\\nThe provided image is a flowchart outlining the <C> NCCN (National Comprehensive Cancer Network) guidelines </C> for the treatment of <CO> cancers of the supraglottic larynx </CO>. This flowchart <A> utilizes a highly structured approach to convey clinical staging and treatment strategies </A>, indicating the various pathways based on <CO> patient conditions and disease features </CO>.\\n\\nSection Name: NCCN Guidelines Version 4.2024\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nMalignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.\\nSupraglottic Cancer : Cancer that occurs in the supraglottic region of the larynx, above the vocal cords.\\nClinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.\\nClinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.\\n\\nRelationships:-\\n1. Entity1: \""Cancer of the Supraglottic Larynx\"", Entity2: \""Clinical Trials\"", Relationship: \""recommended management strategy\""\\n\\nCausalities:-\\n- All recommendations are category 2A unless otherwise indicated.\\n- <A> Participation in clinical trials </A> is especially encouraged.\\n\\nSection Name: Key Components of the Flowchart\\n====================\\nEntities:-\\nNeoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.\\nRadiotherapy : The use of ionizing radiation to treat cancer.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.\\nNeoplasm Recurrence, Local : The return of a tumor at the original site after treatment.\\nClinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.\\n\\nRelationships:-\\n1. Entity1: \""Clinical Staging\"", Entity2: \""Treatment of Primary and Neck\"", Relationship: \""determines\""\\n2. Entity1: \""Evaluation and Follow-Up\"", Entity2: \""Adverse and No Adverse Features\"", Relationship: \""leads to decision based on\""\\n3. Entity1: \""Adjuvant Treatment\"", Entity2: \""Adverse pathologic features\"", Relationship: \""considered if present\""\\n4. Entity1: \""Clinical Trials\"", Entity2: \""Treatment Pathway\"", Relationship: \""part of\""\\n\\nCausalities:-\\n### Key Components of the Flowchart\\n\\n1. **Clinical Staging**: The flowchart starts with <A>clinical staging</A>, indicating that <CO>patients must first be evaluated to determine the extent of cancer</CO>. This is essential for <E>deciding on appropriate treatment options</E>.\\n\\n2. **Treatment of Primary and Neck**: The flowchart details multiple treatment strategies, including:\\n   - <A>**Concurrent systemic therapy/RT**</A>: This suggests a combination approach for <CO>patients eligible for such treatment</CO>.\\n   - <A>**Definitive Radiation Therapy (RT)**</A>: Recommended for <CO>low-volume diseases or patients who cannot tolerate systemic therapy</CO>.\\n   - <A>**Surgical Options**</A>: It highlights options such as endoscopic or open partial laryngectomy and neck dissection, which are <CO>contingent on clinical evaluations</CO>.\\n\\n3. **Evaluation and Follow-Up**: After initial treatment approaches, the chart directs clinicians to perform a <A>\""Post Systemic Therapy/RT or RT Neck Evaluation\""</A>. This step <E>assesses whether there are adverse pathologic features</E>, guiding subsequent treatment decisions.\\n\\n4. **Adverse and No Adverse Features**: The decision pathway diverges based on findings:\\n   - <CO>Patients with **adverse pathologic features**</CO> may have <A>additional diagnostic imaging (CT or MRI)</A> and may require <A>further systemic treatment</A>.\\n   - <CO>Patients with **no adverse features**</CO> may be directed towards <A>considerations for radiation therapy</A>.\\n\\n5. **Adjuvant Treatment and Recurrence**: The chart also addresses <E>management of any recurrent or persistent disease</E>, emphasizing the importance of <A>regular follow-up assessments</A>. Various options for <A>adjuvant treatment</A> are mentioned, focusing on tailored approaches towards ongoing management of the disease.\\n\\n6. **Clinical Trials**: The flowchart encourages <A>participation in clinical trials</A>, indicating a commitment to <E>exploring new treatments and improving patient outcomes</E>.\\n\\nSection Name: Principles\\n====================\\nEntities:-\\nImaging : The process of producing images of the body or parts of the body to diagnose or examine disease.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nRadiation Therapy : The use of ionizing radiation to treat cancer and other diseases.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Imaging\"", Entity2: \""Surgery\"", Relationship: \""Both are foundational principles in medical practice.\""\\n2. Entity1: \""Radiation therapy\"", Entity2: \""Systemic Therapy\"", Relationship: \""Both are treatment modalities for cancer.\""\\n\\nCausalities:-\\n#### Principles\\n- **Principles of Imaging (IMG-A)**\\n- **Principles of Surgery (SURG-A)**\\n- **Principles of Radiation Therapy (SUPRA-A)**\\n- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**\\n\\nSection Name: Adverse Pathologic Features\\n====================\\nEntities:-\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margins : The presence of cancer cells at the edge of the tissue removed during surgery.\\nPerineural Invasion : Cancer cells found surrounding or tracking along a nerve within the perineural space.\\nVascular Invasion : The presence of cancer cells within blood vessels.\\nLymphatic Invasion : The presence of cancer cells within lymphatic vessels.\\n\\nRelationships:-\\n1. Entity1: \""Extranodal Extension\"", Entity2: \""Positive Surgical Margins\"", Relationship: \""Both indicate cancer spread beyond original site.\""\\n2. Entity1: \""Perineural Invasion\"", Entity2: \""Vascular Invasion\"", Relationship: \""Both are pathways for cancer spread.\""\\n3. Entity1: \""pT3 or pT4 primary\"", Entity2: \""pN2 or pN3 nodal disease\"", Relationship: \""Both indicate advanced cancer stages.\""\\n\\nCausalities:-\\n<C> Extranodal extension </C>\\n<C> Positive margins </C>\\n<C> Close margins </C>\\n<C> pT3 or pT4 primary </C>\\n<C> pN2 or pN3 nodal disease </C>\\n<C> Perineural invasion </C>\\n<C> Vascular invasion </C>\\n<C> Lymphatic invasion </C>\\n\\nSection Name: Clinical Staging and Treatment of Primary and Neck\\n====================\\nEntities:-\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.\\nFollow-Up Procedure : A procedure performed to monitor the progress of a patient after treatment.\\nRecurrent Disease : A disease that returns after a period of remission.\\nLaryngectomy : Surgical removal of the larynx, often used to treat cancer.\\nRadiation Therapy : The use of ionizing radiation to treat cancer and other diseases.\\nClinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat cancer.\\nChemotherapy : Treatment of disease by the use of chemical substances, especially cancer by cytotoxic drugs.\\n\\nRelationships:-\\n1. Entity1: \""Adjuvant Treatment\"", Entity2: \""Treatment of Primary and Neck\"", Relationship: \""part of\""\\n2. Entity1: \""Follow-up\"", Entity2: \""Treatment of Primary and Neck\"", Relationship: \""part of\""\\n3. Entity1: \""Recurrent or Persistent Disease\"", Entity2: \""Treatment of Primary and Neck\"", Relationship: \""part of\""\\n4. Entity1: \""Larynx-Preserving Surgery\"", Entity2: \""Treatment Options\"", Relationship: \""is a treatment option for\""\\n5. Entity1: \""Concurrent Systemic Therapy/RT\"", Entity2: \""Treatment Options\"", Relationship: \""is a treatment option for\""\\n6. Entity1: \""Clinical Trials or Definitive RT\"", Entity2: \""Treatment Options\"", Relationship: \""is a treatment option for\""\\n7. Entity1: \""Endoscopic or Open Partial Laryngectomy and Neck Dissection(s)\"", Entity2: \""Treatment Options\"", Relationship: \""is a treatment option for\""\\n8. Entity1: \""Induction Chemotherapy\"", Entity2: \""Treatment Options\"", Relationship: \""is a treatment option for\""\\n\\nCausalities:-\\n<A> Amenable to Larynx-Preserving (Conservation) Surgery </A>: <CO> T1\u20132, N+ and selected T3, N1 </CO>\\n<A> Concurrent Systemic Therapy/RT </A>: <CO> i, k, l </CO>\\n<A> Clinical Trials or Definitive RT </A>: <CO> i </CO>\\n<A> Endoscopic or Open Partial Laryngectomy and Neck Dissection(s) </A>: <CO> h </CO>\\n<A> Induction Chemotherapy </A>: <CO> k, m </CO>\\n\\nSection Name: Pathologic Features and Response Assessment\\n====================\\nEntities:-\\nRadiation Therapy : The use of ionizing radiation to treat cancer and other diseases.\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margin : Cancer cells are found at the edge of the material removed during surgery, indicating that some cancer may have been left behind.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Extranodal extension\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n2. Entity1: \""Positive margin\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n3. Entity1: \""Systemic Therapy\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""considered in response to\""\\n4. Entity1: \""Radiation Therapy\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""considered in response to\""\\n\\nCausalities:-\\n#### Pathologic Features\\n- **No Adverse Pathologic Features**: j\\n  - <A> Consider RT </A>: i\\n- **Adverse Pathologic Features**: j\\n  - <CO> Extranodal extension and/or positive margin </CO>: n\\n  - Other risk features\\n  - <A> Systemic therapy/RT </A>: i, k (category 1)\\n  - <A> Consider systemic therapy/RT </A>: i, k\\n\\n#### Response Assessment\\n- **Response Assessment** (SUPRA-7)\\n\\nSection Name: Imaging and Recurrent or Persistent Disease\\n====================\\nEntities:-\\nTomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient.\\nMagnetic Resonance Imaging : Medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.\\nComputed Tomography : Medical imaging technique used in radiology to obtain detailed internal images of the body.\\n\\nRelationships:-\\n1. Entity1: \""CT\"", Entity2: \""primary and neck\"", Relationship: \""used for imaging\""\\n2. Entity1: \""MRI\"", Entity2: \""primary and neck\"", Relationship: \""used for imaging\""\\n3. Entity1: \""Post Systemic Therapy/RT\"", Entity2: \""Recurrent or Persistent Disease\"", Relationship: \""evaluation after treatment\""\\n4. Entity1: \""RT Neck Evaluation\"", Entity2: \""Recurrent or Persistent Disease\"", Relationship: \""evaluation after treatment\""\\n\\nCausalities:-\\n<A> CT (with contrast) or MRI (with and without contrast) of primary and neck </A>\\n\\n<CO> Recurrent or Persistent Disease </CO>\\n\\n<CO> Post Systemic Therapy/RT or RT Neck Evaluation </CO>\\n\\nSection Name: Conclusion\\n====================\\nEntities:-\\nOncologists : Medical doctors who specialize in the diagnosis and treatment of cancer.\\nSupraglottic Larynx Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is the area above the vocal cords.\\nClinical Staging : The process of determining the extent of cancer in the body, usually based on physical examination, imaging tests, and biopsies.\\nTreatment Strategies : Plans or methods developed to treat diseases, including cancer, which may involve surgery, chemotherapy, radiation therapy, or other modalities.\\nFollow-Up Evaluations : Medical assessments conducted after initial treatment to monitor a patient\\'s progress and detect any recurrence of disease.\\nClinical Efficacy : The ability of a treatment to produce the desired therapeutic effect in clinical settings.\\nResearch : Systematic investigation and study conducted to establish facts and reach new conclusions.\\nTreatment Paradigms : Standard models or patterns of treatment used in medical practice, often based on clinical guidelines and research findings.\\n\\nRelationships:-\\n1. Entity1: \""Oncologists\"", Entity2: \""Supraglottic Larynx Cancer\"", Relationship: \""use flowchart for decision-making\""\\n2. Entity1: \""Clinical Staging\"", Entity2: \""Treatment Strategies\"", Relationship: \""part of management process\""\\n3. Entity1: \""Treatment Strategies\"", Entity2: \""Follow-Up Evaluations\"", Relationship: \""part of management process\""\\n\\nCausalities:-\\n<A> The flowchart serves as a comprehensive guide for oncologists and healthcare providers </A>, <A> facilitating informed decision-making in the treatment of supraglottic larynx cancer </A>. <A> By visualizing the complex interactions between clinical staging, treatment strategies, and follow-up evaluations </A>, <E> it streamlines the management process </E>, <E> ensuring that patients receive appropriate care tailored to their specific needs </E>. <E> The detailed pathways not only enhance clinical efficacy </E> but also <E> underscore the importance of ongoing research and adaptation of treatment paradigms in oncology </E>.\\n'}""",valid,increases risk,2,B,"edge - The edge which needs to be verified.
explanation - Explanation of what the edge represents and its validity.
causal_direction - Either Positive or Negative or Unknown. A positive influence direction indicates that both factors change in the same direction (e.g. an increase causes an increase effect). A negative influence direction indicates the opposite changes (e.g. an increase causes a decrease effect).
causal_factor - Is necessary or sufficient condition for an effect to occur. Exposure is a term commonly used in epidemiology to denote any condition that is considered as a possible cause of disease. Exposure is considered necessary when it always precedes the effects (e.g. symptoms) and always presents when the effects occur. A sufficient cause is a causal factor whose presence or occurrence guarantees the occurrence of symptom.
causal_distance - Either Distal or Proximal or Unknown. The distal factors lie towards the beginning of causal chain (i.e. indirect causal factors). The the proximal factors lie towards the end of the chain (i.e. cause directly or almost directly the effect).

Causality Tags:
<A> for action, <C> for cause, <CO> for condition and <E> for effect.
Cause (C): The reason or origin that leads to an effect. Causes often involve disease conditions, risk factors, or underlying mechanisms.
Effect (E): The outcome or result of a cause. Effects usually represent clinical outcomes, complications, or results of a specific cause.
Condition (CO): The circumstance or prerequisite required for an action or effect to occur. Conditions may include patient characteristics, clinical scenarios, or specific diagnostic criteria.
Action (A): The recommended or described response or activity to address a cause or condition. Actions typically involve clinical interventions, diagnostic procedures, or treatment recommendations.


`NODE1`:
id: Location_of_Involved_Lymph_Nodes_4
label: Position of Affected Lymph Nodes in Patient
description: This node represents the location of lymph nodes that are involved or affected in a patient's condition. Understanding whether the lymph nodes are ipsilateral, bilateral, or contralateral is crucial for determining the extent of disease spread and planning appropriate treatment strategies.
type: Patient Situation
observability: Unobserved
states: [{'state_name': 'ipsilateral', 'state_description': 'The involved lymph nodes are on the same side of the body as the primary tumor or reference point. This can indicate localized spread of disease.'}, {'state_name': 'bilateral', 'state_description': 'The involved lymph nodes are on both sides of the body. This may suggest a more extensive spread of disease and can impact treatment decisions.'}, {'state_name': 'contralateral', 'state_description': 'The involved lymph nodes are on the opposite side of the body from the primary tumor or reference point. This can indicate metastatic spread and may affect staging and treatment planning.'}]

`NODE2`:
id: Examination_13
label: Diagnostic Examination Result
description: This node represents the result of a diagnostic examination focused on identifying patterns of lymph node metastasis, which is crucial for cancer staging and determining the appropriate treatment strategy.
type: Examination Result
observability: Observed
states: [{'state_name': 'bilateral_lymph_node_metastasis', 'state_description': 'Metastasis is present in lymph nodes on both sides of the body, indicating a more advanced spread of cancer.'}, {'state_name': 'ipsilateral_lymph_node_metastasis', 'state_description': 'Metastasis is present in lymph nodes on the same side of the body as the primary tumor, suggesting a localized spread.'}, {'state_name': 'contralateral_lymph_node_metastasis', 'state_description': 'Metastasis is present in lymph nodes on the opposite side of the body from the primary tumor, indicating a more extensive spread of cancer.'}]

`EDGE1`:
{'edges_ids': ['Location_of_Involved_Lymph_Nodes_4', 'Examination_13'], 'edge': '(Location_of_Involved_Lymph_Nodes_4) causes (Examination_13)', 'explanation': ['The edge represents the causal relationship between the position of involved lymph nodes and the results of a diagnostic examination.', 'The `Location_of_Involved_Lymph_Nodes_4` node describes the position of lymph nodes (ipsilateral, bilateral, contralateral) in a patient.', 'The `Examination_13` node describes the result of a diagnostic examination that identifies patterns of lymph node metastasis.', 'The position of involved lymph nodes directly influences the examination results, as the examination is designed to detect these patterns.', 'Therefore, the edge is valid as the location of lymph nodes can cause the examination to show corresponding metastasis patterns.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': True}, 'causal_distance': 'Proximal'}

`EDGE2`:
{'edges_ids': ['Examination_13', 'Location_of_Involved_Lymph_Nodes_4'], 'edge': '(Examination_13) causes (Location_of_Involved_Lymph_Nodes_4)', 'explanation': ['The edge represents the causal relationship where the result of a diagnostic examination (Examination_13) determines the location of involved lymph nodes (Location_of_Involved_Lymph_Nodes_4).', 'Examination_13 provides information about the presence and pattern of lymph node metastasis, which directly informs the location of involved lymph nodes.', 'The causal direction is positive because the examination result directly influences the determination of lymph node location.', 'The examination result is necessary for determining the lymph node location, but not sufficient by itself, as other clinical factors may also play a role.', 'The causal distance is proximal because the examination result directly informs the location of involved lymph nodes.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': True, 'sufficient': False}, 'causal_distance': 'Proximal'}

`INFORMATION FROM KNOWLEDGE BASE`:
--------------------------------------------------
Page Number: 51

Section Name: Introduction
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Malignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.
Supraglottic Laryngeal Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is above the vocal cords.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network (NCCN)"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""provides guidelines for""
2. Entity1: ""healthcare professionals"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""manage""

Causalities:-
The provided image is a detailed flowchart from the National Comprehensive Cancer Network (NCCN) guidelines regarding the <C> clinical staging and treatment protocols for cancer of the supraglottic larynx </C>. This flowchart is structured to <A> guide healthcare professionals through the stages of treatment </A> based on <CO> clinical findings </CO>, emphasizing the <E> complexity and systematic approach required in managing this type of cancer </E>.

Section Name: Clinical Staging
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Total Laryngectomy : A surgical procedure to remove the entire larynx, often used in the treatment of advanced laryngeal cancer.
Neoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.
Cancer Staging : The process of determining the extent of cancer in the body, often using the TNM system.
Tnm Staging System : A cancer staging system that describes the extent of cancer using Tumor size (T), Node involvement (N), and Metastasis (M).

Relationships:-
1. Entity1: ""Clinical staging criteria"", Entity2: ""Total laryngectomy"", Relationship: ""determines necessity of""
2. Entity1: ""T3, N0"", Entity2: ""Clinical staging criteria"", Relationship: ""is a categorization of""

Causalities:-
The flowchart begins with the <C> clinical staging criteria </C>, specifically focusing on <CO> cases that require total laryngectomy, denoted as requiring (amenable to) total laryngectomy (T3, N0) </CO>. This <A> categorization </A> is crucial as it <E> forms the basis for determining the appropriate treatment strategy </E>.

Section Name: Treatment of Primary and Neck
====================
Entities:-
Neoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.
Lymphatic Metastasis : Transfer of a neoplasm from one organ or part of the body to another remote from the primary site.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Radiation Therapy"", Relationship: ""combined with""
2. Entity1: ""Laryngectomy"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""
3. Entity1: ""Thyroidectomy"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""
4. Entity1: ""Neck Dissection"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""

Causalities:-
<CO> Once clinical staging is established </CO>, the chart outlines various treatment options. <A> The initial step may involve either concurrent systemic therapy combined with radiation therapy (RT) or opting for RT alone </A>, <CO> especially if the patient is not a medical candidate for both therapies </CO>. <A> Laryngectomy, thyroidectomy, and neck dissection are considered </A> <CO> based on the extent of lymph node involvement </CO>.

Section Name: Surgical Options
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Lymph Node Excision : Surgical removal of one or more lymph nodes.
Lymphadenectomy : Surgical removal of one or more groups of lymph nodes.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.

Relationships:-
1. Entity1: ""Laryngectomy"", Entity2: ""Thyroidectomy"", Relationship: ""combined with""
2. Entity1: ""Lymph Node Dissection"", Entity2: ""Surgical Intervention"", Relationship: ""extent of""
3. Entity1: ""Surgical Intervention"", Entity2: ""Advanced Cases"", Relationship: ""management option for""

Causalities:-
<CO> If concurrent therapies are not suitable </CO>, <A> the chart presents laryngectomy combined with thyroidectomy </A>, <CO> depending on the extent of lymph node dissection required </CO>. <E> This highlights surgical intervention as a viable option in the management of advanced cases </E>.

Section Name: Induction Chemotherapy
====================
Entities:-
Induction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Therapeutic Approach : A method or strategy used in the treatment of disease or injury.

Relationships:-
1. Entity1: ""Induction Chemotherapy"", Entity2: ""Surgical Intervention"", Relationship: ""alternative or sequential treatment option""

Causalities:-
<C> immediate surgical intervention is either not feasible or considered insufficient </C> <E> The flowchart also considers the option of induction chemotherapy </E> <CO> in cases where immediate surgical intervention is either not feasible or considered insufficient </CO>. <A> tailoring therapeutic approaches tailored to individual patient needs </A>.

Section Name: Adjuvant Treatment
====================
Entities:-
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Neoplasm Recurrence, Local : The return of a cancer, at the same site, after it has been treated.
Disease Progression : The worsening of a disease over time.

Relationships:-
1. Entity1: ""Primary Treatment"", Entity2: ""Adjuvant Treatment"", Relationship: ""followed by""
2. Entity1: ""Adjuvant Treatment"", Entity2: ""Systemic Therapy"", Relationship: ""includes""
3. Entity1: ""Adjuvant Treatment"", Entity2: ""Radiotherapy"", Relationship: ""includes""
4. Entity1: ""Follow-up Assessments"", Entity2: ""Treatment Efficacy"", Relationship: ""used to evaluate""

Causalities:-
<C> Following primary treatment </C>, <E> the flowchart addresses the potential for adjuvant treatment pathways </E>. This may include systemic therapy, RT, or further evaluations based on <CO> the patient's response and any recurrence or persistent disease </CO>. It emphasizes <A> the need for follow-up assessments to evaluate treatment efficacy </A>.

Section Name: Risk Features and Response Assessment
====================
Entities:-
Neoplasm Invasiveness : The property of a neoplasm to infiltrate and destroy surrounding tissue.
Surgical Margins : The edge or border of the tissue removed in cancer surgery.
Neoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.
Extramural Extension : Extension of a tumor beyond the wall of an organ.
Positive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.
Cancer Management : The process of planning and coordinating the treatment of cancer.
Cancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""Extramural extension"", Entity2: ""Treatment decisions"", Relationship: ""influences""
2. Entity1: ""Positive surgical margin"", Entity2: ""Treatment decisions"", Relationship: ""influences""
3. Entity1: ""Ongoing assessment"", Entity2: ""Response evaluation"", Relationship: ""leads to""
4. Entity1: ""Response evaluation"", Entity2: ""Adjustments to treatment"", Relationship: ""leads to""
5. Entity1: ""Management of cancer"", Entity2: ""Treatment decisions"", Relationship: ""involves""
6. Entity1: ""Management of cancer"", Entity2: ""Ongoing assessment"", Relationship: ""involves""
7. Entity1: ""Management of cancer"", Entity2: ""Adjustments to treatment"", Relationship: ""involves""

Causalities:-
The chart incorporates a segment that takes into account <CO> adverse pathologic features, such as extramural extension or positive margins </CO>, <E> which could influence subsequent treatment decisions </E>. This highlights the importance of <A> ongoing assessment in the management of cancer, leading to response evaluation and adjustments to treatment as necessary </A>.

Section Name: NCCN Guidelines Version 4.2024
====================
Entities:-
Clinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.
Neoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.
Clinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Malignant Neoplasm : A malignant neoplasm is a cancerous growth that has the potential to invade and destroy nearby tissue and spread to other parts of the body.
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Cancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network"", Entity2: ""NCCN Guidelines"", Relationship: ""provides""
2. Entity1: ""NCCN Guidelines"", Entity2: ""Clinical Trials"", Relationship: ""recommend""
3. Entity1: ""NCCN Guidelines"", Entity2: ""Cancer"", Relationship: ""related to management of""

Causalities:-
<CO> any patient with cancer </CO> <A> the best management is in a clinical trial </A>. <A> Participation in clinical trials is especially encouraged </A>.

Section Name: SUPRA-3
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.
Chemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Clinical Trials As Topic : Research studies that prospectively assign human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Induction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.
Clinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.

Relationships:-
1. Entity1: ""Total laryngectomy"", Entity2: ""Laryngectomy"", Relationship: ""is a type of""
2. Entity1: ""Systemic therapy"", Entity2: ""RT"", Relationship: ""concurrent treatment option""
3. Entity1: ""Induction chemotherapy"", Entity2: ""Other treatments"", Relationship: ""initial treatment option before""

Causalities:-
<CO> Requiring (amenable to) total laryngectomy (T3,N0) </CO>
  - <A> Concurrent systemic therapy/RT </A> or <A> RT if patient not medical candidate for concurrent systemic therapy/RT </A>
  - <A> Laryngectomy, thyroidectomy and with ipsilateral, central, or bilateral neck dissection </A>
  - or
  - <A> Induction chemotherapy </A>
  - or
  - <A> Clinical trials </A>

Section Name: Follow-up
====================
Entities:-
Follow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.
Follow-Up Procedure : A procedure performed to monitor the progress of a patient's condition after initial treatment.
Follow-Up : Medical care given to a patient over time after initial treatment.
Disease Recurrence : The return of a sign, symptom, or disease after a remission.
Recurrent Disease : The reappearance of a disease after a period of improvement.

Relationships:-
1. Entity1: ""Follow-up"", Entity2: ""Recurrent or persistent disease"", Relationship: ""monitoring""

Causalities:-
- **Follow-up (FOLL-A, 1 of 2)**
  - <CO> Recurrent or persistent disease </CO> (ADV-3)

Section Name: Adverse Pathologic Features
====================
Entities:-
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Extranodal Extension : The spread of cancer beyond the lymph node capsule.
Positive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""pN1"", Entity2: ""Radiotherapy"", Relationship: ""Consideration for treatment""
2. Entity1: ""Extranodal extension"", Entity2: ""Systemic Therapy"", Relationship: ""Treatment option""
3. Entity1: ""Extranodal extension"", Entity2: ""Radiotherapy"", Relationship: ""Treatment option""
4. Entity1: ""Positive surgical margin"", Entity2: ""Systemic Therapy"", Relationship: ""Treatment option""
5. Entity1: ""Positive surgical margin"", Entity2: ""Radiotherapy"", Relationship: ""Treatment option""

Causalities:-
- <CO>pN1 without other risk features</CO>
  - <C>Adverse pathologic features</C>
  - <A>Consider RT</A>
  - <CO>Extranodal extension and/or positive margin</CO>
  - <CO>Other risk features</CO>
  - <A>Systemic therapy/RT (category 1)</A>
  - <A>RT or Consider systemic therapy/RT</A>

Section Name: Response Assessment
====================
Entities:-
Response Evaluation : The process of assessing the response of a disease to treatment, often used in clinical trials to determine the effectiveness of a therapy.
Response To Treatment : A clinical finding indicating the response of a condition to a therapeutic intervention.

Relationships:-

Section Name: Principles of Surgery and Radiation Therapy
====================
Entities:-
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Radiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.

Relationships:-
1. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Radiation Therapy"", Relationship: ""complementary treatments""

Causalities:-
**Principles of Surgery (SURG-A).**

**Principles of Radiation Therapy (SUPRA-A).**

Section Name: Principles of Systemic Therapy
====================
Entities:-
Cisplatin : An inorganic and water-soluble platinum complex, cisplatin is an antineoplastic agent that is used in the treatment of various cancers.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Radiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.

Relationships:-
1. Entity1: ""Cisplatin"", Entity2: ""Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""preferred agent""
2. Entity1: ""Cisplatin"", Entity2: ""Concurrent Systemic Therapy/RT"", Relationship: ""used in""

Causalities:-
<CO> When using concurrent systemic therapy/RT </CO>, <A> the preferred agent is cisplatin (category 1) </A>.
--------------------------------------------------
Page Number: 70

Section Name: Diagnosis
====================
Entities:-
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Clinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Personalized Medicine : A medical model that proposes the customization of healthcare, with medical decisions, practices, and/or products being tailored to the individual patient.

Relationships:-
1. Entity1: ""recurrent or persistent disease"", Entity2: ""distant metastases"", Relationship: ""has condition""
2. Entity1: ""Clinical trials"", Entity2: ""recurrent or persistent disease with distant metastases"", Relationship: ""recommended for""
3. Entity1: ""locoregional failure"", Entity2: ""locoregional treatment"", Relationship: ""treatment response to""

Causalities:-
In the **Diagnosis** section, the focus is on <C> recurrent or persistent disease with distant metastases </C>. <A> Clinical trials are preferred </A> for <CO> patients diagnosed at this stage </CO>. <CO> If there is locoregional failure </CO>, <A> locoregional treatment should be considered based on the extent of the disease and symptoms presented </A>. This highlights the importance of personalized treatment approaches, taking into account the unique circumstances of each patient.

Section Name: Treatment
====================
Entities:-
Therapeutics : The branch of medicine concerned with the treatment of disease and the action of remedial agents.
Performance Status : A measure of how well a patient is able to perform ordinary tasks and carry out daily activities.
Systemic Therapy : A type of treatment that uses substances that travel through the bloodstream, reaching and affecting cells all over the body.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Palliative Care : An interdisciplinary medical caregiving approach aimed at optimizing quality of life and mitigating suffering among people with serious, complex illness.
Radiation Therapy : The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.

Relationships:-
1. Entity1: ""Performance Status"", Entity2: ""Systemic Therapy"", Relationship: ""Treatment option for PS 0-1, PS 2, and PS 3 patients""
2. Entity1: ""Performance Status"", Entity2: ""Surgery"", Relationship: ""Treatment option for PS 0-1 patients""
3. Entity1: ""Performance Status"", Entity2: ""Best Supportive Care"", Relationship: ""Treatment option for PS 0-1 and PS 3 patients""
4. Entity1: ""Performance Status"", Entity2: ""Palliative Treatments"", Relationship: ""Treatment option for PS 2 and PS 3 patients""
5. Entity1: ""Performance Status"", Entity2: ""Radiation Therapy"", Relationship: ""Consideration for PS 3 patients""

Causalities:-
The <C> Treatment section </C> outlines pathways based on <C> performance status (PS) </C>. For <CO> PS 0-1 patients </CO>, <A> options include combination systemic therapy, single-agent systemic therapy, surgery, or best supportive care for those with limited metastases </A>. For <CO> PS 2 patients </CO>, <A> recommendations include single-agent systemic therapy, supportive care, or palliative treatments </A>. For <CO> PS 3 patients </CO>, <A> the focus is on single-agent therapy and best supportive care, with consideration of palliative radiation therapy (RT) and palliative surgery </A>. This section addresses the evolving needs of patients as their <C> performance status declines </C>.

Section Name: Persistent Disease or Progression
====================
Entities:-
Disease Progression : The worsening of a disease over time.
Systemic Therapy : A type of treatment that uses substances that travel through the bloodstream, reaching and affecting cells all over the body.
Clinical Trials : Research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.
Palliative Care : An interdisciplinary medical caregiving approach aimed at optimizing quality of life and mitigating suffering among people with serious, complex illness.
Quality Of Life : An individual's overall appraisal of their situation and well-being.
Supportive Care : Care given to improve the quality of life of patients who have a serious or life-threatening disease.

Relationships:-
1. Entity1: ""Persistent Disease or Progression"", Entity2: ""Systemic Therapy"", Relationship: ""option for management""
2. Entity1: ""Persistent Disease or Progression"", Entity2: ""Clinical Trials"", Relationship: ""option for management""
3. Entity1: ""Persistent Disease or Progression"", Entity2: ""Palliative Care"", Relationship: ""option for management""
4. Entity1: ""Best Supportive Care"", Entity2: ""Quality of Life"", Relationship: ""improves""
5. Entity1: ""Best Supportive Care"", Entity2: ""Advanced Illness"", Relationship: ""applied in context of""

Causalities:-
<A> continued evaluation of treatment efficacy </A> is reiterated. <A> Options include systemic therapy, clinical trials, or palliative care </A> <CO> based on the specific patient condition </CO>. <A> Best supportive care is emphasized </A>, <E> prioritizing the patient's quality of life </E>, <CO> particularly in the context of advanced illness </CO>.

Section Name: NCCN Guidelines Overview
====================
Entities:-
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.
Clinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Neoplasms : New abnormal growth of tissue that may be benign or malignant.
Malignant Neoplastic Disease : A disease in which abnormal cells divide uncontrollably and destroy body tissue.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""cancer"", Entity2: ""clinical trial"", Relationship: ""best management through""

Causalities:-
<CO> any patient with cancer </CO> <A> Participation in clinical trials is especially encouraged </A>.

Section Name: Principles and Considerations
====================
Entities:-
Radiation Therapy : The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Surgery : A medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Surgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Genomic Profiling : The measurement of the activity (the expression) of thousands of genes at once, to create a global picture of cellular function.
Biomarkers : Biological molecules found in blood, other body fluids, or tissues that are a sign of a normal or abnormal process, or of a condition or disease.
Biomarker : A biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease.
Palliative Care : An interdisciplinary medical caregiving approach aimed at optimizing quality of life and mitigating suffering among people with serious, complex illness.
Bone Neoplasms : Tumors or cancer of the bone.
Bone Metastasis : The spread of cancer cells from their original site to a bone.

Relationships:-
1. Entity1: ""Palliative RT"", Entity2: ""Bone Metastases"", Relationship: ""treatment for""

Causalities:-
- **Principles of Radiation Therapy (ADV-A).**
- **Principles of Surgery (SURG-A).**
<A> Consider NGS genomic profiling for biomarker identification. </A>
<A> Consider palliative RT </A> <CO> as clinically indicated (e.g., bone metastases) </CO> (RAD-A).
- See Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A) or Systemic Therapy for Nasopharyngeal Cancers (NASO-B).
--------------------------------------------------
Page Number: 55

Section Name: General Information
====================
Entities:-
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Nccn Guidelines : Clinical practice guidelines in oncology developed by the National Comprehensive Cancer Network.

Relationships:-
1. Entity1: ""NCCN Guidelines"", Entity2: ""National Comprehensive Cancer Network"", Relationship: ""produced by""

Section Name: Important Notes
====================
Entities:-
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medical, surgical, or behavioral interventions.
Clinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Neoplasms : New abnormal growth of tissue that can be benign or malignant.
Malignant Neoplastic Disease : A disease resulting from the growth of malignant neoplasms.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""Clinical Trials"", Entity2: ""Cancer"", Relationship: ""recommended for""
2. Entity1: ""NCCN"", Entity2: ""Clinical Trials"", Relationship: ""encourages participation in""

Causalities:-
<C> NCCN believes that the best management of any patient with cancer is in a clinical trial </C>. <A> Participation in clinical trials is especially encouraged </A>.

Section Name: Principles
====================
Entities:-
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Chemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.

Relationships:-
1. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Radiation Therapy"", Relationship: ""Both are principles of cancer treatment methods.""
2. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""Both are principles of cancer treatment methods.""
3. Entity1: ""Principles of Radiation Therapy"", Entity2: ""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""Both are principles of cancer treatment methods.""

Causalities:-
### Principles

- **Principles of Surgery (SURG-A)**
- **Principles of Radiation Therapy (SUPRA-A)**
- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**

Section Name: Adverse Pathologic Features
====================
Entities:-
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.
Perineural Invasion : The presence of cancer cells surrounding or tracking along a nerve within the perineural space.
Vascular Invasion : The invasion of cancer cells into blood vessels.
Lymphatic Invasion : The invasion of cancer cells into lymphatic vessels.

Relationships:-
1. Entity1: ""Extranodal extension"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
2. Entity1: ""Positive margins"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
3. Entity1: ""Close margins"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
4. Entity1: ""pT3 or pT4 primary"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
5. Entity1: ""pN2 or pN3 nodal disease"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
6. Entity1: ""Perineural invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
7. Entity1: ""Vascular invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
8. Entity1: ""Lymphatic invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""

Causalities:-
<C> Extranodal extension </C>
<C> Positive margins </C>
<C> Close margins </C>
<C> pT3 or pT4 primary </C>
<C> pN2 or pN3 nodal disease </C>
<C> Perineural invasion </C>
<C> Vascular invasion </C>
<C> Lymphatic invasion </C>

Section Name: Response Assessment
====================
Entities:-
Chemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Primary Site : The original location where a tumor or cancer begins.
Complete Remission : The disappearance of all signs of cancer in response to treatment.
Partial Remission : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
Radiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.

Relationships:-
1. Entity1: ""induction chemotherapy"", Entity2: ""Primary site"", Relationship: ""treatment outcome""
2. Entity1: ""Definitive RT"", Entity2: ""Primary site"", Relationship: ""treatment option""
3. Entity1: ""RT"", Entity2: ""Primary site"", Relationship: ""treatment option""
4. Entity1: ""Surgery"", Entity2: ""unresectable nodal disease"", Relationship: ""treatment option""

Causalities:-
<C> Response after induction chemotherapy </C>: <E> Primary site: CR </E> <E> Primary site: PR </E> <E> Primary site: < PR </E> <A> Definitive RT </A> (category 1) <A> RT </A> (category 1) or <A> systemic therapy/RT </A> (category 2B) <A> Surgery </A> or <A> unresectable nodal disease </A>

Section Name: Follow-up
====================
Entities:-
Follow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.
Follow-Up Procedure : A procedure where a patient is monitored over time to assess the progress of a condition or the effects of treatment.
Follow-Up (Medicine) : The process of monitoring a patient's health over time after treatment or diagnosis.
Disease Recurrence : The return of a sign, symptom, or disease after a remission.
Recurrent Disease : A disease that returns after a period of remission.
Recurrence (Medicine) : The return of a disease or condition after a period of improvement.

Relationships:-
1. Entity1: ""Follow-up"", Entity2: ""Recurrent or persistent disease"", Relationship: ""monitoring""

Causalities:-
### Follow-up

- **Follow-up** (FOLL-A, 1 of 2)
- **Recurrent or persistent disease** (ADV-3)

Section Name: Risk Features
====================
Entities:-
Radiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Adverse pathologic features"", Entity2: ""RT"", Relationship: ""Consideration for treatment""
2. Entity1: ""Adverse pathologic features"", Entity2: ""Systemic therapy"", Relationship: ""Consideration for treatment""

Causalities:-
- **No adverse pathologic features**
- **Other risk features**
- **Adverse pathologic features**:
  - <C> Extranodal extension and/or positive margin </C>
  - <A> RT or consider systemic therapy/RT </A>

Section Name: Post-Therapy Evaluation
====================
Entities:-
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Neck : The neck is the part of the body that separates the head from the torso and provides the mobility and movements of the head.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Neck Evaluation"", Relationship: ""evaluated in""
2. Entity1: ""RT"", Entity2: ""Neck Evaluation"", Relationship: ""evaluated in""

Causalities:-
<CO> Post Systemic Therapy/RT or RT Neck </CO> <A> Evaluation </A>

Section Name: Flowchart Overview
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Supraglottic Larynx : The part of the larynx located above the vocal cords, including the epiglottis and aryepiglottic folds.
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.

Relationships:-
1. Entity1: ""NCCN Guidelines"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""guides management of""
2. Entity1: ""NCCN Guidelines"", Entity2: ""healthcare professionals"", Relationship: ""used by""

Causalities:-
<C> cancer of the supraglottic larynx </C> <E> evaluate patient responses following treatment </E> <CO> based on observed outcomes </CO> <A> evaluation of the primary site and determining subsequent steps </A>.

Section Name: Assessment and Treatment Decisions
====================
Entities:-
Induction Chemotherapy : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Complete Response : The disappearance of all signs of cancer in response to treatment.
Partial Response : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Complete Response"", Entity2: ""Radiation Therapy"", Relationship: ""leads to""
2. Entity1: ""Complete Response"", Entity2: ""Surgery"", Relationship: ""leads to""
3. Entity1: ""Partial Response"", Entity2: ""Systemic Therapy"", Relationship: ""leads to""
4. Entity1: ""Partial Response"", Entity2: ""Radiation Therapy"", Relationship: ""leads to""

Causalities:-
<C> responses to initial treatments such as induction chemotherapy </C> <E> Three main response categories are recognized: Complete Response (CR), Partial Response (PR), and less than Partial Response (< PR) </E>. These categories are pivotal in determining the next steps. <C> CR </C> <E> indicates full resolution of the disease at the primary site </E>, <A> leading to the consideration of definitive radiation therapy or the likelihood of surgery </A>. Conversely, <C> PR </C> <E> suggests that the disease has improved but not completely resolved </E>, <A> which directs the pathway towards either systemic therapy or continued radiation therapy </A>, <A> with further evaluation necessary </A>.

Section Name: Adverse Pathologic Features and Follow-up
====================
Entities:-
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Neoplasm Recurrence, Local : The return of a tumor or cancer, at the original site, after it has been treated.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Recurrent Neoplasm : A neoplasm that has returned after treatment.
Metastatic Neoplasm : A neoplasm that has spread from its original site to one or more other places in the body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Cancer Recurrence : The return of cancer after treatment and after a period of time during which the cancer was undetectable.
Metastasis : Spread of a cancer or other disease from one organ or part to another not directly connected with it.

Relationships:-
1. Entity1: ""Adverse pathologic features"", Entity2: ""Treatment decisions"", Relationship: ""Influence""
2. Entity1: ""Adverse features"", Entity2: ""Surgical intervention"", Relationship: ""Recommendation""
3. Entity1: ""Absence of adverse features"", Entity2: ""Radiation therapy"", Relationship: ""Pathway""
4. Entity1: ""Follow-up process"", Entity2: ""Recurrent or persistent disease"", Relationship: ""Detection""
5. Entity1: ""Recurrent or persistent disease"", Entity2: ""Advanced disease management"", Relationship: ""Necessity""

Causalities:-
<C> The presence of adverse pathologic features — such as extranodal extension or positive margins </C> <E> can directly influence treatment decisions </E>. <CO> If adverse features are found </CO>, <A> surgical intervention is recommended </A>. <CO> In cases where there are no adverse features </CO>, the patient may proceed directly to radiation therapy or continued systemic treatment, emphasizing the tailored approach based on the individual patient's disease characteristics.

Furthermore, the chart includes a section addressing the follow-up process after initial treatment. <CO> If there are signs of recurrent or persistent disease </CO>, <A> additional evaluations and treatment modalities may be necessary </A>. These evaluations <E> lead to specific recommendations for advanced disease management, denoted as ADV-3 on the chart </E>, emphasizing the importance of continuous monitoring and assessment in cancer care.
--------------------------------------------------
Page Number: 68

Section Name: Diagnosis Section
====================
Entities:-
Diagnosis : The process of determining which disease or condition explains a person's symptoms and signs.
Metastatic Disease : A disease in which cancer cells spread from the place where they first formed to another part of the body.
Clinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Locoregional Therapy : Treatment that is directed to a specific area of the body, often used in cancer treatment.

Relationships:-
1. Entity1: ""Diagnosis"", Entity2: ""Decision-making process"", Relationship: ""initiates""
2. Entity1: ""Metastatic disease"", Entity2: ""Clinical trial"", Relationship: ""preferred pathway""
3. Entity1: ""Locoregional treatment"", Entity2: ""Primary site algorithms"", Relationship: ""based on""

Causalities:-
<CO> for patients presenting with metastatic disease </CO>, <A> a clinical trial is the preferred pathway </A>, emphasizing the critical nature of innovative therapies in advanced cancer care. The option to <A> ""Consider locoregional treatment based on primary site algorithms"" </A> suggests that specific treatment strategies may be tailored <CO> depending on the exact location and characteristics of the cancer </CO>.

Section Name: Treatment Pathways
====================
Entities:-
Performance Status : A measure of a patient's general well-being and ability to perform ordinary tasks, often used in oncology to determine the appropriate treatment.
Systemic Therapy : A treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Surgery : A medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Palliative Care : Specialized medical care for people living with a serious illness, focused on providing relief from the symptoms and stress of the illness.
Supportive Care : Care given to improve the quality of life of patients who have a serious or life-threatening disease.

Relationships:-
1. Entity1: ""Performance Status"", Entity2: ""Systemic Therapy"", Relationship: ""affects choice of""
2. Entity1: ""Performance Status"", Entity2: ""Surgery"", Relationship: ""affects choice of""
3. Entity1: ""Performance Status"", Entity2: ""Radiation Therapy"", Relationship: ""affects choice of""
4. Entity1: ""Performance Status"", Entity2: ""Palliative Care"", Relationship: ""affects choice of""
5. Entity1: ""Performance Status"", Entity2: ""Supportive Care"", Relationship: ""affects choice of""
6. Entity1: ""PS 0-1 Patients"", Entity2: ""Combination Systemic Therapy"", Relationship: ""suitable for""
7. Entity1: ""PS 2 Patients"", Entity2: ""Palliative Radiation Therapy"", Relationship: ""may receive""
8. Entity1: ""PS 3 Patients"", Entity2: ""Supportive Care"", Relationship: ""recommended""

Causalities:-
The treatment section branches into various pathways depending on <CO> the patient’s performance status (PS) </CO>, which is a measure of their general well-being and ability to function. - **For PS 0-1 Patients:** The flowchart indicates several treatment options, including <A> combination systemic therapy, single-agent systemic therapy, surgery, and radiation therapy (RT) </A>. This group is highlighted as those who are most capable of handling intensive treatments and <E> may benefit significantly from combination therapies </E>. - **For PS 2 Patients:** The recommended approach varies slightly, with a continued emphasis on <A> systemic therapies, palliative radiation therapy, or best supportive care </A>. This indicates a level of compromise in treatment options, suggesting that while aggressive treatment is still possible, <E> the focus might shift more towards quality of life </E>. - **For PS 3 Patients:** The treatment options further narrow, still recommending <A> systemic therapy or supportive care </A> but highlighting palliative approaches, reflecting a recognition of <E> the more advanced disease and potentially limited treatment efficacy </E>.

Section Name: Principles of Treatment
====================
Entities:-
Antineoplastic Combined Chemotherapy Protocols : Protocols for the administration of more than one antineoplastic agent in combination to treat malignant neoplasms.
Radiotherapy : The use of radiation, usually X-rays or gamma rays, to treat disease, especially cancer.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Systemic Therapy : A treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Surgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Chemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.
Surgery : A medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Radiation Therapy"", Relationship: ""Different modalities of cancer treatment""
2. Entity1: ""Systemic Therapy"", Entity2: ""Surgery"", Relationship: ""Different modalities of cancer treatment""
3. Entity1: ""Radiation Therapy"", Entity2: ""Surgery"", Relationship: ""Different modalities of cancer treatment""

Causalities:-
- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)** - **Principles of Radiation Therapy (ADV-A)** - **Principles of Surgery (SURG-A)**

Section Name: Diagnosis and Treatment of Head and Neck Cancer
====================
Entities:-
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Metastatic Malignant Neoplasm : A malignant neoplasm that has spread from its original site to a different site.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.
Clinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Performance Status : A measure of a patient's general well-being and ability to perform ordinary tasks, often used in oncology to determine the appropriate treatment.

Relationships:-
1. Entity1: ""Metastatic disease"", Entity2: ""Clinical trial"", Relationship: ""preferred treatment option""
2. Entity1: ""Performance Status 0-1"", Entity2: ""Combination systemic therapy"", Relationship: ""treatment option""
3. Entity1: ""Performance Status 2"", Entity2: ""Single-agent systemic therapy"", Relationship: ""treatment option""
4. Entity1: ""Performance Status 3"", Entity2: ""Systemic therapy"", Relationship: ""treatment option""

Causalities:-
- <CO>Metastatic (M1) disease at initial presentation</CO>
  <A>Clinical trial preferred</A>
  <E>Distant metastases</E>
  <A>Consider locoregional treatment based on primary site algorithms (Table of Contents)</A>

#### Performance Status (PS)
- <CO>PS 0–1</CO>
  <A>Combination systemic therapy</A> or <A>Single-agent systemic therapy</A> or <A>Surgery</A> or <A>RT</A> or <A>systemic therapy/RT for selected patients with limited metastases</A> or <A>Best supportive care</A>
- <CO>PS 2</CO>
  <A>Single-agent systemic therapy</A> or <A>Best supportive care ± Palliative RT</A> or <A>Palliative surgery</A>
- <CO>PS 3</CO>
  <A>Systemic therapy, clinical trial preferred</A> or <A>Palliative RT</A> or <A>Best supportive care</A>

Section Name: Persistent Disease or Progression
====================
Entities:-
Palliative Care : Specialized medical care for people living with a serious illness, focused on providing relief from the symptoms and stress of the illness.
Supportive Care : Care given to improve the quality of life of patients who have a serious or life-threatening disease.
Antineoplastic Agents : Substances that inhibit or prevent the proliferation of neoplasms.
Systemic Therapy : A treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Chemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.
Radiotherapy : The use of radiation, usually X-rays or gamma rays, to treat disease, especially cancer.
Palliative Radiotherapy : Radiotherapy given to relieve symptoms and reduce suffering caused by cancer.
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.

Relationships:-
1. Entity1: ""Best supportive care"", Entity2: ""Alternate single-agent systemic therapy"", Relationship: ""alternative treatment options""
2. Entity1: ""Best supportive care"", Entity2: ""Palliative RT"", Relationship: ""alternative treatment options""
3. Entity1: ""Alternate single-agent systemic therapy"", Entity2: ""Palliative RT"", Relationship: ""alternative treatment options""

Causalities:-
<A> Best supportive care </A> or <A> Alternate single-agent systemic therapy </A> or <A> Palliative RT </A>
--------------------------------------------------
Page Number: 53

Section Name: Introduction
====================
Entities:-
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives.
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Malignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network"", Entity2: ""Malignant neoplasm of supraglottis"", Relationship: ""provides guidelines for""
2. Entity1: ""clinical staging"", Entity2: ""treatment strategies"", Relationship: ""part of flowchart for""

Causalities:-
The provided image is a flowchart outlining the <C> NCCN (National Comprehensive Cancer Network) guidelines </C> for the treatment of <CO> cancers of the supraglottic larynx </CO>. This flowchart <A> utilizes a highly structured approach to convey clinical staging and treatment strategies </A>, indicating the various pathways based on <CO> patient conditions and disease features </CO>.

Section Name: NCCN Guidelines Version 4.2024
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Malignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.
Supraglottic Cancer : Cancer that occurs in the supraglottic region of the larynx, above the vocal cords.
Clinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.
Clinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.

Relationships:-
1. Entity1: ""Cancer of the Supraglottic Larynx"", Entity2: ""Clinical Trials"", Relationship: ""recommended management strategy""

Causalities:-
- All recommendations are category 2A unless otherwise indicated.
- <A> Participation in clinical trials </A> is especially encouraged.

Section Name: Key Components of the Flowchart
====================
Entities:-
Neoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.
Radiotherapy : The use of ionizing radiation to treat cancer.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.
Neoplasm Recurrence, Local : The return of a tumor at the original site after treatment.
Clinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.

Relationships:-
1. Entity1: ""Clinical Staging"", Entity2: ""Treatment of Primary and Neck"", Relationship: ""determines""
2. Entity1: ""Evaluation and Follow-Up"", Entity2: ""Adverse and No Adverse Features"", Relationship: ""leads to decision based on""
3. Entity1: ""Adjuvant Treatment"", Entity2: ""Adverse pathologic features"", Relationship: ""considered if present""
4. Entity1: ""Clinical Trials"", Entity2: ""Treatment Pathway"", Relationship: ""part of""

Causalities:-
### Key Components of the Flowchart

1. **Clinical Staging**: The flowchart starts with <A>clinical staging</A>, indicating that <CO>patients must first be evaluated to determine the extent of cancer</CO>. This is essential for <E>deciding on appropriate treatment options</E>.

2. **Treatment of Primary and Neck**: The flowchart details multiple treatment strategies, including:
   - <A>**Concurrent systemic therapy/RT**</A>: This suggests a combination approach for <CO>patients eligible for such treatment</CO>.
   - <A>**Definitive Radiation Therapy (RT)**</A>: Recommended for <CO>low-volume diseases or patients who cannot tolerate systemic therapy</CO>.
   - <A>**Surgical Options**</A>: It highlights options such as endoscopic or open partial laryngectomy and neck dissection, which are <CO>contingent on clinical evaluations</CO>.

3. **Evaluation and Follow-Up**: After initial treatment approaches, the chart directs clinicians to perform a <A>""Post Systemic Therapy/RT or RT Neck Evaluation""</A>. This step <E>assesses whether there are adverse pathologic features</E>, guiding subsequent treatment decisions.

4. **Adverse and No Adverse Features**: The decision pathway diverges based on findings:
   - <CO>Patients with **adverse pathologic features**</CO> may have <A>additional diagnostic imaging (CT or MRI)</A> and may require <A>further systemic treatment</A>.
   - <CO>Patients with **no adverse features**</CO> may be directed towards <A>considerations for radiation therapy</A>.

5. **Adjuvant Treatment and Recurrence**: The chart also addresses <E>management of any recurrent or persistent disease</E>, emphasizing the importance of <A>regular follow-up assessments</A>. Various options for <A>adjuvant treatment</A> are mentioned, focusing on tailored approaches towards ongoing management of the disease.

6. **Clinical Trials**: The flowchart encourages <A>participation in clinical trials</A>, indicating a commitment to <E>exploring new treatments and improving patient outcomes</E>.

Section Name: Principles
====================
Entities:-
Imaging : The process of producing images of the body or parts of the body to diagnose or examine disease.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Radiation Therapy : The use of ionizing radiation to treat cancer and other diseases.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Imaging"", Entity2: ""Surgery"", Relationship: ""Both are foundational principles in medical practice.""
2. Entity1: ""Radiation therapy"", Entity2: ""Systemic Therapy"", Relationship: ""Both are treatment modalities for cancer.""

Causalities:-
#### Principles
- **Principles of Imaging (IMG-A)**
- **Principles of Surgery (SURG-A)**
- **Principles of Radiation Therapy (SUPRA-A)**
- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**

Section Name: Adverse Pathologic Features
====================
Entities:-
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margins : The presence of cancer cells at the edge of the tissue removed during surgery.
Perineural Invasion : Cancer cells found surrounding or tracking along a nerve within the perineural space.
Vascular Invasion : The presence of cancer cells within blood vessels.
Lymphatic Invasion : The presence of cancer cells within lymphatic vessels.

Relationships:-
1. Entity1: ""Extranodal Extension"", Entity2: ""Positive Surgical Margins"", Relationship: ""Both indicate cancer spread beyond original site.""
2. Entity1: ""Perineural Invasion"", Entity2: ""Vascular Invasion"", Relationship: ""Both are pathways for cancer spread.""
3. Entity1: ""pT3 or pT4 primary"", Entity2: ""pN2 or pN3 nodal disease"", Relationship: ""Both indicate advanced cancer stages.""

Causalities:-
<C> Extranodal extension </C>
<C> Positive margins </C>
<C> Close margins </C>
<C> pT3 or pT4 primary </C>
<C> pN2 or pN3 nodal disease </C>
<C> Perineural invasion </C>
<C> Vascular invasion </C>
<C> Lymphatic invasion </C>

Section Name: Clinical Staging and Treatment of Primary and Neck
====================
Entities:-
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.
Follow-Up Procedure : A procedure performed to monitor the progress of a patient after treatment.
Recurrent Disease : A disease that returns after a period of remission.
Laryngectomy : Surgical removal of the larynx, often used to treat cancer.
Radiation Therapy : The use of ionizing radiation to treat cancer and other diseases.
Clinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat cancer.
Chemotherapy : Treatment of disease by the use of chemical substances, especially cancer by cytotoxic drugs.

Relationships:-
1. Entity1: ""Adjuvant Treatment"", Entity2: ""Treatment of Primary and Neck"", Relationship: ""part of""
2. Entity1: ""Follow-up"", Entity2: ""Treatment of Primary and Neck"", Relationship: ""part of""
3. Entity1: ""Recurrent or Persistent Disease"", Entity2: ""Treatment of Primary and Neck"", Relationship: ""part of""
4. Entity1: ""Larynx-Preserving Surgery"", Entity2: ""Treatment Options"", Relationship: ""is a treatment option for""
5. Entity1: ""Concurrent Systemic Therapy/RT"", Entity2: ""Treatment Options"", Relationship: ""is a treatment option for""
6. Entity1: ""Clinical Trials or Definitive RT"", Entity2: ""Treatment Options"", Relationship: ""is a treatment option for""
7. Entity1: ""Endoscopic or Open Partial Laryngectomy and Neck Dissection(s)"", Entity2: ""Treatment Options"", Relationship: ""is a treatment option for""
8. Entity1: ""Induction Chemotherapy"", Entity2: ""Treatment Options"", Relationship: ""is a treatment option for""

Causalities:-
<A> Amenable to Larynx-Preserving (Conservation) Surgery </A>: <CO> T1–2, N+ and selected T3, N1 </CO>
<A> Concurrent Systemic Therapy/RT </A>: <CO> i, k, l </CO>
<A> Clinical Trials or Definitive RT </A>: <CO> i </CO>
<A> Endoscopic or Open Partial Laryngectomy and Neck Dissection(s) </A>: <CO> h </CO>
<A> Induction Chemotherapy </A>: <CO> k, m </CO>

Section Name: Pathologic Features and Response Assessment
====================
Entities:-
Radiation Therapy : The use of ionizing radiation to treat cancer and other diseases.
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margin : Cancer cells are found at the edge of the material removed during surgery, indicating that some cancer may have been left behind.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Extranodal extension"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
2. Entity1: ""Positive margin"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
3. Entity1: ""Systemic Therapy"", Entity2: ""Adverse Pathologic Features"", Relationship: ""considered in response to""
4. Entity1: ""Radiation Therapy"", Entity2: ""Adverse Pathologic Features"", Relationship: ""considered in response to""

Causalities:-
#### Pathologic Features
- **No Adverse Pathologic Features**: j
  - <A> Consider RT </A>: i
- **Adverse Pathologic Features**: j
  - <CO> Extranodal extension and/or positive margin </CO>: n
  - Other risk features
  - <A> Systemic therapy/RT </A>: i, k (category 1)
  - <A> Consider systemic therapy/RT </A>: i, k

#### Response Assessment
- **Response Assessment** (SUPRA-7)

Section Name: Imaging and Recurrent or Persistent Disease
====================
Entities:-
Tomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient.
Magnetic Resonance Imaging : Medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.
Computed Tomography : Medical imaging technique used in radiology to obtain detailed internal images of the body.

Relationships:-
1. Entity1: ""CT"", Entity2: ""primary and neck"", Relationship: ""used for imaging""
2. Entity1: ""MRI"", Entity2: ""primary and neck"", Relationship: ""used for imaging""
3. Entity1: ""Post Systemic Therapy/RT"", Entity2: ""Recurrent or Persistent Disease"", Relationship: ""evaluation after treatment""
4. Entity1: ""RT Neck Evaluation"", Entity2: ""Recurrent or Persistent Disease"", Relationship: ""evaluation after treatment""

Causalities:-
<A> CT (with contrast) or MRI (with and without contrast) of primary and neck </A>

<CO> Recurrent or Persistent Disease </CO>

<CO> Post Systemic Therapy/RT or RT Neck Evaluation </CO>

Section Name: Conclusion
====================
Entities:-
Oncologists : Medical doctors who specialize in the diagnosis and treatment of cancer.
Supraglottic Larynx Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is the area above the vocal cords.
Clinical Staging : The process of determining the extent of cancer in the body, usually based on physical examination, imaging tests, and biopsies.
Treatment Strategies : Plans or methods developed to treat diseases, including cancer, which may involve surgery, chemotherapy, radiation therapy, or other modalities.
Follow-Up Evaluations : Medical assessments conducted after initial treatment to monitor a patient's progress and detect any recurrence of disease.
Clinical Efficacy : The ability of a treatment to produce the desired therapeutic effect in clinical settings.
Research : Systematic investigation and study conducted to establish facts and reach new conclusions.
Treatment Paradigms : Standard models or patterns of treatment used in medical practice, often based on clinical guidelines and research findings.

Relationships:-
1. Entity1: ""Oncologists"", Entity2: ""Supraglottic Larynx Cancer"", Relationship: ""use flowchart for decision-making""
2. Entity1: ""Clinical Staging"", Entity2: ""Treatment Strategies"", Relationship: ""part of management process""
3. Entity1: ""Treatment Strategies"", Entity2: ""Follow-Up Evaluations"", Relationship: ""part of management process""

Causalities:-
<A> The flowchart serves as a comprehensive guide for oncologists and healthcare providers </A>, <A> facilitating informed decision-making in the treatment of supraglottic larynx cancer </A>. <A> By visualizing the complex interactions between clinical staging, treatment strategies, and follow-up evaluations </A>, <E> it streamlines the management process </E>, <E> ensuring that patients receive appropriate care tailored to their specific needs </E>. <E> The detailed pathways not only enhance clinical efficacy </E> but also <E> underscore the importance of ongoing research and adaptation of treatment paradigms in oncology </E>.


Among these two options which one is the most likely true:

(A) `Location_of_Involved_Lymph_Nodes_4` increases risk `Examination_13`
(B) `Examination_13` `increases risk `Location_of_Involved_Lymph_Nodes_4`

The answer is: ...

1. State the evidences in detail of the validity of option (A) or (B) by cross referencing
NCCN Clinical Practitioner’s Guidelines for Head and Neck Cancer.
2. If the evidences are obtained from `INFORMATION FROM KNOWLEDGE BASE`,
mention their corresponding Page Numbers, Section Name, entities, relationships and causalities.

DESIRED OUTPUT FORMAT:
<thinking>
...
</thinking>
<answer>
{
   ""thinking"": [""..."", ...],
   ""evidences"": [""..."", ...],
   ""answer"": ...
}
</answer>

Before providing the answer in <answer> tags, think step by step in detail in <thinking> tags and analyze every part.
Output inside <answer> tag in JSON format. Only output valid JSON.
DO NOT HALLUCINATE. DO NOT MAKE UP FACTUAL INFORMATION.
","1. The edge (Location_of_Involved_Lymph_Nodes_4) causes (Examination_13) suggests that the position of lymph nodes influences the diagnostic examination results. This is a proximal causal relationship with a positive direction, indicating that the location of lymph nodes directly affects the examination outcome.
2. The edge (Examination_13) causes (Location_of_Involved_Lymph_Nodes_4) suggests that the diagnostic examination results determine the location of involved lymph nodes. This is also a proximal causal relationship with a positive direction, indicating that the examination results directly inform the lymph node location.
3. In the NCCN Guidelines, the clinical staging and treatment of head and neck cancer often involve assessing lymph node involvement to determine the extent of disease and appropriate treatment strategies. This aligns with the idea that the location of lymph nodes (Node1) influences examination results (Node2).
4. The NCCN Guidelines emphasize the importance of diagnostic examinations in identifying patterns of lymph node metastasis, which is crucial for cancer staging and treatment planning. This supports the idea that examination results (Node2) inform the location of lymph nodes (Node1).
5. The causal factor for EDGE1 is sufficient but not necessary, meaning the location of lymph nodes can cause the examination to show corresponding metastasis patterns, but other factors may also lead to similar examination results.
6. The causal factor for EDGE2 is necessary but not sufficient, meaning the examination result is required to determine lymph node location, but other clinical factors may also play a role.
7. The NCCN Guidelines (Page 51, Section: Clinical Staging) highlight the role of clinical staging criteria in determining treatment strategies, which often involve assessing lymph node involvement. This supports the idea that lymph node location influences examination results.
8. The NCCN Guidelines (Page 70, Section: Diagnosis) emphasize the importance of diagnostic examinations in identifying metastasis patterns, which directly inform treatment decisions. This supports the idea that examination results inform lymph node location.
","1. Page 51, Section: Clinical Staging - Emphasizes the role of clinical staging criteria in determining treatment strategies, involving lymph node assessment.
2. Page 70, Section: Diagnosis - Highlights the importance of diagnostic examinations in identifying metastasis patterns, informing treatment decisions.
",A,"{'A': 98.9, 'B': 1.1}",yes,A,"1. The AI assistant's reasoning for selecting option (A) is based on the causal relationship described in EDGE1, where the location of lymph nodes is said to influence the results of a diagnostic examination. This is supported by the explanation that the examination is designed to detect patterns of lymph node metastasis, which are directly influenced by their location.
2. The assistant also references the NCCN Guidelines, particularly the sections on Clinical Staging and Diagnosis, to support the idea that lymph node location is a critical factor in determining examination outcomes and subsequent treatment strategies.
3. The assistant's reasoning for not selecting option (B) is based on the explanation provided in EDGE2, where the examination results are necessary but not sufficient to determine lymph node location. This suggests that while examination results are important, they do not directly cause changes in lymph node location.
4. The assistant's conclusion that option (A) is more consistent with the reasoning provided is supported by the causal direction and factor analysis in EDGE1, as well as the supporting evidence from the NCCN Guidelines.
"
6,gpt-4o,"Location_of_Involved_Lymph_Nodes_4,Magnetic_Resonance_Imaging_MRI_14","""{'NODE1': {'id': 'Location_of_Involved_Lymph_Nodes_4', 'label': 'Position of Affected Lymph Nodes in Patient', 'description': \""This node represents the location of lymph nodes that are involved or affected in a patient's condition. Understanding whether the lymph nodes are ipsilateral, bilateral, or contralateral is crucial for determining the extent of disease spread and planning appropriate treatment strategies.\"", 'type': 'Patient Situation', 'observability': 'Unobserved', 'states': [{'state_name': 'ipsilateral', 'state_description': 'The involved lymph nodes are on the same side of the body as the primary tumor or reference point. This can indicate localized spread of disease.'}, {'state_name': 'bilateral', 'state_description': 'The involved lymph nodes are on both sides of the body. This may suggest a more extensive spread of disease and can impact treatment decisions.'}, {'state_name': 'contralateral', 'state_description': 'The involved lymph nodes are on the opposite side of the body from the primary tumor or reference point. This can indicate metastatic spread and may affect staging and treatment planning.'}]}, 'NODE2': {'id': 'Magnetic_Resonance_Imaging_MRI_14', 'label': 'Magnetic Resonance Imaging', 'description': 'This node represents the results of an MRI examination focused on detecting lymph node metastasis. It indicates whether metastasis is present in lymph nodes and specifies the pattern of metastasis (bilateral, ipsilateral, or contralateral) as observed through MRI.', 'type': 'Examination Result', 'observability': 'Observed', 'states': [{'state_name': 'bilateral_lymph_node_metastasis', 'state_description': 'Metastasis is present in lymph nodes on both sides of the body as detected by MRI.'}, {'state_name': 'ipsilateral_lymph_node_metastasis', 'state_description': 'Metastasis is present in lymph nodes on the same side as the primary tumor as detected by MRI.'}, {'state_name': 'contralateral_lymph_node_metastasis', 'state_description': 'Metastasis is present in lymph nodes on the opposite side of the primary tumor as detected by MRI.'}]}, 'EDGE1': {'edges_ids': ['Location_of_Involved_Lymph_Nodes_4', 'Magnetic_Resonance_Imaging_MRI_14'], 'edge': '(Location_of_Involved_Lymph_Nodes_4) causes (Magnetic_Resonance_Imaging_MRI_14)', 'explanation': ['The edge suggests that the location of involved lymph nodes causes the MRI results, which is not valid.', 'The MRI results are an observation of the lymph node involvement, not caused by it.', 'The MRI is used to detect the presence and pattern of lymph node metastasis, not influenced by the lymph node location.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}, 'EDGE2': {'edges_ids': ['Magnetic_Resonance_Imaging_MRI_14', 'Location_of_Involved_Lymph_Nodes_4'], 'edge': '(Magnetic_Resonance_Imaging_MRI_14) causes (Location_of_Involved_Lymph_Nodes_4)', 'explanation': ['The edge represents the idea that the results of an MRI examination (Magnetic_Resonance_Imaging_MRI_14) could cause or determine the location of involved lymph nodes (Location_of_Involved_Lymph_Nodes_4).', 'However, the MRI results are an observation of the lymph nodes` state, not a cause of their state. The MRI detects whether metastasis is present and its pattern, but it does not influence or cause the lymph nodes to be in a particular location.', 'Therefore, the edge is not valid as a causal relationship. The MRI results do not cause the lymph nodes to be ipsilateral, bilateral, or contralateral; they simply report on the state of the lymph nodes as observed.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}, 'ENTITIES_MATCHING_PAGES_INFO': {'94': {'matching_entities': [{'LYMPH NODE METASTASIS': 0.9812612}, {'MAGNETIC RESONANCE IMAGING': 0.9692417}, {'LYMPHATIC METASTASIS': 0.9677353}, {'NEOPLASM METASTASIS': 0.95823944}, {'COMPUTED TOMOGRAPHY': 0.9228411}, {'TOMOGRAPHY, X-RAY COMPUTED': 0.9212845}], 'count': 6}, '53': {'matching_entities': [{'MAGNETIC RESONANCE IMAGING': 0.9692417}, {'LYMPHATIC INVASION': 0.9282598}, {'COMPUTED TOMOGRAPHY': 0.9228411}, {'IMAGING': 0.9221975}, {'TOMOGRAPHY, X-RAY COMPUTED': 0.9212845}, {'EXTRANODAL EXTENSION': 0.9208998}], 'count': 6}, '41': {'matching_entities': [{'LYMPHATIC METASTASIS': 0.9677353}, {'MAGNETIC RESONANCE IMAGING (MRI)': 0.94132537}, {'COMPUTED TOMOGRAPHY (CT)': 0.9349672}, {'METASTASIS': 0.9265935}, {'IMAGING': 0.9221975}], 'count': 5}, '44': {'matching_entities': [{'MAGNETIC RESONANCE IMAGING': 0.9692417}, {'LYMPHATIC METASTASIS': 0.9677353}, {'COMPUTED TOMOGRAPHY': 0.9228411}, {'TOMOGRAPHY, X-RAY COMPUTED': 0.9212845}, {'EXTRANODAL EXTENSION': 0.9208998}], 'count': 5}, '46': {'matching_entities': [{'MAGNETIC RESONANCE IMAGING': 0.9692417}, {'MAGNETIC RESONANCE IMAGING (MRI)': 0.94132537}, {'COMPUTED TOMOGRAPHY (CT)': 0.9349672}, {'COMPUTED TOMOGRAPHY': 0.9228411}, {'EXTRANODAL EXTENSION': 0.9208998}], 'count': 5}}, 'GUIDELINE_PAGES_INFO': '--------------------------------------------------\\nPage Number: 94\\n\\nSection Name: Head and Neck Cancers - Principles of Imaging\\n====================\\nEntities:-\\nPositron Emission Tomography Computed Tomography : A medical imaging technique combining PET and CT capabilities to provide detailed information about the body\\'s function and structure.\\nPositron Emission Tomography : A nuclear medicine functional imaging technique that is used to observe metabolic processes in the body.\\nComputed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.\\nHead And Neck Neoplasms : Cancers that arise in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\n\\nRelationships:-\\n1. Entity1: \""PET/CT\"", Entity2: \""PET scan\"", Relationship: \""preferred over\""\\n2. Entity1: \""PET-CT\"", Entity2: \""head neck cancers\"", Relationship: \""used in study of\""\\n\\nCausalities:-\\n<A> PET/CT is preferred over PET scan alone (i.e., without superimposed CT scan) </A>. <C> PET/CT provides more accurate anatomical localization of abnormalities </C> <E> more accurate anatomical localization of abnormalities </E>.\\n\\nSection Name: Initial Workup - Nodal Metastases\\n====================\\nEntities:-\\nLymphatic Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site via the lymphatic system.\\nTomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient, producing signals that are processed by the machine\\'s computer to generate cross-sectional images.\\nMagnetic Resonance Imaging : A non-invasive imaging technique that uses magnetic fields and radio waves to create detailed images of the organs and tissues within the body.\\nPositron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption.\\nLymph Node Metastasis : The spread of cancer cells to lymph nodes, which are part of the lymphatic system.\\nCt Of Neck : A computed tomography scan of the neck region.\\nMri Of Neck : A magnetic resonance imaging scan of the neck region.\\nFdg-Pet Scan : A type of positron emission tomography using fluorodeoxyglucose to assess metabolic activity.\\nComputed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.\\nPositron Emission Tomography : A nuclear medicine functional imaging technique that is used to observe metabolic processes in the body.\\n\\nRelationships:-\\n1. Entity1: \""CT\"", Entity2: \""lymph node metastases\"", Relationship: \""used to evaluate\""\\n2. Entity1: \""MRI\"", Entity2: \""lymph node metastases\"", Relationship: \""used to evaluate\""\\n3. Entity1: \""FDG-PET/CT\"", Entity2: \""lymph node metastases\"", Relationship: \""used for detection\""\\n4. Entity1: \""FDG-PET/CT\"", Entity2: \""surgical primary approach\"", Relationship: \""used to determine\""\\n5. Entity1: \""FDG-PET/CT\"", Entity2: \""definitive RT approach\"", Relationship: \""used to identify\""\\n\\nCausalities:-\\n<A> Evaluation of lymph node metastases should be conducted with CT or MRI of the neck </A>, using whichever imaging study is suitable for primary site evaluation (IMG-A, 1 of 4).\\n<CO> For patients with multistation or lower neck nodal involvement or high-grade tumor histology </CO>, <A> consider CT of the chest to assess for mediastinal lymph node metastases or FDG-PET/CT </A>, <C> which is associated with higher sensitivity for both nodal and distant metastases </C>.\\n<CO> For patients who are under consideration for a surgical primary approach </CO>, <A> the higher sensitivity of FDG-PET/CT is warranted for tumors approaching the midline, to determine the surgical approach to the contralateral neck </A>. <CO> Similarly, patients who are scheduled for a definitive RT approach </CO> <A> may benefit from the higher sensitivity of FDG-PET/CT for identifying involved lymph nodes </A>.\\n\\nSection Name: Initial Workup - Distant Metastases\\n====================\\nEntities:-\\nPositron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption.\\nMagnetic Resonance Imaging : A non-invasive imaging technique that uses magnetic fields and radio waves to create detailed images of the organs and tissues within the body.\\nTomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient, producing signals that are processed by the machine\\'s computer to generate cross-sectional images.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nLung Neoplasms : Tumors or cancer of the lung.\\nSmoking : The inhalation of the smoke of burning tobacco encased in cigarettes, pipes, and cigars.\\n\\nRelationships:-\\n1. Entity1: \""FDG-PET/CT\"", Entity2: \""Distant Metastases\"", Relationship: \""used to evaluate\""\\n2. Entity1: \""Contrast-enhanced brain MRI\"", Entity2: \""Brain Metastasis\"", Relationship: \""recommended for evaluation\""\\n3. Entity1: \""CT of the chest\"", Entity2: \""Pulmonary Metastases\"", Relationship: \""performed to assess\""\\n4. Entity1: \""Non-contrast CT of the chest\"", Entity2: \""Lung Parenchymal Metastases\"", Relationship: \""used to screen\""\\n5. Entity1: \""Annual CT screening\"", Entity2: \""Lung Metastasis\"", Relationship: \""considered for high risk\""\\n6. Entity1: \""Directed CT or MRI\"", Entity2: \""Distant Disease\"", Relationship: \""used for assessment\""\\n7. Entity1: \""FDG-PET/CT\"", Entity2: \""Recurrent Disease\"", Relationship: \""used for staging\""\\n\\nCausalities:-\\n<C> Patients with locoregionally advanced cancer (e.g., T3\u2013T4 primary or \u2265N1 nodal staging) </C>, <A> FDG-PET/CT is preferred to evaluate for distant disease and thoracic metastases </A>. <CO> For cancers where brain metastasis is a concern, such as mucosal melanoma or high-grade neuroendocrine carcinomas or adenocarcinomas </CO>, <A> contrast-enhanced brain MRI should be additionally obtained </A>.\\n<CO> If FDG-PET/CT is not performed </CO>, <A> CT of the chest should be performed to assess for presence of pulmonary metastases as well as mediastinal lymph node involvement </A>.\\n<CO> Non-contrast CT of the chest can be sufficient to screen for lung parenchymal metastases </CO> but <CO> is not adequate for assessment of mediastinal adenopathy </CO>. <CO> This is an appropriate lung cancer screening intervention for patients with a history of smoking </CO>.\\n<CO> Following primary definitive treatment (surgery, RT, or systemic therapy/RT) </CO> the role of annual CT screening for lung metastasis is controversial. <E> While this approach does detect early metastasis </E>, <CO> further study is needed to determine the extent of the positive effect and/or cost-effectiveness of this approach in specific subpopulations and timepoints post-treatment </CO>. <CO> For patients with a substantial smoking history or who are at high risk for lung metastases </CO>, <A> annual chest CT can be considered </A>.\\n<CO> If clinical concern for metastatic disease is confined to a specific anatomical area </CO>, <A> the assessment of distant disease can be performed with directed CT or MRI examination </A>.\\n<CO> FDG-PET/CT may complement or replace other imaging modalities when staging recurrent disease before any therapy for relapsed/refractory disease </CO> <A> in order to explore distant disease or second primaries that may significantly impact choice of therapy </A>.\\n--------------------------------------------------\\nPage Number: 53\\n\\nSection Name: Introduction\\n====================\\nEntities:-\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives.\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nMalignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network\"", Entity2: \""Malignant neoplasm of supraglottis\"", Relationship: \""provides guidelines for\""\\n2. Entity1: \""clinical staging\"", Entity2: \""treatment strategies\"", Relationship: \""part of flowchart for\""\\n\\nCausalities:-\\nThe provided image is a flowchart outlining the <C> NCCN (National Comprehensive Cancer Network) guidelines </C> for the treatment of <CO> cancers of the supraglottic larynx </CO>. This flowchart <A> utilizes a highly structured approach to convey clinical staging and treatment strategies </A>, indicating the various pathways based on <CO> patient conditions and disease features </CO>.\\n\\nSection Name: NCCN Guidelines Version 4.2024\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nMalignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.\\nSupraglottic Cancer : Cancer that occurs in the supraglottic region of the larynx, above the vocal cords.\\nClinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.\\nClinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.\\n\\nRelationships:-\\n1. Entity1: \""Cancer of the Supraglottic Larynx\"", Entity2: \""Clinical Trials\"", Relationship: \""recommended management strategy\""\\n\\nCausalities:-\\n- All recommendations are category 2A unless otherwise indicated.\\n- <A> Participation in clinical trials </A> is especially encouraged.\\n\\nSection Name: Key Components of the Flowchart\\n====================\\nEntities:-\\nNeoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.\\nRadiotherapy : The use of ionizing radiation to treat cancer.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.\\nNeoplasm Recurrence, Local : The return of a tumor at the original site after treatment.\\nClinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.\\n\\nRelationships:-\\n1. Entity1: \""Clinical Staging\"", Entity2: \""Treatment of Primary and Neck\"", Relationship: \""determines\""\\n2. Entity1: \""Evaluation and Follow-Up\"", Entity2: \""Adverse and No Adverse Features\"", Relationship: \""leads to decision based on\""\\n3. Entity1: \""Adjuvant Treatment\"", Entity2: \""Adverse pathologic features\"", Relationship: \""considered if present\""\\n4. Entity1: \""Clinical Trials\"", Entity2: \""Treatment Pathway\"", Relationship: \""part of\""\\n\\nCausalities:-\\n### Key Components of the Flowchart\\n\\n1. **Clinical Staging**: The flowchart starts with <A>clinical staging</A>, indicating that <CO>patients must first be evaluated to determine the extent of cancer</CO>. This is essential for <E>deciding on appropriate treatment options</E>.\\n\\n2. **Treatment of Primary and Neck**: The flowchart details multiple treatment strategies, including:\\n   - <A>**Concurrent systemic therapy/RT**</A>: This suggests a combination approach for <CO>patients eligible for such treatment</CO>.\\n   - <A>**Definitive Radiation Therapy (RT)**</A>: Recommended for <CO>low-volume diseases or patients who cannot tolerate systemic therapy</CO>.\\n   - <A>**Surgical Options**</A>: It highlights options such as endoscopic or open partial laryngectomy and neck dissection, which are <CO>contingent on clinical evaluations</CO>.\\n\\n3. **Evaluation and Follow-Up**: After initial treatment approaches, the chart directs clinicians to perform a <A>\""Post Systemic Therapy/RT or RT Neck Evaluation\""</A>. This step <E>assesses whether there are adverse pathologic features</E>, guiding subsequent treatment decisions.\\n\\n4. **Adverse and No Adverse Features**: The decision pathway diverges based on findings:\\n   - <CO>Patients with **adverse pathologic features**</CO> may have <A>additional diagnostic imaging (CT or MRI)</A> and may require <A>further systemic treatment</A>.\\n   - <CO>Patients with **no adverse features**</CO> may be directed towards <A>considerations for radiation therapy</A>.\\n\\n5. **Adjuvant Treatment and Recurrence**: The chart also addresses <E>management of any recurrent or persistent disease</E>, emphasizing the importance of <A>regular follow-up assessments</A>. Various options for <A>adjuvant treatment</A> are mentioned, focusing on tailored approaches towards ongoing management of the disease.\\n\\n6. **Clinical Trials**: The flowchart encourages <A>participation in clinical trials</A>, indicating a commitment to <E>exploring new treatments and improving patient outcomes</E>.\\n\\nSection Name: Principles\\n====================\\nEntities:-\\nImaging : The process of producing images of the body or parts of the body to diagnose or examine disease.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nRadiation Therapy : The use of ionizing radiation to treat cancer and other diseases.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Imaging\"", Entity2: \""Surgery\"", Relationship: \""Both are foundational principles in medical practice.\""\\n2. Entity1: \""Radiation therapy\"", Entity2: \""Systemic Therapy\"", Relationship: \""Both are treatment modalities for cancer.\""\\n\\nCausalities:-\\n#### Principles\\n- **Principles of Imaging (IMG-A)**\\n- **Principles of Surgery (SURG-A)**\\n- **Principles of Radiation Therapy (SUPRA-A)**\\n- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**\\n\\nSection Name: Adverse Pathologic Features\\n====================\\nEntities:-\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margins : The presence of cancer cells at the edge of the tissue removed during surgery.\\nPerineural Invasion : Cancer cells found surrounding or tracking along a nerve within the perineural space.\\nVascular Invasion : The presence of cancer cells within blood vessels.\\nLymphatic Invasion : The presence of cancer cells within lymphatic vessels.\\n\\nRelationships:-\\n1. Entity1: \""Extranodal Extension\"", Entity2: \""Positive Surgical Margins\"", Relationship: \""Both indicate cancer spread beyond original site.\""\\n2. Entity1: \""Perineural Invasion\"", Entity2: \""Vascular Invasion\"", Relationship: \""Both are pathways for cancer spread.\""\\n3. Entity1: \""pT3 or pT4 primary\"", Entity2: \""pN2 or pN3 nodal disease\"", Relationship: \""Both indicate advanced cancer stages.\""\\n\\nCausalities:-\\n<C> Extranodal extension </C>\\n<C> Positive margins </C>\\n<C> Close margins </C>\\n<C> pT3 or pT4 primary </C>\\n<C> pN2 or pN3 nodal disease </C>\\n<C> Perineural invasion </C>\\n<C> Vascular invasion </C>\\n<C> Lymphatic invasion </C>\\n\\nSection Name: Clinical Staging and Treatment of Primary and Neck\\n====================\\nEntities:-\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.\\nFollow-Up Procedure : A procedure performed to monitor the progress of a patient after treatment.\\nRecurrent Disease : A disease that returns after a period of remission.\\nLaryngectomy : Surgical removal of the larynx, often used to treat cancer.\\nRadiation Therapy : The use of ionizing radiation to treat cancer and other diseases.\\nClinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat cancer.\\nChemotherapy : Treatment of disease by the use of chemical substances, especially cancer by cytotoxic drugs.\\n\\nRelationships:-\\n1. Entity1: \""Adjuvant Treatment\"", Entity2: \""Treatment of Primary and Neck\"", Relationship: \""part of\""\\n2. Entity1: \""Follow-up\"", Entity2: \""Treatment of Primary and Neck\"", Relationship: \""part of\""\\n3. Entity1: \""Recurrent or Persistent Disease\"", Entity2: \""Treatment of Primary and Neck\"", Relationship: \""part of\""\\n4. Entity1: \""Larynx-Preserving Surgery\"", Entity2: \""Treatment Options\"", Relationship: \""is a treatment option for\""\\n5. Entity1: \""Concurrent Systemic Therapy/RT\"", Entity2: \""Treatment Options\"", Relationship: \""is a treatment option for\""\\n6. Entity1: \""Clinical Trials or Definitive RT\"", Entity2: \""Treatment Options\"", Relationship: \""is a treatment option for\""\\n7. Entity1: \""Endoscopic or Open Partial Laryngectomy and Neck Dissection(s)\"", Entity2: \""Treatment Options\"", Relationship: \""is a treatment option for\""\\n8. Entity1: \""Induction Chemotherapy\"", Entity2: \""Treatment Options\"", Relationship: \""is a treatment option for\""\\n\\nCausalities:-\\n<A> Amenable to Larynx-Preserving (Conservation) Surgery </A>: <CO> T1\u20132, N+ and selected T3, N1 </CO>\\n<A> Concurrent Systemic Therapy/RT </A>: <CO> i, k, l </CO>\\n<A> Clinical Trials or Definitive RT </A>: <CO> i </CO>\\n<A> Endoscopic or Open Partial Laryngectomy and Neck Dissection(s) </A>: <CO> h </CO>\\n<A> Induction Chemotherapy </A>: <CO> k, m </CO>\\n\\nSection Name: Pathologic Features and Response Assessment\\n====================\\nEntities:-\\nRadiation Therapy : The use of ionizing radiation to treat cancer and other diseases.\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margin : Cancer cells are found at the edge of the material removed during surgery, indicating that some cancer may have been left behind.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Extranodal extension\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n2. Entity1: \""Positive margin\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n3. Entity1: \""Systemic Therapy\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""considered in response to\""\\n4. Entity1: \""Radiation Therapy\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""considered in response to\""\\n\\nCausalities:-\\n#### Pathologic Features\\n- **No Adverse Pathologic Features**: j\\n  - <A> Consider RT </A>: i\\n- **Adverse Pathologic Features**: j\\n  - <CO> Extranodal extension and/or positive margin </CO>: n\\n  - Other risk features\\n  - <A> Systemic therapy/RT </A>: i, k (category 1)\\n  - <A> Consider systemic therapy/RT </A>: i, k\\n\\n#### Response Assessment\\n- **Response Assessment** (SUPRA-7)\\n\\nSection Name: Imaging and Recurrent or Persistent Disease\\n====================\\nEntities:-\\nTomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient.\\nMagnetic Resonance Imaging : Medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.\\nComputed Tomography : Medical imaging technique used in radiology to obtain detailed internal images of the body.\\n\\nRelationships:-\\n1. Entity1: \""CT\"", Entity2: \""primary and neck\"", Relationship: \""used for imaging\""\\n2. Entity1: \""MRI\"", Entity2: \""primary and neck\"", Relationship: \""used for imaging\""\\n3. Entity1: \""Post Systemic Therapy/RT\"", Entity2: \""Recurrent or Persistent Disease\"", Relationship: \""evaluation after treatment\""\\n4. Entity1: \""RT Neck Evaluation\"", Entity2: \""Recurrent or Persistent Disease\"", Relationship: \""evaluation after treatment\""\\n\\nCausalities:-\\n<A> CT (with contrast) or MRI (with and without contrast) of primary and neck </A>\\n\\n<CO> Recurrent or Persistent Disease </CO>\\n\\n<CO> Post Systemic Therapy/RT or RT Neck Evaluation </CO>\\n\\nSection Name: Conclusion\\n====================\\nEntities:-\\nOncologists : Medical doctors who specialize in the diagnosis and treatment of cancer.\\nSupraglottic Larynx Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is the area above the vocal cords.\\nClinical Staging : The process of determining the extent of cancer in the body, usually based on physical examination, imaging tests, and biopsies.\\nTreatment Strategies : Plans or methods developed to treat diseases, including cancer, which may involve surgery, chemotherapy, radiation therapy, or other modalities.\\nFollow-Up Evaluations : Medical assessments conducted after initial treatment to monitor a patient\\'s progress and detect any recurrence of disease.\\nClinical Efficacy : The ability of a treatment to produce the desired therapeutic effect in clinical settings.\\nResearch : Systematic investigation and study conducted to establish facts and reach new conclusions.\\nTreatment Paradigms : Standard models or patterns of treatment used in medical practice, often based on clinical guidelines and research findings.\\n\\nRelationships:-\\n1. Entity1: \""Oncologists\"", Entity2: \""Supraglottic Larynx Cancer\"", Relationship: \""use flowchart for decision-making\""\\n2. Entity1: \""Clinical Staging\"", Entity2: \""Treatment Strategies\"", Relationship: \""part of management process\""\\n3. Entity1: \""Treatment Strategies\"", Entity2: \""Follow-Up Evaluations\"", Relationship: \""part of management process\""\\n\\nCausalities:-\\n<A> The flowchart serves as a comprehensive guide for oncologists and healthcare providers </A>, <A> facilitating informed decision-making in the treatment of supraglottic larynx cancer </A>. <A> By visualizing the complex interactions between clinical staging, treatment strategies, and follow-up evaluations </A>, <E> it streamlines the management process </E>, <E> ensuring that patients receive appropriate care tailored to their specific needs </E>. <E> The detailed pathways not only enhance clinical efficacy </E> but also <E> underscore the importance of ongoing research and adaptation of treatment paradigms in oncology </E>.\\n--------------------------------------------------\\nPage Number: 41\\n\\nSection Name: Workup\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.\\nHistory And Physical Examination : A comprehensive assessment of a patient\\'s medical history and physical condition.\\nTobacco Smoking : The act of smoking tobacco products, which is a risk factor for many diseases.\\nAlcohol Drinking : The consumption of beverages containing ethyl alcohol.\\nSmoking Cessation : The process of discontinuing tobacco smoking.\\nBiopsy : A medical test involving the extraction of sample cells or tissues for examination.\\nLaryngoscopy : A procedure to examine the larynx, often using a scope.\\nComputed Tomography (Ct) : A diagnostic imaging procedure that uses computer-processed combinations of many X-ray measurements taken from different angles to produce cross-sectional images of specific areas of a scanned object.\\nMagnetic Resonance Imaging (Mri) : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.\\nPositron-Emission Tomography : A type of nuclear medicine imaging that measures metabolic activity of the cells of body tissues.\\nPulmonary Function Test : Tests that measure how well the lungs are working.\\nDental Examination : An evaluation of the teeth and gums to assess oral health.\\nNutritional Support : Therapies to provide nutrition to patients who cannot obtain nutrition by mouth.\\nSpeech Therapy : Therapy to improve speech and communication skills.\\nSwallowing Therapy : Therapy to help individuals with swallowing difficulties.\\nMultidisciplinary Care Team : A group of healthcare professionals from different specialties working together to manage patient care.\\n\\nRelationships:-\\n1. Entity1: \""glottic larynx cancer\"", Entity2: \""history and physical examination\"", Relationship: \""initial diagnostic step\""\\n2. Entity1: \""glottic larynx cancer\"", Entity2: \""biopsy\"", Relationship: \""required diagnostic procedure\""\\n3. Entity1: \""glottic larynx cancer\"", Entity2: \""direct laryngoscopy\"", Relationship: \""recommended procedure\""\\n4. Entity1: \""glottic larynx cancer\"", Entity2: \""CT scans\"", Relationship: \""imaging study\""\\n5. Entity1: \""glottic larynx cancer\"", Entity2: \""MRI\"", Relationship: \""imaging study\""\\n6. Entity1: \""glottic larynx cancer\"", Entity2: \""multidisciplinary consultation\"", Relationship: \""advised as clinically indicated\""\\n\\nCausalities:-\\nThe workup section outlines the initial steps for diagnosing <C>glottic larynx cancer</C>. It includes <A>a comprehensive history and physical examination (H&P)</A>, which should document tobacco and alcohol use, and provide counseling for smoking cessation. <A>A biopsy of the primary site is required</A>, and <A>direct laryngoscopy under anesthesia is generally recommended</A>. <A>Imaging studies such as CT scans with contrast and possibly MRI are used to evaluate the larynx and neck</A>. Additional evaluations may include <A>chest CT, FDG-PET/CT, pulmonary function tests, dental evaluation, and nutrition, speech, and swallowing therapy</A>. <A>Multidisciplinary consultation is advised</A> <CO>as clinically indicated</CO>.\\n\\nSection Name: Clinical Staging\\n====================\\nEntities:-\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\nCarcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.\\nBiopsy : A medical test involving the extraction of sample cells or tissues for examination.\\nLaryngectomy : A surgical procedure to remove the larynx.\\n\\nRelationships:-\\n1. Entity1: \""Clinical staging\"", Entity2: \""Cancer\"", Relationship: \""involves\""\\n2. Entity1: \""Carcinoma in situ\"", Entity2: \""Stages T1-T4\"", Relationship: \""is a stage of\""\\n3. Entity1: \""Biopsy\"", Entity2: \""Cancer\"", Relationship: \""used in staging\""\\n4. Entity1: \""Larynx-preserving surgeries\"", Entity2: \""Stages T1-T2\"", Relationship: \""considered for\""\\n5. Entity1: \""Total laryngectomy\"", Entity2: \""Stages T3-T4\"", Relationship: \""required for\""\\n\\nCausalities:-\\n<C> Clinical staging involves categorizing the cancer based on its aggressiveness </C>. It starts with carcinoma in situ, which is non-invasive, and progresses through stages T1-T4. <CO> Staging is based on H&P, biopsy, and imaging studies </CO>. <CO> For T1-T2 </CO>, <A> larynx-preserving surgeries are considered </A>, while <CO> more advanced stages like T3 or T4 </CO> <A> may require total laryngectomy </A>. <A> Additional evaluations such as videostrobe, audiogram, and fertility counseling may be considered </A>.\\n\\nSection Name: Treatment\\n====================\\nEntities:-\\nCarcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.\\nLaryngectomy : A surgical procedure to remove the larynx.\\nMetastasis : The transfer of a disease from one organ or part to another not directly connected with it.\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\n\\nRelationships:-\\n1. Entity1: \""Carcinoma in situ\"", Entity2: \""Larynx-preserving surgery\"", Relationship: \""treated with\""\\n2. Entity1: \""T1-T2 stages\"", Entity2: \""Conservation surgery\"", Relationship: \""treated with\""\\n3. Entity1: \""T3 stages\"", Entity2: \""Total laryngectomy\"", Relationship: \""may require\""\\n4. Entity1: \""T4a disease\"", Entity2: \""Complex interventions\"", Relationship: \""require\""\\n5. Entity1: \""Guidelines\"", Entity2: \""Multidisciplinary consultations\"", Relationship: \""emphasize importance of\""\\n6. Entity1: \""Guidelines\"", Entity2: \""Clinical trials\"", Relationship: \""consider as best option\""\\n\\nCausalities:-\\n<CO>Treatment recommendations vary by stage</CO>. <CO>Carcinoma in situ</CO> <A>may be treated with larynx-preserving surgery</A>. <CO>T1-T2 stages</CO> <A>may also be amenable to conservation surgery</A>. <CO>T3 stages</CO> <A>may require total laryngectomy</A>, <CO>especially if nodal involvement is present</CO>. <CO>T4a disease and unresectable or metastatic cases</CO> <A>require more complex interventions</A>. <A>The guidelines emphasize the importance of multidisciplinary consultations</A> and <A>consider clinical trials as the best management option</A>.\\n\\nSection Name: Additional Notes\\n====================\\nEntities:-\\nBiopsy, Needle : A procedure to remove a small sample of tissue for examination under a microscope.\\nImage-Guided Biopsy : A biopsy procedure that uses imaging techniques to guide the needle to the precise location of the tissue to be sampled.\\nBiopsy : A medical test involving the extraction of sample cells or tissues for examination.\\nDiagnostic Techniques And Procedures : Methods and procedures for the diagnosis of disease or dysfunction.\\nImaging : The process of producing images of the body for clinical purposes.\\nDental Care : The total of dental diagnostic, preventive, and corrective procedures.\\nNutritional Physiological Phenomena : The functions and properties of nutrients in living organisms.\\nFertility : The capacity to conceive or induce conception.\\nReproductive Health : A state of physical, mental, and social well-being in all matters relating to the reproductive system.\\nLymphatic Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nGlottis : The part of the larynx consisting of the vocal cords and the opening between them.\\n\\nRelationships:-\\n1. Entity1: \""image-guided needle biopsy\"", Entity2: \""diagnostic yield\"", Relationship: \""used for\""\\n2. Entity1: \""nodal disease\"", Entity2: \""glottic tumors\"", Relationship: \""is rare in\""\\n\\nCausalities:-\\n<A> use of image-guided needle biopsy </A> for <E> better diagnostic yield </E>, principles of imaging, dental evaluation, and nutrition management. The guidelines also address fertility and reproductive considerations, and note that <CO> nodal disease in glottic tumors is rare </CO>.\\n--------------------------------------------------\\nPage Number: 44\\n\\nSection Name: Flowchart Structure\\n====================\\nEntities:-\\nNeoplasm Staging : Methods used for staging neoplasms based on extent of tumor spread according to standardized criteria.\\nLaryngectomy : Surgical procedure to remove the larynx, often used to treat laryngeal cancer.\\nChemotherapy, Adjuvant : Drug therapy given in addition to the primary treatment to enhance its effectiveness.\\nRadiotherapy : The use of radiation, usually high-energy X-rays, to damage cancer cells and treat cancer.\\nTomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.\\nMagnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body\\'s soft tissue and bones.\\nNeoplasm Recurrence, Local : The return of a tumor at the original site after treatment.\\n\\nRelationships:-\\n1. Entity1: \""Clinical Staging\"", Entity2: \""T3 tumors\"", Relationship: \""determines treatment approach\""\\n2. Entity1: \""Adverse Pathologic Features\"", Entity2: \""Systemic Therapy\"", Relationship: \""directs to\""\\n3. Entity1: \""Adverse Pathologic Features\"", Entity2: \""Radiation Treatment\"", Relationship: \""directs to\""\\n4. Entity1: \""Induction Chemotherapy\"", Entity2: \""Imaging (CT or MRI)\"", Relationship: \""leads to\""\\n\\nCausalities:-\\n1. <A> The flow begins with the clinical staging of T3 tumors </A> <C> that require total laryngectomy (N2\u20133) </C>. <CO> This staging </CO> <E> is crucial for determining the appropriate therapeutic approach </E>.\\n\\n2. The flowchart provides multiple pathways for treatment, indicating that <CO> patients </CO> <A> may undergo either \""Concurrent systemic therapy/RT\"" or \""Surgery\"" </A>. There is also an <A> option for \""Induction chemotherapy,\"" leading to further imaging (CT or MRI) to assess the primary site and neck status </A>.\\n\\n3. For <CO> patients who have surgery </CO>, the flowchart distinguishes between those with adverse pathologic features and those without. <CO> Patients with adverse features\u2014such as extranodal extension or positive margins </CO>\u2014are <A> directed toward systemic therapy or radiation treatment </A>, while those without may follow a different management path.\\n\\n4. The flowchart concludes by <A> outlining follow-up procedures for recurrent or persistent disease </A>, suggesting additional assessments and treatments based on the risk features identified during earlier stages.\\n\\nSection Name: Detailed Explanation\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.\\nAdverse Pathological Feature : A pathological feature that indicates a worse prognosis or outcome.\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\n\\nRelationships:-\\n1. Entity1: \""Systemic therapy\"", Entity2: \""Radiation\"", Relationship: \""Concurrent treatment\""\\n2. Entity1: \""Clinical trials\"", Entity2: \""Personalized treatment plans\"", Relationship: \""Development of\""\\n\\nCausalities:-\\n<A> The flowchart is designed to provide healthcare professionals with a systematic pathway for managing glottic larynx cancer </A>. Each step is meticulously organized to ensure that important factors are considered, such as <C> the presence of adverse pathological features </C>, which <E> strongly influence treatment decisions </E>.\\n\\n<A> The emphasis on concurrent treatments, such as systemic therapy combined with radiation </A>, reflects current best practices in oncology, where multimodal approaches are often necessary to achieve better outcomes. <A> The inclusion of clinical trials </A> indicates an emphasis on maintaining up-to-date practices and personalized treatment plans as part of patient management strategies.\\n\\nFurthermore, <A> the chart\\'s organization into treatment and follow-up segments </A> allows for a straightforward interpretation, guiding oncologists through complex decisions in a logical manner. This can <E> improve consistency in care and enhance patient safety through meticulous monitoring and responses to treatment efficacy or disease progression </E>.\\n\\nIn summary, <E> this flowchart serves as an essential resource for oncologists, facilitating a better understanding of treatment protocols for glottic larynx cancer while promoting a patient-centered approach to oncological care </E>.\\n\\nSection Name: NCCN Guidelines Version 4.2024\\n====================\\nEntities:-\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\nClinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nNeoplasms : New abnormal growth of tissue that may be benign or malignant.\\nMalignant Neoplastic Disease : A disease in which abnormal cells divide uncontrollably and destroy body tissue.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\nNational Comprehensive Cancer Network : An alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network\"", Entity2: \""NCCN Guidelines\"", Relationship: \""publishes\""\\n2. Entity1: \""Clinical trial\"", Entity2: \""Cancer\"", Relationship: \""manages\""\\n\\nCausalities:-\\n<C> any patient with cancer </C> <E> the best management is in a clinical trial </E>. <A> Participation in clinical trials is especially encouraged </A>.\\n\\nSection Name: Principles of Treatment\\n====================\\nEntities:-\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nExtranodal Extension : The spread of cancer beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margins : Cancer cells are found at the edge of the material removed during surgery, indicating that some cancer may have been left behind.\\nPerineural Invasion : Cancer cells are found surrounding or tracking along a nerve within the perineural space.\\nVascular Invasion : The presence of cancer cells within blood vessels.\\nLymphatic Metastasis : The spread of cancer cells through the lymphatic system to distant sites.\\n\\nRelationships:-\\n1. Entity1: \""Principles of Radiation Therapy\"", Entity2: \""Extranodal Extension\"", Relationship: \""management of\""\\n2. Entity1: \""Principles of Surgery\"", Entity2: \""Positive Surgical Margins\"", Relationship: \""concerned with avoiding\""\\n3. Entity1: \""Principles of Radiation Therapy\"", Entity2: \""Perineural Invasion\"", Relationship: \""consideration in treatment planning\""\\n\\nCausalities:-\\n<C> Extranodal extension </C> <C> Positive margins </C> <C> Close margins </C> <C> pT4 primary </C> <C> pN2 or pN3 nodal disease </C> <C> Perineural invasion </C> <C> Vascular invasion </C> <C> Lymphatic invasion </C> <C> Subglottic extension </C>\\n\\nSection Name: Clinical Staging\\n====================\\nEntities:-\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to enhance its effectiveness.\\nAdjuvant Therapy : A therapy given in addition to the primary or initial therapy to maximize its effectiveness.\\nFollow-Up Studies : Studies that continue to monitor patients after treatment to assess long-term outcomes.\\nFollow-Up Procedure : A procedure performed to monitor the progress of a patient after initial treatment.\\nFollow-Up : The act of monitoring a patient\\'s health over time after treatment.\\nNeoplasm Recurrence, Local : The return of a tumor at the original site after treatment.\\nRecurrent Disease : A disease that has returned after a period of remission.\\n\\nRelationships:-\\n1. Entity1: \""Adjuvant Treatment\"", Entity2: \""Recurrent or Persistent Disease\"", Relationship: \""prevention\""\\n2. Entity1: \""Follow-up\"", Entity2: \""Recurrent or Persistent Disease\"", Relationship: \""monitoring\""\\n\\nSection Name: Treatment Options\\n====================\\nEntities:-\\nLaryngectomy : Surgical procedure to remove the larynx, often used to treat laryngeal cancer.\\nTotal Laryngectomy : A surgical procedure to remove the entire larynx.\\nChemotherapy, Adjuvant : Drug therapy given in addition to the primary treatment to enhance its effectiveness.\\nInduction Chemotherapy : Chemotherapy given as a first step to shrink a tumor before the main treatment.\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\nClinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\n\\nRelationships:-\\n1. Entity1: \""T3 requiring total laryngectomy\"", Entity2: \""Concurrent systemic therapy/RT\"", Relationship: \""treatment option\""\\n2. Entity1: \""T3 requiring total laryngectomy\"", Entity2: \""Induction chemotherapy\"", Relationship: \""treatment option\""\\n3. Entity1: \""T3 requiring total laryngectomy\"", Entity2: \""Clinical trials\"", Relationship: \""research option\""\\n\\nCausalities:-\\n<CO> T3 requiring (amenable to) total laryngectomy (N2\u20133) </CO> <A> Concurrent systemic therapy/RT </A> <A> Surgery </A> <A> Induction chemotherapy </A> <A> Clinical trials </A>\\n\\nSection Name: Surgical Considerations\\n====================\\nEntities:-\\nLaryngectomy : Surgical procedure to remove the larynx, often used to treat laryngeal cancer.\\nThyroidectomy : Surgical removal of all or part of the thyroid gland.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue in the neck.\\nLymph Node Excision : Surgical removal of one or more lymph nodes.\\nLymph Node Dissection : A surgical procedure to remove lymph nodes.\\nLymphadenectomy : Surgical removal of one or more groups of lymph nodes.\\n\\nRelationships:-\\n1. Entity1: \""Laryngectomy\"", Entity2: \""Thyroidectomy\"", Relationship: \""performed with\""\\n2. Entity1: \""Neck Dissection\"", Entity2: \""Lymph Node Excision\"", Relationship: \""includes\""\\n3. Entity1: \""Neck Dissection\"", Entity2: \""Lymph Node Excision\"", Relationship: \""includes specific types\""\\n\\nCausalities:-\\n<A> Laryngectomy with thyroidectomy as indicated, ipsilateral or bilateral neck dissection, and pretracheal and ipsilateral paratracheal lymph node dissection </A>\\n\\nSection Name: Pathologic Features\\n====================\\nEntities:-\\nExtranodal Extension : The spread of cancer beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margins : Cancer cells are found at the edge of the material removed during surgery, indicating that some cancer may have been left behind.\\nPositive Margin : A surgical margin that contains residual tumor cells.\\n\\nRelationships:-\\n1. Entity1: \""Adverse pathologic features\"", Entity2: \""Extranodal extension\"", Relationship: \""includes\""\\n2. Entity1: \""Adverse pathologic features\"", Entity2: \""Positive margin\"", Relationship: \""includes\""\\n\\nCausalities:-\\n- **No adverse pathologic features**\\n- **Adverse pathologic features**\\n  - <C> Extranodal extension and/or positive margin </C>\\n  - Other risk features\\n\\nSection Name: Systemic Therapy\\n====================\\nEntities:-\\nAntineoplastic Agents : Drugs used to treat cancer by inhibiting the growth of cancerous cells.\\nSystemic Therapy : A treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiotherapy : The use of radiation, usually high-energy X-rays, to damage cancer cells and treat cancer.\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\n\\nRelationships:-\\n1. Entity1: \""Systemic therapy\"", Entity2: \""RT\"", Relationship: \""Consideration\""\\n\\nCausalities:-\\n<A> Systemic therapy/RT (category 1) </A>\\n<A> RT </A>\\n<A> Consider systemic therapy/RT </A>\\n\\nSection Name: Imaging\\n====================\\nEntities:-\\nTomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.\\nMagnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body\\'s soft tissue and bones.\\nNeck : Part of the body, on many terrestrial or secondarily aquatic vertebrates, that distinguishes the head from the torso or trunk.\\nComputed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images (often called slices), both horizontally and vertically, of the body.\\nNeck Structure : The anatomical structure that connects the head to the torso.\\n\\nRelationships:-\\n1. Entity1: \""CT\"", Entity2: \""Neck\"", Relationship: \""imaging of\""\\n2. Entity1: \""MRI\"", Entity2: \""Neck\"", Relationship: \""imaging of\""\\n\\nCausalities:-\\n<A> CT (with contrast) or MRI (with and without contrast) of primary and neck </A>\\n\\nSection Name: Post-Treatment Evaluation\\n====================\\nEntities:-\\nRadiotherapy : The use of radiation, usually high-energy X-rays, to damage cancer cells and treat cancer.\\nPn1 Category : A pathological classification indicating regional lymph node metastasis in cancer staging.\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\n\\nRelationships:-\\n1. Entity1: \""Post Systemic Therapy/RT or RT Neck Evaluation\"", Entity2: \""pN1\"", Relationship: \""evaluation of cancer staging\""\\n2. Entity1: \""pN1\"", Entity2: \""Consider RT\"", Relationship: \""treatment recommendation\""\\n\\nCausalities:-\\n<CO> pN1 without other risk features </CO> <A> Consider RT </A>\\n\\nSection Name: Additional Notes\\n====================\\nEntities:-\\nAntineoplastic Combined Chemotherapy Protocols : Protocols for the administration of more than one antineoplastic agent in combination to treat malignant neoplasms.\\nCisplatin : A platinum-containing antineoplastic agent used in the treatment of various cancers.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Non-Nasopharyngeal Cancers\"", Relationship: \""used for\""\\n2. Entity1: \""Cisplatin\"", Entity2: \""Systemic Therapy\"", Relationship: \""preferred agent in\""\\n3. Entity1: \""Induction Chemotherapy\"", Entity2: \""Systemic Therapy\"", Relationship: \""discussed in context of\""\\n\\nCausalities:-\\n- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**\\n- **<CO> When using concurrent systemic therapy/RT </CO>, <A> the preferred agent is cisplatin (category 1) </A>. See Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A).**\\n- **<A> See Discussion on induction chemotherapy. </A>**\\n--------------------------------------------------\\nPage Number: 46\\n\\nSection Name: Introduction\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, including the glottis.\\nMalignant Neoplasm Of Glottis : A malignant tumor located in the glottis, part of the larynx.\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness, often used in cancer treatment.\\nAdjuvant Therapy : Treatment given in addition to the primary (main) treatment to enhance its effectiveness.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network\"", Entity2: \""Laryngeal Neoplasms\"", Relationship: \""provides treatment guidelines for\""\\n2. Entity1: \""treatment guidelines\"", Entity2: \""Adjuvant therapy\"", Relationship: \""guide clinical decision-making for\""\\n\\nCausalities:-\\n<C> cancer of the glottic larynx </C> <E> treatment guidelines </E> <CO> based on various clinical stages and specific patient conditions </CO> <A> guide healthcare professionals through clinical decision-making </A>.\\n\\nSection Name: NCCN Guidelines Version 4.2024\\n====================\\nEntities:-\\nClinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network\"", Entity2: \""Clinical Trials\"", Relationship: \""encourages participation in\""\\n\\nCausalities:-\\n<A>Participation in clinical trials</A> is especially encouraged.\\n\\nSection Name: Clinical Staging and Treatment\\n====================\\nEntities:-\\nNeoplasm Staging : Methods used for staging of neoplasms based on extent of tumor spread.\\nT4A : A clinical stage indicating a tumor that has grown into nearby structures.\\nN0\u20133 : A range of clinical stages indicating the extent of regional lymph node involvement.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue in the neck.\\nPathology : The study of the nature and cause of disease which involves changes in structure and function.\\nAntineoplastic Combined Chemotherapy Protocols : The use of drug combinations to treat cancer.\\nRadiotherapy : The use of ionizing radiation to treat cancer.\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\n\\nRelationships:-\\n1. Entity1: \""Clinical Staging\"", Entity2: \""Surgical Intervention\"", Relationship: \""determines\""\\n2. Entity1: \""T4a\"", Entity2: \""Surgical Intervention\"", Relationship: \""relates to\""\\n3. Entity1: \""Systemic Therapy\"", Entity2: \""Radiotherapy\"", Relationship: \""considered with\""\\n4. Entity1: \""Clinical Trials\"", Entity2: \""Treatment of Primary and Neck\"", Relationship: \""option for\""\\n\\nCausalities:-\\n<CO> Clinical staging indicator labeled \""T4a,N0\u20133\"" </CO> <A> emphasizes the importance of surgical intervention </A>, highlighting procedures such as bilateral neck dissection and the need to address certain pathologic features. <CO> Selected T4a patients who decline surgery </CO> <A> consider concurrent systemic therapy/RT or clinical trial for function-preserving surgical or RT management or induction chemotherapy </A>.\\n\\nSection Name: Principles of Treatment\\n====================\\nEntities:-\\nThyroidectomy : Surgical removal of the thyroid gland.\\nExtranodal Extension : Spread of cancer beyond the lymph node capsule.\\nRadiation Therapy : Medical use of ionizing radiation to treat cancer.\\n\\nRelationships:-\\n1. Entity1: \""Surgery\"", Entity2: \""Thyroidectomy\"", Relationship: \""involves\""\\n2. Entity1: \""Radiation therapy\"", Entity2: \""Adverse pathologic features\"", Relationship: \""treats\""\\n\\nCausalities:-\\n- **Principles of Radiation Therapy (GLOT-A):**  \\n  - <C> Adverse pathologic features: extranodal extension, positive margins, close margins, pT4 primary, pN2 or pN3 nodal disease, perineural invasion, vascular invasion, lymphatic invasion, and subglottic extension </C> (Discussion).  \\n\\n- **Principles of Surgery (SURG-A):**  \\n  - <A> Surgery, including ipsilateral or bilateral neck dissection; thyroidectomy to clear central compartment nodes </A>, <CO> especially when there is thyroid cartilage with gross invasion of the thyroid gland and significant subglottic extension </CO>.\\n\\nSection Name: Adjuvant Treatment and Follow-up\\n====================\\nEntities:-\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nClinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nComputed Tomography (Ct) : A medical imaging technique used in radiology to obtain detailed internal images of the body noninvasively for diagnostic purposes.\\nMagnetic Resonance Imaging (Mri) : A noninvasive medical test that physicians use to diagnose and treat medical conditions.\\nRecurrent Disease : A disease that has returned after a period of remission.\\nRadiation Therapy (Rt) : The use of ionizing radiation to treat cancer and other diseases.\\n\\nRelationships:-\\n1. Entity1: \""Adverse Features\"", Entity2: \""Specific Treatments\"", Relationship: \""Suggests\""\\n2. Entity1: \""Systemic Therapy\"", Entity2: \""Patients who decline surgery\"", Relationship: \""Option for\""\\n3. Entity1: \""CT or MRI\"", Entity2: \""Primary and Neck\"", Relationship: \""Used for imaging\""\\n4. Entity1: \""Recurrent or Persistent Disease\"", Entity2: \""Follow-up\"", Relationship: \""Condition for\""\\n5. Entity1: \""pN1 without other risk features\"", Entity2: \""RT\"", Relationship: \""Suggests considering\""\\n\\nCausalities:-\\n<C> adverse features such as extralateral extension or positive margins </C> <E> specific treatments are suggested </E>. The guidelines recommend <A> considering options like concurrent systemic therapy or clinical trials </A> <CO> for patients who decline surgery </CO>.\\n\\n- **Adjuvant Treatment:**  \\n  - <A> CT (with contrast) or MRI (with and without contrast) of primary and neck </A>.  \\n\\n- **Follow-up (FOLL-A, 1 of 2):**  \\n  - <CO> Recurrent or persistent disease (ADV-3) </CO>.  \\n\\n- **Post Systemic Therapy/RT or RT Neck Evaluation (FOLL-A, 2 of 2):**  \\n  - <CO> pN1 without other risk features </CO>: <A> Consider RT </A>.\\n\\nSection Name: Response Assessment\\n====================\\nEntities:-\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness, often used in cancer treatment.\\nComputed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.\\nMagnetic Resonance Imaging : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.\\nNeoplasm Recurrence, Local : The return of a cancer, at the same site as the original (primary) tumor, after it had disappeared.\\n\\nRelationships:-\\n1. Entity1: \""Adjuvant treatment\"", Entity2: \""Treatment responses\"", Relationship: \""affects\""\\n2. Entity1: \""Follow-up assessments\"", Entity2: \""CT or MRI scans\"", Relationship: \""conducted using\""\\n3. Entity1: \""Response Assessment (GLOT-5)\"", Entity2: \""Recurrent or persistent disease (ADV-3)\"", Relationship: \""determines\""\\n\\nCausalities:-\\nAs the flowchart progresses to the adjuvant treatment section, it depicts further decision points based on treatment responses and disease recurrence. The inclusion of references to follow-up assessments, such as CT or MRI scans, underscores the emphasis on continuous monitoring and evaluation of treatment efficacy.  - **Response Assessment (GLOT-5):**   - <C>Recurrent or persistent disease (ADV-3)</C>.\\n'}""",valid,increases risk,2,B,"edge - The edge which needs to be verified.
explanation - Explanation of what the edge represents and its validity.
causal_direction - Either Positive or Negative or Unknown. A positive influence direction indicates that both factors change in the same direction (e.g. an increase causes an increase effect). A negative influence direction indicates the opposite changes (e.g. an increase causes a decrease effect).
causal_factor - Is necessary or sufficient condition for an effect to occur. Exposure is a term commonly used in epidemiology to denote any condition that is considered as a possible cause of disease. Exposure is considered necessary when it always precedes the effects (e.g. symptoms) and always presents when the effects occur. A sufficient cause is a causal factor whose presence or occurrence guarantees the occurrence of symptom.
causal_distance - Either Distal or Proximal or Unknown. The distal factors lie towards the beginning of causal chain (i.e. indirect causal factors). The the proximal factors lie towards the end of the chain (i.e. cause directly or almost directly the effect).

Causality Tags:
<A> for action, <C> for cause, <CO> for condition and <E> for effect.
Cause (C): The reason or origin that leads to an effect. Causes often involve disease conditions, risk factors, or underlying mechanisms.
Effect (E): The outcome or result of a cause. Effects usually represent clinical outcomes, complications, or results of a specific cause.
Condition (CO): The circumstance or prerequisite required for an action or effect to occur. Conditions may include patient characteristics, clinical scenarios, or specific diagnostic criteria.
Action (A): The recommended or described response or activity to address a cause or condition. Actions typically involve clinical interventions, diagnostic procedures, or treatment recommendations.


`NODE1`:
id: Location_of_Involved_Lymph_Nodes_4
label: Position of Affected Lymph Nodes in Patient
description: This node represents the location of lymph nodes that are involved or affected in a patient's condition. Understanding whether the lymph nodes are ipsilateral, bilateral, or contralateral is crucial for determining the extent of disease spread and planning appropriate treatment strategies.
type: Patient Situation
observability: Unobserved
states: [{'state_name': 'ipsilateral', 'state_description': 'The involved lymph nodes are on the same side of the body as the primary tumor or reference point. This can indicate localized spread of disease.'}, {'state_name': 'bilateral', 'state_description': 'The involved lymph nodes are on both sides of the body. This may suggest a more extensive spread of disease and can impact treatment decisions.'}, {'state_name': 'contralateral', 'state_description': 'The involved lymph nodes are on the opposite side of the body from the primary tumor or reference point. This can indicate metastatic spread and may affect staging and treatment planning.'}]

`NODE2`:
id: Magnetic_Resonance_Imaging_MRI_14
label: Magnetic Resonance Imaging
description: This node represents the results of an MRI examination focused on detecting lymph node metastasis. It indicates whether metastasis is present in lymph nodes and specifies the pattern of metastasis (bilateral, ipsilateral, or contralateral) as observed through MRI.
type: Examination Result
observability: Observed
states: [{'state_name': 'bilateral_lymph_node_metastasis', 'state_description': 'Metastasis is present in lymph nodes on both sides of the body as detected by MRI.'}, {'state_name': 'ipsilateral_lymph_node_metastasis', 'state_description': 'Metastasis is present in lymph nodes on the same side as the primary tumor as detected by MRI.'}, {'state_name': 'contralateral_lymph_node_metastasis', 'state_description': 'Metastasis is present in lymph nodes on the opposite side of the primary tumor as detected by MRI.'}]

`EDGE1`:
{'edges_ids': ['Location_of_Involved_Lymph_Nodes_4', 'Magnetic_Resonance_Imaging_MRI_14'], 'edge': '(Location_of_Involved_Lymph_Nodes_4) causes (Magnetic_Resonance_Imaging_MRI_14)', 'explanation': ['The edge suggests that the location of involved lymph nodes causes the MRI results, which is not valid.', 'The MRI results are an observation of the lymph node involvement, not caused by it.', 'The MRI is used to detect the presence and pattern of lymph node metastasis, not influenced by the lymph node location.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}

`EDGE2`:
{'edges_ids': ['Magnetic_Resonance_Imaging_MRI_14', 'Location_of_Involved_Lymph_Nodes_4'], 'edge': '(Magnetic_Resonance_Imaging_MRI_14) causes (Location_of_Involved_Lymph_Nodes_4)', 'explanation': ['The edge represents the idea that the results of an MRI examination (Magnetic_Resonance_Imaging_MRI_14) could cause or determine the location of involved lymph nodes (Location_of_Involved_Lymph_Nodes_4).', 'However, the MRI results are an observation of the lymph nodes` state, not a cause of their state. The MRI detects whether metastasis is present and its pattern, but it does not influence or cause the lymph nodes to be in a particular location.', 'Therefore, the edge is not valid as a causal relationship. The MRI results do not cause the lymph nodes to be ipsilateral, bilateral, or contralateral; they simply report on the state of the lymph nodes as observed.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}

`INFORMATION FROM KNOWLEDGE BASE`:
--------------------------------------------------
Page Number: 94

Section Name: Head and Neck Cancers - Principles of Imaging
====================
Entities:-
Positron Emission Tomography Computed Tomography : A medical imaging technique combining PET and CT capabilities to provide detailed information about the body's function and structure.
Positron Emission Tomography : A nuclear medicine functional imaging technique that is used to observe metabolic processes in the body.
Computed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.
Head And Neck Neoplasms : Cancers that arise in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.

Relationships:-
1. Entity1: ""PET/CT"", Entity2: ""PET scan"", Relationship: ""preferred over""
2. Entity1: ""PET-CT"", Entity2: ""head neck cancers"", Relationship: ""used in study of""

Causalities:-
<A> PET/CT is preferred over PET scan alone (i.e., without superimposed CT scan) </A>. <C> PET/CT provides more accurate anatomical localization of abnormalities </C> <E> more accurate anatomical localization of abnormalities </E>.

Section Name: Initial Workup - Nodal Metastases
====================
Entities:-
Lymphatic Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site via the lymphatic system.
Tomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient, producing signals that are processed by the machine's computer to generate cross-sectional images.
Magnetic Resonance Imaging : A non-invasive imaging technique that uses magnetic fields and radio waves to create detailed images of the organs and tissues within the body.
Positron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption.
Lymph Node Metastasis : The spread of cancer cells to lymph nodes, which are part of the lymphatic system.
Ct Of Neck : A computed tomography scan of the neck region.
Mri Of Neck : A magnetic resonance imaging scan of the neck region.
Fdg-Pet Scan : A type of positron emission tomography using fluorodeoxyglucose to assess metabolic activity.
Computed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.
Positron Emission Tomography : A nuclear medicine functional imaging technique that is used to observe metabolic processes in the body.

Relationships:-
1. Entity1: ""CT"", Entity2: ""lymph node metastases"", Relationship: ""used to evaluate""
2. Entity1: ""MRI"", Entity2: ""lymph node metastases"", Relationship: ""used to evaluate""
3. Entity1: ""FDG-PET/CT"", Entity2: ""lymph node metastases"", Relationship: ""used for detection""
4. Entity1: ""FDG-PET/CT"", Entity2: ""surgical primary approach"", Relationship: ""used to determine""
5. Entity1: ""FDG-PET/CT"", Entity2: ""definitive RT approach"", Relationship: ""used to identify""

Causalities:-
<A> Evaluation of lymph node metastases should be conducted with CT or MRI of the neck </A>, using whichever imaging study is suitable for primary site evaluation (IMG-A, 1 of 4).
<CO> For patients with multistation or lower neck nodal involvement or high-grade tumor histology </CO>, <A> consider CT of the chest to assess for mediastinal lymph node metastases or FDG-PET/CT </A>, <C> which is associated with higher sensitivity for both nodal and distant metastases </C>.
<CO> For patients who are under consideration for a surgical primary approach </CO>, <A> the higher sensitivity of FDG-PET/CT is warranted for tumors approaching the midline, to determine the surgical approach to the contralateral neck </A>. <CO> Similarly, patients who are scheduled for a definitive RT approach </CO> <A> may benefit from the higher sensitivity of FDG-PET/CT for identifying involved lymph nodes </A>.

Section Name: Initial Workup - Distant Metastases
====================
Entities:-
Positron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption.
Magnetic Resonance Imaging : A non-invasive imaging technique that uses magnetic fields and radio waves to create detailed images of the organs and tissues within the body.
Tomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient, producing signals that are processed by the machine's computer to generate cross-sectional images.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Lung Neoplasms : Tumors or cancer of the lung.
Smoking : The inhalation of the smoke of burning tobacco encased in cigarettes, pipes, and cigars.

Relationships:-
1. Entity1: ""FDG-PET/CT"", Entity2: ""Distant Metastases"", Relationship: ""used to evaluate""
2. Entity1: ""Contrast-enhanced brain MRI"", Entity2: ""Brain Metastasis"", Relationship: ""recommended for evaluation""
3. Entity1: ""CT of the chest"", Entity2: ""Pulmonary Metastases"", Relationship: ""performed to assess""
4. Entity1: ""Non-contrast CT of the chest"", Entity2: ""Lung Parenchymal Metastases"", Relationship: ""used to screen""
5. Entity1: ""Annual CT screening"", Entity2: ""Lung Metastasis"", Relationship: ""considered for high risk""
6. Entity1: ""Directed CT or MRI"", Entity2: ""Distant Disease"", Relationship: ""used for assessment""
7. Entity1: ""FDG-PET/CT"", Entity2: ""Recurrent Disease"", Relationship: ""used for staging""

Causalities:-
<C> Patients with locoregionally advanced cancer (e.g., T3–T4 primary or ≥N1 nodal staging) </C>, <A> FDG-PET/CT is preferred to evaluate for distant disease and thoracic metastases </A>. <CO> For cancers where brain metastasis is a concern, such as mucosal melanoma or high-grade neuroendocrine carcinomas or adenocarcinomas </CO>, <A> contrast-enhanced brain MRI should be additionally obtained </A>.
<CO> If FDG-PET/CT is not performed </CO>, <A> CT of the chest should be performed to assess for presence of pulmonary metastases as well as mediastinal lymph node involvement </A>.
<CO> Non-contrast CT of the chest can be sufficient to screen for lung parenchymal metastases </CO> but <CO> is not adequate for assessment of mediastinal adenopathy </CO>. <CO> This is an appropriate lung cancer screening intervention for patients with a history of smoking </CO>.
<CO> Following primary definitive treatment (surgery, RT, or systemic therapy/RT) </CO> the role of annual CT screening for lung metastasis is controversial. <E> While this approach does detect early metastasis </E>, <CO> further study is needed to determine the extent of the positive effect and/or cost-effectiveness of this approach in specific subpopulations and timepoints post-treatment </CO>. <CO> For patients with a substantial smoking history or who are at high risk for lung metastases </CO>, <A> annual chest CT can be considered </A>.
<CO> If clinical concern for metastatic disease is confined to a specific anatomical area </CO>, <A> the assessment of distant disease can be performed with directed CT or MRI examination </A>.
<CO> FDG-PET/CT may complement or replace other imaging modalities when staging recurrent disease before any therapy for relapsed/refractory disease </CO> <A> in order to explore distant disease or second primaries that may significantly impact choice of therapy </A>.
--------------------------------------------------
Page Number: 53

Section Name: Introduction
====================
Entities:-
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives.
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Malignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network"", Entity2: ""Malignant neoplasm of supraglottis"", Relationship: ""provides guidelines for""
2. Entity1: ""clinical staging"", Entity2: ""treatment strategies"", Relationship: ""part of flowchart for""

Causalities:-
The provided image is a flowchart outlining the <C> NCCN (National Comprehensive Cancer Network) guidelines </C> for the treatment of <CO> cancers of the supraglottic larynx </CO>. This flowchart <A> utilizes a highly structured approach to convey clinical staging and treatment strategies </A>, indicating the various pathways based on <CO> patient conditions and disease features </CO>.

Section Name: NCCN Guidelines Version 4.2024
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Malignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.
Supraglottic Cancer : Cancer that occurs in the supraglottic region of the larynx, above the vocal cords.
Clinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.
Clinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.

Relationships:-
1. Entity1: ""Cancer of the Supraglottic Larynx"", Entity2: ""Clinical Trials"", Relationship: ""recommended management strategy""

Causalities:-
- All recommendations are category 2A unless otherwise indicated.
- <A> Participation in clinical trials </A> is especially encouraged.

Section Name: Key Components of the Flowchart
====================
Entities:-
Neoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.
Radiotherapy : The use of ionizing radiation to treat cancer.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.
Neoplasm Recurrence, Local : The return of a tumor at the original site after treatment.
Clinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.

Relationships:-
1. Entity1: ""Clinical Staging"", Entity2: ""Treatment of Primary and Neck"", Relationship: ""determines""
2. Entity1: ""Evaluation and Follow-Up"", Entity2: ""Adverse and No Adverse Features"", Relationship: ""leads to decision based on""
3. Entity1: ""Adjuvant Treatment"", Entity2: ""Adverse pathologic features"", Relationship: ""considered if present""
4. Entity1: ""Clinical Trials"", Entity2: ""Treatment Pathway"", Relationship: ""part of""

Causalities:-
### Key Components of the Flowchart

1. **Clinical Staging**: The flowchart starts with <A>clinical staging</A>, indicating that <CO>patients must first be evaluated to determine the extent of cancer</CO>. This is essential for <E>deciding on appropriate treatment options</E>.

2. **Treatment of Primary and Neck**: The flowchart details multiple treatment strategies, including:
   - <A>**Concurrent systemic therapy/RT**</A>: This suggests a combination approach for <CO>patients eligible for such treatment</CO>.
   - <A>**Definitive Radiation Therapy (RT)**</A>: Recommended for <CO>low-volume diseases or patients who cannot tolerate systemic therapy</CO>.
   - <A>**Surgical Options**</A>: It highlights options such as endoscopic or open partial laryngectomy and neck dissection, which are <CO>contingent on clinical evaluations</CO>.

3. **Evaluation and Follow-Up**: After initial treatment approaches, the chart directs clinicians to perform a <A>""Post Systemic Therapy/RT or RT Neck Evaluation""</A>. This step <E>assesses whether there are adverse pathologic features</E>, guiding subsequent treatment decisions.

4. **Adverse and No Adverse Features**: The decision pathway diverges based on findings:
   - <CO>Patients with **adverse pathologic features**</CO> may have <A>additional diagnostic imaging (CT or MRI)</A> and may require <A>further systemic treatment</A>.
   - <CO>Patients with **no adverse features**</CO> may be directed towards <A>considerations for radiation therapy</A>.

5. **Adjuvant Treatment and Recurrence**: The chart also addresses <E>management of any recurrent or persistent disease</E>, emphasizing the importance of <A>regular follow-up assessments</A>. Various options for <A>adjuvant treatment</A> are mentioned, focusing on tailored approaches towards ongoing management of the disease.

6. **Clinical Trials**: The flowchart encourages <A>participation in clinical trials</A>, indicating a commitment to <E>exploring new treatments and improving patient outcomes</E>.

Section Name: Principles
====================
Entities:-
Imaging : The process of producing images of the body or parts of the body to diagnose or examine disease.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Radiation Therapy : The use of ionizing radiation to treat cancer and other diseases.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Imaging"", Entity2: ""Surgery"", Relationship: ""Both are foundational principles in medical practice.""
2. Entity1: ""Radiation therapy"", Entity2: ""Systemic Therapy"", Relationship: ""Both are treatment modalities for cancer.""

Causalities:-
#### Principles
- **Principles of Imaging (IMG-A)**
- **Principles of Surgery (SURG-A)**
- **Principles of Radiation Therapy (SUPRA-A)**
- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**

Section Name: Adverse Pathologic Features
====================
Entities:-
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margins : The presence of cancer cells at the edge of the tissue removed during surgery.
Perineural Invasion : Cancer cells found surrounding or tracking along a nerve within the perineural space.
Vascular Invasion : The presence of cancer cells within blood vessels.
Lymphatic Invasion : The presence of cancer cells within lymphatic vessels.

Relationships:-
1. Entity1: ""Extranodal Extension"", Entity2: ""Positive Surgical Margins"", Relationship: ""Both indicate cancer spread beyond original site.""
2. Entity1: ""Perineural Invasion"", Entity2: ""Vascular Invasion"", Relationship: ""Both are pathways for cancer spread.""
3. Entity1: ""pT3 or pT4 primary"", Entity2: ""pN2 or pN3 nodal disease"", Relationship: ""Both indicate advanced cancer stages.""

Causalities:-
<C> Extranodal extension </C>
<C> Positive margins </C>
<C> Close margins </C>
<C> pT3 or pT4 primary </C>
<C> pN2 or pN3 nodal disease </C>
<C> Perineural invasion </C>
<C> Vascular invasion </C>
<C> Lymphatic invasion </C>

Section Name: Clinical Staging and Treatment of Primary and Neck
====================
Entities:-
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.
Follow-Up Procedure : A procedure performed to monitor the progress of a patient after treatment.
Recurrent Disease : A disease that returns after a period of remission.
Laryngectomy : Surgical removal of the larynx, often used to treat cancer.
Radiation Therapy : The use of ionizing radiation to treat cancer and other diseases.
Clinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat cancer.
Chemotherapy : Treatment of disease by the use of chemical substances, especially cancer by cytotoxic drugs.

Relationships:-
1. Entity1: ""Adjuvant Treatment"", Entity2: ""Treatment of Primary and Neck"", Relationship: ""part of""
2. Entity1: ""Follow-up"", Entity2: ""Treatment of Primary and Neck"", Relationship: ""part of""
3. Entity1: ""Recurrent or Persistent Disease"", Entity2: ""Treatment of Primary and Neck"", Relationship: ""part of""
4. Entity1: ""Larynx-Preserving Surgery"", Entity2: ""Treatment Options"", Relationship: ""is a treatment option for""
5. Entity1: ""Concurrent Systemic Therapy/RT"", Entity2: ""Treatment Options"", Relationship: ""is a treatment option for""
6. Entity1: ""Clinical Trials or Definitive RT"", Entity2: ""Treatment Options"", Relationship: ""is a treatment option for""
7. Entity1: ""Endoscopic or Open Partial Laryngectomy and Neck Dissection(s)"", Entity2: ""Treatment Options"", Relationship: ""is a treatment option for""
8. Entity1: ""Induction Chemotherapy"", Entity2: ""Treatment Options"", Relationship: ""is a treatment option for""

Causalities:-
<A> Amenable to Larynx-Preserving (Conservation) Surgery </A>: <CO> T1–2, N+ and selected T3, N1 </CO>
<A> Concurrent Systemic Therapy/RT </A>: <CO> i, k, l </CO>
<A> Clinical Trials or Definitive RT </A>: <CO> i </CO>
<A> Endoscopic or Open Partial Laryngectomy and Neck Dissection(s) </A>: <CO> h </CO>
<A> Induction Chemotherapy </A>: <CO> k, m </CO>

Section Name: Pathologic Features and Response Assessment
====================
Entities:-
Radiation Therapy : The use of ionizing radiation to treat cancer and other diseases.
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margin : Cancer cells are found at the edge of the material removed during surgery, indicating that some cancer may have been left behind.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Extranodal extension"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
2. Entity1: ""Positive margin"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
3. Entity1: ""Systemic Therapy"", Entity2: ""Adverse Pathologic Features"", Relationship: ""considered in response to""
4. Entity1: ""Radiation Therapy"", Entity2: ""Adverse Pathologic Features"", Relationship: ""considered in response to""

Causalities:-
#### Pathologic Features
- **No Adverse Pathologic Features**: j
  - <A> Consider RT </A>: i
- **Adverse Pathologic Features**: j
  - <CO> Extranodal extension and/or positive margin </CO>: n
  - Other risk features
  - <A> Systemic therapy/RT </A>: i, k (category 1)
  - <A> Consider systemic therapy/RT </A>: i, k

#### Response Assessment
- **Response Assessment** (SUPRA-7)

Section Name: Imaging and Recurrent or Persistent Disease
====================
Entities:-
Tomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient.
Magnetic Resonance Imaging : Medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.
Computed Tomography : Medical imaging technique used in radiology to obtain detailed internal images of the body.

Relationships:-
1. Entity1: ""CT"", Entity2: ""primary and neck"", Relationship: ""used for imaging""
2. Entity1: ""MRI"", Entity2: ""primary and neck"", Relationship: ""used for imaging""
3. Entity1: ""Post Systemic Therapy/RT"", Entity2: ""Recurrent or Persistent Disease"", Relationship: ""evaluation after treatment""
4. Entity1: ""RT Neck Evaluation"", Entity2: ""Recurrent or Persistent Disease"", Relationship: ""evaluation after treatment""

Causalities:-
<A> CT (with contrast) or MRI (with and without contrast) of primary and neck </A>

<CO> Recurrent or Persistent Disease </CO>

<CO> Post Systemic Therapy/RT or RT Neck Evaluation </CO>

Section Name: Conclusion
====================
Entities:-
Oncologists : Medical doctors who specialize in the diagnosis and treatment of cancer.
Supraglottic Larynx Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is the area above the vocal cords.
Clinical Staging : The process of determining the extent of cancer in the body, usually based on physical examination, imaging tests, and biopsies.
Treatment Strategies : Plans or methods developed to treat diseases, including cancer, which may involve surgery, chemotherapy, radiation therapy, or other modalities.
Follow-Up Evaluations : Medical assessments conducted after initial treatment to monitor a patient's progress and detect any recurrence of disease.
Clinical Efficacy : The ability of a treatment to produce the desired therapeutic effect in clinical settings.
Research : Systematic investigation and study conducted to establish facts and reach new conclusions.
Treatment Paradigms : Standard models or patterns of treatment used in medical practice, often based on clinical guidelines and research findings.

Relationships:-
1. Entity1: ""Oncologists"", Entity2: ""Supraglottic Larynx Cancer"", Relationship: ""use flowchart for decision-making""
2. Entity1: ""Clinical Staging"", Entity2: ""Treatment Strategies"", Relationship: ""part of management process""
3. Entity1: ""Treatment Strategies"", Entity2: ""Follow-Up Evaluations"", Relationship: ""part of management process""

Causalities:-
<A> The flowchart serves as a comprehensive guide for oncologists and healthcare providers </A>, <A> facilitating informed decision-making in the treatment of supraglottic larynx cancer </A>. <A> By visualizing the complex interactions between clinical staging, treatment strategies, and follow-up evaluations </A>, <E> it streamlines the management process </E>, <E> ensuring that patients receive appropriate care tailored to their specific needs </E>. <E> The detailed pathways not only enhance clinical efficacy </E> but also <E> underscore the importance of ongoing research and adaptation of treatment paradigms in oncology </E>.
--------------------------------------------------
Page Number: 41

Section Name: Workup
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.
History And Physical Examination : A comprehensive assessment of a patient's medical history and physical condition.
Tobacco Smoking : The act of smoking tobacco products, which is a risk factor for many diseases.
Alcohol Drinking : The consumption of beverages containing ethyl alcohol.
Smoking Cessation : The process of discontinuing tobacco smoking.
Biopsy : A medical test involving the extraction of sample cells or tissues for examination.
Laryngoscopy : A procedure to examine the larynx, often using a scope.
Computed Tomography (Ct) : A diagnostic imaging procedure that uses computer-processed combinations of many X-ray measurements taken from different angles to produce cross-sectional images of specific areas of a scanned object.
Magnetic Resonance Imaging (Mri) : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.
Positron-Emission Tomography : A type of nuclear medicine imaging that measures metabolic activity of the cells of body tissues.
Pulmonary Function Test : Tests that measure how well the lungs are working.
Dental Examination : An evaluation of the teeth and gums to assess oral health.
Nutritional Support : Therapies to provide nutrition to patients who cannot obtain nutrition by mouth.
Speech Therapy : Therapy to improve speech and communication skills.
Swallowing Therapy : Therapy to help individuals with swallowing difficulties.
Multidisciplinary Care Team : A group of healthcare professionals from different specialties working together to manage patient care.

Relationships:-
1. Entity1: ""glottic larynx cancer"", Entity2: ""history and physical examination"", Relationship: ""initial diagnostic step""
2. Entity1: ""glottic larynx cancer"", Entity2: ""biopsy"", Relationship: ""required diagnostic procedure""
3. Entity1: ""glottic larynx cancer"", Entity2: ""direct laryngoscopy"", Relationship: ""recommended procedure""
4. Entity1: ""glottic larynx cancer"", Entity2: ""CT scans"", Relationship: ""imaging study""
5. Entity1: ""glottic larynx cancer"", Entity2: ""MRI"", Relationship: ""imaging study""
6. Entity1: ""glottic larynx cancer"", Entity2: ""multidisciplinary consultation"", Relationship: ""advised as clinically indicated""

Causalities:-
The workup section outlines the initial steps for diagnosing <C>glottic larynx cancer</C>. It includes <A>a comprehensive history and physical examination (H&P)</A>, which should document tobacco and alcohol use, and provide counseling for smoking cessation. <A>A biopsy of the primary site is required</A>, and <A>direct laryngoscopy under anesthesia is generally recommended</A>. <A>Imaging studies such as CT scans with contrast and possibly MRI are used to evaluate the larynx and neck</A>. Additional evaluations may include <A>chest CT, FDG-PET/CT, pulmonary function tests, dental evaluation, and nutrition, speech, and swallowing therapy</A>. <A>Multidisciplinary consultation is advised</A> <CO>as clinically indicated</CO>.

Section Name: Clinical Staging
====================
Entities:-
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.
Carcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.
Biopsy : A medical test involving the extraction of sample cells or tissues for examination.
Laryngectomy : A surgical procedure to remove the larynx.

Relationships:-
1. Entity1: ""Clinical staging"", Entity2: ""Cancer"", Relationship: ""involves""
2. Entity1: ""Carcinoma in situ"", Entity2: ""Stages T1-T4"", Relationship: ""is a stage of""
3. Entity1: ""Biopsy"", Entity2: ""Cancer"", Relationship: ""used in staging""
4. Entity1: ""Larynx-preserving surgeries"", Entity2: ""Stages T1-T2"", Relationship: ""considered for""
5. Entity1: ""Total laryngectomy"", Entity2: ""Stages T3-T4"", Relationship: ""required for""

Causalities:-
<C> Clinical staging involves categorizing the cancer based on its aggressiveness </C>. It starts with carcinoma in situ, which is non-invasive, and progresses through stages T1-T4. <CO> Staging is based on H&P, biopsy, and imaging studies </CO>. <CO> For T1-T2 </CO>, <A> larynx-preserving surgeries are considered </A>, while <CO> more advanced stages like T3 or T4 </CO> <A> may require total laryngectomy </A>. <A> Additional evaluations such as videostrobe, audiogram, and fertility counseling may be considered </A>.

Section Name: Treatment
====================
Entities:-
Carcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.
Laryngectomy : A surgical procedure to remove the larynx.
Metastasis : The transfer of a disease from one organ or part to another not directly connected with it.
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.

Relationships:-
1. Entity1: ""Carcinoma in situ"", Entity2: ""Larynx-preserving surgery"", Relationship: ""treated with""
2. Entity1: ""T1-T2 stages"", Entity2: ""Conservation surgery"", Relationship: ""treated with""
3. Entity1: ""T3 stages"", Entity2: ""Total laryngectomy"", Relationship: ""may require""
4. Entity1: ""T4a disease"", Entity2: ""Complex interventions"", Relationship: ""require""
5. Entity1: ""Guidelines"", Entity2: ""Multidisciplinary consultations"", Relationship: ""emphasize importance of""
6. Entity1: ""Guidelines"", Entity2: ""Clinical trials"", Relationship: ""consider as best option""

Causalities:-
<CO>Treatment recommendations vary by stage</CO>. <CO>Carcinoma in situ</CO> <A>may be treated with larynx-preserving surgery</A>. <CO>T1-T2 stages</CO> <A>may also be amenable to conservation surgery</A>. <CO>T3 stages</CO> <A>may require total laryngectomy</A>, <CO>especially if nodal involvement is present</CO>. <CO>T4a disease and unresectable or metastatic cases</CO> <A>require more complex interventions</A>. <A>The guidelines emphasize the importance of multidisciplinary consultations</A> and <A>consider clinical trials as the best management option</A>.

Section Name: Additional Notes
====================
Entities:-
Biopsy, Needle : A procedure to remove a small sample of tissue for examination under a microscope.
Image-Guided Biopsy : A biopsy procedure that uses imaging techniques to guide the needle to the precise location of the tissue to be sampled.
Biopsy : A medical test involving the extraction of sample cells or tissues for examination.
Diagnostic Techniques And Procedures : Methods and procedures for the diagnosis of disease or dysfunction.
Imaging : The process of producing images of the body for clinical purposes.
Dental Care : The total of dental diagnostic, preventive, and corrective procedures.
Nutritional Physiological Phenomena : The functions and properties of nutrients in living organisms.
Fertility : The capacity to conceive or induce conception.
Reproductive Health : A state of physical, mental, and social well-being in all matters relating to the reproductive system.
Lymphatic Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Glottis : The part of the larynx consisting of the vocal cords and the opening between them.

Relationships:-
1. Entity1: ""image-guided needle biopsy"", Entity2: ""diagnostic yield"", Relationship: ""used for""
2. Entity1: ""nodal disease"", Entity2: ""glottic tumors"", Relationship: ""is rare in""

Causalities:-
<A> use of image-guided needle biopsy </A> for <E> better diagnostic yield </E>, principles of imaging, dental evaluation, and nutrition management. The guidelines also address fertility and reproductive considerations, and note that <CO> nodal disease in glottic tumors is rare </CO>.
--------------------------------------------------
Page Number: 44

Section Name: Flowchart Structure
====================
Entities:-
Neoplasm Staging : Methods used for staging neoplasms based on extent of tumor spread according to standardized criteria.
Laryngectomy : Surgical procedure to remove the larynx, often used to treat laryngeal cancer.
Chemotherapy, Adjuvant : Drug therapy given in addition to the primary treatment to enhance its effectiveness.
Radiotherapy : The use of radiation, usually high-energy X-rays, to damage cancer cells and treat cancer.
Tomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.
Magnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body's soft tissue and bones.
Neoplasm Recurrence, Local : The return of a tumor at the original site after treatment.

Relationships:-
1. Entity1: ""Clinical Staging"", Entity2: ""T3 tumors"", Relationship: ""determines treatment approach""
2. Entity1: ""Adverse Pathologic Features"", Entity2: ""Systemic Therapy"", Relationship: ""directs to""
3. Entity1: ""Adverse Pathologic Features"", Entity2: ""Radiation Treatment"", Relationship: ""directs to""
4. Entity1: ""Induction Chemotherapy"", Entity2: ""Imaging (CT or MRI)"", Relationship: ""leads to""

Causalities:-
1. <A> The flow begins with the clinical staging of T3 tumors </A> <C> that require total laryngectomy (N2–3) </C>. <CO> This staging </CO> <E> is crucial for determining the appropriate therapeutic approach </E>.

2. The flowchart provides multiple pathways for treatment, indicating that <CO> patients </CO> <A> may undergo either ""Concurrent systemic therapy/RT"" or ""Surgery"" </A>. There is also an <A> option for ""Induction chemotherapy,"" leading to further imaging (CT or MRI) to assess the primary site and neck status </A>.

3. For <CO> patients who have surgery </CO>, the flowchart distinguishes between those with adverse pathologic features and those without. <CO> Patients with adverse features—such as extranodal extension or positive margins </CO>—are <A> directed toward systemic therapy or radiation treatment </A>, while those without may follow a different management path.

4. The flowchart concludes by <A> outlining follow-up procedures for recurrent or persistent disease </A>, suggesting additional assessments and treatments based on the risk features identified during earlier stages.

Section Name: Detailed Explanation
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.
Adverse Pathological Feature : A pathological feature that indicates a worse prognosis or outcome.
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.

Relationships:-
1. Entity1: ""Systemic therapy"", Entity2: ""Radiation"", Relationship: ""Concurrent treatment""
2. Entity1: ""Clinical trials"", Entity2: ""Personalized treatment plans"", Relationship: ""Development of""

Causalities:-
<A> The flowchart is designed to provide healthcare professionals with a systematic pathway for managing glottic larynx cancer </A>. Each step is meticulously organized to ensure that important factors are considered, such as <C> the presence of adverse pathological features </C>, which <E> strongly influence treatment decisions </E>.

<A> The emphasis on concurrent treatments, such as systemic therapy combined with radiation </A>, reflects current best practices in oncology, where multimodal approaches are often necessary to achieve better outcomes. <A> The inclusion of clinical trials </A> indicates an emphasis on maintaining up-to-date practices and personalized treatment plans as part of patient management strategies.

Furthermore, <A> the chart's organization into treatment and follow-up segments </A> allows for a straightforward interpretation, guiding oncologists through complex decisions in a logical manner. This can <E> improve consistency in care and enhance patient safety through meticulous monitoring and responses to treatment efficacy or disease progression </E>.

In summary, <E> this flowchart serves as an essential resource for oncologists, facilitating a better understanding of treatment protocols for glottic larynx cancer while promoting a patient-centered approach to oncological care </E>.

Section Name: NCCN Guidelines Version 4.2024
====================
Entities:-
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.
Clinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Neoplasms : New abnormal growth of tissue that may be benign or malignant.
Malignant Neoplastic Disease : A disease in which abnormal cells divide uncontrollably and destroy body tissue.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.
National Comprehensive Cancer Network : An alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network"", Entity2: ""NCCN Guidelines"", Relationship: ""publishes""
2. Entity1: ""Clinical trial"", Entity2: ""Cancer"", Relationship: ""manages""

Causalities:-
<C> any patient with cancer </C> <E> the best management is in a clinical trial </E>. <A> Participation in clinical trials is especially encouraged </A>.

Section Name: Principles of Treatment
====================
Entities:-
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Extranodal Extension : The spread of cancer beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margins : Cancer cells are found at the edge of the material removed during surgery, indicating that some cancer may have been left behind.
Perineural Invasion : Cancer cells are found surrounding or tracking along a nerve within the perineural space.
Vascular Invasion : The presence of cancer cells within blood vessels.
Lymphatic Metastasis : The spread of cancer cells through the lymphatic system to distant sites.

Relationships:-
1. Entity1: ""Principles of Radiation Therapy"", Entity2: ""Extranodal Extension"", Relationship: ""management of""
2. Entity1: ""Principles of Surgery"", Entity2: ""Positive Surgical Margins"", Relationship: ""concerned with avoiding""
3. Entity1: ""Principles of Radiation Therapy"", Entity2: ""Perineural Invasion"", Relationship: ""consideration in treatment planning""

Causalities:-
<C> Extranodal extension </C> <C> Positive margins </C> <C> Close margins </C> <C> pT4 primary </C> <C> pN2 or pN3 nodal disease </C> <C> Perineural invasion </C> <C> Vascular invasion </C> <C> Lymphatic invasion </C> <C> Subglottic extension </C>

Section Name: Clinical Staging
====================
Entities:-
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to enhance its effectiveness.
Adjuvant Therapy : A therapy given in addition to the primary or initial therapy to maximize its effectiveness.
Follow-Up Studies : Studies that continue to monitor patients after treatment to assess long-term outcomes.
Follow-Up Procedure : A procedure performed to monitor the progress of a patient after initial treatment.
Follow-Up : The act of monitoring a patient's health over time after treatment.
Neoplasm Recurrence, Local : The return of a tumor at the original site after treatment.
Recurrent Disease : A disease that has returned after a period of remission.

Relationships:-
1. Entity1: ""Adjuvant Treatment"", Entity2: ""Recurrent or Persistent Disease"", Relationship: ""prevention""
2. Entity1: ""Follow-up"", Entity2: ""Recurrent or Persistent Disease"", Relationship: ""monitoring""

Section Name: Treatment Options
====================
Entities:-
Laryngectomy : Surgical procedure to remove the larynx, often used to treat laryngeal cancer.
Total Laryngectomy : A surgical procedure to remove the entire larynx.
Chemotherapy, Adjuvant : Drug therapy given in addition to the primary treatment to enhance its effectiveness.
Induction Chemotherapy : Chemotherapy given as a first step to shrink a tumor before the main treatment.
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.
Clinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.

Relationships:-
1. Entity1: ""T3 requiring total laryngectomy"", Entity2: ""Concurrent systemic therapy/RT"", Relationship: ""treatment option""
2. Entity1: ""T3 requiring total laryngectomy"", Entity2: ""Induction chemotherapy"", Relationship: ""treatment option""
3. Entity1: ""T3 requiring total laryngectomy"", Entity2: ""Clinical trials"", Relationship: ""research option""

Causalities:-
<CO> T3 requiring (amenable to) total laryngectomy (N2–3) </CO> <A> Concurrent systemic therapy/RT </A> <A> Surgery </A> <A> Induction chemotherapy </A> <A> Clinical trials </A>

Section Name: Surgical Considerations
====================
Entities:-
Laryngectomy : Surgical procedure to remove the larynx, often used to treat laryngeal cancer.
Thyroidectomy : Surgical removal of all or part of the thyroid gland.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue in the neck.
Lymph Node Excision : Surgical removal of one or more lymph nodes.
Lymph Node Dissection : A surgical procedure to remove lymph nodes.
Lymphadenectomy : Surgical removal of one or more groups of lymph nodes.

Relationships:-
1. Entity1: ""Laryngectomy"", Entity2: ""Thyroidectomy"", Relationship: ""performed with""
2. Entity1: ""Neck Dissection"", Entity2: ""Lymph Node Excision"", Relationship: ""includes""
3. Entity1: ""Neck Dissection"", Entity2: ""Lymph Node Excision"", Relationship: ""includes specific types""

Causalities:-
<A> Laryngectomy with thyroidectomy as indicated, ipsilateral or bilateral neck dissection, and pretracheal and ipsilateral paratracheal lymph node dissection </A>

Section Name: Pathologic Features
====================
Entities:-
Extranodal Extension : The spread of cancer beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margins : Cancer cells are found at the edge of the material removed during surgery, indicating that some cancer may have been left behind.
Positive Margin : A surgical margin that contains residual tumor cells.

Relationships:-
1. Entity1: ""Adverse pathologic features"", Entity2: ""Extranodal extension"", Relationship: ""includes""
2. Entity1: ""Adverse pathologic features"", Entity2: ""Positive margin"", Relationship: ""includes""

Causalities:-
- **No adverse pathologic features**
- **Adverse pathologic features**
  - <C> Extranodal extension and/or positive margin </C>
  - Other risk features

Section Name: Systemic Therapy
====================
Entities:-
Antineoplastic Agents : Drugs used to treat cancer by inhibiting the growth of cancerous cells.
Systemic Therapy : A treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiotherapy : The use of radiation, usually high-energy X-rays, to damage cancer cells and treat cancer.
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.

Relationships:-
1. Entity1: ""Systemic therapy"", Entity2: ""RT"", Relationship: ""Consideration""

Causalities:-
<A> Systemic therapy/RT (category 1) </A>
<A> RT </A>
<A> Consider systemic therapy/RT </A>

Section Name: Imaging
====================
Entities:-
Tomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.
Magnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body's soft tissue and bones.
Neck : Part of the body, on many terrestrial or secondarily aquatic vertebrates, that distinguishes the head from the torso or trunk.
Computed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images (often called slices), both horizontally and vertically, of the body.
Neck Structure : The anatomical structure that connects the head to the torso.

Relationships:-
1. Entity1: ""CT"", Entity2: ""Neck"", Relationship: ""imaging of""
2. Entity1: ""MRI"", Entity2: ""Neck"", Relationship: ""imaging of""

Causalities:-
<A> CT (with contrast) or MRI (with and without contrast) of primary and neck </A>

Section Name: Post-Treatment Evaluation
====================
Entities:-
Radiotherapy : The use of radiation, usually high-energy X-rays, to damage cancer cells and treat cancer.
Pn1 Category : A pathological classification indicating regional lymph node metastasis in cancer staging.
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.

Relationships:-
1. Entity1: ""Post Systemic Therapy/RT or RT Neck Evaluation"", Entity2: ""pN1"", Relationship: ""evaluation of cancer staging""
2. Entity1: ""pN1"", Entity2: ""Consider RT"", Relationship: ""treatment recommendation""

Causalities:-
<CO> pN1 without other risk features </CO> <A> Consider RT </A>

Section Name: Additional Notes
====================
Entities:-
Antineoplastic Combined Chemotherapy Protocols : Protocols for the administration of more than one antineoplastic agent in combination to treat malignant neoplasms.
Cisplatin : A platinum-containing antineoplastic agent used in the treatment of various cancers.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Non-Nasopharyngeal Cancers"", Relationship: ""used for""
2. Entity1: ""Cisplatin"", Entity2: ""Systemic Therapy"", Relationship: ""preferred agent in""
3. Entity1: ""Induction Chemotherapy"", Entity2: ""Systemic Therapy"", Relationship: ""discussed in context of""

Causalities:-
- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**
- **<CO> When using concurrent systemic therapy/RT </CO>, <A> the preferred agent is cisplatin (category 1) </A>. See Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A).**
- **<A> See Discussion on induction chemotherapy. </A>**
--------------------------------------------------
Page Number: 46

Section Name: Introduction
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, including the glottis.
Malignant Neoplasm Of Glottis : A malignant tumor located in the glottis, part of the larynx.
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness, often used in cancer treatment.
Adjuvant Therapy : Treatment given in addition to the primary (main) treatment to enhance its effectiveness.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network"", Entity2: ""Laryngeal Neoplasms"", Relationship: ""provides treatment guidelines for""
2. Entity1: ""treatment guidelines"", Entity2: ""Adjuvant therapy"", Relationship: ""guide clinical decision-making for""

Causalities:-
<C> cancer of the glottic larynx </C> <E> treatment guidelines </E> <CO> based on various clinical stages and specific patient conditions </CO> <A> guide healthcare professionals through clinical decision-making </A>.

Section Name: NCCN Guidelines Version 4.2024
====================
Entities:-
Clinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network"", Entity2: ""Clinical Trials"", Relationship: ""encourages participation in""

Causalities:-
<A>Participation in clinical trials</A> is especially encouraged.

Section Name: Clinical Staging and Treatment
====================
Entities:-
Neoplasm Staging : Methods used for staging of neoplasms based on extent of tumor spread.
T4A : A clinical stage indicating a tumor that has grown into nearby structures.
N0–3 : A range of clinical stages indicating the extent of regional lymph node involvement.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue in the neck.
Pathology : The study of the nature and cause of disease which involves changes in structure and function.
Antineoplastic Combined Chemotherapy Protocols : The use of drug combinations to treat cancer.
Radiotherapy : The use of ionizing radiation to treat cancer.
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.

Relationships:-
1. Entity1: ""Clinical Staging"", Entity2: ""Surgical Intervention"", Relationship: ""determines""
2. Entity1: ""T4a"", Entity2: ""Surgical Intervention"", Relationship: ""relates to""
3. Entity1: ""Systemic Therapy"", Entity2: ""Radiotherapy"", Relationship: ""considered with""
4. Entity1: ""Clinical Trials"", Entity2: ""Treatment of Primary and Neck"", Relationship: ""option for""

Causalities:-
<CO> Clinical staging indicator labeled ""T4a,N0–3"" </CO> <A> emphasizes the importance of surgical intervention </A>, highlighting procedures such as bilateral neck dissection and the need to address certain pathologic features. <CO> Selected T4a patients who decline surgery </CO> <A> consider concurrent systemic therapy/RT or clinical trial for function-preserving surgical or RT management or induction chemotherapy </A>.

Section Name: Principles of Treatment
====================
Entities:-
Thyroidectomy : Surgical removal of the thyroid gland.
Extranodal Extension : Spread of cancer beyond the lymph node capsule.
Radiation Therapy : Medical use of ionizing radiation to treat cancer.

Relationships:-
1. Entity1: ""Surgery"", Entity2: ""Thyroidectomy"", Relationship: ""involves""
2. Entity1: ""Radiation therapy"", Entity2: ""Adverse pathologic features"", Relationship: ""treats""

Causalities:-
- **Principles of Radiation Therapy (GLOT-A):**  
  - <C> Adverse pathologic features: extranodal extension, positive margins, close margins, pT4 primary, pN2 or pN3 nodal disease, perineural invasion, vascular invasion, lymphatic invasion, and subglottic extension </C> (Discussion).  

- **Principles of Surgery (SURG-A):**  
  - <A> Surgery, including ipsilateral or bilateral neck dissection; thyroidectomy to clear central compartment nodes </A>, <CO> especially when there is thyroid cartilage with gross invasion of the thyroid gland and significant subglottic extension </CO>.

Section Name: Adjuvant Treatment and Follow-up
====================
Entities:-
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Clinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Computed Tomography (Ct) : A medical imaging technique used in radiology to obtain detailed internal images of the body noninvasively for diagnostic purposes.
Magnetic Resonance Imaging (Mri) : A noninvasive medical test that physicians use to diagnose and treat medical conditions.
Recurrent Disease : A disease that has returned after a period of remission.
Radiation Therapy (Rt) : The use of ionizing radiation to treat cancer and other diseases.

Relationships:-
1. Entity1: ""Adverse Features"", Entity2: ""Specific Treatments"", Relationship: ""Suggests""
2. Entity1: ""Systemic Therapy"", Entity2: ""Patients who decline surgery"", Relationship: ""Option for""
3. Entity1: ""CT or MRI"", Entity2: ""Primary and Neck"", Relationship: ""Used for imaging""
4. Entity1: ""Recurrent or Persistent Disease"", Entity2: ""Follow-up"", Relationship: ""Condition for""
5. Entity1: ""pN1 without other risk features"", Entity2: ""RT"", Relationship: ""Suggests considering""

Causalities:-
<C> adverse features such as extralateral extension or positive margins </C> <E> specific treatments are suggested </E>. The guidelines recommend <A> considering options like concurrent systemic therapy or clinical trials </A> <CO> for patients who decline surgery </CO>.

- **Adjuvant Treatment:**  
  - <A> CT (with contrast) or MRI (with and without contrast) of primary and neck </A>.  

- **Follow-up (FOLL-A, 1 of 2):**  
  - <CO> Recurrent or persistent disease (ADV-3) </CO>.  

- **Post Systemic Therapy/RT or RT Neck Evaluation (FOLL-A, 2 of 2):**  
  - <CO> pN1 without other risk features </CO>: <A> Consider RT </A>.

Section Name: Response Assessment
====================
Entities:-
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness, often used in cancer treatment.
Computed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.
Magnetic Resonance Imaging : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.
Neoplasm Recurrence, Local : The return of a cancer, at the same site as the original (primary) tumor, after it had disappeared.

Relationships:-
1. Entity1: ""Adjuvant treatment"", Entity2: ""Treatment responses"", Relationship: ""affects""
2. Entity1: ""Follow-up assessments"", Entity2: ""CT or MRI scans"", Relationship: ""conducted using""
3. Entity1: ""Response Assessment (GLOT-5)"", Entity2: ""Recurrent or persistent disease (ADV-3)"", Relationship: ""determines""

Causalities:-
As the flowchart progresses to the adjuvant treatment section, it depicts further decision points based on treatment responses and disease recurrence. The inclusion of references to follow-up assessments, such as CT or MRI scans, underscores the emphasis on continuous monitoring and evaluation of treatment efficacy.  - **Response Assessment (GLOT-5):**   - <C>Recurrent or persistent disease (ADV-3)</C>.


Among these two options which one is the most likely true:

(A) `Location_of_Involved_Lymph_Nodes_4` increases risk `Magnetic_Resonance_Imaging_MRI_14`
(B) `Magnetic_Resonance_Imaging_MRI_14` `increases risk `Location_of_Involved_Lymph_Nodes_4`

The answer is: ...

1. State the evidences in detail of the validity of option (A) or (B) by cross referencing
NCCN Clinical Practitioner’s Guidelines for Head and Neck Cancer.
2. If the evidences are obtained from `INFORMATION FROM KNOWLEDGE BASE`,
mention their corresponding Page Numbers, Section Name, entities, relationships and causalities.

DESIRED OUTPUT FORMAT:
<thinking>
...
</thinking>
<answer>
{
   ""thinking"": [""..."", ...],
   ""evidences"": [""..."", ...],
   ""answer"": ...
}
</answer>

Before providing the answer in <answer> tags, think step by step in detail in <thinking> tags and analyze every part.
Output inside <answer> tag in JSON format. Only output valid JSON.
DO NOT HALLUCINATE. DO NOT MAKE UP FACTUAL INFORMATION.
","1. The edge in question is between 'Location_of_Involved_Lymph_Nodes_4' and 'Magnetic_Resonance_Imaging_MRI_14'.
2. Option (A) suggests that the location of involved lymph nodes increases the risk of MRI results, which is not valid as MRI results are observations, not influenced by lymph node location.
3. Option (B) suggests that MRI results increase the risk of lymph node location, which is also not valid as MRI results are observations, not causes.
4. The NCCN guidelines emphasize the use of imaging techniques like MRI to evaluate lymph node metastasis, not to influence or cause it.
5. The knowledge base indicates that MRI is used to detect the presence and pattern of lymph node metastasis, not to influence the location of lymph nodes.
6. Page 94, Section 'Initial Workup - Nodal Metastases' states that MRI is used to evaluate lymph node metastases, supporting the idea that MRI is an observational tool, not a causal factor.
7. Both options (A) and (B) are invalid as they suggest a causal relationship where none exists.
","1. Page 94, Section 'Initial Workup - Nodal Metastases': MRI is used to evaluate lymph node metastases.
2. MRI is an observational tool, not a causal factor for lymph node location.
",A,"{'A': 53.12, 'B': 46.88}",yes,A,"1. The AI assistant's reasoning is based on the understanding that MRI results are observational and not causal. This aligns with the general medical understanding that imaging techniques like MRI are used to detect and evaluate conditions rather than cause them.
2. The assistant correctly identifies that both options (A) and (B) suggest a causal relationship that does not exist. This is consistent with the explanation provided in the edge analysis, where it is stated that the MRI results are an observation of the lymph node involvement, not caused by it.
3. The assistant references the NCCN guidelines and the knowledge base to support its reasoning, specifically pointing out that MRI is used to evaluate lymph node metastases, which is an observational role rather than a causal one.
4. The assistant's conclusion that both options are invalid is consistent with the evidence provided, as neither option accurately reflects the nature of the relationship between lymph node location and MRI results.
"
7,gpt-4o,"Location_of_Involved_Lymph_Nodes_4,Positron_Emission_Tomography_PET_15","""{'NODE1': {'id': 'Location_of_Involved_Lymph_Nodes_4', 'label': 'Position of Affected Lymph Nodes in Patient', 'description': \""This node represents the location of lymph nodes that are involved or affected in a patient's condition. Understanding whether the lymph nodes are ipsilateral, bilateral, or contralateral is crucial for determining the extent of disease spread and planning appropriate treatment strategies.\"", 'type': 'Patient Situation', 'observability': 'Unobserved', 'states': [{'state_name': 'ipsilateral', 'state_description': 'The involved lymph nodes are on the same side of the body as the primary tumor or reference point. This can indicate localized spread of disease.'}, {'state_name': 'bilateral', 'state_description': 'The involved lymph nodes are on both sides of the body. This may suggest a more extensive spread of disease and can impact treatment decisions.'}, {'state_name': 'contralateral', 'state_description': 'The involved lymph nodes are on the opposite side of the body from the primary tumor or reference point. This can indicate metastatic spread and may affect staging and treatment planning.'}]}, 'NODE2': {'id': 'Positron_Emission_Tomography_PET_15', 'label': 'Positron Emission Tomography (PET) Examination Result', 'description': 'This node represents the result of a Positron Emission Tomography (PET) scan, which is used to detect the presence and extent of lymph node metastasis in cancer patients. The PET scan provides critical information about whether cancer has spread to lymph nodes and the pattern of such metastasis, which is crucial for staging and treatment planning.', 'type': 'Examination Result', 'observability': 'Observed', 'states': [{'state_name': 'bilateral_lymph_node_metastasis', 'state_description': 'The PET scan shows metastasis in lymph nodes on both sides of the body, indicating a more widespread dissemination of cancer.'}, {'state_name': 'ipsilateral_lymph_node_metastasis', 'state_description': 'The PET scan shows metastasis in lymph nodes on the same side of the body as the primary tumor, suggesting localized spread.'}, {'state_name': 'contralateral_lymph_node_metastasis', 'state_description': 'The PET scan shows metastasis in lymph nodes on the opposite side of the body from the primary tumor, indicating cross-body spread of cancer.'}]}, 'EDGE1': {'edges_ids': ['Location_of_Involved_Lymph_Nodes_4', 'Positron_Emission_Tomography_PET_15'], 'edge': '(Location_of_Involved_Lymph_Nodes_4) causes (Positron_Emission_Tomography_PET_15)', 'explanation': ['The edge suggests that the location of involved lymph nodes causes the PET scan results.', 'However, the PET scan results are an observation of the current state of lymph nodes, not caused by their location.', 'The PET scan detects the presence and extent of lymph node metastasis, which is a reflection of the underlying condition.', 'Therefore, the edge is not valid as a causal relationship because the PET scan result is an effect of the underlying condition, not caused by the location of lymph nodes.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}, 'EDGE2': {'edges_ids': ['Positron_Emission_Tomography_PET_15', 'Location_of_Involved_Lymph_Nodes_4'], 'edge': '(Positron_Emission_Tomography_PET_15) causes (Location_of_Involved_Lymph_Nodes_4)', 'explanation': ['The edge is not valid because the PET scan result does not cause the location of the lymph nodes. It only detects and reports the existing condition of the lymph nodes.', 'The PET scan provides information about the spread of cancer to lymph nodes, but it does not influence or change the location of the lymph nodes.', 'The location of the lymph nodes is determined by the biological spread of cancer, not by the imaging result.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}, 'ENTITIES_MATCHING_PAGES_INFO': {'94': {'matching_entities': [{'LYMPH NODE METASTASIS': 0.9767965}, {'POSITRON-EMISSION TOMOGRAPHY': 0.9655257}, {'LYMPHATIC METASTASIS': 0.9638432}, {'NEOPLASM METASTASIS': 0.95823944}, {'POSITRON EMISSION TOMOGRAPHY': 0.9552841}, {'POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY': 0.9447995}, {'MAGNETIC RESONANCE IMAGING': 0.9216922}], 'count': 7}, '92': {'matching_entities': [{'POSITRON EMISSION TOMOGRAPHY (PROCEDURE)': 0.9864658}, {'POSITRON-EMISSION TOMOGRAPHY': 0.9655257}, {'POSITRON EMISSION TOMOGRAPHY': 0.9552841}, {'METASTASIS': 0.9265935}, {'MAGNETIC RESONANCE IMAGING': 0.9216922}], 'count': 5}, '130': {'matching_entities': [{'LYMPH NODE STRUCTURE': 0.99134904}, {'LYMPH NODE': 0.98570025}, {'LYMPH NODES': 0.97445965}, {'NEOPLASM METASTASIS': 0.95823944}, {'METASTASIS': 0.9265935}], 'count': 5}, '96': {'matching_entities': [{'POSITRON-EMISSION TOMOGRAPHY': 0.9655257}, {'POSITRON EMISSION TOMOGRAPHY': 0.9552841}, {'LOCOREGIONAL RECURRENCE OF TUMOR': 0.92573977}, {'MAGNETIC RESONANCE IMAGING': 0.9216922}], 'count': 4}, '148': {'matching_entities': [{'POSITRON-EMISSION TOMOGRAPHY': 0.9655257}, {'LYMPHATIC METASTASIS': 0.9638432}, {'METASTASIS': 0.9265935}, {'MAGNETIC RESONANCE IMAGING': 0.9216922}], 'count': 4}}, 'GUIDELINE_PAGES_INFO': '--------------------------------------------------\\nPage Number: 94\\n\\nSection Name: Head and Neck Cancers - Principles of Imaging\\n====================\\nEntities:-\\nPositron Emission Tomography Computed Tomography : A medical imaging technique combining PET and CT capabilities to provide detailed information about the body\\'s function and structure.\\nPositron Emission Tomography : A nuclear medicine functional imaging technique that is used to observe metabolic processes in the body.\\nComputed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.\\nHead And Neck Neoplasms : Cancers that arise in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\n\\nRelationships:-\\n1. Entity1: \""PET/CT\"", Entity2: \""PET scan\"", Relationship: \""preferred over\""\\n2. Entity1: \""PET-CT\"", Entity2: \""head neck cancers\"", Relationship: \""used in study of\""\\n\\nCausalities:-\\n<A> PET/CT is preferred over PET scan alone (i.e., without superimposed CT scan) </A>. <C> PET/CT provides more accurate anatomical localization of abnormalities </C> <E> more accurate anatomical localization of abnormalities </E>.\\n\\nSection Name: Initial Workup - Nodal Metastases\\n====================\\nEntities:-\\nLymphatic Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site via the lymphatic system.\\nTomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient, producing signals that are processed by the machine\\'s computer to generate cross-sectional images.\\nMagnetic Resonance Imaging : A non-invasive imaging technique that uses magnetic fields and radio waves to create detailed images of the organs and tissues within the body.\\nPositron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption.\\nLymph Node Metastasis : The spread of cancer cells to lymph nodes, which are part of the lymphatic system.\\nCt Of Neck : A computed tomography scan of the neck region.\\nMri Of Neck : A magnetic resonance imaging scan of the neck region.\\nFdg-Pet Scan : A type of positron emission tomography using fluorodeoxyglucose to assess metabolic activity.\\nComputed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.\\nPositron Emission Tomography : A nuclear medicine functional imaging technique that is used to observe metabolic processes in the body.\\n\\nRelationships:-\\n1. Entity1: \""CT\"", Entity2: \""lymph node metastases\"", Relationship: \""used to evaluate\""\\n2. Entity1: \""MRI\"", Entity2: \""lymph node metastases\"", Relationship: \""used to evaluate\""\\n3. Entity1: \""FDG-PET/CT\"", Entity2: \""lymph node metastases\"", Relationship: \""used for detection\""\\n4. Entity1: \""FDG-PET/CT\"", Entity2: \""surgical primary approach\"", Relationship: \""used to determine\""\\n5. Entity1: \""FDG-PET/CT\"", Entity2: \""definitive RT approach\"", Relationship: \""used to identify\""\\n\\nCausalities:-\\n<A> Evaluation of lymph node metastases should be conducted with CT or MRI of the neck </A>, using whichever imaging study is suitable for primary site evaluation (IMG-A, 1 of 4).\\n<CO> For patients with multistation or lower neck nodal involvement or high-grade tumor histology </CO>, <A> consider CT of the chest to assess for mediastinal lymph node metastases or FDG-PET/CT </A>, <C> which is associated with higher sensitivity for both nodal and distant metastases </C>.\\n<CO> For patients who are under consideration for a surgical primary approach </CO>, <A> the higher sensitivity of FDG-PET/CT is warranted for tumors approaching the midline, to determine the surgical approach to the contralateral neck </A>. <CO> Similarly, patients who are scheduled for a definitive RT approach </CO> <A> may benefit from the higher sensitivity of FDG-PET/CT for identifying involved lymph nodes </A>.\\n\\nSection Name: Initial Workup - Distant Metastases\\n====================\\nEntities:-\\nPositron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption.\\nMagnetic Resonance Imaging : A non-invasive imaging technique that uses magnetic fields and radio waves to create detailed images of the organs and tissues within the body.\\nTomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient, producing signals that are processed by the machine\\'s computer to generate cross-sectional images.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nLung Neoplasms : Tumors or cancer of the lung.\\nSmoking : The inhalation of the smoke of burning tobacco encased in cigarettes, pipes, and cigars.\\n\\nRelationships:-\\n1. Entity1: \""FDG-PET/CT\"", Entity2: \""Distant Metastases\"", Relationship: \""used to evaluate\""\\n2. Entity1: \""Contrast-enhanced brain MRI\"", Entity2: \""Brain Metastasis\"", Relationship: \""recommended for evaluation\""\\n3. Entity1: \""CT of the chest\"", Entity2: \""Pulmonary Metastases\"", Relationship: \""performed to assess\""\\n4. Entity1: \""Non-contrast CT of the chest\"", Entity2: \""Lung Parenchymal Metastases\"", Relationship: \""used to screen\""\\n5. Entity1: \""Annual CT screening\"", Entity2: \""Lung Metastasis\"", Relationship: \""considered for high risk\""\\n6. Entity1: \""Directed CT or MRI\"", Entity2: \""Distant Disease\"", Relationship: \""used for assessment\""\\n7. Entity1: \""FDG-PET/CT\"", Entity2: \""Recurrent Disease\"", Relationship: \""used for staging\""\\n\\nCausalities:-\\n<C> Patients with locoregionally advanced cancer (e.g., T3\u2013T4 primary or \u2265N1 nodal staging) </C>, <A> FDG-PET/CT is preferred to evaluate for distant disease and thoracic metastases </A>. <CO> For cancers where brain metastasis is a concern, such as mucosal melanoma or high-grade neuroendocrine carcinomas or adenocarcinomas </CO>, <A> contrast-enhanced brain MRI should be additionally obtained </A>.\\n<CO> If FDG-PET/CT is not performed </CO>, <A> CT of the chest should be performed to assess for presence of pulmonary metastases as well as mediastinal lymph node involvement </A>.\\n<CO> Non-contrast CT of the chest can be sufficient to screen for lung parenchymal metastases </CO> but <CO> is not adequate for assessment of mediastinal adenopathy </CO>. <CO> This is an appropriate lung cancer screening intervention for patients with a history of smoking </CO>.\\n<CO> Following primary definitive treatment (surgery, RT, or systemic therapy/RT) </CO> the role of annual CT screening for lung metastasis is controversial. <E> While this approach does detect early metastasis </E>, <CO> further study is needed to determine the extent of the positive effect and/or cost-effectiveness of this approach in specific subpopulations and timepoints post-treatment </CO>. <CO> For patients with a substantial smoking history or who are at high risk for lung metastases </CO>, <A> annual chest CT can be considered </A>.\\n<CO> If clinical concern for metastatic disease is confined to a specific anatomical area </CO>, <A> the assessment of distant disease can be performed with directed CT or MRI examination </A>.\\n<CO> FDG-PET/CT may complement or replace other imaging modalities when staging recurrent disease before any therapy for relapsed/refractory disease </CO> <A> in order to explore distant disease or second primaries that may significantly impact choice of therapy </A>.\\n--------------------------------------------------\\nPage Number: 92\\n\\nSection Name: NCCN Guidelines Overview\\n====================\\nEntities:-\\nHead And Neck Neoplasms : Cancers that arise in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\nMalignant Neoplasm Of Head And Neck : A malignant tumor located in the head and neck region.\\nHead And Neck Cancer : A group of cancers that originate in the head and neck region.\\nAntineoplastic Agents : Drugs used to treat cancer by inhibiting the growth of cancerous cells.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.\\nRadiation Therapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.\\n\\nRelationships:-\\n1. Entity1: \""Head and neck cancers\"", Entity2: \""Systemic therapy\"", Relationship: \""follow-up recommendations after\""\\n2. Entity1: \""Head and neck cancers\"", Entity2: \""Radiation therapy\"", Relationship: \""follow-up recommendations after\""\\n\\nCausalities:-\\nThe image presents a flowchart from the National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2024, especially focusing on <A> follow-up recommendations </A> for <CO> patients with head and neck cancers after systemic therapy or radiation therapy (RT) </CO>. All recommendations are categorized as level A unless stated otherwise, highlighting the importance of clinical trials in cancer management.\\n\\nSection Name: Imaging and Assessment Protocols\\n====================\\nEntities:-\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.\\nClinical Assessment : A systematic evaluation of a patient\\'s health status, often involving a physical examination and medical history.\\nPositron-Emission Tomography : An imaging technique using a radioactive substance called a tracer to look for disease in the body.\\nComputed Tomography : A medical imaging technique used in radiology to obtain detailed internal images of the body.\\nMagnetic Resonance Imaging : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis.\\nDisease : A disorder of structure or function in a human, animal, or plant, especially one that produces specific symptoms.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\nResidual Neoplasm : Remaining cancer cells after treatment.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Clinical Assessment\"", Relationship: \""occurs before\""\\n2. Entity1: \""FDG-PET/CT Scan\"", Entity2: \""Distant Metastases\"", Relationship: \""assesses\""\\n3. Entity1: \""FDG-PET/CT Scan\"", Entity2: \""Observation\"", Relationship: \""leads to if negative\""\\n4. Entity1: \""FDG-PET/CT Scan\"", Entity2: \""CT Scan\"", Relationship: \""leads to if strongly positive\""\\n5. Entity1: \""CT Scan\"", Entity2: \""Neck Dissection\"", Relationship: \""leads to if positive\""\\n\\nCausalities:-\\n<CO> After systemic therapy or RT </CO>, <A> a clinical assessment should occur 4 to 8 weeks later </A>. <CO> If there is a response </CO>, <A> it is necessary to assess the extent of disease or distant metastases, preferably through a FDG-PET/CT scan at a minimum of 12 weeks post-treatment </A>. <CO> If the FDG-PET/CT results are negative </CO>, <A> the patient may continue with monitoring through observation </A>. <CO> In cases where the results are equivocal </CO>, <A> observation or repeat FDG-PET/CT within 3 to 6 months is prescribed </A>.\\n\\n<CO> In cases where the FDG-PET/CT results are strongly positive </CO>, <A> further imaging via CT scan with contrast of the primary site and neck, or MRI with and without contrast, becomes necessary </A>. <CO> If these imaging results confirm positive findings </CO>, <A> neck dissection may be considered, depending on the evidence of residual or persistent disease </A>. <CO> If the imaging findings are negative </CO>, <A> the patient might continue in observation </A>.\\n\\nSection Name: Outcomes Based on Disease Resectability\\n====================\\nEntities:-\\nDisease : A disorder of structure or function in a human, animal, or plant, especially one that produces specific symptoms.\\nResectable : Capable of being surgically removed.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis.\\n\\nRelationships:-\\n1. Entity1: \""Disease\"", Entity2: \""Resectable\"", Relationship: \""Classification\""\\n2. Entity1: \""Unresectable\"", Entity2: \""Treatment plans (ADV-3)\"", Relationship: \""Treatment recommendation\""\\n3. Entity1: \""Resectable\"", Entity2: \""Resection and/or Neck dissection\"", Relationship: \""Surgical procedure\""\\n\\nCausalities:-\\n<CO> If there is confirmed residual or persistent disease </CO>, the options split into two pathways: \\'Unresectable\\' or \\'Resectable.\\' <CO> If the disease is classified as unresectable </CO>, <A> advances in treatment plans (labeled ADV-3) are called for </A>. Conversely, <CO> if it is deemed resectable </CO>, <A> a resection of the primary and/or neck dissection may occur </A>, <CO> contingent upon the disease status </CO>.\\n\\nSection Name: Important Notes\\n====================\\nEntities:-\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\nClinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.\\nPositron-Emission Tomography : An imaging technique using a radioactive substance called a tracer to look for disease in the body.\\nPositron Emission Tomography (Procedure) : A diagnostic imaging procedure that uses a radioactive tracer to visualize and measure changes in metabolic processes.\\nPositron Emission Tomography : A nuclear medicine functional imaging technique used to observe metabolic processes in the body.\\nNeoplasms : New abnormal growth of tissue in animals or plants; a tumor.\\nMalignant Neoplasm : A cancerous growth that has the potential to spread to other parts of the body.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""NCCN\"", Entity2: \""Clinical trials\"", Relationship: \""emphasizes participation in\""\\n2. Entity1: \""FDG-PET/CT\"", Entity2: \""Persistent cancer\"", Relationship: \""used to detect\""\\n3. Entity1: \""FDG-PET/CT\"", Entity2: \""PET negative\"", Relationship: \""interpretation of results\""\\n4. Entity1: \""FDG-PET/CT\"", Entity2: \""PET positive\"", Relationship: \""interpretation of results\""\\n\\nCausalities:-\\n<A> NCCN emphasizes that the best management for any cancer patient is participation in clinical trials </A>, especially encouraged for all patients. Additional notes clarify that <CO> if the FDG-PET/CT is negative for persistent cancer </CO>, <A> further cross-sectional imaging is optional </A>. The interpretations define <CO> PET negative as no or low-grade uptake not suspicious for disease </CO>, while <CO> PET positive implies suspicion for disease </CO>.\\n--------------------------------------------------\\nPage Number: 130\\n\\nSection Name: Pathological N (pN)\\n====================\\nEntities:-\\nLymph Nodes : Small, bean-shaped structures that are part of the body\\'s lymphatic system. They filter lymph fluid and store white blood cells that help fight infection.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nTnm Staging : A system used to describe the size and spread of cancer in a standardized way. T refers to the size of the tumor, N to the involvement of lymph nodes, and M to metastasis.\\nLymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\nTnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient\\'s body.\\nLymph Node : An organ of the lymphatic system and the adaptive immune system.\\n\\nRelationships:-\\n1. Entity1: \""Lymph Nodes\"", Entity2: \""Neoplasm Metastasis\"", Relationship: \""involved in\""\\n2. Entity1: \""TNM Staging\"", Entity2: \""Lymph Nodes\"", Relationship: \""includes\""\\n3. Entity1: \""TNM Staging\"", Entity2: \""Neoplasm Metastasis\"", Relationship: \""describes\""\\n\\nCausalities:-\\n<CO> NX: Regional lymph nodes cannot be assessed </CO>\\n<CO> N0: No regional lymph node metastasis </CO>\\n<CO> N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(\u2013) </CO>\\n<CO> N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2212); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(\u2212); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2a: Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N3: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(\u2212); or metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>\\n<CO> N3a: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N3b: Metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>\\n<CO> Note: A designation of \u201cU\u201d or \u201cL\u201d may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L). Similarly, clinical and pathological ENE should be recorded as ENE(\u2212) or ENE(+). </CO>\\n\\nSection Name: Distant Metastasis (M)\\n====================\\nEntities:-\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\n\\nRelationships:-\\n1. Entity1: \""M0\"", Entity2: \""Distant Metastasis\"", Relationship: \""is a category of\""\\n2. Entity1: \""M1\"", Entity2: \""Distant Metastasis\"", Relationship: \""is a category of\""\\n\\nCausalities:-\\n### Distant Metastasis (M)\\n\\n- **M0**: No distant metastasis\\n- **M1**: Distant metastasis\\n\\nSection Name: Histologic Grade (G)\\n====================\\nEntities:-\\nNeoplasm Grading : A system of classifying cancer cells in terms of how abnormal they look under a microscope and how quickly the tumor is likely to grow and spread.\\nHistologic Grade : A measure of how much tumor cells differ from healthy cells, used to assess the aggressiveness of cancer.\\n\\nRelationships:-\\n1. Entity1: \""GX\"", Entity2: \""Grade cannot be assessed\"", Relationship: \""is described as\""\\n2. Entity1: \""G1\"", Entity2: \""Well differentiated\"", Relationship: \""is described as\""\\n3. Entity1: \""G2\"", Entity2: \""Moderately differentiated\"", Relationship: \""is described as\""\\n4. Entity1: \""G3\"", Entity2: \""Poorly differentiated\"", Relationship: \""is described as\""\\n\\nCausalities:-\\n<CO>GX</CO>: <E>Grade cannot be assessed</E>\\n<CO>G1</CO>: <E>Well differentiated</E>\\n<CO>G2</CO>: <E>Moderately differentiated</E>\\n<CO>G3</CO>: <E>Poorly differentiated</E>\\n\\nSection Name: Prognostic Stage Groups\\n====================\\nEntities:-\\nNeoplasm Staging : Methods and systems of classifying neoplasms according to extent of disease.\\nTumor Staging : A system for describing the size and spread of cancer within the body.\\nTnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient\\'s body.\\n\\nRelationships:-\\n1. Entity1: \""Stage 0\"", Entity2: \""Tis N0 M0\"", Relationship: \""defined by\""\\n2. Entity1: \""Stage I\"", Entity2: \""T1 N0 M0\"", Relationship: \""defined by\""\\n3. Entity1: \""Stage II\"", Entity2: \""T2 N0 M0\"", Relationship: \""defined by\""\\n4. Entity1: \""Stage III\"", Entity2: \""T3 N0 M0, T1 N1 M0, T2 N1 M0, T3 N1 M0\"", Relationship: \""defined by\""\\n5. Entity1: \""Stage IVA\"", Entity2: \""T1 N2 M0, T2 N2 M0, T3 N2 M0, T4a N0,N1,N2 M0\"", Relationship: \""defined by\""\\n6. Entity1: \""Stage IVB\"", Entity2: \""Any T N3 M0, T4b Any N M0\"", Relationship: \""defined by\""\\n7. Entity1: \""Stage IVC\"", Entity2: \""Any T Any N M1\"", Relationship: \""defined by\""\\n--------------------------------------------------\\nPage Number: 96\\n\\nSection Name: Head and Neck Cancers\\n====================\\nEntities:-\\nHead And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\nPositron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes.\\nSurveillance : The ongoing systematic collection, analysis, and interpretation of health data essential to the planning, implementation, and evaluation of public health practice.\\nLocoregional Recurrence Of Tumor : The return of cancer in the original tumor location or nearby lymph nodes after treatment.\\nAsymptomatic : A condition or a person showing no symptoms of disease.\\nMagnetic Resonance Imaging : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.\\nUltrasound : A medical imaging technique that uses high-frequency sound waves to visualize soft tissues such as muscles and internal organs.\\n\\nRelationships:-\\n1. Entity1: \""FDG-PET/CT\"", Entity2: \""Head and Neck Neoplasms\"", Relationship: \""used for surveillance imaging\""\\n2. Entity1: \""Recurrence\"", Entity2: \""Post-treatment period\"", Relationship: \""occurs within\""\\n3. Entity1: \""Imaging Modalities\"", Entity2: \""Surveillance\"", Relationship: \""used for\""\\n\\nCausalities:-\\n<C> The majority of recurrences after treatment of head and neck cancer occur in the first 2 years </C>. <C> Surveillance can be challenging </C> <C> because of altered anatomy and/or fibrosis from surgery, radiation, and/or chemotherapy </C>. <CO> There are no consensus guidelines on the frequency and modality of routine post-treatment imaging in the asymptomatic patient </CO>. <A> Practice varies widely across institutions </A>.\\n\\n<C> US, CT, MRI, and PET/CT all have unique advantages and disadvantages when used as surveillance imaging </C>. <C> There is evidence that FDG-PET/CT may be the most sensitive of these modalities </C>. <E> A 12-month PET has been shown to reveal recurrent or second primary cancers in approximately 10% of treated patients </E>; <E> a 24-month FDG-PET/CT imaging revealed these findings in approximately 5% of treated cases </E>. <CO> Most cases of asymptomatic FDG-PET/CT lesion localization occur at distant sites </CO>. <CO> Whether earlier detection leads to improved disease-specific survival is not established </CO>.\\n\\n<A> Standardized multi-institutional imaging-based trials are needed to clearly elucidate the value of routine imaging in the clinically asymptomatic patient </A>. <CO> There may be little proven benefit in further imaging if the initial 3-month FDG-PET/CT scan was negative </CO>. <C> Ho et al reported no significant difference in 3-year disease-free survival in patients undergoing imaging surveillance versus those only receiving clinical surveillance </C> <E> (41% vs. 46%, P = .91) in this setting </E>.\\n\\n<CO> If an FDG-PET/CT at 3 months post-treatment is negative </CO>, <CO> there are no data to support substantial benefit for further routine imaging in an asymptomatic patient with negative exam </CO>. <A> In the absence of multi-institutional prospective data, a tailored approach to surveillance with attention to tumor type, stage, prognostic factors, symptomatology, and physical exam changes or restrictions is appropriate </A>.\\n\\n<A> US of the neck is a well-established tool for nodal surveillance </A>. <C> US is generally widely available, safe, fast, inexpensive, and an accurate modality for examination of the neck for any suspicious nodal disease </C>.\\n\\n<CO> Additional post-treatment imaging is indicated for worrisome or equivocal signs/symptoms </CO>.\\n\\n<CO> Routine annual imaging (repeat use of pretreatment imaging modality) may be indicated to visualize areas inaccessible to routine clinical examination </CO> <CO> (deep-seated anatomic locations or areas obscured by extensive treatment change) </CO>.\\n\\nSection Name: Principles of Imaging\\n====================\\nEntities:-\\nHead And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\nHead And Neck Cancer : A group of cancers that originate in the head and neck region.\\nPositron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes.\\nPositron Emission Tomography : A type of nuclear medicine imaging that uses small amounts of radioactive materials to diagnose or treat a variety of diseases.\\nTomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient, producing signals that are processed by the computer to generate cross-sectional images.\\nComputed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images.\\nNeck : The part of the body on many vertebrates that separates the head from the torso or trunk.\\n\\nRelationships:-\\n1. Entity1: \""Surveillance imaging\"", Entity2: \""Head and neck cancer\"", Relationship: \""used for monitoring\""\\n2. Entity1: \""PET-CT\"", Entity2: \""Head and neck cancer\"", Relationship: \""used for detection\""\\n3. Entity1: \""Positron emission tomography/computed tomography\"", Entity2: \""Head and neck cancer\"", Relationship: \""used for surveillance\""\\n\\nSection Name: NCCN Guidelines\\n====================\\nEntities:-\\nNeoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.\\nClinical Trial : A clinical trial is a research study conducted with patients to evaluate a new medical treatment, drug, or device.\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\n\\nRelationships:-\\n1. Entity1: \""Neoplasms\"", Entity2: \""Clinical trial\"", Relationship: \""best management through\""\\n\\nCausalities:-\\n<C> NCCN believes that the best management of any patient with cancer is in a clinical trial </C>. <A> Participation in clinical trials is especially encouraged </A>.\\n--------------------------------------------------\\nPage Number: 148\\n\\nSection Name: Head and Neck Cancers Imaging\\n====================\\nEntities:-\\nMagnetic Resonance Imaging : A non-invasive imaging technique that uses magnetic fields and radio waves to produce detailed images of the organs and tissues in the body.\\nTomography, X-Ray Computed : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.\\nPositron-Emission Tomography : A nuclear medicine functional imaging technique used to observe metabolic processes in the body.\\nHead And Neck Neoplasms : Cancers that occur in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, and larynx.\\nLymphatic Metastasis : The spread of cancer cells through the lymphatic system to distant lymph nodes.\\nSquamous Cell Carcinoma Of Head And Neck : A type of cancer that arises from the squamous cells lining the head and neck region.\\nCranial Nerves : The twelve pairs of nerves that arise directly from the brain and pass through various foramina in the skull.\\nSkull Base : The area of the skull where the brain rests, including the bones and foramina at the base of the skull.\\nBone Marrow : The soft, spongy tissue found in the center of bones, responsible for producing blood cells.\\nCortical Bone : The dense outer surface of bone that forms a protective layer around the internal cavity.\\nPeriosteum : A dense layer of vascular connective tissue enveloping the bones except at the surfaces of the joints.\\nMetastasis : The spread of cancer cells from the place where they first formed to another part of the body.\\nDental Radiography : The use of X-rays to view the teeth and surrounding structures.\\n\\nRelationships:-\\n1. Entity1: \""Magnetic Resonance Imaging\"", Entity2: \""Cranial Nerves\"", Relationship: \""preferred for evaluation\""\\n2. Entity1: \""Tomography, X-Ray Computed\"", Entity2: \""Cortical Bone\"", Relationship: \""used for evaluation\""\\n3. Entity1: \""Positron-Emission Tomography\"", Entity2: \""Lymphatic Metastasis\"", Relationship: \""superior for detection\""\\n4. Entity1: \""Magnetic Resonance Imaging\"", Entity2: \""Bone Marrow\"", Relationship: \""used for evaluation\""\\n5. Entity1: \""Dental Radiography\"", Entity2: \""Dentition\"", Relationship: \""used for evaluation\""\\n\\nCausalities:-\\n<C> Appropriate selection and utilization of imaging studies </C> <E> is crucial for proper care of patients with head and neck cancers </E>.\\n<A> Initial imaging of the primary site is performed with CT and/or MRI </A>.\\n<CO> in patients with symptoms involving the cranial nerves or tumors encroaching on the skull base </CO> <A> MRI is generally preferred over CT </A>.\\n<CO> for evaluation of bony erosion or cartilage invasion that may occur with some head and neck tumors (e.g., laryngeal cancer) </CO> <A> CT is complementary to MRI </A>.\\n<CO> in patients with head and neck cancers involving the bone </CO> <A> MRI is needed to evaluate the extent of bone marrow invasion </A>.\\n<CO> in patients with head and neck cancers involving the bone </CO> <A> CT is preferred to evaluate cortical bone erosion or periosteal invasion </A>.\\n<CO> for cancers originating in the base of the tongue </CO> <A> MRI can often delineate the boundary between gross tumor and normal muscle more effectively than CT </A>.\\n<CO> for differentiating tumor extent from obstructed sinuses or secretions and to evaluate intracranial/dural involvement </CO> <A> MRI is also preferable to CT </A>.\\n<CO> depending on the primary site </CO> <A> Evaluation of lymph node metastases can be done with either CT or MRI </A>.\\n<C> There is evidence to support the superiority of FDG-PET/CT </C> <E> for detecting locoregional nodal and distant metastases in patients with head and neck cancers </E>.\\n<CO> in patients with clinically node-negative SCCHN </CO> <E> the positive predictive value (PPV) and negative predictive value (NPV) of FDG-PET/CT for detection of cervical lymph node involvement was 0.62 (95% CI, 0.55\u20130.69) and 0.83 (95% CI, 0.79\u20130.86), respectively </E>.\\n<CO> in patients with cN0 disease </CO> <E> 125/144 (87%) negative PET scans were pathologically negative at neck dissection </E>.\\n<E> Findings from PET/CT changed the surgical plan in 22% of patients </E>.\\n<CO> for detection of cervical lymph node metastases by FDG-PET/CT </CO> <E> a prospective single-center study from Germany (N = 150) showed an NPV of 93.3% (95% CI, 88.2%\u201398.5%) </E>.\\n<CO> if there is concern about metastasis to a specific anatomic area </CO> <A> directed CT or MRI may also be performed </A>.\\n<C> Head and neck cancers rarely metastasize to the brain by a hematogenous route </C> <E> ordering a full brain study as part of the initial imaging workup is not routine </E>.\\n<CO> for patients who are dentulous and expected to receive postoperative RT </CO> <A> a panoramic dental x-ray should be completed before treatment as part of the dental evaluation </A>.\\n<CO> if a marginal resection is being considered </CO> <E> Panorex is also helpful for evaluation of dentition and mandibular height </E>.\\n\\nSection Name: Quality of Life and Patient-Reported Outcomes\\n====================\\nEntities:-\\nQuality Of Life : A generic term for the general well-being of individuals and societies, outlining negative and positive features of life.\\nPatient-Reported Outcome Measures : Assessments of a patient\\'s health status that come directly from the patient, without interpretation by clinicians or others.\\nPerformance Status : A measure of how well a patient is able to perform ordinary tasks and carry out daily activities.\\nOral Mucositis : Inflammation and ulceration that occurs in the mouth, often as a side effect of cancer treatment.\\n\\nRelationships:-\\n1. Entity1: \""University of Washington Quality of Life Questionnaire (UW-QOL)\"", Entity2: \""Quality of Life\"", Relationship: \""used to measure\""\\n2. Entity1: \""European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Head and Neck Module (EORTC-QLQ-H&N35)\"", Entity2: \""Quality of Life\"", Relationship: \""used to measure\""\\n3. Entity1: \""Functional Assessment of Cancer Therapy Head and Neck (FACT-H&N) scale\"", Entity2: \""Quality of Life\"", Relationship: \""used to measure\""\\n4. Entity1: \""Performance Status Scale\"", Entity2: \""Performance Status\"", Relationship: \""used to assess\""\\n5. Entity1: \""Oral Mucositis Weekly Questionnaire HN (OMWQ-HN)\"", Entity2: \""Oral Mucositis\"", Relationship: \""measures symptoms of\""\\n6. Entity1: \""Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events\"", Entity2: \""Patient-Reported Outcome Measures\"", Relationship: \""used to evaluate\""\\n\\nCausalities:-\\n<A> Patient-completed scales should be used to measure Quality of Life (QOL) </A>. Three validated and accepted measures for head and neck cancer-specific issues are: 1. The University of Washington Quality of Life Questionnaire (UW-QOL) 2. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Head and Neck Module (EORTC-QLQ-H&N35) 3. The Functional Assessment of Cancer Therapy Head and Neck (FACT-H&N) scale\\n\\n- The Performance Status Scale is a clinician-rated performance scale widely used for patients with head and neck cancers.\\n\\n- The Oral Mucositis Weekly Questionnaire HN (OMWQ-HN) is a validated patient-reported instrument that measures the symptoms of oral mucositis, including mouth and throat pain, and its impact on well-being and function.\\n\\n<A> Use of the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events is encouraged to facilitate evaluation of symptomatic toxicity in patients enrolled in cancer clinical trials </A>.\\n'}""",valid,increases risk,2,B,"edge - The edge which needs to be verified.
explanation - Explanation of what the edge represents and its validity.
causal_direction - Either Positive or Negative or Unknown. A positive influence direction indicates that both factors change in the same direction (e.g. an increase causes an increase effect). A negative influence direction indicates the opposite changes (e.g. an increase causes a decrease effect).
causal_factor - Is necessary or sufficient condition for an effect to occur. Exposure is a term commonly used in epidemiology to denote any condition that is considered as a possible cause of disease. Exposure is considered necessary when it always precedes the effects (e.g. symptoms) and always presents when the effects occur. A sufficient cause is a causal factor whose presence or occurrence guarantees the occurrence of symptom.
causal_distance - Either Distal or Proximal or Unknown. The distal factors lie towards the beginning of causal chain (i.e. indirect causal factors). The the proximal factors lie towards the end of the chain (i.e. cause directly or almost directly the effect).

Causality Tags:
<A> for action, <C> for cause, <CO> for condition and <E> for effect.
Cause (C): The reason or origin that leads to an effect. Causes often involve disease conditions, risk factors, or underlying mechanisms.
Effect (E): The outcome or result of a cause. Effects usually represent clinical outcomes, complications, or results of a specific cause.
Condition (CO): The circumstance or prerequisite required for an action or effect to occur. Conditions may include patient characteristics, clinical scenarios, or specific diagnostic criteria.
Action (A): The recommended or described response or activity to address a cause or condition. Actions typically involve clinical interventions, diagnostic procedures, or treatment recommendations.


`NODE1`:
id: Location_of_Involved_Lymph_Nodes_4
label: Position of Affected Lymph Nodes in Patient
description: This node represents the location of lymph nodes that are involved or affected in a patient's condition. Understanding whether the lymph nodes are ipsilateral, bilateral, or contralateral is crucial for determining the extent of disease spread and planning appropriate treatment strategies.
type: Patient Situation
observability: Unobserved
states: [{'state_name': 'ipsilateral', 'state_description': 'The involved lymph nodes are on the same side of the body as the primary tumor or reference point. This can indicate localized spread of disease.'}, {'state_name': 'bilateral', 'state_description': 'The involved lymph nodes are on both sides of the body. This may suggest a more extensive spread of disease and can impact treatment decisions.'}, {'state_name': 'contralateral', 'state_description': 'The involved lymph nodes are on the opposite side of the body from the primary tumor or reference point. This can indicate metastatic spread and may affect staging and treatment planning.'}]

`NODE2`:
id: Positron_Emission_Tomography_PET_15
label: Positron Emission Tomography (PET) Examination Result
description: This node represents the result of a Positron Emission Tomography (PET) scan, which is used to detect the presence and extent of lymph node metastasis in cancer patients. The PET scan provides critical information about whether cancer has spread to lymph nodes and the pattern of such metastasis, which is crucial for staging and treatment planning.
type: Examination Result
observability: Observed
states: [{'state_name': 'bilateral_lymph_node_metastasis', 'state_description': 'The PET scan shows metastasis in lymph nodes on both sides of the body, indicating a more widespread dissemination of cancer.'}, {'state_name': 'ipsilateral_lymph_node_metastasis', 'state_description': 'The PET scan shows metastasis in lymph nodes on the same side of the body as the primary tumor, suggesting localized spread.'}, {'state_name': 'contralateral_lymph_node_metastasis', 'state_description': 'The PET scan shows metastasis in lymph nodes on the opposite side of the body from the primary tumor, indicating cross-body spread of cancer.'}]

`EDGE1`:
{'edges_ids': ['Location_of_Involved_Lymph_Nodes_4', 'Positron_Emission_Tomography_PET_15'], 'edge': '(Location_of_Involved_Lymph_Nodes_4) causes (Positron_Emission_Tomography_PET_15)', 'explanation': ['The edge suggests that the location of involved lymph nodes causes the PET scan results.', 'However, the PET scan results are an observation of the current state of lymph nodes, not caused by their location.', 'The PET scan detects the presence and extent of lymph node metastasis, which is a reflection of the underlying condition.', 'Therefore, the edge is not valid as a causal relationship because the PET scan result is an effect of the underlying condition, not caused by the location of lymph nodes.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}

`EDGE2`:
{'edges_ids': ['Positron_Emission_Tomography_PET_15', 'Location_of_Involved_Lymph_Nodes_4'], 'edge': '(Positron_Emission_Tomography_PET_15) causes (Location_of_Involved_Lymph_Nodes_4)', 'explanation': ['The edge is not valid because the PET scan result does not cause the location of the lymph nodes. It only detects and reports the existing condition of the lymph nodes.', 'The PET scan provides information about the spread of cancer to lymph nodes, but it does not influence or change the location of the lymph nodes.', 'The location of the lymph nodes is determined by the biological spread of cancer, not by the imaging result.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}

`INFORMATION FROM KNOWLEDGE BASE`:
--------------------------------------------------
Page Number: 94

Section Name: Head and Neck Cancers - Principles of Imaging
====================
Entities:-
Positron Emission Tomography Computed Tomography : A medical imaging technique combining PET and CT capabilities to provide detailed information about the body's function and structure.
Positron Emission Tomography : A nuclear medicine functional imaging technique that is used to observe metabolic processes in the body.
Computed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.
Head And Neck Neoplasms : Cancers that arise in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.

Relationships:-
1. Entity1: ""PET/CT"", Entity2: ""PET scan"", Relationship: ""preferred over""
2. Entity1: ""PET-CT"", Entity2: ""head neck cancers"", Relationship: ""used in study of""

Causalities:-
<A> PET/CT is preferred over PET scan alone (i.e., without superimposed CT scan) </A>. <C> PET/CT provides more accurate anatomical localization of abnormalities </C> <E> more accurate anatomical localization of abnormalities </E>.

Section Name: Initial Workup - Nodal Metastases
====================
Entities:-
Lymphatic Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site via the lymphatic system.
Tomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient, producing signals that are processed by the machine's computer to generate cross-sectional images.
Magnetic Resonance Imaging : A non-invasive imaging technique that uses magnetic fields and radio waves to create detailed images of the organs and tissues within the body.
Positron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption.
Lymph Node Metastasis : The spread of cancer cells to lymph nodes, which are part of the lymphatic system.
Ct Of Neck : A computed tomography scan of the neck region.
Mri Of Neck : A magnetic resonance imaging scan of the neck region.
Fdg-Pet Scan : A type of positron emission tomography using fluorodeoxyglucose to assess metabolic activity.
Computed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.
Positron Emission Tomography : A nuclear medicine functional imaging technique that is used to observe metabolic processes in the body.

Relationships:-
1. Entity1: ""CT"", Entity2: ""lymph node metastases"", Relationship: ""used to evaluate""
2. Entity1: ""MRI"", Entity2: ""lymph node metastases"", Relationship: ""used to evaluate""
3. Entity1: ""FDG-PET/CT"", Entity2: ""lymph node metastases"", Relationship: ""used for detection""
4. Entity1: ""FDG-PET/CT"", Entity2: ""surgical primary approach"", Relationship: ""used to determine""
5. Entity1: ""FDG-PET/CT"", Entity2: ""definitive RT approach"", Relationship: ""used to identify""

Causalities:-
<A> Evaluation of lymph node metastases should be conducted with CT or MRI of the neck </A>, using whichever imaging study is suitable for primary site evaluation (IMG-A, 1 of 4).
<CO> For patients with multistation or lower neck nodal involvement or high-grade tumor histology </CO>, <A> consider CT of the chest to assess for mediastinal lymph node metastases or FDG-PET/CT </A>, <C> which is associated with higher sensitivity for both nodal and distant metastases </C>.
<CO> For patients who are under consideration for a surgical primary approach </CO>, <A> the higher sensitivity of FDG-PET/CT is warranted for tumors approaching the midline, to determine the surgical approach to the contralateral neck </A>. <CO> Similarly, patients who are scheduled for a definitive RT approach </CO> <A> may benefit from the higher sensitivity of FDG-PET/CT for identifying involved lymph nodes </A>.

Section Name: Initial Workup - Distant Metastases
====================
Entities:-
Positron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption.
Magnetic Resonance Imaging : A non-invasive imaging technique that uses magnetic fields and radio waves to create detailed images of the organs and tissues within the body.
Tomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient, producing signals that are processed by the machine's computer to generate cross-sectional images.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Lung Neoplasms : Tumors or cancer of the lung.
Smoking : The inhalation of the smoke of burning tobacco encased in cigarettes, pipes, and cigars.

Relationships:-
1. Entity1: ""FDG-PET/CT"", Entity2: ""Distant Metastases"", Relationship: ""used to evaluate""
2. Entity1: ""Contrast-enhanced brain MRI"", Entity2: ""Brain Metastasis"", Relationship: ""recommended for evaluation""
3. Entity1: ""CT of the chest"", Entity2: ""Pulmonary Metastases"", Relationship: ""performed to assess""
4. Entity1: ""Non-contrast CT of the chest"", Entity2: ""Lung Parenchymal Metastases"", Relationship: ""used to screen""
5. Entity1: ""Annual CT screening"", Entity2: ""Lung Metastasis"", Relationship: ""considered for high risk""
6. Entity1: ""Directed CT or MRI"", Entity2: ""Distant Disease"", Relationship: ""used for assessment""
7. Entity1: ""FDG-PET/CT"", Entity2: ""Recurrent Disease"", Relationship: ""used for staging""

Causalities:-
<C> Patients with locoregionally advanced cancer (e.g., T3–T4 primary or ≥N1 nodal staging) </C>, <A> FDG-PET/CT is preferred to evaluate for distant disease and thoracic metastases </A>. <CO> For cancers where brain metastasis is a concern, such as mucosal melanoma or high-grade neuroendocrine carcinomas or adenocarcinomas </CO>, <A> contrast-enhanced brain MRI should be additionally obtained </A>.
<CO> If FDG-PET/CT is not performed </CO>, <A> CT of the chest should be performed to assess for presence of pulmonary metastases as well as mediastinal lymph node involvement </A>.
<CO> Non-contrast CT of the chest can be sufficient to screen for lung parenchymal metastases </CO> but <CO> is not adequate for assessment of mediastinal adenopathy </CO>. <CO> This is an appropriate lung cancer screening intervention for patients with a history of smoking </CO>.
<CO> Following primary definitive treatment (surgery, RT, or systemic therapy/RT) </CO> the role of annual CT screening for lung metastasis is controversial. <E> While this approach does detect early metastasis </E>, <CO> further study is needed to determine the extent of the positive effect and/or cost-effectiveness of this approach in specific subpopulations and timepoints post-treatment </CO>. <CO> For patients with a substantial smoking history or who are at high risk for lung metastases </CO>, <A> annual chest CT can be considered </A>.
<CO> If clinical concern for metastatic disease is confined to a specific anatomical area </CO>, <A> the assessment of distant disease can be performed with directed CT or MRI examination </A>.
<CO> FDG-PET/CT may complement or replace other imaging modalities when staging recurrent disease before any therapy for relapsed/refractory disease </CO> <A> in order to explore distant disease or second primaries that may significantly impact choice of therapy </A>.
--------------------------------------------------
Page Number: 92

Section Name: NCCN Guidelines Overview
====================
Entities:-
Head And Neck Neoplasms : Cancers that arise in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Malignant Neoplasm Of Head And Neck : A malignant tumor located in the head and neck region.
Head And Neck Cancer : A group of cancers that originate in the head and neck region.
Antineoplastic Agents : Drugs used to treat cancer by inhibiting the growth of cancerous cells.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.
Radiation Therapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.

Relationships:-
1. Entity1: ""Head and neck cancers"", Entity2: ""Systemic therapy"", Relationship: ""follow-up recommendations after""
2. Entity1: ""Head and neck cancers"", Entity2: ""Radiation therapy"", Relationship: ""follow-up recommendations after""

Causalities:-
The image presents a flowchart from the National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2024, especially focusing on <A> follow-up recommendations </A> for <CO> patients with head and neck cancers after systemic therapy or radiation therapy (RT) </CO>. All recommendations are categorized as level A unless stated otherwise, highlighting the importance of clinical trials in cancer management.

Section Name: Imaging and Assessment Protocols
====================
Entities:-
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.
Clinical Assessment : A systematic evaluation of a patient's health status, often involving a physical examination and medical history.
Positron-Emission Tomography : An imaging technique using a radioactive substance called a tracer to look for disease in the body.
Computed Tomography : A medical imaging technique used in radiology to obtain detailed internal images of the body.
Magnetic Resonance Imaging : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis.
Disease : A disorder of structure or function in a human, animal, or plant, especially one that produces specific symptoms.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.
Residual Neoplasm : Remaining cancer cells after treatment.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Clinical Assessment"", Relationship: ""occurs before""
2. Entity1: ""FDG-PET/CT Scan"", Entity2: ""Distant Metastases"", Relationship: ""assesses""
3. Entity1: ""FDG-PET/CT Scan"", Entity2: ""Observation"", Relationship: ""leads to if negative""
4. Entity1: ""FDG-PET/CT Scan"", Entity2: ""CT Scan"", Relationship: ""leads to if strongly positive""
5. Entity1: ""CT Scan"", Entity2: ""Neck Dissection"", Relationship: ""leads to if positive""

Causalities:-
<CO> After systemic therapy or RT </CO>, <A> a clinical assessment should occur 4 to 8 weeks later </A>. <CO> If there is a response </CO>, <A> it is necessary to assess the extent of disease or distant metastases, preferably through a FDG-PET/CT scan at a minimum of 12 weeks post-treatment </A>. <CO> If the FDG-PET/CT results are negative </CO>, <A> the patient may continue with monitoring through observation </A>. <CO> In cases where the results are equivocal </CO>, <A> observation or repeat FDG-PET/CT within 3 to 6 months is prescribed </A>.

<CO> In cases where the FDG-PET/CT results are strongly positive </CO>, <A> further imaging via CT scan with contrast of the primary site and neck, or MRI with and without contrast, becomes necessary </A>. <CO> If these imaging results confirm positive findings </CO>, <A> neck dissection may be considered, depending on the evidence of residual or persistent disease </A>. <CO> If the imaging findings are negative </CO>, <A> the patient might continue in observation </A>.

Section Name: Outcomes Based on Disease Resectability
====================
Entities:-
Disease : A disorder of structure or function in a human, animal, or plant, especially one that produces specific symptoms.
Resectable : Capable of being surgically removed.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis.

Relationships:-
1. Entity1: ""Disease"", Entity2: ""Resectable"", Relationship: ""Classification""
2. Entity1: ""Unresectable"", Entity2: ""Treatment plans (ADV-3)"", Relationship: ""Treatment recommendation""
3. Entity1: ""Resectable"", Entity2: ""Resection and/or Neck dissection"", Relationship: ""Surgical procedure""

Causalities:-
<CO> If there is confirmed residual or persistent disease </CO>, the options split into two pathways: 'Unresectable' or 'Resectable.' <CO> If the disease is classified as unresectable </CO>, <A> advances in treatment plans (labeled ADV-3) are called for </A>. Conversely, <CO> if it is deemed resectable </CO>, <A> a resection of the primary and/or neck dissection may occur </A>, <CO> contingent upon the disease status </CO>.

Section Name: Important Notes
====================
Entities:-
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.
Clinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.
Positron-Emission Tomography : An imaging technique using a radioactive substance called a tracer to look for disease in the body.
Positron Emission Tomography (Procedure) : A diagnostic imaging procedure that uses a radioactive tracer to visualize and measure changes in metabolic processes.
Positron Emission Tomography : A nuclear medicine functional imaging technique used to observe metabolic processes in the body.
Neoplasms : New abnormal growth of tissue in animals or plants; a tumor.
Malignant Neoplasm : A cancerous growth that has the potential to spread to other parts of the body.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""NCCN"", Entity2: ""Clinical trials"", Relationship: ""emphasizes participation in""
2. Entity1: ""FDG-PET/CT"", Entity2: ""Persistent cancer"", Relationship: ""used to detect""
3. Entity1: ""FDG-PET/CT"", Entity2: ""PET negative"", Relationship: ""interpretation of results""
4. Entity1: ""FDG-PET/CT"", Entity2: ""PET positive"", Relationship: ""interpretation of results""

Causalities:-
<A> NCCN emphasizes that the best management for any cancer patient is participation in clinical trials </A>, especially encouraged for all patients. Additional notes clarify that <CO> if the FDG-PET/CT is negative for persistent cancer </CO>, <A> further cross-sectional imaging is optional </A>. The interpretations define <CO> PET negative as no or low-grade uptake not suspicious for disease </CO>, while <CO> PET positive implies suspicion for disease </CO>.
--------------------------------------------------
Page Number: 130

Section Name: Pathological N (pN)
====================
Entities:-
Lymph Nodes : Small, bean-shaped structures that are part of the body's lymphatic system. They filter lymph fluid and store white blood cells that help fight infection.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Tnm Staging : A system used to describe the size and spread of cancer in a standardized way. T refers to the size of the tumor, N to the involvement of lymph nodes, and M to metastasis.
Lymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.
Tnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient's body.
Lymph Node : An organ of the lymphatic system and the adaptive immune system.

Relationships:-
1. Entity1: ""Lymph Nodes"", Entity2: ""Neoplasm Metastasis"", Relationship: ""involved in""
2. Entity1: ""TNM Staging"", Entity2: ""Lymph Nodes"", Relationship: ""includes""
3. Entity1: ""TNM Staging"", Entity2: ""Neoplasm Metastasis"", Relationship: ""describes""

Causalities:-
<CO> NX: Regional lymph nodes cannot be assessed </CO>
<CO> N0: No regional lymph node metastasis </CO>
<CO> N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(–) </CO>
<CO> N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2a: Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N3: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(−); or metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>
<CO> N3a: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N3b: Metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>
<CO> Note: A designation of “U” or “L” may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L). Similarly, clinical and pathological ENE should be recorded as ENE(−) or ENE(+). </CO>

Section Name: Distant Metastasis (M)
====================
Entities:-
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.

Relationships:-
1. Entity1: ""M0"", Entity2: ""Distant Metastasis"", Relationship: ""is a category of""
2. Entity1: ""M1"", Entity2: ""Distant Metastasis"", Relationship: ""is a category of""

Causalities:-
### Distant Metastasis (M)

- **M0**: No distant metastasis
- **M1**: Distant metastasis

Section Name: Histologic Grade (G)
====================
Entities:-
Neoplasm Grading : A system of classifying cancer cells in terms of how abnormal they look under a microscope and how quickly the tumor is likely to grow and spread.
Histologic Grade : A measure of how much tumor cells differ from healthy cells, used to assess the aggressiveness of cancer.

Relationships:-
1. Entity1: ""GX"", Entity2: ""Grade cannot be assessed"", Relationship: ""is described as""
2. Entity1: ""G1"", Entity2: ""Well differentiated"", Relationship: ""is described as""
3. Entity1: ""G2"", Entity2: ""Moderately differentiated"", Relationship: ""is described as""
4. Entity1: ""G3"", Entity2: ""Poorly differentiated"", Relationship: ""is described as""

Causalities:-
<CO>GX</CO>: <E>Grade cannot be assessed</E>
<CO>G1</CO>: <E>Well differentiated</E>
<CO>G2</CO>: <E>Moderately differentiated</E>
<CO>G3</CO>: <E>Poorly differentiated</E>

Section Name: Prognostic Stage Groups
====================
Entities:-
Neoplasm Staging : Methods and systems of classifying neoplasms according to extent of disease.
Tumor Staging : A system for describing the size and spread of cancer within the body.
Tnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient's body.

Relationships:-
1. Entity1: ""Stage 0"", Entity2: ""Tis N0 M0"", Relationship: ""defined by""
2. Entity1: ""Stage I"", Entity2: ""T1 N0 M0"", Relationship: ""defined by""
3. Entity1: ""Stage II"", Entity2: ""T2 N0 M0"", Relationship: ""defined by""
4. Entity1: ""Stage III"", Entity2: ""T3 N0 M0, T1 N1 M0, T2 N1 M0, T3 N1 M0"", Relationship: ""defined by""
5. Entity1: ""Stage IVA"", Entity2: ""T1 N2 M0, T2 N2 M0, T3 N2 M0, T4a N0,N1,N2 M0"", Relationship: ""defined by""
6. Entity1: ""Stage IVB"", Entity2: ""Any T N3 M0, T4b Any N M0"", Relationship: ""defined by""
7. Entity1: ""Stage IVC"", Entity2: ""Any T Any N M1"", Relationship: ""defined by""
--------------------------------------------------
Page Number: 96

Section Name: Head and Neck Cancers
====================
Entities:-
Head And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Positron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes.
Surveillance : The ongoing systematic collection, analysis, and interpretation of health data essential to the planning, implementation, and evaluation of public health practice.
Locoregional Recurrence Of Tumor : The return of cancer in the original tumor location or nearby lymph nodes after treatment.
Asymptomatic : A condition or a person showing no symptoms of disease.
Magnetic Resonance Imaging : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.
Ultrasound : A medical imaging technique that uses high-frequency sound waves to visualize soft tissues such as muscles and internal organs.

Relationships:-
1. Entity1: ""FDG-PET/CT"", Entity2: ""Head and Neck Neoplasms"", Relationship: ""used for surveillance imaging""
2. Entity1: ""Recurrence"", Entity2: ""Post-treatment period"", Relationship: ""occurs within""
3. Entity1: ""Imaging Modalities"", Entity2: ""Surveillance"", Relationship: ""used for""

Causalities:-
<C> The majority of recurrences after treatment of head and neck cancer occur in the first 2 years </C>. <C> Surveillance can be challenging </C> <C> because of altered anatomy and/or fibrosis from surgery, radiation, and/or chemotherapy </C>. <CO> There are no consensus guidelines on the frequency and modality of routine post-treatment imaging in the asymptomatic patient </CO>. <A> Practice varies widely across institutions </A>.

<C> US, CT, MRI, and PET/CT all have unique advantages and disadvantages when used as surveillance imaging </C>. <C> There is evidence that FDG-PET/CT may be the most sensitive of these modalities </C>. <E> A 12-month PET has been shown to reveal recurrent or second primary cancers in approximately 10% of treated patients </E>; <E> a 24-month FDG-PET/CT imaging revealed these findings in approximately 5% of treated cases </E>. <CO> Most cases of asymptomatic FDG-PET/CT lesion localization occur at distant sites </CO>. <CO> Whether earlier detection leads to improved disease-specific survival is not established </CO>.

<A> Standardized multi-institutional imaging-based trials are needed to clearly elucidate the value of routine imaging in the clinically asymptomatic patient </A>. <CO> There may be little proven benefit in further imaging if the initial 3-month FDG-PET/CT scan was negative </CO>. <C> Ho et al reported no significant difference in 3-year disease-free survival in patients undergoing imaging surveillance versus those only receiving clinical surveillance </C> <E> (41% vs. 46%, P = .91) in this setting </E>.

<CO> If an FDG-PET/CT at 3 months post-treatment is negative </CO>, <CO> there are no data to support substantial benefit for further routine imaging in an asymptomatic patient with negative exam </CO>. <A> In the absence of multi-institutional prospective data, a tailored approach to surveillance with attention to tumor type, stage, prognostic factors, symptomatology, and physical exam changes or restrictions is appropriate </A>.

<A> US of the neck is a well-established tool for nodal surveillance </A>. <C> US is generally widely available, safe, fast, inexpensive, and an accurate modality for examination of the neck for any suspicious nodal disease </C>.

<CO> Additional post-treatment imaging is indicated for worrisome or equivocal signs/symptoms </CO>.

<CO> Routine annual imaging (repeat use of pretreatment imaging modality) may be indicated to visualize areas inaccessible to routine clinical examination </CO> <CO> (deep-seated anatomic locations or areas obscured by extensive treatment change) </CO>.

Section Name: Principles of Imaging
====================
Entities:-
Head And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Head And Neck Cancer : A group of cancers that originate in the head and neck region.
Positron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes.
Positron Emission Tomography : A type of nuclear medicine imaging that uses small amounts of radioactive materials to diagnose or treat a variety of diseases.
Tomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient, producing signals that are processed by the computer to generate cross-sectional images.
Computed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images.
Neck : The part of the body on many vertebrates that separates the head from the torso or trunk.

Relationships:-
1. Entity1: ""Surveillance imaging"", Entity2: ""Head and neck cancer"", Relationship: ""used for monitoring""
2. Entity1: ""PET-CT"", Entity2: ""Head and neck cancer"", Relationship: ""used for detection""
3. Entity1: ""Positron emission tomography/computed tomography"", Entity2: ""Head and neck cancer"", Relationship: ""used for surveillance""

Section Name: NCCN Guidelines
====================
Entities:-
Neoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.
Clinical Trial : A clinical trial is a research study conducted with patients to evaluate a new medical treatment, drug, or device.
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.

Relationships:-
1. Entity1: ""Neoplasms"", Entity2: ""Clinical trial"", Relationship: ""best management through""

Causalities:-
<C> NCCN believes that the best management of any patient with cancer is in a clinical trial </C>. <A> Participation in clinical trials is especially encouraged </A>.
--------------------------------------------------
Page Number: 148

Section Name: Head and Neck Cancers Imaging
====================
Entities:-
Magnetic Resonance Imaging : A non-invasive imaging technique that uses magnetic fields and radio waves to produce detailed images of the organs and tissues in the body.
Tomography, X-Ray Computed : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.
Positron-Emission Tomography : A nuclear medicine functional imaging technique used to observe metabolic processes in the body.
Head And Neck Neoplasms : Cancers that occur in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, and larynx.
Lymphatic Metastasis : The spread of cancer cells through the lymphatic system to distant lymph nodes.
Squamous Cell Carcinoma Of Head And Neck : A type of cancer that arises from the squamous cells lining the head and neck region.
Cranial Nerves : The twelve pairs of nerves that arise directly from the brain and pass through various foramina in the skull.
Skull Base : The area of the skull where the brain rests, including the bones and foramina at the base of the skull.
Bone Marrow : The soft, spongy tissue found in the center of bones, responsible for producing blood cells.
Cortical Bone : The dense outer surface of bone that forms a protective layer around the internal cavity.
Periosteum : A dense layer of vascular connective tissue enveloping the bones except at the surfaces of the joints.
Metastasis : The spread of cancer cells from the place where they first formed to another part of the body.
Dental Radiography : The use of X-rays to view the teeth and surrounding structures.

Relationships:-
1. Entity1: ""Magnetic Resonance Imaging"", Entity2: ""Cranial Nerves"", Relationship: ""preferred for evaluation""
2. Entity1: ""Tomography, X-Ray Computed"", Entity2: ""Cortical Bone"", Relationship: ""used for evaluation""
3. Entity1: ""Positron-Emission Tomography"", Entity2: ""Lymphatic Metastasis"", Relationship: ""superior for detection""
4. Entity1: ""Magnetic Resonance Imaging"", Entity2: ""Bone Marrow"", Relationship: ""used for evaluation""
5. Entity1: ""Dental Radiography"", Entity2: ""Dentition"", Relationship: ""used for evaluation""

Causalities:-
<C> Appropriate selection and utilization of imaging studies </C> <E> is crucial for proper care of patients with head and neck cancers </E>.
<A> Initial imaging of the primary site is performed with CT and/or MRI </A>.
<CO> in patients with symptoms involving the cranial nerves or tumors encroaching on the skull base </CO> <A> MRI is generally preferred over CT </A>.
<CO> for evaluation of bony erosion or cartilage invasion that may occur with some head and neck tumors (e.g., laryngeal cancer) </CO> <A> CT is complementary to MRI </A>.
<CO> in patients with head and neck cancers involving the bone </CO> <A> MRI is needed to evaluate the extent of bone marrow invasion </A>.
<CO> in patients with head and neck cancers involving the bone </CO> <A> CT is preferred to evaluate cortical bone erosion or periosteal invasion </A>.
<CO> for cancers originating in the base of the tongue </CO> <A> MRI can often delineate the boundary between gross tumor and normal muscle more effectively than CT </A>.
<CO> for differentiating tumor extent from obstructed sinuses or secretions and to evaluate intracranial/dural involvement </CO> <A> MRI is also preferable to CT </A>.
<CO> depending on the primary site </CO> <A> Evaluation of lymph node metastases can be done with either CT or MRI </A>.
<C> There is evidence to support the superiority of FDG-PET/CT </C> <E> for detecting locoregional nodal and distant metastases in patients with head and neck cancers </E>.
<CO> in patients with clinically node-negative SCCHN </CO> <E> the positive predictive value (PPV) and negative predictive value (NPV) of FDG-PET/CT for detection of cervical lymph node involvement was 0.62 (95% CI, 0.55–0.69) and 0.83 (95% CI, 0.79–0.86), respectively </E>.
<CO> in patients with cN0 disease </CO> <E> 125/144 (87%) negative PET scans were pathologically negative at neck dissection </E>.
<E> Findings from PET/CT changed the surgical plan in 22% of patients </E>.
<CO> for detection of cervical lymph node metastases by FDG-PET/CT </CO> <E> a prospective single-center study from Germany (N = 150) showed an NPV of 93.3% (95% CI, 88.2%–98.5%) </E>.
<CO> if there is concern about metastasis to a specific anatomic area </CO> <A> directed CT or MRI may also be performed </A>.
<C> Head and neck cancers rarely metastasize to the brain by a hematogenous route </C> <E> ordering a full brain study as part of the initial imaging workup is not routine </E>.
<CO> for patients who are dentulous and expected to receive postoperative RT </CO> <A> a panoramic dental x-ray should be completed before treatment as part of the dental evaluation </A>.
<CO> if a marginal resection is being considered </CO> <E> Panorex is also helpful for evaluation of dentition and mandibular height </E>.

Section Name: Quality of Life and Patient-Reported Outcomes
====================
Entities:-
Quality Of Life : A generic term for the general well-being of individuals and societies, outlining negative and positive features of life.
Patient-Reported Outcome Measures : Assessments of a patient's health status that come directly from the patient, without interpretation by clinicians or others.
Performance Status : A measure of how well a patient is able to perform ordinary tasks and carry out daily activities.
Oral Mucositis : Inflammation and ulceration that occurs in the mouth, often as a side effect of cancer treatment.

Relationships:-
1. Entity1: ""University of Washington Quality of Life Questionnaire (UW-QOL)"", Entity2: ""Quality of Life"", Relationship: ""used to measure""
2. Entity1: ""European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Head and Neck Module (EORTC-QLQ-H&N35)"", Entity2: ""Quality of Life"", Relationship: ""used to measure""
3. Entity1: ""Functional Assessment of Cancer Therapy Head and Neck (FACT-H&N) scale"", Entity2: ""Quality of Life"", Relationship: ""used to measure""
4. Entity1: ""Performance Status Scale"", Entity2: ""Performance Status"", Relationship: ""used to assess""
5. Entity1: ""Oral Mucositis Weekly Questionnaire HN (OMWQ-HN)"", Entity2: ""Oral Mucositis"", Relationship: ""measures symptoms of""
6. Entity1: ""Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events"", Entity2: ""Patient-Reported Outcome Measures"", Relationship: ""used to evaluate""

Causalities:-
<A> Patient-completed scales should be used to measure Quality of Life (QOL) </A>. Three validated and accepted measures for head and neck cancer-specific issues are: 1. The University of Washington Quality of Life Questionnaire (UW-QOL) 2. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Head and Neck Module (EORTC-QLQ-H&N35) 3. The Functional Assessment of Cancer Therapy Head and Neck (FACT-H&N) scale

- The Performance Status Scale is a clinician-rated performance scale widely used for patients with head and neck cancers.

- The Oral Mucositis Weekly Questionnaire HN (OMWQ-HN) is a validated patient-reported instrument that measures the symptoms of oral mucositis, including mouth and throat pain, and its impact on well-being and function.

<A> Use of the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events is encouraged to facilitate evaluation of symptomatic toxicity in patients enrolled in cancer clinical trials </A>.


Among these two options which one is the most likely true:

(A) `Location_of_Involved_Lymph_Nodes_4` increases risk `Positron_Emission_Tomography_PET_15`
(B) `Positron_Emission_Tomography_PET_15` `increases risk `Location_of_Involved_Lymph_Nodes_4`

The answer is: ...

1. State the evidences in detail of the validity of option (A) or (B) by cross referencing
NCCN Clinical Practitioner’s Guidelines for Head and Neck Cancer.
2. If the evidences are obtained from `INFORMATION FROM KNOWLEDGE BASE`,
mention their corresponding Page Numbers, Section Name, entities, relationships and causalities.

DESIRED OUTPUT FORMAT:
<thinking>
...
</thinking>
<answer>
{
   ""thinking"": [""..."", ...],
   ""evidences"": [""..."", ...],
   ""answer"": ...
}
</answer>

Before providing the answer in <answer> tags, think step by step in detail in <thinking> tags and analyze every part.
Output inside <answer> tag in JSON format. Only output valid JSON.
DO NOT HALLUCINATE. DO NOT MAKE UP FACTUAL INFORMATION.
","1. The edge in question is between the location of involved lymph nodes and the results of a PET scan.
2. Option (A) suggests that the location of lymph nodes increases the risk of certain PET scan results.
3. Option (B) suggests that the PET scan results increase the risk of lymph node location.
4. The explanation for EDGE1 indicates that the location of lymph nodes does not cause PET scan results. Instead, PET scan results are observations of the current state of lymph nodes.
5. The explanation for EDGE2 indicates that PET scan results do not cause the location of lymph nodes. The PET scan only detects the existing condition of lymph nodes.
6. The causal direction for both edges is marked as 'Unknown', indicating no clear causal relationship.
7. The causal factor for both edges is marked as neither necessary nor sufficient, further supporting the lack of a causal relationship.
8. The causal distance for both edges is marked as 'Unknown', indicating no direct or indirect causal link.
9. From the knowledge base, PET scans are used to detect and evaluate lymph node metastasis, not to influence or change lymph node location (Page 94, Section: Initial Workup - Nodal Metastases).
10. The PET scan provides information about the spread of cancer to lymph nodes but does not affect their location (Page 96, Section: Principles of Imaging).
","1. Page 94, Section: Initial Workup - Nodal Metastases, Entity: FDG-PET/CT, Relationship: used for detection of lymph node metastases.
2. Page 96, Section: Principles of Imaging, Entity: Positron-Emission Tomography, Relationship: used for detection of lymphatic metastasis.
",A,"{'A': 50.0, 'B': 50.0}",yes,A,"1. The AI assistant is tasked with determining whether the final answer (A) is consistent with the reasoning provided.
2. The question involves analyzing the causal relationship between the location of involved lymph nodes and the results of a PET scan.
3. The AI assistant's reasoning correctly identifies that the location of lymph nodes does not cause PET scan results. Instead, PET scans are used to observe the current state of lymph nodes.
4. The explanation for EDGE1 and EDGE2 both indicate that there is no causal relationship between the location of lymph nodes and PET scan results. This is consistent with the AI assistant's reasoning.
5. The causal direction, factor, and distance are all marked as 'Unknown' or neither necessary nor sufficient, supporting the lack of a causal relationship.
6. The AI assistant references the knowledge base, which supports the conclusion that PET scans are used for detection and evaluation, not for influencing lymph node location.
7. The AI assistant's final answer (A) is consistent with the reasoning provided, as it correctly identifies that the location of lymph nodes does not increase the risk of certain PET scan results.
"
8,gpt-4o,"Location_of_Involved_Lymph_Nodes_4,Ultrasonography_16","""{'NODE1': {'id': 'Location_of_Involved_Lymph_Nodes_4', 'label': 'Position of Affected Lymph Nodes in Patient', 'description': \""This node represents the location of lymph nodes that are involved or affected in a patient's condition. Understanding whether the lymph nodes are ipsilateral, bilateral, or contralateral is crucial for determining the extent of disease spread and planning appropriate treatment strategies.\"", 'type': 'Patient Situation', 'observability': 'Unobserved', 'states': [{'state_name': 'ipsilateral', 'state_description': 'The involved lymph nodes are on the same side of the body as the primary tumor or reference point. This can indicate localized spread of disease.'}, {'state_name': 'bilateral', 'state_description': 'The involved lymph nodes are on both sides of the body. This may suggest a more extensive spread of disease and can impact treatment decisions.'}, {'state_name': 'contralateral', 'state_description': 'The involved lymph nodes are on the opposite side of the body from the primary tumor or reference point. This can indicate metastatic spread and may affect staging and treatment planning.'}]}, 'NODE2': {'id': 'Ultrasonography_16', 'label': 'Ultrasound Examination Result', 'description': 'This node represents the results of an ultrasound examination aimed at detecting lymph node metastasis. It provides information on whether metastasis is present in lymph nodes and specifies the location relative to the primary tumor site.', 'type': 'Examination Result', 'observability': 'Observed', 'states': [{'state_name': 'bilateral_lymph_node_metastasis', 'state_description': 'Metastasis is present in lymph nodes on both sides of the body relative to the primary tumor site.'}, {'state_name': 'ipsilateral_lymph_node_metastasis', 'state_description': 'Metastasis is present in lymph nodes on the same side of the body as the primary tumor site.'}, {'state_name': 'contralateral_lymph_node_metastasis', 'state_description': 'Metastasis is present in lymph nodes on the opposite side of the body from the primary tumor site.'}]}, 'EDGE1': {'edges_ids': ['Location_of_Involved_Lymph_Nodes_4', 'Ultrasonography_16'], 'edge': '(Location_of_Involved_Lymph_Nodes_4) causes (Ultrasonography_16)', 'explanation': ['The edge represents the causal relationship where the position of the affected lymph nodes (Node 1) influences the results of an ultrasound examination (Node 2).', 'The location of the lymph nodes (ipsilateral, bilateral, contralateral) is a factor that the ultrasound examination detects and reports on.', 'The causal direction is positive because the state of the lymph nodes directly affects the ultrasound findings.', 'The causal factor is not necessary or sufficient because the ultrasound can detect lymph nodes in any location, and the presence of metastasis is required for a specific result.', 'The causal distance is proximal because the location of the lymph nodes directly influences the ultrasound result.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Proximal'}, 'EDGE2': {'edges_ids': ['Ultrasonography_16', 'Location_of_Involved_Lymph_Nodes_4'], 'edge': '(Ultrasonography_16) causes (Location_of_Involved_Lymph_Nodes_4)', 'explanation': ['The edge represents the causal relationship where the results of an ultrasound examination (Ultrasonography_16) determine the location of involved lymph nodes (Location_of_Involved_Lymph_Nodes_4).', 'Ultrasonography_16 provides direct information on whether lymph node metastasis is present and specifies the location relative to the primary tumor site.', 'Location_of_Involved_Lymph_Nodes_4 describes the position of affected lymph nodes as ipsilateral, bilateral, or contralateral, which is directly informed by the ultrasound results.', 'The ultrasound examination is a direct method to observe and report the state and location of lymph node metastasis, making the edge valid.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': True}, 'causal_distance': 'Proximal'}, 'ENTITIES_MATCHING_PAGES_INFO': {'55': {'matching_entities': [{'NEOPLASM METASTASIS': 1.0}, {'METASTASIS': 0.9630129}, {'METASTATIC NEOPLASM': 0.96172774}, {'MALIGNANT NEOPLASTIC DISEASE': 0.9424237}, {'CANCER': 0.92851335}], 'count': 5}, '130': {'matching_entities': [{'NEOPLASM METASTASIS': 1.0}, {'LYMPH NODE STRUCTURE': 0.99134904}, {'LYMPH NODE': 0.98570025}, {'LYMPH NODES': 0.97445965}, {'METASTASIS': 0.9630129}], 'count': 5}, '68': {'matching_entities': [{'NEOPLASM METASTASIS': 1.0}, {'METASTASIS': 0.9630129}, {'METASTATIC DISEASE': 0.95668894}, {'METASTATIC MALIGNANT NEOPLASM': 0.93472815}], 'count': 4}, '190': {'matching_entities': [{'NEOPLASM METASTASIS': 1.0}, {'METASTASIS': 0.9630129}, {'METASTATIC CANCER': 0.9463331}, {'METASTATIC MALIGNANT NEOPLASM': 0.93472815}], 'count': 4}, '93': {'matching_entities': [{'ULTRASOUND': 0.9518404}, {'MALIGNANT NEOPLASTIC DISEASE': 0.9424237}, {'CANCER': 0.92851335}], 'count': 3}}, 'GUIDELINE_PAGES_INFO': '--------------------------------------------------\\nPage Number: 55\\n\\nSection Name: General Information\\n====================\\nEntities:-\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nNccn Guidelines : Clinical practice guidelines in oncology developed by the National Comprehensive Cancer Network.\\n\\nRelationships:-\\n1. Entity1: \""NCCN Guidelines\"", Entity2: \""National Comprehensive Cancer Network\"", Relationship: \""produced by\""\\n\\nSection Name: Important Notes\\n====================\\nEntities:-\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medical, surgical, or behavioral interventions.\\nClinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nNeoplasms : New abnormal growth of tissue that can be benign or malignant.\\nMalignant Neoplastic Disease : A disease resulting from the growth of malignant neoplasms.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""Clinical Trials\"", Entity2: \""Cancer\"", Relationship: \""recommended for\""\\n2. Entity1: \""NCCN\"", Entity2: \""Clinical Trials\"", Relationship: \""encourages participation in\""\\n\\nCausalities:-\\n<C> NCCN believes that the best management of any patient with cancer is in a clinical trial </C>. <A> Participation in clinical trials is especially encouraged </A>.\\n\\nSection Name: Principles\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nChemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.\\n\\nRelationships:-\\n1. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Radiation Therapy\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n2. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n3. Entity1: \""Principles of Radiation Therapy\"", Entity2: \""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n\\nCausalities:-\\n### Principles\\n\\n- **Principles of Surgery (SURG-A)**\\n- **Principles of Radiation Therapy (SUPRA-A)**\\n- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**\\n\\nSection Name: Adverse Pathologic Features\\n====================\\nEntities:-\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.\\nPerineural Invasion : The presence of cancer cells surrounding or tracking along a nerve within the perineural space.\\nVascular Invasion : The invasion of cancer cells into blood vessels.\\nLymphatic Invasion : The invasion of cancer cells into lymphatic vessels.\\n\\nRelationships:-\\n1. Entity1: \""Extranodal extension\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n2. Entity1: \""Positive margins\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n3. Entity1: \""Close margins\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n4. Entity1: \""pT3 or pT4 primary\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n5. Entity1: \""pN2 or pN3 nodal disease\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n6. Entity1: \""Perineural invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n7. Entity1: \""Vascular invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n8. Entity1: \""Lymphatic invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n\\nCausalities:-\\n<C> Extranodal extension </C>\\n<C> Positive margins </C>\\n<C> Close margins </C>\\n<C> pT3 or pT4 primary </C>\\n<C> pN2 or pN3 nodal disease </C>\\n<C> Perineural invasion </C>\\n<C> Vascular invasion </C>\\n<C> Lymphatic invasion </C>\\n\\nSection Name: Response Assessment\\n====================\\nEntities:-\\nChemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nPrimary Site : The original location where a tumor or cancer begins.\\nComplete Remission : The disappearance of all signs of cancer in response to treatment.\\nPartial Remission : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.\\nRadiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""induction chemotherapy\"", Entity2: \""Primary site\"", Relationship: \""treatment outcome\""\\n2. Entity1: \""Definitive RT\"", Entity2: \""Primary site\"", Relationship: \""treatment option\""\\n3. Entity1: \""RT\"", Entity2: \""Primary site\"", Relationship: \""treatment option\""\\n4. Entity1: \""Surgery\"", Entity2: \""unresectable nodal disease\"", Relationship: \""treatment option\""\\n\\nCausalities:-\\n<C> Response after induction chemotherapy </C>: <E> Primary site: CR </E> <E> Primary site: PR </E> <E> Primary site: < PR </E> <A> Definitive RT </A> (category 1) <A> RT </A> (category 1) or <A> systemic therapy/RT </A> (category 2B) <A> Surgery </A> or <A> unresectable nodal disease </A>\\n\\nSection Name: Follow-up\\n====================\\nEntities:-\\nFollow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.\\nFollow-Up Procedure : A procedure where a patient is monitored over time to assess the progress of a condition or the effects of treatment.\\nFollow-Up (Medicine) : The process of monitoring a patient\\'s health over time after treatment or diagnosis.\\nDisease Recurrence : The return of a sign, symptom, or disease after a remission.\\nRecurrent Disease : A disease that returns after a period of remission.\\nRecurrence (Medicine) : The return of a disease or condition after a period of improvement.\\n\\nRelationships:-\\n1. Entity1: \""Follow-up\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""monitoring\""\\n\\nCausalities:-\\n### Follow-up\\n\\n- **Follow-up** (FOLL-A, 1 of 2)\\n- **Recurrent or persistent disease** (ADV-3)\\n\\nSection Name: Risk Features\\n====================\\nEntities:-\\nRadiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Adverse pathologic features\"", Entity2: \""RT\"", Relationship: \""Consideration for treatment\""\\n2. Entity1: \""Adverse pathologic features\"", Entity2: \""Systemic therapy\"", Relationship: \""Consideration for treatment\""\\n\\nCausalities:-\\n- **No adverse pathologic features**\\n- **Other risk features**\\n- **Adverse pathologic features**:\\n  - <C> Extranodal extension and/or positive margin </C>\\n  - <A> RT or consider systemic therapy/RT </A>\\n\\nSection Name: Post-Therapy Evaluation\\n====================\\nEntities:-\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nNeck : The neck is the part of the body that separates the head from the torso and provides the mobility and movements of the head.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Neck Evaluation\"", Relationship: \""evaluated in\""\\n2. Entity1: \""RT\"", Entity2: \""Neck Evaluation\"", Relationship: \""evaluated in\""\\n\\nCausalities:-\\n<CO> Post Systemic Therapy/RT or RT Neck </CO> <A> Evaluation </A>\\n\\nSection Name: Flowchart Overview\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nSupraglottic Larynx : The part of the larynx located above the vocal cords, including the epiglottis and aryepiglottic folds.\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\n\\nRelationships:-\\n1. Entity1: \""NCCN Guidelines\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""guides management of\""\\n2. Entity1: \""NCCN Guidelines\"", Entity2: \""healthcare professionals\"", Relationship: \""used by\""\\n\\nCausalities:-\\n<C> cancer of the supraglottic larynx </C> <E> evaluate patient responses following treatment </E> <CO> based on observed outcomes </CO> <A> evaluation of the primary site and determining subsequent steps </A>.\\n\\nSection Name: Assessment and Treatment Decisions\\n====================\\nEntities:-\\nInduction Chemotherapy : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nComplete Response : The disappearance of all signs of cancer in response to treatment.\\nPartial Response : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Complete Response\"", Entity2: \""Radiation Therapy\"", Relationship: \""leads to\""\\n2. Entity1: \""Complete Response\"", Entity2: \""Surgery\"", Relationship: \""leads to\""\\n3. Entity1: \""Partial Response\"", Entity2: \""Systemic Therapy\"", Relationship: \""leads to\""\\n4. Entity1: \""Partial Response\"", Entity2: \""Radiation Therapy\"", Relationship: \""leads to\""\\n\\nCausalities:-\\n<C> responses to initial treatments such as induction chemotherapy </C> <E> Three main response categories are recognized: Complete Response (CR), Partial Response (PR), and less than Partial Response (< PR) </E>. These categories are pivotal in determining the next steps. <C> CR </C> <E> indicates full resolution of the disease at the primary site </E>, <A> leading to the consideration of definitive radiation therapy or the likelihood of surgery </A>. Conversely, <C> PR </C> <E> suggests that the disease has improved but not completely resolved </E>, <A> which directs the pathway towards either systemic therapy or continued radiation therapy </A>, <A> with further evaluation necessary </A>.\\n\\nSection Name: Adverse Pathologic Features and Follow-up\\n====================\\nEntities:-\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nNeoplasm Recurrence, Local : The return of a tumor or cancer, at the original site, after it has been treated.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nRecurrent Neoplasm : A neoplasm that has returned after treatment.\\nMetastatic Neoplasm : A neoplasm that has spread from its original site to one or more other places in the body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nCancer Recurrence : The return of cancer after treatment and after a period of time during which the cancer was undetectable.\\nMetastasis : Spread of a cancer or other disease from one organ or part to another not directly connected with it.\\n\\nRelationships:-\\n1. Entity1: \""Adverse pathologic features\"", Entity2: \""Treatment decisions\"", Relationship: \""Influence\""\\n2. Entity1: \""Adverse features\"", Entity2: \""Surgical intervention\"", Relationship: \""Recommendation\""\\n3. Entity1: \""Absence of adverse features\"", Entity2: \""Radiation therapy\"", Relationship: \""Pathway\""\\n4. Entity1: \""Follow-up process\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""Detection\""\\n5. Entity1: \""Recurrent or persistent disease\"", Entity2: \""Advanced disease management\"", Relationship: \""Necessity\""\\n\\nCausalities:-\\n<C> The presence of adverse pathologic features \u2014 such as extranodal extension or positive margins </C> <E> can directly influence treatment decisions </E>. <CO> If adverse features are found </CO>, <A> surgical intervention is recommended </A>. <CO> In cases where there are no adverse features </CO>, the patient may proceed directly to radiation therapy or continued systemic treatment, emphasizing the tailored approach based on the individual patient\\'s disease characteristics.\\n\\nFurthermore, the chart includes a section addressing the follow-up process after initial treatment. <CO> If there are signs of recurrent or persistent disease </CO>, <A> additional evaluations and treatment modalities may be necessary </A>. These evaluations <E> lead to specific recommendations for advanced disease management, denoted as ADV-3 on the chart </E>, emphasizing the importance of continuous monitoring and assessment in cancer care.\\n--------------------------------------------------\\nPage Number: 130\\n\\nSection Name: Pathological N (pN)\\n====================\\nEntities:-\\nLymph Nodes : Small, bean-shaped structures that are part of the body\\'s lymphatic system. They filter lymph fluid and store white blood cells that help fight infection.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nTnm Staging : A system used to describe the size and spread of cancer in a standardized way. T refers to the size of the tumor, N to the involvement of lymph nodes, and M to metastasis.\\nLymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\nTnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient\\'s body.\\nLymph Node : An organ of the lymphatic system and the adaptive immune system.\\n\\nRelationships:-\\n1. Entity1: \""Lymph Nodes\"", Entity2: \""Neoplasm Metastasis\"", Relationship: \""involved in\""\\n2. Entity1: \""TNM Staging\"", Entity2: \""Lymph Nodes\"", Relationship: \""includes\""\\n3. Entity1: \""TNM Staging\"", Entity2: \""Neoplasm Metastasis\"", Relationship: \""describes\""\\n\\nCausalities:-\\n<CO> NX: Regional lymph nodes cannot be assessed </CO>\\n<CO> N0: No regional lymph node metastasis </CO>\\n<CO> N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(\u2013) </CO>\\n<CO> N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2212); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(\u2212); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2a: Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N3: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(\u2212); or metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>\\n<CO> N3a: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N3b: Metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>\\n<CO> Note: A designation of \u201cU\u201d or \u201cL\u201d may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L). Similarly, clinical and pathological ENE should be recorded as ENE(\u2212) or ENE(+). </CO>\\n\\nSection Name: Distant Metastasis (M)\\n====================\\nEntities:-\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\n\\nRelationships:-\\n1. Entity1: \""M0\"", Entity2: \""Distant Metastasis\"", Relationship: \""is a category of\""\\n2. Entity1: \""M1\"", Entity2: \""Distant Metastasis\"", Relationship: \""is a category of\""\\n\\nCausalities:-\\n### Distant Metastasis (M)\\n\\n- **M0**: No distant metastasis\\n- **M1**: Distant metastasis\\n\\nSection Name: Histologic Grade (G)\\n====================\\nEntities:-\\nNeoplasm Grading : A system of classifying cancer cells in terms of how abnormal they look under a microscope and how quickly the tumor is likely to grow and spread.\\nHistologic Grade : A measure of how much tumor cells differ from healthy cells, used to assess the aggressiveness of cancer.\\n\\nRelationships:-\\n1. Entity1: \""GX\"", Entity2: \""Grade cannot be assessed\"", Relationship: \""is described as\""\\n2. Entity1: \""G1\"", Entity2: \""Well differentiated\"", Relationship: \""is described as\""\\n3. Entity1: \""G2\"", Entity2: \""Moderately differentiated\"", Relationship: \""is described as\""\\n4. Entity1: \""G3\"", Entity2: \""Poorly differentiated\"", Relationship: \""is described as\""\\n\\nCausalities:-\\n<CO>GX</CO>: <E>Grade cannot be assessed</E>\\n<CO>G1</CO>: <E>Well differentiated</E>\\n<CO>G2</CO>: <E>Moderately differentiated</E>\\n<CO>G3</CO>: <E>Poorly differentiated</E>\\n\\nSection Name: Prognostic Stage Groups\\n====================\\nEntities:-\\nNeoplasm Staging : Methods and systems of classifying neoplasms according to extent of disease.\\nTumor Staging : A system for describing the size and spread of cancer within the body.\\nTnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient\\'s body.\\n\\nRelationships:-\\n1. Entity1: \""Stage 0\"", Entity2: \""Tis N0 M0\"", Relationship: \""defined by\""\\n2. Entity1: \""Stage I\"", Entity2: \""T1 N0 M0\"", Relationship: \""defined by\""\\n3. Entity1: \""Stage II\"", Entity2: \""T2 N0 M0\"", Relationship: \""defined by\""\\n4. Entity1: \""Stage III\"", Entity2: \""T3 N0 M0, T1 N1 M0, T2 N1 M0, T3 N1 M0\"", Relationship: \""defined by\""\\n5. Entity1: \""Stage IVA\"", Entity2: \""T1 N2 M0, T2 N2 M0, T3 N2 M0, T4a N0,N1,N2 M0\"", Relationship: \""defined by\""\\n6. Entity1: \""Stage IVB\"", Entity2: \""Any T N3 M0, T4b Any N M0\"", Relationship: \""defined by\""\\n7. Entity1: \""Stage IVC\"", Entity2: \""Any T Any N M1\"", Relationship: \""defined by\""\\n--------------------------------------------------\\nPage Number: 68\\n\\nSection Name: Diagnosis Section\\n====================\\nEntities:-\\nDiagnosis : The process of determining which disease or condition explains a person\\'s symptoms and signs.\\nMetastatic Disease : A disease in which cancer cells spread from the place where they first formed to another part of the body.\\nClinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nLocoregional Therapy : Treatment that is directed to a specific area of the body, often used in cancer treatment.\\n\\nRelationships:-\\n1. Entity1: \""Diagnosis\"", Entity2: \""Decision-making process\"", Relationship: \""initiates\""\\n2. Entity1: \""Metastatic disease\"", Entity2: \""Clinical trial\"", Relationship: \""preferred pathway\""\\n3. Entity1: \""Locoregional treatment\"", Entity2: \""Primary site algorithms\"", Relationship: \""based on\""\\n\\nCausalities:-\\n<CO> for patients presenting with metastatic disease </CO>, <A> a clinical trial is the preferred pathway </A>, emphasizing the critical nature of innovative therapies in advanced cancer care. The option to <A> \""Consider locoregional treatment based on primary site algorithms\"" </A> suggests that specific treatment strategies may be tailored <CO> depending on the exact location and characteristics of the cancer </CO>.\\n\\nSection Name: Treatment Pathways\\n====================\\nEntities:-\\nPerformance Status : A measure of a patient\\'s general well-being and ability to perform ordinary tasks, often used in oncology to determine the appropriate treatment.\\nSystemic Therapy : A treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nSurgery : A medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nPalliative Care : Specialized medical care for people living with a serious illness, focused on providing relief from the symptoms and stress of the illness.\\nSupportive Care : Care given to improve the quality of life of patients who have a serious or life-threatening disease.\\n\\nRelationships:-\\n1. Entity1: \""Performance Status\"", Entity2: \""Systemic Therapy\"", Relationship: \""affects choice of\""\\n2. Entity1: \""Performance Status\"", Entity2: \""Surgery\"", Relationship: \""affects choice of\""\\n3. Entity1: \""Performance Status\"", Entity2: \""Radiation Therapy\"", Relationship: \""affects choice of\""\\n4. Entity1: \""Performance Status\"", Entity2: \""Palliative Care\"", Relationship: \""affects choice of\""\\n5. Entity1: \""Performance Status\"", Entity2: \""Supportive Care\"", Relationship: \""affects choice of\""\\n6. Entity1: \""PS 0-1 Patients\"", Entity2: \""Combination Systemic Therapy\"", Relationship: \""suitable for\""\\n7. Entity1: \""PS 2 Patients\"", Entity2: \""Palliative Radiation Therapy\"", Relationship: \""may receive\""\\n8. Entity1: \""PS 3 Patients\"", Entity2: \""Supportive Care\"", Relationship: \""recommended\""\\n\\nCausalities:-\\nThe treatment section branches into various pathways depending on <CO> the patient\u2019s performance status (PS) </CO>, which is a measure of their general well-being and ability to function. - **For PS 0-1 Patients:** The flowchart indicates several treatment options, including <A> combination systemic therapy, single-agent systemic therapy, surgery, and radiation therapy (RT) </A>. This group is highlighted as those who are most capable of handling intensive treatments and <E> may benefit significantly from combination therapies </E>. - **For PS 2 Patients:** The recommended approach varies slightly, with a continued emphasis on <A> systemic therapies, palliative radiation therapy, or best supportive care </A>. This indicates a level of compromise in treatment options, suggesting that while aggressive treatment is still possible, <E> the focus might shift more towards quality of life </E>. - **For PS 3 Patients:** The treatment options further narrow, still recommending <A> systemic therapy or supportive care </A> but highlighting palliative approaches, reflecting a recognition of <E> the more advanced disease and potentially limited treatment efficacy </E>.\\n\\nSection Name: Principles of Treatment\\n====================\\nEntities:-\\nAntineoplastic Combined Chemotherapy Protocols : Protocols for the administration of more than one antineoplastic agent in combination to treat malignant neoplasms.\\nRadiotherapy : The use of radiation, usually X-rays or gamma rays, to treat disease, especially cancer.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nSystemic Therapy : A treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nSurgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nChemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.\\nSurgery : A medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Radiation Therapy\"", Relationship: \""Different modalities of cancer treatment\""\\n2. Entity1: \""Systemic Therapy\"", Entity2: \""Surgery\"", Relationship: \""Different modalities of cancer treatment\""\\n3. Entity1: \""Radiation Therapy\"", Entity2: \""Surgery\"", Relationship: \""Different modalities of cancer treatment\""\\n\\nCausalities:-\\n- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)** - **Principles of Radiation Therapy (ADV-A)** - **Principles of Surgery (SURG-A)**\\n\\nSection Name: Diagnosis and Treatment of Head and Neck Cancer\\n====================\\nEntities:-\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nMetastatic Malignant Neoplasm : A malignant neoplasm that has spread from its original site to a different site.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\nClinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nPerformance Status : A measure of a patient\\'s general well-being and ability to perform ordinary tasks, often used in oncology to determine the appropriate treatment.\\n\\nRelationships:-\\n1. Entity1: \""Metastatic disease\"", Entity2: \""Clinical trial\"", Relationship: \""preferred treatment option\""\\n2. Entity1: \""Performance Status 0-1\"", Entity2: \""Combination systemic therapy\"", Relationship: \""treatment option\""\\n3. Entity1: \""Performance Status 2\"", Entity2: \""Single-agent systemic therapy\"", Relationship: \""treatment option\""\\n4. Entity1: \""Performance Status 3\"", Entity2: \""Systemic therapy\"", Relationship: \""treatment option\""\\n\\nCausalities:-\\n- <CO>Metastatic (M1) disease at initial presentation</CO>\\n  <A>Clinical trial preferred</A>\\n  <E>Distant metastases</E>\\n  <A>Consider locoregional treatment based on primary site algorithms (Table of Contents)</A>\\n\\n#### Performance Status (PS)\\n- <CO>PS 0\u20131</CO>\\n  <A>Combination systemic therapy</A> or <A>Single-agent systemic therapy</A> or <A>Surgery</A> or <A>RT</A> or <A>systemic therapy/RT for selected patients with limited metastases</A> or <A>Best supportive care</A>\\n- <CO>PS 2</CO>\\n  <A>Single-agent systemic therapy</A> or <A>Best supportive care \u00b1 Palliative RT</A> or <A>Palliative surgery</A>\\n- <CO>PS 3</CO>\\n  <A>Systemic therapy, clinical trial preferred</A> or <A>Palliative RT</A> or <A>Best supportive care</A>\\n\\nSection Name: Persistent Disease or Progression\\n====================\\nEntities:-\\nPalliative Care : Specialized medical care for people living with a serious illness, focused on providing relief from the symptoms and stress of the illness.\\nSupportive Care : Care given to improve the quality of life of patients who have a serious or life-threatening disease.\\nAntineoplastic Agents : Substances that inhibit or prevent the proliferation of neoplasms.\\nSystemic Therapy : A treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nChemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.\\nRadiotherapy : The use of radiation, usually X-rays or gamma rays, to treat disease, especially cancer.\\nPalliative Radiotherapy : Radiotherapy given to relieve symptoms and reduce suffering caused by cancer.\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\n\\nRelationships:-\\n1. Entity1: \""Best supportive care\"", Entity2: \""Alternate single-agent systemic therapy\"", Relationship: \""alternative treatment options\""\\n2. Entity1: \""Best supportive care\"", Entity2: \""Palliative RT\"", Relationship: \""alternative treatment options\""\\n3. Entity1: \""Alternate single-agent systemic therapy\"", Entity2: \""Palliative RT\"", Relationship: \""alternative treatment options\""\\n\\nCausalities:-\\n<A> Best supportive care </A> or <A> Alternate single-agent systemic therapy </A> or <A> Palliative RT </A>\\n--------------------------------------------------\\nPage Number: 190\\n\\nSection Name: NCCN Guidelines Version 4.2024\\n====================\\nEntities:-\\nNccn Guidelines : The NCCN Guidelines are a set of clinical practice guidelines for oncology, developed by the National Comprehensive Cancer Network, which provide evidence-based recommendations for cancer care.\\n\\nRelationships:-\\n\\nCausalities:-\\nNCCN Guidelines Version 4.2024\\n\\nSection Name: Head and Neck Cancers\\n====================\\nEntities:-\\nHead And Neck Neoplasms : Cancers that arise in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\nMalignant Neoplasm Of Head And Neck : A malignant tumor located in the head and neck region.\\nHead And Neck Cancer : A group of cancers that originate in the head and neck region, such as the throat, lips, mouth, nose, and salivary glands.\\n\\nRelationships:-\\n\\nSection Name: Follow-up\\n====================\\nEntities:-\\nNccn Guidelines For Head And Neck Cancers : A set of clinical practice guidelines developed by the National Comprehensive Cancer Network for the management of head and neck cancers.\\n\\nRelationships:-\\n1. Entity1: \""Follow-up Recommendations\"", Entity2: \""NCCN Guidelines for Head and Neck Cancers\"", Relationship: \""part of\""\\n\\nCausalities:-\\n<A> Recommendations for surveillance are provided in the algorithm </A> (see *Follow-up Recommendations* in the NCCN Guidelines for Head and Neck Cancers).\\n\\nSection Name: Very Advanced Head and Neck Cancers\\n====================\\nEntities:-\\nHead And Neck Neoplasms : Cancers that arise in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\nLocally Advanced Malignant Neoplasm : A cancer that has spread from where it started to nearby tissue or lymph nodes.\\nMetastatic Cancer : Cancer that has spread from the primary site of origin to different areas of the body.\\nPalliative Care : An interdisciplinary medical caregiving approach aimed at optimizing quality of life and mitigating suffering among people with serious, complex illness.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nRadiation Therapy : The use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\n\\nRelationships:-\\n1. Entity1: \""Locally advanced malignant neoplasm\"", Entity2: \""Cure\"", Relationship: \""Treatment goal\""\\n2. Entity1: \""Metastatic cancer\"", Entity2: \""Palliative Care\"", Relationship: \""Treatment goal\""\\n3. Entity1: \""Surgical procedure\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""Potential treatment\""\\n4. Entity1: \""Radiation therapy\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""Potential treatment\""\\n\\nCausalities:-\\n<C> newly diagnosed locoregional but unresectable disease </C> <E> the treatment goal is usually cure </E>. <CO> if surgery or radiation remains feasible </CO> <E> the goal is cure </E>, or <CO> if the patient has received previous RT and the disease is unresectable </CO> <E> the goal is palliation </E>. <C> patients with widely metastatic disease </C> <E> the goal is palliation or prolongation of life </E>.\\n\\nSection Name: Treatment\\n====================\\nEntities:-\\nHead And Neck Neoplasms : Cancers that arise in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\nPerformance Status : A measure of how well a patient is able to perform ordinary tasks and carry out daily activities.\\nCancer Treatment : Medical treatment aimed at curing or alleviating cancer.\\n\\nRelationships:-\\n1. Entity1: \""patient\u2019s PS\"", Entity2: \""treatment options\"", Relationship: \""affects\""\\n2. Entity1: \""unresectable locoregional, persistent, recurrent, or metastatic H&N cancers\"", Entity2: \""treatment options\"", Relationship: \""dictates\""\\n\\nCausalities:-\\n<A> The treatment of patients with unresectable locoregional, persistent, recurrent, or metastatic H&N cancers </A> is dictated by <C> the patient\u2019s PS and intent of treatment (i.e., palliative vs. curative) </C>. <CO> Patients with good PS </CO> <E> may tolerate a wide range of treatment options </E>, whereas <CO> patients with reduced PS </CO> <E> cannot </E>.\\n\\nSection Name: Newly Diagnosed Locoregionally Advanced Disease\\n====================\\nEntities:-\\nCisplatin : An inorganic and water-soluble platinum complex. It is used as an antineoplastic in the treatment of various cancers.\\nCarboplatin : A platinum-containing antineoplastic agent used in the treatment of various cancers, often as an alternative to cisplatin.\\nFluorouracil : A pyrimidine analog used as an antineoplastic agent, often in combination with other drugs.\\nCetuximab : A chimeric monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR), used in cancer treatment.\\nDocetaxel : A semisynthetic taxoid used as an antineoplastic agent, particularly in the treatment of breast, ovarian, and non-small cell lung cancer.\\nHydroxyurea : An antineoplastic agent that inhibits ribonucleotide reductase, used in the treatment of various cancers and sickle cell anemia.\\nRadiotherapy : A treatment that uses high doses of radiation to kill cancer cells and shrink tumors.\\nChemoradiotherapy : Combined chemotherapy and radiotherapy treatment, often used in cancer treatment.\\n\\nRelationships:-\\n1. Entity1: \""Cisplatin\"", Entity2: \""Radiotherapy\"", Relationship: \""recommended treatment\""\\n2. Entity1: \""Carboplatin\"", Entity2: \""Radiotherapy\"", Relationship: \""supported treatment\""\\n3. Entity1: \""Cetuximab\"", Entity2: \""Radiotherapy\"", Relationship: \""alternative treatment\""\\n4. Entity1: \""Docetaxel\"", Entity2: \""Chemoradiotherapy\"", Relationship: \""alternative treatment\""\\n\\nCausalities:-\\n<CO> In patients with a PS of 0 or 1 </CO>, <A> the recommended treatment of newly diagnosed, very advanced disease is concurrent systemic therapy/RT, with a large amount of phase III data supporting high-dose cisplatin as a category 1 preferred recommendation </A>.\\n\\n<C> There are also considerable phase III data from Europe </C> that <E> support the use of carboplatin/5-FU with concurrent RT </E>. <A> This treatment is also considered a category 1 preferred option </A>.\\n\\n<C> Cisplatin-based induction systemic therapy has been studied, followed by RT alone or chemoradiation with a weekly platinum or cetuximab </C>. However, <E> an improvement in OS with the incorporation of induction chemotherapy, compared to proceeding directly to state-of-the-art concurrent systemic therapy/RT, has not been established in randomized studies </E>.\\n\\n<A> Cetuximab with concurrent RT is a category 2B option based on phase II and phase III data </A> but <E> is distinctly inferior to cisplatin with concurrent RT </E>, <CO> particularly in patients with HPV-positive disease </CO>.\\n\\n<A> Other chemoradiation options include carboplatin/paclitaxel (category 2B based on less panel consensus), weekly cisplatin 40 mg/m\u00b2, and docetaxel (for patients not eligible for cisplatin) </A>. Category 2B chemoradiation options that the panel has deemed useful only in select circumstances are 5-FU/hydroxyurea, cisplatin with infusional 5-FU, and cisplatin/paclitaxel.\\n\\n<CO> Other options for patients with a PS of 2\u20133 </CO> are described in the algorithm.\\n\\nSection Name: Metastatic Disease\\n====================\\nEntities:-\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nMetastatic Malignant Neoplasm : A malignant neoplasm that has spread from its original site to a different location.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\nPalliative Care : An interdisciplinary medical caregiving approach aimed at optimizing quality of life and mitigating suffering among people with serious, complex illness.\\nRadiotherapy : A treatment that uses high doses of radiation to kill cancer cells and shrink tumors.\\nRadiation Therapy : The use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nSurgery : A medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nAnalgesics : Drugs that relieve pain without causing loss of consciousness.\\nAnalgesic : Any member of the group of drugs used to achieve analgesia, relief from pain.\\nPain : An unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage.\\nHypercalcemia : A condition in which the calcium level in your blood is above normal.\\n\\nRelationships:-\\n1. Entity1: \""Metastatic Disease\"", Entity2: \""Palliative Adjunctive Measures\"", Relationship: \""treatment\""\\n2. Entity1: \""RT\"", Entity2: \""Palliative Adjunctive Measures\"", Relationship: \""type of\""\\n3. Entity1: \""Surgery\"", Entity2: \""Palliative Adjunctive Measures\"", Relationship: \""type of\""\\n4. Entity1: \""Analgesics\"", Entity2: \""Palliative Adjunctive Measures\"", Relationship: \""type of\""\\n5. Entity1: \""Therapies\"", Entity2: \""Palliative Adjunctive Measures\"", Relationship: \""type of\""\\n6. Entity1: \""Pain\"", Entity2: \""Metastatic Disease\"", Relationship: \""manifestation\""\\n7. Entity1: \""Hypercalcemia\"", Entity2: \""Metastatic Disease\"", Relationship: \""manifestation\""\\n\\nCausalities:-\\n<CO> For patients with metastatic (M1) disease at initial presentation </CO>, <A> palliative adjunctive measures include RT, surgery, analgesics, and other therapies </A> <E> to control manifestations of disease spread </E> (e.g., pain, hypercalcemia).\\n--------------------------------------------------\\nPage Number: 93\\n\\nSection Name: PRINCIPLES OF IMAGING\\n====================\\nEntities:-\\nImaging, Diagnostic : The production of a visual representation of parts of the body, for the purpose of clinical analysis and medical intervention.\\nHead And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\nTomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.\\nMagnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body\\'s soft tissue and bones.\\nContrast Media : Substances used to enhance the contrast of structures or fluids within the body in medical imaging.\\n\\nRelationships:-\\n1. Entity1: \""Imaging, Diagnostic\"", Entity2: \""Head and Neck Neoplasms\"", Relationship: \""used for\""\\n2. Entity1: \""Tomography, X-Ray Computed\"", Entity2: \""Contrast Media\"", Relationship: \""uses\""\\n3. Entity1: \""Magnetic Resonance Imaging\"", Entity2: \""Contrast Media\"", Relationship: \""uses\""\\n\\nCausalities:-\\n<C> Imaging </C> plays an essential role in the clinical care of patients with head and neck cancer. <A> The proper selection and utilization of imaging studies </A> is critical in caring for patients with head and neck cancer. <A> CT is performed with contrast </A>, while <A> CT imaging of the chest can be performed with or without contrast </A>, <CO> as clinically indicated </CO>. <A> MRI is performed with and without contrast </A>, <CO> unless contraindicated </CO>.\\n\\nSection Name: Initial Workup - Primary Site\\n====================\\nEntities:-\\nTomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.\\nMagnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body\\'s soft tissue and bones.\\nHead And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\nNeck Structure : The anatomical structure of the neck, which is the part of the body that connects the head to the torso.\\nSkull Base : The bottom part of the skull, which separates the brain from other facial structures.\\nThoracic Inlet : The opening at the top of the thoracic cavity, through which pass the trachea, esophagus, and major blood vessels.\\n\\nRelationships:-\\n1. Entity1: \""CT\"", Entity2: \""MRI\"", Relationship: \""complementary in imaging head and neck cancers\""\\n2. Entity1: \""CT\"", Entity2: \""Head and Neck Neoplasms\"", Relationship: \""used to evaluate\""\\n3. Entity1: \""MRI\"", Entity2: \""Head and Neck Neoplasms\"", Relationship: \""preferred for evaluating\""\\n4. Entity1: \""Skull base\"", Entity2: \""Thoracic inlet\"", Relationship: \""imaging range for evaluation\""\\n\\nCausalities:-\\n<A>Imaging assessment of the primary site</A> can be performed with <A>CT of the soft tissues of the neck</A> or <A>MRI of the neck</A>. <C>CT is complementary to MRI for head and neck cancers</C>. <A>It is utilized to evaluate cortical bone erosion or periosteal invasion, cartilage invasion, and bony erosion or destruction</A>. <CO>in certain conditions, such as evaluating the extent of bone marrow invasion or in patients with extensive dental amalgam obscuring anatomy on CT, assessing skull base invasion and cranial nerve involvement, and differentiating tumor from obstructed sinuses</CO>, <A>MRI is preferred over CT</A>. <CO>when involved lymph nodes or upper mediastinal cancers are present</CO>, <A>Complete evaluation of primary and nodal disease requires imaging from the skull base to the thoracic inlet, extending to the carina</A>.\\n\\nSection Name: PET/CT and Biopsy\\n====================\\nEntities:-\\nPositron Emission Tomography Computed Tomography : A medical imaging technique that combines PET and CT capabilities to provide detailed images of the body.\\nExamination Under Anesthesia : A procedure where a patient is examined while under anesthesia to allow for a more thorough examination.\\nBiopsy : A medical test involving the extraction of sample cells or tissues for examination to determine the presence or extent of a disease.\\nTonsillectomy : A surgical procedure to remove the tonsils, often performed to treat recurrent tonsillitis or sleep apnea.\\nFine Needle Aspiration : A type of biopsy procedure that uses a thin, hollow needle to extract cells from a lump or mass for examination.\\nUltrasound : A medical imaging technique that uses high-frequency sound waves to visualize internal organs and structures.\\nComputed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.\\n\\nRelationships:-\\n1. Entity1: \""PET/CT\"", Entity2: \""EUA\"", Relationship: \""recommended before\""\\n2. Entity1: \""Fine Needle Aspiration (FNA)\"", Entity2: \""metastatic nodes\"", Relationship: \""used for biopsy of\""\\n3. Entity1: \""Image-guided needle biopsy\"", Entity2: \""cystic neck nodes\"", Relationship: \""recommended for initial diagnosis of\""\\n\\nCausalities:-\\n<CO> If imaging does not reveal an obvious primary cancer </CO>, <A> a PET/CT should be ordered before EUA, biopsies, and tonsillectomy </A>. <E> This helps identify potential primary sites </E> before any interventions take place. Additionally, <A> Fine Needle Aspiration (FNA) biopsy of metastatic nodes </A> <E> may provide pathologically informative results </E>. <CO> For initial diagnosis in cystic neck nodes </CO>, <A> image-guided needle biopsy (ultrasound or CT) </A> <E> may yield better results than FNA by palpation alone </E>.\\n\\nSection Name: Postoperative Imaging Advice\\n====================\\nEntities:-\\nPanoramic Radiography : A type of dental x-ray that provides a wide view of the upper and lower jaws, teeth, temporomandibular joints, and sinuses.\\nOral Cavity : The cavity of the mouth, including the lips, the lining inside the cheeks and lips, the front two-thirds of the tongue, the gums, the floor of the mouth under the tongue, the hard palate, and the small area of the gum behind the wisdom teeth.\\nRadiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.\\nMandibulotomy : A surgical procedure involving the cutting of the mandible.\\nMandibulectomy : A surgical procedure involving the removal of part or all of the mandible.\\nOropharynx : The part of the throat at the back of the mouth behind the oral cavity.\\n\\nRelationships:-\\n1. Entity1: \""panoramic dental x-ray\"", Entity2: \""oral cavity cancers\"", Relationship: \""recommended for\""\\n2. Entity1: \""panoramic dental x-ray\"", Entity2: \""postoperative radiotherapy\"", Relationship: \""essential for pre-radiation evaluation\""\\n3. Entity1: \""pre-radiation dental evaluation\"", Entity2: \""dental procedures or extractions\"", Relationship: \""determine necessity of\""\\n\\nCausalities:-\\n<A> A panoramic dental x-ray is recommended </A> <C> for oral cavity cancers requiring mandibulotomy and/or mandibulectomy </C>. <CO> When postoperative radiotherapy (RT) is anticipated for areas like the lip, oral cavity subsites, or oropharynx </CO>, <A> panoramic x-ray is essential for a comprehensive pre-radiation dental evaluation </A> <E> to assess the health of affected teeth and determine if pre-radiation dental procedures or extractions are necessary </E>.\\n\\nSection Name: NCCN Guidelines Note\\n====================\\nEntities:-\\nNeoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.\\nMalignant Neoplastic Disease : A disease characterized by uncontrolled, abnormal growth of cells that can invade or spread to other parts of the body.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\nClinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.\\nClinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\n\\nRelationships:-\\n1. Entity1: \""NCCN\"", Entity2: \""Clinical Trials\"", Relationship: \""encourages participation in\""\\n2. Entity1: \""NCCN\"", Entity2: \""Cancer\"", Relationship: \""recommends clinical trials for\""\\n\\nCausalities:-\\n<A> NCCN believes that the best management of any patient with cancer is through participation in clinical trials </A>, <A> which is especially encouraged </A>.\\n'}""",valid,increases risk,2,B,"edge - The edge which needs to be verified.
explanation - Explanation of what the edge represents and its validity.
causal_direction - Either Positive or Negative or Unknown. A positive influence direction indicates that both factors change in the same direction (e.g. an increase causes an increase effect). A negative influence direction indicates the opposite changes (e.g. an increase causes a decrease effect).
causal_factor - Is necessary or sufficient condition for an effect to occur. Exposure is a term commonly used in epidemiology to denote any condition that is considered as a possible cause of disease. Exposure is considered necessary when it always precedes the effects (e.g. symptoms) and always presents when the effects occur. A sufficient cause is a causal factor whose presence or occurrence guarantees the occurrence of symptom.
causal_distance - Either Distal or Proximal or Unknown. The distal factors lie towards the beginning of causal chain (i.e. indirect causal factors). The the proximal factors lie towards the end of the chain (i.e. cause directly or almost directly the effect).

Causality Tags:
<A> for action, <C> for cause, <CO> for condition and <E> for effect.
Cause (C): The reason or origin that leads to an effect. Causes often involve disease conditions, risk factors, or underlying mechanisms.
Effect (E): The outcome or result of a cause. Effects usually represent clinical outcomes, complications, or results of a specific cause.
Condition (CO): The circumstance or prerequisite required for an action or effect to occur. Conditions may include patient characteristics, clinical scenarios, or specific diagnostic criteria.
Action (A): The recommended or described response or activity to address a cause or condition. Actions typically involve clinical interventions, diagnostic procedures, or treatment recommendations.


`NODE1`:
id: Location_of_Involved_Lymph_Nodes_4
label: Position of Affected Lymph Nodes in Patient
description: This node represents the location of lymph nodes that are involved or affected in a patient's condition. Understanding whether the lymph nodes are ipsilateral, bilateral, or contralateral is crucial for determining the extent of disease spread and planning appropriate treatment strategies.
type: Patient Situation
observability: Unobserved
states: [{'state_name': 'ipsilateral', 'state_description': 'The involved lymph nodes are on the same side of the body as the primary tumor or reference point. This can indicate localized spread of disease.'}, {'state_name': 'bilateral', 'state_description': 'The involved lymph nodes are on both sides of the body. This may suggest a more extensive spread of disease and can impact treatment decisions.'}, {'state_name': 'contralateral', 'state_description': 'The involved lymph nodes are on the opposite side of the body from the primary tumor or reference point. This can indicate metastatic spread and may affect staging and treatment planning.'}]

`NODE2`:
id: Ultrasonography_16
label: Ultrasound Examination Result
description: This node represents the results of an ultrasound examination aimed at detecting lymph node metastasis. It provides information on whether metastasis is present in lymph nodes and specifies the location relative to the primary tumor site.
type: Examination Result
observability: Observed
states: [{'state_name': 'bilateral_lymph_node_metastasis', 'state_description': 'Metastasis is present in lymph nodes on both sides of the body relative to the primary tumor site.'}, {'state_name': 'ipsilateral_lymph_node_metastasis', 'state_description': 'Metastasis is present in lymph nodes on the same side of the body as the primary tumor site.'}, {'state_name': 'contralateral_lymph_node_metastasis', 'state_description': 'Metastasis is present in lymph nodes on the opposite side of the body from the primary tumor site.'}]

`EDGE1`:
{'edges_ids': ['Location_of_Involved_Lymph_Nodes_4', 'Ultrasonography_16'], 'edge': '(Location_of_Involved_Lymph_Nodes_4) causes (Ultrasonography_16)', 'explanation': ['The edge represents the causal relationship where the position of the affected lymph nodes (Node 1) influences the results of an ultrasound examination (Node 2).', 'The location of the lymph nodes (ipsilateral, bilateral, contralateral) is a factor that the ultrasound examination detects and reports on.', 'The causal direction is positive because the state of the lymph nodes directly affects the ultrasound findings.', 'The causal factor is not necessary or sufficient because the ultrasound can detect lymph nodes in any location, and the presence of metastasis is required for a specific result.', 'The causal distance is proximal because the location of the lymph nodes directly influences the ultrasound result.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Proximal'}

`EDGE2`:
{'edges_ids': ['Ultrasonography_16', 'Location_of_Involved_Lymph_Nodes_4'], 'edge': '(Ultrasonography_16) causes (Location_of_Involved_Lymph_Nodes_4)', 'explanation': ['The edge represents the causal relationship where the results of an ultrasound examination (Ultrasonography_16) determine the location of involved lymph nodes (Location_of_Involved_Lymph_Nodes_4).', 'Ultrasonography_16 provides direct information on whether lymph node metastasis is present and specifies the location relative to the primary tumor site.', 'Location_of_Involved_Lymph_Nodes_4 describes the position of affected lymph nodes as ipsilateral, bilateral, or contralateral, which is directly informed by the ultrasound results.', 'The ultrasound examination is a direct method to observe and report the state and location of lymph node metastasis, making the edge valid.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': True}, 'causal_distance': 'Proximal'}

`INFORMATION FROM KNOWLEDGE BASE`:
--------------------------------------------------
Page Number: 55

Section Name: General Information
====================
Entities:-
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Nccn Guidelines : Clinical practice guidelines in oncology developed by the National Comprehensive Cancer Network.

Relationships:-
1. Entity1: ""NCCN Guidelines"", Entity2: ""National Comprehensive Cancer Network"", Relationship: ""produced by""

Section Name: Important Notes
====================
Entities:-
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medical, surgical, or behavioral interventions.
Clinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Neoplasms : New abnormal growth of tissue that can be benign or malignant.
Malignant Neoplastic Disease : A disease resulting from the growth of malignant neoplasms.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""Clinical Trials"", Entity2: ""Cancer"", Relationship: ""recommended for""
2. Entity1: ""NCCN"", Entity2: ""Clinical Trials"", Relationship: ""encourages participation in""

Causalities:-
<C> NCCN believes that the best management of any patient with cancer is in a clinical trial </C>. <A> Participation in clinical trials is especially encouraged </A>.

Section Name: Principles
====================
Entities:-
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Chemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.

Relationships:-
1. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Radiation Therapy"", Relationship: ""Both are principles of cancer treatment methods.""
2. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""Both are principles of cancer treatment methods.""
3. Entity1: ""Principles of Radiation Therapy"", Entity2: ""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""Both are principles of cancer treatment methods.""

Causalities:-
### Principles

- **Principles of Surgery (SURG-A)**
- **Principles of Radiation Therapy (SUPRA-A)**
- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**

Section Name: Adverse Pathologic Features
====================
Entities:-
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.
Perineural Invasion : The presence of cancer cells surrounding or tracking along a nerve within the perineural space.
Vascular Invasion : The invasion of cancer cells into blood vessels.
Lymphatic Invasion : The invasion of cancer cells into lymphatic vessels.

Relationships:-
1. Entity1: ""Extranodal extension"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
2. Entity1: ""Positive margins"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
3. Entity1: ""Close margins"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
4. Entity1: ""pT3 or pT4 primary"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
5. Entity1: ""pN2 or pN3 nodal disease"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
6. Entity1: ""Perineural invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
7. Entity1: ""Vascular invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
8. Entity1: ""Lymphatic invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""

Causalities:-
<C> Extranodal extension </C>
<C> Positive margins </C>
<C> Close margins </C>
<C> pT3 or pT4 primary </C>
<C> pN2 or pN3 nodal disease </C>
<C> Perineural invasion </C>
<C> Vascular invasion </C>
<C> Lymphatic invasion </C>

Section Name: Response Assessment
====================
Entities:-
Chemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Primary Site : The original location where a tumor or cancer begins.
Complete Remission : The disappearance of all signs of cancer in response to treatment.
Partial Remission : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
Radiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.

Relationships:-
1. Entity1: ""induction chemotherapy"", Entity2: ""Primary site"", Relationship: ""treatment outcome""
2. Entity1: ""Definitive RT"", Entity2: ""Primary site"", Relationship: ""treatment option""
3. Entity1: ""RT"", Entity2: ""Primary site"", Relationship: ""treatment option""
4. Entity1: ""Surgery"", Entity2: ""unresectable nodal disease"", Relationship: ""treatment option""

Causalities:-
<C> Response after induction chemotherapy </C>: <E> Primary site: CR </E> <E> Primary site: PR </E> <E> Primary site: < PR </E> <A> Definitive RT </A> (category 1) <A> RT </A> (category 1) or <A> systemic therapy/RT </A> (category 2B) <A> Surgery </A> or <A> unresectable nodal disease </A>

Section Name: Follow-up
====================
Entities:-
Follow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.
Follow-Up Procedure : A procedure where a patient is monitored over time to assess the progress of a condition or the effects of treatment.
Follow-Up (Medicine) : The process of monitoring a patient's health over time after treatment or diagnosis.
Disease Recurrence : The return of a sign, symptom, or disease after a remission.
Recurrent Disease : A disease that returns after a period of remission.
Recurrence (Medicine) : The return of a disease or condition after a period of improvement.

Relationships:-
1. Entity1: ""Follow-up"", Entity2: ""Recurrent or persistent disease"", Relationship: ""monitoring""

Causalities:-
### Follow-up

- **Follow-up** (FOLL-A, 1 of 2)
- **Recurrent or persistent disease** (ADV-3)

Section Name: Risk Features
====================
Entities:-
Radiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Adverse pathologic features"", Entity2: ""RT"", Relationship: ""Consideration for treatment""
2. Entity1: ""Adverse pathologic features"", Entity2: ""Systemic therapy"", Relationship: ""Consideration for treatment""

Causalities:-
- **No adverse pathologic features**
- **Other risk features**
- **Adverse pathologic features**:
  - <C> Extranodal extension and/or positive margin </C>
  - <A> RT or consider systemic therapy/RT </A>

Section Name: Post-Therapy Evaluation
====================
Entities:-
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Neck : The neck is the part of the body that separates the head from the torso and provides the mobility and movements of the head.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Neck Evaluation"", Relationship: ""evaluated in""
2. Entity1: ""RT"", Entity2: ""Neck Evaluation"", Relationship: ""evaluated in""

Causalities:-
<CO> Post Systemic Therapy/RT or RT Neck </CO> <A> Evaluation </A>

Section Name: Flowchart Overview
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Supraglottic Larynx : The part of the larynx located above the vocal cords, including the epiglottis and aryepiglottic folds.
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.

Relationships:-
1. Entity1: ""NCCN Guidelines"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""guides management of""
2. Entity1: ""NCCN Guidelines"", Entity2: ""healthcare professionals"", Relationship: ""used by""

Causalities:-
<C> cancer of the supraglottic larynx </C> <E> evaluate patient responses following treatment </E> <CO> based on observed outcomes </CO> <A> evaluation of the primary site and determining subsequent steps </A>.

Section Name: Assessment and Treatment Decisions
====================
Entities:-
Induction Chemotherapy : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Complete Response : The disappearance of all signs of cancer in response to treatment.
Partial Response : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Complete Response"", Entity2: ""Radiation Therapy"", Relationship: ""leads to""
2. Entity1: ""Complete Response"", Entity2: ""Surgery"", Relationship: ""leads to""
3. Entity1: ""Partial Response"", Entity2: ""Systemic Therapy"", Relationship: ""leads to""
4. Entity1: ""Partial Response"", Entity2: ""Radiation Therapy"", Relationship: ""leads to""

Causalities:-
<C> responses to initial treatments such as induction chemotherapy </C> <E> Three main response categories are recognized: Complete Response (CR), Partial Response (PR), and less than Partial Response (< PR) </E>. These categories are pivotal in determining the next steps. <C> CR </C> <E> indicates full resolution of the disease at the primary site </E>, <A> leading to the consideration of definitive radiation therapy or the likelihood of surgery </A>. Conversely, <C> PR </C> <E> suggests that the disease has improved but not completely resolved </E>, <A> which directs the pathway towards either systemic therapy or continued radiation therapy </A>, <A> with further evaluation necessary </A>.

Section Name: Adverse Pathologic Features and Follow-up
====================
Entities:-
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Neoplasm Recurrence, Local : The return of a tumor or cancer, at the original site, after it has been treated.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Recurrent Neoplasm : A neoplasm that has returned after treatment.
Metastatic Neoplasm : A neoplasm that has spread from its original site to one or more other places in the body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Cancer Recurrence : The return of cancer after treatment and after a period of time during which the cancer was undetectable.
Metastasis : Spread of a cancer or other disease from one organ or part to another not directly connected with it.

Relationships:-
1. Entity1: ""Adverse pathologic features"", Entity2: ""Treatment decisions"", Relationship: ""Influence""
2. Entity1: ""Adverse features"", Entity2: ""Surgical intervention"", Relationship: ""Recommendation""
3. Entity1: ""Absence of adverse features"", Entity2: ""Radiation therapy"", Relationship: ""Pathway""
4. Entity1: ""Follow-up process"", Entity2: ""Recurrent or persistent disease"", Relationship: ""Detection""
5. Entity1: ""Recurrent or persistent disease"", Entity2: ""Advanced disease management"", Relationship: ""Necessity""

Causalities:-
<C> The presence of adverse pathologic features — such as extranodal extension or positive margins </C> <E> can directly influence treatment decisions </E>. <CO> If adverse features are found </CO>, <A> surgical intervention is recommended </A>. <CO> In cases where there are no adverse features </CO>, the patient may proceed directly to radiation therapy or continued systemic treatment, emphasizing the tailored approach based on the individual patient's disease characteristics.

Furthermore, the chart includes a section addressing the follow-up process after initial treatment. <CO> If there are signs of recurrent or persistent disease </CO>, <A> additional evaluations and treatment modalities may be necessary </A>. These evaluations <E> lead to specific recommendations for advanced disease management, denoted as ADV-3 on the chart </E>, emphasizing the importance of continuous monitoring and assessment in cancer care.
--------------------------------------------------
Page Number: 130

Section Name: Pathological N (pN)
====================
Entities:-
Lymph Nodes : Small, bean-shaped structures that are part of the body's lymphatic system. They filter lymph fluid and store white blood cells that help fight infection.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Tnm Staging : A system used to describe the size and spread of cancer in a standardized way. T refers to the size of the tumor, N to the involvement of lymph nodes, and M to metastasis.
Lymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.
Tnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient's body.
Lymph Node : An organ of the lymphatic system and the adaptive immune system.

Relationships:-
1. Entity1: ""Lymph Nodes"", Entity2: ""Neoplasm Metastasis"", Relationship: ""involved in""
2. Entity1: ""TNM Staging"", Entity2: ""Lymph Nodes"", Relationship: ""includes""
3. Entity1: ""TNM Staging"", Entity2: ""Neoplasm Metastasis"", Relationship: ""describes""

Causalities:-
<CO> NX: Regional lymph nodes cannot be assessed </CO>
<CO> N0: No regional lymph node metastasis </CO>
<CO> N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(–) </CO>
<CO> N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2a: Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N3: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(−); or metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>
<CO> N3a: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N3b: Metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>
<CO> Note: A designation of “U” or “L” may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L). Similarly, clinical and pathological ENE should be recorded as ENE(−) or ENE(+). </CO>

Section Name: Distant Metastasis (M)
====================
Entities:-
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.

Relationships:-
1. Entity1: ""M0"", Entity2: ""Distant Metastasis"", Relationship: ""is a category of""
2. Entity1: ""M1"", Entity2: ""Distant Metastasis"", Relationship: ""is a category of""

Causalities:-
### Distant Metastasis (M)

- **M0**: No distant metastasis
- **M1**: Distant metastasis

Section Name: Histologic Grade (G)
====================
Entities:-
Neoplasm Grading : A system of classifying cancer cells in terms of how abnormal they look under a microscope and how quickly the tumor is likely to grow and spread.
Histologic Grade : A measure of how much tumor cells differ from healthy cells, used to assess the aggressiveness of cancer.

Relationships:-
1. Entity1: ""GX"", Entity2: ""Grade cannot be assessed"", Relationship: ""is described as""
2. Entity1: ""G1"", Entity2: ""Well differentiated"", Relationship: ""is described as""
3. Entity1: ""G2"", Entity2: ""Moderately differentiated"", Relationship: ""is described as""
4. Entity1: ""G3"", Entity2: ""Poorly differentiated"", Relationship: ""is described as""

Causalities:-
<CO>GX</CO>: <E>Grade cannot be assessed</E>
<CO>G1</CO>: <E>Well differentiated</E>
<CO>G2</CO>: <E>Moderately differentiated</E>
<CO>G3</CO>: <E>Poorly differentiated</E>

Section Name: Prognostic Stage Groups
====================
Entities:-
Neoplasm Staging : Methods and systems of classifying neoplasms according to extent of disease.
Tumor Staging : A system for describing the size and spread of cancer within the body.
Tnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient's body.

Relationships:-
1. Entity1: ""Stage 0"", Entity2: ""Tis N0 M0"", Relationship: ""defined by""
2. Entity1: ""Stage I"", Entity2: ""T1 N0 M0"", Relationship: ""defined by""
3. Entity1: ""Stage II"", Entity2: ""T2 N0 M0"", Relationship: ""defined by""
4. Entity1: ""Stage III"", Entity2: ""T3 N0 M0, T1 N1 M0, T2 N1 M0, T3 N1 M0"", Relationship: ""defined by""
5. Entity1: ""Stage IVA"", Entity2: ""T1 N2 M0, T2 N2 M0, T3 N2 M0, T4a N0,N1,N2 M0"", Relationship: ""defined by""
6. Entity1: ""Stage IVB"", Entity2: ""Any T N3 M0, T4b Any N M0"", Relationship: ""defined by""
7. Entity1: ""Stage IVC"", Entity2: ""Any T Any N M1"", Relationship: ""defined by""
--------------------------------------------------
Page Number: 68

Section Name: Diagnosis Section
====================
Entities:-
Diagnosis : The process of determining which disease or condition explains a person's symptoms and signs.
Metastatic Disease : A disease in which cancer cells spread from the place where they first formed to another part of the body.
Clinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Locoregional Therapy : Treatment that is directed to a specific area of the body, often used in cancer treatment.

Relationships:-
1. Entity1: ""Diagnosis"", Entity2: ""Decision-making process"", Relationship: ""initiates""
2. Entity1: ""Metastatic disease"", Entity2: ""Clinical trial"", Relationship: ""preferred pathway""
3. Entity1: ""Locoregional treatment"", Entity2: ""Primary site algorithms"", Relationship: ""based on""

Causalities:-
<CO> for patients presenting with metastatic disease </CO>, <A> a clinical trial is the preferred pathway </A>, emphasizing the critical nature of innovative therapies in advanced cancer care. The option to <A> ""Consider locoregional treatment based on primary site algorithms"" </A> suggests that specific treatment strategies may be tailored <CO> depending on the exact location and characteristics of the cancer </CO>.

Section Name: Treatment Pathways
====================
Entities:-
Performance Status : A measure of a patient's general well-being and ability to perform ordinary tasks, often used in oncology to determine the appropriate treatment.
Systemic Therapy : A treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Surgery : A medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Palliative Care : Specialized medical care for people living with a serious illness, focused on providing relief from the symptoms and stress of the illness.
Supportive Care : Care given to improve the quality of life of patients who have a serious or life-threatening disease.

Relationships:-
1. Entity1: ""Performance Status"", Entity2: ""Systemic Therapy"", Relationship: ""affects choice of""
2. Entity1: ""Performance Status"", Entity2: ""Surgery"", Relationship: ""affects choice of""
3. Entity1: ""Performance Status"", Entity2: ""Radiation Therapy"", Relationship: ""affects choice of""
4. Entity1: ""Performance Status"", Entity2: ""Palliative Care"", Relationship: ""affects choice of""
5. Entity1: ""Performance Status"", Entity2: ""Supportive Care"", Relationship: ""affects choice of""
6. Entity1: ""PS 0-1 Patients"", Entity2: ""Combination Systemic Therapy"", Relationship: ""suitable for""
7. Entity1: ""PS 2 Patients"", Entity2: ""Palliative Radiation Therapy"", Relationship: ""may receive""
8. Entity1: ""PS 3 Patients"", Entity2: ""Supportive Care"", Relationship: ""recommended""

Causalities:-
The treatment section branches into various pathways depending on <CO> the patient’s performance status (PS) </CO>, which is a measure of their general well-being and ability to function. - **For PS 0-1 Patients:** The flowchart indicates several treatment options, including <A> combination systemic therapy, single-agent systemic therapy, surgery, and radiation therapy (RT) </A>. This group is highlighted as those who are most capable of handling intensive treatments and <E> may benefit significantly from combination therapies </E>. - **For PS 2 Patients:** The recommended approach varies slightly, with a continued emphasis on <A> systemic therapies, palliative radiation therapy, or best supportive care </A>. This indicates a level of compromise in treatment options, suggesting that while aggressive treatment is still possible, <E> the focus might shift more towards quality of life </E>. - **For PS 3 Patients:** The treatment options further narrow, still recommending <A> systemic therapy or supportive care </A> but highlighting palliative approaches, reflecting a recognition of <E> the more advanced disease and potentially limited treatment efficacy </E>.

Section Name: Principles of Treatment
====================
Entities:-
Antineoplastic Combined Chemotherapy Protocols : Protocols for the administration of more than one antineoplastic agent in combination to treat malignant neoplasms.
Radiotherapy : The use of radiation, usually X-rays or gamma rays, to treat disease, especially cancer.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Systemic Therapy : A treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Surgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Chemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.
Surgery : A medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Radiation Therapy"", Relationship: ""Different modalities of cancer treatment""
2. Entity1: ""Systemic Therapy"", Entity2: ""Surgery"", Relationship: ""Different modalities of cancer treatment""
3. Entity1: ""Radiation Therapy"", Entity2: ""Surgery"", Relationship: ""Different modalities of cancer treatment""

Causalities:-
- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)** - **Principles of Radiation Therapy (ADV-A)** - **Principles of Surgery (SURG-A)**

Section Name: Diagnosis and Treatment of Head and Neck Cancer
====================
Entities:-
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Metastatic Malignant Neoplasm : A malignant neoplasm that has spread from its original site to a different site.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.
Clinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Performance Status : A measure of a patient's general well-being and ability to perform ordinary tasks, often used in oncology to determine the appropriate treatment.

Relationships:-
1. Entity1: ""Metastatic disease"", Entity2: ""Clinical trial"", Relationship: ""preferred treatment option""
2. Entity1: ""Performance Status 0-1"", Entity2: ""Combination systemic therapy"", Relationship: ""treatment option""
3. Entity1: ""Performance Status 2"", Entity2: ""Single-agent systemic therapy"", Relationship: ""treatment option""
4. Entity1: ""Performance Status 3"", Entity2: ""Systemic therapy"", Relationship: ""treatment option""

Causalities:-
- <CO>Metastatic (M1) disease at initial presentation</CO>
  <A>Clinical trial preferred</A>
  <E>Distant metastases</E>
  <A>Consider locoregional treatment based on primary site algorithms (Table of Contents)</A>

#### Performance Status (PS)
- <CO>PS 0–1</CO>
  <A>Combination systemic therapy</A> or <A>Single-agent systemic therapy</A> or <A>Surgery</A> or <A>RT</A> or <A>systemic therapy/RT for selected patients with limited metastases</A> or <A>Best supportive care</A>
- <CO>PS 2</CO>
  <A>Single-agent systemic therapy</A> or <A>Best supportive care ± Palliative RT</A> or <A>Palliative surgery</A>
- <CO>PS 3</CO>
  <A>Systemic therapy, clinical trial preferred</A> or <A>Palliative RT</A> or <A>Best supportive care</A>

Section Name: Persistent Disease or Progression
====================
Entities:-
Palliative Care : Specialized medical care for people living with a serious illness, focused on providing relief from the symptoms and stress of the illness.
Supportive Care : Care given to improve the quality of life of patients who have a serious or life-threatening disease.
Antineoplastic Agents : Substances that inhibit or prevent the proliferation of neoplasms.
Systemic Therapy : A treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Chemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.
Radiotherapy : The use of radiation, usually X-rays or gamma rays, to treat disease, especially cancer.
Palliative Radiotherapy : Radiotherapy given to relieve symptoms and reduce suffering caused by cancer.
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.

Relationships:-
1. Entity1: ""Best supportive care"", Entity2: ""Alternate single-agent systemic therapy"", Relationship: ""alternative treatment options""
2. Entity1: ""Best supportive care"", Entity2: ""Palliative RT"", Relationship: ""alternative treatment options""
3. Entity1: ""Alternate single-agent systemic therapy"", Entity2: ""Palliative RT"", Relationship: ""alternative treatment options""

Causalities:-
<A> Best supportive care </A> or <A> Alternate single-agent systemic therapy </A> or <A> Palliative RT </A>
--------------------------------------------------
Page Number: 190

Section Name: NCCN Guidelines Version 4.2024
====================
Entities:-
Nccn Guidelines : The NCCN Guidelines are a set of clinical practice guidelines for oncology, developed by the National Comprehensive Cancer Network, which provide evidence-based recommendations for cancer care.

Relationships:-

Causalities:-
NCCN Guidelines Version 4.2024

Section Name: Head and Neck Cancers
====================
Entities:-
Head And Neck Neoplasms : Cancers that arise in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Malignant Neoplasm Of Head And Neck : A malignant tumor located in the head and neck region.
Head And Neck Cancer : A group of cancers that originate in the head and neck region, such as the throat, lips, mouth, nose, and salivary glands.

Relationships:-

Section Name: Follow-up
====================
Entities:-
Nccn Guidelines For Head And Neck Cancers : A set of clinical practice guidelines developed by the National Comprehensive Cancer Network for the management of head and neck cancers.

Relationships:-
1. Entity1: ""Follow-up Recommendations"", Entity2: ""NCCN Guidelines for Head and Neck Cancers"", Relationship: ""part of""

Causalities:-
<A> Recommendations for surveillance are provided in the algorithm </A> (see *Follow-up Recommendations* in the NCCN Guidelines for Head and Neck Cancers).

Section Name: Very Advanced Head and Neck Cancers
====================
Entities:-
Head And Neck Neoplasms : Cancers that arise in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Locally Advanced Malignant Neoplasm : A cancer that has spread from where it started to nearby tissue or lymph nodes.
Metastatic Cancer : Cancer that has spread from the primary site of origin to different areas of the body.
Palliative Care : An interdisciplinary medical caregiving approach aimed at optimizing quality of life and mitigating suffering among people with serious, complex illness.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Radiation Therapy : The use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.

Relationships:-
1. Entity1: ""Locally advanced malignant neoplasm"", Entity2: ""Cure"", Relationship: ""Treatment goal""
2. Entity1: ""Metastatic cancer"", Entity2: ""Palliative Care"", Relationship: ""Treatment goal""
3. Entity1: ""Surgical procedure"", Entity2: ""Recurrent or persistent disease"", Relationship: ""Potential treatment""
4. Entity1: ""Radiation therapy"", Entity2: ""Recurrent or persistent disease"", Relationship: ""Potential treatment""

Causalities:-
<C> newly diagnosed locoregional but unresectable disease </C> <E> the treatment goal is usually cure </E>. <CO> if surgery or radiation remains feasible </CO> <E> the goal is cure </E>, or <CO> if the patient has received previous RT and the disease is unresectable </CO> <E> the goal is palliation </E>. <C> patients with widely metastatic disease </C> <E> the goal is palliation or prolongation of life </E>.

Section Name: Treatment
====================
Entities:-
Head And Neck Neoplasms : Cancers that arise in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Performance Status : A measure of how well a patient is able to perform ordinary tasks and carry out daily activities.
Cancer Treatment : Medical treatment aimed at curing or alleviating cancer.

Relationships:-
1. Entity1: ""patient’s PS"", Entity2: ""treatment options"", Relationship: ""affects""
2. Entity1: ""unresectable locoregional, persistent, recurrent, or metastatic H&N cancers"", Entity2: ""treatment options"", Relationship: ""dictates""

Causalities:-
<A> The treatment of patients with unresectable locoregional, persistent, recurrent, or metastatic H&N cancers </A> is dictated by <C> the patient’s PS and intent of treatment (i.e., palliative vs. curative) </C>. <CO> Patients with good PS </CO> <E> may tolerate a wide range of treatment options </E>, whereas <CO> patients with reduced PS </CO> <E> cannot </E>.

Section Name: Newly Diagnosed Locoregionally Advanced Disease
====================
Entities:-
Cisplatin : An inorganic and water-soluble platinum complex. It is used as an antineoplastic in the treatment of various cancers.
Carboplatin : A platinum-containing antineoplastic agent used in the treatment of various cancers, often as an alternative to cisplatin.
Fluorouracil : A pyrimidine analog used as an antineoplastic agent, often in combination with other drugs.
Cetuximab : A chimeric monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR), used in cancer treatment.
Docetaxel : A semisynthetic taxoid used as an antineoplastic agent, particularly in the treatment of breast, ovarian, and non-small cell lung cancer.
Hydroxyurea : An antineoplastic agent that inhibits ribonucleotide reductase, used in the treatment of various cancers and sickle cell anemia.
Radiotherapy : A treatment that uses high doses of radiation to kill cancer cells and shrink tumors.
Chemoradiotherapy : Combined chemotherapy and radiotherapy treatment, often used in cancer treatment.

Relationships:-
1. Entity1: ""Cisplatin"", Entity2: ""Radiotherapy"", Relationship: ""recommended treatment""
2. Entity1: ""Carboplatin"", Entity2: ""Radiotherapy"", Relationship: ""supported treatment""
3. Entity1: ""Cetuximab"", Entity2: ""Radiotherapy"", Relationship: ""alternative treatment""
4. Entity1: ""Docetaxel"", Entity2: ""Chemoradiotherapy"", Relationship: ""alternative treatment""

Causalities:-
<CO> In patients with a PS of 0 or 1 </CO>, <A> the recommended treatment of newly diagnosed, very advanced disease is concurrent systemic therapy/RT, with a large amount of phase III data supporting high-dose cisplatin as a category 1 preferred recommendation </A>.

<C> There are also considerable phase III data from Europe </C> that <E> support the use of carboplatin/5-FU with concurrent RT </E>. <A> This treatment is also considered a category 1 preferred option </A>.

<C> Cisplatin-based induction systemic therapy has been studied, followed by RT alone or chemoradiation with a weekly platinum or cetuximab </C>. However, <E> an improvement in OS with the incorporation of induction chemotherapy, compared to proceeding directly to state-of-the-art concurrent systemic therapy/RT, has not been established in randomized studies </E>.

<A> Cetuximab with concurrent RT is a category 2B option based on phase II and phase III data </A> but <E> is distinctly inferior to cisplatin with concurrent RT </E>, <CO> particularly in patients with HPV-positive disease </CO>.

<A> Other chemoradiation options include carboplatin/paclitaxel (category 2B based on less panel consensus), weekly cisplatin 40 mg/m², and docetaxel (for patients not eligible for cisplatin) </A>. Category 2B chemoradiation options that the panel has deemed useful only in select circumstances are 5-FU/hydroxyurea, cisplatin with infusional 5-FU, and cisplatin/paclitaxel.

<CO> Other options for patients with a PS of 2–3 </CO> are described in the algorithm.

Section Name: Metastatic Disease
====================
Entities:-
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Metastatic Malignant Neoplasm : A malignant neoplasm that has spread from its original site to a different location.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.
Palliative Care : An interdisciplinary medical caregiving approach aimed at optimizing quality of life and mitigating suffering among people with serious, complex illness.
Radiotherapy : A treatment that uses high doses of radiation to kill cancer cells and shrink tumors.
Radiation Therapy : The use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Surgery : A medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Analgesics : Drugs that relieve pain without causing loss of consciousness.
Analgesic : Any member of the group of drugs used to achieve analgesia, relief from pain.
Pain : An unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage.
Hypercalcemia : A condition in which the calcium level in your blood is above normal.

Relationships:-
1. Entity1: ""Metastatic Disease"", Entity2: ""Palliative Adjunctive Measures"", Relationship: ""treatment""
2. Entity1: ""RT"", Entity2: ""Palliative Adjunctive Measures"", Relationship: ""type of""
3. Entity1: ""Surgery"", Entity2: ""Palliative Adjunctive Measures"", Relationship: ""type of""
4. Entity1: ""Analgesics"", Entity2: ""Palliative Adjunctive Measures"", Relationship: ""type of""
5. Entity1: ""Therapies"", Entity2: ""Palliative Adjunctive Measures"", Relationship: ""type of""
6. Entity1: ""Pain"", Entity2: ""Metastatic Disease"", Relationship: ""manifestation""
7. Entity1: ""Hypercalcemia"", Entity2: ""Metastatic Disease"", Relationship: ""manifestation""

Causalities:-
<CO> For patients with metastatic (M1) disease at initial presentation </CO>, <A> palliative adjunctive measures include RT, surgery, analgesics, and other therapies </A> <E> to control manifestations of disease spread </E> (e.g., pain, hypercalcemia).
--------------------------------------------------
Page Number: 93

Section Name: PRINCIPLES OF IMAGING
====================
Entities:-
Imaging, Diagnostic : The production of a visual representation of parts of the body, for the purpose of clinical analysis and medical intervention.
Head And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Tomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.
Magnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body's soft tissue and bones.
Contrast Media : Substances used to enhance the contrast of structures or fluids within the body in medical imaging.

Relationships:-
1. Entity1: ""Imaging, Diagnostic"", Entity2: ""Head and Neck Neoplasms"", Relationship: ""used for""
2. Entity1: ""Tomography, X-Ray Computed"", Entity2: ""Contrast Media"", Relationship: ""uses""
3. Entity1: ""Magnetic Resonance Imaging"", Entity2: ""Contrast Media"", Relationship: ""uses""

Causalities:-
<C> Imaging </C> plays an essential role in the clinical care of patients with head and neck cancer. <A> The proper selection and utilization of imaging studies </A> is critical in caring for patients with head and neck cancer. <A> CT is performed with contrast </A>, while <A> CT imaging of the chest can be performed with or without contrast </A>, <CO> as clinically indicated </CO>. <A> MRI is performed with and without contrast </A>, <CO> unless contraindicated </CO>.

Section Name: Initial Workup - Primary Site
====================
Entities:-
Tomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.
Magnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body's soft tissue and bones.
Head And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Neck Structure : The anatomical structure of the neck, which is the part of the body that connects the head to the torso.
Skull Base : The bottom part of the skull, which separates the brain from other facial structures.
Thoracic Inlet : The opening at the top of the thoracic cavity, through which pass the trachea, esophagus, and major blood vessels.

Relationships:-
1. Entity1: ""CT"", Entity2: ""MRI"", Relationship: ""complementary in imaging head and neck cancers""
2. Entity1: ""CT"", Entity2: ""Head and Neck Neoplasms"", Relationship: ""used to evaluate""
3. Entity1: ""MRI"", Entity2: ""Head and Neck Neoplasms"", Relationship: ""preferred for evaluating""
4. Entity1: ""Skull base"", Entity2: ""Thoracic inlet"", Relationship: ""imaging range for evaluation""

Causalities:-
<A>Imaging assessment of the primary site</A> can be performed with <A>CT of the soft tissues of the neck</A> or <A>MRI of the neck</A>. <C>CT is complementary to MRI for head and neck cancers</C>. <A>It is utilized to evaluate cortical bone erosion or periosteal invasion, cartilage invasion, and bony erosion or destruction</A>. <CO>in certain conditions, such as evaluating the extent of bone marrow invasion or in patients with extensive dental amalgam obscuring anatomy on CT, assessing skull base invasion and cranial nerve involvement, and differentiating tumor from obstructed sinuses</CO>, <A>MRI is preferred over CT</A>. <CO>when involved lymph nodes or upper mediastinal cancers are present</CO>, <A>Complete evaluation of primary and nodal disease requires imaging from the skull base to the thoracic inlet, extending to the carina</A>.

Section Name: PET/CT and Biopsy
====================
Entities:-
Positron Emission Tomography Computed Tomography : A medical imaging technique that combines PET and CT capabilities to provide detailed images of the body.
Examination Under Anesthesia : A procedure where a patient is examined while under anesthesia to allow for a more thorough examination.
Biopsy : A medical test involving the extraction of sample cells or tissues for examination to determine the presence or extent of a disease.
Tonsillectomy : A surgical procedure to remove the tonsils, often performed to treat recurrent tonsillitis or sleep apnea.
Fine Needle Aspiration : A type of biopsy procedure that uses a thin, hollow needle to extract cells from a lump or mass for examination.
Ultrasound : A medical imaging technique that uses high-frequency sound waves to visualize internal organs and structures.
Computed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.

Relationships:-
1. Entity1: ""PET/CT"", Entity2: ""EUA"", Relationship: ""recommended before""
2. Entity1: ""Fine Needle Aspiration (FNA)"", Entity2: ""metastatic nodes"", Relationship: ""used for biopsy of""
3. Entity1: ""Image-guided needle biopsy"", Entity2: ""cystic neck nodes"", Relationship: ""recommended for initial diagnosis of""

Causalities:-
<CO> If imaging does not reveal an obvious primary cancer </CO>, <A> a PET/CT should be ordered before EUA, biopsies, and tonsillectomy </A>. <E> This helps identify potential primary sites </E> before any interventions take place. Additionally, <A> Fine Needle Aspiration (FNA) biopsy of metastatic nodes </A> <E> may provide pathologically informative results </E>. <CO> For initial diagnosis in cystic neck nodes </CO>, <A> image-guided needle biopsy (ultrasound or CT) </A> <E> may yield better results than FNA by palpation alone </E>.

Section Name: Postoperative Imaging Advice
====================
Entities:-
Panoramic Radiography : A type of dental x-ray that provides a wide view of the upper and lower jaws, teeth, temporomandibular joints, and sinuses.
Oral Cavity : The cavity of the mouth, including the lips, the lining inside the cheeks and lips, the front two-thirds of the tongue, the gums, the floor of the mouth under the tongue, the hard palate, and the small area of the gum behind the wisdom teeth.
Radiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.
Mandibulotomy : A surgical procedure involving the cutting of the mandible.
Mandibulectomy : A surgical procedure involving the removal of part or all of the mandible.
Oropharynx : The part of the throat at the back of the mouth behind the oral cavity.

Relationships:-
1. Entity1: ""panoramic dental x-ray"", Entity2: ""oral cavity cancers"", Relationship: ""recommended for""
2. Entity1: ""panoramic dental x-ray"", Entity2: ""postoperative radiotherapy"", Relationship: ""essential for pre-radiation evaluation""
3. Entity1: ""pre-radiation dental evaluation"", Entity2: ""dental procedures or extractions"", Relationship: ""determine necessity of""

Causalities:-
<A> A panoramic dental x-ray is recommended </A> <C> for oral cavity cancers requiring mandibulotomy and/or mandibulectomy </C>. <CO> When postoperative radiotherapy (RT) is anticipated for areas like the lip, oral cavity subsites, or oropharynx </CO>, <A> panoramic x-ray is essential for a comprehensive pre-radiation dental evaluation </A> <E> to assess the health of affected teeth and determine if pre-radiation dental procedures or extractions are necessary </E>.

Section Name: NCCN Guidelines Note
====================
Entities:-
Neoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.
Malignant Neoplastic Disease : A disease characterized by uncontrolled, abnormal growth of cells that can invade or spread to other parts of the body.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.
Clinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.
Clinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.

Relationships:-
1. Entity1: ""NCCN"", Entity2: ""Clinical Trials"", Relationship: ""encourages participation in""
2. Entity1: ""NCCN"", Entity2: ""Cancer"", Relationship: ""recommends clinical trials for""

Causalities:-
<A> NCCN believes that the best management of any patient with cancer is through participation in clinical trials </A>, <A> which is especially encouraged </A>.


Among these two options which one is the most likely true:

(A) `Location_of_Involved_Lymph_Nodes_4` increases risk `Ultrasonography_16`
(B) `Ultrasonography_16` `increases risk `Location_of_Involved_Lymph_Nodes_4`

The answer is: ...

1. State the evidences in detail of the validity of option (A) or (B) by cross referencing
NCCN Clinical Practitioner’s Guidelines for Head and Neck Cancer.
2. If the evidences are obtained from `INFORMATION FROM KNOWLEDGE BASE`,
mention their corresponding Page Numbers, Section Name, entities, relationships and causalities.

DESIRED OUTPUT FORMAT:
<thinking>
...
</thinking>
<answer>
{
   ""thinking"": [""..."", ...],
   ""evidences"": [""..."", ...],
   ""answer"": ...
}
</answer>

Before providing the answer in <answer> tags, think step by step in detail in <thinking> tags and analyze every part.
Output inside <answer> tag in JSON format. Only output valid JSON.
DO NOT HALLUCINATE. DO NOT MAKE UP FACTUAL INFORMATION.
","1. The edge (A) suggests that the position of involved lymph nodes influences the ultrasound examination results. This is a logical causal relationship because the ultrasound is used to detect and report the state of lymph nodes, which are already affected by the disease.
2. The edge (B) suggests that the ultrasound examination results influence the position of involved lymph nodes. This is less logical because the ultrasound is a diagnostic tool and does not affect the physical state of the lymph nodes.
3. In the NCCN Guidelines, the role of imaging, including ultrasound, is primarily diagnostic. It is used to assess the extent of disease and guide treatment decisions, not to influence the physical state of the disease itself.
4. The causal direction in edge (A) is positive, indicating that the state of the lymph nodes directly affects the ultrasound findings. This aligns with the role of diagnostic imaging in assessing disease spread.
5. The causal factor in edge (A) is neither necessary nor sufficient, which is consistent with the fact that ultrasound can detect lymph nodes in any location, but the presence of metastasis is required for a specific result.
6. The causal distance in edge (A) is proximal, indicating a direct influence of lymph node location on ultrasound results, which is logical given the diagnostic nature of ultrasound.
7. The NCCN Guidelines emphasize the use of imaging for diagnosis and staging, not for influencing the physical state of lymph nodes.
","1. Page 93, Section Name: PRINCIPLES OF IMAGING, Entities: Imaging, Diagnostic; Head And Neck Neoplasms, Relationships: Imaging, Diagnostic used for Head and Neck Neoplasms, Causalities: Imaging plays an essential role in the clinical care of patients with head and neck cancer.
2. Page 93, Section Name: Initial Workup - Primary Site, Entities: Tomography, X-Ray Computed; Magnetic Resonance Imaging; Head And Neck Neoplasms, Relationships: CT used to evaluate Head and Neck Neoplasms, Causalities: Imaging assessment of the primary site can be performed with CT or MRI.
",A,"{'A': 99.94, 'B': 0.06}",yes,A,"1. The AI assistant's reasoning for option (A) is based on the logical flow that the position of lymph nodes (Node 1) influences the ultrasound results (Node 2). This is consistent with the role of ultrasound as a diagnostic tool that reports on the state of lymph nodes, which are already affected by the disease.
2. The assistant correctly identifies that the causal direction is positive, meaning the state of the lymph nodes directly affects the ultrasound findings. This aligns with the diagnostic purpose of ultrasound, which is to assess and report on the condition of lymph nodes.
3. The assistant notes that the causal factor is neither necessary nor sufficient, which is accurate because while the ultrasound can detect lymph nodes in any location, the presence of metastasis is required for a specific result. This reflects the nature of diagnostic imaging, which reports on existing conditions rather than causing them.
4. The causal distance is described as proximal, indicating a direct influence of lymph node location on ultrasound results. This is logical given that the ultrasound is used to directly observe and report on the state of lymph nodes.
5. The assistant's reasoning for option (B) is less logical because it suggests that the ultrasound results influence the physical state of the lymph nodes, which is not consistent with the role of ultrasound as a diagnostic tool.
6. The NCCN Guidelines emphasize the use of imaging for diagnosis and staging, not for influencing the physical state of lymph nodes. This supports the assistant's conclusion that option (A) is more consistent with the reasoning provided.
"
9,gpt-4o,"N_State_1__patient,Number_of_Involved_Lymph_Nodes_3","""{'NODE1': {'id': 'N_State_1__patient', 'label': 'State of Nearby Lymph Nodes with Cancer in Patient', 'description': 'This node represents the state of involvement of nearby lymph nodes in a patient with cancer. It is a decision node used to predict the extent of lymph node metastasis, which is crucial for cancer staging and treatment planning. The states range from no involvement (n0) to extensive involvement (n3), with intermediate states indicating varying degrees of lymph node cancer presence.', 'type': 'Decision Node', 'observability': 'Needs to be Predicted', 'states': [{'state_name': 'nx', 'state_description': 'The regional lymph nodes cannot be assessed.'}, {'state_name': 'n3', 'state_description': 'Metastasis in lymph node(s) along the course of a major blood vessel or in a lymph node that is more than 6 cm in greatest dimension.'}, {'state_name': 'n2c', 'state_description': 'Metastasis in bilateral or contralateral lymph nodes, each 6 cm or less in greatest dimension.'}, {'state_name': 'n2b', 'state_description': 'Metastasis in multiple ipsilateral lymph nodes, each 6 cm or less in greatest dimension.'}, {'state_name': 'n2a', 'state_description': 'Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension.'}, {'state_name': 'n2', 'state_description': 'Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension, or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension.'}, {'state_name': 'n1', 'state_description': 'Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension.'}, {'state_name': 'n0', 'state_description': 'No regional lymph node metastasis.'}]}, 'NODE2': {'id': 'Number_of_Involved_Lymph_Nodes_3', 'label': 'Number of Involved Lymph Nodes', 'description': \""This node represents the number of lymph nodes that are involved with cancer in a patient's situation. It is a critical factor in determining the stage and prognosis of cancer, as the involvement of lymph nodes often indicates the spread of cancer beyond the primary site.\"", 'type': 'Patient Situation', 'observability': 'Unobserved', 'states': [{'state_name': 'zero_involved_lymph_nodes', 'state_description': 'No lymph nodes are involved with cancer, indicating that the cancer has not spread to nearby lymph nodes.'}, {'state_name': 'one_three_involved_lymph_nodes', 'state_description': 'Between one and three lymph nodes are involved with cancer, suggesting limited regional spread of the disease.'}, {'state_name': 'four_or_more_involved_lymph_nodes', 'state_description': 'Four or more lymph nodes are involved with cancer, indicating a more extensive spread of the disease and potentially a more advanced stage.'}]}, 'EDGE1': {'edges_ids': ['N_State_1__patient', 'Number_of_Involved_Lymph_Nodes_3'], 'edge': '(N_State_1__patient) causes (Number_of_Involved_Lymph_Nodes_3)', 'explanation': ['The edge represents the causal relationship where the state of lymph node involvement in a patient (N_State_1__patient) influences the number of lymph nodes involved with cancer (Number_of_Involved_Lymph_Nodes_3).', 'In cancer staging, the state of lymph node involvement is used to predict the extent of lymph node metastasis, which directly relates to the number of involved lymph nodes.', 'A higher state of lymph node involvement (e.g., n3) would typically correspond to a higher number of involved lymph nodes, indicating a positive causal direction.', 'The state of lymph node involvement is a sufficient condition for predicting the number of involved lymph nodes, as it is a key factor in cancer staging.', 'The causal distance is proximal because the state of lymph node involvement directly affects the number of involved lymph nodes.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': True}, 'causal_distance': 'Proximal'}, 'EDGE2': {'edges_ids': ['Number_of_Involved_Lymph_Nodes_3', 'N_State_1__patient'], 'edge': '(Number_of_Involved_Lymph_Nodes_3) causes (N_State_1__patient)', 'explanation': ['The `Number_of_Involved_Lymph_Nodes_3` node represents the number of lymph nodes involved with cancer, which is a critical factor in determining the stage and prognosis of cancer.', \""The 'N_State_1__patient' node represents the state of involvement of nearby lymph nodes in a patient with cancer, which is crucial for cancer staging and treatment planning.\"", 'The number of involved lymph nodes directly influences the N state, as more involved lymph nodes typically correspond to a higher N state.', \""Therefore, the edge '(Number_of_Involved_Lymph_Nodes_3) causes (N_State_1__patient)' is valid.\"", 'The causal direction is positive because an increase in the number of involved lymph nodes leads to a higher N state.', 'The number of involved lymph nodes is a necessary factor for determining the N state, as the N state is defined based on lymph node involvement.', 'The causal distance is proximal because the number of involved lymph nodes directly affects the N state without intermediate steps.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': True, 'sufficient': False}, 'causal_distance': 'Proximal'}, 'ENTITIES_MATCHING_PAGES_INFO': {'102': {'matching_entities': [{'LYMPHATIC SYSTEM': 0.95855314}, {'LYMPHATIC STRUCTURE': 0.9469132}, {'METASTASIS': 0.9401313}, {'CANCER STAGING': 0.93824553}, {'TUMOR': 0.9323624}, {'STAGING': 0.9208425}], 'count': 6}, '55': {'matching_entities': [{'MALIGNANT NEOPLASTIC DISEASE': 0.97725874}, {'METASTASIS': 0.9401313}, {'CANCER': 0.9363244}, {'METASTATIC NEOPLASM': 0.9314138}, {'NEOPLASM METASTASIS': 0.9250777}, {'LARYNGEAL NEOPLASMS': 0.9236878}], 'count': 6}, '51': {'matching_entities': [{'MALIGNANT NEOPLASM': 0.9774111}, {'CANCER STAGING': 0.93824553}, {'CANCER': 0.9363244}, {'LARYNGEAL NEOPLASMS': 0.9236878}, {'NEOPLASM INVASIVENESS': 0.92347366}], 'count': 5}, '130': {'matching_entities': [{'LYMPH NODE STRUCTURE': 0.99134904}, {'LYMPH NODE': 0.98570025}, {'LYMPH NODES': 0.97445965}, {'METASTASIS': 0.9401313}, {'NEOPLASM METASTASIS': 0.9250777}], 'count': 5}, '47': {'matching_entities': [{'MALIGNANT NEOPLASM': 0.9774111}, {'LARYNGEAL CANCER': 0.95521915}, {'CANCER': 0.9363244}, {'LARYNGEAL NEOPLASMS': 0.9236878}], 'count': 4}}, 'GUIDELINE_PAGES_INFO': '--------------------------------------------------\\nPage Number: 102\\n\\nSection Name: Head and Neck Cancers - Principles of Surgery\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Manual or operative procedures used in the treatment of disease, injuries, or deformities.\\nLymphatic System : Part of the circulatory system and a vital part of the immune system, comprising a network of lymphatic vessels that carry a clear fluid called lymph.\\nNeoplasms : New abnormal growth of tissue in animals or plants; a tumor.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nNeoplasm Staging : Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.\\nMetastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.\\nSurgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nLymphatic Structure : Anatomical structure that is part of the lymphatic system.\\nTumor : An abnormal mass of tissue that results when cells divide more than they should or do not die when they should.\\nStaging : The process of determining the size and spread of cancer within the body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nCancer Staging : The process of determining the extent to which a cancer has developed by growing and spreading.\\n\\nRelationships:-\\n1. Entity1: \""surgical management\"", Entity2: \""regional lymphatics\"", Relationship: \""dictated by tumor staging\""\\n2. Entity1: \""neck dissections\"", Entity2: \""primary tumor\"", Relationship: \""part of treatment\""\\n3. Entity1: \""surgery\"", Entity2: \""ipsilateral side of the neck\"", Relationship: \""risk for metastases\""\\n\\nCausalities:-\\n<C> The extent of the tumor at initial tumor staging </C> <E> dictates the surgical management of regional lymphatics </E>. These guidelines apply to the performance of neck dissections as part of treatment of the primary tumor. <CO> Patients undergoing surgery for resection of the primary tumor </CO> <A> will undergo dissection of the ipsilateral side of the neck that is at greatest risk for metastases </A>.\\n\\nSection Name: Neck Management\\n====================\\nEntities:-\\nTongue : A muscular organ in the mouth that is involved in tasting, swallowing, and speech.\\nPalate : The roof of the mouth, separating the oral and nasal cavities.\\nLarynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.\\nHypopharynx : The bottom part of the pharynx, which is the cavity behind the nose and mouth.\\nNasopharynx : The upper part of the pharynx, connecting with the nasal cavity above the soft palate.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nMetastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.\\nSquamous Cell Carcinoma : A type of cancer that begins in the squamous cells, which are thin, flat cells that look like fish scales.\\nBiopsy : The removal of cells or tissues for examination under a microscope.\\n\\nRelationships:-\\n1. Entity1: \""Tumor sites\"", Entity2: \""Bilateral lymphatic drainage\"", Relationship: \""associated with\""\\n2. Entity1: \""Elective neck dissection\"", Entity2: \""Risk of occult metastasis\"", Relationship: \""based on\""\\n3. Entity1: \""SLN biopsy\"", Entity2: \""Elective neck dissection\"", Relationship: \""guides decision-making for\""\\n\\nCausalities:-\\n- **<C> Tumor sites that frequently have bilateral lymphatic drainage </C>** (e.g., base of tongue, palate, supraglottic larynx, hypopharynx, nasopharynx, deep pre-epiglottic space involvement) <E> often should have both sides of the neck dissected </E> with the extent of dissection determined as suggested below. For those patients with tumors at or approaching the midline, <CO> both sides of the neck are at risk for metastases </CO>, and <A> bilateral neck dissections should be performed </A>.\\n\\n- <CO> Patients with advanced lesions involving the anterior tongue, floor of the mouth, or alveolus that approximate or cross the midline </CO> <A> should undergo contralateral selective/modified neck dissection </A> as necessary to achieve adequate tumor resection.\\n\\n- **<C> Elective neck dissection </C>** <A> should be based on risk of occult metastasis in the appropriate nodal basin </A>. For oral cavity squamous cell carcinoma, <C> SLN biopsy or the primary tumor depth of invasion </C> is currently <E> the best predictor of occult metastatic disease </E> and <A> should be used to guide decision-making </A>. <CO> For tumors with a depth greater than 3 mm </CO>, <A> elective dissection should be strongly considered if RT is not already planned </A>. Recent randomized trial evidence supports the effectiveness of elective neck dissection in patients with oral cavity cancers greater than 3 mm in depth of invasion.\\n\\n  - <CO> For a depth less than 2 mm </CO>, <A> elective dissection is only indicated in highly selective situations </A>. <CO> For a depth of 2\u20134 mm </CO>, <A> clinical judgment (as to reliability of follow-up, clinical suspicion, and other factors) must be utilized to determine appropriateness of elective dissection </A>. Elective dissections are generally selective, preserving all major structures, unless operative findings dictate otherwise.\\n\\nSection Name: Types of Neck Dissection\\n====================\\nEntities:-\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nLarynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.\\n\\nRelationships:-\\n1. Entity1: \""N0\"", Entity2: \""Selective neck dissection\"", Relationship: \""associated with\""\\n2. Entity1: \""N3\"", Entity2: \""Comprehensive neck dissection\"", Relationship: \""associated with\""\\n3. Entity1: \""Level VI neck dissection\"", Entity2: \""Larynx\"", Relationship: \""performed for\""\\n4. Entity1: \""Level VI neck dissection\"", Entity2: \""Hypopharynx\"", Relationship: \""performed for\""\\n\\nCausalities:-\\n- **The type of neck dissection (comprehensive or selective)** is defined according to <CO> preoperative clinical staging </CO>, is determined at the discretion of the surgeon, and is based on the initial preoperative staging as follows:\\n  - **N0:** <A> Selective neck dissection </A>\\n    - Oral cavity at least levels I\u2013III\\n    - Oropharynx at least levels II\u2013IV\\n    - Hypopharynx at least levels II\u2013IV and level VI when appropriate\\n    - Larynx at least levels II\u2013IV and level VI when appropriate\\n  - **N1\u2013N2a\u2013c:** <A> Selective or comprehensive neck dissection </A> (Discussion)\\n  - **N3:** <A> Comprehensive neck dissection </A>\\n\\n- <C> Level VI neck dissections are performed for certain primary sites (such as the larynx and hypopharynx) </C> <E> as required to resect the primary tumor and any clinically evident neck nodes </E>. <CO> Elective dissection depends on primary tumor extent and site </CO>. <CO> For advanced glottic and hypopharyngeal cancers treated with primary surgery </CO>, <A> a level VI dissection (including pretracheal lymph nodes, the Delphian lymph node, and unilateral or bilateral paratracheal lymph nodes) and hemithyroidectomy to total thyroidectomy are appropriate </A>.\\n\\n- <CO> For primary subglottic tumors or glottic cancers with significant subglottic extension </CO>, <A> a level VI dissection with unilateral or total thyroidectomy is considered appropriate </A> based on the extent of the primary tumor. <CO> For example, a T4a glottic tumor with extension through the cricothyroid membrane and subglottic extension </CO> <A> should include thyroidectomy and pretracheal and bilateral paratracheal lymph node dissection </A>. <A> Parathyroid glands should be preserved in situ or auto transplanted as indicated </A>.\\n--------------------------------------------------\\nPage Number: 55\\n\\nSection Name: General Information\\n====================\\nEntities:-\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nNccn Guidelines : Clinical practice guidelines in oncology developed by the National Comprehensive Cancer Network.\\n\\nRelationships:-\\n1. Entity1: \""NCCN Guidelines\"", Entity2: \""National Comprehensive Cancer Network\"", Relationship: \""produced by\""\\n\\nSection Name: Important Notes\\n====================\\nEntities:-\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medical, surgical, or behavioral interventions.\\nClinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nNeoplasms : New abnormal growth of tissue that can be benign or malignant.\\nMalignant Neoplastic Disease : A disease resulting from the growth of malignant neoplasms.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""Clinical Trials\"", Entity2: \""Cancer\"", Relationship: \""recommended for\""\\n2. Entity1: \""NCCN\"", Entity2: \""Clinical Trials\"", Relationship: \""encourages participation in\""\\n\\nCausalities:-\\n<C> NCCN believes that the best management of any patient with cancer is in a clinical trial </C>. <A> Participation in clinical trials is especially encouraged </A>.\\n\\nSection Name: Principles\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nChemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.\\n\\nRelationships:-\\n1. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Radiation Therapy\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n2. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n3. Entity1: \""Principles of Radiation Therapy\"", Entity2: \""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n\\nCausalities:-\\n### Principles\\n\\n- **Principles of Surgery (SURG-A)**\\n- **Principles of Radiation Therapy (SUPRA-A)**\\n- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**\\n\\nSection Name: Adverse Pathologic Features\\n====================\\nEntities:-\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.\\nPerineural Invasion : The presence of cancer cells surrounding or tracking along a nerve within the perineural space.\\nVascular Invasion : The invasion of cancer cells into blood vessels.\\nLymphatic Invasion : The invasion of cancer cells into lymphatic vessels.\\n\\nRelationships:-\\n1. Entity1: \""Extranodal extension\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n2. Entity1: \""Positive margins\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n3. Entity1: \""Close margins\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n4. Entity1: \""pT3 or pT4 primary\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n5. Entity1: \""pN2 or pN3 nodal disease\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n6. Entity1: \""Perineural invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n7. Entity1: \""Vascular invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n8. Entity1: \""Lymphatic invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n\\nCausalities:-\\n<C> Extranodal extension </C>\\n<C> Positive margins </C>\\n<C> Close margins </C>\\n<C> pT3 or pT4 primary </C>\\n<C> pN2 or pN3 nodal disease </C>\\n<C> Perineural invasion </C>\\n<C> Vascular invasion </C>\\n<C> Lymphatic invasion </C>\\n\\nSection Name: Response Assessment\\n====================\\nEntities:-\\nChemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nPrimary Site : The original location where a tumor or cancer begins.\\nComplete Remission : The disappearance of all signs of cancer in response to treatment.\\nPartial Remission : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.\\nRadiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""induction chemotherapy\"", Entity2: \""Primary site\"", Relationship: \""treatment outcome\""\\n2. Entity1: \""Definitive RT\"", Entity2: \""Primary site\"", Relationship: \""treatment option\""\\n3. Entity1: \""RT\"", Entity2: \""Primary site\"", Relationship: \""treatment option\""\\n4. Entity1: \""Surgery\"", Entity2: \""unresectable nodal disease\"", Relationship: \""treatment option\""\\n\\nCausalities:-\\n<C> Response after induction chemotherapy </C>: <E> Primary site: CR </E> <E> Primary site: PR </E> <E> Primary site: < PR </E> <A> Definitive RT </A> (category 1) <A> RT </A> (category 1) or <A> systemic therapy/RT </A> (category 2B) <A> Surgery </A> or <A> unresectable nodal disease </A>\\n\\nSection Name: Follow-up\\n====================\\nEntities:-\\nFollow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.\\nFollow-Up Procedure : A procedure where a patient is monitored over time to assess the progress of a condition or the effects of treatment.\\nFollow-Up (Medicine) : The process of monitoring a patient\\'s health over time after treatment or diagnosis.\\nDisease Recurrence : The return of a sign, symptom, or disease after a remission.\\nRecurrent Disease : A disease that returns after a period of remission.\\nRecurrence (Medicine) : The return of a disease or condition after a period of improvement.\\n\\nRelationships:-\\n1. Entity1: \""Follow-up\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""monitoring\""\\n\\nCausalities:-\\n### Follow-up\\n\\n- **Follow-up** (FOLL-A, 1 of 2)\\n- **Recurrent or persistent disease** (ADV-3)\\n\\nSection Name: Risk Features\\n====================\\nEntities:-\\nRadiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Adverse pathologic features\"", Entity2: \""RT\"", Relationship: \""Consideration for treatment\""\\n2. Entity1: \""Adverse pathologic features\"", Entity2: \""Systemic therapy\"", Relationship: \""Consideration for treatment\""\\n\\nCausalities:-\\n- **No adverse pathologic features**\\n- **Other risk features**\\n- **Adverse pathologic features**:\\n  - <C> Extranodal extension and/or positive margin </C>\\n  - <A> RT or consider systemic therapy/RT </A>\\n\\nSection Name: Post-Therapy Evaluation\\n====================\\nEntities:-\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nNeck : The neck is the part of the body that separates the head from the torso and provides the mobility and movements of the head.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Neck Evaluation\"", Relationship: \""evaluated in\""\\n2. Entity1: \""RT\"", Entity2: \""Neck Evaluation\"", Relationship: \""evaluated in\""\\n\\nCausalities:-\\n<CO> Post Systemic Therapy/RT or RT Neck </CO> <A> Evaluation </A>\\n\\nSection Name: Flowchart Overview\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nSupraglottic Larynx : The part of the larynx located above the vocal cords, including the epiglottis and aryepiglottic folds.\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\n\\nRelationships:-\\n1. Entity1: \""NCCN Guidelines\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""guides management of\""\\n2. Entity1: \""NCCN Guidelines\"", Entity2: \""healthcare professionals\"", Relationship: \""used by\""\\n\\nCausalities:-\\n<C> cancer of the supraglottic larynx </C> <E> evaluate patient responses following treatment </E> <CO> based on observed outcomes </CO> <A> evaluation of the primary site and determining subsequent steps </A>.\\n\\nSection Name: Assessment and Treatment Decisions\\n====================\\nEntities:-\\nInduction Chemotherapy : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nComplete Response : The disappearance of all signs of cancer in response to treatment.\\nPartial Response : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Complete Response\"", Entity2: \""Radiation Therapy\"", Relationship: \""leads to\""\\n2. Entity1: \""Complete Response\"", Entity2: \""Surgery\"", Relationship: \""leads to\""\\n3. Entity1: \""Partial Response\"", Entity2: \""Systemic Therapy\"", Relationship: \""leads to\""\\n4. Entity1: \""Partial Response\"", Entity2: \""Radiation Therapy\"", Relationship: \""leads to\""\\n\\nCausalities:-\\n<C> responses to initial treatments such as induction chemotherapy </C> <E> Three main response categories are recognized: Complete Response (CR), Partial Response (PR), and less than Partial Response (< PR) </E>. These categories are pivotal in determining the next steps. <C> CR </C> <E> indicates full resolution of the disease at the primary site </E>, <A> leading to the consideration of definitive radiation therapy or the likelihood of surgery </A>. Conversely, <C> PR </C> <E> suggests that the disease has improved but not completely resolved </E>, <A> which directs the pathway towards either systemic therapy or continued radiation therapy </A>, <A> with further evaluation necessary </A>.\\n\\nSection Name: Adverse Pathologic Features and Follow-up\\n====================\\nEntities:-\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nNeoplasm Recurrence, Local : The return of a tumor or cancer, at the original site, after it has been treated.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nRecurrent Neoplasm : A neoplasm that has returned after treatment.\\nMetastatic Neoplasm : A neoplasm that has spread from its original site to one or more other places in the body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nCancer Recurrence : The return of cancer after treatment and after a period of time during which the cancer was undetectable.\\nMetastasis : Spread of a cancer or other disease from one organ or part to another not directly connected with it.\\n\\nRelationships:-\\n1. Entity1: \""Adverse pathologic features\"", Entity2: \""Treatment decisions\"", Relationship: \""Influence\""\\n2. Entity1: \""Adverse features\"", Entity2: \""Surgical intervention\"", Relationship: \""Recommendation\""\\n3. Entity1: \""Absence of adverse features\"", Entity2: \""Radiation therapy\"", Relationship: \""Pathway\""\\n4. Entity1: \""Follow-up process\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""Detection\""\\n5. Entity1: \""Recurrent or persistent disease\"", Entity2: \""Advanced disease management\"", Relationship: \""Necessity\""\\n\\nCausalities:-\\n<C> The presence of adverse pathologic features \u2014 such as extranodal extension or positive margins </C> <E> can directly influence treatment decisions </E>. <CO> If adverse features are found </CO>, <A> surgical intervention is recommended </A>. <CO> In cases where there are no adverse features </CO>, the patient may proceed directly to radiation therapy or continued systemic treatment, emphasizing the tailored approach based on the individual patient\\'s disease characteristics.\\n\\nFurthermore, the chart includes a section addressing the follow-up process after initial treatment. <CO> If there are signs of recurrent or persistent disease </CO>, <A> additional evaluations and treatment modalities may be necessary </A>. These evaluations <E> lead to specific recommendations for advanced disease management, denoted as ADV-3 on the chart </E>, emphasizing the importance of continuous monitoring and assessment in cancer care.\\n--------------------------------------------------\\nPage Number: 51\\n\\nSection Name: Introduction\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nMalignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.\\nSupraglottic Laryngeal Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is above the vocal cords.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network (NCCN)\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""provides guidelines for\""\\n2. Entity1: \""healthcare professionals\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""manage\""\\n\\nCausalities:-\\nThe provided image is a detailed flowchart from the National Comprehensive Cancer Network (NCCN) guidelines regarding the <C> clinical staging and treatment protocols for cancer of the supraglottic larynx </C>. This flowchart is structured to <A> guide healthcare professionals through the stages of treatment </A> based on <CO> clinical findings </CO>, emphasizing the <E> complexity and systematic approach required in managing this type of cancer </E>.\\n\\nSection Name: Clinical Staging\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nTotal Laryngectomy : A surgical procedure to remove the entire larynx, often used in the treatment of advanced laryngeal cancer.\\nNeoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.\\nCancer Staging : The process of determining the extent of cancer in the body, often using the TNM system.\\nTnm Staging System : A cancer staging system that describes the extent of cancer using Tumor size (T), Node involvement (N), and Metastasis (M).\\n\\nRelationships:-\\n1. Entity1: \""Clinical staging criteria\"", Entity2: \""Total laryngectomy\"", Relationship: \""determines necessity of\""\\n2. Entity1: \""T3, N0\"", Entity2: \""Clinical staging criteria\"", Relationship: \""is a categorization of\""\\n\\nCausalities:-\\nThe flowchart begins with the <C> clinical staging criteria </C>, specifically focusing on <CO> cases that require total laryngectomy, denoted as requiring (amenable to) total laryngectomy (T3, N0) </CO>. This <A> categorization </A> is crucial as it <E> forms the basis for determining the appropriate treatment strategy </E>.\\n\\nSection Name: Treatment of Primary and Neck\\n====================\\nEntities:-\\nNeoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.\\nLymphatic Metastasis : Transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Radiation Therapy\"", Relationship: \""combined with\""\\n2. Entity1: \""Laryngectomy\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n3. Entity1: \""Thyroidectomy\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n4. Entity1: \""Neck Dissection\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n\\nCausalities:-\\n<CO> Once clinical staging is established </CO>, the chart outlines various treatment options. <A> The initial step may involve either concurrent systemic therapy combined with radiation therapy (RT) or opting for RT alone </A>, <CO> especially if the patient is not a medical candidate for both therapies </CO>. <A> Laryngectomy, thyroidectomy, and neck dissection are considered </A> <CO> based on the extent of lymph node involvement </CO>.\\n\\nSection Name: Surgical Options\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nLymph Node Excision : Surgical removal of one or more lymph nodes.\\nLymphadenectomy : Surgical removal of one or more groups of lymph nodes.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""Laryngectomy\"", Entity2: \""Thyroidectomy\"", Relationship: \""combined with\""\\n2. Entity1: \""Lymph Node Dissection\"", Entity2: \""Surgical Intervention\"", Relationship: \""extent of\""\\n3. Entity1: \""Surgical Intervention\"", Entity2: \""Advanced Cases\"", Relationship: \""management option for\""\\n\\nCausalities:-\\n<CO> If concurrent therapies are not suitable </CO>, <A> the chart presents laryngectomy combined with thyroidectomy </A>, <CO> depending on the extent of lymph node dissection required </CO>. <E> This highlights surgical intervention as a viable option in the management of advanced cases </E>.\\n\\nSection Name: Induction Chemotherapy\\n====================\\nEntities:-\\nInduction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nTherapeutic Approach : A method or strategy used in the treatment of disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""Induction Chemotherapy\"", Entity2: \""Surgical Intervention\"", Relationship: \""alternative or sequential treatment option\""\\n\\nCausalities:-\\n<C> immediate surgical intervention is either not feasible or considered insufficient </C> <E> The flowchart also considers the option of induction chemotherapy </E> <CO> in cases where immediate surgical intervention is either not feasible or considered insufficient </CO>. <A> tailoring therapeutic approaches tailored to individual patient needs </A>.\\n\\nSection Name: Adjuvant Treatment\\n====================\\nEntities:-\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nNeoplasm Recurrence, Local : The return of a cancer, at the same site, after it has been treated.\\nDisease Progression : The worsening of a disease over time.\\n\\nRelationships:-\\n1. Entity1: \""Primary Treatment\"", Entity2: \""Adjuvant Treatment\"", Relationship: \""followed by\""\\n2. Entity1: \""Adjuvant Treatment\"", Entity2: \""Systemic Therapy\"", Relationship: \""includes\""\\n3. Entity1: \""Adjuvant Treatment\"", Entity2: \""Radiotherapy\"", Relationship: \""includes\""\\n4. Entity1: \""Follow-up Assessments\"", Entity2: \""Treatment Efficacy\"", Relationship: \""used to evaluate\""\\n\\nCausalities:-\\n<C> Following primary treatment </C>, <E> the flowchart addresses the potential for adjuvant treatment pathways </E>. This may include systemic therapy, RT, or further evaluations based on <CO> the patient\\'s response and any recurrence or persistent disease </CO>. It emphasizes <A> the need for follow-up assessments to evaluate treatment efficacy </A>.\\n\\nSection Name: Risk Features and Response Assessment\\n====================\\nEntities:-\\nNeoplasm Invasiveness : The property of a neoplasm to infiltrate and destroy surrounding tissue.\\nSurgical Margins : The edge or border of the tissue removed in cancer surgery.\\nNeoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.\\nExtramural Extension : Extension of a tumor beyond the wall of an organ.\\nPositive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.\\nCancer Management : The process of planning and coordinating the treatment of cancer.\\nCancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""Extramural extension\"", Entity2: \""Treatment decisions\"", Relationship: \""influences\""\\n2. Entity1: \""Positive surgical margin\"", Entity2: \""Treatment decisions\"", Relationship: \""influences\""\\n3. Entity1: \""Ongoing assessment\"", Entity2: \""Response evaluation\"", Relationship: \""leads to\""\\n4. Entity1: \""Response evaluation\"", Entity2: \""Adjustments to treatment\"", Relationship: \""leads to\""\\n5. Entity1: \""Management of cancer\"", Entity2: \""Treatment decisions\"", Relationship: \""involves\""\\n6. Entity1: \""Management of cancer\"", Entity2: \""Ongoing assessment\"", Relationship: \""involves\""\\n7. Entity1: \""Management of cancer\"", Entity2: \""Adjustments to treatment\"", Relationship: \""involves\""\\n\\nCausalities:-\\nThe chart incorporates a segment that takes into account <CO> adverse pathologic features, such as extramural extension or positive margins </CO>, <E> which could influence subsequent treatment decisions </E>. This highlights the importance of <A> ongoing assessment in the management of cancer, leading to response evaluation and adjustments to treatment as necessary </A>.\\n\\nSection Name: NCCN Guidelines Version 4.2024\\n====================\\nEntities:-\\nClinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.\\nNeoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.\\nClinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nMalignant Neoplasm : A malignant neoplasm is a cancerous growth that has the potential to invade and destroy nearby tissue and spread to other parts of the body.\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nCancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network\"", Entity2: \""NCCN Guidelines\"", Relationship: \""provides\""\\n2. Entity1: \""NCCN Guidelines\"", Entity2: \""Clinical Trials\"", Relationship: \""recommend\""\\n3. Entity1: \""NCCN Guidelines\"", Entity2: \""Cancer\"", Relationship: \""related to management of\""\\n\\nCausalities:-\\n<CO> any patient with cancer </CO> <A> the best management is in a clinical trial </A>. <A> Participation in clinical trials is especially encouraged </A>.\\n\\nSection Name: SUPRA-3\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.\\nChemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nClinical Trials As Topic : Research studies that prospectively assign human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nInduction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.\\nClinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\n\\nRelationships:-\\n1. Entity1: \""Total laryngectomy\"", Entity2: \""Laryngectomy\"", Relationship: \""is a type of\""\\n2. Entity1: \""Systemic therapy\"", Entity2: \""RT\"", Relationship: \""concurrent treatment option\""\\n3. Entity1: \""Induction chemotherapy\"", Entity2: \""Other treatments\"", Relationship: \""initial treatment option before\""\\n\\nCausalities:-\\n<CO> Requiring (amenable to) total laryngectomy (T3,N0) </CO>\\n  - <A> Concurrent systemic therapy/RT </A> or <A> RT if patient not medical candidate for concurrent systemic therapy/RT </A>\\n  - <A> Laryngectomy, thyroidectomy and with ipsilateral, central, or bilateral neck dissection </A>\\n  - or\\n  - <A> Induction chemotherapy </A>\\n  - or\\n  - <A> Clinical trials </A>\\n\\nSection Name: Follow-up\\n====================\\nEntities:-\\nFollow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.\\nFollow-Up Procedure : A procedure performed to monitor the progress of a patient\\'s condition after initial treatment.\\nFollow-Up : Medical care given to a patient over time after initial treatment.\\nDisease Recurrence : The return of a sign, symptom, or disease after a remission.\\nRecurrent Disease : The reappearance of a disease after a period of improvement.\\n\\nRelationships:-\\n1. Entity1: \""Follow-up\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""monitoring\""\\n\\nCausalities:-\\n- **Follow-up (FOLL-A, 1 of 2)**\\n  - <CO> Recurrent or persistent disease </CO> (ADV-3)\\n\\nSection Name: Adverse Pathologic Features\\n====================\\nEntities:-\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nExtranodal Extension : The spread of cancer beyond the lymph node capsule.\\nPositive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""pN1\"", Entity2: \""Radiotherapy\"", Relationship: \""Consideration for treatment\""\\n2. Entity1: \""Extranodal extension\"", Entity2: \""Systemic Therapy\"", Relationship: \""Treatment option\""\\n3. Entity1: \""Extranodal extension\"", Entity2: \""Radiotherapy\"", Relationship: \""Treatment option\""\\n4. Entity1: \""Positive surgical margin\"", Entity2: \""Systemic Therapy\"", Relationship: \""Treatment option\""\\n5. Entity1: \""Positive surgical margin\"", Entity2: \""Radiotherapy\"", Relationship: \""Treatment option\""\\n\\nCausalities:-\\n- <CO>pN1 without other risk features</CO>\\n  - <C>Adverse pathologic features</C>\\n  - <A>Consider RT</A>\\n  - <CO>Extranodal extension and/or positive margin</CO>\\n  - <CO>Other risk features</CO>\\n  - <A>Systemic therapy/RT (category 1)</A>\\n  - <A>RT or Consider systemic therapy/RT</A>\\n\\nSection Name: Response Assessment\\n====================\\nEntities:-\\nResponse Evaluation : The process of assessing the response of a disease to treatment, often used in clinical trials to determine the effectiveness of a therapy.\\nResponse To Treatment : A clinical finding indicating the response of a condition to a therapeutic intervention.\\n\\nRelationships:-\\n\\nSection Name: Principles of Surgery and Radiation Therapy\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nRadiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\n\\nRelationships:-\\n1. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Radiation Therapy\"", Relationship: \""complementary treatments\""\\n\\nCausalities:-\\n**Principles of Surgery (SURG-A).**\\n\\n**Principles of Radiation Therapy (SUPRA-A).**\\n\\nSection Name: Principles of Systemic Therapy\\n====================\\nEntities:-\\nCisplatin : An inorganic and water-soluble platinum complex, cisplatin is an antineoplastic agent that is used in the treatment of various cancers.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nRadiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\n\\nRelationships:-\\n1. Entity1: \""Cisplatin\"", Entity2: \""Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""preferred agent\""\\n2. Entity1: \""Cisplatin\"", Entity2: \""Concurrent Systemic Therapy/RT\"", Relationship: \""used in\""\\n\\nCausalities:-\\n<CO> When using concurrent systemic therapy/RT </CO>, <A> the preferred agent is cisplatin (category 1) </A>.\\n--------------------------------------------------\\nPage Number: 130\\n\\nSection Name: Pathological N (pN)\\n====================\\nEntities:-\\nLymph Nodes : Small, bean-shaped structures that are part of the body\\'s lymphatic system. They filter lymph fluid and store white blood cells that help fight infection.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nTnm Staging : A system used to describe the size and spread of cancer in a standardized way. T refers to the size of the tumor, N to the involvement of lymph nodes, and M to metastasis.\\nLymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\nTnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient\\'s body.\\nLymph Node : An organ of the lymphatic system and the adaptive immune system.\\n\\nRelationships:-\\n1. Entity1: \""Lymph Nodes\"", Entity2: \""Neoplasm Metastasis\"", Relationship: \""involved in\""\\n2. Entity1: \""TNM Staging\"", Entity2: \""Lymph Nodes\"", Relationship: \""includes\""\\n3. Entity1: \""TNM Staging\"", Entity2: \""Neoplasm Metastasis\"", Relationship: \""describes\""\\n\\nCausalities:-\\n<CO> NX: Regional lymph nodes cannot be assessed </CO>\\n<CO> N0: No regional lymph node metastasis </CO>\\n<CO> N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(\u2013) </CO>\\n<CO> N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2212); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(\u2212); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2a: Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N3: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(\u2212); or metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>\\n<CO> N3a: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N3b: Metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>\\n<CO> Note: A designation of \u201cU\u201d or \u201cL\u201d may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L). Similarly, clinical and pathological ENE should be recorded as ENE(\u2212) or ENE(+). </CO>\\n\\nSection Name: Distant Metastasis (M)\\n====================\\nEntities:-\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\n\\nRelationships:-\\n1. Entity1: \""M0\"", Entity2: \""Distant Metastasis\"", Relationship: \""is a category of\""\\n2. Entity1: \""M1\"", Entity2: \""Distant Metastasis\"", Relationship: \""is a category of\""\\n\\nCausalities:-\\n### Distant Metastasis (M)\\n\\n- **M0**: No distant metastasis\\n- **M1**: Distant metastasis\\n\\nSection Name: Histologic Grade (G)\\n====================\\nEntities:-\\nNeoplasm Grading : A system of classifying cancer cells in terms of how abnormal they look under a microscope and how quickly the tumor is likely to grow and spread.\\nHistologic Grade : A measure of how much tumor cells differ from healthy cells, used to assess the aggressiveness of cancer.\\n\\nRelationships:-\\n1. Entity1: \""GX\"", Entity2: \""Grade cannot be assessed\"", Relationship: \""is described as\""\\n2. Entity1: \""G1\"", Entity2: \""Well differentiated\"", Relationship: \""is described as\""\\n3. Entity1: \""G2\"", Entity2: \""Moderately differentiated\"", Relationship: \""is described as\""\\n4. Entity1: \""G3\"", Entity2: \""Poorly differentiated\"", Relationship: \""is described as\""\\n\\nCausalities:-\\n<CO>GX</CO>: <E>Grade cannot be assessed</E>\\n<CO>G1</CO>: <E>Well differentiated</E>\\n<CO>G2</CO>: <E>Moderately differentiated</E>\\n<CO>G3</CO>: <E>Poorly differentiated</E>\\n\\nSection Name: Prognostic Stage Groups\\n====================\\nEntities:-\\nNeoplasm Staging : Methods and systems of classifying neoplasms according to extent of disease.\\nTumor Staging : A system for describing the size and spread of cancer within the body.\\nTnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient\\'s body.\\n\\nRelationships:-\\n1. Entity1: \""Stage 0\"", Entity2: \""Tis N0 M0\"", Relationship: \""defined by\""\\n2. Entity1: \""Stage I\"", Entity2: \""T1 N0 M0\"", Relationship: \""defined by\""\\n3. Entity1: \""Stage II\"", Entity2: \""T2 N0 M0\"", Relationship: \""defined by\""\\n4. Entity1: \""Stage III\"", Entity2: \""T3 N0 M0, T1 N1 M0, T2 N1 M0, T3 N1 M0\"", Relationship: \""defined by\""\\n5. Entity1: \""Stage IVA\"", Entity2: \""T1 N2 M0, T2 N2 M0, T3 N2 M0, T4a N0,N1,N2 M0\"", Relationship: \""defined by\""\\n6. Entity1: \""Stage IVB\"", Entity2: \""Any T N3 M0, T4b Any N M0\"", Relationship: \""defined by\""\\n7. Entity1: \""Stage IVC\"", Entity2: \""Any T Any N M1\"", Relationship: \""defined by\""\\n--------------------------------------------------\\nPage Number: 47\\n\\nSection Name: Overview of Radiation Therapy Guidelines\\n====================\\nEntities:-\\nRadiation Therapy : The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\nMalignant Neoplasm : A disease characterized by uncontrolled, abnormal growth of cells that can invade and destroy nearby tissue and spread to other parts of the body.\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.\\nGlottic Larynx Cancer : A malignant neoplasm located in the glottic region of the larynx.\\nLaryngeal Cancer : Cancer that occurs in the larynx, or voice box, which may include the glottic region.\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\n\\nRelationships:-\\n1. Entity1: \""Radiation Therapy\"", Entity2: \""Cancer\"", Relationship: \""treats\""\\n2. Entity1: \""NCCN Guidelines\"", Entity2: \""Cancer\"", Relationship: \""guides treatment for\""\\n3. Entity1: \""NCCN Guidelines\"", Entity2: \""Radiation Therapy\"", Relationship: \""specifies use of\""\\n\\nCausalities:-\\nThe image presents a detailed flowchart outlining the principles of radiation therapy specifically for the <C> treatment of cancer in the glottic larynx </C>, <CO> as per the National Comprehensive Cancer Network (NCCN) guidelines (version 2.2024) </CO>. <E> This structured guidance delineates various treatment protocols </E>, <A> stratified by risk levels and therapeutic approaches </A>.\\n\\nSection Name: Principles of Radiation Therapy\\n====================\\nEntities:-\\nRadiation Therapy : The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nGy : Gray, a unit of ionizing radiation dose in the International System of Units (SI), defined as the absorption of one joule of radiation energy per kilogram of matter.\\nGray (Unit) : A unit of absorbed radiation dose of ionizing radiation, defined as the absorption of one joule of radiation energy per kilogram of matter.\\n\\nRelationships:-\\n1. Entity1: \""Tis, N0\"", Entity2: \""60.75 Gy (2.25 Gy/fraction) to 66 Gy (2.0 Gy/fraction)\"", Relationship: \""treatment protocol\""\\n2. Entity1: \""T1, N0\"", Entity2: \""63 Gy (2.25 Gy/fraction) to 66 Gy (2.0 Gy/fraction) or 50 Gy (3.12 Gy/fraction) to 52 Gy (3.28 Gy/fraction)\"", Relationship: \""treatment protocol\""\\n3. Entity1: \""T2, N0\"", Entity2: \""65.25 Gy (2.25 Gy/fraction) to 70 Gy (2.0 Gy/fraction)\"", Relationship: \""treatment protocol\""\\n4. Entity1: \""\u2265T2, N1 (PTV High risk)\"", Entity2: \""66 Gy (2.2 Gy/fraction) to 70 Gy (2.0 Gy/fraction)\"", Relationship: \""treatment protocol\""\\n5. Entity1: \""\u2265T2, N1 (Low to intermediate risk)\"", Entity2: \""44\u201350 Gy (2.0 Gy/fraction) to 54\u201363 Gy (1.6\u20131.8 Gy/fraction)\"", Relationship: \""treatment protocol\""\\n\\nCausalities:-\\n<CO>Tis, N0</CO>: <A>60.75 Gy (2.25 Gy/fraction) to 66 Gy (2.0 Gy/fraction)</A>\\n<CO>T1, N0</CO>: <A>63 Gy (2.25 Gy/fraction, preferred) to 66 Gy (2.0 Gy/fraction) or 50 Gy (3.12 Gy/fraction) to 52 Gy (3.28 Gy/fraction)</A>\\n<CO>T2, N0</CO>: <A>65.25 (2.25 Gy/fraction) to 70 Gy (2.0 Gy/fraction)</A>\\n<CO>\u2265T2, N1</CO>: <A>PTV High risk: Primary tumor and involved lymph nodes (includes possible local subclinical infiltration at the primary site and at the high-risk level lymph node(s))</A>\\n<A>Fractionation: 66 Gy (2.2 Gy/fraction) to 70 Gy (2.0 Gy/fraction); daily Monday\u2013Friday in 6\u20137 weeks</A>\\n<A>Concomitant boost accelerated RT: 72 Gy/6 weeks (1.8 Gy/fraction, large field; 1.5 Gy boost as second daily fraction during last 12 treatment days)</A>\\n<A>66\u201370 Gy (2.0 Gy/fraction; 6 fractions/wk accelerated)</A>\\n<A>Hyperfractionation: 79.2\u201381.6 Gy/7 weeks (1.2 Gy/fraction, twice daily)</A>\\n<CO>Low to intermediate risk</CO>: <A>Sites of suspected subclinical spread</A>\\n<A>44\u201350 Gy (2.0 Gy/fraction) to 54\u201363 Gy (1.6\u20131.8 Gy/fraction)</A>\\n\\nSection Name: Concurrent Systemic Therapy/RT\\n====================\\nEntities:-\\nCisplatin : A platinum-containing antineoplastic agent used in the treatment of various cancers.\\nCarboplatin : An organoplatinum compound that possesses antineoplastic activity.\\nFluorouracil : A chemotherapy drug used to treat various types of cancer.\\n\\nRelationships:-\\n1. Entity1: \""concurrent systemic therapy/RT\"", Entity2: \""cisplatin\"", Relationship: \""uses\""\\n2. Entity1: \""concurrent systemic therapy/RT\"", Entity2: \""carboplatin and 5-FU\"", Relationship: \""uses\""\\n3. Entity1: \""multiagent chemotherapy\"", Entity2: \""toxicity burden\"", Relationship: \""increases\""\\n\\nCausalities:-\\n<CO>Based on published data</CO>, <A>concurrent systemic therapy/RT most commonly uses conventional fractionation at 2.0 Gy per fraction to a typical dose of 70 Gy in 7 weeks with single-agent cisplatin given every 3 weeks at 100 mg/m\u00b2</A>; <CO>2\u20133 cycles of chemotherapy are used depending on the radiation fractionation scheme (RTOG 0129)</CO>. <CO>When carboplatin and 5-FU are used</CO>, <A>the recommended regimen is standard fractionation plus 3 cycles of chemotherapy</A>. <CO>Other fraction sizes (e.g., 1.8 Gy, conventional), multiagent chemotherapy, other dosing schedules of cisplatin, or altered fractionation with chemotherapy</CO> <E>are efficacious</E>, and <C>there is no consensus on the optimal approach</C>. <C>In general, the use of concurrent systemic therapy/RT</C> <E>carries a high toxicity burden</E>; <C>multiagent chemotherapy</C> <E>will likely further increase the toxicity burden</E>. <A>For any systemic therapy/RT approach, close attention should be paid to published reports for the specific chemotherapy agent, dose, and schedule of administration</A>. <A>Systemic therapy/RT should be performed by an experienced team and should include substantial supportive care</A>.\\n\\nSection Name: Treatment Modalities\\n====================\\nEntities:-\\nIntensity-Modulated Radiotherapy : A type of conformal radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.\\nIntensity Modulated Radiation Therapy : A type of conformal radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.\\nIntensity-Modulated Radiation Therapy : An advanced type of high-precision radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.\\nRadiotherapy, Conformal : A type of radiotherapy that uses imaging to conform the radiation dose to the shape of the tumor.\\n3D Conformal Radiation Therapy : A technique in radiotherapy that uses imaging to conform the radiation dose to the shape of the tumor.\\nChemotherapy, Adjuvant : Treatment with drugs that kill cancer cells, often used in conjunction with other therapies.\\nChemotherapy : The treatment of disease by the use of chemical substances, especially the treatment of cancer by cytotoxic and other drugs.\\nDrug Therapy, Combination : The use of two or more drugs to achieve a therapeutic effect.\\nSystemic Therapy : A type of therapy that uses substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Intensity-Modulated Radiation Therapy (IMRT)\"", Entity2: \""3D Conformal Radiation Therapy (3D-CRT)\"", Relationship: \""are delivery methods for radiation therapy\""\\n2. Entity1: \""Chemotherapy\"", Entity2: \""Radiation Therapy\"", Relationship: \""is integrated with for aggressive or advanced cancer cases\""\\n\\nCausalities:-\\n<CO> contingent upon patient-specific considerations </CO> <A> suggests either Intensity-Modulated Radiation Therapy (IMRT) or 3D Conformal Radiation Therapy (3D-CRT) as delivery methods </A>. <A> These advanced techniques are employed to optimize treatment accuracy </A>, <E> preserving surrounding healthy tissue and improving overall patient outcomes </E>. <A> a focus on concurrent systemic therapies underlines the importance of integrating chemotherapy </A>, particularly <CO> for patients with more aggressive forms of cancer or those demonstrating advanced disease characteristics </CO>.\\n\\nSection Name: Additional Information\\n====================\\nEntities:-\\nClinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.\\nClinical Trial : A clinical trial is a research study in which one or more human subjects are prospectively assigned to one or more interventions to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes.\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nIntensity-Modulated Radiation Therapy : An advanced type of high-precision radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.\\nIntensity Modulated Radiation Therapy : A type of conformal radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.\\nThree-Dimensional Conformal Radiation Therapy : A type of external beam radiation therapy that uses a computer to create a 3-dimensional picture of the tumor so that multiple radiation beams can be shaped exactly to the contour of the treatment area.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network\"", Entity2: \""Clinical trial\"", Relationship: \""encourages participation in\""\\n2. Entity1: \""Intensity-Modulated Radiation Therapy\"", Entity2: \""Three-Dimensional Conformal Radiation Therapy\"", Relationship: \""recommended alternatives\""\\n\\nCausalities:-\\n<A> Participation in clinical trials </A> is especially encouraged. <A> Either IMRT (preferred) or 3D-CRT is recommended. </A>\\n\\nSection Name: Conclusion\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.\\nMalignant Neoplasm Of Glottis : A malignant tumor located in the glottic region of the larynx.\\nLaryngeal Cancer : Cancer that occurs in the larynx, or voice box, which may include the glottic region.\\nPrognosis : A medical term for predicting the likely or expected development of a disease.\\nEvidence-Based Practice : Healthcare practices that are based on scientific evidence and research.\\nEvidence-Based Medicine : An approach to medical practice intended to optimize decision-making by emphasizing the use of evidence from well-designed and conducted research.\\n\\nRelationships:-\\n1. Entity1: \""treatment paradigms\"", Entity2: \""glottic larynx cancer\"", Relationship: \""encapsulates\""\\n2. Entity1: \""personalized treatment plans\"", Entity2: \""prognosis\"", Relationship: \""improves\""\\n\\nCausalities:-\\n<C> glottic larynx cancer </C>. <CO> the nuances of each patient\\'s condition </CO>. <A> personalized treatment plans </A> <E> promoting effective management and improved prognosis </E>. <A> deliver clear, evidence-based interventions </A> <CO> considering the complexities involved in cancer treatment </CO>.\\n'}""",valid,increases risk,2,B,"edge - The edge which needs to be verified.
explanation - Explanation of what the edge represents and its validity.
causal_direction - Either Positive or Negative or Unknown. A positive influence direction indicates that both factors change in the same direction (e.g. an increase causes an increase effect). A negative influence direction indicates the opposite changes (e.g. an increase causes a decrease effect).
causal_factor - Is necessary or sufficient condition for an effect to occur. Exposure is a term commonly used in epidemiology to denote any condition that is considered as a possible cause of disease. Exposure is considered necessary when it always precedes the effects (e.g. symptoms) and always presents when the effects occur. A sufficient cause is a causal factor whose presence or occurrence guarantees the occurrence of symptom.
causal_distance - Either Distal or Proximal or Unknown. The distal factors lie towards the beginning of causal chain (i.e. indirect causal factors). The the proximal factors lie towards the end of the chain (i.e. cause directly or almost directly the effect).

Causality Tags:
<A> for action, <C> for cause, <CO> for condition and <E> for effect.
Cause (C): The reason or origin that leads to an effect. Causes often involve disease conditions, risk factors, or underlying mechanisms.
Effect (E): The outcome or result of a cause. Effects usually represent clinical outcomes, complications, or results of a specific cause.
Condition (CO): The circumstance or prerequisite required for an action or effect to occur. Conditions may include patient characteristics, clinical scenarios, or specific diagnostic criteria.
Action (A): The recommended or described response or activity to address a cause or condition. Actions typically involve clinical interventions, diagnostic procedures, or treatment recommendations.


`NODE1`:
id: N_State_1__patient
label: State of Nearby Lymph Nodes with Cancer in Patient
description: This node represents the state of involvement of nearby lymph nodes in a patient with cancer. It is a decision node used to predict the extent of lymph node metastasis, which is crucial for cancer staging and treatment planning. The states range from no involvement (n0) to extensive involvement (n3), with intermediate states indicating varying degrees of lymph node cancer presence.
type: Decision Node
observability: Needs to be Predicted
states: [{'state_name': 'nx', 'state_description': 'The regional lymph nodes cannot be assessed.'}, {'state_name': 'n3', 'state_description': 'Metastasis in lymph node(s) along the course of a major blood vessel or in a lymph node that is more than 6 cm in greatest dimension.'}, {'state_name': 'n2c', 'state_description': 'Metastasis in bilateral or contralateral lymph nodes, each 6 cm or less in greatest dimension.'}, {'state_name': 'n2b', 'state_description': 'Metastasis in multiple ipsilateral lymph nodes, each 6 cm or less in greatest dimension.'}, {'state_name': 'n2a', 'state_description': 'Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension.'}, {'state_name': 'n2', 'state_description': 'Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension, or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension.'}, {'state_name': 'n1', 'state_description': 'Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension.'}, {'state_name': 'n0', 'state_description': 'No regional lymph node metastasis.'}]

`NODE2`:
id: Number_of_Involved_Lymph_Nodes_3
label: Number of Involved Lymph Nodes
description: This node represents the number of lymph nodes that are involved with cancer in a patient's situation. It is a critical factor in determining the stage and prognosis of cancer, as the involvement of lymph nodes often indicates the spread of cancer beyond the primary site.
type: Patient Situation
observability: Unobserved
states: [{'state_name': 'zero_involved_lymph_nodes', 'state_description': 'No lymph nodes are involved with cancer, indicating that the cancer has not spread to nearby lymph nodes.'}, {'state_name': 'one_three_involved_lymph_nodes', 'state_description': 'Between one and three lymph nodes are involved with cancer, suggesting limited regional spread of the disease.'}, {'state_name': 'four_or_more_involved_lymph_nodes', 'state_description': 'Four or more lymph nodes are involved with cancer, indicating a more extensive spread of the disease and potentially a more advanced stage.'}]

`EDGE1`:
{'edges_ids': ['N_State_1__patient', 'Number_of_Involved_Lymph_Nodes_3'], 'edge': '(N_State_1__patient) causes (Number_of_Involved_Lymph_Nodes_3)', 'explanation': ['The edge represents the causal relationship where the state of lymph node involvement in a patient (N_State_1__patient) influences the number of lymph nodes involved with cancer (Number_of_Involved_Lymph_Nodes_3).', 'In cancer staging, the state of lymph node involvement is used to predict the extent of lymph node metastasis, which directly relates to the number of involved lymph nodes.', 'A higher state of lymph node involvement (e.g., n3) would typically correspond to a higher number of involved lymph nodes, indicating a positive causal direction.', 'The state of lymph node involvement is a sufficient condition for predicting the number of involved lymph nodes, as it is a key factor in cancer staging.', 'The causal distance is proximal because the state of lymph node involvement directly affects the number of involved lymph nodes.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': True}, 'causal_distance': 'Proximal'}

`EDGE2`:
{'edges_ids': ['Number_of_Involved_Lymph_Nodes_3', 'N_State_1__patient'], 'edge': '(Number_of_Involved_Lymph_Nodes_3) causes (N_State_1__patient)', 'explanation': ['The `Number_of_Involved_Lymph_Nodes_3` node represents the number of lymph nodes involved with cancer, which is a critical factor in determining the stage and prognosis of cancer.', 'The `N_State_1__patient` node represents the state of involvement of nearby lymph nodes in a patient with cancer, which is crucial for cancer staging and treatment planning.', 'The number of involved lymph nodes directly influences the N state, as more involved lymph nodes typically correspond to a higher N state.', 'Therefore, the edge `(Number_of_Involved_Lymph_Nodes_3) causes (N_State_1__patient)` is valid.', 'The causal direction is positive because an increase in the number of involved lymph nodes leads to a higher N state.', 'The number of involved lymph nodes is a necessary factor for determining the N state, as the N state is defined based on lymph node involvement.', 'The causal distance is proximal because the number of involved lymph nodes directly affects the N state without intermediate steps.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': True, 'sufficient': False}, 'causal_distance': 'Proximal'}

`INFORMATION FROM KNOWLEDGE BASE`:
--------------------------------------------------
Page Number: 102

Section Name: Head and Neck Cancers - Principles of Surgery
====================
Entities:-
Surgical Procedures, Operative : Manual or operative procedures used in the treatment of disease, injuries, or deformities.
Lymphatic System : Part of the circulatory system and a vital part of the immune system, comprising a network of lymphatic vessels that carry a clear fluid called lymph.
Neoplasms : New abnormal growth of tissue in animals or plants; a tumor.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Neoplasm Staging : Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Metastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.
Surgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Lymphatic Structure : Anatomical structure that is part of the lymphatic system.
Tumor : An abnormal mass of tissue that results when cells divide more than they should or do not die when they should.
Staging : The process of determining the size and spread of cancer within the body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Cancer Staging : The process of determining the extent to which a cancer has developed by growing and spreading.

Relationships:-
1. Entity1: ""surgical management"", Entity2: ""regional lymphatics"", Relationship: ""dictated by tumor staging""
2. Entity1: ""neck dissections"", Entity2: ""primary tumor"", Relationship: ""part of treatment""
3. Entity1: ""surgery"", Entity2: ""ipsilateral side of the neck"", Relationship: ""risk for metastases""

Causalities:-
<C> The extent of the tumor at initial tumor staging </C> <E> dictates the surgical management of regional lymphatics </E>. These guidelines apply to the performance of neck dissections as part of treatment of the primary tumor. <CO> Patients undergoing surgery for resection of the primary tumor </CO> <A> will undergo dissection of the ipsilateral side of the neck that is at greatest risk for metastases </A>.

Section Name: Neck Management
====================
Entities:-
Tongue : A muscular organ in the mouth that is involved in tasting, swallowing, and speech.
Palate : The roof of the mouth, separating the oral and nasal cavities.
Larynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.
Hypopharynx : The bottom part of the pharynx, which is the cavity behind the nose and mouth.
Nasopharynx : The upper part of the pharynx, connecting with the nasal cavity above the soft palate.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Metastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.
Squamous Cell Carcinoma : A type of cancer that begins in the squamous cells, which are thin, flat cells that look like fish scales.
Biopsy : The removal of cells or tissues for examination under a microscope.

Relationships:-
1. Entity1: ""Tumor sites"", Entity2: ""Bilateral lymphatic drainage"", Relationship: ""associated with""
2. Entity1: ""Elective neck dissection"", Entity2: ""Risk of occult metastasis"", Relationship: ""based on""
3. Entity1: ""SLN biopsy"", Entity2: ""Elective neck dissection"", Relationship: ""guides decision-making for""

Causalities:-
- **<C> Tumor sites that frequently have bilateral lymphatic drainage </C>** (e.g., base of tongue, palate, supraglottic larynx, hypopharynx, nasopharynx, deep pre-epiglottic space involvement) <E> often should have both sides of the neck dissected </E> with the extent of dissection determined as suggested below. For those patients with tumors at or approaching the midline, <CO> both sides of the neck are at risk for metastases </CO>, and <A> bilateral neck dissections should be performed </A>.

- <CO> Patients with advanced lesions involving the anterior tongue, floor of the mouth, or alveolus that approximate or cross the midline </CO> <A> should undergo contralateral selective/modified neck dissection </A> as necessary to achieve adequate tumor resection.

- **<C> Elective neck dissection </C>** <A> should be based on risk of occult metastasis in the appropriate nodal basin </A>. For oral cavity squamous cell carcinoma, <C> SLN biopsy or the primary tumor depth of invasion </C> is currently <E> the best predictor of occult metastatic disease </E> and <A> should be used to guide decision-making </A>. <CO> For tumors with a depth greater than 3 mm </CO>, <A> elective dissection should be strongly considered if RT is not already planned </A>. Recent randomized trial evidence supports the effectiveness of elective neck dissection in patients with oral cavity cancers greater than 3 mm in depth of invasion.

  - <CO> For a depth less than 2 mm </CO>, <A> elective dissection is only indicated in highly selective situations </A>. <CO> For a depth of 2–4 mm </CO>, <A> clinical judgment (as to reliability of follow-up, clinical suspicion, and other factors) must be utilized to determine appropriateness of elective dissection </A>. Elective dissections are generally selective, preserving all major structures, unless operative findings dictate otherwise.

Section Name: Types of Neck Dissection
====================
Entities:-
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Larynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.

Relationships:-
1. Entity1: ""N0"", Entity2: ""Selective neck dissection"", Relationship: ""associated with""
2. Entity1: ""N3"", Entity2: ""Comprehensive neck dissection"", Relationship: ""associated with""
3. Entity1: ""Level VI neck dissection"", Entity2: ""Larynx"", Relationship: ""performed for""
4. Entity1: ""Level VI neck dissection"", Entity2: ""Hypopharynx"", Relationship: ""performed for""

Causalities:-
- **The type of neck dissection (comprehensive or selective)** is defined according to <CO> preoperative clinical staging </CO>, is determined at the discretion of the surgeon, and is based on the initial preoperative staging as follows:
  - **N0:** <A> Selective neck dissection </A>
    - Oral cavity at least levels I–III
    - Oropharynx at least levels II–IV
    - Hypopharynx at least levels II–IV and level VI when appropriate
    - Larynx at least levels II–IV and level VI when appropriate
  - **N1–N2a–c:** <A> Selective or comprehensive neck dissection </A> (Discussion)
  - **N3:** <A> Comprehensive neck dissection </A>

- <C> Level VI neck dissections are performed for certain primary sites (such as the larynx and hypopharynx) </C> <E> as required to resect the primary tumor and any clinically evident neck nodes </E>. <CO> Elective dissection depends on primary tumor extent and site </CO>. <CO> For advanced glottic and hypopharyngeal cancers treated with primary surgery </CO>, <A> a level VI dissection (including pretracheal lymph nodes, the Delphian lymph node, and unilateral or bilateral paratracheal lymph nodes) and hemithyroidectomy to total thyroidectomy are appropriate </A>.

- <CO> For primary subglottic tumors or glottic cancers with significant subglottic extension </CO>, <A> a level VI dissection with unilateral or total thyroidectomy is considered appropriate </A> based on the extent of the primary tumor. <CO> For example, a T4a glottic tumor with extension through the cricothyroid membrane and subglottic extension </CO> <A> should include thyroidectomy and pretracheal and bilateral paratracheal lymph node dissection </A>. <A> Parathyroid glands should be preserved in situ or auto transplanted as indicated </A>.
--------------------------------------------------
Page Number: 55

Section Name: General Information
====================
Entities:-
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Nccn Guidelines : Clinical practice guidelines in oncology developed by the National Comprehensive Cancer Network.

Relationships:-
1. Entity1: ""NCCN Guidelines"", Entity2: ""National Comprehensive Cancer Network"", Relationship: ""produced by""

Section Name: Important Notes
====================
Entities:-
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medical, surgical, or behavioral interventions.
Clinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Neoplasms : New abnormal growth of tissue that can be benign or malignant.
Malignant Neoplastic Disease : A disease resulting from the growth of malignant neoplasms.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""Clinical Trials"", Entity2: ""Cancer"", Relationship: ""recommended for""
2. Entity1: ""NCCN"", Entity2: ""Clinical Trials"", Relationship: ""encourages participation in""

Causalities:-
<C> NCCN believes that the best management of any patient with cancer is in a clinical trial </C>. <A> Participation in clinical trials is especially encouraged </A>.

Section Name: Principles
====================
Entities:-
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Chemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.

Relationships:-
1. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Radiation Therapy"", Relationship: ""Both are principles of cancer treatment methods.""
2. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""Both are principles of cancer treatment methods.""
3. Entity1: ""Principles of Radiation Therapy"", Entity2: ""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""Both are principles of cancer treatment methods.""

Causalities:-
### Principles

- **Principles of Surgery (SURG-A)**
- **Principles of Radiation Therapy (SUPRA-A)**
- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**

Section Name: Adverse Pathologic Features
====================
Entities:-
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.
Perineural Invasion : The presence of cancer cells surrounding or tracking along a nerve within the perineural space.
Vascular Invasion : The invasion of cancer cells into blood vessels.
Lymphatic Invasion : The invasion of cancer cells into lymphatic vessels.

Relationships:-
1. Entity1: ""Extranodal extension"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
2. Entity1: ""Positive margins"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
3. Entity1: ""Close margins"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
4. Entity1: ""pT3 or pT4 primary"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
5. Entity1: ""pN2 or pN3 nodal disease"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
6. Entity1: ""Perineural invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
7. Entity1: ""Vascular invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
8. Entity1: ""Lymphatic invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""

Causalities:-
<C> Extranodal extension </C>
<C> Positive margins </C>
<C> Close margins </C>
<C> pT3 or pT4 primary </C>
<C> pN2 or pN3 nodal disease </C>
<C> Perineural invasion </C>
<C> Vascular invasion </C>
<C> Lymphatic invasion </C>

Section Name: Response Assessment
====================
Entities:-
Chemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Primary Site : The original location where a tumor or cancer begins.
Complete Remission : The disappearance of all signs of cancer in response to treatment.
Partial Remission : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
Radiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.

Relationships:-
1. Entity1: ""induction chemotherapy"", Entity2: ""Primary site"", Relationship: ""treatment outcome""
2. Entity1: ""Definitive RT"", Entity2: ""Primary site"", Relationship: ""treatment option""
3. Entity1: ""RT"", Entity2: ""Primary site"", Relationship: ""treatment option""
4. Entity1: ""Surgery"", Entity2: ""unresectable nodal disease"", Relationship: ""treatment option""

Causalities:-
<C> Response after induction chemotherapy </C>: <E> Primary site: CR </E> <E> Primary site: PR </E> <E> Primary site: < PR </E> <A> Definitive RT </A> (category 1) <A> RT </A> (category 1) or <A> systemic therapy/RT </A> (category 2B) <A> Surgery </A> or <A> unresectable nodal disease </A>

Section Name: Follow-up
====================
Entities:-
Follow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.
Follow-Up Procedure : A procedure where a patient is monitored over time to assess the progress of a condition or the effects of treatment.
Follow-Up (Medicine) : The process of monitoring a patient's health over time after treatment or diagnosis.
Disease Recurrence : The return of a sign, symptom, or disease after a remission.
Recurrent Disease : A disease that returns after a period of remission.
Recurrence (Medicine) : The return of a disease or condition after a period of improvement.

Relationships:-
1. Entity1: ""Follow-up"", Entity2: ""Recurrent or persistent disease"", Relationship: ""monitoring""

Causalities:-
### Follow-up

- **Follow-up** (FOLL-A, 1 of 2)
- **Recurrent or persistent disease** (ADV-3)

Section Name: Risk Features
====================
Entities:-
Radiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Adverse pathologic features"", Entity2: ""RT"", Relationship: ""Consideration for treatment""
2. Entity1: ""Adverse pathologic features"", Entity2: ""Systemic therapy"", Relationship: ""Consideration for treatment""

Causalities:-
- **No adverse pathologic features**
- **Other risk features**
- **Adverse pathologic features**:
  - <C> Extranodal extension and/or positive margin </C>
  - <A> RT or consider systemic therapy/RT </A>

Section Name: Post-Therapy Evaluation
====================
Entities:-
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Neck : The neck is the part of the body that separates the head from the torso and provides the mobility and movements of the head.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Neck Evaluation"", Relationship: ""evaluated in""
2. Entity1: ""RT"", Entity2: ""Neck Evaluation"", Relationship: ""evaluated in""

Causalities:-
<CO> Post Systemic Therapy/RT or RT Neck </CO> <A> Evaluation </A>

Section Name: Flowchart Overview
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Supraglottic Larynx : The part of the larynx located above the vocal cords, including the epiglottis and aryepiglottic folds.
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.

Relationships:-
1. Entity1: ""NCCN Guidelines"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""guides management of""
2. Entity1: ""NCCN Guidelines"", Entity2: ""healthcare professionals"", Relationship: ""used by""

Causalities:-
<C> cancer of the supraglottic larynx </C> <E> evaluate patient responses following treatment </E> <CO> based on observed outcomes </CO> <A> evaluation of the primary site and determining subsequent steps </A>.

Section Name: Assessment and Treatment Decisions
====================
Entities:-
Induction Chemotherapy : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Complete Response : The disappearance of all signs of cancer in response to treatment.
Partial Response : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Complete Response"", Entity2: ""Radiation Therapy"", Relationship: ""leads to""
2. Entity1: ""Complete Response"", Entity2: ""Surgery"", Relationship: ""leads to""
3. Entity1: ""Partial Response"", Entity2: ""Systemic Therapy"", Relationship: ""leads to""
4. Entity1: ""Partial Response"", Entity2: ""Radiation Therapy"", Relationship: ""leads to""

Causalities:-
<C> responses to initial treatments such as induction chemotherapy </C> <E> Three main response categories are recognized: Complete Response (CR), Partial Response (PR), and less than Partial Response (< PR) </E>. These categories are pivotal in determining the next steps. <C> CR </C> <E> indicates full resolution of the disease at the primary site </E>, <A> leading to the consideration of definitive radiation therapy or the likelihood of surgery </A>. Conversely, <C> PR </C> <E> suggests that the disease has improved but not completely resolved </E>, <A> which directs the pathway towards either systemic therapy or continued radiation therapy </A>, <A> with further evaluation necessary </A>.

Section Name: Adverse Pathologic Features and Follow-up
====================
Entities:-
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Neoplasm Recurrence, Local : The return of a tumor or cancer, at the original site, after it has been treated.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Recurrent Neoplasm : A neoplasm that has returned after treatment.
Metastatic Neoplasm : A neoplasm that has spread from its original site to one or more other places in the body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Cancer Recurrence : The return of cancer after treatment and after a period of time during which the cancer was undetectable.
Metastasis : Spread of a cancer or other disease from one organ or part to another not directly connected with it.

Relationships:-
1. Entity1: ""Adverse pathologic features"", Entity2: ""Treatment decisions"", Relationship: ""Influence""
2. Entity1: ""Adverse features"", Entity2: ""Surgical intervention"", Relationship: ""Recommendation""
3. Entity1: ""Absence of adverse features"", Entity2: ""Radiation therapy"", Relationship: ""Pathway""
4. Entity1: ""Follow-up process"", Entity2: ""Recurrent or persistent disease"", Relationship: ""Detection""
5. Entity1: ""Recurrent or persistent disease"", Entity2: ""Advanced disease management"", Relationship: ""Necessity""

Causalities:-
<C> The presence of adverse pathologic features — such as extranodal extension or positive margins </C> <E> can directly influence treatment decisions </E>. <CO> If adverse features are found </CO>, <A> surgical intervention is recommended </A>. <CO> In cases where there are no adverse features </CO>, the patient may proceed directly to radiation therapy or continued systemic treatment, emphasizing the tailored approach based on the individual patient's disease characteristics.

Furthermore, the chart includes a section addressing the follow-up process after initial treatment. <CO> If there are signs of recurrent or persistent disease </CO>, <A> additional evaluations and treatment modalities may be necessary </A>. These evaluations <E> lead to specific recommendations for advanced disease management, denoted as ADV-3 on the chart </E>, emphasizing the importance of continuous monitoring and assessment in cancer care.
--------------------------------------------------
Page Number: 51

Section Name: Introduction
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Malignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.
Supraglottic Laryngeal Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is above the vocal cords.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network (NCCN)"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""provides guidelines for""
2. Entity1: ""healthcare professionals"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""manage""

Causalities:-
The provided image is a detailed flowchart from the National Comprehensive Cancer Network (NCCN) guidelines regarding the <C> clinical staging and treatment protocols for cancer of the supraglottic larynx </C>. This flowchart is structured to <A> guide healthcare professionals through the stages of treatment </A> based on <CO> clinical findings </CO>, emphasizing the <E> complexity and systematic approach required in managing this type of cancer </E>.

Section Name: Clinical Staging
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Total Laryngectomy : A surgical procedure to remove the entire larynx, often used in the treatment of advanced laryngeal cancer.
Neoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.
Cancer Staging : The process of determining the extent of cancer in the body, often using the TNM system.
Tnm Staging System : A cancer staging system that describes the extent of cancer using Tumor size (T), Node involvement (N), and Metastasis (M).

Relationships:-
1. Entity1: ""Clinical staging criteria"", Entity2: ""Total laryngectomy"", Relationship: ""determines necessity of""
2. Entity1: ""T3, N0"", Entity2: ""Clinical staging criteria"", Relationship: ""is a categorization of""

Causalities:-
The flowchart begins with the <C> clinical staging criteria </C>, specifically focusing on <CO> cases that require total laryngectomy, denoted as requiring (amenable to) total laryngectomy (T3, N0) </CO>. This <A> categorization </A> is crucial as it <E> forms the basis for determining the appropriate treatment strategy </E>.

Section Name: Treatment of Primary and Neck
====================
Entities:-
Neoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.
Lymphatic Metastasis : Transfer of a neoplasm from one organ or part of the body to another remote from the primary site.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Radiation Therapy"", Relationship: ""combined with""
2. Entity1: ""Laryngectomy"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""
3. Entity1: ""Thyroidectomy"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""
4. Entity1: ""Neck Dissection"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""

Causalities:-
<CO> Once clinical staging is established </CO>, the chart outlines various treatment options. <A> The initial step may involve either concurrent systemic therapy combined with radiation therapy (RT) or opting for RT alone </A>, <CO> especially if the patient is not a medical candidate for both therapies </CO>. <A> Laryngectomy, thyroidectomy, and neck dissection are considered </A> <CO> based on the extent of lymph node involvement </CO>.

Section Name: Surgical Options
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Lymph Node Excision : Surgical removal of one or more lymph nodes.
Lymphadenectomy : Surgical removal of one or more groups of lymph nodes.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.

Relationships:-
1. Entity1: ""Laryngectomy"", Entity2: ""Thyroidectomy"", Relationship: ""combined with""
2. Entity1: ""Lymph Node Dissection"", Entity2: ""Surgical Intervention"", Relationship: ""extent of""
3. Entity1: ""Surgical Intervention"", Entity2: ""Advanced Cases"", Relationship: ""management option for""

Causalities:-
<CO> If concurrent therapies are not suitable </CO>, <A> the chart presents laryngectomy combined with thyroidectomy </A>, <CO> depending on the extent of lymph node dissection required </CO>. <E> This highlights surgical intervention as a viable option in the management of advanced cases </E>.

Section Name: Induction Chemotherapy
====================
Entities:-
Induction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Therapeutic Approach : A method or strategy used in the treatment of disease or injury.

Relationships:-
1. Entity1: ""Induction Chemotherapy"", Entity2: ""Surgical Intervention"", Relationship: ""alternative or sequential treatment option""

Causalities:-
<C> immediate surgical intervention is either not feasible or considered insufficient </C> <E> The flowchart also considers the option of induction chemotherapy </E> <CO> in cases where immediate surgical intervention is either not feasible or considered insufficient </CO>. <A> tailoring therapeutic approaches tailored to individual patient needs </A>.

Section Name: Adjuvant Treatment
====================
Entities:-
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Neoplasm Recurrence, Local : The return of a cancer, at the same site, after it has been treated.
Disease Progression : The worsening of a disease over time.

Relationships:-
1. Entity1: ""Primary Treatment"", Entity2: ""Adjuvant Treatment"", Relationship: ""followed by""
2. Entity1: ""Adjuvant Treatment"", Entity2: ""Systemic Therapy"", Relationship: ""includes""
3. Entity1: ""Adjuvant Treatment"", Entity2: ""Radiotherapy"", Relationship: ""includes""
4. Entity1: ""Follow-up Assessments"", Entity2: ""Treatment Efficacy"", Relationship: ""used to evaluate""

Causalities:-
<C> Following primary treatment </C>, <E> the flowchart addresses the potential for adjuvant treatment pathways </E>. This may include systemic therapy, RT, or further evaluations based on <CO> the patient's response and any recurrence or persistent disease </CO>. It emphasizes <A> the need for follow-up assessments to evaluate treatment efficacy </A>.

Section Name: Risk Features and Response Assessment
====================
Entities:-
Neoplasm Invasiveness : The property of a neoplasm to infiltrate and destroy surrounding tissue.
Surgical Margins : The edge or border of the tissue removed in cancer surgery.
Neoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.
Extramural Extension : Extension of a tumor beyond the wall of an organ.
Positive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.
Cancer Management : The process of planning and coordinating the treatment of cancer.
Cancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""Extramural extension"", Entity2: ""Treatment decisions"", Relationship: ""influences""
2. Entity1: ""Positive surgical margin"", Entity2: ""Treatment decisions"", Relationship: ""influences""
3. Entity1: ""Ongoing assessment"", Entity2: ""Response evaluation"", Relationship: ""leads to""
4. Entity1: ""Response evaluation"", Entity2: ""Adjustments to treatment"", Relationship: ""leads to""
5. Entity1: ""Management of cancer"", Entity2: ""Treatment decisions"", Relationship: ""involves""
6. Entity1: ""Management of cancer"", Entity2: ""Ongoing assessment"", Relationship: ""involves""
7. Entity1: ""Management of cancer"", Entity2: ""Adjustments to treatment"", Relationship: ""involves""

Causalities:-
The chart incorporates a segment that takes into account <CO> adverse pathologic features, such as extramural extension or positive margins </CO>, <E> which could influence subsequent treatment decisions </E>. This highlights the importance of <A> ongoing assessment in the management of cancer, leading to response evaluation and adjustments to treatment as necessary </A>.

Section Name: NCCN Guidelines Version 4.2024
====================
Entities:-
Clinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.
Neoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.
Clinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Malignant Neoplasm : A malignant neoplasm is a cancerous growth that has the potential to invade and destroy nearby tissue and spread to other parts of the body.
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Cancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network"", Entity2: ""NCCN Guidelines"", Relationship: ""provides""
2. Entity1: ""NCCN Guidelines"", Entity2: ""Clinical Trials"", Relationship: ""recommend""
3. Entity1: ""NCCN Guidelines"", Entity2: ""Cancer"", Relationship: ""related to management of""

Causalities:-
<CO> any patient with cancer </CO> <A> the best management is in a clinical trial </A>. <A> Participation in clinical trials is especially encouraged </A>.

Section Name: SUPRA-3
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.
Chemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Clinical Trials As Topic : Research studies that prospectively assign human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Induction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.
Clinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.

Relationships:-
1. Entity1: ""Total laryngectomy"", Entity2: ""Laryngectomy"", Relationship: ""is a type of""
2. Entity1: ""Systemic therapy"", Entity2: ""RT"", Relationship: ""concurrent treatment option""
3. Entity1: ""Induction chemotherapy"", Entity2: ""Other treatments"", Relationship: ""initial treatment option before""

Causalities:-
<CO> Requiring (amenable to) total laryngectomy (T3,N0) </CO>
  - <A> Concurrent systemic therapy/RT </A> or <A> RT if patient not medical candidate for concurrent systemic therapy/RT </A>
  - <A> Laryngectomy, thyroidectomy and with ipsilateral, central, or bilateral neck dissection </A>
  - or
  - <A> Induction chemotherapy </A>
  - or
  - <A> Clinical trials </A>

Section Name: Follow-up
====================
Entities:-
Follow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.
Follow-Up Procedure : A procedure performed to monitor the progress of a patient's condition after initial treatment.
Follow-Up : Medical care given to a patient over time after initial treatment.
Disease Recurrence : The return of a sign, symptom, or disease after a remission.
Recurrent Disease : The reappearance of a disease after a period of improvement.

Relationships:-
1. Entity1: ""Follow-up"", Entity2: ""Recurrent or persistent disease"", Relationship: ""monitoring""

Causalities:-
- **Follow-up (FOLL-A, 1 of 2)**
  - <CO> Recurrent or persistent disease </CO> (ADV-3)

Section Name: Adverse Pathologic Features
====================
Entities:-
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Extranodal Extension : The spread of cancer beyond the lymph node capsule.
Positive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""pN1"", Entity2: ""Radiotherapy"", Relationship: ""Consideration for treatment""
2. Entity1: ""Extranodal extension"", Entity2: ""Systemic Therapy"", Relationship: ""Treatment option""
3. Entity1: ""Extranodal extension"", Entity2: ""Radiotherapy"", Relationship: ""Treatment option""
4. Entity1: ""Positive surgical margin"", Entity2: ""Systemic Therapy"", Relationship: ""Treatment option""
5. Entity1: ""Positive surgical margin"", Entity2: ""Radiotherapy"", Relationship: ""Treatment option""

Causalities:-
- <CO>pN1 without other risk features</CO>
  - <C>Adverse pathologic features</C>
  - <A>Consider RT</A>
  - <CO>Extranodal extension and/or positive margin</CO>
  - <CO>Other risk features</CO>
  - <A>Systemic therapy/RT (category 1)</A>
  - <A>RT or Consider systemic therapy/RT</A>

Section Name: Response Assessment
====================
Entities:-
Response Evaluation : The process of assessing the response of a disease to treatment, often used in clinical trials to determine the effectiveness of a therapy.
Response To Treatment : A clinical finding indicating the response of a condition to a therapeutic intervention.

Relationships:-

Section Name: Principles of Surgery and Radiation Therapy
====================
Entities:-
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Radiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.

Relationships:-
1. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Radiation Therapy"", Relationship: ""complementary treatments""

Causalities:-
**Principles of Surgery (SURG-A).**

**Principles of Radiation Therapy (SUPRA-A).**

Section Name: Principles of Systemic Therapy
====================
Entities:-
Cisplatin : An inorganic and water-soluble platinum complex, cisplatin is an antineoplastic agent that is used in the treatment of various cancers.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Radiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.

Relationships:-
1. Entity1: ""Cisplatin"", Entity2: ""Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""preferred agent""
2. Entity1: ""Cisplatin"", Entity2: ""Concurrent Systemic Therapy/RT"", Relationship: ""used in""

Causalities:-
<CO> When using concurrent systemic therapy/RT </CO>, <A> the preferred agent is cisplatin (category 1) </A>.
--------------------------------------------------
Page Number: 130

Section Name: Pathological N (pN)
====================
Entities:-
Lymph Nodes : Small, bean-shaped structures that are part of the body's lymphatic system. They filter lymph fluid and store white blood cells that help fight infection.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Tnm Staging : A system used to describe the size and spread of cancer in a standardized way. T refers to the size of the tumor, N to the involvement of lymph nodes, and M to metastasis.
Lymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.
Tnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient's body.
Lymph Node : An organ of the lymphatic system and the adaptive immune system.

Relationships:-
1. Entity1: ""Lymph Nodes"", Entity2: ""Neoplasm Metastasis"", Relationship: ""involved in""
2. Entity1: ""TNM Staging"", Entity2: ""Lymph Nodes"", Relationship: ""includes""
3. Entity1: ""TNM Staging"", Entity2: ""Neoplasm Metastasis"", Relationship: ""describes""

Causalities:-
<CO> NX: Regional lymph nodes cannot be assessed </CO>
<CO> N0: No regional lymph node metastasis </CO>
<CO> N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(–) </CO>
<CO> N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2a: Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N3: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(−); or metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>
<CO> N3a: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N3b: Metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>
<CO> Note: A designation of “U” or “L” may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L). Similarly, clinical and pathological ENE should be recorded as ENE(−) or ENE(+). </CO>

Section Name: Distant Metastasis (M)
====================
Entities:-
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.

Relationships:-
1. Entity1: ""M0"", Entity2: ""Distant Metastasis"", Relationship: ""is a category of""
2. Entity1: ""M1"", Entity2: ""Distant Metastasis"", Relationship: ""is a category of""

Causalities:-
### Distant Metastasis (M)

- **M0**: No distant metastasis
- **M1**: Distant metastasis

Section Name: Histologic Grade (G)
====================
Entities:-
Neoplasm Grading : A system of classifying cancer cells in terms of how abnormal they look under a microscope and how quickly the tumor is likely to grow and spread.
Histologic Grade : A measure of how much tumor cells differ from healthy cells, used to assess the aggressiveness of cancer.

Relationships:-
1. Entity1: ""GX"", Entity2: ""Grade cannot be assessed"", Relationship: ""is described as""
2. Entity1: ""G1"", Entity2: ""Well differentiated"", Relationship: ""is described as""
3. Entity1: ""G2"", Entity2: ""Moderately differentiated"", Relationship: ""is described as""
4. Entity1: ""G3"", Entity2: ""Poorly differentiated"", Relationship: ""is described as""

Causalities:-
<CO>GX</CO>: <E>Grade cannot be assessed</E>
<CO>G1</CO>: <E>Well differentiated</E>
<CO>G2</CO>: <E>Moderately differentiated</E>
<CO>G3</CO>: <E>Poorly differentiated</E>

Section Name: Prognostic Stage Groups
====================
Entities:-
Neoplasm Staging : Methods and systems of classifying neoplasms according to extent of disease.
Tumor Staging : A system for describing the size and spread of cancer within the body.
Tnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient's body.

Relationships:-
1. Entity1: ""Stage 0"", Entity2: ""Tis N0 M0"", Relationship: ""defined by""
2. Entity1: ""Stage I"", Entity2: ""T1 N0 M0"", Relationship: ""defined by""
3. Entity1: ""Stage II"", Entity2: ""T2 N0 M0"", Relationship: ""defined by""
4. Entity1: ""Stage III"", Entity2: ""T3 N0 M0, T1 N1 M0, T2 N1 M0, T3 N1 M0"", Relationship: ""defined by""
5. Entity1: ""Stage IVA"", Entity2: ""T1 N2 M0, T2 N2 M0, T3 N2 M0, T4a N0,N1,N2 M0"", Relationship: ""defined by""
6. Entity1: ""Stage IVB"", Entity2: ""Any T N3 M0, T4b Any N M0"", Relationship: ""defined by""
7. Entity1: ""Stage IVC"", Entity2: ""Any T Any N M1"", Relationship: ""defined by""
--------------------------------------------------
Page Number: 47

Section Name: Overview of Radiation Therapy Guidelines
====================
Entities:-
Radiation Therapy : The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.
Malignant Neoplasm : A disease characterized by uncontrolled, abnormal growth of cells that can invade and destroy nearby tissue and spread to other parts of the body.
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.
Glottic Larynx Cancer : A malignant neoplasm located in the glottic region of the larynx.
Laryngeal Cancer : Cancer that occurs in the larynx, or voice box, which may include the glottic region.
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.

Relationships:-
1. Entity1: ""Radiation Therapy"", Entity2: ""Cancer"", Relationship: ""treats""
2. Entity1: ""NCCN Guidelines"", Entity2: ""Cancer"", Relationship: ""guides treatment for""
3. Entity1: ""NCCN Guidelines"", Entity2: ""Radiation Therapy"", Relationship: ""specifies use of""

Causalities:-
The image presents a detailed flowchart outlining the principles of radiation therapy specifically for the <C> treatment of cancer in the glottic larynx </C>, <CO> as per the National Comprehensive Cancer Network (NCCN) guidelines (version 2.2024) </CO>. <E> This structured guidance delineates various treatment protocols </E>, <A> stratified by risk levels and therapeutic approaches </A>.

Section Name: Principles of Radiation Therapy
====================
Entities:-
Radiation Therapy : The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Gy : Gray, a unit of ionizing radiation dose in the International System of Units (SI), defined as the absorption of one joule of radiation energy per kilogram of matter.
Gray (Unit) : A unit of absorbed radiation dose of ionizing radiation, defined as the absorption of one joule of radiation energy per kilogram of matter.

Relationships:-
1. Entity1: ""Tis, N0"", Entity2: ""60.75 Gy (2.25 Gy/fraction) to 66 Gy (2.0 Gy/fraction)"", Relationship: ""treatment protocol""
2. Entity1: ""T1, N0"", Entity2: ""63 Gy (2.25 Gy/fraction) to 66 Gy (2.0 Gy/fraction) or 50 Gy (3.12 Gy/fraction) to 52 Gy (3.28 Gy/fraction)"", Relationship: ""treatment protocol""
3. Entity1: ""T2, N0"", Entity2: ""65.25 Gy (2.25 Gy/fraction) to 70 Gy (2.0 Gy/fraction)"", Relationship: ""treatment protocol""
4. Entity1: ""≥T2, N1 (PTV High risk)"", Entity2: ""66 Gy (2.2 Gy/fraction) to 70 Gy (2.0 Gy/fraction)"", Relationship: ""treatment protocol""
5. Entity1: ""≥T2, N1 (Low to intermediate risk)"", Entity2: ""44–50 Gy (2.0 Gy/fraction) to 54–63 Gy (1.6–1.8 Gy/fraction)"", Relationship: ""treatment protocol""

Causalities:-
<CO>Tis, N0</CO>: <A>60.75 Gy (2.25 Gy/fraction) to 66 Gy (2.0 Gy/fraction)</A>
<CO>T1, N0</CO>: <A>63 Gy (2.25 Gy/fraction, preferred) to 66 Gy (2.0 Gy/fraction) or 50 Gy (3.12 Gy/fraction) to 52 Gy (3.28 Gy/fraction)</A>
<CO>T2, N0</CO>: <A>65.25 (2.25 Gy/fraction) to 70 Gy (2.0 Gy/fraction)</A>
<CO>≥T2, N1</CO>: <A>PTV High risk: Primary tumor and involved lymph nodes (includes possible local subclinical infiltration at the primary site and at the high-risk level lymph node(s))</A>
<A>Fractionation: 66 Gy (2.2 Gy/fraction) to 70 Gy (2.0 Gy/fraction); daily Monday–Friday in 6–7 weeks</A>
<A>Concomitant boost accelerated RT: 72 Gy/6 weeks (1.8 Gy/fraction, large field; 1.5 Gy boost as second daily fraction during last 12 treatment days)</A>
<A>66–70 Gy (2.0 Gy/fraction; 6 fractions/wk accelerated)</A>
<A>Hyperfractionation: 79.2–81.6 Gy/7 weeks (1.2 Gy/fraction, twice daily)</A>
<CO>Low to intermediate risk</CO>: <A>Sites of suspected subclinical spread</A>
<A>44–50 Gy (2.0 Gy/fraction) to 54–63 Gy (1.6–1.8 Gy/fraction)</A>

Section Name: Concurrent Systemic Therapy/RT
====================
Entities:-
Cisplatin : A platinum-containing antineoplastic agent used in the treatment of various cancers.
Carboplatin : An organoplatinum compound that possesses antineoplastic activity.
Fluorouracil : A chemotherapy drug used to treat various types of cancer.

Relationships:-
1. Entity1: ""concurrent systemic therapy/RT"", Entity2: ""cisplatin"", Relationship: ""uses""
2. Entity1: ""concurrent systemic therapy/RT"", Entity2: ""carboplatin and 5-FU"", Relationship: ""uses""
3. Entity1: ""multiagent chemotherapy"", Entity2: ""toxicity burden"", Relationship: ""increases""

Causalities:-
<CO>Based on published data</CO>, <A>concurrent systemic therapy/RT most commonly uses conventional fractionation at 2.0 Gy per fraction to a typical dose of 70 Gy in 7 weeks with single-agent cisplatin given every 3 weeks at 100 mg/m²</A>; <CO>2–3 cycles of chemotherapy are used depending on the radiation fractionation scheme (RTOG 0129)</CO>. <CO>When carboplatin and 5-FU are used</CO>, <A>the recommended regimen is standard fractionation plus 3 cycles of chemotherapy</A>. <CO>Other fraction sizes (e.g., 1.8 Gy, conventional), multiagent chemotherapy, other dosing schedules of cisplatin, or altered fractionation with chemotherapy</CO> <E>are efficacious</E>, and <C>there is no consensus on the optimal approach</C>. <C>In general, the use of concurrent systemic therapy/RT</C> <E>carries a high toxicity burden</E>; <C>multiagent chemotherapy</C> <E>will likely further increase the toxicity burden</E>. <A>For any systemic therapy/RT approach, close attention should be paid to published reports for the specific chemotherapy agent, dose, and schedule of administration</A>. <A>Systemic therapy/RT should be performed by an experienced team and should include substantial supportive care</A>.

Section Name: Treatment Modalities
====================
Entities:-
Intensity-Modulated Radiotherapy : A type of conformal radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.
Intensity Modulated Radiation Therapy : A type of conformal radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.
Intensity-Modulated Radiation Therapy : An advanced type of high-precision radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.
Radiotherapy, Conformal : A type of radiotherapy that uses imaging to conform the radiation dose to the shape of the tumor.
3D Conformal Radiation Therapy : A technique in radiotherapy that uses imaging to conform the radiation dose to the shape of the tumor.
Chemotherapy, Adjuvant : Treatment with drugs that kill cancer cells, often used in conjunction with other therapies.
Chemotherapy : The treatment of disease by the use of chemical substances, especially the treatment of cancer by cytotoxic and other drugs.
Drug Therapy, Combination : The use of two or more drugs to achieve a therapeutic effect.
Systemic Therapy : A type of therapy that uses substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Intensity-Modulated Radiation Therapy (IMRT)"", Entity2: ""3D Conformal Radiation Therapy (3D-CRT)"", Relationship: ""are delivery methods for radiation therapy""
2. Entity1: ""Chemotherapy"", Entity2: ""Radiation Therapy"", Relationship: ""is integrated with for aggressive or advanced cancer cases""

Causalities:-
<CO> contingent upon patient-specific considerations </CO> <A> suggests either Intensity-Modulated Radiation Therapy (IMRT) or 3D Conformal Radiation Therapy (3D-CRT) as delivery methods </A>. <A> These advanced techniques are employed to optimize treatment accuracy </A>, <E> preserving surrounding healthy tissue and improving overall patient outcomes </E>. <A> a focus on concurrent systemic therapies underlines the importance of integrating chemotherapy </A>, particularly <CO> for patients with more aggressive forms of cancer or those demonstrating advanced disease characteristics </CO>.

Section Name: Additional Information
====================
Entities:-
Clinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.
Clinical Trial : A clinical trial is a research study in which one or more human subjects are prospectively assigned to one or more interventions to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes.
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Intensity-Modulated Radiation Therapy : An advanced type of high-precision radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.
Intensity Modulated Radiation Therapy : A type of conformal radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.
Three-Dimensional Conformal Radiation Therapy : A type of external beam radiation therapy that uses a computer to create a 3-dimensional picture of the tumor so that multiple radiation beams can be shaped exactly to the contour of the treatment area.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network"", Entity2: ""Clinical trial"", Relationship: ""encourages participation in""
2. Entity1: ""Intensity-Modulated Radiation Therapy"", Entity2: ""Three-Dimensional Conformal Radiation Therapy"", Relationship: ""recommended alternatives""

Causalities:-
<A> Participation in clinical trials </A> is especially encouraged. <A> Either IMRT (preferred) or 3D-CRT is recommended. </A>

Section Name: Conclusion
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.
Malignant Neoplasm Of Glottis : A malignant tumor located in the glottic region of the larynx.
Laryngeal Cancer : Cancer that occurs in the larynx, or voice box, which may include the glottic region.
Prognosis : A medical term for predicting the likely or expected development of a disease.
Evidence-Based Practice : Healthcare practices that are based on scientific evidence and research.
Evidence-Based Medicine : An approach to medical practice intended to optimize decision-making by emphasizing the use of evidence from well-designed and conducted research.

Relationships:-
1. Entity1: ""treatment paradigms"", Entity2: ""glottic larynx cancer"", Relationship: ""encapsulates""
2. Entity1: ""personalized treatment plans"", Entity2: ""prognosis"", Relationship: ""improves""

Causalities:-
<C> glottic larynx cancer </C>. <CO> the nuances of each patient's condition </CO>. <A> personalized treatment plans </A> <E> promoting effective management and improved prognosis </E>. <A> deliver clear, evidence-based interventions </A> <CO> considering the complexities involved in cancer treatment </CO>.


Among these two options which one is the most likely true:

(A) `N_State_1__patient` increases risk `Number_of_Involved_Lymph_Nodes_3`
(B) `Number_of_Involved_Lymph_Nodes_3` `increases risk `N_State_1__patient`

The answer is: ...

1. State the evidences in detail of the validity of option (A) or (B) by cross referencing
NCCN Clinical Practitioner’s Guidelines for Head and Neck Cancer.
2. If the evidences are obtained from `INFORMATION FROM KNOWLEDGE BASE`,
mention their corresponding Page Numbers, Section Name, entities, relationships and causalities.

DESIRED OUTPUT FORMAT:
<thinking>
...
</thinking>
<answer>
{
   ""thinking"": [""..."", ...],
   ""evidences"": [""..."", ...],
   ""answer"": ...
}
</answer>

Before providing the answer in <answer> tags, think step by step in detail in <thinking> tags and analyze every part.
Output inside <answer> tag in JSON format. Only output valid JSON.
DO NOT HALLUCINATE. DO NOT MAKE UP FACTUAL INFORMATION.
","1. The edge (N_State_1__patient) causes (Number_of_Involved_Lymph_Nodes_3) suggests that the state of lymph node involvement influences the number of involved lymph nodes.
2. The explanation for EDGE1 indicates a positive causal direction, meaning a higher state of lymph node involvement corresponds to a higher number of involved lymph nodes.
3. The causal factor is sufficient, meaning the state of lymph node involvement is a key factor in predicting the number of involved lymph nodes.
4. The causal distance is proximal, indicating a direct relationship between the state of lymph node involvement and the number of involved lymph nodes.
5. The edge (Number_of_Involved_Lymph_Nodes_3) causes (N_State_1__patient) suggests that the number of involved lymph nodes influences the state of lymph node involvement.
6. The explanation for EDGE2 indicates a positive causal direction, meaning an increase in the number of involved lymph nodes leads to a higher N state.
7. The causal factor is necessary, meaning the number of involved lymph nodes is required to determine the N state.
8. The causal distance is proximal, indicating a direct relationship between the number of involved lymph nodes and the N state.
9. The NCCN Guidelines for Head and Neck Cancer emphasize the importance of lymph node involvement in cancer staging and treatment planning.
10. The guidelines suggest that the state of lymph node involvement is used to predict the extent of lymph node metastasis, which directly relates to the number of involved lymph nodes.
11. The guidelines also indicate that the number of involved lymph nodes is a critical factor in determining the stage and prognosis of cancer.
12. Based on the explanations and guidelines, the causal relationship in EDGE1 is more aligned with the NCCN Guidelines, as the state of lymph node involvement is a key factor in predicting the number of involved lymph nodes.
","1. Page Number: 102, Section Name: Head and Neck Cancers - Principles of Surgery, Entities: Lymphatic System, Neoplasm Staging, Metastasis, Relationships: Entity1: 'surgical management', Entity2: 'regional lymphatics', Relationship: 'dictated by tumor staging', Causalities: <C> The extent of the tumor at initial tumor staging </C> <E> dictates the surgical management of regional lymphatics </E>.
2. Page Number: 130, Section Name: Pathological N (pN), Entities: Lymph Nodes, Neoplasm Metastasis, TNM Staging, Relationships: Entity1: 'Lymph Nodes', Entity2: 'Neoplasm Metastasis', Relationship: 'involved in', Causalities: <CO> NX: Regional lymph nodes cannot be assessed </CO> <CO> N0: No regional lymph node metastasis </CO> <CO> N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(–) </CO>
",A,"{'A': 99.99, 'B': 0.01}",yes,A,"1. The AI assistant's reasoning is based on the causal relationships described in the EDGE1 and EDGE2 explanations.
2. EDGE1 suggests that the state of lymph node involvement (N_State_1__patient) influences the number of involved lymph nodes (Number_of_Involved_Lymph_Nodes_3). This is supported by the explanation that a higher state of lymph node involvement corresponds to a higher number of involved lymph nodes, indicating a positive causal direction.
3. EDGE2 suggests the opposite causal relationship, where the number of involved lymph nodes influences the state of lymph node involvement. This is also described as a positive causal direction, where an increase in the number of involved lymph nodes leads to a higher N state.
4. The AI assistant references the NCCN Guidelines, which emphasize the importance of lymph node involvement in cancer staging and treatment planning. The guidelines suggest that the state of lymph node involvement is used to predict the extent of lymph node metastasis, aligning with the explanation for EDGE1.
5. The assistant concludes that the causal relationship in EDGE1 is more aligned with the NCCN Guidelines, as the state of lymph node involvement is a key factor in predicting the number of involved lymph nodes.
6. The evidences provided from the knowledge base support the assistant's conclusion, as they highlight the role of lymph node involvement in cancer staging and its impact on treatment decisions.
"
10,gpt-4o,"N_State_1__patient,Size_of_Involved_Lymph_Nodes_6","""{'NODE1': {'id': 'N_State_1__patient', 'label': 'State of Nearby Lymph Nodes with Cancer in Patient', 'description': 'This node represents the state of involvement of nearby lymph nodes in a patient with cancer. It is a decision node used to predict the extent of lymph node metastasis, which is crucial for cancer staging and treatment planning. The states range from no involvement (n0) to extensive involvement (n3), with intermediate states indicating varying degrees of lymph node cancer presence.', 'type': 'Decision Node', 'observability': 'Needs to be Predicted', 'states': [{'state_name': 'nx', 'state_description': 'The regional lymph nodes cannot be assessed.'}, {'state_name': 'n3', 'state_description': 'Metastasis in lymph node(s) along the course of a major blood vessel or in a lymph node that is more than 6 cm in greatest dimension.'}, {'state_name': 'n2c', 'state_description': 'Metastasis in bilateral or contralateral lymph nodes, each 6 cm or less in greatest dimension.'}, {'state_name': 'n2b', 'state_description': 'Metastasis in multiple ipsilateral lymph nodes, each 6 cm or less in greatest dimension.'}, {'state_name': 'n2a', 'state_description': 'Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension.'}, {'state_name': 'n2', 'state_description': 'Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension, or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension.'}, {'state_name': 'n1', 'state_description': 'Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension.'}, {'state_name': 'n0', 'state_description': 'No regional lymph node metastasis.'}]}, 'NODE2': {'id': 'Size_of_Involved_Lymph_Nodes_6', 'label': 'Size of Involved Lymph Nodes', 'description': 'This node represents the size of lymph nodes that are involved, potentially indicating the extent of lymphatic spread in a cancerous process. The size of involved lymph nodes is a critical factor in staging cancer, assessing prognosis, and determining treatment strategies. Larger lymph nodes may suggest more extensive disease and could influence clinical decisions.', 'type': 'Patient Situation', 'observability': 'Unobserved', 'states': [{'state_name': 'more_than_6_cm', 'state_description': 'The lymph nodes involved are larger than 6 centimeters, indicating significant enlargement, which may suggest advanced disease or extensive lymphatic involvement.'}, {'state_name': 'three_cm_to_six_cm', 'state_description': 'The lymph nodes involved are between 3 and 6 centimeters in size, indicating moderate enlargement, which may suggest a moderate level of disease involvement.'}, {'state_name': 'smaller_than_three_cm', 'state_description': 'The lymph nodes involved are smaller than 3 centimeters, indicating mild enlargement, which may suggest early or limited disease involvement.'}, {'state_name': 'absent', 'state_description': 'No lymph nodes are involved, indicating no detectable lymphatic spread of the disease.'}]}, 'EDGE1': {'edges_ids': ['N_State_1__patient', 'Size_of_Involved_Lymph_Nodes_6'], 'edge': '(N_State_1__patient) causes (Size_of_Involved_Lymph_Nodes_6)', 'explanation': ['The edge suggests that the state of nearby lymph nodes with cancer in a patient causes the size of the involved lymph nodes.', 'In clinical practice, the size of the lymph nodes is a factor that helps determine the state of involvement, not the other way around.', 'Therefore, the causal relationship is not valid as described. The size of the lymph nodes contributes to determining the state of involvement, not the state causing the size.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Proximal'}, 'EDGE2': {'edges_ids': ['Size_of_Involved_Lymph_Nodes_6', 'N_State_1__patient'], 'edge': '(Size_of_Involved_Lymph_Nodes_6) causes (N_State_1__patient)', 'explanation': ['The size of involved lymph nodes is a critical factor in determining the N state in cancer staging.', 'Larger lymph nodes often correlate with more advanced N states, such as n2 or n3, indicating more extensive lymphatic involvement.', 'The causal direction is positive because an increase in lymph node size is associated with a more advanced N state.', 'The causal factor is neither necessary nor sufficient on its own, as other factors also influence the N state.', 'The causal distance is proximal because the size of lymph nodes directly affects the N state.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Proximal'}, 'ENTITIES_MATCHING_PAGES_INFO': {'102': {'matching_entities': [{'LYMPHATIC SYSTEM': 0.95855314}, {'LYMPHATIC STRUCTURE': 0.9469132}, {'METASTASIS': 0.9401313}, {'CANCER STAGING': 0.93824553}, {'TUMOR': 0.9323624}, {'STAGING': 0.9208425}], 'count': 6}, '55': {'matching_entities': [{'MALIGNANT NEOPLASTIC DISEASE': 0.97725874}, {'METASTASIS': 0.9401313}, {'CANCER': 0.9363244}, {'METASTATIC NEOPLASM': 0.9314138}, {'NEOPLASM METASTASIS': 0.9250777}, {'LARYNGEAL NEOPLASMS': 0.9236878}], 'count': 6}, '51': {'matching_entities': [{'MALIGNANT NEOPLASM': 0.9774111}, {'CANCER STAGING': 0.93824553}, {'CANCER': 0.9363244}, {'LARYNGEAL NEOPLASMS': 0.9236878}, {'NEOPLASM INVASIVENESS': 0.92347366}], 'count': 5}, '130': {'matching_entities': [{'LYMPH NODE STRUCTURE': 0.99134904}, {'LYMPH NODE': 0.98570025}, {'LYMPH NODES': 0.97445965}, {'METASTASIS': 0.9401313}, {'NEOPLASM METASTASIS': 0.9250777}], 'count': 5}, '47': {'matching_entities': [{'MALIGNANT NEOPLASM': 0.9774111}, {'LARYNGEAL CANCER': 0.95521915}, {'CANCER': 0.9363244}, {'LARYNGEAL NEOPLASMS': 0.9236878}], 'count': 4}}, 'GUIDELINE_PAGES_INFO': '--------------------------------------------------\\nPage Number: 102\\n\\nSection Name: Head and Neck Cancers - Principles of Surgery\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Manual or operative procedures used in the treatment of disease, injuries, or deformities.\\nLymphatic System : Part of the circulatory system and a vital part of the immune system, comprising a network of lymphatic vessels that carry a clear fluid called lymph.\\nNeoplasms : New abnormal growth of tissue in animals or plants; a tumor.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nNeoplasm Staging : Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.\\nMetastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.\\nSurgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nLymphatic Structure : Anatomical structure that is part of the lymphatic system.\\nTumor : An abnormal mass of tissue that results when cells divide more than they should or do not die when they should.\\nStaging : The process of determining the size and spread of cancer within the body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nCancer Staging : The process of determining the extent to which a cancer has developed by growing and spreading.\\n\\nRelationships:-\\n1. Entity1: \""surgical management\"", Entity2: \""regional lymphatics\"", Relationship: \""dictated by tumor staging\""\\n2. Entity1: \""neck dissections\"", Entity2: \""primary tumor\"", Relationship: \""part of treatment\""\\n3. Entity1: \""surgery\"", Entity2: \""ipsilateral side of the neck\"", Relationship: \""risk for metastases\""\\n\\nCausalities:-\\n<C> The extent of the tumor at initial tumor staging </C> <E> dictates the surgical management of regional lymphatics </E>. These guidelines apply to the performance of neck dissections as part of treatment of the primary tumor. <CO> Patients undergoing surgery for resection of the primary tumor </CO> <A> will undergo dissection of the ipsilateral side of the neck that is at greatest risk for metastases </A>.\\n\\nSection Name: Neck Management\\n====================\\nEntities:-\\nTongue : A muscular organ in the mouth that is involved in tasting, swallowing, and speech.\\nPalate : The roof of the mouth, separating the oral and nasal cavities.\\nLarynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.\\nHypopharynx : The bottom part of the pharynx, which is the cavity behind the nose and mouth.\\nNasopharynx : The upper part of the pharynx, connecting with the nasal cavity above the soft palate.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nMetastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.\\nSquamous Cell Carcinoma : A type of cancer that begins in the squamous cells, which are thin, flat cells that look like fish scales.\\nBiopsy : The removal of cells or tissues for examination under a microscope.\\n\\nRelationships:-\\n1. Entity1: \""Tumor sites\"", Entity2: \""Bilateral lymphatic drainage\"", Relationship: \""associated with\""\\n2. Entity1: \""Elective neck dissection\"", Entity2: \""Risk of occult metastasis\"", Relationship: \""based on\""\\n3. Entity1: \""SLN biopsy\"", Entity2: \""Elective neck dissection\"", Relationship: \""guides decision-making for\""\\n\\nCausalities:-\\n- **<C> Tumor sites that frequently have bilateral lymphatic drainage </C>** (e.g., base of tongue, palate, supraglottic larynx, hypopharynx, nasopharynx, deep pre-epiglottic space involvement) <E> often should have both sides of the neck dissected </E> with the extent of dissection determined as suggested below. For those patients with tumors at or approaching the midline, <CO> both sides of the neck are at risk for metastases </CO>, and <A> bilateral neck dissections should be performed </A>.\\n\\n- <CO> Patients with advanced lesions involving the anterior tongue, floor of the mouth, or alveolus that approximate or cross the midline </CO> <A> should undergo contralateral selective/modified neck dissection </A> as necessary to achieve adequate tumor resection.\\n\\n- **<C> Elective neck dissection </C>** <A> should be based on risk of occult metastasis in the appropriate nodal basin </A>. For oral cavity squamous cell carcinoma, <C> SLN biopsy or the primary tumor depth of invasion </C> is currently <E> the best predictor of occult metastatic disease </E> and <A> should be used to guide decision-making </A>. <CO> For tumors with a depth greater than 3 mm </CO>, <A> elective dissection should be strongly considered if RT is not already planned </A>. Recent randomized trial evidence supports the effectiveness of elective neck dissection in patients with oral cavity cancers greater than 3 mm in depth of invasion.\\n\\n  - <CO> For a depth less than 2 mm </CO>, <A> elective dissection is only indicated in highly selective situations </A>. <CO> For a depth of 2\u20134 mm </CO>, <A> clinical judgment (as to reliability of follow-up, clinical suspicion, and other factors) must be utilized to determine appropriateness of elective dissection </A>. Elective dissections are generally selective, preserving all major structures, unless operative findings dictate otherwise.\\n\\nSection Name: Types of Neck Dissection\\n====================\\nEntities:-\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nLarynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.\\n\\nRelationships:-\\n1. Entity1: \""N0\"", Entity2: \""Selective neck dissection\"", Relationship: \""associated with\""\\n2. Entity1: \""N3\"", Entity2: \""Comprehensive neck dissection\"", Relationship: \""associated with\""\\n3. Entity1: \""Level VI neck dissection\"", Entity2: \""Larynx\"", Relationship: \""performed for\""\\n4. Entity1: \""Level VI neck dissection\"", Entity2: \""Hypopharynx\"", Relationship: \""performed for\""\\n\\nCausalities:-\\n- **The type of neck dissection (comprehensive or selective)** is defined according to <CO> preoperative clinical staging </CO>, is determined at the discretion of the surgeon, and is based on the initial preoperative staging as follows:\\n  - **N0:** <A> Selective neck dissection </A>\\n    - Oral cavity at least levels I\u2013III\\n    - Oropharynx at least levels II\u2013IV\\n    - Hypopharynx at least levels II\u2013IV and level VI when appropriate\\n    - Larynx at least levels II\u2013IV and level VI when appropriate\\n  - **N1\u2013N2a\u2013c:** <A> Selective or comprehensive neck dissection </A> (Discussion)\\n  - **N3:** <A> Comprehensive neck dissection </A>\\n\\n- <C> Level VI neck dissections are performed for certain primary sites (such as the larynx and hypopharynx) </C> <E> as required to resect the primary tumor and any clinically evident neck nodes </E>. <CO> Elective dissection depends on primary tumor extent and site </CO>. <CO> For advanced glottic and hypopharyngeal cancers treated with primary surgery </CO>, <A> a level VI dissection (including pretracheal lymph nodes, the Delphian lymph node, and unilateral or bilateral paratracheal lymph nodes) and hemithyroidectomy to total thyroidectomy are appropriate </A>.\\n\\n- <CO> For primary subglottic tumors or glottic cancers with significant subglottic extension </CO>, <A> a level VI dissection with unilateral or total thyroidectomy is considered appropriate </A> based on the extent of the primary tumor. <CO> For example, a T4a glottic tumor with extension through the cricothyroid membrane and subglottic extension </CO> <A> should include thyroidectomy and pretracheal and bilateral paratracheal lymph node dissection </A>. <A> Parathyroid glands should be preserved in situ or auto transplanted as indicated </A>.\\n--------------------------------------------------\\nPage Number: 55\\n\\nSection Name: General Information\\n====================\\nEntities:-\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nNccn Guidelines : Clinical practice guidelines in oncology developed by the National Comprehensive Cancer Network.\\n\\nRelationships:-\\n1. Entity1: \""NCCN Guidelines\"", Entity2: \""National Comprehensive Cancer Network\"", Relationship: \""produced by\""\\n\\nSection Name: Important Notes\\n====================\\nEntities:-\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medical, surgical, or behavioral interventions.\\nClinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nNeoplasms : New abnormal growth of tissue that can be benign or malignant.\\nMalignant Neoplastic Disease : A disease resulting from the growth of malignant neoplasms.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""Clinical Trials\"", Entity2: \""Cancer\"", Relationship: \""recommended for\""\\n2. Entity1: \""NCCN\"", Entity2: \""Clinical Trials\"", Relationship: \""encourages participation in\""\\n\\nCausalities:-\\n<C> NCCN believes that the best management of any patient with cancer is in a clinical trial </C>. <A> Participation in clinical trials is especially encouraged </A>.\\n\\nSection Name: Principles\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nChemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.\\n\\nRelationships:-\\n1. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Radiation Therapy\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n2. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n3. Entity1: \""Principles of Radiation Therapy\"", Entity2: \""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n\\nCausalities:-\\n### Principles\\n\\n- **Principles of Surgery (SURG-A)**\\n- **Principles of Radiation Therapy (SUPRA-A)**\\n- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**\\n\\nSection Name: Adverse Pathologic Features\\n====================\\nEntities:-\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.\\nPerineural Invasion : The presence of cancer cells surrounding or tracking along a nerve within the perineural space.\\nVascular Invasion : The invasion of cancer cells into blood vessels.\\nLymphatic Invasion : The invasion of cancer cells into lymphatic vessels.\\n\\nRelationships:-\\n1. Entity1: \""Extranodal extension\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n2. Entity1: \""Positive margins\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n3. Entity1: \""Close margins\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n4. Entity1: \""pT3 or pT4 primary\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n5. Entity1: \""pN2 or pN3 nodal disease\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n6. Entity1: \""Perineural invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n7. Entity1: \""Vascular invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n8. Entity1: \""Lymphatic invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n\\nCausalities:-\\n<C> Extranodal extension </C>\\n<C> Positive margins </C>\\n<C> Close margins </C>\\n<C> pT3 or pT4 primary </C>\\n<C> pN2 or pN3 nodal disease </C>\\n<C> Perineural invasion </C>\\n<C> Vascular invasion </C>\\n<C> Lymphatic invasion </C>\\n\\nSection Name: Response Assessment\\n====================\\nEntities:-\\nChemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nPrimary Site : The original location where a tumor or cancer begins.\\nComplete Remission : The disappearance of all signs of cancer in response to treatment.\\nPartial Remission : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.\\nRadiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""induction chemotherapy\"", Entity2: \""Primary site\"", Relationship: \""treatment outcome\""\\n2. Entity1: \""Definitive RT\"", Entity2: \""Primary site\"", Relationship: \""treatment option\""\\n3. Entity1: \""RT\"", Entity2: \""Primary site\"", Relationship: \""treatment option\""\\n4. Entity1: \""Surgery\"", Entity2: \""unresectable nodal disease\"", Relationship: \""treatment option\""\\n\\nCausalities:-\\n<C> Response after induction chemotherapy </C>: <E> Primary site: CR </E> <E> Primary site: PR </E> <E> Primary site: < PR </E> <A> Definitive RT </A> (category 1) <A> RT </A> (category 1) or <A> systemic therapy/RT </A> (category 2B) <A> Surgery </A> or <A> unresectable nodal disease </A>\\n\\nSection Name: Follow-up\\n====================\\nEntities:-\\nFollow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.\\nFollow-Up Procedure : A procedure where a patient is monitored over time to assess the progress of a condition or the effects of treatment.\\nFollow-Up (Medicine) : The process of monitoring a patient\\'s health over time after treatment or diagnosis.\\nDisease Recurrence : The return of a sign, symptom, or disease after a remission.\\nRecurrent Disease : A disease that returns after a period of remission.\\nRecurrence (Medicine) : The return of a disease or condition after a period of improvement.\\n\\nRelationships:-\\n1. Entity1: \""Follow-up\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""monitoring\""\\n\\nCausalities:-\\n### Follow-up\\n\\n- **Follow-up** (FOLL-A, 1 of 2)\\n- **Recurrent or persistent disease** (ADV-3)\\n\\nSection Name: Risk Features\\n====================\\nEntities:-\\nRadiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Adverse pathologic features\"", Entity2: \""RT\"", Relationship: \""Consideration for treatment\""\\n2. Entity1: \""Adverse pathologic features\"", Entity2: \""Systemic therapy\"", Relationship: \""Consideration for treatment\""\\n\\nCausalities:-\\n- **No adverse pathologic features**\\n- **Other risk features**\\n- **Adverse pathologic features**:\\n  - <C> Extranodal extension and/or positive margin </C>\\n  - <A> RT or consider systemic therapy/RT </A>\\n\\nSection Name: Post-Therapy Evaluation\\n====================\\nEntities:-\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nNeck : The neck is the part of the body that separates the head from the torso and provides the mobility and movements of the head.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Neck Evaluation\"", Relationship: \""evaluated in\""\\n2. Entity1: \""RT\"", Entity2: \""Neck Evaluation\"", Relationship: \""evaluated in\""\\n\\nCausalities:-\\n<CO> Post Systemic Therapy/RT or RT Neck </CO> <A> Evaluation </A>\\n\\nSection Name: Flowchart Overview\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nSupraglottic Larynx : The part of the larynx located above the vocal cords, including the epiglottis and aryepiglottic folds.\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\n\\nRelationships:-\\n1. Entity1: \""NCCN Guidelines\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""guides management of\""\\n2. Entity1: \""NCCN Guidelines\"", Entity2: \""healthcare professionals\"", Relationship: \""used by\""\\n\\nCausalities:-\\n<C> cancer of the supraglottic larynx </C> <E> evaluate patient responses following treatment </E> <CO> based on observed outcomes </CO> <A> evaluation of the primary site and determining subsequent steps </A>.\\n\\nSection Name: Assessment and Treatment Decisions\\n====================\\nEntities:-\\nInduction Chemotherapy : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nComplete Response : The disappearance of all signs of cancer in response to treatment.\\nPartial Response : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Complete Response\"", Entity2: \""Radiation Therapy\"", Relationship: \""leads to\""\\n2. Entity1: \""Complete Response\"", Entity2: \""Surgery\"", Relationship: \""leads to\""\\n3. Entity1: \""Partial Response\"", Entity2: \""Systemic Therapy\"", Relationship: \""leads to\""\\n4. Entity1: \""Partial Response\"", Entity2: \""Radiation Therapy\"", Relationship: \""leads to\""\\n\\nCausalities:-\\n<C> responses to initial treatments such as induction chemotherapy </C> <E> Three main response categories are recognized: Complete Response (CR), Partial Response (PR), and less than Partial Response (< PR) </E>. These categories are pivotal in determining the next steps. <C> CR </C> <E> indicates full resolution of the disease at the primary site </E>, <A> leading to the consideration of definitive radiation therapy or the likelihood of surgery </A>. Conversely, <C> PR </C> <E> suggests that the disease has improved but not completely resolved </E>, <A> which directs the pathway towards either systemic therapy or continued radiation therapy </A>, <A> with further evaluation necessary </A>.\\n\\nSection Name: Adverse Pathologic Features and Follow-up\\n====================\\nEntities:-\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nNeoplasm Recurrence, Local : The return of a tumor or cancer, at the original site, after it has been treated.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nRecurrent Neoplasm : A neoplasm that has returned after treatment.\\nMetastatic Neoplasm : A neoplasm that has spread from its original site to one or more other places in the body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nCancer Recurrence : The return of cancer after treatment and after a period of time during which the cancer was undetectable.\\nMetastasis : Spread of a cancer or other disease from one organ or part to another not directly connected with it.\\n\\nRelationships:-\\n1. Entity1: \""Adverse pathologic features\"", Entity2: \""Treatment decisions\"", Relationship: \""Influence\""\\n2. Entity1: \""Adverse features\"", Entity2: \""Surgical intervention\"", Relationship: \""Recommendation\""\\n3. Entity1: \""Absence of adverse features\"", Entity2: \""Radiation therapy\"", Relationship: \""Pathway\""\\n4. Entity1: \""Follow-up process\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""Detection\""\\n5. Entity1: \""Recurrent or persistent disease\"", Entity2: \""Advanced disease management\"", Relationship: \""Necessity\""\\n\\nCausalities:-\\n<C> The presence of adverse pathologic features \u2014 such as extranodal extension or positive margins </C> <E> can directly influence treatment decisions </E>. <CO> If adverse features are found </CO>, <A> surgical intervention is recommended </A>. <CO> In cases where there are no adverse features </CO>, the patient may proceed directly to radiation therapy or continued systemic treatment, emphasizing the tailored approach based on the individual patient\\'s disease characteristics.\\n\\nFurthermore, the chart includes a section addressing the follow-up process after initial treatment. <CO> If there are signs of recurrent or persistent disease </CO>, <A> additional evaluations and treatment modalities may be necessary </A>. These evaluations <E> lead to specific recommendations for advanced disease management, denoted as ADV-3 on the chart </E>, emphasizing the importance of continuous monitoring and assessment in cancer care.\\n--------------------------------------------------\\nPage Number: 51\\n\\nSection Name: Introduction\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nMalignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.\\nSupraglottic Laryngeal Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is above the vocal cords.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network (NCCN)\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""provides guidelines for\""\\n2. Entity1: \""healthcare professionals\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""manage\""\\n\\nCausalities:-\\nThe provided image is a detailed flowchart from the National Comprehensive Cancer Network (NCCN) guidelines regarding the <C> clinical staging and treatment protocols for cancer of the supraglottic larynx </C>. This flowchart is structured to <A> guide healthcare professionals through the stages of treatment </A> based on <CO> clinical findings </CO>, emphasizing the <E> complexity and systematic approach required in managing this type of cancer </E>.\\n\\nSection Name: Clinical Staging\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nTotal Laryngectomy : A surgical procedure to remove the entire larynx, often used in the treatment of advanced laryngeal cancer.\\nNeoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.\\nCancer Staging : The process of determining the extent of cancer in the body, often using the TNM system.\\nTnm Staging System : A cancer staging system that describes the extent of cancer using Tumor size (T), Node involvement (N), and Metastasis (M).\\n\\nRelationships:-\\n1. Entity1: \""Clinical staging criteria\"", Entity2: \""Total laryngectomy\"", Relationship: \""determines necessity of\""\\n2. Entity1: \""T3, N0\"", Entity2: \""Clinical staging criteria\"", Relationship: \""is a categorization of\""\\n\\nCausalities:-\\nThe flowchart begins with the <C> clinical staging criteria </C>, specifically focusing on <CO> cases that require total laryngectomy, denoted as requiring (amenable to) total laryngectomy (T3, N0) </CO>. This <A> categorization </A> is crucial as it <E> forms the basis for determining the appropriate treatment strategy </E>.\\n\\nSection Name: Treatment of Primary and Neck\\n====================\\nEntities:-\\nNeoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.\\nLymphatic Metastasis : Transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Radiation Therapy\"", Relationship: \""combined with\""\\n2. Entity1: \""Laryngectomy\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n3. Entity1: \""Thyroidectomy\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n4. Entity1: \""Neck Dissection\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n\\nCausalities:-\\n<CO> Once clinical staging is established </CO>, the chart outlines various treatment options. <A> The initial step may involve either concurrent systemic therapy combined with radiation therapy (RT) or opting for RT alone </A>, <CO> especially if the patient is not a medical candidate for both therapies </CO>. <A> Laryngectomy, thyroidectomy, and neck dissection are considered </A> <CO> based on the extent of lymph node involvement </CO>.\\n\\nSection Name: Surgical Options\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nLymph Node Excision : Surgical removal of one or more lymph nodes.\\nLymphadenectomy : Surgical removal of one or more groups of lymph nodes.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""Laryngectomy\"", Entity2: \""Thyroidectomy\"", Relationship: \""combined with\""\\n2. Entity1: \""Lymph Node Dissection\"", Entity2: \""Surgical Intervention\"", Relationship: \""extent of\""\\n3. Entity1: \""Surgical Intervention\"", Entity2: \""Advanced Cases\"", Relationship: \""management option for\""\\n\\nCausalities:-\\n<CO> If concurrent therapies are not suitable </CO>, <A> the chart presents laryngectomy combined with thyroidectomy </A>, <CO> depending on the extent of lymph node dissection required </CO>. <E> This highlights surgical intervention as a viable option in the management of advanced cases </E>.\\n\\nSection Name: Induction Chemotherapy\\n====================\\nEntities:-\\nInduction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nTherapeutic Approach : A method or strategy used in the treatment of disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""Induction Chemotherapy\"", Entity2: \""Surgical Intervention\"", Relationship: \""alternative or sequential treatment option\""\\n\\nCausalities:-\\n<C> immediate surgical intervention is either not feasible or considered insufficient </C> <E> The flowchart also considers the option of induction chemotherapy </E> <CO> in cases where immediate surgical intervention is either not feasible or considered insufficient </CO>. <A> tailoring therapeutic approaches tailored to individual patient needs </A>.\\n\\nSection Name: Adjuvant Treatment\\n====================\\nEntities:-\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nNeoplasm Recurrence, Local : The return of a cancer, at the same site, after it has been treated.\\nDisease Progression : The worsening of a disease over time.\\n\\nRelationships:-\\n1. Entity1: \""Primary Treatment\"", Entity2: \""Adjuvant Treatment\"", Relationship: \""followed by\""\\n2. Entity1: \""Adjuvant Treatment\"", Entity2: \""Systemic Therapy\"", Relationship: \""includes\""\\n3. Entity1: \""Adjuvant Treatment\"", Entity2: \""Radiotherapy\"", Relationship: \""includes\""\\n4. Entity1: \""Follow-up Assessments\"", Entity2: \""Treatment Efficacy\"", Relationship: \""used to evaluate\""\\n\\nCausalities:-\\n<C> Following primary treatment </C>, <E> the flowchart addresses the potential for adjuvant treatment pathways </E>. This may include systemic therapy, RT, or further evaluations based on <CO> the patient\\'s response and any recurrence or persistent disease </CO>. It emphasizes <A> the need for follow-up assessments to evaluate treatment efficacy </A>.\\n\\nSection Name: Risk Features and Response Assessment\\n====================\\nEntities:-\\nNeoplasm Invasiveness : The property of a neoplasm to infiltrate and destroy surrounding tissue.\\nSurgical Margins : The edge or border of the tissue removed in cancer surgery.\\nNeoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.\\nExtramural Extension : Extension of a tumor beyond the wall of an organ.\\nPositive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.\\nCancer Management : The process of planning and coordinating the treatment of cancer.\\nCancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""Extramural extension\"", Entity2: \""Treatment decisions\"", Relationship: \""influences\""\\n2. Entity1: \""Positive surgical margin\"", Entity2: \""Treatment decisions\"", Relationship: \""influences\""\\n3. Entity1: \""Ongoing assessment\"", Entity2: \""Response evaluation\"", Relationship: \""leads to\""\\n4. Entity1: \""Response evaluation\"", Entity2: \""Adjustments to treatment\"", Relationship: \""leads to\""\\n5. Entity1: \""Management of cancer\"", Entity2: \""Treatment decisions\"", Relationship: \""involves\""\\n6. Entity1: \""Management of cancer\"", Entity2: \""Ongoing assessment\"", Relationship: \""involves\""\\n7. Entity1: \""Management of cancer\"", Entity2: \""Adjustments to treatment\"", Relationship: \""involves\""\\n\\nCausalities:-\\nThe chart incorporates a segment that takes into account <CO> adverse pathologic features, such as extramural extension or positive margins </CO>, <E> which could influence subsequent treatment decisions </E>. This highlights the importance of <A> ongoing assessment in the management of cancer, leading to response evaluation and adjustments to treatment as necessary </A>.\\n\\nSection Name: NCCN Guidelines Version 4.2024\\n====================\\nEntities:-\\nClinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.\\nNeoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.\\nClinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nMalignant Neoplasm : A malignant neoplasm is a cancerous growth that has the potential to invade and destroy nearby tissue and spread to other parts of the body.\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nCancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network\"", Entity2: \""NCCN Guidelines\"", Relationship: \""provides\""\\n2. Entity1: \""NCCN Guidelines\"", Entity2: \""Clinical Trials\"", Relationship: \""recommend\""\\n3. Entity1: \""NCCN Guidelines\"", Entity2: \""Cancer\"", Relationship: \""related to management of\""\\n\\nCausalities:-\\n<CO> any patient with cancer </CO> <A> the best management is in a clinical trial </A>. <A> Participation in clinical trials is especially encouraged </A>.\\n\\nSection Name: SUPRA-3\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.\\nChemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nClinical Trials As Topic : Research studies that prospectively assign human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nInduction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.\\nClinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\n\\nRelationships:-\\n1. Entity1: \""Total laryngectomy\"", Entity2: \""Laryngectomy\"", Relationship: \""is a type of\""\\n2. Entity1: \""Systemic therapy\"", Entity2: \""RT\"", Relationship: \""concurrent treatment option\""\\n3. Entity1: \""Induction chemotherapy\"", Entity2: \""Other treatments\"", Relationship: \""initial treatment option before\""\\n\\nCausalities:-\\n<CO> Requiring (amenable to) total laryngectomy (T3,N0) </CO>\\n  - <A> Concurrent systemic therapy/RT </A> or <A> RT if patient not medical candidate for concurrent systemic therapy/RT </A>\\n  - <A> Laryngectomy, thyroidectomy and with ipsilateral, central, or bilateral neck dissection </A>\\n  - or\\n  - <A> Induction chemotherapy </A>\\n  - or\\n  - <A> Clinical trials </A>\\n\\nSection Name: Follow-up\\n====================\\nEntities:-\\nFollow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.\\nFollow-Up Procedure : A procedure performed to monitor the progress of a patient\\'s condition after initial treatment.\\nFollow-Up : Medical care given to a patient over time after initial treatment.\\nDisease Recurrence : The return of a sign, symptom, or disease after a remission.\\nRecurrent Disease : The reappearance of a disease after a period of improvement.\\n\\nRelationships:-\\n1. Entity1: \""Follow-up\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""monitoring\""\\n\\nCausalities:-\\n- **Follow-up (FOLL-A, 1 of 2)**\\n  - <CO> Recurrent or persistent disease </CO> (ADV-3)\\n\\nSection Name: Adverse Pathologic Features\\n====================\\nEntities:-\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nExtranodal Extension : The spread of cancer beyond the lymph node capsule.\\nPositive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""pN1\"", Entity2: \""Radiotherapy\"", Relationship: \""Consideration for treatment\""\\n2. Entity1: \""Extranodal extension\"", Entity2: \""Systemic Therapy\"", Relationship: \""Treatment option\""\\n3. Entity1: \""Extranodal extension\"", Entity2: \""Radiotherapy\"", Relationship: \""Treatment option\""\\n4. Entity1: \""Positive surgical margin\"", Entity2: \""Systemic Therapy\"", Relationship: \""Treatment option\""\\n5. Entity1: \""Positive surgical margin\"", Entity2: \""Radiotherapy\"", Relationship: \""Treatment option\""\\n\\nCausalities:-\\n- <CO>pN1 without other risk features</CO>\\n  - <C>Adverse pathologic features</C>\\n  - <A>Consider RT</A>\\n  - <CO>Extranodal extension and/or positive margin</CO>\\n  - <CO>Other risk features</CO>\\n  - <A>Systemic therapy/RT (category 1)</A>\\n  - <A>RT or Consider systemic therapy/RT</A>\\n\\nSection Name: Response Assessment\\n====================\\nEntities:-\\nResponse Evaluation : The process of assessing the response of a disease to treatment, often used in clinical trials to determine the effectiveness of a therapy.\\nResponse To Treatment : A clinical finding indicating the response of a condition to a therapeutic intervention.\\n\\nRelationships:-\\n\\nSection Name: Principles of Surgery and Radiation Therapy\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nRadiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\n\\nRelationships:-\\n1. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Radiation Therapy\"", Relationship: \""complementary treatments\""\\n\\nCausalities:-\\n**Principles of Surgery (SURG-A).**\\n\\n**Principles of Radiation Therapy (SUPRA-A).**\\n\\nSection Name: Principles of Systemic Therapy\\n====================\\nEntities:-\\nCisplatin : An inorganic and water-soluble platinum complex, cisplatin is an antineoplastic agent that is used in the treatment of various cancers.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nRadiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\n\\nRelationships:-\\n1. Entity1: \""Cisplatin\"", Entity2: \""Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""preferred agent\""\\n2. Entity1: \""Cisplatin\"", Entity2: \""Concurrent Systemic Therapy/RT\"", Relationship: \""used in\""\\n\\nCausalities:-\\n<CO> When using concurrent systemic therapy/RT </CO>, <A> the preferred agent is cisplatin (category 1) </A>.\\n--------------------------------------------------\\nPage Number: 130\\n\\nSection Name: Pathological N (pN)\\n====================\\nEntities:-\\nLymph Nodes : Small, bean-shaped structures that are part of the body\\'s lymphatic system. They filter lymph fluid and store white blood cells that help fight infection.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nTnm Staging : A system used to describe the size and spread of cancer in a standardized way. T refers to the size of the tumor, N to the involvement of lymph nodes, and M to metastasis.\\nLymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\nTnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient\\'s body.\\nLymph Node : An organ of the lymphatic system and the adaptive immune system.\\n\\nRelationships:-\\n1. Entity1: \""Lymph Nodes\"", Entity2: \""Neoplasm Metastasis\"", Relationship: \""involved in\""\\n2. Entity1: \""TNM Staging\"", Entity2: \""Lymph Nodes\"", Relationship: \""includes\""\\n3. Entity1: \""TNM Staging\"", Entity2: \""Neoplasm Metastasis\"", Relationship: \""describes\""\\n\\nCausalities:-\\n<CO> NX: Regional lymph nodes cannot be assessed </CO>\\n<CO> N0: No regional lymph node metastasis </CO>\\n<CO> N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(\u2013) </CO>\\n<CO> N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2212); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(\u2212); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2a: Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N3: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(\u2212); or metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>\\n<CO> N3a: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N3b: Metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>\\n<CO> Note: A designation of \u201cU\u201d or \u201cL\u201d may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L). Similarly, clinical and pathological ENE should be recorded as ENE(\u2212) or ENE(+). </CO>\\n\\nSection Name: Distant Metastasis (M)\\n====================\\nEntities:-\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\n\\nRelationships:-\\n1. Entity1: \""M0\"", Entity2: \""Distant Metastasis\"", Relationship: \""is a category of\""\\n2. Entity1: \""M1\"", Entity2: \""Distant Metastasis\"", Relationship: \""is a category of\""\\n\\nCausalities:-\\n### Distant Metastasis (M)\\n\\n- **M0**: No distant metastasis\\n- **M1**: Distant metastasis\\n\\nSection Name: Histologic Grade (G)\\n====================\\nEntities:-\\nNeoplasm Grading : A system of classifying cancer cells in terms of how abnormal they look under a microscope and how quickly the tumor is likely to grow and spread.\\nHistologic Grade : A measure of how much tumor cells differ from healthy cells, used to assess the aggressiveness of cancer.\\n\\nRelationships:-\\n1. Entity1: \""GX\"", Entity2: \""Grade cannot be assessed\"", Relationship: \""is described as\""\\n2. Entity1: \""G1\"", Entity2: \""Well differentiated\"", Relationship: \""is described as\""\\n3. Entity1: \""G2\"", Entity2: \""Moderately differentiated\"", Relationship: \""is described as\""\\n4. Entity1: \""G3\"", Entity2: \""Poorly differentiated\"", Relationship: \""is described as\""\\n\\nCausalities:-\\n<CO>GX</CO>: <E>Grade cannot be assessed</E>\\n<CO>G1</CO>: <E>Well differentiated</E>\\n<CO>G2</CO>: <E>Moderately differentiated</E>\\n<CO>G3</CO>: <E>Poorly differentiated</E>\\n\\nSection Name: Prognostic Stage Groups\\n====================\\nEntities:-\\nNeoplasm Staging : Methods and systems of classifying neoplasms according to extent of disease.\\nTumor Staging : A system for describing the size and spread of cancer within the body.\\nTnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient\\'s body.\\n\\nRelationships:-\\n1. Entity1: \""Stage 0\"", Entity2: \""Tis N0 M0\"", Relationship: \""defined by\""\\n2. Entity1: \""Stage I\"", Entity2: \""T1 N0 M0\"", Relationship: \""defined by\""\\n3. Entity1: \""Stage II\"", Entity2: \""T2 N0 M0\"", Relationship: \""defined by\""\\n4. Entity1: \""Stage III\"", Entity2: \""T3 N0 M0, T1 N1 M0, T2 N1 M0, T3 N1 M0\"", Relationship: \""defined by\""\\n5. Entity1: \""Stage IVA\"", Entity2: \""T1 N2 M0, T2 N2 M0, T3 N2 M0, T4a N0,N1,N2 M0\"", Relationship: \""defined by\""\\n6. Entity1: \""Stage IVB\"", Entity2: \""Any T N3 M0, T4b Any N M0\"", Relationship: \""defined by\""\\n7. Entity1: \""Stage IVC\"", Entity2: \""Any T Any N M1\"", Relationship: \""defined by\""\\n--------------------------------------------------\\nPage Number: 47\\n\\nSection Name: Overview of Radiation Therapy Guidelines\\n====================\\nEntities:-\\nRadiation Therapy : The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\nMalignant Neoplasm : A disease characterized by uncontrolled, abnormal growth of cells that can invade and destroy nearby tissue and spread to other parts of the body.\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.\\nGlottic Larynx Cancer : A malignant neoplasm located in the glottic region of the larynx.\\nLaryngeal Cancer : Cancer that occurs in the larynx, or voice box, which may include the glottic region.\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\n\\nRelationships:-\\n1. Entity1: \""Radiation Therapy\"", Entity2: \""Cancer\"", Relationship: \""treats\""\\n2. Entity1: \""NCCN Guidelines\"", Entity2: \""Cancer\"", Relationship: \""guides treatment for\""\\n3. Entity1: \""NCCN Guidelines\"", Entity2: \""Radiation Therapy\"", Relationship: \""specifies use of\""\\n\\nCausalities:-\\nThe image presents a detailed flowchart outlining the principles of radiation therapy specifically for the <C> treatment of cancer in the glottic larynx </C>, <CO> as per the National Comprehensive Cancer Network (NCCN) guidelines (version 2.2024) </CO>. <E> This structured guidance delineates various treatment protocols </E>, <A> stratified by risk levels and therapeutic approaches </A>.\\n\\nSection Name: Principles of Radiation Therapy\\n====================\\nEntities:-\\nRadiation Therapy : The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nGy : Gray, a unit of ionizing radiation dose in the International System of Units (SI), defined as the absorption of one joule of radiation energy per kilogram of matter.\\nGray (Unit) : A unit of absorbed radiation dose of ionizing radiation, defined as the absorption of one joule of radiation energy per kilogram of matter.\\n\\nRelationships:-\\n1. Entity1: \""Tis, N0\"", Entity2: \""60.75 Gy (2.25 Gy/fraction) to 66 Gy (2.0 Gy/fraction)\"", Relationship: \""treatment protocol\""\\n2. Entity1: \""T1, N0\"", Entity2: \""63 Gy (2.25 Gy/fraction) to 66 Gy (2.0 Gy/fraction) or 50 Gy (3.12 Gy/fraction) to 52 Gy (3.28 Gy/fraction)\"", Relationship: \""treatment protocol\""\\n3. Entity1: \""T2, N0\"", Entity2: \""65.25 Gy (2.25 Gy/fraction) to 70 Gy (2.0 Gy/fraction)\"", Relationship: \""treatment protocol\""\\n4. Entity1: \""\u2265T2, N1 (PTV High risk)\"", Entity2: \""66 Gy (2.2 Gy/fraction) to 70 Gy (2.0 Gy/fraction)\"", Relationship: \""treatment protocol\""\\n5. Entity1: \""\u2265T2, N1 (Low to intermediate risk)\"", Entity2: \""44\u201350 Gy (2.0 Gy/fraction) to 54\u201363 Gy (1.6\u20131.8 Gy/fraction)\"", Relationship: \""treatment protocol\""\\n\\nCausalities:-\\n<CO>Tis, N0</CO>: <A>60.75 Gy (2.25 Gy/fraction) to 66 Gy (2.0 Gy/fraction)</A>\\n<CO>T1, N0</CO>: <A>63 Gy (2.25 Gy/fraction, preferred) to 66 Gy (2.0 Gy/fraction) or 50 Gy (3.12 Gy/fraction) to 52 Gy (3.28 Gy/fraction)</A>\\n<CO>T2, N0</CO>: <A>65.25 (2.25 Gy/fraction) to 70 Gy (2.0 Gy/fraction)</A>\\n<CO>\u2265T2, N1</CO>: <A>PTV High risk: Primary tumor and involved lymph nodes (includes possible local subclinical infiltration at the primary site and at the high-risk level lymph node(s))</A>\\n<A>Fractionation: 66 Gy (2.2 Gy/fraction) to 70 Gy (2.0 Gy/fraction); daily Monday\u2013Friday in 6\u20137 weeks</A>\\n<A>Concomitant boost accelerated RT: 72 Gy/6 weeks (1.8 Gy/fraction, large field; 1.5 Gy boost as second daily fraction during last 12 treatment days)</A>\\n<A>66\u201370 Gy (2.0 Gy/fraction; 6 fractions/wk accelerated)</A>\\n<A>Hyperfractionation: 79.2\u201381.6 Gy/7 weeks (1.2 Gy/fraction, twice daily)</A>\\n<CO>Low to intermediate risk</CO>: <A>Sites of suspected subclinical spread</A>\\n<A>44\u201350 Gy (2.0 Gy/fraction) to 54\u201363 Gy (1.6\u20131.8 Gy/fraction)</A>\\n\\nSection Name: Concurrent Systemic Therapy/RT\\n====================\\nEntities:-\\nCisplatin : A platinum-containing antineoplastic agent used in the treatment of various cancers.\\nCarboplatin : An organoplatinum compound that possesses antineoplastic activity.\\nFluorouracil : A chemotherapy drug used to treat various types of cancer.\\n\\nRelationships:-\\n1. Entity1: \""concurrent systemic therapy/RT\"", Entity2: \""cisplatin\"", Relationship: \""uses\""\\n2. Entity1: \""concurrent systemic therapy/RT\"", Entity2: \""carboplatin and 5-FU\"", Relationship: \""uses\""\\n3. Entity1: \""multiagent chemotherapy\"", Entity2: \""toxicity burden\"", Relationship: \""increases\""\\n\\nCausalities:-\\n<CO>Based on published data</CO>, <A>concurrent systemic therapy/RT most commonly uses conventional fractionation at 2.0 Gy per fraction to a typical dose of 70 Gy in 7 weeks with single-agent cisplatin given every 3 weeks at 100 mg/m\u00b2</A>; <CO>2\u20133 cycles of chemotherapy are used depending on the radiation fractionation scheme (RTOG 0129)</CO>. <CO>When carboplatin and 5-FU are used</CO>, <A>the recommended regimen is standard fractionation plus 3 cycles of chemotherapy</A>. <CO>Other fraction sizes (e.g., 1.8 Gy, conventional), multiagent chemotherapy, other dosing schedules of cisplatin, or altered fractionation with chemotherapy</CO> <E>are efficacious</E>, and <C>there is no consensus on the optimal approach</C>. <C>In general, the use of concurrent systemic therapy/RT</C> <E>carries a high toxicity burden</E>; <C>multiagent chemotherapy</C> <E>will likely further increase the toxicity burden</E>. <A>For any systemic therapy/RT approach, close attention should be paid to published reports for the specific chemotherapy agent, dose, and schedule of administration</A>. <A>Systemic therapy/RT should be performed by an experienced team and should include substantial supportive care</A>.\\n\\nSection Name: Treatment Modalities\\n====================\\nEntities:-\\nIntensity-Modulated Radiotherapy : A type of conformal radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.\\nIntensity Modulated Radiation Therapy : A type of conformal radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.\\nIntensity-Modulated Radiation Therapy : An advanced type of high-precision radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.\\nRadiotherapy, Conformal : A type of radiotherapy that uses imaging to conform the radiation dose to the shape of the tumor.\\n3D Conformal Radiation Therapy : A technique in radiotherapy that uses imaging to conform the radiation dose to the shape of the tumor.\\nChemotherapy, Adjuvant : Treatment with drugs that kill cancer cells, often used in conjunction with other therapies.\\nChemotherapy : The treatment of disease by the use of chemical substances, especially the treatment of cancer by cytotoxic and other drugs.\\nDrug Therapy, Combination : The use of two or more drugs to achieve a therapeutic effect.\\nSystemic Therapy : A type of therapy that uses substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Intensity-Modulated Radiation Therapy (IMRT)\"", Entity2: \""3D Conformal Radiation Therapy (3D-CRT)\"", Relationship: \""are delivery methods for radiation therapy\""\\n2. Entity1: \""Chemotherapy\"", Entity2: \""Radiation Therapy\"", Relationship: \""is integrated with for aggressive or advanced cancer cases\""\\n\\nCausalities:-\\n<CO> contingent upon patient-specific considerations </CO> <A> suggests either Intensity-Modulated Radiation Therapy (IMRT) or 3D Conformal Radiation Therapy (3D-CRT) as delivery methods </A>. <A> These advanced techniques are employed to optimize treatment accuracy </A>, <E> preserving surrounding healthy tissue and improving overall patient outcomes </E>. <A> a focus on concurrent systemic therapies underlines the importance of integrating chemotherapy </A>, particularly <CO> for patients with more aggressive forms of cancer or those demonstrating advanced disease characteristics </CO>.\\n\\nSection Name: Additional Information\\n====================\\nEntities:-\\nClinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.\\nClinical Trial : A clinical trial is a research study in which one or more human subjects are prospectively assigned to one or more interventions to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes.\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nIntensity-Modulated Radiation Therapy : An advanced type of high-precision radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.\\nIntensity Modulated Radiation Therapy : A type of conformal radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.\\nThree-Dimensional Conformal Radiation Therapy : A type of external beam radiation therapy that uses a computer to create a 3-dimensional picture of the tumor so that multiple radiation beams can be shaped exactly to the contour of the treatment area.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network\"", Entity2: \""Clinical trial\"", Relationship: \""encourages participation in\""\\n2. Entity1: \""Intensity-Modulated Radiation Therapy\"", Entity2: \""Three-Dimensional Conformal Radiation Therapy\"", Relationship: \""recommended alternatives\""\\n\\nCausalities:-\\n<A> Participation in clinical trials </A> is especially encouraged. <A> Either IMRT (preferred) or 3D-CRT is recommended. </A>\\n\\nSection Name: Conclusion\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.\\nMalignant Neoplasm Of Glottis : A malignant tumor located in the glottic region of the larynx.\\nLaryngeal Cancer : Cancer that occurs in the larynx, or voice box, which may include the glottic region.\\nPrognosis : A medical term for predicting the likely or expected development of a disease.\\nEvidence-Based Practice : Healthcare practices that are based on scientific evidence and research.\\nEvidence-Based Medicine : An approach to medical practice intended to optimize decision-making by emphasizing the use of evidence from well-designed and conducted research.\\n\\nRelationships:-\\n1. Entity1: \""treatment paradigms\"", Entity2: \""glottic larynx cancer\"", Relationship: \""encapsulates\""\\n2. Entity1: \""personalized treatment plans\"", Entity2: \""prognosis\"", Relationship: \""improves\""\\n\\nCausalities:-\\n<C> glottic larynx cancer </C>. <CO> the nuances of each patient\\'s condition </CO>. <A> personalized treatment plans </A> <E> promoting effective management and improved prognosis </E>. <A> deliver clear, evidence-based interventions </A> <CO> considering the complexities involved in cancer treatment </CO>.\\n'}""",valid,increases risk,2,B,"edge - The edge which needs to be verified.
explanation - Explanation of what the edge represents and its validity.
causal_direction - Either Positive or Negative or Unknown. A positive influence direction indicates that both factors change in the same direction (e.g. an increase causes an increase effect). A negative influence direction indicates the opposite changes (e.g. an increase causes a decrease effect).
causal_factor - Is necessary or sufficient condition for an effect to occur. Exposure is a term commonly used in epidemiology to denote any condition that is considered as a possible cause of disease. Exposure is considered necessary when it always precedes the effects (e.g. symptoms) and always presents when the effects occur. A sufficient cause is a causal factor whose presence or occurrence guarantees the occurrence of symptom.
causal_distance - Either Distal or Proximal or Unknown. The distal factors lie towards the beginning of causal chain (i.e. indirect causal factors). The the proximal factors lie towards the end of the chain (i.e. cause directly or almost directly the effect).

Causality Tags:
<A> for action, <C> for cause, <CO> for condition and <E> for effect.
Cause (C): The reason or origin that leads to an effect. Causes often involve disease conditions, risk factors, or underlying mechanisms.
Effect (E): The outcome or result of a cause. Effects usually represent clinical outcomes, complications, or results of a specific cause.
Condition (CO): The circumstance or prerequisite required for an action or effect to occur. Conditions may include patient characteristics, clinical scenarios, or specific diagnostic criteria.
Action (A): The recommended or described response or activity to address a cause or condition. Actions typically involve clinical interventions, diagnostic procedures, or treatment recommendations.


`NODE1`:
id: N_State_1__patient
label: State of Nearby Lymph Nodes with Cancer in Patient
description: This node represents the state of involvement of nearby lymph nodes in a patient with cancer. It is a decision node used to predict the extent of lymph node metastasis, which is crucial for cancer staging and treatment planning. The states range from no involvement (n0) to extensive involvement (n3), with intermediate states indicating varying degrees of lymph node cancer presence.
type: Decision Node
observability: Needs to be Predicted
states: [{'state_name': 'nx', 'state_description': 'The regional lymph nodes cannot be assessed.'}, {'state_name': 'n3', 'state_description': 'Metastasis in lymph node(s) along the course of a major blood vessel or in a lymph node that is more than 6 cm in greatest dimension.'}, {'state_name': 'n2c', 'state_description': 'Metastasis in bilateral or contralateral lymph nodes, each 6 cm or less in greatest dimension.'}, {'state_name': 'n2b', 'state_description': 'Metastasis in multiple ipsilateral lymph nodes, each 6 cm or less in greatest dimension.'}, {'state_name': 'n2a', 'state_description': 'Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension.'}, {'state_name': 'n2', 'state_description': 'Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension, or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension.'}, {'state_name': 'n1', 'state_description': 'Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension.'}, {'state_name': 'n0', 'state_description': 'No regional lymph node metastasis.'}]

`NODE2`:
id: Size_of_Involved_Lymph_Nodes_6
label: Size of Involved Lymph Nodes
description: This node represents the size of lymph nodes that are involved, potentially indicating the extent of lymphatic spread in a cancerous process. The size of involved lymph nodes is a critical factor in staging cancer, assessing prognosis, and determining treatment strategies. Larger lymph nodes may suggest more extensive disease and could influence clinical decisions.
type: Patient Situation
observability: Unobserved
states: [{'state_name': 'more_than_6_cm', 'state_description': 'The lymph nodes involved are larger than 6 centimeters, indicating significant enlargement, which may suggest advanced disease or extensive lymphatic involvement.'}, {'state_name': 'three_cm_to_six_cm', 'state_description': 'The lymph nodes involved are between 3 and 6 centimeters in size, indicating moderate enlargement, which may suggest a moderate level of disease involvement.'}, {'state_name': 'smaller_than_three_cm', 'state_description': 'The lymph nodes involved are smaller than 3 centimeters, indicating mild enlargement, which may suggest early or limited disease involvement.'}, {'state_name': 'absent', 'state_description': 'No lymph nodes are involved, indicating no detectable lymphatic spread of the disease.'}]

`EDGE1`:
{'edges_ids': ['N_State_1__patient', 'Size_of_Involved_Lymph_Nodes_6'], 'edge': '(N_State_1__patient) causes (Size_of_Involved_Lymph_Nodes_6)', 'explanation': ['The edge suggests that the state of nearby lymph nodes with cancer in a patient causes the size of the involved lymph nodes.', 'In clinical practice, the size of the lymph nodes is a factor that helps determine the state of involvement, not the other way around.', 'Therefore, the causal relationship is not valid as described. The size of the lymph nodes contributes to determining the state of involvement, not the state causing the size.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Proximal'}

`EDGE2`:
{'edges_ids': ['Size_of_Involved_Lymph_Nodes_6', 'N_State_1__patient'], 'edge': '(Size_of_Involved_Lymph_Nodes_6) causes (N_State_1__patient)', 'explanation': ['The size of involved lymph nodes is a critical factor in determining the N state in cancer staging.', 'Larger lymph nodes often correlate with more advanced N states, such as n2 or n3, indicating more extensive lymphatic involvement.', 'The causal direction is positive because an increase in lymph node size is associated with a more advanced N state.', 'The causal factor is neither necessary nor sufficient on its own, as other factors also influence the N state.', 'The causal distance is proximal because the size of lymph nodes directly affects the N state.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Proximal'}

`INFORMATION FROM KNOWLEDGE BASE`:
--------------------------------------------------
Page Number: 102

Section Name: Head and Neck Cancers - Principles of Surgery
====================
Entities:-
Surgical Procedures, Operative : Manual or operative procedures used in the treatment of disease, injuries, or deformities.
Lymphatic System : Part of the circulatory system and a vital part of the immune system, comprising a network of lymphatic vessels that carry a clear fluid called lymph.
Neoplasms : New abnormal growth of tissue in animals or plants; a tumor.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Neoplasm Staging : Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Metastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.
Surgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Lymphatic Structure : Anatomical structure that is part of the lymphatic system.
Tumor : An abnormal mass of tissue that results when cells divide more than they should or do not die when they should.
Staging : The process of determining the size and spread of cancer within the body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Cancer Staging : The process of determining the extent to which a cancer has developed by growing and spreading.

Relationships:-
1. Entity1: ""surgical management"", Entity2: ""regional lymphatics"", Relationship: ""dictated by tumor staging""
2. Entity1: ""neck dissections"", Entity2: ""primary tumor"", Relationship: ""part of treatment""
3. Entity1: ""surgery"", Entity2: ""ipsilateral side of the neck"", Relationship: ""risk for metastases""

Causalities:-
<C> The extent of the tumor at initial tumor staging </C> <E> dictates the surgical management of regional lymphatics </E>. These guidelines apply to the performance of neck dissections as part of treatment of the primary tumor. <CO> Patients undergoing surgery for resection of the primary tumor </CO> <A> will undergo dissection of the ipsilateral side of the neck that is at greatest risk for metastases </A>.

Section Name: Neck Management
====================
Entities:-
Tongue : A muscular organ in the mouth that is involved in tasting, swallowing, and speech.
Palate : The roof of the mouth, separating the oral and nasal cavities.
Larynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.
Hypopharynx : The bottom part of the pharynx, which is the cavity behind the nose and mouth.
Nasopharynx : The upper part of the pharynx, connecting with the nasal cavity above the soft palate.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Metastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.
Squamous Cell Carcinoma : A type of cancer that begins in the squamous cells, which are thin, flat cells that look like fish scales.
Biopsy : The removal of cells or tissues for examination under a microscope.

Relationships:-
1. Entity1: ""Tumor sites"", Entity2: ""Bilateral lymphatic drainage"", Relationship: ""associated with""
2. Entity1: ""Elective neck dissection"", Entity2: ""Risk of occult metastasis"", Relationship: ""based on""
3. Entity1: ""SLN biopsy"", Entity2: ""Elective neck dissection"", Relationship: ""guides decision-making for""

Causalities:-
- **<C> Tumor sites that frequently have bilateral lymphatic drainage </C>** (e.g., base of tongue, palate, supraglottic larynx, hypopharynx, nasopharynx, deep pre-epiglottic space involvement) <E> often should have both sides of the neck dissected </E> with the extent of dissection determined as suggested below. For those patients with tumors at or approaching the midline, <CO> both sides of the neck are at risk for metastases </CO>, and <A> bilateral neck dissections should be performed </A>.

- <CO> Patients with advanced lesions involving the anterior tongue, floor of the mouth, or alveolus that approximate or cross the midline </CO> <A> should undergo contralateral selective/modified neck dissection </A> as necessary to achieve adequate tumor resection.

- **<C> Elective neck dissection </C>** <A> should be based on risk of occult metastasis in the appropriate nodal basin </A>. For oral cavity squamous cell carcinoma, <C> SLN biopsy or the primary tumor depth of invasion </C> is currently <E> the best predictor of occult metastatic disease </E> and <A> should be used to guide decision-making </A>. <CO> For tumors with a depth greater than 3 mm </CO>, <A> elective dissection should be strongly considered if RT is not already planned </A>. Recent randomized trial evidence supports the effectiveness of elective neck dissection in patients with oral cavity cancers greater than 3 mm in depth of invasion.

  - <CO> For a depth less than 2 mm </CO>, <A> elective dissection is only indicated in highly selective situations </A>. <CO> For a depth of 2–4 mm </CO>, <A> clinical judgment (as to reliability of follow-up, clinical suspicion, and other factors) must be utilized to determine appropriateness of elective dissection </A>. Elective dissections are generally selective, preserving all major structures, unless operative findings dictate otherwise.

Section Name: Types of Neck Dissection
====================
Entities:-
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Larynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.

Relationships:-
1. Entity1: ""N0"", Entity2: ""Selective neck dissection"", Relationship: ""associated with""
2. Entity1: ""N3"", Entity2: ""Comprehensive neck dissection"", Relationship: ""associated with""
3. Entity1: ""Level VI neck dissection"", Entity2: ""Larynx"", Relationship: ""performed for""
4. Entity1: ""Level VI neck dissection"", Entity2: ""Hypopharynx"", Relationship: ""performed for""

Causalities:-
- **The type of neck dissection (comprehensive or selective)** is defined according to <CO> preoperative clinical staging </CO>, is determined at the discretion of the surgeon, and is based on the initial preoperative staging as follows:
  - **N0:** <A> Selective neck dissection </A>
    - Oral cavity at least levels I–III
    - Oropharynx at least levels II–IV
    - Hypopharynx at least levels II–IV and level VI when appropriate
    - Larynx at least levels II–IV and level VI when appropriate
  - **N1–N2a–c:** <A> Selective or comprehensive neck dissection </A> (Discussion)
  - **N3:** <A> Comprehensive neck dissection </A>

- <C> Level VI neck dissections are performed for certain primary sites (such as the larynx and hypopharynx) </C> <E> as required to resect the primary tumor and any clinically evident neck nodes </E>. <CO> Elective dissection depends on primary tumor extent and site </CO>. <CO> For advanced glottic and hypopharyngeal cancers treated with primary surgery </CO>, <A> a level VI dissection (including pretracheal lymph nodes, the Delphian lymph node, and unilateral or bilateral paratracheal lymph nodes) and hemithyroidectomy to total thyroidectomy are appropriate </A>.

- <CO> For primary subglottic tumors or glottic cancers with significant subglottic extension </CO>, <A> a level VI dissection with unilateral or total thyroidectomy is considered appropriate </A> based on the extent of the primary tumor. <CO> For example, a T4a glottic tumor with extension through the cricothyroid membrane and subglottic extension </CO> <A> should include thyroidectomy and pretracheal and bilateral paratracheal lymph node dissection </A>. <A> Parathyroid glands should be preserved in situ or auto transplanted as indicated </A>.
--------------------------------------------------
Page Number: 55

Section Name: General Information
====================
Entities:-
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Nccn Guidelines : Clinical practice guidelines in oncology developed by the National Comprehensive Cancer Network.

Relationships:-
1. Entity1: ""NCCN Guidelines"", Entity2: ""National Comprehensive Cancer Network"", Relationship: ""produced by""

Section Name: Important Notes
====================
Entities:-
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medical, surgical, or behavioral interventions.
Clinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Neoplasms : New abnormal growth of tissue that can be benign or malignant.
Malignant Neoplastic Disease : A disease resulting from the growth of malignant neoplasms.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""Clinical Trials"", Entity2: ""Cancer"", Relationship: ""recommended for""
2. Entity1: ""NCCN"", Entity2: ""Clinical Trials"", Relationship: ""encourages participation in""

Causalities:-
<C> NCCN believes that the best management of any patient with cancer is in a clinical trial </C>. <A> Participation in clinical trials is especially encouraged </A>.

Section Name: Principles
====================
Entities:-
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Chemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.

Relationships:-
1. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Radiation Therapy"", Relationship: ""Both are principles of cancer treatment methods.""
2. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""Both are principles of cancer treatment methods.""
3. Entity1: ""Principles of Radiation Therapy"", Entity2: ""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""Both are principles of cancer treatment methods.""

Causalities:-
### Principles

- **Principles of Surgery (SURG-A)**
- **Principles of Radiation Therapy (SUPRA-A)**
- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**

Section Name: Adverse Pathologic Features
====================
Entities:-
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.
Perineural Invasion : The presence of cancer cells surrounding or tracking along a nerve within the perineural space.
Vascular Invasion : The invasion of cancer cells into blood vessels.
Lymphatic Invasion : The invasion of cancer cells into lymphatic vessels.

Relationships:-
1. Entity1: ""Extranodal extension"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
2. Entity1: ""Positive margins"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
3. Entity1: ""Close margins"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
4. Entity1: ""pT3 or pT4 primary"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
5. Entity1: ""pN2 or pN3 nodal disease"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
6. Entity1: ""Perineural invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
7. Entity1: ""Vascular invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
8. Entity1: ""Lymphatic invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""

Causalities:-
<C> Extranodal extension </C>
<C> Positive margins </C>
<C> Close margins </C>
<C> pT3 or pT4 primary </C>
<C> pN2 or pN3 nodal disease </C>
<C> Perineural invasion </C>
<C> Vascular invasion </C>
<C> Lymphatic invasion </C>

Section Name: Response Assessment
====================
Entities:-
Chemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Primary Site : The original location where a tumor or cancer begins.
Complete Remission : The disappearance of all signs of cancer in response to treatment.
Partial Remission : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
Radiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.

Relationships:-
1. Entity1: ""induction chemotherapy"", Entity2: ""Primary site"", Relationship: ""treatment outcome""
2. Entity1: ""Definitive RT"", Entity2: ""Primary site"", Relationship: ""treatment option""
3. Entity1: ""RT"", Entity2: ""Primary site"", Relationship: ""treatment option""
4. Entity1: ""Surgery"", Entity2: ""unresectable nodal disease"", Relationship: ""treatment option""

Causalities:-
<C> Response after induction chemotherapy </C>: <E> Primary site: CR </E> <E> Primary site: PR </E> <E> Primary site: < PR </E> <A> Definitive RT </A> (category 1) <A> RT </A> (category 1) or <A> systemic therapy/RT </A> (category 2B) <A> Surgery </A> or <A> unresectable nodal disease </A>

Section Name: Follow-up
====================
Entities:-
Follow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.
Follow-Up Procedure : A procedure where a patient is monitored over time to assess the progress of a condition or the effects of treatment.
Follow-Up (Medicine) : The process of monitoring a patient's health over time after treatment or diagnosis.
Disease Recurrence : The return of a sign, symptom, or disease after a remission.
Recurrent Disease : A disease that returns after a period of remission.
Recurrence (Medicine) : The return of a disease or condition after a period of improvement.

Relationships:-
1. Entity1: ""Follow-up"", Entity2: ""Recurrent or persistent disease"", Relationship: ""monitoring""

Causalities:-
### Follow-up

- **Follow-up** (FOLL-A, 1 of 2)
- **Recurrent or persistent disease** (ADV-3)

Section Name: Risk Features
====================
Entities:-
Radiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Adverse pathologic features"", Entity2: ""RT"", Relationship: ""Consideration for treatment""
2. Entity1: ""Adverse pathologic features"", Entity2: ""Systemic therapy"", Relationship: ""Consideration for treatment""

Causalities:-
- **No adverse pathologic features**
- **Other risk features**
- **Adverse pathologic features**:
  - <C> Extranodal extension and/or positive margin </C>
  - <A> RT or consider systemic therapy/RT </A>

Section Name: Post-Therapy Evaluation
====================
Entities:-
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Neck : The neck is the part of the body that separates the head from the torso and provides the mobility and movements of the head.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Neck Evaluation"", Relationship: ""evaluated in""
2. Entity1: ""RT"", Entity2: ""Neck Evaluation"", Relationship: ""evaluated in""

Causalities:-
<CO> Post Systemic Therapy/RT or RT Neck </CO> <A> Evaluation </A>

Section Name: Flowchart Overview
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Supraglottic Larynx : The part of the larynx located above the vocal cords, including the epiglottis and aryepiglottic folds.
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.

Relationships:-
1. Entity1: ""NCCN Guidelines"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""guides management of""
2. Entity1: ""NCCN Guidelines"", Entity2: ""healthcare professionals"", Relationship: ""used by""

Causalities:-
<C> cancer of the supraglottic larynx </C> <E> evaluate patient responses following treatment </E> <CO> based on observed outcomes </CO> <A> evaluation of the primary site and determining subsequent steps </A>.

Section Name: Assessment and Treatment Decisions
====================
Entities:-
Induction Chemotherapy : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Complete Response : The disappearance of all signs of cancer in response to treatment.
Partial Response : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Complete Response"", Entity2: ""Radiation Therapy"", Relationship: ""leads to""
2. Entity1: ""Complete Response"", Entity2: ""Surgery"", Relationship: ""leads to""
3. Entity1: ""Partial Response"", Entity2: ""Systemic Therapy"", Relationship: ""leads to""
4. Entity1: ""Partial Response"", Entity2: ""Radiation Therapy"", Relationship: ""leads to""

Causalities:-
<C> responses to initial treatments such as induction chemotherapy </C> <E> Three main response categories are recognized: Complete Response (CR), Partial Response (PR), and less than Partial Response (< PR) </E>. These categories are pivotal in determining the next steps. <C> CR </C> <E> indicates full resolution of the disease at the primary site </E>, <A> leading to the consideration of definitive radiation therapy or the likelihood of surgery </A>. Conversely, <C> PR </C> <E> suggests that the disease has improved but not completely resolved </E>, <A> which directs the pathway towards either systemic therapy or continued radiation therapy </A>, <A> with further evaluation necessary </A>.

Section Name: Adverse Pathologic Features and Follow-up
====================
Entities:-
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Neoplasm Recurrence, Local : The return of a tumor or cancer, at the original site, after it has been treated.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Recurrent Neoplasm : A neoplasm that has returned after treatment.
Metastatic Neoplasm : A neoplasm that has spread from its original site to one or more other places in the body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Cancer Recurrence : The return of cancer after treatment and after a period of time during which the cancer was undetectable.
Metastasis : Spread of a cancer or other disease from one organ or part to another not directly connected with it.

Relationships:-
1. Entity1: ""Adverse pathologic features"", Entity2: ""Treatment decisions"", Relationship: ""Influence""
2. Entity1: ""Adverse features"", Entity2: ""Surgical intervention"", Relationship: ""Recommendation""
3. Entity1: ""Absence of adverse features"", Entity2: ""Radiation therapy"", Relationship: ""Pathway""
4. Entity1: ""Follow-up process"", Entity2: ""Recurrent or persistent disease"", Relationship: ""Detection""
5. Entity1: ""Recurrent or persistent disease"", Entity2: ""Advanced disease management"", Relationship: ""Necessity""

Causalities:-
<C> The presence of adverse pathologic features — such as extranodal extension or positive margins </C> <E> can directly influence treatment decisions </E>. <CO> If adverse features are found </CO>, <A> surgical intervention is recommended </A>. <CO> In cases where there are no adverse features </CO>, the patient may proceed directly to radiation therapy or continued systemic treatment, emphasizing the tailored approach based on the individual patient's disease characteristics.

Furthermore, the chart includes a section addressing the follow-up process after initial treatment. <CO> If there are signs of recurrent or persistent disease </CO>, <A> additional evaluations and treatment modalities may be necessary </A>. These evaluations <E> lead to specific recommendations for advanced disease management, denoted as ADV-3 on the chart </E>, emphasizing the importance of continuous monitoring and assessment in cancer care.
--------------------------------------------------
Page Number: 51

Section Name: Introduction
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Malignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.
Supraglottic Laryngeal Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is above the vocal cords.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network (NCCN)"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""provides guidelines for""
2. Entity1: ""healthcare professionals"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""manage""

Causalities:-
The provided image is a detailed flowchart from the National Comprehensive Cancer Network (NCCN) guidelines regarding the <C> clinical staging and treatment protocols for cancer of the supraglottic larynx </C>. This flowchart is structured to <A> guide healthcare professionals through the stages of treatment </A> based on <CO> clinical findings </CO>, emphasizing the <E> complexity and systematic approach required in managing this type of cancer </E>.

Section Name: Clinical Staging
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Total Laryngectomy : A surgical procedure to remove the entire larynx, often used in the treatment of advanced laryngeal cancer.
Neoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.
Cancer Staging : The process of determining the extent of cancer in the body, often using the TNM system.
Tnm Staging System : A cancer staging system that describes the extent of cancer using Tumor size (T), Node involvement (N), and Metastasis (M).

Relationships:-
1. Entity1: ""Clinical staging criteria"", Entity2: ""Total laryngectomy"", Relationship: ""determines necessity of""
2. Entity1: ""T3, N0"", Entity2: ""Clinical staging criteria"", Relationship: ""is a categorization of""

Causalities:-
The flowchart begins with the <C> clinical staging criteria </C>, specifically focusing on <CO> cases that require total laryngectomy, denoted as requiring (amenable to) total laryngectomy (T3, N0) </CO>. This <A> categorization </A> is crucial as it <E> forms the basis for determining the appropriate treatment strategy </E>.

Section Name: Treatment of Primary and Neck
====================
Entities:-
Neoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.
Lymphatic Metastasis : Transfer of a neoplasm from one organ or part of the body to another remote from the primary site.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Radiation Therapy"", Relationship: ""combined with""
2. Entity1: ""Laryngectomy"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""
3. Entity1: ""Thyroidectomy"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""
4. Entity1: ""Neck Dissection"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""

Causalities:-
<CO> Once clinical staging is established </CO>, the chart outlines various treatment options. <A> The initial step may involve either concurrent systemic therapy combined with radiation therapy (RT) or opting for RT alone </A>, <CO> especially if the patient is not a medical candidate for both therapies </CO>. <A> Laryngectomy, thyroidectomy, and neck dissection are considered </A> <CO> based on the extent of lymph node involvement </CO>.

Section Name: Surgical Options
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Lymph Node Excision : Surgical removal of one or more lymph nodes.
Lymphadenectomy : Surgical removal of one or more groups of lymph nodes.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.

Relationships:-
1. Entity1: ""Laryngectomy"", Entity2: ""Thyroidectomy"", Relationship: ""combined with""
2. Entity1: ""Lymph Node Dissection"", Entity2: ""Surgical Intervention"", Relationship: ""extent of""
3. Entity1: ""Surgical Intervention"", Entity2: ""Advanced Cases"", Relationship: ""management option for""

Causalities:-
<CO> If concurrent therapies are not suitable </CO>, <A> the chart presents laryngectomy combined with thyroidectomy </A>, <CO> depending on the extent of lymph node dissection required </CO>. <E> This highlights surgical intervention as a viable option in the management of advanced cases </E>.

Section Name: Induction Chemotherapy
====================
Entities:-
Induction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Therapeutic Approach : A method or strategy used in the treatment of disease or injury.

Relationships:-
1. Entity1: ""Induction Chemotherapy"", Entity2: ""Surgical Intervention"", Relationship: ""alternative or sequential treatment option""

Causalities:-
<C> immediate surgical intervention is either not feasible or considered insufficient </C> <E> The flowchart also considers the option of induction chemotherapy </E> <CO> in cases where immediate surgical intervention is either not feasible or considered insufficient </CO>. <A> tailoring therapeutic approaches tailored to individual patient needs </A>.

Section Name: Adjuvant Treatment
====================
Entities:-
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Neoplasm Recurrence, Local : The return of a cancer, at the same site, after it has been treated.
Disease Progression : The worsening of a disease over time.

Relationships:-
1. Entity1: ""Primary Treatment"", Entity2: ""Adjuvant Treatment"", Relationship: ""followed by""
2. Entity1: ""Adjuvant Treatment"", Entity2: ""Systemic Therapy"", Relationship: ""includes""
3. Entity1: ""Adjuvant Treatment"", Entity2: ""Radiotherapy"", Relationship: ""includes""
4. Entity1: ""Follow-up Assessments"", Entity2: ""Treatment Efficacy"", Relationship: ""used to evaluate""

Causalities:-
<C> Following primary treatment </C>, <E> the flowchart addresses the potential for adjuvant treatment pathways </E>. This may include systemic therapy, RT, or further evaluations based on <CO> the patient's response and any recurrence or persistent disease </CO>. It emphasizes <A> the need for follow-up assessments to evaluate treatment efficacy </A>.

Section Name: Risk Features and Response Assessment
====================
Entities:-
Neoplasm Invasiveness : The property of a neoplasm to infiltrate and destroy surrounding tissue.
Surgical Margins : The edge or border of the tissue removed in cancer surgery.
Neoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.
Extramural Extension : Extension of a tumor beyond the wall of an organ.
Positive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.
Cancer Management : The process of planning and coordinating the treatment of cancer.
Cancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""Extramural extension"", Entity2: ""Treatment decisions"", Relationship: ""influences""
2. Entity1: ""Positive surgical margin"", Entity2: ""Treatment decisions"", Relationship: ""influences""
3. Entity1: ""Ongoing assessment"", Entity2: ""Response evaluation"", Relationship: ""leads to""
4. Entity1: ""Response evaluation"", Entity2: ""Adjustments to treatment"", Relationship: ""leads to""
5. Entity1: ""Management of cancer"", Entity2: ""Treatment decisions"", Relationship: ""involves""
6. Entity1: ""Management of cancer"", Entity2: ""Ongoing assessment"", Relationship: ""involves""
7. Entity1: ""Management of cancer"", Entity2: ""Adjustments to treatment"", Relationship: ""involves""

Causalities:-
The chart incorporates a segment that takes into account <CO> adverse pathologic features, such as extramural extension or positive margins </CO>, <E> which could influence subsequent treatment decisions </E>. This highlights the importance of <A> ongoing assessment in the management of cancer, leading to response evaluation and adjustments to treatment as necessary </A>.

Section Name: NCCN Guidelines Version 4.2024
====================
Entities:-
Clinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.
Neoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.
Clinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Malignant Neoplasm : A malignant neoplasm is a cancerous growth that has the potential to invade and destroy nearby tissue and spread to other parts of the body.
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Cancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network"", Entity2: ""NCCN Guidelines"", Relationship: ""provides""
2. Entity1: ""NCCN Guidelines"", Entity2: ""Clinical Trials"", Relationship: ""recommend""
3. Entity1: ""NCCN Guidelines"", Entity2: ""Cancer"", Relationship: ""related to management of""

Causalities:-
<CO> any patient with cancer </CO> <A> the best management is in a clinical trial </A>. <A> Participation in clinical trials is especially encouraged </A>.

Section Name: SUPRA-3
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.
Chemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Clinical Trials As Topic : Research studies that prospectively assign human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Induction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.
Clinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.

Relationships:-
1. Entity1: ""Total laryngectomy"", Entity2: ""Laryngectomy"", Relationship: ""is a type of""
2. Entity1: ""Systemic therapy"", Entity2: ""RT"", Relationship: ""concurrent treatment option""
3. Entity1: ""Induction chemotherapy"", Entity2: ""Other treatments"", Relationship: ""initial treatment option before""

Causalities:-
<CO> Requiring (amenable to) total laryngectomy (T3,N0) </CO>
  - <A> Concurrent systemic therapy/RT </A> or <A> RT if patient not medical candidate for concurrent systemic therapy/RT </A>
  - <A> Laryngectomy, thyroidectomy and with ipsilateral, central, or bilateral neck dissection </A>
  - or
  - <A> Induction chemotherapy </A>
  - or
  - <A> Clinical trials </A>

Section Name: Follow-up
====================
Entities:-
Follow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.
Follow-Up Procedure : A procedure performed to monitor the progress of a patient's condition after initial treatment.
Follow-Up : Medical care given to a patient over time after initial treatment.
Disease Recurrence : The return of a sign, symptom, or disease after a remission.
Recurrent Disease : The reappearance of a disease after a period of improvement.

Relationships:-
1. Entity1: ""Follow-up"", Entity2: ""Recurrent or persistent disease"", Relationship: ""monitoring""

Causalities:-
- **Follow-up (FOLL-A, 1 of 2)**
  - <CO> Recurrent or persistent disease </CO> (ADV-3)

Section Name: Adverse Pathologic Features
====================
Entities:-
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Extranodal Extension : The spread of cancer beyond the lymph node capsule.
Positive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""pN1"", Entity2: ""Radiotherapy"", Relationship: ""Consideration for treatment""
2. Entity1: ""Extranodal extension"", Entity2: ""Systemic Therapy"", Relationship: ""Treatment option""
3. Entity1: ""Extranodal extension"", Entity2: ""Radiotherapy"", Relationship: ""Treatment option""
4. Entity1: ""Positive surgical margin"", Entity2: ""Systemic Therapy"", Relationship: ""Treatment option""
5. Entity1: ""Positive surgical margin"", Entity2: ""Radiotherapy"", Relationship: ""Treatment option""

Causalities:-
- <CO>pN1 without other risk features</CO>
  - <C>Adverse pathologic features</C>
  - <A>Consider RT</A>
  - <CO>Extranodal extension and/or positive margin</CO>
  - <CO>Other risk features</CO>
  - <A>Systemic therapy/RT (category 1)</A>
  - <A>RT or Consider systemic therapy/RT</A>

Section Name: Response Assessment
====================
Entities:-
Response Evaluation : The process of assessing the response of a disease to treatment, often used in clinical trials to determine the effectiveness of a therapy.
Response To Treatment : A clinical finding indicating the response of a condition to a therapeutic intervention.

Relationships:-

Section Name: Principles of Surgery and Radiation Therapy
====================
Entities:-
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Radiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.

Relationships:-
1. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Radiation Therapy"", Relationship: ""complementary treatments""

Causalities:-
**Principles of Surgery (SURG-A).**

**Principles of Radiation Therapy (SUPRA-A).**

Section Name: Principles of Systemic Therapy
====================
Entities:-
Cisplatin : An inorganic and water-soluble platinum complex, cisplatin is an antineoplastic agent that is used in the treatment of various cancers.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Radiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.

Relationships:-
1. Entity1: ""Cisplatin"", Entity2: ""Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""preferred agent""
2. Entity1: ""Cisplatin"", Entity2: ""Concurrent Systemic Therapy/RT"", Relationship: ""used in""

Causalities:-
<CO> When using concurrent systemic therapy/RT </CO>, <A> the preferred agent is cisplatin (category 1) </A>.
--------------------------------------------------
Page Number: 130

Section Name: Pathological N (pN)
====================
Entities:-
Lymph Nodes : Small, bean-shaped structures that are part of the body's lymphatic system. They filter lymph fluid and store white blood cells that help fight infection.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Tnm Staging : A system used to describe the size and spread of cancer in a standardized way. T refers to the size of the tumor, N to the involvement of lymph nodes, and M to metastasis.
Lymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.
Tnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient's body.
Lymph Node : An organ of the lymphatic system and the adaptive immune system.

Relationships:-
1. Entity1: ""Lymph Nodes"", Entity2: ""Neoplasm Metastasis"", Relationship: ""involved in""
2. Entity1: ""TNM Staging"", Entity2: ""Lymph Nodes"", Relationship: ""includes""
3. Entity1: ""TNM Staging"", Entity2: ""Neoplasm Metastasis"", Relationship: ""describes""

Causalities:-
<CO> NX: Regional lymph nodes cannot be assessed </CO>
<CO> N0: No regional lymph node metastasis </CO>
<CO> N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(–) </CO>
<CO> N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2a: Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N3: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(−); or metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>
<CO> N3a: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N3b: Metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>
<CO> Note: A designation of “U” or “L” may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L). Similarly, clinical and pathological ENE should be recorded as ENE(−) or ENE(+). </CO>

Section Name: Distant Metastasis (M)
====================
Entities:-
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.

Relationships:-
1. Entity1: ""M0"", Entity2: ""Distant Metastasis"", Relationship: ""is a category of""
2. Entity1: ""M1"", Entity2: ""Distant Metastasis"", Relationship: ""is a category of""

Causalities:-
### Distant Metastasis (M)

- **M0**: No distant metastasis
- **M1**: Distant metastasis

Section Name: Histologic Grade (G)
====================
Entities:-
Neoplasm Grading : A system of classifying cancer cells in terms of how abnormal they look under a microscope and how quickly the tumor is likely to grow and spread.
Histologic Grade : A measure of how much tumor cells differ from healthy cells, used to assess the aggressiveness of cancer.

Relationships:-
1. Entity1: ""GX"", Entity2: ""Grade cannot be assessed"", Relationship: ""is described as""
2. Entity1: ""G1"", Entity2: ""Well differentiated"", Relationship: ""is described as""
3. Entity1: ""G2"", Entity2: ""Moderately differentiated"", Relationship: ""is described as""
4. Entity1: ""G3"", Entity2: ""Poorly differentiated"", Relationship: ""is described as""

Causalities:-
<CO>GX</CO>: <E>Grade cannot be assessed</E>
<CO>G1</CO>: <E>Well differentiated</E>
<CO>G2</CO>: <E>Moderately differentiated</E>
<CO>G3</CO>: <E>Poorly differentiated</E>

Section Name: Prognostic Stage Groups
====================
Entities:-
Neoplasm Staging : Methods and systems of classifying neoplasms according to extent of disease.
Tumor Staging : A system for describing the size and spread of cancer within the body.
Tnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient's body.

Relationships:-
1. Entity1: ""Stage 0"", Entity2: ""Tis N0 M0"", Relationship: ""defined by""
2. Entity1: ""Stage I"", Entity2: ""T1 N0 M0"", Relationship: ""defined by""
3. Entity1: ""Stage II"", Entity2: ""T2 N0 M0"", Relationship: ""defined by""
4. Entity1: ""Stage III"", Entity2: ""T3 N0 M0, T1 N1 M0, T2 N1 M0, T3 N1 M0"", Relationship: ""defined by""
5. Entity1: ""Stage IVA"", Entity2: ""T1 N2 M0, T2 N2 M0, T3 N2 M0, T4a N0,N1,N2 M0"", Relationship: ""defined by""
6. Entity1: ""Stage IVB"", Entity2: ""Any T N3 M0, T4b Any N M0"", Relationship: ""defined by""
7. Entity1: ""Stage IVC"", Entity2: ""Any T Any N M1"", Relationship: ""defined by""
--------------------------------------------------
Page Number: 47

Section Name: Overview of Radiation Therapy Guidelines
====================
Entities:-
Radiation Therapy : The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.
Malignant Neoplasm : A disease characterized by uncontrolled, abnormal growth of cells that can invade and destroy nearby tissue and spread to other parts of the body.
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.
Glottic Larynx Cancer : A malignant neoplasm located in the glottic region of the larynx.
Laryngeal Cancer : Cancer that occurs in the larynx, or voice box, which may include the glottic region.
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.

Relationships:-
1. Entity1: ""Radiation Therapy"", Entity2: ""Cancer"", Relationship: ""treats""
2. Entity1: ""NCCN Guidelines"", Entity2: ""Cancer"", Relationship: ""guides treatment for""
3. Entity1: ""NCCN Guidelines"", Entity2: ""Radiation Therapy"", Relationship: ""specifies use of""

Causalities:-
The image presents a detailed flowchart outlining the principles of radiation therapy specifically for the <C> treatment of cancer in the glottic larynx </C>, <CO> as per the National Comprehensive Cancer Network (NCCN) guidelines (version 2.2024) </CO>. <E> This structured guidance delineates various treatment protocols </E>, <A> stratified by risk levels and therapeutic approaches </A>.

Section Name: Principles of Radiation Therapy
====================
Entities:-
Radiation Therapy : The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Gy : Gray, a unit of ionizing radiation dose in the International System of Units (SI), defined as the absorption of one joule of radiation energy per kilogram of matter.
Gray (Unit) : A unit of absorbed radiation dose of ionizing radiation, defined as the absorption of one joule of radiation energy per kilogram of matter.

Relationships:-
1. Entity1: ""Tis, N0"", Entity2: ""60.75 Gy (2.25 Gy/fraction) to 66 Gy (2.0 Gy/fraction)"", Relationship: ""treatment protocol""
2. Entity1: ""T1, N0"", Entity2: ""63 Gy (2.25 Gy/fraction) to 66 Gy (2.0 Gy/fraction) or 50 Gy (3.12 Gy/fraction) to 52 Gy (3.28 Gy/fraction)"", Relationship: ""treatment protocol""
3. Entity1: ""T2, N0"", Entity2: ""65.25 Gy (2.25 Gy/fraction) to 70 Gy (2.0 Gy/fraction)"", Relationship: ""treatment protocol""
4. Entity1: ""≥T2, N1 (PTV High risk)"", Entity2: ""66 Gy (2.2 Gy/fraction) to 70 Gy (2.0 Gy/fraction)"", Relationship: ""treatment protocol""
5. Entity1: ""≥T2, N1 (Low to intermediate risk)"", Entity2: ""44–50 Gy (2.0 Gy/fraction) to 54–63 Gy (1.6–1.8 Gy/fraction)"", Relationship: ""treatment protocol""

Causalities:-
<CO>Tis, N0</CO>: <A>60.75 Gy (2.25 Gy/fraction) to 66 Gy (2.0 Gy/fraction)</A>
<CO>T1, N0</CO>: <A>63 Gy (2.25 Gy/fraction, preferred) to 66 Gy (2.0 Gy/fraction) or 50 Gy (3.12 Gy/fraction) to 52 Gy (3.28 Gy/fraction)</A>
<CO>T2, N0</CO>: <A>65.25 (2.25 Gy/fraction) to 70 Gy (2.0 Gy/fraction)</A>
<CO>≥T2, N1</CO>: <A>PTV High risk: Primary tumor and involved lymph nodes (includes possible local subclinical infiltration at the primary site and at the high-risk level lymph node(s))</A>
<A>Fractionation: 66 Gy (2.2 Gy/fraction) to 70 Gy (2.0 Gy/fraction); daily Monday–Friday in 6–7 weeks</A>
<A>Concomitant boost accelerated RT: 72 Gy/6 weeks (1.8 Gy/fraction, large field; 1.5 Gy boost as second daily fraction during last 12 treatment days)</A>
<A>66–70 Gy (2.0 Gy/fraction; 6 fractions/wk accelerated)</A>
<A>Hyperfractionation: 79.2–81.6 Gy/7 weeks (1.2 Gy/fraction, twice daily)</A>
<CO>Low to intermediate risk</CO>: <A>Sites of suspected subclinical spread</A>
<A>44–50 Gy (2.0 Gy/fraction) to 54–63 Gy (1.6–1.8 Gy/fraction)</A>

Section Name: Concurrent Systemic Therapy/RT
====================
Entities:-
Cisplatin : A platinum-containing antineoplastic agent used in the treatment of various cancers.
Carboplatin : An organoplatinum compound that possesses antineoplastic activity.
Fluorouracil : A chemotherapy drug used to treat various types of cancer.

Relationships:-
1. Entity1: ""concurrent systemic therapy/RT"", Entity2: ""cisplatin"", Relationship: ""uses""
2. Entity1: ""concurrent systemic therapy/RT"", Entity2: ""carboplatin and 5-FU"", Relationship: ""uses""
3. Entity1: ""multiagent chemotherapy"", Entity2: ""toxicity burden"", Relationship: ""increases""

Causalities:-
<CO>Based on published data</CO>, <A>concurrent systemic therapy/RT most commonly uses conventional fractionation at 2.0 Gy per fraction to a typical dose of 70 Gy in 7 weeks with single-agent cisplatin given every 3 weeks at 100 mg/m²</A>; <CO>2–3 cycles of chemotherapy are used depending on the radiation fractionation scheme (RTOG 0129)</CO>. <CO>When carboplatin and 5-FU are used</CO>, <A>the recommended regimen is standard fractionation plus 3 cycles of chemotherapy</A>. <CO>Other fraction sizes (e.g., 1.8 Gy, conventional), multiagent chemotherapy, other dosing schedules of cisplatin, or altered fractionation with chemotherapy</CO> <E>are efficacious</E>, and <C>there is no consensus on the optimal approach</C>. <C>In general, the use of concurrent systemic therapy/RT</C> <E>carries a high toxicity burden</E>; <C>multiagent chemotherapy</C> <E>will likely further increase the toxicity burden</E>. <A>For any systemic therapy/RT approach, close attention should be paid to published reports for the specific chemotherapy agent, dose, and schedule of administration</A>. <A>Systemic therapy/RT should be performed by an experienced team and should include substantial supportive care</A>.

Section Name: Treatment Modalities
====================
Entities:-
Intensity-Modulated Radiotherapy : A type of conformal radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.
Intensity Modulated Radiation Therapy : A type of conformal radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.
Intensity-Modulated Radiation Therapy : An advanced type of high-precision radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.
Radiotherapy, Conformal : A type of radiotherapy that uses imaging to conform the radiation dose to the shape of the tumor.
3D Conformal Radiation Therapy : A technique in radiotherapy that uses imaging to conform the radiation dose to the shape of the tumor.
Chemotherapy, Adjuvant : Treatment with drugs that kill cancer cells, often used in conjunction with other therapies.
Chemotherapy : The treatment of disease by the use of chemical substances, especially the treatment of cancer by cytotoxic and other drugs.
Drug Therapy, Combination : The use of two or more drugs to achieve a therapeutic effect.
Systemic Therapy : A type of therapy that uses substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Intensity-Modulated Radiation Therapy (IMRT)"", Entity2: ""3D Conformal Radiation Therapy (3D-CRT)"", Relationship: ""are delivery methods for radiation therapy""
2. Entity1: ""Chemotherapy"", Entity2: ""Radiation Therapy"", Relationship: ""is integrated with for aggressive or advanced cancer cases""

Causalities:-
<CO> contingent upon patient-specific considerations </CO> <A> suggests either Intensity-Modulated Radiation Therapy (IMRT) or 3D Conformal Radiation Therapy (3D-CRT) as delivery methods </A>. <A> These advanced techniques are employed to optimize treatment accuracy </A>, <E> preserving surrounding healthy tissue and improving overall patient outcomes </E>. <A> a focus on concurrent systemic therapies underlines the importance of integrating chemotherapy </A>, particularly <CO> for patients with more aggressive forms of cancer or those demonstrating advanced disease characteristics </CO>.

Section Name: Additional Information
====================
Entities:-
Clinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.
Clinical Trial : A clinical trial is a research study in which one or more human subjects are prospectively assigned to one or more interventions to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes.
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Intensity-Modulated Radiation Therapy : An advanced type of high-precision radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.
Intensity Modulated Radiation Therapy : A type of conformal radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.
Three-Dimensional Conformal Radiation Therapy : A type of external beam radiation therapy that uses a computer to create a 3-dimensional picture of the tumor so that multiple radiation beams can be shaped exactly to the contour of the treatment area.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network"", Entity2: ""Clinical trial"", Relationship: ""encourages participation in""
2. Entity1: ""Intensity-Modulated Radiation Therapy"", Entity2: ""Three-Dimensional Conformal Radiation Therapy"", Relationship: ""recommended alternatives""

Causalities:-
<A> Participation in clinical trials </A> is especially encouraged. <A> Either IMRT (preferred) or 3D-CRT is recommended. </A>

Section Name: Conclusion
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.
Malignant Neoplasm Of Glottis : A malignant tumor located in the glottic region of the larynx.
Laryngeal Cancer : Cancer that occurs in the larynx, or voice box, which may include the glottic region.
Prognosis : A medical term for predicting the likely or expected development of a disease.
Evidence-Based Practice : Healthcare practices that are based on scientific evidence and research.
Evidence-Based Medicine : An approach to medical practice intended to optimize decision-making by emphasizing the use of evidence from well-designed and conducted research.

Relationships:-
1. Entity1: ""treatment paradigms"", Entity2: ""glottic larynx cancer"", Relationship: ""encapsulates""
2. Entity1: ""personalized treatment plans"", Entity2: ""prognosis"", Relationship: ""improves""

Causalities:-
<C> glottic larynx cancer </C>. <CO> the nuances of each patient's condition </CO>. <A> personalized treatment plans </A> <E> promoting effective management and improved prognosis </E>. <A> deliver clear, evidence-based interventions </A> <CO> considering the complexities involved in cancer treatment </CO>.


Among these two options which one is the most likely true:

(A) `N_State_1__patient` increases risk `Size_of_Involved_Lymph_Nodes_6`
(B) `Size_of_Involved_Lymph_Nodes_6` `increases risk `N_State_1__patient`

The answer is: ...

1. State the evidences in detail of the validity of option (A) or (B) by cross referencing
NCCN Clinical Practitioner’s Guidelines for Head and Neck Cancer.
2. If the evidences are obtained from `INFORMATION FROM KNOWLEDGE BASE`,
mention their corresponding Page Numbers, Section Name, entities, relationships and causalities.

DESIRED OUTPUT FORMAT:
<thinking>
...
</thinking>
<answer>
{
   ""thinking"": [""..."", ...],
   ""evidences"": [""..."", ...],
   ""answer"": ...
}
</answer>

Before providing the answer in <answer> tags, think step by step in detail in <thinking> tags and analyze every part.
Output inside <answer> tag in JSON format. Only output valid JSON.
DO NOT HALLUCINATE. DO NOT MAKE UP FACTUAL INFORMATION.
","1. The edge in question is between two nodes: `N_State_1__patient` and `Size_of_Involved_Lymph_Nodes_6`.
2. `N_State_1__patient` represents the state of lymph node involvement in cancer staging, which is a decision node used to predict the extent of lymph node metastasis.
3. `Size_of_Involved_Lymph_Nodes_6` represents the size of the lymph nodes involved, which is a critical factor in cancer staging and prognosis.
4. The causal relationship between these nodes is being evaluated to determine which influences the other.
5. Option (A) suggests that the state of lymph node involvement (`N_State_1__patient`) increases the risk of larger lymph node size (`Size_of_Involved_Lymph_Nodes_6`).
6. Option (B) suggests that the size of the lymph nodes (`Size_of_Involved_Lymph_Nodes_6`) increases the risk of a more advanced state of lymph node involvement (`N_State_1__patient`).
7. In clinical practice, the size of the lymph nodes is often used to determine the N state in cancer staging, not the other way around.
8. The NCCN guidelines and the knowledge base information suggest that larger lymph nodes often correlate with more advanced N states, indicating more extensive lymphatic involvement.
9. The causal direction is positive because an increase in lymph node size is associated with a more advanced N state.
10. The causal factor is neither necessary nor sufficient on its own, as other factors also influence the N state.
11. The causal distance is proximal because the size of lymph nodes directly affects the N state.
","1. Page Number: 102, Section Name: Head and Neck Cancers - Principles of Surgery
2. Entities: Lymphatic System, Neoplasm Staging, Metastasis
3. Relationships: Entity1: ""surgical management"", Entity2: ""regional lymphatics"", Relationship: ""dictated by tumor staging""
4. Causalities: <C> The extent of the tumor at initial tumor staging </C> <E> dictates the surgical management of regional lymphatics </E>.
",B,"{'A': 0.0, 'B': 100.0}",yes,B,"1. The AI assistant is tasked with determining whether the final answer (B) is consistent with the reasoning provided.
2. The question involves two nodes: `N_State_1__patient` and `Size_of_Involved_Lymph_Nodes_6`.
3. `N_State_1__patient` refers to the state of lymph node involvement in cancer staging, which is crucial for determining the extent of metastasis.
4. `Size_of_Involved_Lymph_Nodes_6` refers to the size of the lymph nodes, which is a critical factor in cancer staging and prognosis.
5. The AI assistant is evaluating the causal relationship between these nodes to determine which influences the other.
6. Option (A) suggests that the state of lymph node involvement increases the risk of larger lymph node size.
7. Option (B) suggests that the size of the lymph nodes increases the risk of a more advanced state of lymph node involvement.
8. The AI assistant's reasoning indicates that in clinical practice, the size of the lymph nodes is often used to determine the N state in cancer staging, not the other way around.
9. The NCCN guidelines and the knowledge base information suggest that larger lymph nodes often correlate with more advanced N states, indicating more extensive lymphatic involvement.
10. The causal direction is positive because an increase in lymph node size is associated with a more advanced N state.
11. The causal factor is neither necessary nor sufficient on its own, as other factors also influence the N state.
12. The causal distance is proximal because the size of lymph nodes directly affects the N state.
13. The AI assistant concludes that Option (B) is more consistent with the reasoning provided, as it aligns with clinical practice and the information from the knowledge base.
"
11,gpt-4o,"N_State_1__patient,Presence_of_Metastasis_in_Lymph_Nodes_5","""{'NODE1': {'id': 'N_State_1__patient', 'label': 'State of Nearby Lymph Nodes with Cancer in Patient', 'description': 'This node represents the state of involvement of nearby lymph nodes in a patient with cancer. It is a decision node used to predict the extent of lymph node metastasis, which is crucial for cancer staging and treatment planning. The states range from no involvement (n0) to extensive involvement (n3), with intermediate states indicating varying degrees of lymph node cancer presence.', 'type': 'Decision Node', 'observability': 'Needs to be Predicted', 'states': [{'state_name': 'nx', 'state_description': 'The regional lymph nodes cannot be assessed.'}, {'state_name': 'n3', 'state_description': 'Metastasis in lymph node(s) along the course of a major blood vessel or in a lymph node that is more than 6 cm in greatest dimension.'}, {'state_name': 'n2c', 'state_description': 'Metastasis in bilateral or contralateral lymph nodes, each 6 cm or less in greatest dimension.'}, {'state_name': 'n2b', 'state_description': 'Metastasis in multiple ipsilateral lymph nodes, each 6 cm or less in greatest dimension.'}, {'state_name': 'n2a', 'state_description': 'Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension.'}, {'state_name': 'n2', 'state_description': 'Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension, or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension.'}, {'state_name': 'n1', 'state_description': 'Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension.'}, {'state_name': 'n0', 'state_description': 'No regional lymph node metastasis.'}]}, 'NODE2': {'id': 'Presence_of_Metastasis_in_Lymph_Nodes_5', 'label': 'Metastasis in Nearby Lymph Nodes', 'description': 'This node represents the clinical situation regarding whether metastasis is present in the nearby lymph nodes of a patient. It is a critical factor in determining the stage and prognosis of cancer, as the spread of cancer to lymph nodes often indicates a more advanced disease and may influence treatment decisions.', 'type': 'Patient Situation', 'observability': 'Unobserved', 'states': [{'state_name': 'unknown', 'state_description': 'The status of metastasis in the lymph nodes is not determined. It is unclear whether cancer has spread to these nodes.'}, {'state_name': 'present', 'state_description': 'Metastasis is confirmed in the lymph nodes, indicating that cancer has spread to these nodes.'}, {'state_name': 'absent', 'state_description': 'There is no metastasis in the lymph nodes, indicating that cancer has not spread to these nodes.'}]}, 'EDGE1': {'edges_ids': ['N_State_1__patient', 'Presence_of_Metastasis_in_Lymph_Nodes_5'], 'edge': '(N_State_1__patient) causes (Presence_of_Metastasis_in_Lymph_Nodes_5)', 'explanation': ['The edge represents the causal relationship where the state of nearby lymph nodes in a patient with cancer (Node 1) influences the presence of metastasis in those lymph nodes (Node 2).', 'The state of lymph nodes (n0 to n3) is a clinical measure used to describe the extent of metastasis, making this a valid causal relationship.', 'The causal direction is positive because an increase in the state (e.g., from n0 to n3) indicates a higher likelihood of metastasis being present.', 'The state of lymph nodes is a necessary condition to assess the presence of metastasis, but it is not sufficient alone as other factors may also play a role.', 'The causal distance is proximal because the state of lymph nodes directly affects the presence of metastasis.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': True, 'sufficient': False}, 'causal_distance': 'Proximal'}, 'EDGE2': {'edges_ids': ['Presence_of_Metastasis_in_Lymph_Nodes_5', 'N_State_1__patient'], 'edge': '(Presence_of_Metastasis_in_Lymph_Nodes_5) causes (N_State_1__patient)', 'explanation': ['The node `Presence_of_Metastasis_in_Lymph_Nodes_5` indicates whether metastasis is present in the lymph nodes, which is a critical factor in cancer staging.', 'The node `N_State_1__patient` represents the N-stage of cancer, which is determined by the extent of lymph node involvement.', 'The presence of metastasis in lymph nodes directly affects the N-stage, making the edge valid.', 'The causal direction is positive because the presence of metastasis leads to a higher N-stage.', 'The presence of metastasis is necessary for a higher N-stage but not sufficient alone, as other factors may also play a role.', 'The causal distance is proximal because the presence of metastasis directly influences the N-stage.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': True, 'sufficient': False}, 'causal_distance': 'Proximal'}, 'ENTITIES_MATCHING_PAGES_INFO': {'102': {'matching_entities': [{'METASTASIS': 0.9630129}, {'LYMPHATIC SYSTEM': 0.95855314}, {'LYMPHATIC STRUCTURE': 0.9469132}, {'CANCER STAGING': 0.93824553}, {'TUMOR': 0.9323624}, {'STAGING': 0.9208425}], 'count': 6}, '51': {'matching_entities': [{'MALIGNANT NEOPLASM': 0.9774111}, {'LYMPHATIC METASTASIS': 0.94962627}, {'CANCER STAGING': 0.93824553}, {'CANCER': 0.9363244}, {'LARYNGEAL NEOPLASMS': 0.9236878}, {'NEOPLASM INVASIVENESS': 0.92347366}], 'count': 6}, '55': {'matching_entities': [{'MALIGNANT NEOPLASTIC DISEASE': 0.97725874}, {'NEOPLASM METASTASIS': 0.96748203}, {'METASTASIS': 0.9630129}, {'METASTATIC NEOPLASM': 0.96172774}, {'CANCER': 0.9363244}, {'LARYNGEAL NEOPLASMS': 0.9236878}], 'count': 6}, '130': {'matching_entities': [{'LYMPH NODE STRUCTURE': 0.99134904}, {'LYMPH NODE': 0.98570025}, {'LYMPH NODES': 0.97445965}, {'NEOPLASM METASTASIS': 0.96748203}, {'METASTASIS': 0.9630129}], 'count': 5}, '41': {'matching_entities': [{'METASTASIS': 0.9630129}, {'LYMPHATIC METASTASIS': 0.94962627}, {'CANCER': 0.9363244}, {'LARYNGEAL NEOPLASMS': 0.9236878}], 'count': 4}}, 'GUIDELINE_PAGES_INFO': '--------------------------------------------------\\nPage Number: 102\\n\\nSection Name: Head and Neck Cancers - Principles of Surgery\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Manual or operative procedures used in the treatment of disease, injuries, or deformities.\\nLymphatic System : Part of the circulatory system and a vital part of the immune system, comprising a network of lymphatic vessels that carry a clear fluid called lymph.\\nNeoplasms : New abnormal growth of tissue in animals or plants; a tumor.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nNeoplasm Staging : Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.\\nMetastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.\\nSurgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nLymphatic Structure : Anatomical structure that is part of the lymphatic system.\\nTumor : An abnormal mass of tissue that results when cells divide more than they should or do not die when they should.\\nStaging : The process of determining the size and spread of cancer within the body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nCancer Staging : The process of determining the extent to which a cancer has developed by growing and spreading.\\n\\nRelationships:-\\n1. Entity1: \""surgical management\"", Entity2: \""regional lymphatics\"", Relationship: \""dictated by tumor staging\""\\n2. Entity1: \""neck dissections\"", Entity2: \""primary tumor\"", Relationship: \""part of treatment\""\\n3. Entity1: \""surgery\"", Entity2: \""ipsilateral side of the neck\"", Relationship: \""risk for metastases\""\\n\\nCausalities:-\\n<C> The extent of the tumor at initial tumor staging </C> <E> dictates the surgical management of regional lymphatics </E>. These guidelines apply to the performance of neck dissections as part of treatment of the primary tumor. <CO> Patients undergoing surgery for resection of the primary tumor </CO> <A> will undergo dissection of the ipsilateral side of the neck that is at greatest risk for metastases </A>.\\n\\nSection Name: Neck Management\\n====================\\nEntities:-\\nTongue : A muscular organ in the mouth that is involved in tasting, swallowing, and speech.\\nPalate : The roof of the mouth, separating the oral and nasal cavities.\\nLarynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.\\nHypopharynx : The bottom part of the pharynx, which is the cavity behind the nose and mouth.\\nNasopharynx : The upper part of the pharynx, connecting with the nasal cavity above the soft palate.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nMetastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.\\nSquamous Cell Carcinoma : A type of cancer that begins in the squamous cells, which are thin, flat cells that look like fish scales.\\nBiopsy : The removal of cells or tissues for examination under a microscope.\\n\\nRelationships:-\\n1. Entity1: \""Tumor sites\"", Entity2: \""Bilateral lymphatic drainage\"", Relationship: \""associated with\""\\n2. Entity1: \""Elective neck dissection\"", Entity2: \""Risk of occult metastasis\"", Relationship: \""based on\""\\n3. Entity1: \""SLN biopsy\"", Entity2: \""Elective neck dissection\"", Relationship: \""guides decision-making for\""\\n\\nCausalities:-\\n- **<C> Tumor sites that frequently have bilateral lymphatic drainage </C>** (e.g., base of tongue, palate, supraglottic larynx, hypopharynx, nasopharynx, deep pre-epiglottic space involvement) <E> often should have both sides of the neck dissected </E> with the extent of dissection determined as suggested below. For those patients with tumors at or approaching the midline, <CO> both sides of the neck are at risk for metastases </CO>, and <A> bilateral neck dissections should be performed </A>.\\n\\n- <CO> Patients with advanced lesions involving the anterior tongue, floor of the mouth, or alveolus that approximate or cross the midline </CO> <A> should undergo contralateral selective/modified neck dissection </A> as necessary to achieve adequate tumor resection.\\n\\n- **<C> Elective neck dissection </C>** <A> should be based on risk of occult metastasis in the appropriate nodal basin </A>. For oral cavity squamous cell carcinoma, <C> SLN biopsy or the primary tumor depth of invasion </C> is currently <E> the best predictor of occult metastatic disease </E> and <A> should be used to guide decision-making </A>. <CO> For tumors with a depth greater than 3 mm </CO>, <A> elective dissection should be strongly considered if RT is not already planned </A>. Recent randomized trial evidence supports the effectiveness of elective neck dissection in patients with oral cavity cancers greater than 3 mm in depth of invasion.\\n\\n  - <CO> For a depth less than 2 mm </CO>, <A> elective dissection is only indicated in highly selective situations </A>. <CO> For a depth of 2\u20134 mm </CO>, <A> clinical judgment (as to reliability of follow-up, clinical suspicion, and other factors) must be utilized to determine appropriateness of elective dissection </A>. Elective dissections are generally selective, preserving all major structures, unless operative findings dictate otherwise.\\n\\nSection Name: Types of Neck Dissection\\n====================\\nEntities:-\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nLarynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.\\n\\nRelationships:-\\n1. Entity1: \""N0\"", Entity2: \""Selective neck dissection\"", Relationship: \""associated with\""\\n2. Entity1: \""N3\"", Entity2: \""Comprehensive neck dissection\"", Relationship: \""associated with\""\\n3. Entity1: \""Level VI neck dissection\"", Entity2: \""Larynx\"", Relationship: \""performed for\""\\n4. Entity1: \""Level VI neck dissection\"", Entity2: \""Hypopharynx\"", Relationship: \""performed for\""\\n\\nCausalities:-\\n- **The type of neck dissection (comprehensive or selective)** is defined according to <CO> preoperative clinical staging </CO>, is determined at the discretion of the surgeon, and is based on the initial preoperative staging as follows:\\n  - **N0:** <A> Selective neck dissection </A>\\n    - Oral cavity at least levels I\u2013III\\n    - Oropharynx at least levels II\u2013IV\\n    - Hypopharynx at least levels II\u2013IV and level VI when appropriate\\n    - Larynx at least levels II\u2013IV and level VI when appropriate\\n  - **N1\u2013N2a\u2013c:** <A> Selective or comprehensive neck dissection </A> (Discussion)\\n  - **N3:** <A> Comprehensive neck dissection </A>\\n\\n- <C> Level VI neck dissections are performed for certain primary sites (such as the larynx and hypopharynx) </C> <E> as required to resect the primary tumor and any clinically evident neck nodes </E>. <CO> Elective dissection depends on primary tumor extent and site </CO>. <CO> For advanced glottic and hypopharyngeal cancers treated with primary surgery </CO>, <A> a level VI dissection (including pretracheal lymph nodes, the Delphian lymph node, and unilateral or bilateral paratracheal lymph nodes) and hemithyroidectomy to total thyroidectomy are appropriate </A>.\\n\\n- <CO> For primary subglottic tumors or glottic cancers with significant subglottic extension </CO>, <A> a level VI dissection with unilateral or total thyroidectomy is considered appropriate </A> based on the extent of the primary tumor. <CO> For example, a T4a glottic tumor with extension through the cricothyroid membrane and subglottic extension </CO> <A> should include thyroidectomy and pretracheal and bilateral paratracheal lymph node dissection </A>. <A> Parathyroid glands should be preserved in situ or auto transplanted as indicated </A>.\\n--------------------------------------------------\\nPage Number: 51\\n\\nSection Name: Introduction\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nMalignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.\\nSupraglottic Laryngeal Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is above the vocal cords.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network (NCCN)\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""provides guidelines for\""\\n2. Entity1: \""healthcare professionals\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""manage\""\\n\\nCausalities:-\\nThe provided image is a detailed flowchart from the National Comprehensive Cancer Network (NCCN) guidelines regarding the <C> clinical staging and treatment protocols for cancer of the supraglottic larynx </C>. This flowchart is structured to <A> guide healthcare professionals through the stages of treatment </A> based on <CO> clinical findings </CO>, emphasizing the <E> complexity and systematic approach required in managing this type of cancer </E>.\\n\\nSection Name: Clinical Staging\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nTotal Laryngectomy : A surgical procedure to remove the entire larynx, often used in the treatment of advanced laryngeal cancer.\\nNeoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.\\nCancer Staging : The process of determining the extent of cancer in the body, often using the TNM system.\\nTnm Staging System : A cancer staging system that describes the extent of cancer using Tumor size (T), Node involvement (N), and Metastasis (M).\\n\\nRelationships:-\\n1. Entity1: \""Clinical staging criteria\"", Entity2: \""Total laryngectomy\"", Relationship: \""determines necessity of\""\\n2. Entity1: \""T3, N0\"", Entity2: \""Clinical staging criteria\"", Relationship: \""is a categorization of\""\\n\\nCausalities:-\\nThe flowchart begins with the <C> clinical staging criteria </C>, specifically focusing on <CO> cases that require total laryngectomy, denoted as requiring (amenable to) total laryngectomy (T3, N0) </CO>. This <A> categorization </A> is crucial as it <E> forms the basis for determining the appropriate treatment strategy </E>.\\n\\nSection Name: Treatment of Primary and Neck\\n====================\\nEntities:-\\nNeoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.\\nLymphatic Metastasis : Transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Radiation Therapy\"", Relationship: \""combined with\""\\n2. Entity1: \""Laryngectomy\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n3. Entity1: \""Thyroidectomy\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n4. Entity1: \""Neck Dissection\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n\\nCausalities:-\\n<CO> Once clinical staging is established </CO>, the chart outlines various treatment options. <A> The initial step may involve either concurrent systemic therapy combined with radiation therapy (RT) or opting for RT alone </A>, <CO> especially if the patient is not a medical candidate for both therapies </CO>. <A> Laryngectomy, thyroidectomy, and neck dissection are considered </A> <CO> based on the extent of lymph node involvement </CO>.\\n\\nSection Name: Surgical Options\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nLymph Node Excision : Surgical removal of one or more lymph nodes.\\nLymphadenectomy : Surgical removal of one or more groups of lymph nodes.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""Laryngectomy\"", Entity2: \""Thyroidectomy\"", Relationship: \""combined with\""\\n2. Entity1: \""Lymph Node Dissection\"", Entity2: \""Surgical Intervention\"", Relationship: \""extent of\""\\n3. Entity1: \""Surgical Intervention\"", Entity2: \""Advanced Cases\"", Relationship: \""management option for\""\\n\\nCausalities:-\\n<CO> If concurrent therapies are not suitable </CO>, <A> the chart presents laryngectomy combined with thyroidectomy </A>, <CO> depending on the extent of lymph node dissection required </CO>. <E> This highlights surgical intervention as a viable option in the management of advanced cases </E>.\\n\\nSection Name: Induction Chemotherapy\\n====================\\nEntities:-\\nInduction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nTherapeutic Approach : A method or strategy used in the treatment of disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""Induction Chemotherapy\"", Entity2: \""Surgical Intervention\"", Relationship: \""alternative or sequential treatment option\""\\n\\nCausalities:-\\n<C> immediate surgical intervention is either not feasible or considered insufficient </C> <E> The flowchart also considers the option of induction chemotherapy </E> <CO> in cases where immediate surgical intervention is either not feasible or considered insufficient </CO>. <A> tailoring therapeutic approaches tailored to individual patient needs </A>.\\n\\nSection Name: Adjuvant Treatment\\n====================\\nEntities:-\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nNeoplasm Recurrence, Local : The return of a cancer, at the same site, after it has been treated.\\nDisease Progression : The worsening of a disease over time.\\n\\nRelationships:-\\n1. Entity1: \""Primary Treatment\"", Entity2: \""Adjuvant Treatment\"", Relationship: \""followed by\""\\n2. Entity1: \""Adjuvant Treatment\"", Entity2: \""Systemic Therapy\"", Relationship: \""includes\""\\n3. Entity1: \""Adjuvant Treatment\"", Entity2: \""Radiotherapy\"", Relationship: \""includes\""\\n4. Entity1: \""Follow-up Assessments\"", Entity2: \""Treatment Efficacy\"", Relationship: \""used to evaluate\""\\n\\nCausalities:-\\n<C> Following primary treatment </C>, <E> the flowchart addresses the potential for adjuvant treatment pathways </E>. This may include systemic therapy, RT, or further evaluations based on <CO> the patient\\'s response and any recurrence or persistent disease </CO>. It emphasizes <A> the need for follow-up assessments to evaluate treatment efficacy </A>.\\n\\nSection Name: Risk Features and Response Assessment\\n====================\\nEntities:-\\nNeoplasm Invasiveness : The property of a neoplasm to infiltrate and destroy surrounding tissue.\\nSurgical Margins : The edge or border of the tissue removed in cancer surgery.\\nNeoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.\\nExtramural Extension : Extension of a tumor beyond the wall of an organ.\\nPositive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.\\nCancer Management : The process of planning and coordinating the treatment of cancer.\\nCancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""Extramural extension\"", Entity2: \""Treatment decisions\"", Relationship: \""influences\""\\n2. Entity1: \""Positive surgical margin\"", Entity2: \""Treatment decisions\"", Relationship: \""influences\""\\n3. Entity1: \""Ongoing assessment\"", Entity2: \""Response evaluation\"", Relationship: \""leads to\""\\n4. Entity1: \""Response evaluation\"", Entity2: \""Adjustments to treatment\"", Relationship: \""leads to\""\\n5. Entity1: \""Management of cancer\"", Entity2: \""Treatment decisions\"", Relationship: \""involves\""\\n6. Entity1: \""Management of cancer\"", Entity2: \""Ongoing assessment\"", Relationship: \""involves\""\\n7. Entity1: \""Management of cancer\"", Entity2: \""Adjustments to treatment\"", Relationship: \""involves\""\\n\\nCausalities:-\\nThe chart incorporates a segment that takes into account <CO> adverse pathologic features, such as extramural extension or positive margins </CO>, <E> which could influence subsequent treatment decisions </E>. This highlights the importance of <A> ongoing assessment in the management of cancer, leading to response evaluation and adjustments to treatment as necessary </A>.\\n\\nSection Name: NCCN Guidelines Version 4.2024\\n====================\\nEntities:-\\nClinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.\\nNeoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.\\nClinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nMalignant Neoplasm : A malignant neoplasm is a cancerous growth that has the potential to invade and destroy nearby tissue and spread to other parts of the body.\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nCancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network\"", Entity2: \""NCCN Guidelines\"", Relationship: \""provides\""\\n2. Entity1: \""NCCN Guidelines\"", Entity2: \""Clinical Trials\"", Relationship: \""recommend\""\\n3. Entity1: \""NCCN Guidelines\"", Entity2: \""Cancer\"", Relationship: \""related to management of\""\\n\\nCausalities:-\\n<CO> any patient with cancer </CO> <A> the best management is in a clinical trial </A>. <A> Participation in clinical trials is especially encouraged </A>.\\n\\nSection Name: SUPRA-3\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.\\nChemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nClinical Trials As Topic : Research studies that prospectively assign human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nInduction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.\\nClinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\n\\nRelationships:-\\n1. Entity1: \""Total laryngectomy\"", Entity2: \""Laryngectomy\"", Relationship: \""is a type of\""\\n2. Entity1: \""Systemic therapy\"", Entity2: \""RT\"", Relationship: \""concurrent treatment option\""\\n3. Entity1: \""Induction chemotherapy\"", Entity2: \""Other treatments\"", Relationship: \""initial treatment option before\""\\n\\nCausalities:-\\n<CO> Requiring (amenable to) total laryngectomy (T3,N0) </CO>\\n  - <A> Concurrent systemic therapy/RT </A> or <A> RT if patient not medical candidate for concurrent systemic therapy/RT </A>\\n  - <A> Laryngectomy, thyroidectomy and with ipsilateral, central, or bilateral neck dissection </A>\\n  - or\\n  - <A> Induction chemotherapy </A>\\n  - or\\n  - <A> Clinical trials </A>\\n\\nSection Name: Follow-up\\n====================\\nEntities:-\\nFollow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.\\nFollow-Up Procedure : A procedure performed to monitor the progress of a patient\\'s condition after initial treatment.\\nFollow-Up : Medical care given to a patient over time after initial treatment.\\nDisease Recurrence : The return of a sign, symptom, or disease after a remission.\\nRecurrent Disease : The reappearance of a disease after a period of improvement.\\n\\nRelationships:-\\n1. Entity1: \""Follow-up\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""monitoring\""\\n\\nCausalities:-\\n- **Follow-up (FOLL-A, 1 of 2)**\\n  - <CO> Recurrent or persistent disease </CO> (ADV-3)\\n\\nSection Name: Adverse Pathologic Features\\n====================\\nEntities:-\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nExtranodal Extension : The spread of cancer beyond the lymph node capsule.\\nPositive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""pN1\"", Entity2: \""Radiotherapy\"", Relationship: \""Consideration for treatment\""\\n2. Entity1: \""Extranodal extension\"", Entity2: \""Systemic Therapy\"", Relationship: \""Treatment option\""\\n3. Entity1: \""Extranodal extension\"", Entity2: \""Radiotherapy\"", Relationship: \""Treatment option\""\\n4. Entity1: \""Positive surgical margin\"", Entity2: \""Systemic Therapy\"", Relationship: \""Treatment option\""\\n5. Entity1: \""Positive surgical margin\"", Entity2: \""Radiotherapy\"", Relationship: \""Treatment option\""\\n\\nCausalities:-\\n- <CO>pN1 without other risk features</CO>\\n  - <C>Adverse pathologic features</C>\\n  - <A>Consider RT</A>\\n  - <CO>Extranodal extension and/or positive margin</CO>\\n  - <CO>Other risk features</CO>\\n  - <A>Systemic therapy/RT (category 1)</A>\\n  - <A>RT or Consider systemic therapy/RT</A>\\n\\nSection Name: Response Assessment\\n====================\\nEntities:-\\nResponse Evaluation : The process of assessing the response of a disease to treatment, often used in clinical trials to determine the effectiveness of a therapy.\\nResponse To Treatment : A clinical finding indicating the response of a condition to a therapeutic intervention.\\n\\nRelationships:-\\n\\nSection Name: Principles of Surgery and Radiation Therapy\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nRadiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\n\\nRelationships:-\\n1. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Radiation Therapy\"", Relationship: \""complementary treatments\""\\n\\nCausalities:-\\n**Principles of Surgery (SURG-A).**\\n\\n**Principles of Radiation Therapy (SUPRA-A).**\\n\\nSection Name: Principles of Systemic Therapy\\n====================\\nEntities:-\\nCisplatin : An inorganic and water-soluble platinum complex, cisplatin is an antineoplastic agent that is used in the treatment of various cancers.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nRadiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\n\\nRelationships:-\\n1. Entity1: \""Cisplatin\"", Entity2: \""Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""preferred agent\""\\n2. Entity1: \""Cisplatin\"", Entity2: \""Concurrent Systemic Therapy/RT\"", Relationship: \""used in\""\\n\\nCausalities:-\\n<CO> When using concurrent systemic therapy/RT </CO>, <A> the preferred agent is cisplatin (category 1) </A>.\\n--------------------------------------------------\\nPage Number: 55\\n\\nSection Name: General Information\\n====================\\nEntities:-\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nNccn Guidelines : Clinical practice guidelines in oncology developed by the National Comprehensive Cancer Network.\\n\\nRelationships:-\\n1. Entity1: \""NCCN Guidelines\"", Entity2: \""National Comprehensive Cancer Network\"", Relationship: \""produced by\""\\n\\nSection Name: Important Notes\\n====================\\nEntities:-\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medical, surgical, or behavioral interventions.\\nClinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nNeoplasms : New abnormal growth of tissue that can be benign or malignant.\\nMalignant Neoplastic Disease : A disease resulting from the growth of malignant neoplasms.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""Clinical Trials\"", Entity2: \""Cancer\"", Relationship: \""recommended for\""\\n2. Entity1: \""NCCN\"", Entity2: \""Clinical Trials\"", Relationship: \""encourages participation in\""\\n\\nCausalities:-\\n<C> NCCN believes that the best management of any patient with cancer is in a clinical trial </C>. <A> Participation in clinical trials is especially encouraged </A>.\\n\\nSection Name: Principles\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nChemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.\\n\\nRelationships:-\\n1. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Radiation Therapy\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n2. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n3. Entity1: \""Principles of Radiation Therapy\"", Entity2: \""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n\\nCausalities:-\\n### Principles\\n\\n- **Principles of Surgery (SURG-A)**\\n- **Principles of Radiation Therapy (SUPRA-A)**\\n- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**\\n\\nSection Name: Adverse Pathologic Features\\n====================\\nEntities:-\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.\\nPerineural Invasion : The presence of cancer cells surrounding or tracking along a nerve within the perineural space.\\nVascular Invasion : The invasion of cancer cells into blood vessels.\\nLymphatic Invasion : The invasion of cancer cells into lymphatic vessels.\\n\\nRelationships:-\\n1. Entity1: \""Extranodal extension\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n2. Entity1: \""Positive margins\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n3. Entity1: \""Close margins\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n4. Entity1: \""pT3 or pT4 primary\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n5. Entity1: \""pN2 or pN3 nodal disease\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n6. Entity1: \""Perineural invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n7. Entity1: \""Vascular invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n8. Entity1: \""Lymphatic invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n\\nCausalities:-\\n<C> Extranodal extension </C>\\n<C> Positive margins </C>\\n<C> Close margins </C>\\n<C> pT3 or pT4 primary </C>\\n<C> pN2 or pN3 nodal disease </C>\\n<C> Perineural invasion </C>\\n<C> Vascular invasion </C>\\n<C> Lymphatic invasion </C>\\n\\nSection Name: Response Assessment\\n====================\\nEntities:-\\nChemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nPrimary Site : The original location where a tumor or cancer begins.\\nComplete Remission : The disappearance of all signs of cancer in response to treatment.\\nPartial Remission : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.\\nRadiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""induction chemotherapy\"", Entity2: \""Primary site\"", Relationship: \""treatment outcome\""\\n2. Entity1: \""Definitive RT\"", Entity2: \""Primary site\"", Relationship: \""treatment option\""\\n3. Entity1: \""RT\"", Entity2: \""Primary site\"", Relationship: \""treatment option\""\\n4. Entity1: \""Surgery\"", Entity2: \""unresectable nodal disease\"", Relationship: \""treatment option\""\\n\\nCausalities:-\\n<C> Response after induction chemotherapy </C>: <E> Primary site: CR </E> <E> Primary site: PR </E> <E> Primary site: < PR </E> <A> Definitive RT </A> (category 1) <A> RT </A> (category 1) or <A> systemic therapy/RT </A> (category 2B) <A> Surgery </A> or <A> unresectable nodal disease </A>\\n\\nSection Name: Follow-up\\n====================\\nEntities:-\\nFollow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.\\nFollow-Up Procedure : A procedure where a patient is monitored over time to assess the progress of a condition or the effects of treatment.\\nFollow-Up (Medicine) : The process of monitoring a patient\\'s health over time after treatment or diagnosis.\\nDisease Recurrence : The return of a sign, symptom, or disease after a remission.\\nRecurrent Disease : A disease that returns after a period of remission.\\nRecurrence (Medicine) : The return of a disease or condition after a period of improvement.\\n\\nRelationships:-\\n1. Entity1: \""Follow-up\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""monitoring\""\\n\\nCausalities:-\\n### Follow-up\\n\\n- **Follow-up** (FOLL-A, 1 of 2)\\n- **Recurrent or persistent disease** (ADV-3)\\n\\nSection Name: Risk Features\\n====================\\nEntities:-\\nRadiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Adverse pathologic features\"", Entity2: \""RT\"", Relationship: \""Consideration for treatment\""\\n2. Entity1: \""Adverse pathologic features\"", Entity2: \""Systemic therapy\"", Relationship: \""Consideration for treatment\""\\n\\nCausalities:-\\n- **No adverse pathologic features**\\n- **Other risk features**\\n- **Adverse pathologic features**:\\n  - <C> Extranodal extension and/or positive margin </C>\\n  - <A> RT or consider systemic therapy/RT </A>\\n\\nSection Name: Post-Therapy Evaluation\\n====================\\nEntities:-\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nNeck : The neck is the part of the body that separates the head from the torso and provides the mobility and movements of the head.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Neck Evaluation\"", Relationship: \""evaluated in\""\\n2. Entity1: \""RT\"", Entity2: \""Neck Evaluation\"", Relationship: \""evaluated in\""\\n\\nCausalities:-\\n<CO> Post Systemic Therapy/RT or RT Neck </CO> <A> Evaluation </A>\\n\\nSection Name: Flowchart Overview\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nSupraglottic Larynx : The part of the larynx located above the vocal cords, including the epiglottis and aryepiglottic folds.\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\n\\nRelationships:-\\n1. Entity1: \""NCCN Guidelines\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""guides management of\""\\n2. Entity1: \""NCCN Guidelines\"", Entity2: \""healthcare professionals\"", Relationship: \""used by\""\\n\\nCausalities:-\\n<C> cancer of the supraglottic larynx </C> <E> evaluate patient responses following treatment </E> <CO> based on observed outcomes </CO> <A> evaluation of the primary site and determining subsequent steps </A>.\\n\\nSection Name: Assessment and Treatment Decisions\\n====================\\nEntities:-\\nInduction Chemotherapy : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nComplete Response : The disappearance of all signs of cancer in response to treatment.\\nPartial Response : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Complete Response\"", Entity2: \""Radiation Therapy\"", Relationship: \""leads to\""\\n2. Entity1: \""Complete Response\"", Entity2: \""Surgery\"", Relationship: \""leads to\""\\n3. Entity1: \""Partial Response\"", Entity2: \""Systemic Therapy\"", Relationship: \""leads to\""\\n4. Entity1: \""Partial Response\"", Entity2: \""Radiation Therapy\"", Relationship: \""leads to\""\\n\\nCausalities:-\\n<C> responses to initial treatments such as induction chemotherapy </C> <E> Three main response categories are recognized: Complete Response (CR), Partial Response (PR), and less than Partial Response (< PR) </E>. These categories are pivotal in determining the next steps. <C> CR </C> <E> indicates full resolution of the disease at the primary site </E>, <A> leading to the consideration of definitive radiation therapy or the likelihood of surgery </A>. Conversely, <C> PR </C> <E> suggests that the disease has improved but not completely resolved </E>, <A> which directs the pathway towards either systemic therapy or continued radiation therapy </A>, <A> with further evaluation necessary </A>.\\n\\nSection Name: Adverse Pathologic Features and Follow-up\\n====================\\nEntities:-\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nNeoplasm Recurrence, Local : The return of a tumor or cancer, at the original site, after it has been treated.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nRecurrent Neoplasm : A neoplasm that has returned after treatment.\\nMetastatic Neoplasm : A neoplasm that has spread from its original site to one or more other places in the body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nCancer Recurrence : The return of cancer after treatment and after a period of time during which the cancer was undetectable.\\nMetastasis : Spread of a cancer or other disease from one organ or part to another not directly connected with it.\\n\\nRelationships:-\\n1. Entity1: \""Adverse pathologic features\"", Entity2: \""Treatment decisions\"", Relationship: \""Influence\""\\n2. Entity1: \""Adverse features\"", Entity2: \""Surgical intervention\"", Relationship: \""Recommendation\""\\n3. Entity1: \""Absence of adverse features\"", Entity2: \""Radiation therapy\"", Relationship: \""Pathway\""\\n4. Entity1: \""Follow-up process\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""Detection\""\\n5. Entity1: \""Recurrent or persistent disease\"", Entity2: \""Advanced disease management\"", Relationship: \""Necessity\""\\n\\nCausalities:-\\n<C> The presence of adverse pathologic features \u2014 such as extranodal extension or positive margins </C> <E> can directly influence treatment decisions </E>. <CO> If adverse features are found </CO>, <A> surgical intervention is recommended </A>. <CO> In cases where there are no adverse features </CO>, the patient may proceed directly to radiation therapy or continued systemic treatment, emphasizing the tailored approach based on the individual patient\\'s disease characteristics.\\n\\nFurthermore, the chart includes a section addressing the follow-up process after initial treatment. <CO> If there are signs of recurrent or persistent disease </CO>, <A> additional evaluations and treatment modalities may be necessary </A>. These evaluations <E> lead to specific recommendations for advanced disease management, denoted as ADV-3 on the chart </E>, emphasizing the importance of continuous monitoring and assessment in cancer care.\\n--------------------------------------------------\\nPage Number: 130\\n\\nSection Name: Pathological N (pN)\\n====================\\nEntities:-\\nLymph Nodes : Small, bean-shaped structures that are part of the body\\'s lymphatic system. They filter lymph fluid and store white blood cells that help fight infection.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nTnm Staging : A system used to describe the size and spread of cancer in a standardized way. T refers to the size of the tumor, N to the involvement of lymph nodes, and M to metastasis.\\nLymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\nTnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient\\'s body.\\nLymph Node : An organ of the lymphatic system and the adaptive immune system.\\n\\nRelationships:-\\n1. Entity1: \""Lymph Nodes\"", Entity2: \""Neoplasm Metastasis\"", Relationship: \""involved in\""\\n2. Entity1: \""TNM Staging\"", Entity2: \""Lymph Nodes\"", Relationship: \""includes\""\\n3. Entity1: \""TNM Staging\"", Entity2: \""Neoplasm Metastasis\"", Relationship: \""describes\""\\n\\nCausalities:-\\n<CO> NX: Regional lymph nodes cannot be assessed </CO>\\n<CO> N0: No regional lymph node metastasis </CO>\\n<CO> N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(\u2013) </CO>\\n<CO> N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2212); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(\u2212); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2a: Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N3: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(\u2212); or metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>\\n<CO> N3a: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N3b: Metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>\\n<CO> Note: A designation of \u201cU\u201d or \u201cL\u201d may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L). Similarly, clinical and pathological ENE should be recorded as ENE(\u2212) or ENE(+). </CO>\\n\\nSection Name: Distant Metastasis (M)\\n====================\\nEntities:-\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\n\\nRelationships:-\\n1. Entity1: \""M0\"", Entity2: \""Distant Metastasis\"", Relationship: \""is a category of\""\\n2. Entity1: \""M1\"", Entity2: \""Distant Metastasis\"", Relationship: \""is a category of\""\\n\\nCausalities:-\\n### Distant Metastasis (M)\\n\\n- **M0**: No distant metastasis\\n- **M1**: Distant metastasis\\n\\nSection Name: Histologic Grade (G)\\n====================\\nEntities:-\\nNeoplasm Grading : A system of classifying cancer cells in terms of how abnormal they look under a microscope and how quickly the tumor is likely to grow and spread.\\nHistologic Grade : A measure of how much tumor cells differ from healthy cells, used to assess the aggressiveness of cancer.\\n\\nRelationships:-\\n1. Entity1: \""GX\"", Entity2: \""Grade cannot be assessed\"", Relationship: \""is described as\""\\n2. Entity1: \""G1\"", Entity2: \""Well differentiated\"", Relationship: \""is described as\""\\n3. Entity1: \""G2\"", Entity2: \""Moderately differentiated\"", Relationship: \""is described as\""\\n4. Entity1: \""G3\"", Entity2: \""Poorly differentiated\"", Relationship: \""is described as\""\\n\\nCausalities:-\\n<CO>GX</CO>: <E>Grade cannot be assessed</E>\\n<CO>G1</CO>: <E>Well differentiated</E>\\n<CO>G2</CO>: <E>Moderately differentiated</E>\\n<CO>G3</CO>: <E>Poorly differentiated</E>\\n\\nSection Name: Prognostic Stage Groups\\n====================\\nEntities:-\\nNeoplasm Staging : Methods and systems of classifying neoplasms according to extent of disease.\\nTumor Staging : A system for describing the size and spread of cancer within the body.\\nTnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient\\'s body.\\n\\nRelationships:-\\n1. Entity1: \""Stage 0\"", Entity2: \""Tis N0 M0\"", Relationship: \""defined by\""\\n2. Entity1: \""Stage I\"", Entity2: \""T1 N0 M0\"", Relationship: \""defined by\""\\n3. Entity1: \""Stage II\"", Entity2: \""T2 N0 M0\"", Relationship: \""defined by\""\\n4. Entity1: \""Stage III\"", Entity2: \""T3 N0 M0, T1 N1 M0, T2 N1 M0, T3 N1 M0\"", Relationship: \""defined by\""\\n5. Entity1: \""Stage IVA\"", Entity2: \""T1 N2 M0, T2 N2 M0, T3 N2 M0, T4a N0,N1,N2 M0\"", Relationship: \""defined by\""\\n6. Entity1: \""Stage IVB\"", Entity2: \""Any T N3 M0, T4b Any N M0\"", Relationship: \""defined by\""\\n7. Entity1: \""Stage IVC\"", Entity2: \""Any T Any N M1\"", Relationship: \""defined by\""\\n--------------------------------------------------\\nPage Number: 41\\n\\nSection Name: Workup\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.\\nHistory And Physical Examination : A comprehensive assessment of a patient\\'s medical history and physical condition.\\nTobacco Smoking : The act of smoking tobacco products, which is a risk factor for many diseases.\\nAlcohol Drinking : The consumption of beverages containing ethyl alcohol.\\nSmoking Cessation : The process of discontinuing tobacco smoking.\\nBiopsy : A medical test involving the extraction of sample cells or tissues for examination.\\nLaryngoscopy : A procedure to examine the larynx, often using a scope.\\nComputed Tomography (Ct) : A diagnostic imaging procedure that uses computer-processed combinations of many X-ray measurements taken from different angles to produce cross-sectional images of specific areas of a scanned object.\\nMagnetic Resonance Imaging (Mri) : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.\\nPositron-Emission Tomography : A type of nuclear medicine imaging that measures metabolic activity of the cells of body tissues.\\nPulmonary Function Test : Tests that measure how well the lungs are working.\\nDental Examination : An evaluation of the teeth and gums to assess oral health.\\nNutritional Support : Therapies to provide nutrition to patients who cannot obtain nutrition by mouth.\\nSpeech Therapy : Therapy to improve speech and communication skills.\\nSwallowing Therapy : Therapy to help individuals with swallowing difficulties.\\nMultidisciplinary Care Team : A group of healthcare professionals from different specialties working together to manage patient care.\\n\\nRelationships:-\\n1. Entity1: \""glottic larynx cancer\"", Entity2: \""history and physical examination\"", Relationship: \""initial diagnostic step\""\\n2. Entity1: \""glottic larynx cancer\"", Entity2: \""biopsy\"", Relationship: \""required diagnostic procedure\""\\n3. Entity1: \""glottic larynx cancer\"", Entity2: \""direct laryngoscopy\"", Relationship: \""recommended procedure\""\\n4. Entity1: \""glottic larynx cancer\"", Entity2: \""CT scans\"", Relationship: \""imaging study\""\\n5. Entity1: \""glottic larynx cancer\"", Entity2: \""MRI\"", Relationship: \""imaging study\""\\n6. Entity1: \""glottic larynx cancer\"", Entity2: \""multidisciplinary consultation\"", Relationship: \""advised as clinically indicated\""\\n\\nCausalities:-\\nThe workup section outlines the initial steps for diagnosing <C>glottic larynx cancer</C>. It includes <A>a comprehensive history and physical examination (H&P)</A>, which should document tobacco and alcohol use, and provide counseling for smoking cessation. <A>A biopsy of the primary site is required</A>, and <A>direct laryngoscopy under anesthesia is generally recommended</A>. <A>Imaging studies such as CT scans with contrast and possibly MRI are used to evaluate the larynx and neck</A>. Additional evaluations may include <A>chest CT, FDG-PET/CT, pulmonary function tests, dental evaluation, and nutrition, speech, and swallowing therapy</A>. <A>Multidisciplinary consultation is advised</A> <CO>as clinically indicated</CO>.\\n\\nSection Name: Clinical Staging\\n====================\\nEntities:-\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\nCarcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.\\nBiopsy : A medical test involving the extraction of sample cells or tissues for examination.\\nLaryngectomy : A surgical procedure to remove the larynx.\\n\\nRelationships:-\\n1. Entity1: \""Clinical staging\"", Entity2: \""Cancer\"", Relationship: \""involves\""\\n2. Entity1: \""Carcinoma in situ\"", Entity2: \""Stages T1-T4\"", Relationship: \""is a stage of\""\\n3. Entity1: \""Biopsy\"", Entity2: \""Cancer\"", Relationship: \""used in staging\""\\n4. Entity1: \""Larynx-preserving surgeries\"", Entity2: \""Stages T1-T2\"", Relationship: \""considered for\""\\n5. Entity1: \""Total laryngectomy\"", Entity2: \""Stages T3-T4\"", Relationship: \""required for\""\\n\\nCausalities:-\\n<C> Clinical staging involves categorizing the cancer based on its aggressiveness </C>. It starts with carcinoma in situ, which is non-invasive, and progresses through stages T1-T4. <CO> Staging is based on H&P, biopsy, and imaging studies </CO>. <CO> For T1-T2 </CO>, <A> larynx-preserving surgeries are considered </A>, while <CO> more advanced stages like T3 or T4 </CO> <A> may require total laryngectomy </A>. <A> Additional evaluations such as videostrobe, audiogram, and fertility counseling may be considered </A>.\\n\\nSection Name: Treatment\\n====================\\nEntities:-\\nCarcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.\\nLaryngectomy : A surgical procedure to remove the larynx.\\nMetastasis : The transfer of a disease from one organ or part to another not directly connected with it.\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\n\\nRelationships:-\\n1. Entity1: \""Carcinoma in situ\"", Entity2: \""Larynx-preserving surgery\"", Relationship: \""treated with\""\\n2. Entity1: \""T1-T2 stages\"", Entity2: \""Conservation surgery\"", Relationship: \""treated with\""\\n3. Entity1: \""T3 stages\"", Entity2: \""Total laryngectomy\"", Relationship: \""may require\""\\n4. Entity1: \""T4a disease\"", Entity2: \""Complex interventions\"", Relationship: \""require\""\\n5. Entity1: \""Guidelines\"", Entity2: \""Multidisciplinary consultations\"", Relationship: \""emphasize importance of\""\\n6. Entity1: \""Guidelines\"", Entity2: \""Clinical trials\"", Relationship: \""consider as best option\""\\n\\nCausalities:-\\n<CO>Treatment recommendations vary by stage</CO>. <CO>Carcinoma in situ</CO> <A>may be treated with larynx-preserving surgery</A>. <CO>T1-T2 stages</CO> <A>may also be amenable to conservation surgery</A>. <CO>T3 stages</CO> <A>may require total laryngectomy</A>, <CO>especially if nodal involvement is present</CO>. <CO>T4a disease and unresectable or metastatic cases</CO> <A>require more complex interventions</A>. <A>The guidelines emphasize the importance of multidisciplinary consultations</A> and <A>consider clinical trials as the best management option</A>.\\n\\nSection Name: Additional Notes\\n====================\\nEntities:-\\nBiopsy, Needle : A procedure to remove a small sample of tissue for examination under a microscope.\\nImage-Guided Biopsy : A biopsy procedure that uses imaging techniques to guide the needle to the precise location of the tissue to be sampled.\\nBiopsy : A medical test involving the extraction of sample cells or tissues for examination.\\nDiagnostic Techniques And Procedures : Methods and procedures for the diagnosis of disease or dysfunction.\\nImaging : The process of producing images of the body for clinical purposes.\\nDental Care : The total of dental diagnostic, preventive, and corrective procedures.\\nNutritional Physiological Phenomena : The functions and properties of nutrients in living organisms.\\nFertility : The capacity to conceive or induce conception.\\nReproductive Health : A state of physical, mental, and social well-being in all matters relating to the reproductive system.\\nLymphatic Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nGlottis : The part of the larynx consisting of the vocal cords and the opening between them.\\n\\nRelationships:-\\n1. Entity1: \""image-guided needle biopsy\"", Entity2: \""diagnostic yield\"", Relationship: \""used for\""\\n2. Entity1: \""nodal disease\"", Entity2: \""glottic tumors\"", Relationship: \""is rare in\""\\n\\nCausalities:-\\n<A> use of image-guided needle biopsy </A> for <E> better diagnostic yield </E>, principles of imaging, dental evaluation, and nutrition management. The guidelines also address fertility and reproductive considerations, and note that <CO> nodal disease in glottic tumors is rare </CO>.\\n'}""",valid,increases risk,2,B,"edge - The edge which needs to be verified.
explanation - Explanation of what the edge represents and its validity.
causal_direction - Either Positive or Negative or Unknown. A positive influence direction indicates that both factors change in the same direction (e.g. an increase causes an increase effect). A negative influence direction indicates the opposite changes (e.g. an increase causes a decrease effect).
causal_factor - Is necessary or sufficient condition for an effect to occur. Exposure is a term commonly used in epidemiology to denote any condition that is considered as a possible cause of disease. Exposure is considered necessary when it always precedes the effects (e.g. symptoms) and always presents when the effects occur. A sufficient cause is a causal factor whose presence or occurrence guarantees the occurrence of symptom.
causal_distance - Either Distal or Proximal or Unknown. The distal factors lie towards the beginning of causal chain (i.e. indirect causal factors). The the proximal factors lie towards the end of the chain (i.e. cause directly or almost directly the effect).

Causality Tags:
<A> for action, <C> for cause, <CO> for condition and <E> for effect.
Cause (C): The reason or origin that leads to an effect. Causes often involve disease conditions, risk factors, or underlying mechanisms.
Effect (E): The outcome or result of a cause. Effects usually represent clinical outcomes, complications, or results of a specific cause.
Condition (CO): The circumstance or prerequisite required for an action or effect to occur. Conditions may include patient characteristics, clinical scenarios, or specific diagnostic criteria.
Action (A): The recommended or described response or activity to address a cause or condition. Actions typically involve clinical interventions, diagnostic procedures, or treatment recommendations.


`NODE1`:
id: N_State_1__patient
label: State of Nearby Lymph Nodes with Cancer in Patient
description: This node represents the state of involvement of nearby lymph nodes in a patient with cancer. It is a decision node used to predict the extent of lymph node metastasis, which is crucial for cancer staging and treatment planning. The states range from no involvement (n0) to extensive involvement (n3), with intermediate states indicating varying degrees of lymph node cancer presence.
type: Decision Node
observability: Needs to be Predicted
states: [{'state_name': 'nx', 'state_description': 'The regional lymph nodes cannot be assessed.'}, {'state_name': 'n3', 'state_description': 'Metastasis in lymph node(s) along the course of a major blood vessel or in a lymph node that is more than 6 cm in greatest dimension.'}, {'state_name': 'n2c', 'state_description': 'Metastasis in bilateral or contralateral lymph nodes, each 6 cm or less in greatest dimension.'}, {'state_name': 'n2b', 'state_description': 'Metastasis in multiple ipsilateral lymph nodes, each 6 cm or less in greatest dimension.'}, {'state_name': 'n2a', 'state_description': 'Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension.'}, {'state_name': 'n2', 'state_description': 'Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension, or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension.'}, {'state_name': 'n1', 'state_description': 'Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension.'}, {'state_name': 'n0', 'state_description': 'No regional lymph node metastasis.'}]

`NODE2`:
id: Presence_of_Metastasis_in_Lymph_Nodes_5
label: Metastasis in Nearby Lymph Nodes
description: This node represents the clinical situation regarding whether metastasis is present in the nearby lymph nodes of a patient. It is a critical factor in determining the stage and prognosis of cancer, as the spread of cancer to lymph nodes often indicates a more advanced disease and may influence treatment decisions.
type: Patient Situation
observability: Unobserved
states: [{'state_name': 'unknown', 'state_description': 'The status of metastasis in the lymph nodes is not determined. It is unclear whether cancer has spread to these nodes.'}, {'state_name': 'present', 'state_description': 'Metastasis is confirmed in the lymph nodes, indicating that cancer has spread to these nodes.'}, {'state_name': 'absent', 'state_description': 'There is no metastasis in the lymph nodes, indicating that cancer has not spread to these nodes.'}]

`EDGE1`:
{'edges_ids': ['N_State_1__patient', 'Presence_of_Metastasis_in_Lymph_Nodes_5'], 'edge': '(N_State_1__patient) causes (Presence_of_Metastasis_in_Lymph_Nodes_5)', 'explanation': ['The edge represents the causal relationship where the state of nearby lymph nodes in a patient with cancer (Node 1) influences the presence of metastasis in those lymph nodes (Node 2).', 'The state of lymph nodes (n0 to n3) is a clinical measure used to describe the extent of metastasis, making this a valid causal relationship.', 'The causal direction is positive because an increase in the state (e.g., from n0 to n3) indicates a higher likelihood of metastasis being present.', 'The state of lymph nodes is a necessary condition to assess the presence of metastasis, but it is not sufficient alone as other factors may also play a role.', 'The causal distance is proximal because the state of lymph nodes directly affects the presence of metastasis.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': True, 'sufficient': False}, 'causal_distance': 'Proximal'}

`EDGE2`:
{'edges_ids': ['Presence_of_Metastasis_in_Lymph_Nodes_5', 'N_State_1__patient'], 'edge': '(Presence_of_Metastasis_in_Lymph_Nodes_5) causes (N_State_1__patient)', 'explanation': ['The node `Presence_of_Metastasis_in_Lymph_Nodes_5` indicates whether metastasis is present in the lymph nodes, which is a critical factor in cancer staging.', 'The node `N_State_1__patient` represents the N-stage of cancer, which is determined by the extent of lymph node involvement.', 'The presence of metastasis in lymph nodes directly affects the N-stage, making the edge valid.', 'The causal direction is positive because the presence of metastasis leads to a higher N-stage.', 'The presence of metastasis is necessary for a higher N-stage but not sufficient alone, as other factors may also play a role.', 'The causal distance is proximal because the presence of metastasis directly influences the N-stage.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': True, 'sufficient': False}, 'causal_distance': 'Proximal'}

`INFORMATION FROM KNOWLEDGE BASE`:
--------------------------------------------------
Page Number: 102

Section Name: Head and Neck Cancers - Principles of Surgery
====================
Entities:-
Surgical Procedures, Operative : Manual or operative procedures used in the treatment of disease, injuries, or deformities.
Lymphatic System : Part of the circulatory system and a vital part of the immune system, comprising a network of lymphatic vessels that carry a clear fluid called lymph.
Neoplasms : New abnormal growth of tissue in animals or plants; a tumor.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Neoplasm Staging : Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Metastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.
Surgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Lymphatic Structure : Anatomical structure that is part of the lymphatic system.
Tumor : An abnormal mass of tissue that results when cells divide more than they should or do not die when they should.
Staging : The process of determining the size and spread of cancer within the body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Cancer Staging : The process of determining the extent to which a cancer has developed by growing and spreading.

Relationships:-
1. Entity1: ""surgical management"", Entity2: ""regional lymphatics"", Relationship: ""dictated by tumor staging""
2. Entity1: ""neck dissections"", Entity2: ""primary tumor"", Relationship: ""part of treatment""
3. Entity1: ""surgery"", Entity2: ""ipsilateral side of the neck"", Relationship: ""risk for metastases""

Causalities:-
<C> The extent of the tumor at initial tumor staging </C> <E> dictates the surgical management of regional lymphatics </E>. These guidelines apply to the performance of neck dissections as part of treatment of the primary tumor. <CO> Patients undergoing surgery for resection of the primary tumor </CO> <A> will undergo dissection of the ipsilateral side of the neck that is at greatest risk for metastases </A>.

Section Name: Neck Management
====================
Entities:-
Tongue : A muscular organ in the mouth that is involved in tasting, swallowing, and speech.
Palate : The roof of the mouth, separating the oral and nasal cavities.
Larynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.
Hypopharynx : The bottom part of the pharynx, which is the cavity behind the nose and mouth.
Nasopharynx : The upper part of the pharynx, connecting with the nasal cavity above the soft palate.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Metastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.
Squamous Cell Carcinoma : A type of cancer that begins in the squamous cells, which are thin, flat cells that look like fish scales.
Biopsy : The removal of cells or tissues for examination under a microscope.

Relationships:-
1. Entity1: ""Tumor sites"", Entity2: ""Bilateral lymphatic drainage"", Relationship: ""associated with""
2. Entity1: ""Elective neck dissection"", Entity2: ""Risk of occult metastasis"", Relationship: ""based on""
3. Entity1: ""SLN biopsy"", Entity2: ""Elective neck dissection"", Relationship: ""guides decision-making for""

Causalities:-
- **<C> Tumor sites that frequently have bilateral lymphatic drainage </C>** (e.g., base of tongue, palate, supraglottic larynx, hypopharynx, nasopharynx, deep pre-epiglottic space involvement) <E> often should have both sides of the neck dissected </E> with the extent of dissection determined as suggested below. For those patients with tumors at or approaching the midline, <CO> both sides of the neck are at risk for metastases </CO>, and <A> bilateral neck dissections should be performed </A>.

- <CO> Patients with advanced lesions involving the anterior tongue, floor of the mouth, or alveolus that approximate or cross the midline </CO> <A> should undergo contralateral selective/modified neck dissection </A> as necessary to achieve adequate tumor resection.

- **<C> Elective neck dissection </C>** <A> should be based on risk of occult metastasis in the appropriate nodal basin </A>. For oral cavity squamous cell carcinoma, <C> SLN biopsy or the primary tumor depth of invasion </C> is currently <E> the best predictor of occult metastatic disease </E> and <A> should be used to guide decision-making </A>. <CO> For tumors with a depth greater than 3 mm </CO>, <A> elective dissection should be strongly considered if RT is not already planned </A>. Recent randomized trial evidence supports the effectiveness of elective neck dissection in patients with oral cavity cancers greater than 3 mm in depth of invasion.

  - <CO> For a depth less than 2 mm </CO>, <A> elective dissection is only indicated in highly selective situations </A>. <CO> For a depth of 2–4 mm </CO>, <A> clinical judgment (as to reliability of follow-up, clinical suspicion, and other factors) must be utilized to determine appropriateness of elective dissection </A>. Elective dissections are generally selective, preserving all major structures, unless operative findings dictate otherwise.

Section Name: Types of Neck Dissection
====================
Entities:-
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Larynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.

Relationships:-
1. Entity1: ""N0"", Entity2: ""Selective neck dissection"", Relationship: ""associated with""
2. Entity1: ""N3"", Entity2: ""Comprehensive neck dissection"", Relationship: ""associated with""
3. Entity1: ""Level VI neck dissection"", Entity2: ""Larynx"", Relationship: ""performed for""
4. Entity1: ""Level VI neck dissection"", Entity2: ""Hypopharynx"", Relationship: ""performed for""

Causalities:-
- **The type of neck dissection (comprehensive or selective)** is defined according to <CO> preoperative clinical staging </CO>, is determined at the discretion of the surgeon, and is based on the initial preoperative staging as follows:
  - **N0:** <A> Selective neck dissection </A>
    - Oral cavity at least levels I–III
    - Oropharynx at least levels II–IV
    - Hypopharynx at least levels II–IV and level VI when appropriate
    - Larynx at least levels II–IV and level VI when appropriate
  - **N1–N2a–c:** <A> Selective or comprehensive neck dissection </A> (Discussion)
  - **N3:** <A> Comprehensive neck dissection </A>

- <C> Level VI neck dissections are performed for certain primary sites (such as the larynx and hypopharynx) </C> <E> as required to resect the primary tumor and any clinically evident neck nodes </E>. <CO> Elective dissection depends on primary tumor extent and site </CO>. <CO> For advanced glottic and hypopharyngeal cancers treated with primary surgery </CO>, <A> a level VI dissection (including pretracheal lymph nodes, the Delphian lymph node, and unilateral or bilateral paratracheal lymph nodes) and hemithyroidectomy to total thyroidectomy are appropriate </A>.

- <CO> For primary subglottic tumors or glottic cancers with significant subglottic extension </CO>, <A> a level VI dissection with unilateral or total thyroidectomy is considered appropriate </A> based on the extent of the primary tumor. <CO> For example, a T4a glottic tumor with extension through the cricothyroid membrane and subglottic extension </CO> <A> should include thyroidectomy and pretracheal and bilateral paratracheal lymph node dissection </A>. <A> Parathyroid glands should be preserved in situ or auto transplanted as indicated </A>.
--------------------------------------------------
Page Number: 51

Section Name: Introduction
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Malignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.
Supraglottic Laryngeal Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is above the vocal cords.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network (NCCN)"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""provides guidelines for""
2. Entity1: ""healthcare professionals"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""manage""

Causalities:-
The provided image is a detailed flowchart from the National Comprehensive Cancer Network (NCCN) guidelines regarding the <C> clinical staging and treatment protocols for cancer of the supraglottic larynx </C>. This flowchart is structured to <A> guide healthcare professionals through the stages of treatment </A> based on <CO> clinical findings </CO>, emphasizing the <E> complexity and systematic approach required in managing this type of cancer </E>.

Section Name: Clinical Staging
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Total Laryngectomy : A surgical procedure to remove the entire larynx, often used in the treatment of advanced laryngeal cancer.
Neoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.
Cancer Staging : The process of determining the extent of cancer in the body, often using the TNM system.
Tnm Staging System : A cancer staging system that describes the extent of cancer using Tumor size (T), Node involvement (N), and Metastasis (M).

Relationships:-
1. Entity1: ""Clinical staging criteria"", Entity2: ""Total laryngectomy"", Relationship: ""determines necessity of""
2. Entity1: ""T3, N0"", Entity2: ""Clinical staging criteria"", Relationship: ""is a categorization of""

Causalities:-
The flowchart begins with the <C> clinical staging criteria </C>, specifically focusing on <CO> cases that require total laryngectomy, denoted as requiring (amenable to) total laryngectomy (T3, N0) </CO>. This <A> categorization </A> is crucial as it <E> forms the basis for determining the appropriate treatment strategy </E>.

Section Name: Treatment of Primary and Neck
====================
Entities:-
Neoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.
Lymphatic Metastasis : Transfer of a neoplasm from one organ or part of the body to another remote from the primary site.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Radiation Therapy"", Relationship: ""combined with""
2. Entity1: ""Laryngectomy"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""
3. Entity1: ""Thyroidectomy"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""
4. Entity1: ""Neck Dissection"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""

Causalities:-
<CO> Once clinical staging is established </CO>, the chart outlines various treatment options. <A> The initial step may involve either concurrent systemic therapy combined with radiation therapy (RT) or opting for RT alone </A>, <CO> especially if the patient is not a medical candidate for both therapies </CO>. <A> Laryngectomy, thyroidectomy, and neck dissection are considered </A> <CO> based on the extent of lymph node involvement </CO>.

Section Name: Surgical Options
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Lymph Node Excision : Surgical removal of one or more lymph nodes.
Lymphadenectomy : Surgical removal of one or more groups of lymph nodes.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.

Relationships:-
1. Entity1: ""Laryngectomy"", Entity2: ""Thyroidectomy"", Relationship: ""combined with""
2. Entity1: ""Lymph Node Dissection"", Entity2: ""Surgical Intervention"", Relationship: ""extent of""
3. Entity1: ""Surgical Intervention"", Entity2: ""Advanced Cases"", Relationship: ""management option for""

Causalities:-
<CO> If concurrent therapies are not suitable </CO>, <A> the chart presents laryngectomy combined with thyroidectomy </A>, <CO> depending on the extent of lymph node dissection required </CO>. <E> This highlights surgical intervention as a viable option in the management of advanced cases </E>.

Section Name: Induction Chemotherapy
====================
Entities:-
Induction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Therapeutic Approach : A method or strategy used in the treatment of disease or injury.

Relationships:-
1. Entity1: ""Induction Chemotherapy"", Entity2: ""Surgical Intervention"", Relationship: ""alternative or sequential treatment option""

Causalities:-
<C> immediate surgical intervention is either not feasible or considered insufficient </C> <E> The flowchart also considers the option of induction chemotherapy </E> <CO> in cases where immediate surgical intervention is either not feasible or considered insufficient </CO>. <A> tailoring therapeutic approaches tailored to individual patient needs </A>.

Section Name: Adjuvant Treatment
====================
Entities:-
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Neoplasm Recurrence, Local : The return of a cancer, at the same site, after it has been treated.
Disease Progression : The worsening of a disease over time.

Relationships:-
1. Entity1: ""Primary Treatment"", Entity2: ""Adjuvant Treatment"", Relationship: ""followed by""
2. Entity1: ""Adjuvant Treatment"", Entity2: ""Systemic Therapy"", Relationship: ""includes""
3. Entity1: ""Adjuvant Treatment"", Entity2: ""Radiotherapy"", Relationship: ""includes""
4. Entity1: ""Follow-up Assessments"", Entity2: ""Treatment Efficacy"", Relationship: ""used to evaluate""

Causalities:-
<C> Following primary treatment </C>, <E> the flowchart addresses the potential for adjuvant treatment pathways </E>. This may include systemic therapy, RT, or further evaluations based on <CO> the patient's response and any recurrence or persistent disease </CO>. It emphasizes <A> the need for follow-up assessments to evaluate treatment efficacy </A>.

Section Name: Risk Features and Response Assessment
====================
Entities:-
Neoplasm Invasiveness : The property of a neoplasm to infiltrate and destroy surrounding tissue.
Surgical Margins : The edge or border of the tissue removed in cancer surgery.
Neoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.
Extramural Extension : Extension of a tumor beyond the wall of an organ.
Positive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.
Cancer Management : The process of planning and coordinating the treatment of cancer.
Cancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""Extramural extension"", Entity2: ""Treatment decisions"", Relationship: ""influences""
2. Entity1: ""Positive surgical margin"", Entity2: ""Treatment decisions"", Relationship: ""influences""
3. Entity1: ""Ongoing assessment"", Entity2: ""Response evaluation"", Relationship: ""leads to""
4. Entity1: ""Response evaluation"", Entity2: ""Adjustments to treatment"", Relationship: ""leads to""
5. Entity1: ""Management of cancer"", Entity2: ""Treatment decisions"", Relationship: ""involves""
6. Entity1: ""Management of cancer"", Entity2: ""Ongoing assessment"", Relationship: ""involves""
7. Entity1: ""Management of cancer"", Entity2: ""Adjustments to treatment"", Relationship: ""involves""

Causalities:-
The chart incorporates a segment that takes into account <CO> adverse pathologic features, such as extramural extension or positive margins </CO>, <E> which could influence subsequent treatment decisions </E>. This highlights the importance of <A> ongoing assessment in the management of cancer, leading to response evaluation and adjustments to treatment as necessary </A>.

Section Name: NCCN Guidelines Version 4.2024
====================
Entities:-
Clinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.
Neoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.
Clinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Malignant Neoplasm : A malignant neoplasm is a cancerous growth that has the potential to invade and destroy nearby tissue and spread to other parts of the body.
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Cancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network"", Entity2: ""NCCN Guidelines"", Relationship: ""provides""
2. Entity1: ""NCCN Guidelines"", Entity2: ""Clinical Trials"", Relationship: ""recommend""
3. Entity1: ""NCCN Guidelines"", Entity2: ""Cancer"", Relationship: ""related to management of""

Causalities:-
<CO> any patient with cancer </CO> <A> the best management is in a clinical trial </A>. <A> Participation in clinical trials is especially encouraged </A>.

Section Name: SUPRA-3
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.
Chemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Clinical Trials As Topic : Research studies that prospectively assign human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Induction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.
Clinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.

Relationships:-
1. Entity1: ""Total laryngectomy"", Entity2: ""Laryngectomy"", Relationship: ""is a type of""
2. Entity1: ""Systemic therapy"", Entity2: ""RT"", Relationship: ""concurrent treatment option""
3. Entity1: ""Induction chemotherapy"", Entity2: ""Other treatments"", Relationship: ""initial treatment option before""

Causalities:-
<CO> Requiring (amenable to) total laryngectomy (T3,N0) </CO>
  - <A> Concurrent systemic therapy/RT </A> or <A> RT if patient not medical candidate for concurrent systemic therapy/RT </A>
  - <A> Laryngectomy, thyroidectomy and with ipsilateral, central, or bilateral neck dissection </A>
  - or
  - <A> Induction chemotherapy </A>
  - or
  - <A> Clinical trials </A>

Section Name: Follow-up
====================
Entities:-
Follow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.
Follow-Up Procedure : A procedure performed to monitor the progress of a patient's condition after initial treatment.
Follow-Up : Medical care given to a patient over time after initial treatment.
Disease Recurrence : The return of a sign, symptom, or disease after a remission.
Recurrent Disease : The reappearance of a disease after a period of improvement.

Relationships:-
1. Entity1: ""Follow-up"", Entity2: ""Recurrent or persistent disease"", Relationship: ""monitoring""

Causalities:-
- **Follow-up (FOLL-A, 1 of 2)**
  - <CO> Recurrent or persistent disease </CO> (ADV-3)

Section Name: Adverse Pathologic Features
====================
Entities:-
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Extranodal Extension : The spread of cancer beyond the lymph node capsule.
Positive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""pN1"", Entity2: ""Radiotherapy"", Relationship: ""Consideration for treatment""
2. Entity1: ""Extranodal extension"", Entity2: ""Systemic Therapy"", Relationship: ""Treatment option""
3. Entity1: ""Extranodal extension"", Entity2: ""Radiotherapy"", Relationship: ""Treatment option""
4. Entity1: ""Positive surgical margin"", Entity2: ""Systemic Therapy"", Relationship: ""Treatment option""
5. Entity1: ""Positive surgical margin"", Entity2: ""Radiotherapy"", Relationship: ""Treatment option""

Causalities:-
- <CO>pN1 without other risk features</CO>
  - <C>Adverse pathologic features</C>
  - <A>Consider RT</A>
  - <CO>Extranodal extension and/or positive margin</CO>
  - <CO>Other risk features</CO>
  - <A>Systemic therapy/RT (category 1)</A>
  - <A>RT or Consider systemic therapy/RT</A>

Section Name: Response Assessment
====================
Entities:-
Response Evaluation : The process of assessing the response of a disease to treatment, often used in clinical trials to determine the effectiveness of a therapy.
Response To Treatment : A clinical finding indicating the response of a condition to a therapeutic intervention.

Relationships:-

Section Name: Principles of Surgery and Radiation Therapy
====================
Entities:-
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Radiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.

Relationships:-
1. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Radiation Therapy"", Relationship: ""complementary treatments""

Causalities:-
**Principles of Surgery (SURG-A).**

**Principles of Radiation Therapy (SUPRA-A).**

Section Name: Principles of Systemic Therapy
====================
Entities:-
Cisplatin : An inorganic and water-soluble platinum complex, cisplatin is an antineoplastic agent that is used in the treatment of various cancers.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Radiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.

Relationships:-
1. Entity1: ""Cisplatin"", Entity2: ""Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""preferred agent""
2. Entity1: ""Cisplatin"", Entity2: ""Concurrent Systemic Therapy/RT"", Relationship: ""used in""

Causalities:-
<CO> When using concurrent systemic therapy/RT </CO>, <A> the preferred agent is cisplatin (category 1) </A>.
--------------------------------------------------
Page Number: 55

Section Name: General Information
====================
Entities:-
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Nccn Guidelines : Clinical practice guidelines in oncology developed by the National Comprehensive Cancer Network.

Relationships:-
1. Entity1: ""NCCN Guidelines"", Entity2: ""National Comprehensive Cancer Network"", Relationship: ""produced by""

Section Name: Important Notes
====================
Entities:-
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medical, surgical, or behavioral interventions.
Clinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Neoplasms : New abnormal growth of tissue that can be benign or malignant.
Malignant Neoplastic Disease : A disease resulting from the growth of malignant neoplasms.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""Clinical Trials"", Entity2: ""Cancer"", Relationship: ""recommended for""
2. Entity1: ""NCCN"", Entity2: ""Clinical Trials"", Relationship: ""encourages participation in""

Causalities:-
<C> NCCN believes that the best management of any patient with cancer is in a clinical trial </C>. <A> Participation in clinical trials is especially encouraged </A>.

Section Name: Principles
====================
Entities:-
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Chemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.

Relationships:-
1. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Radiation Therapy"", Relationship: ""Both are principles of cancer treatment methods.""
2. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""Both are principles of cancer treatment methods.""
3. Entity1: ""Principles of Radiation Therapy"", Entity2: ""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""Both are principles of cancer treatment methods.""

Causalities:-
### Principles

- **Principles of Surgery (SURG-A)**
- **Principles of Radiation Therapy (SUPRA-A)**
- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**

Section Name: Adverse Pathologic Features
====================
Entities:-
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.
Perineural Invasion : The presence of cancer cells surrounding or tracking along a nerve within the perineural space.
Vascular Invasion : The invasion of cancer cells into blood vessels.
Lymphatic Invasion : The invasion of cancer cells into lymphatic vessels.

Relationships:-
1. Entity1: ""Extranodal extension"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
2. Entity1: ""Positive margins"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
3. Entity1: ""Close margins"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
4. Entity1: ""pT3 or pT4 primary"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
5. Entity1: ""pN2 or pN3 nodal disease"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
6. Entity1: ""Perineural invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
7. Entity1: ""Vascular invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
8. Entity1: ""Lymphatic invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""

Causalities:-
<C> Extranodal extension </C>
<C> Positive margins </C>
<C> Close margins </C>
<C> pT3 or pT4 primary </C>
<C> pN2 or pN3 nodal disease </C>
<C> Perineural invasion </C>
<C> Vascular invasion </C>
<C> Lymphatic invasion </C>

Section Name: Response Assessment
====================
Entities:-
Chemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Primary Site : The original location where a tumor or cancer begins.
Complete Remission : The disappearance of all signs of cancer in response to treatment.
Partial Remission : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
Radiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.

Relationships:-
1. Entity1: ""induction chemotherapy"", Entity2: ""Primary site"", Relationship: ""treatment outcome""
2. Entity1: ""Definitive RT"", Entity2: ""Primary site"", Relationship: ""treatment option""
3. Entity1: ""RT"", Entity2: ""Primary site"", Relationship: ""treatment option""
4. Entity1: ""Surgery"", Entity2: ""unresectable nodal disease"", Relationship: ""treatment option""

Causalities:-
<C> Response after induction chemotherapy </C>: <E> Primary site: CR </E> <E> Primary site: PR </E> <E> Primary site: < PR </E> <A> Definitive RT </A> (category 1) <A> RT </A> (category 1) or <A> systemic therapy/RT </A> (category 2B) <A> Surgery </A> or <A> unresectable nodal disease </A>

Section Name: Follow-up
====================
Entities:-
Follow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.
Follow-Up Procedure : A procedure where a patient is monitored over time to assess the progress of a condition or the effects of treatment.
Follow-Up (Medicine) : The process of monitoring a patient's health over time after treatment or diagnosis.
Disease Recurrence : The return of a sign, symptom, or disease after a remission.
Recurrent Disease : A disease that returns after a period of remission.
Recurrence (Medicine) : The return of a disease or condition after a period of improvement.

Relationships:-
1. Entity1: ""Follow-up"", Entity2: ""Recurrent or persistent disease"", Relationship: ""monitoring""

Causalities:-
### Follow-up

- **Follow-up** (FOLL-A, 1 of 2)
- **Recurrent or persistent disease** (ADV-3)

Section Name: Risk Features
====================
Entities:-
Radiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Adverse pathologic features"", Entity2: ""RT"", Relationship: ""Consideration for treatment""
2. Entity1: ""Adverse pathologic features"", Entity2: ""Systemic therapy"", Relationship: ""Consideration for treatment""

Causalities:-
- **No adverse pathologic features**
- **Other risk features**
- **Adverse pathologic features**:
  - <C> Extranodal extension and/or positive margin </C>
  - <A> RT or consider systemic therapy/RT </A>

Section Name: Post-Therapy Evaluation
====================
Entities:-
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Neck : The neck is the part of the body that separates the head from the torso and provides the mobility and movements of the head.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Neck Evaluation"", Relationship: ""evaluated in""
2. Entity1: ""RT"", Entity2: ""Neck Evaluation"", Relationship: ""evaluated in""

Causalities:-
<CO> Post Systemic Therapy/RT or RT Neck </CO> <A> Evaluation </A>

Section Name: Flowchart Overview
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Supraglottic Larynx : The part of the larynx located above the vocal cords, including the epiglottis and aryepiglottic folds.
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.

Relationships:-
1. Entity1: ""NCCN Guidelines"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""guides management of""
2. Entity1: ""NCCN Guidelines"", Entity2: ""healthcare professionals"", Relationship: ""used by""

Causalities:-
<C> cancer of the supraglottic larynx </C> <E> evaluate patient responses following treatment </E> <CO> based on observed outcomes </CO> <A> evaluation of the primary site and determining subsequent steps </A>.

Section Name: Assessment and Treatment Decisions
====================
Entities:-
Induction Chemotherapy : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Complete Response : The disappearance of all signs of cancer in response to treatment.
Partial Response : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Complete Response"", Entity2: ""Radiation Therapy"", Relationship: ""leads to""
2. Entity1: ""Complete Response"", Entity2: ""Surgery"", Relationship: ""leads to""
3. Entity1: ""Partial Response"", Entity2: ""Systemic Therapy"", Relationship: ""leads to""
4. Entity1: ""Partial Response"", Entity2: ""Radiation Therapy"", Relationship: ""leads to""

Causalities:-
<C> responses to initial treatments such as induction chemotherapy </C> <E> Three main response categories are recognized: Complete Response (CR), Partial Response (PR), and less than Partial Response (< PR) </E>. These categories are pivotal in determining the next steps. <C> CR </C> <E> indicates full resolution of the disease at the primary site </E>, <A> leading to the consideration of definitive radiation therapy or the likelihood of surgery </A>. Conversely, <C> PR </C> <E> suggests that the disease has improved but not completely resolved </E>, <A> which directs the pathway towards either systemic therapy or continued radiation therapy </A>, <A> with further evaluation necessary </A>.

Section Name: Adverse Pathologic Features and Follow-up
====================
Entities:-
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Neoplasm Recurrence, Local : The return of a tumor or cancer, at the original site, after it has been treated.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Recurrent Neoplasm : A neoplasm that has returned after treatment.
Metastatic Neoplasm : A neoplasm that has spread from its original site to one or more other places in the body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Cancer Recurrence : The return of cancer after treatment and after a period of time during which the cancer was undetectable.
Metastasis : Spread of a cancer or other disease from one organ or part to another not directly connected with it.

Relationships:-
1. Entity1: ""Adverse pathologic features"", Entity2: ""Treatment decisions"", Relationship: ""Influence""
2. Entity1: ""Adverse features"", Entity2: ""Surgical intervention"", Relationship: ""Recommendation""
3. Entity1: ""Absence of adverse features"", Entity2: ""Radiation therapy"", Relationship: ""Pathway""
4. Entity1: ""Follow-up process"", Entity2: ""Recurrent or persistent disease"", Relationship: ""Detection""
5. Entity1: ""Recurrent or persistent disease"", Entity2: ""Advanced disease management"", Relationship: ""Necessity""

Causalities:-
<C> The presence of adverse pathologic features — such as extranodal extension or positive margins </C> <E> can directly influence treatment decisions </E>. <CO> If adverse features are found </CO>, <A> surgical intervention is recommended </A>. <CO> In cases where there are no adverse features </CO>, the patient may proceed directly to radiation therapy or continued systemic treatment, emphasizing the tailored approach based on the individual patient's disease characteristics.

Furthermore, the chart includes a section addressing the follow-up process after initial treatment. <CO> If there are signs of recurrent or persistent disease </CO>, <A> additional evaluations and treatment modalities may be necessary </A>. These evaluations <E> lead to specific recommendations for advanced disease management, denoted as ADV-3 on the chart </E>, emphasizing the importance of continuous monitoring and assessment in cancer care.
--------------------------------------------------
Page Number: 130

Section Name: Pathological N (pN)
====================
Entities:-
Lymph Nodes : Small, bean-shaped structures that are part of the body's lymphatic system. They filter lymph fluid and store white blood cells that help fight infection.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Tnm Staging : A system used to describe the size and spread of cancer in a standardized way. T refers to the size of the tumor, N to the involvement of lymph nodes, and M to metastasis.
Lymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.
Tnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient's body.
Lymph Node : An organ of the lymphatic system and the adaptive immune system.

Relationships:-
1. Entity1: ""Lymph Nodes"", Entity2: ""Neoplasm Metastasis"", Relationship: ""involved in""
2. Entity1: ""TNM Staging"", Entity2: ""Lymph Nodes"", Relationship: ""includes""
3. Entity1: ""TNM Staging"", Entity2: ""Neoplasm Metastasis"", Relationship: ""describes""

Causalities:-
<CO> NX: Regional lymph nodes cannot be assessed </CO>
<CO> N0: No regional lymph node metastasis </CO>
<CO> N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(–) </CO>
<CO> N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2a: Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N3: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(−); or metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>
<CO> N3a: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N3b: Metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>
<CO> Note: A designation of “U” or “L” may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L). Similarly, clinical and pathological ENE should be recorded as ENE(−) or ENE(+). </CO>

Section Name: Distant Metastasis (M)
====================
Entities:-
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.

Relationships:-
1. Entity1: ""M0"", Entity2: ""Distant Metastasis"", Relationship: ""is a category of""
2. Entity1: ""M1"", Entity2: ""Distant Metastasis"", Relationship: ""is a category of""

Causalities:-
### Distant Metastasis (M)

- **M0**: No distant metastasis
- **M1**: Distant metastasis

Section Name: Histologic Grade (G)
====================
Entities:-
Neoplasm Grading : A system of classifying cancer cells in terms of how abnormal they look under a microscope and how quickly the tumor is likely to grow and spread.
Histologic Grade : A measure of how much tumor cells differ from healthy cells, used to assess the aggressiveness of cancer.

Relationships:-
1. Entity1: ""GX"", Entity2: ""Grade cannot be assessed"", Relationship: ""is described as""
2. Entity1: ""G1"", Entity2: ""Well differentiated"", Relationship: ""is described as""
3. Entity1: ""G2"", Entity2: ""Moderately differentiated"", Relationship: ""is described as""
4. Entity1: ""G3"", Entity2: ""Poorly differentiated"", Relationship: ""is described as""

Causalities:-
<CO>GX</CO>: <E>Grade cannot be assessed</E>
<CO>G1</CO>: <E>Well differentiated</E>
<CO>G2</CO>: <E>Moderately differentiated</E>
<CO>G3</CO>: <E>Poorly differentiated</E>

Section Name: Prognostic Stage Groups
====================
Entities:-
Neoplasm Staging : Methods and systems of classifying neoplasms according to extent of disease.
Tumor Staging : A system for describing the size and spread of cancer within the body.
Tnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient's body.

Relationships:-
1. Entity1: ""Stage 0"", Entity2: ""Tis N0 M0"", Relationship: ""defined by""
2. Entity1: ""Stage I"", Entity2: ""T1 N0 M0"", Relationship: ""defined by""
3. Entity1: ""Stage II"", Entity2: ""T2 N0 M0"", Relationship: ""defined by""
4. Entity1: ""Stage III"", Entity2: ""T3 N0 M0, T1 N1 M0, T2 N1 M0, T3 N1 M0"", Relationship: ""defined by""
5. Entity1: ""Stage IVA"", Entity2: ""T1 N2 M0, T2 N2 M0, T3 N2 M0, T4a N0,N1,N2 M0"", Relationship: ""defined by""
6. Entity1: ""Stage IVB"", Entity2: ""Any T N3 M0, T4b Any N M0"", Relationship: ""defined by""
7. Entity1: ""Stage IVC"", Entity2: ""Any T Any N M1"", Relationship: ""defined by""
--------------------------------------------------
Page Number: 41

Section Name: Workup
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.
History And Physical Examination : A comprehensive assessment of a patient's medical history and physical condition.
Tobacco Smoking : The act of smoking tobacco products, which is a risk factor for many diseases.
Alcohol Drinking : The consumption of beverages containing ethyl alcohol.
Smoking Cessation : The process of discontinuing tobacco smoking.
Biopsy : A medical test involving the extraction of sample cells or tissues for examination.
Laryngoscopy : A procedure to examine the larynx, often using a scope.
Computed Tomography (Ct) : A diagnostic imaging procedure that uses computer-processed combinations of many X-ray measurements taken from different angles to produce cross-sectional images of specific areas of a scanned object.
Magnetic Resonance Imaging (Mri) : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.
Positron-Emission Tomography : A type of nuclear medicine imaging that measures metabolic activity of the cells of body tissues.
Pulmonary Function Test : Tests that measure how well the lungs are working.
Dental Examination : An evaluation of the teeth and gums to assess oral health.
Nutritional Support : Therapies to provide nutrition to patients who cannot obtain nutrition by mouth.
Speech Therapy : Therapy to improve speech and communication skills.
Swallowing Therapy : Therapy to help individuals with swallowing difficulties.
Multidisciplinary Care Team : A group of healthcare professionals from different specialties working together to manage patient care.

Relationships:-
1. Entity1: ""glottic larynx cancer"", Entity2: ""history and physical examination"", Relationship: ""initial diagnostic step""
2. Entity1: ""glottic larynx cancer"", Entity2: ""biopsy"", Relationship: ""required diagnostic procedure""
3. Entity1: ""glottic larynx cancer"", Entity2: ""direct laryngoscopy"", Relationship: ""recommended procedure""
4. Entity1: ""glottic larynx cancer"", Entity2: ""CT scans"", Relationship: ""imaging study""
5. Entity1: ""glottic larynx cancer"", Entity2: ""MRI"", Relationship: ""imaging study""
6. Entity1: ""glottic larynx cancer"", Entity2: ""multidisciplinary consultation"", Relationship: ""advised as clinically indicated""

Causalities:-
The workup section outlines the initial steps for diagnosing <C>glottic larynx cancer</C>. It includes <A>a comprehensive history and physical examination (H&P)</A>, which should document tobacco and alcohol use, and provide counseling for smoking cessation. <A>A biopsy of the primary site is required</A>, and <A>direct laryngoscopy under anesthesia is generally recommended</A>. <A>Imaging studies such as CT scans with contrast and possibly MRI are used to evaluate the larynx and neck</A>. Additional evaluations may include <A>chest CT, FDG-PET/CT, pulmonary function tests, dental evaluation, and nutrition, speech, and swallowing therapy</A>. <A>Multidisciplinary consultation is advised</A> <CO>as clinically indicated</CO>.

Section Name: Clinical Staging
====================
Entities:-
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.
Carcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.
Biopsy : A medical test involving the extraction of sample cells or tissues for examination.
Laryngectomy : A surgical procedure to remove the larynx.

Relationships:-
1. Entity1: ""Clinical staging"", Entity2: ""Cancer"", Relationship: ""involves""
2. Entity1: ""Carcinoma in situ"", Entity2: ""Stages T1-T4"", Relationship: ""is a stage of""
3. Entity1: ""Biopsy"", Entity2: ""Cancer"", Relationship: ""used in staging""
4. Entity1: ""Larynx-preserving surgeries"", Entity2: ""Stages T1-T2"", Relationship: ""considered for""
5. Entity1: ""Total laryngectomy"", Entity2: ""Stages T3-T4"", Relationship: ""required for""

Causalities:-
<C> Clinical staging involves categorizing the cancer based on its aggressiveness </C>. It starts with carcinoma in situ, which is non-invasive, and progresses through stages T1-T4. <CO> Staging is based on H&P, biopsy, and imaging studies </CO>. <CO> For T1-T2 </CO>, <A> larynx-preserving surgeries are considered </A>, while <CO> more advanced stages like T3 or T4 </CO> <A> may require total laryngectomy </A>. <A> Additional evaluations such as videostrobe, audiogram, and fertility counseling may be considered </A>.

Section Name: Treatment
====================
Entities:-
Carcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.
Laryngectomy : A surgical procedure to remove the larynx.
Metastasis : The transfer of a disease from one organ or part to another not directly connected with it.
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.

Relationships:-
1. Entity1: ""Carcinoma in situ"", Entity2: ""Larynx-preserving surgery"", Relationship: ""treated with""
2. Entity1: ""T1-T2 stages"", Entity2: ""Conservation surgery"", Relationship: ""treated with""
3. Entity1: ""T3 stages"", Entity2: ""Total laryngectomy"", Relationship: ""may require""
4. Entity1: ""T4a disease"", Entity2: ""Complex interventions"", Relationship: ""require""
5. Entity1: ""Guidelines"", Entity2: ""Multidisciplinary consultations"", Relationship: ""emphasize importance of""
6. Entity1: ""Guidelines"", Entity2: ""Clinical trials"", Relationship: ""consider as best option""

Causalities:-
<CO>Treatment recommendations vary by stage</CO>. <CO>Carcinoma in situ</CO> <A>may be treated with larynx-preserving surgery</A>. <CO>T1-T2 stages</CO> <A>may also be amenable to conservation surgery</A>. <CO>T3 stages</CO> <A>may require total laryngectomy</A>, <CO>especially if nodal involvement is present</CO>. <CO>T4a disease and unresectable or metastatic cases</CO> <A>require more complex interventions</A>. <A>The guidelines emphasize the importance of multidisciplinary consultations</A> and <A>consider clinical trials as the best management option</A>.

Section Name: Additional Notes
====================
Entities:-
Biopsy, Needle : A procedure to remove a small sample of tissue for examination under a microscope.
Image-Guided Biopsy : A biopsy procedure that uses imaging techniques to guide the needle to the precise location of the tissue to be sampled.
Biopsy : A medical test involving the extraction of sample cells or tissues for examination.
Diagnostic Techniques And Procedures : Methods and procedures for the diagnosis of disease or dysfunction.
Imaging : The process of producing images of the body for clinical purposes.
Dental Care : The total of dental diagnostic, preventive, and corrective procedures.
Nutritional Physiological Phenomena : The functions and properties of nutrients in living organisms.
Fertility : The capacity to conceive or induce conception.
Reproductive Health : A state of physical, mental, and social well-being in all matters relating to the reproductive system.
Lymphatic Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Glottis : The part of the larynx consisting of the vocal cords and the opening between them.

Relationships:-
1. Entity1: ""image-guided needle biopsy"", Entity2: ""diagnostic yield"", Relationship: ""used for""
2. Entity1: ""nodal disease"", Entity2: ""glottic tumors"", Relationship: ""is rare in""

Causalities:-
<A> use of image-guided needle biopsy </A> for <E> better diagnostic yield </E>, principles of imaging, dental evaluation, and nutrition management. The guidelines also address fertility and reproductive considerations, and note that <CO> nodal disease in glottic tumors is rare </CO>.


Among these two options which one is the most likely true:

(A) `N_State_1__patient` increases risk `Presence_of_Metastasis_in_Lymph_Nodes_5`
(B) `Presence_of_Metastasis_in_Lymph_Nodes_5` `increases risk `N_State_1__patient`

The answer is: ...

1. State the evidences in detail of the validity of option (A) or (B) by cross referencing
NCCN Clinical Practitioner’s Guidelines for Head and Neck Cancer.
2. If the evidences are obtained from `INFORMATION FROM KNOWLEDGE BASE`,
mention their corresponding Page Numbers, Section Name, entities, relationships and causalities.

DESIRED OUTPUT FORMAT:
<thinking>
...
</thinking>
<answer>
{
   ""thinking"": [""..."", ...],
   ""evidences"": [""..."", ...],
   ""answer"": ...
}
</answer>

Before providing the answer in <answer> tags, think step by step in detail in <thinking> tags and analyze every part.
Output inside <answer> tag in JSON format. Only output valid JSON.
DO NOT HALLUCINATE. DO NOT MAKE UP FACTUAL INFORMATION.
","1. The edge in question is between two nodes: `N_State_1__patient` and `Presence_of_Metastasis_in_Lymph_Nodes_5`.
2. `N_State_1__patient` represents the state of lymph nodes in a cancer patient, which is a decision node used to predict the extent of lymph node metastasis.
3. `Presence_of_Metastasis_in_Lymph_Nodes_5` represents whether metastasis is present in the lymph nodes, a critical factor in cancer staging.
4. The causal direction for EDGE1 is positive, indicating that an increase in the state of lymph nodes (e.g., from n0 to n3) increases the likelihood of metastasis being present.
5. The causal direction for EDGE2 is also positive, indicating that the presence of metastasis leads to a higher N-stage.
6. Both edges are described as having a proximal causal distance, meaning the factors directly influence each other.
7. The NCCN guidelines emphasize the importance of lymph node involvement in cancer staging and treatment decisions.
8. The guidelines suggest that the presence of metastasis in lymph nodes is a critical factor in determining the N-stage of cancer, which aligns with EDGE2.
9. The state of lymph nodes is necessary to assess metastasis presence, but not sufficient alone, as other factors may play a role.
10. The presence of metastasis is necessary for a higher N-stage but not sufficient alone, as other factors may also play a role.
11. The knowledge base information supports the idea that lymph node involvement is a key factor in cancer staging and treatment decisions.
","1. Page 102, Section: Head and Neck Cancers - Principles of Surgery, emphasizes the role of lymph node involvement in cancer staging.
2. Page 130, Section: Pathological N (pN), describes the TNM staging system, which includes lymph node involvement as a critical factor.
3. Page 41, Section: Workup, outlines the importance of assessing lymph node involvement in cancer diagnosis and staging.
",A,"{'A': 70.58, 'B': 29.42}",yes,A,"1. The AI assistant's reasoning begins by identifying the nodes involved in the causal relationship: `N_State_1__patient` and `Presence_of_Metastasis_in_Lymph_Nodes_5`.
2. The assistant correctly identifies that `N_State_1__patient` represents the state of lymph nodes, which is crucial for predicting metastasis extent, and `Presence_of_Metastasis_in_Lymph_Nodes_5` indicates whether metastasis is present.
3. The assistant notes that both edges (EDGE1 and EDGE2) have a positive causal direction, meaning an increase in one node's state leads to an increase in the other node's state.
4. The assistant highlights that both edges are described as having a proximal causal distance, indicating a direct influence between the nodes.
5. The assistant references the NCCN guidelines, emphasizing the importance of lymph node involvement in cancer staging and treatment decisions.
6. The assistant concludes that the presence of metastasis in lymph nodes is a critical factor in determining the N-stage of cancer, aligning with EDGE2.
7. The assistant's reasoning is consistent with the information provided in the knowledge base, which supports the idea that lymph node involvement is key in cancer staging and treatment decisions.
8. The assistant's final answer is (A), which states that `N_State_1__patient` increases the risk of `Presence_of_Metastasis_in_Lymph_Nodes_5`.
9. The reasoning provided by the assistant is consistent with the final answer, as it aligns with the causal direction and the importance of lymph node involvement in cancer staging.
"
12,gpt-4o,"N_State_1__patient,Location_of_Involved_Lymph_Nodes_4","""{'NODE1': {'id': 'N_State_1__patient', 'label': 'State of Nearby Lymph Nodes with Cancer in Patient', 'description': 'This node represents the state of involvement of nearby lymph nodes in a patient with cancer. It is a decision node used to predict the extent of lymph node metastasis, which is crucial for cancer staging and treatment planning. The states range from no involvement (n0) to extensive involvement (n3), with intermediate states indicating varying degrees of lymph node cancer presence.', 'type': 'Decision Node', 'observability': 'Needs to be Predicted', 'states': [{'state_name': 'nx', 'state_description': 'The regional lymph nodes cannot be assessed.'}, {'state_name': 'n3', 'state_description': 'Metastasis in lymph node(s) along the course of a major blood vessel or in a lymph node that is more than 6 cm in greatest dimension.'}, {'state_name': 'n2c', 'state_description': 'Metastasis in bilateral or contralateral lymph nodes, each 6 cm or less in greatest dimension.'}, {'state_name': 'n2b', 'state_description': 'Metastasis in multiple ipsilateral lymph nodes, each 6 cm or less in greatest dimension.'}, {'state_name': 'n2a', 'state_description': 'Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension.'}, {'state_name': 'n2', 'state_description': 'Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension, or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension.'}, {'state_name': 'n1', 'state_description': 'Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension.'}, {'state_name': 'n0', 'state_description': 'No regional lymph node metastasis.'}]}, 'NODE2': {'id': 'Location_of_Involved_Lymph_Nodes_4', 'label': 'Position of Affected Lymph Nodes in Patient', 'description': \""This node represents the location of lymph nodes that are involved or affected in a patient's condition. Understanding whether the lymph nodes are ipsilateral, bilateral, or contralateral is crucial for determining the extent of disease spread and planning appropriate treatment strategies.\"", 'type': 'Patient Situation', 'observability': 'Unobserved', 'states': [{'state_name': 'ipsilateral', 'state_description': 'The involved lymph nodes are on the same side of the body as the primary tumor or reference point. This can indicate localized spread of disease.'}, {'state_name': 'bilateral', 'state_description': 'The involved lymph nodes are on both sides of the body. This may suggest a more extensive spread of disease and can impact treatment decisions.'}, {'state_name': 'contralateral', 'state_description': 'The involved lymph nodes are on the opposite side of the body from the primary tumor or reference point. This can indicate metastatic spread and may affect staging and treatment planning.'}]}, 'EDGE1': {'edges_ids': ['N_State_1__patient', 'Location_of_Involved_Lymph_Nodes_4'], 'edge': '(N_State_1__patient) causes (Location_of_Involved_Lymph_Nodes_4)', 'explanation': ['The edge represents the causal relationship where the state of nearby lymph nodes with cancer in a patient influences the location of involved lymph nodes.', 'The state of lymph node involvement (N_State_1__patient) is a predictor of the extent and location of lymph node spread (Location_of_Involved_Lymph_Nodes_4).', 'As the involvement state increases (e.g., from n0 to n3), the likelihood of more extensive spread (e.g., bilateral or contralateral) increases, indicating a positive causal direction.', 'The causal factor is neither necessary nor sufficient because other factors can influence the location, and the state does not guarantee a specific location.', 'The causal distance is proximal because the state of involvement directly affects the location of involved lymph nodes.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Proximal'}, 'EDGE2': {'edges_ids': ['Location_of_Involved_Lymph_Nodes_4', 'N_State_1__patient'], 'edge': '(Location_of_Involved_Lymph_Nodes_4) causes (N_State_1__patient)', 'explanation': ['The edge represents the causal relationship where the location of involved lymph nodes (ipsilateral, bilateral, contralateral) influences the predicted state of lymph node involvement (n0 to n3).', 'The location of lymph nodes is a critical factor in determining the extent of lymph node metastasis, which is crucial for cancer staging.', 'The causal direction is positive because more extensive lymph node involvement (e.g., bilateral or contralateral) is likely to lead to a higher N state.', 'The causal factor is neither necessary nor sufficient because other factors also contribute to the N state, such as the size of the lymph nodes.', 'The causal distance is proximal because the location of lymph nodes is directly related to the N state classification.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Proximal'}, 'ENTITIES_MATCHING_PAGES_INFO': {'102': {'matching_entities': [{'LYMPHATIC SYSTEM': 0.95855314}, {'LYMPHATIC STRUCTURE': 0.9469132}, {'METASTASIS': 0.9401313}, {'CANCER STAGING': 0.93824553}, {'TUMOR': 0.9323624}, {'STAGING': 0.9208425}], 'count': 6}, '55': {'matching_entities': [{'MALIGNANT NEOPLASTIC DISEASE': 0.97725874}, {'METASTASIS': 0.9401313}, {'CANCER': 0.9363244}, {'METASTATIC NEOPLASM': 0.9314138}, {'NEOPLASM METASTASIS': 0.9250777}, {'LARYNGEAL NEOPLASMS': 0.9236878}], 'count': 6}, '51': {'matching_entities': [{'MALIGNANT NEOPLASM': 0.9774111}, {'CANCER STAGING': 0.93824553}, {'CANCER': 0.9363244}, {'LARYNGEAL NEOPLASMS': 0.9236878}, {'NEOPLASM INVASIVENESS': 0.92347366}], 'count': 5}, '130': {'matching_entities': [{'LYMPH NODE STRUCTURE': 0.99134904}, {'LYMPH NODE': 0.98570025}, {'LYMPH NODES': 0.97445965}, {'METASTASIS': 0.9401313}, {'NEOPLASM METASTASIS': 0.9250777}], 'count': 5}, '47': {'matching_entities': [{'MALIGNANT NEOPLASM': 0.9774111}, {'LARYNGEAL CANCER': 0.95521915}, {'CANCER': 0.9363244}, {'LARYNGEAL NEOPLASMS': 0.9236878}], 'count': 4}}, 'GUIDELINE_PAGES_INFO': '--------------------------------------------------\\nPage Number: 102\\n\\nSection Name: Head and Neck Cancers - Principles of Surgery\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Manual or operative procedures used in the treatment of disease, injuries, or deformities.\\nLymphatic System : Part of the circulatory system and a vital part of the immune system, comprising a network of lymphatic vessels that carry a clear fluid called lymph.\\nNeoplasms : New abnormal growth of tissue in animals or plants; a tumor.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nNeoplasm Staging : Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.\\nMetastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.\\nSurgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nLymphatic Structure : Anatomical structure that is part of the lymphatic system.\\nTumor : An abnormal mass of tissue that results when cells divide more than they should or do not die when they should.\\nStaging : The process of determining the size and spread of cancer within the body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nCancer Staging : The process of determining the extent to which a cancer has developed by growing and spreading.\\n\\nRelationships:-\\n1. Entity1: \""surgical management\"", Entity2: \""regional lymphatics\"", Relationship: \""dictated by tumor staging\""\\n2. Entity1: \""neck dissections\"", Entity2: \""primary tumor\"", Relationship: \""part of treatment\""\\n3. Entity1: \""surgery\"", Entity2: \""ipsilateral side of the neck\"", Relationship: \""risk for metastases\""\\n\\nCausalities:-\\n<C> The extent of the tumor at initial tumor staging </C> <E> dictates the surgical management of regional lymphatics </E>. These guidelines apply to the performance of neck dissections as part of treatment of the primary tumor. <CO> Patients undergoing surgery for resection of the primary tumor </CO> <A> will undergo dissection of the ipsilateral side of the neck that is at greatest risk for metastases </A>.\\n\\nSection Name: Neck Management\\n====================\\nEntities:-\\nTongue : A muscular organ in the mouth that is involved in tasting, swallowing, and speech.\\nPalate : The roof of the mouth, separating the oral and nasal cavities.\\nLarynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.\\nHypopharynx : The bottom part of the pharynx, which is the cavity behind the nose and mouth.\\nNasopharynx : The upper part of the pharynx, connecting with the nasal cavity above the soft palate.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nMetastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.\\nSquamous Cell Carcinoma : A type of cancer that begins in the squamous cells, which are thin, flat cells that look like fish scales.\\nBiopsy : The removal of cells or tissues for examination under a microscope.\\n\\nRelationships:-\\n1. Entity1: \""Tumor sites\"", Entity2: \""Bilateral lymphatic drainage\"", Relationship: \""associated with\""\\n2. Entity1: \""Elective neck dissection\"", Entity2: \""Risk of occult metastasis\"", Relationship: \""based on\""\\n3. Entity1: \""SLN biopsy\"", Entity2: \""Elective neck dissection\"", Relationship: \""guides decision-making for\""\\n\\nCausalities:-\\n- **<C> Tumor sites that frequently have bilateral lymphatic drainage </C>** (e.g., base of tongue, palate, supraglottic larynx, hypopharynx, nasopharynx, deep pre-epiglottic space involvement) <E> often should have both sides of the neck dissected </E> with the extent of dissection determined as suggested below. For those patients with tumors at or approaching the midline, <CO> both sides of the neck are at risk for metastases </CO>, and <A> bilateral neck dissections should be performed </A>.\\n\\n- <CO> Patients with advanced lesions involving the anterior tongue, floor of the mouth, or alveolus that approximate or cross the midline </CO> <A> should undergo contralateral selective/modified neck dissection </A> as necessary to achieve adequate tumor resection.\\n\\n- **<C> Elective neck dissection </C>** <A> should be based on risk of occult metastasis in the appropriate nodal basin </A>. For oral cavity squamous cell carcinoma, <C> SLN biopsy or the primary tumor depth of invasion </C> is currently <E> the best predictor of occult metastatic disease </E> and <A> should be used to guide decision-making </A>. <CO> For tumors with a depth greater than 3 mm </CO>, <A> elective dissection should be strongly considered if RT is not already planned </A>. Recent randomized trial evidence supports the effectiveness of elective neck dissection in patients with oral cavity cancers greater than 3 mm in depth of invasion.\\n\\n  - <CO> For a depth less than 2 mm </CO>, <A> elective dissection is only indicated in highly selective situations </A>. <CO> For a depth of 2\u20134 mm </CO>, <A> clinical judgment (as to reliability of follow-up, clinical suspicion, and other factors) must be utilized to determine appropriateness of elective dissection </A>. Elective dissections are generally selective, preserving all major structures, unless operative findings dictate otherwise.\\n\\nSection Name: Types of Neck Dissection\\n====================\\nEntities:-\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nLarynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.\\n\\nRelationships:-\\n1. Entity1: \""N0\"", Entity2: \""Selective neck dissection\"", Relationship: \""associated with\""\\n2. Entity1: \""N3\"", Entity2: \""Comprehensive neck dissection\"", Relationship: \""associated with\""\\n3. Entity1: \""Level VI neck dissection\"", Entity2: \""Larynx\"", Relationship: \""performed for\""\\n4. Entity1: \""Level VI neck dissection\"", Entity2: \""Hypopharynx\"", Relationship: \""performed for\""\\n\\nCausalities:-\\n- **The type of neck dissection (comprehensive or selective)** is defined according to <CO> preoperative clinical staging </CO>, is determined at the discretion of the surgeon, and is based on the initial preoperative staging as follows:\\n  - **N0:** <A> Selective neck dissection </A>\\n    - Oral cavity at least levels I\u2013III\\n    - Oropharynx at least levels II\u2013IV\\n    - Hypopharynx at least levels II\u2013IV and level VI when appropriate\\n    - Larynx at least levels II\u2013IV and level VI when appropriate\\n  - **N1\u2013N2a\u2013c:** <A> Selective or comprehensive neck dissection </A> (Discussion)\\n  - **N3:** <A> Comprehensive neck dissection </A>\\n\\n- <C> Level VI neck dissections are performed for certain primary sites (such as the larynx and hypopharynx) </C> <E> as required to resect the primary tumor and any clinically evident neck nodes </E>. <CO> Elective dissection depends on primary tumor extent and site </CO>. <CO> For advanced glottic and hypopharyngeal cancers treated with primary surgery </CO>, <A> a level VI dissection (including pretracheal lymph nodes, the Delphian lymph node, and unilateral or bilateral paratracheal lymph nodes) and hemithyroidectomy to total thyroidectomy are appropriate </A>.\\n\\n- <CO> For primary subglottic tumors or glottic cancers with significant subglottic extension </CO>, <A> a level VI dissection with unilateral or total thyroidectomy is considered appropriate </A> based on the extent of the primary tumor. <CO> For example, a T4a glottic tumor with extension through the cricothyroid membrane and subglottic extension </CO> <A> should include thyroidectomy and pretracheal and bilateral paratracheal lymph node dissection </A>. <A> Parathyroid glands should be preserved in situ or auto transplanted as indicated </A>.\\n--------------------------------------------------\\nPage Number: 55\\n\\nSection Name: General Information\\n====================\\nEntities:-\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nNccn Guidelines : Clinical practice guidelines in oncology developed by the National Comprehensive Cancer Network.\\n\\nRelationships:-\\n1. Entity1: \""NCCN Guidelines\"", Entity2: \""National Comprehensive Cancer Network\"", Relationship: \""produced by\""\\n\\nSection Name: Important Notes\\n====================\\nEntities:-\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medical, surgical, or behavioral interventions.\\nClinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nNeoplasms : New abnormal growth of tissue that can be benign or malignant.\\nMalignant Neoplastic Disease : A disease resulting from the growth of malignant neoplasms.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""Clinical Trials\"", Entity2: \""Cancer\"", Relationship: \""recommended for\""\\n2. Entity1: \""NCCN\"", Entity2: \""Clinical Trials\"", Relationship: \""encourages participation in\""\\n\\nCausalities:-\\n<C> NCCN believes that the best management of any patient with cancer is in a clinical trial </C>. <A> Participation in clinical trials is especially encouraged </A>.\\n\\nSection Name: Principles\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nChemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.\\n\\nRelationships:-\\n1. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Radiation Therapy\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n2. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n3. Entity1: \""Principles of Radiation Therapy\"", Entity2: \""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n\\nCausalities:-\\n### Principles\\n\\n- **Principles of Surgery (SURG-A)**\\n- **Principles of Radiation Therapy (SUPRA-A)**\\n- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**\\n\\nSection Name: Adverse Pathologic Features\\n====================\\nEntities:-\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.\\nPerineural Invasion : The presence of cancer cells surrounding or tracking along a nerve within the perineural space.\\nVascular Invasion : The invasion of cancer cells into blood vessels.\\nLymphatic Invasion : The invasion of cancer cells into lymphatic vessels.\\n\\nRelationships:-\\n1. Entity1: \""Extranodal extension\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n2. Entity1: \""Positive margins\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n3. Entity1: \""Close margins\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n4. Entity1: \""pT3 or pT4 primary\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n5. Entity1: \""pN2 or pN3 nodal disease\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n6. Entity1: \""Perineural invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n7. Entity1: \""Vascular invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n8. Entity1: \""Lymphatic invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n\\nCausalities:-\\n<C> Extranodal extension </C>\\n<C> Positive margins </C>\\n<C> Close margins </C>\\n<C> pT3 or pT4 primary </C>\\n<C> pN2 or pN3 nodal disease </C>\\n<C> Perineural invasion </C>\\n<C> Vascular invasion </C>\\n<C> Lymphatic invasion </C>\\n\\nSection Name: Response Assessment\\n====================\\nEntities:-\\nChemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nPrimary Site : The original location where a tumor or cancer begins.\\nComplete Remission : The disappearance of all signs of cancer in response to treatment.\\nPartial Remission : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.\\nRadiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""induction chemotherapy\"", Entity2: \""Primary site\"", Relationship: \""treatment outcome\""\\n2. Entity1: \""Definitive RT\"", Entity2: \""Primary site\"", Relationship: \""treatment option\""\\n3. Entity1: \""RT\"", Entity2: \""Primary site\"", Relationship: \""treatment option\""\\n4. Entity1: \""Surgery\"", Entity2: \""unresectable nodal disease\"", Relationship: \""treatment option\""\\n\\nCausalities:-\\n<C> Response after induction chemotherapy </C>: <E> Primary site: CR </E> <E> Primary site: PR </E> <E> Primary site: < PR </E> <A> Definitive RT </A> (category 1) <A> RT </A> (category 1) or <A> systemic therapy/RT </A> (category 2B) <A> Surgery </A> or <A> unresectable nodal disease </A>\\n\\nSection Name: Follow-up\\n====================\\nEntities:-\\nFollow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.\\nFollow-Up Procedure : A procedure where a patient is monitored over time to assess the progress of a condition or the effects of treatment.\\nFollow-Up (Medicine) : The process of monitoring a patient\\'s health over time after treatment or diagnosis.\\nDisease Recurrence : The return of a sign, symptom, or disease after a remission.\\nRecurrent Disease : A disease that returns after a period of remission.\\nRecurrence (Medicine) : The return of a disease or condition after a period of improvement.\\n\\nRelationships:-\\n1. Entity1: \""Follow-up\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""monitoring\""\\n\\nCausalities:-\\n### Follow-up\\n\\n- **Follow-up** (FOLL-A, 1 of 2)\\n- **Recurrent or persistent disease** (ADV-3)\\n\\nSection Name: Risk Features\\n====================\\nEntities:-\\nRadiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Adverse pathologic features\"", Entity2: \""RT\"", Relationship: \""Consideration for treatment\""\\n2. Entity1: \""Adverse pathologic features\"", Entity2: \""Systemic therapy\"", Relationship: \""Consideration for treatment\""\\n\\nCausalities:-\\n- **No adverse pathologic features**\\n- **Other risk features**\\n- **Adverse pathologic features**:\\n  - <C> Extranodal extension and/or positive margin </C>\\n  - <A> RT or consider systemic therapy/RT </A>\\n\\nSection Name: Post-Therapy Evaluation\\n====================\\nEntities:-\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nNeck : The neck is the part of the body that separates the head from the torso and provides the mobility and movements of the head.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Neck Evaluation\"", Relationship: \""evaluated in\""\\n2. Entity1: \""RT\"", Entity2: \""Neck Evaluation\"", Relationship: \""evaluated in\""\\n\\nCausalities:-\\n<CO> Post Systemic Therapy/RT or RT Neck </CO> <A> Evaluation </A>\\n\\nSection Name: Flowchart Overview\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nSupraglottic Larynx : The part of the larynx located above the vocal cords, including the epiglottis and aryepiglottic folds.\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\n\\nRelationships:-\\n1. Entity1: \""NCCN Guidelines\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""guides management of\""\\n2. Entity1: \""NCCN Guidelines\"", Entity2: \""healthcare professionals\"", Relationship: \""used by\""\\n\\nCausalities:-\\n<C> cancer of the supraglottic larynx </C> <E> evaluate patient responses following treatment </E> <CO> based on observed outcomes </CO> <A> evaluation of the primary site and determining subsequent steps </A>.\\n\\nSection Name: Assessment and Treatment Decisions\\n====================\\nEntities:-\\nInduction Chemotherapy : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nComplete Response : The disappearance of all signs of cancer in response to treatment.\\nPartial Response : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Complete Response\"", Entity2: \""Radiation Therapy\"", Relationship: \""leads to\""\\n2. Entity1: \""Complete Response\"", Entity2: \""Surgery\"", Relationship: \""leads to\""\\n3. Entity1: \""Partial Response\"", Entity2: \""Systemic Therapy\"", Relationship: \""leads to\""\\n4. Entity1: \""Partial Response\"", Entity2: \""Radiation Therapy\"", Relationship: \""leads to\""\\n\\nCausalities:-\\n<C> responses to initial treatments such as induction chemotherapy </C> <E> Three main response categories are recognized: Complete Response (CR), Partial Response (PR), and less than Partial Response (< PR) </E>. These categories are pivotal in determining the next steps. <C> CR </C> <E> indicates full resolution of the disease at the primary site </E>, <A> leading to the consideration of definitive radiation therapy or the likelihood of surgery </A>. Conversely, <C> PR </C> <E> suggests that the disease has improved but not completely resolved </E>, <A> which directs the pathway towards either systemic therapy or continued radiation therapy </A>, <A> with further evaluation necessary </A>.\\n\\nSection Name: Adverse Pathologic Features and Follow-up\\n====================\\nEntities:-\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nNeoplasm Recurrence, Local : The return of a tumor or cancer, at the original site, after it has been treated.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nRecurrent Neoplasm : A neoplasm that has returned after treatment.\\nMetastatic Neoplasm : A neoplasm that has spread from its original site to one or more other places in the body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nCancer Recurrence : The return of cancer after treatment and after a period of time during which the cancer was undetectable.\\nMetastasis : Spread of a cancer or other disease from one organ or part to another not directly connected with it.\\n\\nRelationships:-\\n1. Entity1: \""Adverse pathologic features\"", Entity2: \""Treatment decisions\"", Relationship: \""Influence\""\\n2. Entity1: \""Adverse features\"", Entity2: \""Surgical intervention\"", Relationship: \""Recommendation\""\\n3. Entity1: \""Absence of adverse features\"", Entity2: \""Radiation therapy\"", Relationship: \""Pathway\""\\n4. Entity1: \""Follow-up process\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""Detection\""\\n5. Entity1: \""Recurrent or persistent disease\"", Entity2: \""Advanced disease management\"", Relationship: \""Necessity\""\\n\\nCausalities:-\\n<C> The presence of adverse pathologic features \u2014 such as extranodal extension or positive margins </C> <E> can directly influence treatment decisions </E>. <CO> If adverse features are found </CO>, <A> surgical intervention is recommended </A>. <CO> In cases where there are no adverse features </CO>, the patient may proceed directly to radiation therapy or continued systemic treatment, emphasizing the tailored approach based on the individual patient\\'s disease characteristics.\\n\\nFurthermore, the chart includes a section addressing the follow-up process after initial treatment. <CO> If there are signs of recurrent or persistent disease </CO>, <A> additional evaluations and treatment modalities may be necessary </A>. These evaluations <E> lead to specific recommendations for advanced disease management, denoted as ADV-3 on the chart </E>, emphasizing the importance of continuous monitoring and assessment in cancer care.\\n--------------------------------------------------\\nPage Number: 51\\n\\nSection Name: Introduction\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nMalignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.\\nSupraglottic Laryngeal Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is above the vocal cords.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network (NCCN)\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""provides guidelines for\""\\n2. Entity1: \""healthcare professionals\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""manage\""\\n\\nCausalities:-\\nThe provided image is a detailed flowchart from the National Comprehensive Cancer Network (NCCN) guidelines regarding the <C> clinical staging and treatment protocols for cancer of the supraglottic larynx </C>. This flowchart is structured to <A> guide healthcare professionals through the stages of treatment </A> based on <CO> clinical findings </CO>, emphasizing the <E> complexity and systematic approach required in managing this type of cancer </E>.\\n\\nSection Name: Clinical Staging\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nTotal Laryngectomy : A surgical procedure to remove the entire larynx, often used in the treatment of advanced laryngeal cancer.\\nNeoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.\\nCancer Staging : The process of determining the extent of cancer in the body, often using the TNM system.\\nTnm Staging System : A cancer staging system that describes the extent of cancer using Tumor size (T), Node involvement (N), and Metastasis (M).\\n\\nRelationships:-\\n1. Entity1: \""Clinical staging criteria\"", Entity2: \""Total laryngectomy\"", Relationship: \""determines necessity of\""\\n2. Entity1: \""T3, N0\"", Entity2: \""Clinical staging criteria\"", Relationship: \""is a categorization of\""\\n\\nCausalities:-\\nThe flowchart begins with the <C> clinical staging criteria </C>, specifically focusing on <CO> cases that require total laryngectomy, denoted as requiring (amenable to) total laryngectomy (T3, N0) </CO>. This <A> categorization </A> is crucial as it <E> forms the basis for determining the appropriate treatment strategy </E>.\\n\\nSection Name: Treatment of Primary and Neck\\n====================\\nEntities:-\\nNeoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.\\nLymphatic Metastasis : Transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Radiation Therapy\"", Relationship: \""combined with\""\\n2. Entity1: \""Laryngectomy\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n3. Entity1: \""Thyroidectomy\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n4. Entity1: \""Neck Dissection\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n\\nCausalities:-\\n<CO> Once clinical staging is established </CO>, the chart outlines various treatment options. <A> The initial step may involve either concurrent systemic therapy combined with radiation therapy (RT) or opting for RT alone </A>, <CO> especially if the patient is not a medical candidate for both therapies </CO>. <A> Laryngectomy, thyroidectomy, and neck dissection are considered </A> <CO> based on the extent of lymph node involvement </CO>.\\n\\nSection Name: Surgical Options\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nLymph Node Excision : Surgical removal of one or more lymph nodes.\\nLymphadenectomy : Surgical removal of one or more groups of lymph nodes.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""Laryngectomy\"", Entity2: \""Thyroidectomy\"", Relationship: \""combined with\""\\n2. Entity1: \""Lymph Node Dissection\"", Entity2: \""Surgical Intervention\"", Relationship: \""extent of\""\\n3. Entity1: \""Surgical Intervention\"", Entity2: \""Advanced Cases\"", Relationship: \""management option for\""\\n\\nCausalities:-\\n<CO> If concurrent therapies are not suitable </CO>, <A> the chart presents laryngectomy combined with thyroidectomy </A>, <CO> depending on the extent of lymph node dissection required </CO>. <E> This highlights surgical intervention as a viable option in the management of advanced cases </E>.\\n\\nSection Name: Induction Chemotherapy\\n====================\\nEntities:-\\nInduction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nTherapeutic Approach : A method or strategy used in the treatment of disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""Induction Chemotherapy\"", Entity2: \""Surgical Intervention\"", Relationship: \""alternative or sequential treatment option\""\\n\\nCausalities:-\\n<C> immediate surgical intervention is either not feasible or considered insufficient </C> <E> The flowchart also considers the option of induction chemotherapy </E> <CO> in cases where immediate surgical intervention is either not feasible or considered insufficient </CO>. <A> tailoring therapeutic approaches tailored to individual patient needs </A>.\\n\\nSection Name: Adjuvant Treatment\\n====================\\nEntities:-\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nNeoplasm Recurrence, Local : The return of a cancer, at the same site, after it has been treated.\\nDisease Progression : The worsening of a disease over time.\\n\\nRelationships:-\\n1. Entity1: \""Primary Treatment\"", Entity2: \""Adjuvant Treatment\"", Relationship: \""followed by\""\\n2. Entity1: \""Adjuvant Treatment\"", Entity2: \""Systemic Therapy\"", Relationship: \""includes\""\\n3. Entity1: \""Adjuvant Treatment\"", Entity2: \""Radiotherapy\"", Relationship: \""includes\""\\n4. Entity1: \""Follow-up Assessments\"", Entity2: \""Treatment Efficacy\"", Relationship: \""used to evaluate\""\\n\\nCausalities:-\\n<C> Following primary treatment </C>, <E> the flowchart addresses the potential for adjuvant treatment pathways </E>. This may include systemic therapy, RT, or further evaluations based on <CO> the patient\\'s response and any recurrence or persistent disease </CO>. It emphasizes <A> the need for follow-up assessments to evaluate treatment efficacy </A>.\\n\\nSection Name: Risk Features and Response Assessment\\n====================\\nEntities:-\\nNeoplasm Invasiveness : The property of a neoplasm to infiltrate and destroy surrounding tissue.\\nSurgical Margins : The edge or border of the tissue removed in cancer surgery.\\nNeoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.\\nExtramural Extension : Extension of a tumor beyond the wall of an organ.\\nPositive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.\\nCancer Management : The process of planning and coordinating the treatment of cancer.\\nCancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""Extramural extension\"", Entity2: \""Treatment decisions\"", Relationship: \""influences\""\\n2. Entity1: \""Positive surgical margin\"", Entity2: \""Treatment decisions\"", Relationship: \""influences\""\\n3. Entity1: \""Ongoing assessment\"", Entity2: \""Response evaluation\"", Relationship: \""leads to\""\\n4. Entity1: \""Response evaluation\"", Entity2: \""Adjustments to treatment\"", Relationship: \""leads to\""\\n5. Entity1: \""Management of cancer\"", Entity2: \""Treatment decisions\"", Relationship: \""involves\""\\n6. Entity1: \""Management of cancer\"", Entity2: \""Ongoing assessment\"", Relationship: \""involves\""\\n7. Entity1: \""Management of cancer\"", Entity2: \""Adjustments to treatment\"", Relationship: \""involves\""\\n\\nCausalities:-\\nThe chart incorporates a segment that takes into account <CO> adverse pathologic features, such as extramural extension or positive margins </CO>, <E> which could influence subsequent treatment decisions </E>. This highlights the importance of <A> ongoing assessment in the management of cancer, leading to response evaluation and adjustments to treatment as necessary </A>.\\n\\nSection Name: NCCN Guidelines Version 4.2024\\n====================\\nEntities:-\\nClinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.\\nNeoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.\\nClinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nMalignant Neoplasm : A malignant neoplasm is a cancerous growth that has the potential to invade and destroy nearby tissue and spread to other parts of the body.\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nCancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network\"", Entity2: \""NCCN Guidelines\"", Relationship: \""provides\""\\n2. Entity1: \""NCCN Guidelines\"", Entity2: \""Clinical Trials\"", Relationship: \""recommend\""\\n3. Entity1: \""NCCN Guidelines\"", Entity2: \""Cancer\"", Relationship: \""related to management of\""\\n\\nCausalities:-\\n<CO> any patient with cancer </CO> <A> the best management is in a clinical trial </A>. <A> Participation in clinical trials is especially encouraged </A>.\\n\\nSection Name: SUPRA-3\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.\\nChemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nClinical Trials As Topic : Research studies that prospectively assign human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nInduction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.\\nClinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\n\\nRelationships:-\\n1. Entity1: \""Total laryngectomy\"", Entity2: \""Laryngectomy\"", Relationship: \""is a type of\""\\n2. Entity1: \""Systemic therapy\"", Entity2: \""RT\"", Relationship: \""concurrent treatment option\""\\n3. Entity1: \""Induction chemotherapy\"", Entity2: \""Other treatments\"", Relationship: \""initial treatment option before\""\\n\\nCausalities:-\\n<CO> Requiring (amenable to) total laryngectomy (T3,N0) </CO>\\n  - <A> Concurrent systemic therapy/RT </A> or <A> RT if patient not medical candidate for concurrent systemic therapy/RT </A>\\n  - <A> Laryngectomy, thyroidectomy and with ipsilateral, central, or bilateral neck dissection </A>\\n  - or\\n  - <A> Induction chemotherapy </A>\\n  - or\\n  - <A> Clinical trials </A>\\n\\nSection Name: Follow-up\\n====================\\nEntities:-\\nFollow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.\\nFollow-Up Procedure : A procedure performed to monitor the progress of a patient\\'s condition after initial treatment.\\nFollow-Up : Medical care given to a patient over time after initial treatment.\\nDisease Recurrence : The return of a sign, symptom, or disease after a remission.\\nRecurrent Disease : The reappearance of a disease after a period of improvement.\\n\\nRelationships:-\\n1. Entity1: \""Follow-up\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""monitoring\""\\n\\nCausalities:-\\n- **Follow-up (FOLL-A, 1 of 2)**\\n  - <CO> Recurrent or persistent disease </CO> (ADV-3)\\n\\nSection Name: Adverse Pathologic Features\\n====================\\nEntities:-\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nExtranodal Extension : The spread of cancer beyond the lymph node capsule.\\nPositive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""pN1\"", Entity2: \""Radiotherapy\"", Relationship: \""Consideration for treatment\""\\n2. Entity1: \""Extranodal extension\"", Entity2: \""Systemic Therapy\"", Relationship: \""Treatment option\""\\n3. Entity1: \""Extranodal extension\"", Entity2: \""Radiotherapy\"", Relationship: \""Treatment option\""\\n4. Entity1: \""Positive surgical margin\"", Entity2: \""Systemic Therapy\"", Relationship: \""Treatment option\""\\n5. Entity1: \""Positive surgical margin\"", Entity2: \""Radiotherapy\"", Relationship: \""Treatment option\""\\n\\nCausalities:-\\n- <CO>pN1 without other risk features</CO>\\n  - <C>Adverse pathologic features</C>\\n  - <A>Consider RT</A>\\n  - <CO>Extranodal extension and/or positive margin</CO>\\n  - <CO>Other risk features</CO>\\n  - <A>Systemic therapy/RT (category 1)</A>\\n  - <A>RT or Consider systemic therapy/RT</A>\\n\\nSection Name: Response Assessment\\n====================\\nEntities:-\\nResponse Evaluation : The process of assessing the response of a disease to treatment, often used in clinical trials to determine the effectiveness of a therapy.\\nResponse To Treatment : A clinical finding indicating the response of a condition to a therapeutic intervention.\\n\\nRelationships:-\\n\\nSection Name: Principles of Surgery and Radiation Therapy\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nRadiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\n\\nRelationships:-\\n1. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Radiation Therapy\"", Relationship: \""complementary treatments\""\\n\\nCausalities:-\\n**Principles of Surgery (SURG-A).**\\n\\n**Principles of Radiation Therapy (SUPRA-A).**\\n\\nSection Name: Principles of Systemic Therapy\\n====================\\nEntities:-\\nCisplatin : An inorganic and water-soluble platinum complex, cisplatin is an antineoplastic agent that is used in the treatment of various cancers.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nRadiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\n\\nRelationships:-\\n1. Entity1: \""Cisplatin\"", Entity2: \""Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""preferred agent\""\\n2. Entity1: \""Cisplatin\"", Entity2: \""Concurrent Systemic Therapy/RT\"", Relationship: \""used in\""\\n\\nCausalities:-\\n<CO> When using concurrent systemic therapy/RT </CO>, <A> the preferred agent is cisplatin (category 1) </A>.\\n--------------------------------------------------\\nPage Number: 130\\n\\nSection Name: Pathological N (pN)\\n====================\\nEntities:-\\nLymph Nodes : Small, bean-shaped structures that are part of the body\\'s lymphatic system. They filter lymph fluid and store white blood cells that help fight infection.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nTnm Staging : A system used to describe the size and spread of cancer in a standardized way. T refers to the size of the tumor, N to the involvement of lymph nodes, and M to metastasis.\\nLymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\nTnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient\\'s body.\\nLymph Node : An organ of the lymphatic system and the adaptive immune system.\\n\\nRelationships:-\\n1. Entity1: \""Lymph Nodes\"", Entity2: \""Neoplasm Metastasis\"", Relationship: \""involved in\""\\n2. Entity1: \""TNM Staging\"", Entity2: \""Lymph Nodes\"", Relationship: \""includes\""\\n3. Entity1: \""TNM Staging\"", Entity2: \""Neoplasm Metastasis\"", Relationship: \""describes\""\\n\\nCausalities:-\\n<CO> NX: Regional lymph nodes cannot be assessed </CO>\\n<CO> N0: No regional lymph node metastasis </CO>\\n<CO> N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(\u2013) </CO>\\n<CO> N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2212); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(\u2212); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2a: Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N3: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(\u2212); or metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>\\n<CO> N3a: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N3b: Metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>\\n<CO> Note: A designation of \u201cU\u201d or \u201cL\u201d may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L). Similarly, clinical and pathological ENE should be recorded as ENE(\u2212) or ENE(+). </CO>\\n\\nSection Name: Distant Metastasis (M)\\n====================\\nEntities:-\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\n\\nRelationships:-\\n1. Entity1: \""M0\"", Entity2: \""Distant Metastasis\"", Relationship: \""is a category of\""\\n2. Entity1: \""M1\"", Entity2: \""Distant Metastasis\"", Relationship: \""is a category of\""\\n\\nCausalities:-\\n### Distant Metastasis (M)\\n\\n- **M0**: No distant metastasis\\n- **M1**: Distant metastasis\\n\\nSection Name: Histologic Grade (G)\\n====================\\nEntities:-\\nNeoplasm Grading : A system of classifying cancer cells in terms of how abnormal they look under a microscope and how quickly the tumor is likely to grow and spread.\\nHistologic Grade : A measure of how much tumor cells differ from healthy cells, used to assess the aggressiveness of cancer.\\n\\nRelationships:-\\n1. Entity1: \""GX\"", Entity2: \""Grade cannot be assessed\"", Relationship: \""is described as\""\\n2. Entity1: \""G1\"", Entity2: \""Well differentiated\"", Relationship: \""is described as\""\\n3. Entity1: \""G2\"", Entity2: \""Moderately differentiated\"", Relationship: \""is described as\""\\n4. Entity1: \""G3\"", Entity2: \""Poorly differentiated\"", Relationship: \""is described as\""\\n\\nCausalities:-\\n<CO>GX</CO>: <E>Grade cannot be assessed</E>\\n<CO>G1</CO>: <E>Well differentiated</E>\\n<CO>G2</CO>: <E>Moderately differentiated</E>\\n<CO>G3</CO>: <E>Poorly differentiated</E>\\n\\nSection Name: Prognostic Stage Groups\\n====================\\nEntities:-\\nNeoplasm Staging : Methods and systems of classifying neoplasms according to extent of disease.\\nTumor Staging : A system for describing the size and spread of cancer within the body.\\nTnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient\\'s body.\\n\\nRelationships:-\\n1. Entity1: \""Stage 0\"", Entity2: \""Tis N0 M0\"", Relationship: \""defined by\""\\n2. Entity1: \""Stage I\"", Entity2: \""T1 N0 M0\"", Relationship: \""defined by\""\\n3. Entity1: \""Stage II\"", Entity2: \""T2 N0 M0\"", Relationship: \""defined by\""\\n4. Entity1: \""Stage III\"", Entity2: \""T3 N0 M0, T1 N1 M0, T2 N1 M0, T3 N1 M0\"", Relationship: \""defined by\""\\n5. Entity1: \""Stage IVA\"", Entity2: \""T1 N2 M0, T2 N2 M0, T3 N2 M0, T4a N0,N1,N2 M0\"", Relationship: \""defined by\""\\n6. Entity1: \""Stage IVB\"", Entity2: \""Any T N3 M0, T4b Any N M0\"", Relationship: \""defined by\""\\n7. Entity1: \""Stage IVC\"", Entity2: \""Any T Any N M1\"", Relationship: \""defined by\""\\n--------------------------------------------------\\nPage Number: 47\\n\\nSection Name: Overview of Radiation Therapy Guidelines\\n====================\\nEntities:-\\nRadiation Therapy : The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\nMalignant Neoplasm : A disease characterized by uncontrolled, abnormal growth of cells that can invade and destroy nearby tissue and spread to other parts of the body.\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.\\nGlottic Larynx Cancer : A malignant neoplasm located in the glottic region of the larynx.\\nLaryngeal Cancer : Cancer that occurs in the larynx, or voice box, which may include the glottic region.\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\n\\nRelationships:-\\n1. Entity1: \""Radiation Therapy\"", Entity2: \""Cancer\"", Relationship: \""treats\""\\n2. Entity1: \""NCCN Guidelines\"", Entity2: \""Cancer\"", Relationship: \""guides treatment for\""\\n3. Entity1: \""NCCN Guidelines\"", Entity2: \""Radiation Therapy\"", Relationship: \""specifies use of\""\\n\\nCausalities:-\\nThe image presents a detailed flowchart outlining the principles of radiation therapy specifically for the <C> treatment of cancer in the glottic larynx </C>, <CO> as per the National Comprehensive Cancer Network (NCCN) guidelines (version 2.2024) </CO>. <E> This structured guidance delineates various treatment protocols </E>, <A> stratified by risk levels and therapeutic approaches </A>.\\n\\nSection Name: Principles of Radiation Therapy\\n====================\\nEntities:-\\nRadiation Therapy : The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nGy : Gray, a unit of ionizing radiation dose in the International System of Units (SI), defined as the absorption of one joule of radiation energy per kilogram of matter.\\nGray (Unit) : A unit of absorbed radiation dose of ionizing radiation, defined as the absorption of one joule of radiation energy per kilogram of matter.\\n\\nRelationships:-\\n1. Entity1: \""Tis, N0\"", Entity2: \""60.75 Gy (2.25 Gy/fraction) to 66 Gy (2.0 Gy/fraction)\"", Relationship: \""treatment protocol\""\\n2. Entity1: \""T1, N0\"", Entity2: \""63 Gy (2.25 Gy/fraction) to 66 Gy (2.0 Gy/fraction) or 50 Gy (3.12 Gy/fraction) to 52 Gy (3.28 Gy/fraction)\"", Relationship: \""treatment protocol\""\\n3. Entity1: \""T2, N0\"", Entity2: \""65.25 Gy (2.25 Gy/fraction) to 70 Gy (2.0 Gy/fraction)\"", Relationship: \""treatment protocol\""\\n4. Entity1: \""\u2265T2, N1 (PTV High risk)\"", Entity2: \""66 Gy (2.2 Gy/fraction) to 70 Gy (2.0 Gy/fraction)\"", Relationship: \""treatment protocol\""\\n5. Entity1: \""\u2265T2, N1 (Low to intermediate risk)\"", Entity2: \""44\u201350 Gy (2.0 Gy/fraction) to 54\u201363 Gy (1.6\u20131.8 Gy/fraction)\"", Relationship: \""treatment protocol\""\\n\\nCausalities:-\\n<CO>Tis, N0</CO>: <A>60.75 Gy (2.25 Gy/fraction) to 66 Gy (2.0 Gy/fraction)</A>\\n<CO>T1, N0</CO>: <A>63 Gy (2.25 Gy/fraction, preferred) to 66 Gy (2.0 Gy/fraction) or 50 Gy (3.12 Gy/fraction) to 52 Gy (3.28 Gy/fraction)</A>\\n<CO>T2, N0</CO>: <A>65.25 (2.25 Gy/fraction) to 70 Gy (2.0 Gy/fraction)</A>\\n<CO>\u2265T2, N1</CO>: <A>PTV High risk: Primary tumor and involved lymph nodes (includes possible local subclinical infiltration at the primary site and at the high-risk level lymph node(s))</A>\\n<A>Fractionation: 66 Gy (2.2 Gy/fraction) to 70 Gy (2.0 Gy/fraction); daily Monday\u2013Friday in 6\u20137 weeks</A>\\n<A>Concomitant boost accelerated RT: 72 Gy/6 weeks (1.8 Gy/fraction, large field; 1.5 Gy boost as second daily fraction during last 12 treatment days)</A>\\n<A>66\u201370 Gy (2.0 Gy/fraction; 6 fractions/wk accelerated)</A>\\n<A>Hyperfractionation: 79.2\u201381.6 Gy/7 weeks (1.2 Gy/fraction, twice daily)</A>\\n<CO>Low to intermediate risk</CO>: <A>Sites of suspected subclinical spread</A>\\n<A>44\u201350 Gy (2.0 Gy/fraction) to 54\u201363 Gy (1.6\u20131.8 Gy/fraction)</A>\\n\\nSection Name: Concurrent Systemic Therapy/RT\\n====================\\nEntities:-\\nCisplatin : A platinum-containing antineoplastic agent used in the treatment of various cancers.\\nCarboplatin : An organoplatinum compound that possesses antineoplastic activity.\\nFluorouracil : A chemotherapy drug used to treat various types of cancer.\\n\\nRelationships:-\\n1. Entity1: \""concurrent systemic therapy/RT\"", Entity2: \""cisplatin\"", Relationship: \""uses\""\\n2. Entity1: \""concurrent systemic therapy/RT\"", Entity2: \""carboplatin and 5-FU\"", Relationship: \""uses\""\\n3. Entity1: \""multiagent chemotherapy\"", Entity2: \""toxicity burden\"", Relationship: \""increases\""\\n\\nCausalities:-\\n<CO>Based on published data</CO>, <A>concurrent systemic therapy/RT most commonly uses conventional fractionation at 2.0 Gy per fraction to a typical dose of 70 Gy in 7 weeks with single-agent cisplatin given every 3 weeks at 100 mg/m\u00b2</A>; <CO>2\u20133 cycles of chemotherapy are used depending on the radiation fractionation scheme (RTOG 0129)</CO>. <CO>When carboplatin and 5-FU are used</CO>, <A>the recommended regimen is standard fractionation plus 3 cycles of chemotherapy</A>. <CO>Other fraction sizes (e.g., 1.8 Gy, conventional), multiagent chemotherapy, other dosing schedules of cisplatin, or altered fractionation with chemotherapy</CO> <E>are efficacious</E>, and <C>there is no consensus on the optimal approach</C>. <C>In general, the use of concurrent systemic therapy/RT</C> <E>carries a high toxicity burden</E>; <C>multiagent chemotherapy</C> <E>will likely further increase the toxicity burden</E>. <A>For any systemic therapy/RT approach, close attention should be paid to published reports for the specific chemotherapy agent, dose, and schedule of administration</A>. <A>Systemic therapy/RT should be performed by an experienced team and should include substantial supportive care</A>.\\n\\nSection Name: Treatment Modalities\\n====================\\nEntities:-\\nIntensity-Modulated Radiotherapy : A type of conformal radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.\\nIntensity Modulated Radiation Therapy : A type of conformal radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.\\nIntensity-Modulated Radiation Therapy : An advanced type of high-precision radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.\\nRadiotherapy, Conformal : A type of radiotherapy that uses imaging to conform the radiation dose to the shape of the tumor.\\n3D Conformal Radiation Therapy : A technique in radiotherapy that uses imaging to conform the radiation dose to the shape of the tumor.\\nChemotherapy, Adjuvant : Treatment with drugs that kill cancer cells, often used in conjunction with other therapies.\\nChemotherapy : The treatment of disease by the use of chemical substances, especially the treatment of cancer by cytotoxic and other drugs.\\nDrug Therapy, Combination : The use of two or more drugs to achieve a therapeutic effect.\\nSystemic Therapy : A type of therapy that uses substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Intensity-Modulated Radiation Therapy (IMRT)\"", Entity2: \""3D Conformal Radiation Therapy (3D-CRT)\"", Relationship: \""are delivery methods for radiation therapy\""\\n2. Entity1: \""Chemotherapy\"", Entity2: \""Radiation Therapy\"", Relationship: \""is integrated with for aggressive or advanced cancer cases\""\\n\\nCausalities:-\\n<CO> contingent upon patient-specific considerations </CO> <A> suggests either Intensity-Modulated Radiation Therapy (IMRT) or 3D Conformal Radiation Therapy (3D-CRT) as delivery methods </A>. <A> These advanced techniques are employed to optimize treatment accuracy </A>, <E> preserving surrounding healthy tissue and improving overall patient outcomes </E>. <A> a focus on concurrent systemic therapies underlines the importance of integrating chemotherapy </A>, particularly <CO> for patients with more aggressive forms of cancer or those demonstrating advanced disease characteristics </CO>.\\n\\nSection Name: Additional Information\\n====================\\nEntities:-\\nClinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.\\nClinical Trial : A clinical trial is a research study in which one or more human subjects are prospectively assigned to one or more interventions to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes.\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nIntensity-Modulated Radiation Therapy : An advanced type of high-precision radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.\\nIntensity Modulated Radiation Therapy : A type of conformal radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.\\nThree-Dimensional Conformal Radiation Therapy : A type of external beam radiation therapy that uses a computer to create a 3-dimensional picture of the tumor so that multiple radiation beams can be shaped exactly to the contour of the treatment area.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network\"", Entity2: \""Clinical trial\"", Relationship: \""encourages participation in\""\\n2. Entity1: \""Intensity-Modulated Radiation Therapy\"", Entity2: \""Three-Dimensional Conformal Radiation Therapy\"", Relationship: \""recommended alternatives\""\\n\\nCausalities:-\\n<A> Participation in clinical trials </A> is especially encouraged. <A> Either IMRT (preferred) or 3D-CRT is recommended. </A>\\n\\nSection Name: Conclusion\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.\\nMalignant Neoplasm Of Glottis : A malignant tumor located in the glottic region of the larynx.\\nLaryngeal Cancer : Cancer that occurs in the larynx, or voice box, which may include the glottic region.\\nPrognosis : A medical term for predicting the likely or expected development of a disease.\\nEvidence-Based Practice : Healthcare practices that are based on scientific evidence and research.\\nEvidence-Based Medicine : An approach to medical practice intended to optimize decision-making by emphasizing the use of evidence from well-designed and conducted research.\\n\\nRelationships:-\\n1. Entity1: \""treatment paradigms\"", Entity2: \""glottic larynx cancer\"", Relationship: \""encapsulates\""\\n2. Entity1: \""personalized treatment plans\"", Entity2: \""prognosis\"", Relationship: \""improves\""\\n\\nCausalities:-\\n<C> glottic larynx cancer </C>. <CO> the nuances of each patient\\'s condition </CO>. <A> personalized treatment plans </A> <E> promoting effective management and improved prognosis </E>. <A> deliver clear, evidence-based interventions </A> <CO> considering the complexities involved in cancer treatment </CO>.\\n'}""",valid,increases risk,2,B,"edge - The edge which needs to be verified.
explanation - Explanation of what the edge represents and its validity.
causal_direction - Either Positive or Negative or Unknown. A positive influence direction indicates that both factors change in the same direction (e.g. an increase causes an increase effect). A negative influence direction indicates the opposite changes (e.g. an increase causes a decrease effect).
causal_factor - Is necessary or sufficient condition for an effect to occur. Exposure is a term commonly used in epidemiology to denote any condition that is considered as a possible cause of disease. Exposure is considered necessary when it always precedes the effects (e.g. symptoms) and always presents when the effects occur. A sufficient cause is a causal factor whose presence or occurrence guarantees the occurrence of symptom.
causal_distance - Either Distal or Proximal or Unknown. The distal factors lie towards the beginning of causal chain (i.e. indirect causal factors). The the proximal factors lie towards the end of the chain (i.e. cause directly or almost directly the effect).

Causality Tags:
<A> for action, <C> for cause, <CO> for condition and <E> for effect.
Cause (C): The reason or origin that leads to an effect. Causes often involve disease conditions, risk factors, or underlying mechanisms.
Effect (E): The outcome or result of a cause. Effects usually represent clinical outcomes, complications, or results of a specific cause.
Condition (CO): The circumstance or prerequisite required for an action or effect to occur. Conditions may include patient characteristics, clinical scenarios, or specific diagnostic criteria.
Action (A): The recommended or described response or activity to address a cause or condition. Actions typically involve clinical interventions, diagnostic procedures, or treatment recommendations.


`NODE1`:
id: N_State_1__patient
label: State of Nearby Lymph Nodes with Cancer in Patient
description: This node represents the state of involvement of nearby lymph nodes in a patient with cancer. It is a decision node used to predict the extent of lymph node metastasis, which is crucial for cancer staging and treatment planning. The states range from no involvement (n0) to extensive involvement (n3), with intermediate states indicating varying degrees of lymph node cancer presence.
type: Decision Node
observability: Needs to be Predicted
states: [{'state_name': 'nx', 'state_description': 'The regional lymph nodes cannot be assessed.'}, {'state_name': 'n3', 'state_description': 'Metastasis in lymph node(s) along the course of a major blood vessel or in a lymph node that is more than 6 cm in greatest dimension.'}, {'state_name': 'n2c', 'state_description': 'Metastasis in bilateral or contralateral lymph nodes, each 6 cm or less in greatest dimension.'}, {'state_name': 'n2b', 'state_description': 'Metastasis in multiple ipsilateral lymph nodes, each 6 cm or less in greatest dimension.'}, {'state_name': 'n2a', 'state_description': 'Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension.'}, {'state_name': 'n2', 'state_description': 'Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension, or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension.'}, {'state_name': 'n1', 'state_description': 'Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension.'}, {'state_name': 'n0', 'state_description': 'No regional lymph node metastasis.'}]

`NODE2`:
id: Location_of_Involved_Lymph_Nodes_4
label: Position of Affected Lymph Nodes in Patient
description: This node represents the location of lymph nodes that are involved or affected in a patient's condition. Understanding whether the lymph nodes are ipsilateral, bilateral, or contralateral is crucial for determining the extent of disease spread and planning appropriate treatment strategies.
type: Patient Situation
observability: Unobserved
states: [{'state_name': 'ipsilateral', 'state_description': 'The involved lymph nodes are on the same side of the body as the primary tumor or reference point. This can indicate localized spread of disease.'}, {'state_name': 'bilateral', 'state_description': 'The involved lymph nodes are on both sides of the body. This may suggest a more extensive spread of disease and can impact treatment decisions.'}, {'state_name': 'contralateral', 'state_description': 'The involved lymph nodes are on the opposite side of the body from the primary tumor or reference point. This can indicate metastatic spread and may affect staging and treatment planning.'}]

`EDGE1`:
{'edges_ids': ['N_State_1__patient', 'Location_of_Involved_Lymph_Nodes_4'], 'edge': '(N_State_1__patient) causes (Location_of_Involved_Lymph_Nodes_4)', 'explanation': ['The edge represents the causal relationship where the state of nearby lymph nodes with cancer in a patient influences the location of involved lymph nodes.', 'The state of lymph node involvement (N_State_1__patient) is a predictor of the extent and location of lymph node spread (Location_of_Involved_Lymph_Nodes_4).', 'As the involvement state increases (e.g., from n0 to n3), the likelihood of more extensive spread (e.g., bilateral or contralateral) increases, indicating a positive causal direction.', 'The causal factor is neither necessary nor sufficient because other factors can influence the location, and the state does not guarantee a specific location.', 'The causal distance is proximal because the state of involvement directly affects the location of involved lymph nodes.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Proximal'}

`EDGE2`:
{'edges_ids': ['Location_of_Involved_Lymph_Nodes_4', 'N_State_1__patient'], 'edge': '(Location_of_Involved_Lymph_Nodes_4) causes (N_State_1__patient)', 'explanation': ['The edge represents the causal relationship where the location of involved lymph nodes (ipsilateral, bilateral, contralateral) influences the predicted state of lymph node involvement (n0 to n3).', 'The location of lymph nodes is a critical factor in determining the extent of lymph node metastasis, which is crucial for cancer staging.', 'The causal direction is positive because more extensive lymph node involvement (e.g., bilateral or contralateral) is likely to lead to a higher N state.', 'The causal factor is neither necessary nor sufficient because other factors also contribute to the N state, such as the size of the lymph nodes.', 'The causal distance is proximal because the location of lymph nodes is directly related to the N state classification.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Proximal'}

`INFORMATION FROM KNOWLEDGE BASE`:
--------------------------------------------------
Page Number: 102

Section Name: Head and Neck Cancers - Principles of Surgery
====================
Entities:-
Surgical Procedures, Operative : Manual or operative procedures used in the treatment of disease, injuries, or deformities.
Lymphatic System : Part of the circulatory system and a vital part of the immune system, comprising a network of lymphatic vessels that carry a clear fluid called lymph.
Neoplasms : New abnormal growth of tissue in animals or plants; a tumor.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Neoplasm Staging : Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Metastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.
Surgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Lymphatic Structure : Anatomical structure that is part of the lymphatic system.
Tumor : An abnormal mass of tissue that results when cells divide more than they should or do not die when they should.
Staging : The process of determining the size and spread of cancer within the body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Cancer Staging : The process of determining the extent to which a cancer has developed by growing and spreading.

Relationships:-
1. Entity1: ""surgical management"", Entity2: ""regional lymphatics"", Relationship: ""dictated by tumor staging""
2. Entity1: ""neck dissections"", Entity2: ""primary tumor"", Relationship: ""part of treatment""
3. Entity1: ""surgery"", Entity2: ""ipsilateral side of the neck"", Relationship: ""risk for metastases""

Causalities:-
<C> The extent of the tumor at initial tumor staging </C> <E> dictates the surgical management of regional lymphatics </E>. These guidelines apply to the performance of neck dissections as part of treatment of the primary tumor. <CO> Patients undergoing surgery for resection of the primary tumor </CO> <A> will undergo dissection of the ipsilateral side of the neck that is at greatest risk for metastases </A>.

Section Name: Neck Management
====================
Entities:-
Tongue : A muscular organ in the mouth that is involved in tasting, swallowing, and speech.
Palate : The roof of the mouth, separating the oral and nasal cavities.
Larynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.
Hypopharynx : The bottom part of the pharynx, which is the cavity behind the nose and mouth.
Nasopharynx : The upper part of the pharynx, connecting with the nasal cavity above the soft palate.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Metastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.
Squamous Cell Carcinoma : A type of cancer that begins in the squamous cells, which are thin, flat cells that look like fish scales.
Biopsy : The removal of cells or tissues for examination under a microscope.

Relationships:-
1. Entity1: ""Tumor sites"", Entity2: ""Bilateral lymphatic drainage"", Relationship: ""associated with""
2. Entity1: ""Elective neck dissection"", Entity2: ""Risk of occult metastasis"", Relationship: ""based on""
3. Entity1: ""SLN biopsy"", Entity2: ""Elective neck dissection"", Relationship: ""guides decision-making for""

Causalities:-
- **<C> Tumor sites that frequently have bilateral lymphatic drainage </C>** (e.g., base of tongue, palate, supraglottic larynx, hypopharynx, nasopharynx, deep pre-epiglottic space involvement) <E> often should have both sides of the neck dissected </E> with the extent of dissection determined as suggested below. For those patients with tumors at or approaching the midline, <CO> both sides of the neck are at risk for metastases </CO>, and <A> bilateral neck dissections should be performed </A>.

- <CO> Patients with advanced lesions involving the anterior tongue, floor of the mouth, or alveolus that approximate or cross the midline </CO> <A> should undergo contralateral selective/modified neck dissection </A> as necessary to achieve adequate tumor resection.

- **<C> Elective neck dissection </C>** <A> should be based on risk of occult metastasis in the appropriate nodal basin </A>. For oral cavity squamous cell carcinoma, <C> SLN biopsy or the primary tumor depth of invasion </C> is currently <E> the best predictor of occult metastatic disease </E> and <A> should be used to guide decision-making </A>. <CO> For tumors with a depth greater than 3 mm </CO>, <A> elective dissection should be strongly considered if RT is not already planned </A>. Recent randomized trial evidence supports the effectiveness of elective neck dissection in patients with oral cavity cancers greater than 3 mm in depth of invasion.

  - <CO> For a depth less than 2 mm </CO>, <A> elective dissection is only indicated in highly selective situations </A>. <CO> For a depth of 2–4 mm </CO>, <A> clinical judgment (as to reliability of follow-up, clinical suspicion, and other factors) must be utilized to determine appropriateness of elective dissection </A>. Elective dissections are generally selective, preserving all major structures, unless operative findings dictate otherwise.

Section Name: Types of Neck Dissection
====================
Entities:-
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Larynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.

Relationships:-
1. Entity1: ""N0"", Entity2: ""Selective neck dissection"", Relationship: ""associated with""
2. Entity1: ""N3"", Entity2: ""Comprehensive neck dissection"", Relationship: ""associated with""
3. Entity1: ""Level VI neck dissection"", Entity2: ""Larynx"", Relationship: ""performed for""
4. Entity1: ""Level VI neck dissection"", Entity2: ""Hypopharynx"", Relationship: ""performed for""

Causalities:-
- **The type of neck dissection (comprehensive or selective)** is defined according to <CO> preoperative clinical staging </CO>, is determined at the discretion of the surgeon, and is based on the initial preoperative staging as follows:
  - **N0:** <A> Selective neck dissection </A>
    - Oral cavity at least levels I–III
    - Oropharynx at least levels II–IV
    - Hypopharynx at least levels II–IV and level VI when appropriate
    - Larynx at least levels II–IV and level VI when appropriate
  - **N1–N2a–c:** <A> Selective or comprehensive neck dissection </A> (Discussion)
  - **N3:** <A> Comprehensive neck dissection </A>

- <C> Level VI neck dissections are performed for certain primary sites (such as the larynx and hypopharynx) </C> <E> as required to resect the primary tumor and any clinically evident neck nodes </E>. <CO> Elective dissection depends on primary tumor extent and site </CO>. <CO> For advanced glottic and hypopharyngeal cancers treated with primary surgery </CO>, <A> a level VI dissection (including pretracheal lymph nodes, the Delphian lymph node, and unilateral or bilateral paratracheal lymph nodes) and hemithyroidectomy to total thyroidectomy are appropriate </A>.

- <CO> For primary subglottic tumors or glottic cancers with significant subglottic extension </CO>, <A> a level VI dissection with unilateral or total thyroidectomy is considered appropriate </A> based on the extent of the primary tumor. <CO> For example, a T4a glottic tumor with extension through the cricothyroid membrane and subglottic extension </CO> <A> should include thyroidectomy and pretracheal and bilateral paratracheal lymph node dissection </A>. <A> Parathyroid glands should be preserved in situ or auto transplanted as indicated </A>.
--------------------------------------------------
Page Number: 55

Section Name: General Information
====================
Entities:-
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Nccn Guidelines : Clinical practice guidelines in oncology developed by the National Comprehensive Cancer Network.

Relationships:-
1. Entity1: ""NCCN Guidelines"", Entity2: ""National Comprehensive Cancer Network"", Relationship: ""produced by""

Section Name: Important Notes
====================
Entities:-
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medical, surgical, or behavioral interventions.
Clinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Neoplasms : New abnormal growth of tissue that can be benign or malignant.
Malignant Neoplastic Disease : A disease resulting from the growth of malignant neoplasms.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""Clinical Trials"", Entity2: ""Cancer"", Relationship: ""recommended for""
2. Entity1: ""NCCN"", Entity2: ""Clinical Trials"", Relationship: ""encourages participation in""

Causalities:-
<C> NCCN believes that the best management of any patient with cancer is in a clinical trial </C>. <A> Participation in clinical trials is especially encouraged </A>.

Section Name: Principles
====================
Entities:-
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Chemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.

Relationships:-
1. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Radiation Therapy"", Relationship: ""Both are principles of cancer treatment methods.""
2. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""Both are principles of cancer treatment methods.""
3. Entity1: ""Principles of Radiation Therapy"", Entity2: ""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""Both are principles of cancer treatment methods.""

Causalities:-
### Principles

- **Principles of Surgery (SURG-A)**
- **Principles of Radiation Therapy (SUPRA-A)**
- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**

Section Name: Adverse Pathologic Features
====================
Entities:-
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.
Perineural Invasion : The presence of cancer cells surrounding or tracking along a nerve within the perineural space.
Vascular Invasion : The invasion of cancer cells into blood vessels.
Lymphatic Invasion : The invasion of cancer cells into lymphatic vessels.

Relationships:-
1. Entity1: ""Extranodal extension"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
2. Entity1: ""Positive margins"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
3. Entity1: ""Close margins"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
4. Entity1: ""pT3 or pT4 primary"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
5. Entity1: ""pN2 or pN3 nodal disease"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
6. Entity1: ""Perineural invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
7. Entity1: ""Vascular invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
8. Entity1: ""Lymphatic invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""

Causalities:-
<C> Extranodal extension </C>
<C> Positive margins </C>
<C> Close margins </C>
<C> pT3 or pT4 primary </C>
<C> pN2 or pN3 nodal disease </C>
<C> Perineural invasion </C>
<C> Vascular invasion </C>
<C> Lymphatic invasion </C>

Section Name: Response Assessment
====================
Entities:-
Chemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Primary Site : The original location where a tumor or cancer begins.
Complete Remission : The disappearance of all signs of cancer in response to treatment.
Partial Remission : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
Radiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.

Relationships:-
1. Entity1: ""induction chemotherapy"", Entity2: ""Primary site"", Relationship: ""treatment outcome""
2. Entity1: ""Definitive RT"", Entity2: ""Primary site"", Relationship: ""treatment option""
3. Entity1: ""RT"", Entity2: ""Primary site"", Relationship: ""treatment option""
4. Entity1: ""Surgery"", Entity2: ""unresectable nodal disease"", Relationship: ""treatment option""

Causalities:-
<C> Response after induction chemotherapy </C>: <E> Primary site: CR </E> <E> Primary site: PR </E> <E> Primary site: < PR </E> <A> Definitive RT </A> (category 1) <A> RT </A> (category 1) or <A> systemic therapy/RT </A> (category 2B) <A> Surgery </A> or <A> unresectable nodal disease </A>

Section Name: Follow-up
====================
Entities:-
Follow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.
Follow-Up Procedure : A procedure where a patient is monitored over time to assess the progress of a condition or the effects of treatment.
Follow-Up (Medicine) : The process of monitoring a patient's health over time after treatment or diagnosis.
Disease Recurrence : The return of a sign, symptom, or disease after a remission.
Recurrent Disease : A disease that returns after a period of remission.
Recurrence (Medicine) : The return of a disease or condition after a period of improvement.

Relationships:-
1. Entity1: ""Follow-up"", Entity2: ""Recurrent or persistent disease"", Relationship: ""monitoring""

Causalities:-
### Follow-up

- **Follow-up** (FOLL-A, 1 of 2)
- **Recurrent or persistent disease** (ADV-3)

Section Name: Risk Features
====================
Entities:-
Radiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Adverse pathologic features"", Entity2: ""RT"", Relationship: ""Consideration for treatment""
2. Entity1: ""Adverse pathologic features"", Entity2: ""Systemic therapy"", Relationship: ""Consideration for treatment""

Causalities:-
- **No adverse pathologic features**
- **Other risk features**
- **Adverse pathologic features**:
  - <C> Extranodal extension and/or positive margin </C>
  - <A> RT or consider systemic therapy/RT </A>

Section Name: Post-Therapy Evaluation
====================
Entities:-
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Neck : The neck is the part of the body that separates the head from the torso and provides the mobility and movements of the head.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Neck Evaluation"", Relationship: ""evaluated in""
2. Entity1: ""RT"", Entity2: ""Neck Evaluation"", Relationship: ""evaluated in""

Causalities:-
<CO> Post Systemic Therapy/RT or RT Neck </CO> <A> Evaluation </A>

Section Name: Flowchart Overview
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Supraglottic Larynx : The part of the larynx located above the vocal cords, including the epiglottis and aryepiglottic folds.
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.

Relationships:-
1. Entity1: ""NCCN Guidelines"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""guides management of""
2. Entity1: ""NCCN Guidelines"", Entity2: ""healthcare professionals"", Relationship: ""used by""

Causalities:-
<C> cancer of the supraglottic larynx </C> <E> evaluate patient responses following treatment </E> <CO> based on observed outcomes </CO> <A> evaluation of the primary site and determining subsequent steps </A>.

Section Name: Assessment and Treatment Decisions
====================
Entities:-
Induction Chemotherapy : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Complete Response : The disappearance of all signs of cancer in response to treatment.
Partial Response : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Complete Response"", Entity2: ""Radiation Therapy"", Relationship: ""leads to""
2. Entity1: ""Complete Response"", Entity2: ""Surgery"", Relationship: ""leads to""
3. Entity1: ""Partial Response"", Entity2: ""Systemic Therapy"", Relationship: ""leads to""
4. Entity1: ""Partial Response"", Entity2: ""Radiation Therapy"", Relationship: ""leads to""

Causalities:-
<C> responses to initial treatments such as induction chemotherapy </C> <E> Three main response categories are recognized: Complete Response (CR), Partial Response (PR), and less than Partial Response (< PR) </E>. These categories are pivotal in determining the next steps. <C> CR </C> <E> indicates full resolution of the disease at the primary site </E>, <A> leading to the consideration of definitive radiation therapy or the likelihood of surgery </A>. Conversely, <C> PR </C> <E> suggests that the disease has improved but not completely resolved </E>, <A> which directs the pathway towards either systemic therapy or continued radiation therapy </A>, <A> with further evaluation necessary </A>.

Section Name: Adverse Pathologic Features and Follow-up
====================
Entities:-
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Neoplasm Recurrence, Local : The return of a tumor or cancer, at the original site, after it has been treated.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Recurrent Neoplasm : A neoplasm that has returned after treatment.
Metastatic Neoplasm : A neoplasm that has spread from its original site to one or more other places in the body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Cancer Recurrence : The return of cancer after treatment and after a period of time during which the cancer was undetectable.
Metastasis : Spread of a cancer or other disease from one organ or part to another not directly connected with it.

Relationships:-
1. Entity1: ""Adverse pathologic features"", Entity2: ""Treatment decisions"", Relationship: ""Influence""
2. Entity1: ""Adverse features"", Entity2: ""Surgical intervention"", Relationship: ""Recommendation""
3. Entity1: ""Absence of adverse features"", Entity2: ""Radiation therapy"", Relationship: ""Pathway""
4. Entity1: ""Follow-up process"", Entity2: ""Recurrent or persistent disease"", Relationship: ""Detection""
5. Entity1: ""Recurrent or persistent disease"", Entity2: ""Advanced disease management"", Relationship: ""Necessity""

Causalities:-
<C> The presence of adverse pathologic features — such as extranodal extension or positive margins </C> <E> can directly influence treatment decisions </E>. <CO> If adverse features are found </CO>, <A> surgical intervention is recommended </A>. <CO> In cases where there are no adverse features </CO>, the patient may proceed directly to radiation therapy or continued systemic treatment, emphasizing the tailored approach based on the individual patient's disease characteristics.

Furthermore, the chart includes a section addressing the follow-up process after initial treatment. <CO> If there are signs of recurrent or persistent disease </CO>, <A> additional evaluations and treatment modalities may be necessary </A>. These evaluations <E> lead to specific recommendations for advanced disease management, denoted as ADV-3 on the chart </E>, emphasizing the importance of continuous monitoring and assessment in cancer care.
--------------------------------------------------
Page Number: 51

Section Name: Introduction
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Malignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.
Supraglottic Laryngeal Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is above the vocal cords.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network (NCCN)"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""provides guidelines for""
2. Entity1: ""healthcare professionals"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""manage""

Causalities:-
The provided image is a detailed flowchart from the National Comprehensive Cancer Network (NCCN) guidelines regarding the <C> clinical staging and treatment protocols for cancer of the supraglottic larynx </C>. This flowchart is structured to <A> guide healthcare professionals through the stages of treatment </A> based on <CO> clinical findings </CO>, emphasizing the <E> complexity and systematic approach required in managing this type of cancer </E>.

Section Name: Clinical Staging
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Total Laryngectomy : A surgical procedure to remove the entire larynx, often used in the treatment of advanced laryngeal cancer.
Neoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.
Cancer Staging : The process of determining the extent of cancer in the body, often using the TNM system.
Tnm Staging System : A cancer staging system that describes the extent of cancer using Tumor size (T), Node involvement (N), and Metastasis (M).

Relationships:-
1. Entity1: ""Clinical staging criteria"", Entity2: ""Total laryngectomy"", Relationship: ""determines necessity of""
2. Entity1: ""T3, N0"", Entity2: ""Clinical staging criteria"", Relationship: ""is a categorization of""

Causalities:-
The flowchart begins with the <C> clinical staging criteria </C>, specifically focusing on <CO> cases that require total laryngectomy, denoted as requiring (amenable to) total laryngectomy (T3, N0) </CO>. This <A> categorization </A> is crucial as it <E> forms the basis for determining the appropriate treatment strategy </E>.

Section Name: Treatment of Primary and Neck
====================
Entities:-
Neoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.
Lymphatic Metastasis : Transfer of a neoplasm from one organ or part of the body to another remote from the primary site.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Radiation Therapy"", Relationship: ""combined with""
2. Entity1: ""Laryngectomy"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""
3. Entity1: ""Thyroidectomy"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""
4. Entity1: ""Neck Dissection"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""

Causalities:-
<CO> Once clinical staging is established </CO>, the chart outlines various treatment options. <A> The initial step may involve either concurrent systemic therapy combined with radiation therapy (RT) or opting for RT alone </A>, <CO> especially if the patient is not a medical candidate for both therapies </CO>. <A> Laryngectomy, thyroidectomy, and neck dissection are considered </A> <CO> based on the extent of lymph node involvement </CO>.

Section Name: Surgical Options
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Lymph Node Excision : Surgical removal of one or more lymph nodes.
Lymphadenectomy : Surgical removal of one or more groups of lymph nodes.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.

Relationships:-
1. Entity1: ""Laryngectomy"", Entity2: ""Thyroidectomy"", Relationship: ""combined with""
2. Entity1: ""Lymph Node Dissection"", Entity2: ""Surgical Intervention"", Relationship: ""extent of""
3. Entity1: ""Surgical Intervention"", Entity2: ""Advanced Cases"", Relationship: ""management option for""

Causalities:-
<CO> If concurrent therapies are not suitable </CO>, <A> the chart presents laryngectomy combined with thyroidectomy </A>, <CO> depending on the extent of lymph node dissection required </CO>. <E> This highlights surgical intervention as a viable option in the management of advanced cases </E>.

Section Name: Induction Chemotherapy
====================
Entities:-
Induction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Therapeutic Approach : A method or strategy used in the treatment of disease or injury.

Relationships:-
1. Entity1: ""Induction Chemotherapy"", Entity2: ""Surgical Intervention"", Relationship: ""alternative or sequential treatment option""

Causalities:-
<C> immediate surgical intervention is either not feasible or considered insufficient </C> <E> The flowchart also considers the option of induction chemotherapy </E> <CO> in cases where immediate surgical intervention is either not feasible or considered insufficient </CO>. <A> tailoring therapeutic approaches tailored to individual patient needs </A>.

Section Name: Adjuvant Treatment
====================
Entities:-
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Neoplasm Recurrence, Local : The return of a cancer, at the same site, after it has been treated.
Disease Progression : The worsening of a disease over time.

Relationships:-
1. Entity1: ""Primary Treatment"", Entity2: ""Adjuvant Treatment"", Relationship: ""followed by""
2. Entity1: ""Adjuvant Treatment"", Entity2: ""Systemic Therapy"", Relationship: ""includes""
3. Entity1: ""Adjuvant Treatment"", Entity2: ""Radiotherapy"", Relationship: ""includes""
4. Entity1: ""Follow-up Assessments"", Entity2: ""Treatment Efficacy"", Relationship: ""used to evaluate""

Causalities:-
<C> Following primary treatment </C>, <E> the flowchart addresses the potential for adjuvant treatment pathways </E>. This may include systemic therapy, RT, or further evaluations based on <CO> the patient's response and any recurrence or persistent disease </CO>. It emphasizes <A> the need for follow-up assessments to evaluate treatment efficacy </A>.

Section Name: Risk Features and Response Assessment
====================
Entities:-
Neoplasm Invasiveness : The property of a neoplasm to infiltrate and destroy surrounding tissue.
Surgical Margins : The edge or border of the tissue removed in cancer surgery.
Neoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.
Extramural Extension : Extension of a tumor beyond the wall of an organ.
Positive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.
Cancer Management : The process of planning and coordinating the treatment of cancer.
Cancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""Extramural extension"", Entity2: ""Treatment decisions"", Relationship: ""influences""
2. Entity1: ""Positive surgical margin"", Entity2: ""Treatment decisions"", Relationship: ""influences""
3. Entity1: ""Ongoing assessment"", Entity2: ""Response evaluation"", Relationship: ""leads to""
4. Entity1: ""Response evaluation"", Entity2: ""Adjustments to treatment"", Relationship: ""leads to""
5. Entity1: ""Management of cancer"", Entity2: ""Treatment decisions"", Relationship: ""involves""
6. Entity1: ""Management of cancer"", Entity2: ""Ongoing assessment"", Relationship: ""involves""
7. Entity1: ""Management of cancer"", Entity2: ""Adjustments to treatment"", Relationship: ""involves""

Causalities:-
The chart incorporates a segment that takes into account <CO> adverse pathologic features, such as extramural extension or positive margins </CO>, <E> which could influence subsequent treatment decisions </E>. This highlights the importance of <A> ongoing assessment in the management of cancer, leading to response evaluation and adjustments to treatment as necessary </A>.

Section Name: NCCN Guidelines Version 4.2024
====================
Entities:-
Clinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.
Neoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.
Clinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Malignant Neoplasm : A malignant neoplasm is a cancerous growth that has the potential to invade and destroy nearby tissue and spread to other parts of the body.
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Cancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network"", Entity2: ""NCCN Guidelines"", Relationship: ""provides""
2. Entity1: ""NCCN Guidelines"", Entity2: ""Clinical Trials"", Relationship: ""recommend""
3. Entity1: ""NCCN Guidelines"", Entity2: ""Cancer"", Relationship: ""related to management of""

Causalities:-
<CO> any patient with cancer </CO> <A> the best management is in a clinical trial </A>. <A> Participation in clinical trials is especially encouraged </A>.

Section Name: SUPRA-3
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.
Chemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Clinical Trials As Topic : Research studies that prospectively assign human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Induction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.
Clinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.

Relationships:-
1. Entity1: ""Total laryngectomy"", Entity2: ""Laryngectomy"", Relationship: ""is a type of""
2. Entity1: ""Systemic therapy"", Entity2: ""RT"", Relationship: ""concurrent treatment option""
3. Entity1: ""Induction chemotherapy"", Entity2: ""Other treatments"", Relationship: ""initial treatment option before""

Causalities:-
<CO> Requiring (amenable to) total laryngectomy (T3,N0) </CO>
  - <A> Concurrent systemic therapy/RT </A> or <A> RT if patient not medical candidate for concurrent systemic therapy/RT </A>
  - <A> Laryngectomy, thyroidectomy and with ipsilateral, central, or bilateral neck dissection </A>
  - or
  - <A> Induction chemotherapy </A>
  - or
  - <A> Clinical trials </A>

Section Name: Follow-up
====================
Entities:-
Follow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.
Follow-Up Procedure : A procedure performed to monitor the progress of a patient's condition after initial treatment.
Follow-Up : Medical care given to a patient over time after initial treatment.
Disease Recurrence : The return of a sign, symptom, or disease after a remission.
Recurrent Disease : The reappearance of a disease after a period of improvement.

Relationships:-
1. Entity1: ""Follow-up"", Entity2: ""Recurrent or persistent disease"", Relationship: ""monitoring""

Causalities:-
- **Follow-up (FOLL-A, 1 of 2)**
  - <CO> Recurrent or persistent disease </CO> (ADV-3)

Section Name: Adverse Pathologic Features
====================
Entities:-
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Extranodal Extension : The spread of cancer beyond the lymph node capsule.
Positive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""pN1"", Entity2: ""Radiotherapy"", Relationship: ""Consideration for treatment""
2. Entity1: ""Extranodal extension"", Entity2: ""Systemic Therapy"", Relationship: ""Treatment option""
3. Entity1: ""Extranodal extension"", Entity2: ""Radiotherapy"", Relationship: ""Treatment option""
4. Entity1: ""Positive surgical margin"", Entity2: ""Systemic Therapy"", Relationship: ""Treatment option""
5. Entity1: ""Positive surgical margin"", Entity2: ""Radiotherapy"", Relationship: ""Treatment option""

Causalities:-
- <CO>pN1 without other risk features</CO>
  - <C>Adverse pathologic features</C>
  - <A>Consider RT</A>
  - <CO>Extranodal extension and/or positive margin</CO>
  - <CO>Other risk features</CO>
  - <A>Systemic therapy/RT (category 1)</A>
  - <A>RT or Consider systemic therapy/RT</A>

Section Name: Response Assessment
====================
Entities:-
Response Evaluation : The process of assessing the response of a disease to treatment, often used in clinical trials to determine the effectiveness of a therapy.
Response To Treatment : A clinical finding indicating the response of a condition to a therapeutic intervention.

Relationships:-

Section Name: Principles of Surgery and Radiation Therapy
====================
Entities:-
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Radiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.

Relationships:-
1. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Radiation Therapy"", Relationship: ""complementary treatments""

Causalities:-
**Principles of Surgery (SURG-A).**

**Principles of Radiation Therapy (SUPRA-A).**

Section Name: Principles of Systemic Therapy
====================
Entities:-
Cisplatin : An inorganic and water-soluble platinum complex, cisplatin is an antineoplastic agent that is used in the treatment of various cancers.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Radiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.

Relationships:-
1. Entity1: ""Cisplatin"", Entity2: ""Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""preferred agent""
2. Entity1: ""Cisplatin"", Entity2: ""Concurrent Systemic Therapy/RT"", Relationship: ""used in""

Causalities:-
<CO> When using concurrent systemic therapy/RT </CO>, <A> the preferred agent is cisplatin (category 1) </A>.
--------------------------------------------------
Page Number: 130

Section Name: Pathological N (pN)
====================
Entities:-
Lymph Nodes : Small, bean-shaped structures that are part of the body's lymphatic system. They filter lymph fluid and store white blood cells that help fight infection.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Tnm Staging : A system used to describe the size and spread of cancer in a standardized way. T refers to the size of the tumor, N to the involvement of lymph nodes, and M to metastasis.
Lymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.
Tnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient's body.
Lymph Node : An organ of the lymphatic system and the adaptive immune system.

Relationships:-
1. Entity1: ""Lymph Nodes"", Entity2: ""Neoplasm Metastasis"", Relationship: ""involved in""
2. Entity1: ""TNM Staging"", Entity2: ""Lymph Nodes"", Relationship: ""includes""
3. Entity1: ""TNM Staging"", Entity2: ""Neoplasm Metastasis"", Relationship: ""describes""

Causalities:-
<CO> NX: Regional lymph nodes cannot be assessed </CO>
<CO> N0: No regional lymph node metastasis </CO>
<CO> N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(–) </CO>
<CO> N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2a: Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N3: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(−); or metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>
<CO> N3a: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N3b: Metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>
<CO> Note: A designation of “U” or “L” may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L). Similarly, clinical and pathological ENE should be recorded as ENE(−) or ENE(+). </CO>

Section Name: Distant Metastasis (M)
====================
Entities:-
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.

Relationships:-
1. Entity1: ""M0"", Entity2: ""Distant Metastasis"", Relationship: ""is a category of""
2. Entity1: ""M1"", Entity2: ""Distant Metastasis"", Relationship: ""is a category of""

Causalities:-
### Distant Metastasis (M)

- **M0**: No distant metastasis
- **M1**: Distant metastasis

Section Name: Histologic Grade (G)
====================
Entities:-
Neoplasm Grading : A system of classifying cancer cells in terms of how abnormal they look under a microscope and how quickly the tumor is likely to grow and spread.
Histologic Grade : A measure of how much tumor cells differ from healthy cells, used to assess the aggressiveness of cancer.

Relationships:-
1. Entity1: ""GX"", Entity2: ""Grade cannot be assessed"", Relationship: ""is described as""
2. Entity1: ""G1"", Entity2: ""Well differentiated"", Relationship: ""is described as""
3. Entity1: ""G2"", Entity2: ""Moderately differentiated"", Relationship: ""is described as""
4. Entity1: ""G3"", Entity2: ""Poorly differentiated"", Relationship: ""is described as""

Causalities:-
<CO>GX</CO>: <E>Grade cannot be assessed</E>
<CO>G1</CO>: <E>Well differentiated</E>
<CO>G2</CO>: <E>Moderately differentiated</E>
<CO>G3</CO>: <E>Poorly differentiated</E>

Section Name: Prognostic Stage Groups
====================
Entities:-
Neoplasm Staging : Methods and systems of classifying neoplasms according to extent of disease.
Tumor Staging : A system for describing the size and spread of cancer within the body.
Tnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient's body.

Relationships:-
1. Entity1: ""Stage 0"", Entity2: ""Tis N0 M0"", Relationship: ""defined by""
2. Entity1: ""Stage I"", Entity2: ""T1 N0 M0"", Relationship: ""defined by""
3. Entity1: ""Stage II"", Entity2: ""T2 N0 M0"", Relationship: ""defined by""
4. Entity1: ""Stage III"", Entity2: ""T3 N0 M0, T1 N1 M0, T2 N1 M0, T3 N1 M0"", Relationship: ""defined by""
5. Entity1: ""Stage IVA"", Entity2: ""T1 N2 M0, T2 N2 M0, T3 N2 M0, T4a N0,N1,N2 M0"", Relationship: ""defined by""
6. Entity1: ""Stage IVB"", Entity2: ""Any T N3 M0, T4b Any N M0"", Relationship: ""defined by""
7. Entity1: ""Stage IVC"", Entity2: ""Any T Any N M1"", Relationship: ""defined by""
--------------------------------------------------
Page Number: 47

Section Name: Overview of Radiation Therapy Guidelines
====================
Entities:-
Radiation Therapy : The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.
Malignant Neoplasm : A disease characterized by uncontrolled, abnormal growth of cells that can invade and destroy nearby tissue and spread to other parts of the body.
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.
Glottic Larynx Cancer : A malignant neoplasm located in the glottic region of the larynx.
Laryngeal Cancer : Cancer that occurs in the larynx, or voice box, which may include the glottic region.
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.

Relationships:-
1. Entity1: ""Radiation Therapy"", Entity2: ""Cancer"", Relationship: ""treats""
2. Entity1: ""NCCN Guidelines"", Entity2: ""Cancer"", Relationship: ""guides treatment for""
3. Entity1: ""NCCN Guidelines"", Entity2: ""Radiation Therapy"", Relationship: ""specifies use of""

Causalities:-
The image presents a detailed flowchart outlining the principles of radiation therapy specifically for the <C> treatment of cancer in the glottic larynx </C>, <CO> as per the National Comprehensive Cancer Network (NCCN) guidelines (version 2.2024) </CO>. <E> This structured guidance delineates various treatment protocols </E>, <A> stratified by risk levels and therapeutic approaches </A>.

Section Name: Principles of Radiation Therapy
====================
Entities:-
Radiation Therapy : The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Gy : Gray, a unit of ionizing radiation dose in the International System of Units (SI), defined as the absorption of one joule of radiation energy per kilogram of matter.
Gray (Unit) : A unit of absorbed radiation dose of ionizing radiation, defined as the absorption of one joule of radiation energy per kilogram of matter.

Relationships:-
1. Entity1: ""Tis, N0"", Entity2: ""60.75 Gy (2.25 Gy/fraction) to 66 Gy (2.0 Gy/fraction)"", Relationship: ""treatment protocol""
2. Entity1: ""T1, N0"", Entity2: ""63 Gy (2.25 Gy/fraction) to 66 Gy (2.0 Gy/fraction) or 50 Gy (3.12 Gy/fraction) to 52 Gy (3.28 Gy/fraction)"", Relationship: ""treatment protocol""
3. Entity1: ""T2, N0"", Entity2: ""65.25 Gy (2.25 Gy/fraction) to 70 Gy (2.0 Gy/fraction)"", Relationship: ""treatment protocol""
4. Entity1: ""≥T2, N1 (PTV High risk)"", Entity2: ""66 Gy (2.2 Gy/fraction) to 70 Gy (2.0 Gy/fraction)"", Relationship: ""treatment protocol""
5. Entity1: ""≥T2, N1 (Low to intermediate risk)"", Entity2: ""44–50 Gy (2.0 Gy/fraction) to 54–63 Gy (1.6–1.8 Gy/fraction)"", Relationship: ""treatment protocol""

Causalities:-
<CO>Tis, N0</CO>: <A>60.75 Gy (2.25 Gy/fraction) to 66 Gy (2.0 Gy/fraction)</A>
<CO>T1, N0</CO>: <A>63 Gy (2.25 Gy/fraction, preferred) to 66 Gy (2.0 Gy/fraction) or 50 Gy (3.12 Gy/fraction) to 52 Gy (3.28 Gy/fraction)</A>
<CO>T2, N0</CO>: <A>65.25 (2.25 Gy/fraction) to 70 Gy (2.0 Gy/fraction)</A>
<CO>≥T2, N1</CO>: <A>PTV High risk: Primary tumor and involved lymph nodes (includes possible local subclinical infiltration at the primary site and at the high-risk level lymph node(s))</A>
<A>Fractionation: 66 Gy (2.2 Gy/fraction) to 70 Gy (2.0 Gy/fraction); daily Monday–Friday in 6–7 weeks</A>
<A>Concomitant boost accelerated RT: 72 Gy/6 weeks (1.8 Gy/fraction, large field; 1.5 Gy boost as second daily fraction during last 12 treatment days)</A>
<A>66–70 Gy (2.0 Gy/fraction; 6 fractions/wk accelerated)</A>
<A>Hyperfractionation: 79.2–81.6 Gy/7 weeks (1.2 Gy/fraction, twice daily)</A>
<CO>Low to intermediate risk</CO>: <A>Sites of suspected subclinical spread</A>
<A>44–50 Gy (2.0 Gy/fraction) to 54–63 Gy (1.6–1.8 Gy/fraction)</A>

Section Name: Concurrent Systemic Therapy/RT
====================
Entities:-
Cisplatin : A platinum-containing antineoplastic agent used in the treatment of various cancers.
Carboplatin : An organoplatinum compound that possesses antineoplastic activity.
Fluorouracil : A chemotherapy drug used to treat various types of cancer.

Relationships:-
1. Entity1: ""concurrent systemic therapy/RT"", Entity2: ""cisplatin"", Relationship: ""uses""
2. Entity1: ""concurrent systemic therapy/RT"", Entity2: ""carboplatin and 5-FU"", Relationship: ""uses""
3. Entity1: ""multiagent chemotherapy"", Entity2: ""toxicity burden"", Relationship: ""increases""

Causalities:-
<CO>Based on published data</CO>, <A>concurrent systemic therapy/RT most commonly uses conventional fractionation at 2.0 Gy per fraction to a typical dose of 70 Gy in 7 weeks with single-agent cisplatin given every 3 weeks at 100 mg/m²</A>; <CO>2–3 cycles of chemotherapy are used depending on the radiation fractionation scheme (RTOG 0129)</CO>. <CO>When carboplatin and 5-FU are used</CO>, <A>the recommended regimen is standard fractionation plus 3 cycles of chemotherapy</A>. <CO>Other fraction sizes (e.g., 1.8 Gy, conventional), multiagent chemotherapy, other dosing schedules of cisplatin, or altered fractionation with chemotherapy</CO> <E>are efficacious</E>, and <C>there is no consensus on the optimal approach</C>. <C>In general, the use of concurrent systemic therapy/RT</C> <E>carries a high toxicity burden</E>; <C>multiagent chemotherapy</C> <E>will likely further increase the toxicity burden</E>. <A>For any systemic therapy/RT approach, close attention should be paid to published reports for the specific chemotherapy agent, dose, and schedule of administration</A>. <A>Systemic therapy/RT should be performed by an experienced team and should include substantial supportive care</A>.

Section Name: Treatment Modalities
====================
Entities:-
Intensity-Modulated Radiotherapy : A type of conformal radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.
Intensity Modulated Radiation Therapy : A type of conformal radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.
Intensity-Modulated Radiation Therapy : An advanced type of high-precision radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.
Radiotherapy, Conformal : A type of radiotherapy that uses imaging to conform the radiation dose to the shape of the tumor.
3D Conformal Radiation Therapy : A technique in radiotherapy that uses imaging to conform the radiation dose to the shape of the tumor.
Chemotherapy, Adjuvant : Treatment with drugs that kill cancer cells, often used in conjunction with other therapies.
Chemotherapy : The treatment of disease by the use of chemical substances, especially the treatment of cancer by cytotoxic and other drugs.
Drug Therapy, Combination : The use of two or more drugs to achieve a therapeutic effect.
Systemic Therapy : A type of therapy that uses substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Intensity-Modulated Radiation Therapy (IMRT)"", Entity2: ""3D Conformal Radiation Therapy (3D-CRT)"", Relationship: ""are delivery methods for radiation therapy""
2. Entity1: ""Chemotherapy"", Entity2: ""Radiation Therapy"", Relationship: ""is integrated with for aggressive or advanced cancer cases""

Causalities:-
<CO> contingent upon patient-specific considerations </CO> <A> suggests either Intensity-Modulated Radiation Therapy (IMRT) or 3D Conformal Radiation Therapy (3D-CRT) as delivery methods </A>. <A> These advanced techniques are employed to optimize treatment accuracy </A>, <E> preserving surrounding healthy tissue and improving overall patient outcomes </E>. <A> a focus on concurrent systemic therapies underlines the importance of integrating chemotherapy </A>, particularly <CO> for patients with more aggressive forms of cancer or those demonstrating advanced disease characteristics </CO>.

Section Name: Additional Information
====================
Entities:-
Clinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.
Clinical Trial : A clinical trial is a research study in which one or more human subjects are prospectively assigned to one or more interventions to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes.
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Intensity-Modulated Radiation Therapy : An advanced type of high-precision radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.
Intensity Modulated Radiation Therapy : A type of conformal radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.
Three-Dimensional Conformal Radiation Therapy : A type of external beam radiation therapy that uses a computer to create a 3-dimensional picture of the tumor so that multiple radiation beams can be shaped exactly to the contour of the treatment area.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network"", Entity2: ""Clinical trial"", Relationship: ""encourages participation in""
2. Entity1: ""Intensity-Modulated Radiation Therapy"", Entity2: ""Three-Dimensional Conformal Radiation Therapy"", Relationship: ""recommended alternatives""

Causalities:-
<A> Participation in clinical trials </A> is especially encouraged. <A> Either IMRT (preferred) or 3D-CRT is recommended. </A>

Section Name: Conclusion
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.
Malignant Neoplasm Of Glottis : A malignant tumor located in the glottic region of the larynx.
Laryngeal Cancer : Cancer that occurs in the larynx, or voice box, which may include the glottic region.
Prognosis : A medical term for predicting the likely or expected development of a disease.
Evidence-Based Practice : Healthcare practices that are based on scientific evidence and research.
Evidence-Based Medicine : An approach to medical practice intended to optimize decision-making by emphasizing the use of evidence from well-designed and conducted research.

Relationships:-
1. Entity1: ""treatment paradigms"", Entity2: ""glottic larynx cancer"", Relationship: ""encapsulates""
2. Entity1: ""personalized treatment plans"", Entity2: ""prognosis"", Relationship: ""improves""

Causalities:-
<C> glottic larynx cancer </C>. <CO> the nuances of each patient's condition </CO>. <A> personalized treatment plans </A> <E> promoting effective management and improved prognosis </E>. <A> deliver clear, evidence-based interventions </A> <CO> considering the complexities involved in cancer treatment </CO>.


Among these two options which one is the most likely true:

(A) `N_State_1__patient` increases risk `Location_of_Involved_Lymph_Nodes_4`
(B) `Location_of_Involved_Lymph_Nodes_4` `increases risk `N_State_1__patient`

The answer is: ...

1. State the evidences in detail of the validity of option (A) or (B) by cross referencing
NCCN Clinical Practitioner’s Guidelines for Head and Neck Cancer.
2. If the evidences are obtained from `INFORMATION FROM KNOWLEDGE BASE`,
mention their corresponding Page Numbers, Section Name, entities, relationships and causalities.

DESIRED OUTPUT FORMAT:
<thinking>
...
</thinking>
<answer>
{
   ""thinking"": [""..."", ...],
   ""evidences"": [""..."", ...],
   ""answer"": ...
}
</answer>

Before providing the answer in <answer> tags, think step by step in detail in <thinking> tags and analyze every part.
Output inside <answer> tag in JSON format. Only output valid JSON.
DO NOT HALLUCINATE. DO NOT MAKE UP FACTUAL INFORMATION.
","1. The edge (N_State_1__patient) causes (Location_of_Involved_Lymph_Nodes_4) suggests that the state of lymph node involvement influences the location of involved lymph nodes. This is supported by the explanation that as the involvement state increases, the likelihood of more extensive spread increases, indicating a positive causal direction.
2. The edge (Location_of_Involved_Lymph_Nodes_4) causes (N_State_1__patient) suggests that the location of involved lymph nodes influences the predicted state of lymph node involvement. The explanation states that more extensive lymph node involvement is likely to lead to a higher N state, indicating a positive causal direction.
3. The NCCN Guidelines for Head and Neck Cancer emphasize the importance of lymph node involvement in cancer staging and treatment planning. The guidelines suggest that the extent of lymph node metastasis is a critical factor in determining the stage of cancer and the appropriate treatment strategy.
4. The knowledge base information on page 102, section 'Head and Neck Cancers - Principles of Surgery', highlights the relationship between tumor staging and surgical management of regional lymphatics, indicating that the extent of lymph node involvement is crucial for treatment decisions.
5. The knowledge base information on page 130, section 'Pathological N (pN)', describes the TNM staging system, which includes lymph node involvement as a key factor in cancer staging. This supports the idea that the state of lymph node involvement is a predictor of the extent and location of lymph node spread.
","1. Page 102, Section 'Head and Neck Cancers - Principles of Surgery': The extent of the tumor at initial tumor staging dictates the surgical management of regional lymphatics.
2. Page 130, Section 'Pathological N (pN)': The TNM staging system includes lymph node involvement as a key factor in cancer staging.
",A,"{'A': 99.24, 'B': 0.76}",yes,A,"1. The AI assistant's reasoning for selecting option (A) is based on the explanation provided in the edge description, which states that the state of lymph node involvement influences the location of involved lymph nodes. This is consistent with the causal direction being positive, as an increase in involvement state (e.g., from n0 to n3) increases the likelihood of more extensive spread (e.g., bilateral or contralateral).
2. The assistant also references the NCCN Guidelines for Head and Neck Cancer, which emphasize the importance of lymph node involvement in cancer staging and treatment planning. This supports the idea that the state of lymph node involvement is a predictor of the extent and location of lymph node spread.
3. The knowledge base information on page 102, section 'Head and Neck Cancers - Principles of Surgery', highlights the relationship between tumor staging and surgical management of regional lymphatics, indicating that the extent of lymph node involvement is crucial for treatment decisions. This aligns with the reasoning that the state of lymph node involvement influences the location of involved lymph nodes.
4. The knowledge base information on page 130, section 'Pathological N (pN)', describes the TNM staging system, which includes lymph node involvement as a key factor in cancer staging. This supports the idea that the state of lymph node involvement is a predictor of the extent and location of lymph node spread.
5. Overall, the assistant's reasoning is consistent with the evidence provided, and the selection of option (A) is justified based on the explanations and references to the NCCN Guidelines and knowledge base information.
"
